PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	EY	PG	WC	SC	GA	UT	PM	OA	HC	HP	DA
J	Schenkel, K; Rijal, S; Koirala, S; Koirala, S; Vanlerberghe, V; Van der Stuyft, P; Gramiccia, M; Boelaert, M				Schenkel, Karl; Rijal, Suman; Koirala, Siddhartha; Koirala, Shekhar; Vanlerberghe, Veerle; Van der Stuyft, Patrick; Gramiccia, Marina; Boelaert, Marleen			Visceral leishmaniasis in southeastern Nepal: A cross-sectional survey on Leishmania donovani infection and its risk factors	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						visceral leishmaniasis; Leishmania donovani; leishmanin skin test; environmental risk factors; Nepal	DIRECT AGGLUTINATION-TEST; KALA-AZAR; RURAL COMMUNITIES; SKIN-TEST	To document the frequency of Leishmania donovani infection at community level in a highly endemic region in southeastern Nepal, and to assess socioeconomic and environmental risk factors. A random cross-sectional population survey was held in two visceral leishmaniasis (VL) foci in Morang District in April to May 2003, enrolling individuals 2 years or older and residing in the endemic area for at least 12 months. Leishmania infection was defined as a direct agglutination test (DAT) titre equal to or higher than 1:3200. Risk factors were identified by logistic regression. The direct agglutination test was positive in 7.5% (95% CI: 5.1-10.8) and the leishmanin skin test (LST) in 13.2% (95% CI: 9.9-17.2) of the 373 study participants. No case of current kala-azar was found, but 5.1 % (95% CI: 3.1-7.8) reported having suffered from VL. Independent risk factors for Leishmania infection were proximity of the house to ponds [odds ratio (OR) 3.7, 95% CI: 1.6-8.5], family size (OR 4.4, 95% CI: 1.6-12.6), age >= 15 years (OR 5.5, 95% CI: 1.2-25.0) and house constructed in mud (OR 3.0, 95% CI: 1.1-7.6). Bednets, not impregnated and in poor condition, were used by 95.2% (95% CI: 92.3-97.0) of the population, but did not show any protective effect. This study shows that there is a serious problem of transmission of VL in this area of Nepal. The risk factors identified are linked with the socioeconomic level and the environment. The population would benefit from a community intervention to improve the environmental and housing conditions in the villages.	Robert Koch Inst, D-13353 Berlin, Germany; Inst Trop Med, B-2000 Antwerp, Belgium; BP Koirala Inst Hlth Sci, Dharan, Nepal; Ist Super Sanita, I-00161 Rome, Italy	Schenkel, K (reprint author), Robert Koch Inst, Seestr 10, D-13353 Berlin, Germany.	schenkelk@rki.de	GRAMICCIA, MARINA/C-4969-2016; Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776			ABDELHAMEED AA, 1989, TROP MED PARASITOL, V40, P470; Alexander B, 2002, EMERG INFECT DIS, V8, P1480, DOI 10.3201/eid0812.010485; Bern C, 2005, EMERG INFECT DIS, V11, P655, DOI 10.3201/eid1105.040718; Bern C, 2000, AM J TROP MED HYG, V63, P184, DOI 10.4269/ajtmh.2000.63.184; Bista MB, 1998, KALA AZAR NEPAL PRIN, P1; Boelaert M, 1999, AM J TROP MED HYG, V60, P129, DOI 10.4269/ajtmh.1999.60.129; Dinesh DS, 2001, ANN TROP MED PARASIT, V95, P197, DOI 10.1080/00034980120041071; HO M, 1983, CLIN EXP IMMUNOL, V51, P207; Joshi A. B., 1999, Southeast Asian Journal of Tropical Medicine and Public Health, V30, P583; Kleinbaum DG, 1998, APPL REGRESSION ANAL; Koirala S, 2004, TROP MED INT HEALTH, V9, P533, DOI 10.1111/j.1365-3156.2004.01212.x; Koirala S, 1998, B WORLD HEALTH ORGAN, V76, P485; KUMAR V, 1995, INDIAN J MED RES, V101, P154; NADIM A, 2000, WHOLEISH9537; RAB MA, 1994, T ROY SOC TROP MED H, V88, P541, DOI 10.1016/0035-9203(94)90153-8; Ranjan A, 2005, AM J TROP MED HYG, V73, P74, DOI 10.4269/ajtmh.2005.73.74; SINGLA N, 1993, T ROY SOC TROP MED H, V87, P276, DOI 10.1016/0035-9203(93)90125-A; SOKAL JE, 1975, NEW ENGL J MED, V293, P501, DOI 10.1056/NEJM197509042931013; SRINIVASAN R, 1992, INDIAN J MED RES-A, V95, P301; *WHO, 1999, WHOCDSCSRISR992	20	48	48	0	2	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	DEC	2006	11	12					1792	1799		10.1111/j.1365-3156.2006.01735.x				8	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	108LP	WOS:000242241600004	17176343	Bronze			2019-03-26	
J	Wordemann, M; Polman, K; Heredia, LTM; Diaz, RJ; Madurga, AMC; Fernandez, FAN; Prado, RAC; Espinosa, AR; Duran, LP; Gorbea, MB; Rivero, LR; Gryseels, B				Woerdemann, Meike; Polman, Katja; Menocal Heredia, Lenina T.; Junco Diaz, Raquel; Collado Madurga, Ana-Maria; Nunez Fernandez, Fidel A.; Cordovi Prado, Raul A.; Ruiz Espinosa, Aniran; Pelayo Duran, Liliana; Bonet Gorbea, Mariano; Rojas Rivero, Lazara; Gryseels, Bruno			Prevalence and risk factors of intestinal parasites in Cuban children	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						paediatric helminths; protozoa; prevalence; risk factors; Cuba	INFECTIONS	To determine the prevalence of intestinal parasite infections and their risk factors in children in urban and rural settings in two Cuban municipalities. A total of 1320 Cuban schoolchildren aged 4-14 were tested by stool examination for intestinal parasite infections and evaluated by parental questionnaire for a number of common environmental, sanitary, socioeconomic and behavioural risk factors. Multivariate regression was applied to examine the relationship between the respective parasite infections and the risk factors. Prevalences of intestinal parasite infections were 58% in Fomento and 45% in San Juan y Martinez; for helminth infections, these were 18% and 24% and for protozoa infections, 50% and 29%, respectively. Helminth infections were associated with high parental education (maternal: OR 0.68, CI 0.50-0.93; paternal: OR 0.71, CI 0.52-0.96), absence of toilet (OR 1.57, CI 1.12-2.19), consumption of water from a well or river (OR 0.56, CI 0.41-0.77) and eating unpeeled/unwashed fruit (OR 1.37, CI 1.01-1.87); protozoa infections were only associated with high maternal education (OR 0.72, CI 0.57-0.91). Paediatric intestinal parasite infections are still prevalent in certain areas in Cuba and associated with a number of common environmental, socioeconomic and sanitary risk factors.	Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium; Natl Inst Hyg Epidemiol & Microbiol, Havana, Cuba; Inst Pedro Kouri, Havana, Cuba	Wordemann, M (reprint author), Inst Trop Med Prince Leopold, Natl Str 155, B-2000 Antwerp, Belgium.	mwoerdemann@itg.be					Asaolu SO, 2002, T ROY SOC TROP MED H, V96, P600, DOI 10.1016/S0035-9203(02)90323-8; BUNDY DAP, 1994, T ROY SOC TROP MED H, V88, P259, DOI 10.1016/0035-9203(94)90069-8; Cartwright CP, 1999, J CLIN MICROBIOL, V37, P2408; *COM EST EST, 1983, HABANA, V15, P35; Cooper PJ, 2003, AM J RESP CRIT CARE, V168, P313, DOI 10.1164/rccm.200211-1320OC; GONZALEZ MG, 1991, REV CIENCIAS BIOMEDI, V5, P255; Herrstrom P, 1997, SCAND J PRIM HEALTH, V15, P146, DOI 10.3109/02813439709018505; Katz N, 1972, Rev Inst Med Trop Sao Paulo, V14, P397; Lora-Suarez F, 2002, BMC PUBLIC HEALTH, V2, DOI 10.1186/1471-2458-2-5; MARINO CA, 2000, REV CUBANA SALUD PUB, V24, P134; Mendoza D, 2001, Rev Cubana Med Trop, V53, P189; Nunez Fernandez F, 1989, Rev Cubana Med Trop, V41, P371; Núñez Fidel A., 2003, Rev Cubana Med Trop, V55, P19; Núñez Fidel Ángel, 2003, Cad. Saúde Pública, V19, P677, DOI 10.1590/S0102-311X2003000200036; Phiri K, 2000, ANN TROP MED PARASIT, V94, P381, DOI 10.1080/00034983.2000.11813553; *PLAN REG INV AMB, 2005, AN SECT AG POT SAN C; Prieto PA, 2000, REV PANAM SALUD PUBL, V7, P313; Rai Diyo Ram, 2005, Nepal Med Coll J, V7, P43; VALDES OV, 1997, ED AMBIENTAL PREVENC; VILLAFRANCA RC, 2001, THESIS I P KOURI CIU	20	32	44	0	7	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	DEC	2006	11	12					1813	1820		10.1111/j.1365-3156.2006.01745.x				8	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	108LP	WOS:000242241600007	17176346	Bronze			2019-03-26	
J	Rodriguez-Hidalgo, R; Benitez-Ortiz, W; Praet, N; Saa, LR; Vercruysse, J; Brandt, J; Dorny, P				Rodriguez-Hidalgo, R.; Benitez-Ortiz, W.; Praet, N.; Saa, L. R.; Vercruysse, J.; Brandt, J.; Dorny, P.			Taeniasis-cysticercosis in Southern Ecuador: assessment of infection status using multiple laboratory diagnostic tools	MEMORIAS DO INSTITUTO OSWALDO CRUZ			English	Article						Taenia solium; taeniasis; cysticercosis; enzyme linked immunosorbent assay; enzyme-linked immunoelectrotransfer blot; polymerase chain reaction; restricted fragment length polymerase; Ecuador	PORCINE CYSTICERCOSIS; TAENIOSIS-CYSTICERCOSIS; SAGINATA CYSTICERCOSIS; SOLIUM; VILLAGE; EPIDEMIOLOGY; PREVALENCE; ANTIGENS; ELISA; PERU	Taenia solium-taeniasis and cysticercosis were studied in the human and porcine populations of a rural community in the Southern Ecuadorian Andes. From the 1059 inhabitants, 800 serum samples and 958 stool samples could he collected. In addition, 646 from the estimated 1148 pigs were tongue inspected. Circulating antigen was detected by enzyme linked immunosorbent assay (Ag-ELISA) in 2.25% of the human population, whereas intestinal taeniasis was detected in 1.46% by the formalin-ether technique. Following treatment and recovery of tapeworm fragments these were all identified as T. solium. Porcine cysticercosis was diagnosed in 3.56% of the pigs by tongue inspection. In addition, enzyme linked immunoelectrotransfer blot (EITB) was performed on a subset group of 100 humans to confirm the results of the Ag-ELISA. One hundred serum samples from pigs were also analysed by EITB. It appeared that 43 and 74% of humans and pigs had antibodies against T. solium cysticerci, respectively. It is concluded that contrary to the high exposure of the human population to T. solium. that is suggested by EITB, the number of active cysticercosis cases, diagnosed by Ag-ELISA, was low, which may indicate endemic stability. The further use of complementary diagnostic methods for a better understanding of the epidemiology of T. solium. is suggested.	Inst Trop Med Prince Leopold, Dept Anim Hlth, B-2000 Antwerp, Belgium; Univ Cent Ecuador, Ctr Int Zoonosis, Quito, Ecuador; Univ Tecn Particular Loja, Lab Serv Agropecuarios, Escuela Ciencias Agropecuarias, Loja, Ecuador; Univ Ghent, Fac Med, Dept Virol Parasitol & Immunol, Merelbeke, Belgium	Dorny, P (reprint author), Inst Trop Med Prince Leopold, Dept Anim Hlth, Natl Str 155, B-2000 Antwerp, Belgium.	pdorny@itg.be	Rodriguez-Hidalgo, Richar/P-8877-2015	Rodriguez-Hidalgo, Richar/0000-0002-9338-1062			BENITEZORTIZ W, 2001, CERDOS LOCALES SISTE, P37; BRANDT JRA, 1992, INT J PARASITOL, V22, P471, DOI 10.1016/0020-7519(92)90148-E; Coluzzi Mario, 1999, Parassitologia (Rome), V41, P277; Cruz Licea V., 2003, Parasitologia Latinoamericana, V58, P41; DIAZ F, 1992, AM J EPIDEMIOL, V135, P875, DOI 10.1093/oxfordjournals.aje.a116383; Dorny P, 2004, TRENDS PARASITOL, V20, P259, DOI 10.1016/j.pt.2004.04.001; Dorny P, 2004, INT J PARASITOL, V34, P569, DOI 10.1016/j.ijpara.2003.11.014; Dorny P, 2000, VET PARASITOL, V88, P43, DOI 10.1016/S0304-4017(99)00196-X; Erhart A, 2002, T ROY SOC TROP MED H, V96, P270, DOI 10.1016/S0035-9203(02)90095-7; FRAMSTAD T, 2004, BLEEDING INTRAVENOUS; Garcia HH, 2001, AM J TROP MED HYG, V65, P31, DOI 10.4269/ajtmh.2001.65.31; Garcia HH, 2003, AM J TROP MED HYG, V68, P268, DOI 10.4269/ajtmh.2003.68.268; GarciaNoval J, 1996, AM J TROP MED HYG, V55, P282, DOI 10.4269/ajtmh.1996.55.282; Gonzales AE, 1996, AM J TROP MED HYG, V54, P391, DOI 10.4269/ajtmh.1996.54.391; GONZALEZ AE, 1990, AM J TROP MED HYG, V43, P194, DOI 10.4269/ajtmh.1990.43.194; GONZALEZ AE, 2006, 11 INT C PAR 7 11 AU; Goodman KA, 1999, AM J TROP MED HYG, V60, P70, DOI 10.4269/ajtmh.1999.60.70; Melrose WD, 2002, INT J PARASITOL, V32, P947, DOI 10.1016/S0020-7519(02)00062-0; Prestes-Carneiro LE, 2006, MEM I OSWALDO CRUZ, V101, P15, DOI 10.1590/S0074-02762006000100004; RITCHIE LAWRENCE S., 1948, BULL U S ARMY MED DEPT, V8, P326; Rodriguez V, 2002, PHYSICA E, V12, P88, DOI 10.1016/S1386-9477(01)00249-1; Rodriguez-Hidalgo R, 2003, VET PARASITOL, V118, P51, DOI 10.1016/j.vetpar.2003.09.019; Sanchez AL, 1997, ANN TROP MED PARASIT, V91, P163, DOI 10.1080/00034983.1997.11813126; TSANG VCW, 1989, J INFECT DIS, V159, P50, DOI 10.1093/infdis/159.1.50; *WHO, 2002, 1318A5523 WHO	25	22	22	0	1	FUNDACO OSWALDO CRUZ	RIO DE JANEIRO, RJ	AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL	0074-0276			MEM I OSWALDO CRUZ	Mem. Inst. Oswaldo Cruz	NOV 15	2006	101	7					779	782		10.1590/S0074-02762006000700012				4	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	109BY	WOS:000242284100012	17160287	DOAJ Gold, Green Published			2019-03-26	
J	Delespaux, V; Chitanga, S; Geysen, D; Goethals, A; Van den Bossche, P; Geerts, S				Delespaux, V.; Chitanga, S.; Geysen, D.; Goethals, A.; Van den Bossche, P.; Geerts, S.			SSCP analysis of the P2 purine transporter TcoAT1 gene of Trypanosoma congolense leads to a simple PCR-RFLP test allowing the rapid identification of diminazene resistant stocks	ACTA TROPICA			English	Article						Trypanosoma congolense; Trypanosoma brucei; drug resistance; diminazene; purine transport; SSCP; PCR-RFLP	SSU-RDNA AMPLIFICATION; DRUG-RESISTANCE; BRUCEI-BRUCEI; NUCLEOSIDE TRANSPORTER; CATTLE; ACETURATE; DIAGNOSIS; AFFINITY	Analyses were made on a Trypanosoma congolense contig coding a putative P2-like nucleoside transporter (the contig was named in this study TcoAT1). The sequence includes a start and stop codon and presents a high similarity with the gene TbAT1 of T brucei (Smallest Sum Probability 2.8e- 136). To investigate a possible link between point mutations and diminazene aceturate (DA) resistance in mice, the TcoAT1 putative genes of 26 T congolense strains, characterised for DA sensitivity in the single dose mouse test, were screened by means of the Single Strand Conformation Polymorphism technique (SSCP). Results showed that the SSCP profiles of 23 out of 26 (88.5%) T congolense strains were confirmed by the sensitivity test in mice with the commonly accepted criterion for sensitivity to diminazene being a CD80 of 20 mg/kg in the mouse test. The remaining T congolense strains showed a resistant SSCP profile and relapsed in mice after treatment at doses lower than 20 mg/kg indicating that the SSCP is more sensitive than the single dose mouse test for the detection of resistance to diminazene. However, none of the strains used in this study showed a sensitive SSCP profile while they were resistant in the single dose mouse test. The sequencing of the TcoAT1 gene of two sensitive, two intermediate and two resistant strains allowed the set up of a PCR-RFLP test for the discrimination between sensitive and resistant strains confirming the SSCP results for the 26 strains of this study. (c) 2006 Elsevier B.V. All rights reserved.	Inst Trop Med, Anim Hlth Dept, B-2000 Antwerp, Belgium; Univ Antwerp, Ctr Med Genet, B-2610 Antwerp, Belgium	Delespaux, V (reprint author), Inst Trop Med, Anim Hlth Dept, Natl Str 155, B-2000 Antwerp, Belgium.	vdelespaux@itg.be	DELESPAUX, Vincent/C-3160-2009	Geerts, Stanny/0000-0001-9885-8846			AFEWORK J, 2006, PARASITOL RES, V99, P253; AINANSHE OA, 1992, TROP ANIM HEALTH PRO, V24, P65, DOI 10.1007/BF02356946; Anene BM, 2006, PARASITOLOGY, V132, P127, DOI 10.1017/S0031182005008760; BARRETT MP, 1995, MOL BIOCHEM PARASIT, V73, P223, DOI 10.1016/0166-6851(95)00120-P; CARTER NS, 1995, J BIOL CHEM, V270, P28153; CARTER NS, 1993, NATURE, V361, P173, DOI 10.1038/361173a0; CHITAMBO H, 1992, ZBL BAKT-INT J MED M, V277, P371; De Koning HP, 1999, MOL PHARMACOL, V56, P1162; de Koning HP, 2005, FEMS MICROBIOL REV, V29, P987, DOI 10.1016/j.femsre.2005.03.004; de Koning HP, 2004, ANTIMICROB AGENTS CH, V48, P1515, DOI 10.1128/AAC.48.5.1515-1519.2004; Delespaux V, 2005, INT J PARASITOL, V35, P235, DOI 10.1016/j.ijpara.2004.11.009; Delespaux V, 2003, VET PARASITOL, V117, P185, DOI 10.1016/j.vetpar.2003.08.004; Eisler MC, 2001, VET PARASITOL, V97, P171, DOI 10.1016/S0304-4017(01)00415-0; Geerts S, 2001, TRENDS PARASITOL, V17, P25, DOI 10.1016/S1471-4922(00)01827-4; GEERTS S, 1998, PAAT TECHNOL SCI SER, V1; Geysen D, 2003, VET PARASITOL, V110, P171, DOI 10.1016/S0304-4017(02)00313-8; GIRGISTAKLA AP, 1974, ANTIMICROB AGENTS CH, V6, P372; Hawking F, 1944, J PHARMACOL EXP THER, V82, P31; Maser P, 1999, SCIENCE, V285, P242, DOI 10.1126/science.285.5425.242; Matovu E, 2003, EUKARYOT CELL, V2, P1003, DOI 10.1128/EC.2.5.1003-1008.2003; PEREGRINE AS, 1993, ACTA TROP, V54, P185, DOI 10.1016/0001-706X(93)90092-P; Rozen S., 2000, BIOINFORMATICS METHO, P365, DOI DOI 10.1385/1-59259-192-2:365; Sinyangwe L, 2004, VET PARASITOL, V119, P125, DOI 10.1016/j.vetpar.2003.11.007; Witola WH, 2004, EXP PARASITOL, V107, P47, DOI 10.1016/j.exppara.2004.03.013	24	20	21	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0001-706X			ACTA TROP	Acta Trop.	NOV	2006	100	1-2					96	102		10.1016/j.actatropica.2006.10.001				7	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	126GR	WOS:000243501200012	17083909				2019-03-26	
J	Davis, S; Makundi, RH; Machang'u, RS; Leirs, H				Davis, S.; Makundi, R. H.; Machang'u, R. S.; Leirs, H.			Demographic and spatio-temporal variation in human plague at a persistent focus in Tanzania	ACTA TROPICA			English	Article						rodent-borne disease; plague focus; Yersinia pestis; zoonotic disease; vector-borne disease	WESTERN USAMBARA MOUNTAINS; NORTHEAST TANZANIA; LUSHOTO DISTRICT; EPIDEMIOLOGY; MADAGASCAR; DOGS	Human plague in the Western Usambara Mountains in Tanzania has been a public health problem since the first outbreak in 1980. The wildlife reservoir is unknown and eradication measures that have proved effective elsewhere in Tanzania appear to fail in this re-ion. We use census data from 2002 and hospital records kept since 1986 to describe the temporal, spatial and demographic variation in human plague. A seasonal peak in cases occurs from December to February with the numbers of cases during this peak varying between 0 and 1150. Variation in incidence, calculated for each village as the mean number of cases per thousand inhabitants per year, indicates that human plague is concentrated around a group of three neighbouring, relatively isolated, high-altitude villages; Nywelo, Madala and Gologolo. However, there was no evidence that these villages were acting as a source of infection for the remainder of the focus. The likelihood of becoming infected with plague is highest between the ages of 5 and 19 and lowest for adult men. This was most clear in the ward encompassing the three high-incidence villages where the risk of plague among children aged 10-14 was 2.2 times hi-her than for adults aged 30-34, and among adults aged 30-34, the risk was 2.4 times higher for women than men. (c) 2006 Elsevier B.V. All rights reserved.	Univ Antwerp, Dept Biol, B-2020 Antwerp, Belgium; Sokoine Univ Agr, Ctr Pest Management, Morogoro, Tanzania; Danish Inst Agr Sci, Danish Pest Infestat Lab, Dept Integrated Pest Management, DK-2800 Lyngby, Denmark	Davis, S (reprint author), Univ Utrecht, Fac Vet Med, Yalelaan 7, NL-3584 CL Utrecht, Netherlands.	S.A.Davis@vet.uu.nl	Leirs, Herwig/B-8197-2008	Leirs, Herwig/0000-0002-7612-5024			BEGON M, 2006, EMERG INFECT DIS, V12, P28; Boisier P, 2002, EMERG INFECT DIS, V8, P311, DOI 10.3201/eid0803.010250; CAVANAUGH D C, 1972, Journal of Wildlife Diseases, V8, P85; CHANTEAU S, 2006, ATLAS PESTE MADASGAS; Collinge SK, 2005, LANDSCAPE ECOL, V20, P941, DOI 10.1007/s10980-005-4617-5; Davis RM, 2002, J VECTOR ECOL, V27, P107; GAGE KL, 2004, ANNU REV ENTOMOL, V50, P505; Gratz N., 1999, PLAGUE MANUAL EPIDEM, P63; Kilonzo B. S., 1994, Central African Journal of Medicine, V40, P186; KILONZO BS, 1992, ACTA TROP, V50, P323, DOI 10.1016/0001-706X(92)90067-8; KILONZO BS, 1993, SCAND J INFECT DIS, V25, P503, DOI 10.3109/00365549309008533; KILONZO BS, 1983, ACTA TROP, V40, P365; KILONZO BS, 1982, T ROY SOC TROP MED H, V76, P172, DOI 10.1016/0035-9203(82)90269-3; KILONZO BS, 1997, TANZANIA ACTA TROP, V68, P215; Kilonzo BS, 2000, P 19 ANN SCI C TANZ, p172 ; Kool JL, 2005, CLIN INFECT DIS, V40, P1166, DOI 10.1086/428617; LYAMUYA EF, 1992, TANZANIA J TROP MED, V95, P1; Migliani R, 2006, TROP MED INT HEALTH, V11, P1228, DOI 10.1111/j.1365-3156.2006.01677.x; MISONE S, 1959, ANN SOC BELG MED TR, V39, P437; NJUNWA KJ, 1989, TANZANIA MED VET ENT, V3, P17; Rousseeuw P. J., 1987, ROBUST REGRESSION OU; TIKHOMIROV E, 1999, PLAGUE MANUAL EPIDEM, P11; *WHO, 2005, PLAGUE WKLY EPIDEMIO, V80, P138	23	15	16	0	12	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0001-706X			ACTA TROP	Acta Trop.	NOV	2006	100	1-2					133	141		10.1016/j.actatropica.2006.10.006				9	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	126GR	WOS:000243501200016	17113555				2019-03-26	
J	He, JK; Vaughn, DW; Dewar, V; Voet, P				He, Junkun; Vaughn, David W.; Dewar, Vincent; Voet, Pierre			Characterization of monoclonal antibodies to hepatitis E virus (HEV) capsid protein and identification of their binding and neutralization activities	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Meeting Abstract									Armed Forces Inst Pathol, Rockville, MD USA; Walter Reed Army Inst Res, Silver Spring, MD USA; GlaxoSmithKline Biol, Rixensart, Belgium								0	0	0	0	0	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	NOV	2006	75	5		S		274	79	80						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	109XW	WOS:000242343900275					2019-03-26	
J	Olliaro, PL; Vaillant, M; Phalkey, R; Phalkey, R; Guthmann, JP; Dorsey, G; Brasseur, P; D'Alessandro, U; Millet, P; Taylor, WBR				Olliaro, Piero L.; Vaillant, Michel; Phalkey, Revati; Phalkey, Revati; Guthmann, Jean-Paul; Dorsey, Grant; Brasseur, Philippe; D'Alessandro, Umberto; Millet, Pascal; Taylor, Walter (Bob) R.			Artesunate plus amodiaquine (AS plus AQ) for the treatment of uncomplicated falciparum malaria: An inventory and systematic review of safety and efficacy data	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Meeting Abstract									UNICEF UNDP WBI WHO Special Programme Res & TDR, Geneva, 94143, Switzerland; CRP Sante, Luxembourg, Luxembourg; Univ Victor Segalen Bordeaux 2, Bordeaux, France; Epictr, Paris, France; Univ Calif San Francisco, San Francisco, CA USA; IRD, Dakar, Senegal; Inst Prince Leopold, Antwerp, Belgium			D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009				0	1	1	0	0	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	NOV	2006	75	5		S		307	89	89						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	109XW	WOS:000242343900308					2019-03-26	
J	Van geertruyden, JP				Van geertruyden, Jean-Pierre			CD4 T count and HIV-1 infection in patients with uncomplicated malaria	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Meeting Abstract									Inst Trop Med Prince Leopold, Antwerp, Belgium			Van geertruyden, Jean-Pierre/K-6425-2014	Van geertruyden, Jean-Pierre/0000-0001-5006-6364				0	0	0	0	0	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	NOV	2006	75	5		S		322	94	94						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	109XW	WOS:000242343900323					2019-03-26	
J	Penali, L; Jansen, FH				Penali, Louis; Jansen, F. H.			Pharmacokinetic study of intramuscular and intrarectal artemether application for the acute attack treatment of malaria	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Meeting Abstract									Inst Pasteur, Abidjan, Cote Ivoire; Dafra Pharma, Turnhout, Belgium								0	0	0	0	0	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	NOV	2006	75	5		S		334	97	97						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	109XW	WOS:000242343900335					2019-03-26	
J	Guthmann, JP; Bonnet, M; Ahoua, L; Dantoine, F; Baquet, S; Balkan, S; van Herp, M; Tamrat, A; Legros, D; Brown, V; Checchi, F				Guthmann, Jean-Paul; Bonnet, Maryline; Ahoua, Laurence; Dantoine, Francois; Baquet, Sophie; Balkan, Suna; van Herp, Michel; Tamrat, Abiy; Legros, Dominique; Brown, Vincent; Checchi, Francesco			High malaria mortality during malaria epidemics in Kenya, Burundi and Ethiopia	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Meeting Abstract									Epicentre, Paris, France; Med Frontieres, Brussels, Belgium; Med Frontieres, Paris, France; Med Frontieres, Geneva, Switzerland								0	0	0	0	0	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	NOV	2006	75	5		S		425	124	124						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	109XW	WOS:000242343900426					2019-03-26	
J	Jansen, FH; Van Miert, S				Jansen, Frans H.; Van Miert, Sabine			Counterfeit anti malaria drugs: The drama of dihydroartemisinin (DHA)	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Meeting Abstract									Dafra Pharma NV, Turnhout, Belgium								0	0	0	0	3	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	NOV	2006	75	5		S		531	154	155						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	109XW	WOS:000242343900532					2019-03-26	
J	Penali, L; Jansen, FH; Van Boxlaer, J				Penali, Louis; Jansen, F. H.; Van Boxlaer, J.			Fixed dose act: Pharmacokinetic study of artesunate-sulfamethoxypyrazine-pyrimethamine (co-arinate FDC) in a black population in ivory coast	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Meeting Abstract									Inst Pasteur, Abidjan, Cote Ivoire; Dafra Pharma, Turnhout, Belgium; Lab Med Biochem & Clin Anal, Ghent, Belgium								0	0	0	0	1	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	NOV	2006	75	5		S		542	157	158						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	109XW	WOS:000242343900543					2019-03-26	
J	Jansen, FH; Jansen-Luts, A; Ameye, C; Penali, L				Jansen, F. H.; Jansen-Luts, Annemie; Ameye, Caroline; Penali, Louis			Is artesunate or its active metabolite dihydroartemisinin being excreted in the milk of lactating mothers?	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Meeting Abstract									ACT ion AFRIQUE, Brussels, Belgium								0	2	2	0	3	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	NOV	2006	75	5		S		543	158	158						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	109XW	WOS:000242343900544					2019-03-26	
J	Lesaffre, E; Garcia Zattera, MJ; Die-Kakou, H; Bissagnene, E; Penali, L; Ameye, C; Jansen, FH				Lesaffre, E.; Garcia Zattera, M. J.; Die-Kakou, H.; Bissagnene, E.; Penali, L.; Ameye, Caroline; Jansen, F. H.			Relative advantages of various artesunate based combination therapies (ACTs). A meta-analysis	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Meeting Abstract									Univ Leuven, Ctr Biostat, Louvain, Belgium								0	0	0	0	0	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	NOV	2006	75	5		S		855	246	246						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	109XW	WOS:000242343901290					2019-03-26	
J	Tinto, H; Karema, C; Rwagacondo, C; Erhart, A; d'Alessandro, U				Tinto, Halidou; Karema, Corine; Rwagacondo, Claude; Erhart, Annette; d'Alessandro, Umberto			In vitro susceptibility of Plasmodium falciparum to monodesethylamodiaquine, dihydroartemisinin and quinine in an area of high chloroquine resistance in Rwanda	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Meeting Abstract									IRSS, Ctr Muraz, Bobo Dioulasso, Burkina Faso; Natl Malaria Control Programme, Kigali, Rwanda; Inst Trop Med, B-2000 Antwerp, Belgium			D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009				0	0	0	0	0	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	NOV	2006	75	5		S		875	252	252						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	109XW	WOS:000242343901310					2019-03-26	
J	Kozyr, N; Ayres, J; Gan, WN; Harkins, T; Gu, ZP; Charlab, R; Li, P; Hendrix, R; Berg, T; Cabrera-Mora, M; Akinyi, S; Dickherber, M; Larsen, C; Staprans, S; Moreno, A; Galinski, MR				Kozyr, Natalia; Ayres, Jennifer; Gan, Weiniu; Harkins, Timothy; Gu, Zhiping; Charlab, Rosane; Li, Peter; Hendrix, Rose; Berg, Tiina; Cabrera-Mora, Monica; Akinyi, Sheila; Dickherber, Megan; Larsen, Christian; Staprans, Silvija; Moreno, Alberto; Galinski, Mary R.			Validation and implementation of rhesus immune profiling gene expression assays in non-human primate models of malaria	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Meeting Abstract									Univ Maryland, Baltimore, MD 21201 USA; Univ Bamako, Bamako, Mali; Walter Reed Army Inst Res, Silver Spring, MD USA; GlaxoSmithKline Biol, Rixensart, Belgium								0	0	0	1	1	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	NOV	2006	75	5		S		891	257	257						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	109XW	WOS:000242343901326					2019-03-26	
J	Lyke, KE; Daou, M; Diarra, I; Kone, A; Thera, MA; Heppner, G; Leach, A; Doumbo, OK; Plowe, CV; Sztein, MB				Lyke, Kirsten E.; Daou, Modibo; Diarra, Issa; Kone, Abdoulaye; Thera, Mohamadou A.; Heppner, Gray; Leach, Amanda; Doumbo, Ogobara K.; Plowe, Christopher V.; Sztein, Marcelo B.			Cell mediated immunity elicited in semi-immune adults in Bandiagara, Mali after a randomized controlled phase I trial of Walter Reed Army Institute of Research's AMA1 antigen adjuvanted in GlaxoSmithKline Biologicals' AS02A	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Meeting Abstract									Univ Maryland, Baltimore, MD 21201 USA; Univ Bamako, Bamako, Mali; Walter Reed Army Inst Res, Silver Spring, MD USA; GlaxoSmithKline Biol, Rixensart, Belgium								0	0	0	0	0	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	NOV	2006	75	5		S		892	257	257						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	109XW	WOS:000242343901327					2019-03-26	
J	Beiting, DF; Gagliardo, LF; Hesse, M; Bliss, SK; Meskill, D; Appleton, JA				Beiting, Daniel F.; Gagliardo, Lucille F.; Hesse, Matthias; Bliss, Susan K.; Meskill, Diana; Appleton, Judith A.			Coordinated control of immunity to muscle stage Trichinella spiralis by IL-10, regulatory T cells and TGF-beta(1)	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Meeting Abstract									Vrije Univ Brussels, Brussels, Belgium; Univ Wurzburg, Wurzburg, Germany								0	0	0	0	0	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	NOV	2006	75	5		S		1116	323	323						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	109XW	WOS:000242343901551					2019-03-26	
J	Hall, KA; Newton, PN; Green, MD; De Veij, M; Vandenabeele, P; Pizzanelli, D; Mayxay, M; Dondorp, A; Fernandez, FM				Hall, Krystyn Alter; Newton, Paul N.; Green, Michael D.; De Veij, Marleen; Vandenabeele, Peter; Pizzanelli, David; Mayxay, Mayfong; Dondorp, Arjen; Fernandez, Facundo M.			Characterization of counterfeit artesunate antimalarial tablets from southeast Asia	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							TANDEM MASS-SPECTROMETRY; ELECTROSPRAY-IONIZATION; PHARMACEUTICAL ANALYSIS; DIETHYLENE GLYCOL; MALARIA; DRUGS; MEDICATION; EPIDEMIC; MURDER; TIME	In southeast Asia, the widespread high prevalence of counterfeits tablets of the vital antimalarial artesunate is of great public health concern. To assess the seriousness of this problem, we quantified the amount of active ingredient present in artesunate tablets by liquid chromatography coupled to mass spectrometry. This method, in conjunction with analysis of the packaging, classified tablets as genuine, substandard, or fake and validated results of the colorimetric Fast Red TR test. Eight (35%) of 23 fake artesunate samples contained the wrong active ingredients, which were identified as different erythromycins and paracetamol. Raman spectroscopy identified calcium carbonate as an excipient in 9 (39%) of 23 fake samples. Multivariate unsupervised pattern recognition results indicated two major clusters of artesunate counterfeits, those with counterfeit foil stickers and containing calcium carbonate, erythromycin, and paracetamol, and those with counterfeit holograms and containing starch but without evidence of erythromycin or paracetamol.	Georgia Inst Technol, Sch Chem & Biochem, Atlanta, GA 30332 USA; Mahosot Hosp, Wellcome Trust Mahosot Hosp, Oxford Trop Med Res Collaborat, Microbiol Lab, Vietiane, Laos; Univ Oxford, Churchill Hosp, Ctr Clin Vaccinol & Trop Med, Oxford, England; Ctr Dis Control & Prevent, Div Parasit Dis, Natl Ctr Infect Dis, Atlanta, GA USA; Univ Ghent, Analyt Chem Lab, B-9000 Ghent, Belgium; Light Impress Intl, Surrey, England; Mahidol Univ, Wellcome Trust Mahidol Univ, Oxford Trop Med Res Program, Fac Trop Med, Bangkok 10700, Thailand	Fernandez, FM (reprint author), Georgia Inst Technol, Sch Chem & Biochem, 770 State St, Atlanta, GA 30332 USA.	facundo.fernandez@chemistry.gatech.edu	Fernandez, Facundo/B-7015-2008; Vandenabeele, Peter/B-8904-2017	Vandenabeele, Peter/0000-0001-5285-9835	Wellcome Trust		Aldhous P, 2005, NATURE, V434, P132, DOI 10.1038/434132a; Allen L.V., 2004, ANSELS PHARM DOSAGE; Basco LK, 2004, AM J TROP MED HYG, V70, P245, DOI 10.4269/ajtmh.2004.70.245; Cockburn Robert, 2005, PLoS Med, V2, pe100, DOI 10.1371/journal.pmed.0020100; Daviss B, 2005, SCIENTIST, V19, P42; Dondorp AM, 2004, TROP MED INT HEALTH, V9, P1241, DOI 10.1111/j.1365-3156.2004.01342.x; Fernandez FM, 2006, CHEMMEDCHEM, V1, P702, DOI 10.1002/cmdc.200600041; Gates PJ, 1999, RAPID COMMUN MASS SP, V13, P242, DOI 10.1002/(SICI)1097-0231(19990228)13:4<242::AID-RCM447>3.0.CO;2-B; Green MD, 2001, TROP MED INT HEALTH, V6, P980, DOI 10.1046/j.1365-3156.2001.00793.x; HANIF M, 1995, BRIT MED J, V311, P88, DOI 10.1136/bmj.311.6997.88; Hartl DL, 2004, NAT REV MICROBIOL, V2, P15, DOI 10.1038/nrmicro795; JAHNKE RW, 2001, B MEKONG MALARIA FOR, V8, P118; Lim CK, 2002, BIOL PHARM BULL, V25, P547, DOI 10.1248/bpb.25.547; Massart D. L., 1997, HDB CHEMOMETRICS QUA; Newton P, 2001, LANCET, V357, P1948, DOI 10.1016/S0140-6736(00)05085-6; Newton PN, 2006, LANCET INFECT DIS, V6, P602, DOI 10.1016/S1473-3099(06)70581-3; Newton PN, 2003, LANCET, V362, P169, DOI 10.1016/S0140-6736(03)13872-X; Newton PN, 2002, BRIT MED J, V324, P800, DOI 10.1136/bmj.324.7341.800; NEWTON PN, 2006, PLOS MED, V3, P1; O'Brien KL, 1998, JAMA-J AM MED ASSOC, V279, P1175, DOI 10.1001/jama.279.15.1175; ROZENDAAL J, 2000, B MEKONG MALARIA FOR, V7, P62; van Agtmael MA, 1999, TRENDS PHARMACOL SCI, V20, P199, DOI 10.1016/S0165-6147(99)01302-4; Vankeirsbilck T, 2002, TRAC-TREND ANAL CHEM, V21, P869, DOI 10.1016/S0165-9936(02)01208-6; Wardrop J, 2000, J PHARM SCI, V89, P1097, DOI 10.1002/1520-6017(200009)89:9<1097::AID-JPS1>3.3.CO;2-4; White NJ, 2004, J CLIN INVEST, V113, P1084, DOI 10.1172/JCI200421682; WHO, 1999, COUNT DRUGS GUID DEV; *WHO, 2006, WHAT ARE SUBST DRUGS; Wolff JC, 2003, RAPID COMMUN MASS SP, V17, P215, DOI 10.1002/rcm.893; 2002, NIST SCI TECHNICAL D; 2006, US PHARMACOPEIA	30	62	62	2	10	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	NOV	2006	75	5					804	811		10.4269/ajtmh.2006.75.804				8	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	107RQ	WOS:000242189100007	17123969	Green Published			2019-03-26	
J	Virreira, M; Alonso-Vega, C; Solano, M; Jijena, J; Brutus, L; Bustamante, Z; Truyens, C; Schneider, D; Torrico, F; Carlier, Y; Svoboda, M				Virreira, Myrna; Alonso-Vega, Cristina; Solano, Marco; Jijena, Juan; Brutus, Laurent; Bustamante, Zulema; Truyens, Carine; Schneider, Dominique; Torrico, Faustino; Carlier, Yves; Svoboda, Michal			Congenital chagas disease in bolivia is not associated with DNA polymorphism of Trypanosoma cruzi	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							POLYMERASE-CHAIN-REACTION; MAJOR PHYLOGENETIC LINEAGES; GENETIC-CHARACTERIZATION; POPULATION-STRUCTURE; INFECTION; PARASITE; IDENTIFICATION; TRANSMISSION; CLONES; CHILE	This study aims to typify the Trypanosoma cruzi (sub)lineage(s) in umbilical cord blood of congenitally infected Bolivian newborns, using PCR amplifications of "Region Markers", mini-exon or kDNA fragments followed by hybridization or sequencing. New probes were also designed to distinguish three variants within the TcIId sublineage. The IIb, IId, or IIe T. cruzi sublineages, as well as different variants of the IId sublineage, were detected in infected neonates, whereas mixed infections were not found. The frequencies of the IId sublineage were similar in neonates (95.1%) and adults of the same area (94.1%). The IId-infected newborns displayed either asymptomatic, or severe and fatal clinical forms of congenital Chagas disease, as well as low or high parasitemia. Altogether these data show that T cruzi DNA polymorphism, based on the presently available markers, is not associated with the occurrence of congenital infection or the development of severe clinical forms of congenital Chagas disease.	ULB, Fac Med, Chim Biol Lab, B-1070 Brussels, Belgium; UMSS, Fac Med, Cochabamba, Bolivia; Hosp San Juan Dios, Unidad Neonatol, Tarija, Bolivia; Mother & Child Hlth Res Unit, La Paz, Bolivia; ULB, Fac Med, Parasitol Lab, B-1070 Brussels, Belgium	Svoboda, M (reprint author), ULB, Fac Med, Chim Biol Lab, 808 Route Lennik CP 611, B-1070 Brussels, Belgium.	msvobod@ulb.ac.be	Brutus, Laurent/A-7430-2011	Brutus, Laurent/0000-0002-9967-0666			ANDRADE SG, 1982, T ROY SOC TROP MED H, V76, P123, DOI 10.1016/0035-9203(82)90036-0; Carlier Yves, 2003, Rev. Soc. Bras. Med. Trop., V36, P767, DOI 10.1590/S0037-86822003000600024; [Anonymous], 1999, MEM I O CRUZ S1, V94, P429; Barnabe C, 2000, PARASITOLOGY, V120, P513, DOI 10.1017/S0031182099005661; Barnabe C, 2001, ACTA TROP, V78, P127, DOI 10.1016/S0001-706X(00)00183-2; BITTENCOURT AI, 1985, ANN TROP MED PARASIT, V79, P393, DOI 10.1080/00034983.1985.11811937; BRENIERE SF, 1989, AM J TROP MED HYG, V41, P521, DOI 10.4269/ajtmh.1989.41.521; Breniere SF, 1998, EXP PARASITOL, V89, P285, DOI 10.1006/expr.1998.4295; Breniere SF, 2002, MEM I OSWALDO CRUZ, V97, P289, DOI 10.1590/S0074-02762002000300002; BRENIERE SF, 1992, AM J TROP MED HYG, V46, P335, DOI 10.4269/ajtmh.1992.46.335; Brisse S, 2000, MOL BIOCHEM PARASIT, V111, P95, DOI 10.1016/S0166-6851(00)00302-9; Brisse S, 2003, INFECT GENET EVOL, V2, P173, DOI 10.1016/S1567-1348(02)00097-7; Buscaglia CA, 2003, MICROBES INFECT, V5, P419, DOI 10.1016/S1286-4579(03)00050-9; Campbell DA, 2004, CURR MOL MED, V4, P549, DOI 10.2174/1566524043360249; Carlier Y, 2005, REV SOC BRAS MED TRO, V38, P105; Carlier Y., 2002, ENCY MED CHIR MALADI; Colorado IA, 2000, HUM IMMUNOL, V61, P320, DOI 10.1016/S0198-8859(99)00177-9; Coura JR, 2002, TRENDS PARASITOL, V18, P171, DOI 10.1016/S1471-4922(01)02200-0; Cruz-Robles D, 2004, HUM IMMUNOL, V65, P60, DOI 10.1016/j.humimm.2003.10.008; Da Silveira P.A., 2000, INT J PARASITOL, V30, P843; de Lana M, 1998, EXP PARASITOL, V90, P20, DOI 10.1006/expr.1998.4304; Devera R, 2003, MEM I OSWALDO CRUZ, V98, P1, DOI 10.1590/S0074-02762003000100001; Fernandes O, 1998, AM J TROP MED HYG, V58, P807, DOI 10.4269/ajtmh.1998.58.807; Franco DJ, 2003, EXP PARASITOL, V104, P54, DOI 10.1016/S0014-4894(03)00119-X; Gaunt MW, 2003, NATURE, V421, P936, DOI 10.1038/nature01438; Gonzalez-Carrasco JL, 1999, INTERMETALLICS, V7, P69, DOI 10.1016/S0966-9795(98)00012-0; Hermann E, 2004, J INFECT DIS, V189, P1274, DOI 10.1086/382511; Hermann E, 2002, BLOOD, V100, P2153; Higo H, 2004, PARASITOL INT, V53, P337, DOI 10.1016/j.parint.2004.06.001; Macedo AM, 2004, MEM I OSWALDO CRUZ, V99, P1, DOI 10.1590/S0074-02762004000100001; Monis PT, 2005, TRENDS PARASITOL, V21, P340, DOI 10.1016/j.pt.2005.05.012; Moreno Elio A., 2003, Invest. clín, V44, P241; MUNOZ S, 1994, REV MED CHILE, V122, P1231; Revollo S, 1998, EXP PARASITOL, V89, P30, DOI 10.1006/expr.1998.4216; Schenone Hugo, 2001, Revista do Instituto de Medicina Tropical de Sao Paulo, V43, P231, DOI 10.1590/S0036-46652001000400011; Solari A, 2001, EXP PARASITOL, V97, P226, DOI 10.1006/expr.2001.4607; Souto RP, 1996, MOL BIOCHEM PARASIT, V83, P141, DOI 10.1016/S0166-6851(96)02755-7; Sturm NR, 2003, INT J PARASITOL, V33, P269, DOI 10.1016/S0020-7519(02)00264-3; Szmaragd C, 2006, INFECT GENET EVOL, V6, P38, DOI 10.1016/j.meegid.2005.01.001; TELLERIA J, 2006, IN PRESS EXP PARASIT; Tibayrenc M, 1999, MICROBES INFECT, V1, P465, DOI 10.1016/S1286-4579(99)80050-1; Torres JP, 2004, PARASITOLOGY, V128, P161, DOI 10.1017/S0031182003004475; Torrico F, 2006, TROP MED INT HEALTH, V11, P628, DOI 10.1111/j.1365-3156.2006.01623.x; Torrico F, 2004, AM J TROP MED HYG, V70, P201, DOI 10.4269/ajtmh.2004.70.201; Torrico MC, 2005, REV SOC BRAS MED TRO, V38, P58; Vago AR, 2000, AM J PATHOL, V156, P1805, DOI 10.1016/S0002-9440(10)65052-3; VEAS F, 1991, CELL MOL BIOL, V37, P73; Virreira M, 2003, AM J TROP MED HYG, V68, P574, DOI 10.4269/ajtmh.2003.68.574; Westenberger SJ, 2005, GENETICS, V171, P527, DOI 10.1534/genetics.104.038745; WINCKER P, 1994, FEMS MICROBIOL LETT, V124, P419; Yeo M, 2005, INT J PARASITOL, V35, P225, DOI 10.1016/j.ijpara.2004.10.024	51	48	49	0	2	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	NOV	2006	75	5					871	879		10.4269/ajtmh.2006.75.871				9	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	107RQ	WOS:000242189100018	17123980				2019-03-26	
J	Cabada, MM; Maldonado, F; Quispe, W; Mozo, K; Serrano, E; Gonzaalez, E; Seas, C; Verdonck, K; Echevarria, JI; Dupont, HL; Gotuzzo, E				Cabada, Miguel M.; Maldonado, Fernando; Quispe, Wanda; Mozo, Karen; Serrano, Edson; Gonzalez, Elsa; Seas, Carlos; Verdonck, Kristien; Echevarria, Juan I.; Dupont, Herbert L.; Gotuzzo, Eduardo			Risk factors associated with diarrhea among international visitors to Cuzco, Peru	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							TRAVELERS DIARRHEA; HEALTH ADVICE; PRETRAVEL ADVICE; DOUBLE-BLIND; EPIDEMIOLOGY; INTERVENTIONS; INFORMATION; PREVENTION; LOPERAMIDE; COUNTRIES	The objective of this study was to determine the risk factors for travelers' diarrhea (TD) reported by visitors to Cuzco, Peru. In this cross-sectional study, self-administered questionnaires looking at perceived occurrence of health problems and pre-travel health advice were obtained from departing travelers at Cuzco's International Airport between August and November 2002. A total of 5,988 travelers participated in the study. The mean age was 35 years, and 51% were women. The prevalence of TD was 24%. Factors associated with TD in the multivariable analysis were use of antibiotic prophylaxis (OR: 3.20), vaccination against cholera (OR: 1.44), history of advice for safe food and water consumption (OR: 1.46), being younger than 35 years of age (OR: 1.37), being a resident of the United States (OR: 1.28), not staying in hotels in Cuzco (OR: 1.13), and number of unsafe food or beverages consumed (OR: 1.04). Remaining in Cuzco < 1 week was a protective factor (OR: 0.58). TD is common among travelers to Cuzco. This study suggests that conventional recommendations are not invariably effective at decreasing TD.	Univ Peruana Cayetano Heredia, Inst Med Trop Alexander von Humboldt, Lima, Peru; Univ Nacl San Antonio Abad Cuzco, Cuzco, Peru; Hosp Nacl Cayetano Heredia, Dept Enfermedades Infecc, Lima, Peru; Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium; Univ Texas, Sch Publ Hlth, Houston, TX USA; St Lukes Episcopal Hosp, Houston, TX 77030 USA; Baylor Coll Med, Houston, TX 77030 USA	Seas, C (reprint author), Univ Peruana Cayetano Heredia, Inst Med Trop Alexander von Humboldt, Av Honorio Delgado 430, Lima, Peru.	03517@upch.edu.pe; fmaldonado66@yahoo.com; thongzhi4@yahoo.com; karenzit@hotmail.com; edsonserrano@yahoo.com; egonzalezlagos@yahoo.com; cseas@upch.edu.pe; verweven@amauta.rcp.net.pe; chito@upch.edu.pe; hdupont@sleh.com; egh@upch.edu.pe		Seas, Carlos/0000-0001-7067-9141; Cabada, Miguel/0000-0003-2545-6197	NIDDK NIH HHS [DK56338]		Al-Abri SS, 2005, LANCET INFECT DIS, V5, P349, DOI 10.1016/S1473-3099(05)70139-0; Ashley DVM, 2004, J TRAVEL MED, V11, P364; BLACK RE, 1986, REV INFECT DIS S, V8, P131; BLASER MJ, 1986, REV INFECT DIS, V8, pS142; BRUNI M, 1997, J TRAVEL MED, V4, P61, DOI DOI 10.1111/J.1708-8305.1997.TB00781.X; Cabada MM, 2005, J TRAVEL MED, V12, P61; Cartwright R. Y., 1997, World Health Statistics Quarterly, V50, P102; Casburn-Jones AC, 2004, J GASTROEN HEPATOL, V19, P610, DOI 10.1111/j.1440-1746.2003.03287.x; Cavalcanti Anamaria, 2002, Rev Panam Salud Publica, V11, P245, DOI 10.1590/S1020-49892002000400006; Cobelens FGJ, 1998, TROP MED INT HEALTH, V3, P896; DuPont HL, 2005, ANN INTERN MED, V142, P805, DOI 10.7326/0003-4819-142-10-200505170-00005; Goldsmid JM, 2003, J TRAVEL MED, V10, P160; GORBACH SL, 1986, REV INFECT DIS S2, V8, pS227; Hill DR, 2000, AM J TROP MED HYG, V62, P585, DOI 10.4269/ajtmh.2000.62.585; Hoge CW, 1996, JAMA-J AM MED ASSOC, V275, P533, DOI 10.1001/jama.275.7.533; Horvath LL, 2003, J TRAVEL MED, V10, P272; Jiang ZD, 2003, J INFECT DIS, V188, P506, DOI 10.1086/377102; Krause E, 1999, J TRAVEL MED, V6, P163, DOI 10.1111/j.1708-8305.1999.tb00854.x; Leggat PA, 2002, J TRAVEL MED, V9, P24, DOI 10.2310/7060.2002.22460; MACDONALD KL, 1986, REV INFECT DIS, V8, pS117; MATTILA L, 1995, J TRAVEL MED, V2, P77; MCINTOSH IB, 1997, BR J GEN PRACT, V47, P68; MURPHY GS, 1993, ANN INTERN MED, V118, P582, DOI 10.7326/0003-4819-118-8-199304150-00002; Okhuysen PC, 2004, AM J GASTROENTEROL, V99, P1774, DOI 10.1111/j.1572-0241.2004.30435.x; Peetermans WE, 2001, ACTA CLIN BELG, V56, P284, DOI 10.1179/acb.2001.042; *PROMPERU, 2000, PERF TUR EXTR; Provost S, 2002, J TRAVEL MED, V9, P3, DOI 10.2310/7060.2002.22494; Reinthaler F F, 1998, J Travel Med, V5, P65, DOI 10.1111/j.1708-8305.1998.tb00466.x; Shlim DR, 2005, INFECT DIS CLIN N AM, V19, P137, DOI 10.1016/j.idc.2004.10.009; STEFFEN R, 1986, REV INFECT DIS, V8, pS122; STEFFEN R, 1983, JAMA-J AM MED ASSOC, V249, P1176; Steffen R, 1999, JAMA-J AM MED ASSOC, V281, P811, DOI 10.1001/jama.281.9.811; VANLOON FPL, 1989, GUT, V30, P492, DOI 10.1136/gut.30.4.492	33	13	15	0	3	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637	1476-1645		AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	NOV	2006	75	5					968	972		10.4269/ajtmh.2006.75.968				5	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	107RQ	WOS:000242189100036	17123998				2019-03-26	
J	Meheus, F; Boelaert, M; Baltussen, R; Sundar, S				Meheus, Filip; Boelaert, Marleen; Baltussen, Rob; Sundar, Shyam			Costs of patient management of visceral leishmaniasis in Muzaffarpur, Bihar, India	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						visceral leishmaniasis; Kala-Azar; Bihar; cost analysis; direct costs; indirect costs	AMPHOTERICIN-B; ECONOMIC COSTS; BURKINA-FASO; HOUSEHOLDS; MALARIA; POLICY; CARE; EXPENDITURE; DISEASE; BURDEN	Objectives To identify and quantify the direct and indirect economic cost of treatment for visceral leishmaniasis (VL) with conventional Amphotericin B deoxycholate, currently the first-line treatment in Muzaffarpur. Methods Costs of patient management for VL were estimated from a societal and household perspective by means of a questionnaire designed for this study, interviews and financial reports. Results The total cost of care per episode of VL from the societal perspective was estimated at US$355, equivalent to 58% of annual household income. The largest cost category was medical costs (55%), followed by indirect costs (36%) and non-medical costs (9%). The cost from the household perspective was equivalent to US$217. The largest cost category was indirect costs (59%), followed by medical costs (27%) and non-medical costs (15%). Loss of income because of illness and hospitalization and expenses for drugs were the largest cost components. Conclusions The economic costs related to VL are substantial, both to society and the patient. Public health authorities in Bihar should focus on policies that detect VL in the early stage and implement interventions that minimize the burden to households affected by VL.	Royal Trop Inst, NL-1090 HA Amsterdam, Netherlands; Banaras Hindu Univ, Inst Med Sci, Varanasi 221005, Uttar Pradesh, India; Erasmus Med Ctr, Inst Med Technol Assessment, Rotterdam, Netherlands; Inst Trop Med, B-2000 Antwerp, Belgium; Univ Antwerp, Inst Dev Policy & Management, B-2020 Antwerp, Belgium	Meheus, F (reprint author), Royal Trop Inst, Mauritskade 63,POB 95001, NL-1090 HA Amsterdam, Netherlands.	f.meheus@kit.nl	Baltussen, R.M.P.M./L-4181-2015; Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776			Ahluwalia IB, 2003, AM J TROP MED HYG, V69, P624, DOI 10.4269/ajtmh.2003.69.624; AsensoOkyere WK, 1997, SOC SCI MED, V45, P659, DOI 10.1016/S0277-9536(96)00383-8; BALTUSSEN R, 2005, HLTH POLICY     1118; Barnum H, 1993, PUBLIC HOSP DEV COUN; Brouwer W, 2001, EC EVALUATION HLTH C, P68; Bryceson A, 2001, TROP MED INT HEALTH, V6, P928, DOI 10.1046/j.1365-3156.2001.00795.x; CHOMINNAING ML, 2004, ACTA TROP, V92, P173; Creese A, 1994, COST ANAL PRIMARY HL; Desjeux P, 1996, CLIN DERMATOL, V14, P417, DOI 10.1016/0738-081X(96)00057-0; Drummond MF, 1997, METHODS EC EVALUATIO; Duraisamy P, 2006, AIDS CARE, V18, P121, DOI 10.1080/09540120500159359; Edejer TT, 2003, MAKING CHOICES HLTH; ETTLING M, 1994, TROP MED PARASITOL, V45, P74; Guerin PJ, 2002, LANCET INFECT DIS, V2, P494, DOI 10.1016/S1473-3099(02)00347-X; Hutton G, 2005, HEALTH POLICY PLANN, V20, P252, DOI 10.1093/heapol/czi025; KOOPMANSCHAP MA, 1995, J HEALTH ECON, V14, P171, DOI 10.1016/0167-6296(94)00044-5; Meessen B, 2003, TROP MED INT HEALTH, V8, P581, DOI 10.1046/j.1365-3156.2003.01081.x; Mugisha F, 2002, TROP MED INT HEALTH, V7, P187, DOI 10.1046/j.1365-3156.2002.00835.x; Murray  H W, 2000, Int J Infect Dis, V4, P158, DOI 10.1016/S1201-9712(00)90078-X; Murray HW, 2004, AM J TROP MED HYG, V71, P787, DOI 10.4269/ajtmh.2004.71.787; Olliaro PL, 2005, LANCET INFECT DIS, V5, P763, DOI 10.1016/S1473-3099(05)70296-6; Rijal S, 2006, T ROY SOC TROP MED H, V100, P838, DOI 10.1016/j.trstmh.2005.09.017; Rijal S, 2003, T ROY SOC TROP MED H, V97, P350, DOI 10.1016/S0035-9203(03)90167-2; Sauerborn R, 1996, SOC SCI MED, V43, P291, DOI 10.1016/0277-9536(95)00375-4; SAUERBORN R, 1991, TROP MED PARASITOL, V42, P219; Sculpher M., 2001, EC EVALUATION HLTH C, P94; SHARMA AD, 2006, TROP MED INT HEALTH, V11, P757; Sundar S, 2004, CLIN INFECT DIS, V38, P377, DOI 10.1086/380971; Sundar S, 2001, TROP MED INT HEALTH, V6, P849, DOI 10.1046/j.1365-3156.2001.00778.x; Sundar S, 2001, BRIT MED J, V323, P419, DOI 10.1136/bmj.323.7310.419; Thakur CP, 2000, T ROY SOC TROP MED H, V94, P156, DOI 10.1016/S0035-9203(00)90255-4; Van Damme W, 2004, TROP MED INT HEALTH, V9, P273, DOI 10.1046/j.1365-3156.2003.01194.x; WHO, 2005, WHOIVB0510; *WHO, 2000, 116 WHO; World Bank, 2005, BIH DEV STRAT	35	36	36	0	2	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	NOV	2006	11	11					1715	1724		10.1111/j.1365-3156.2006.01732.x				10	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	096WL	WOS:000241407400012	17054752	Bronze			2019-03-26	
J	Holt, J; Davis, S; Leirs, H				Holt, J.; Davis, S.; Leirs, H.			A model of Leptospirosis infection in an African rodent to determine risk to humans: Seasonal fluctuations and the impact of rodent control	ACTA TROPICA			English	Article						zoonosis; Mastomys natalensis; epidemiology; population dynamics; mathematical model; Tanzania	TANZANIA; TRANSMISSION; POPULATION; GROWTH; AREAS	Human leptospirosis (Leptospira spp. infection) is a worldwide public health problem that is of greatest concern for humid tropical and subtropical regions. The magnitude of the problem in these areas is larger because of the climatic and environmental conditions the bacterium face outside their hosts but also because of the frequency of contacts between people and sources of infection. Rodents are thought to play the most important role in the transmission of human leptospirosis. We here model the dynamics of infection in an African rodent (Mastomys natalensis) that is thought to be the principal source of infection in parts of Tanzania. Our model, representing the climatic conditions in central Tanzania, suggests a strong seasonality in the force of infection on humans with a peak in the abundance of infectious mice between January and April in agricultural environments. In urban areas the dynamics are predicted to be more stable and the period of high numbers of infectious animals runs from February to July. Our results indicate that removal of animals by trapping rather than reducing the suitability of the environment for rodents will have the greater impact on reducing human cases of leptospirosis. (c) 2006 Elsevier B.V. All rights reserved.	Univ Greenwich, Nat Resources Inst, Chatham ME4 4TB, Kent, England; Univ Antwerp, Dept Biol, Evolutionary Biol Grp, B-2020 Antwerp, Belgium; Danish Inst Agr Sci, Dept Integrated Pest Management, Danish Pest Infestat Lab, DK-2800 Lyngby, Denmark	Holt, J (reprint author), Univ Greenwich, Nat Resources Inst, Cent Ave, Chatham ME4 4TB, Kent, England.	j.holt@gre.ac.uk	Leirs, Herwig/B-8197-2008	Leirs, Herwig/0000-0002-7612-5024			Barlow N. D., 1995, P230, DOI 10.1017/CBO9780511629396.009; Begon M, 2002, EPIDEMIOL INFECT, V129, P147, DOI 10.1017/S0950268802007148; Caley P, 2001, J APPL ECOL, V38, P1362, DOI 10.1046/j.0021-8901.2001.00676.x; Chanteau S, 2000, MICROBES INFECT, V2, P25, DOI 10.1016/S1286-4579(00)00289-6; Dalu JM, 1997, BELG J ZOOL, V127, P105; Davis S, 2005, VECTOR-BORNE ZOONOT, V5, P305, DOI 10.1089/vbz.2005.5.305; DEKROON H, 1986, ECOLOGY, V67, P1427, DOI 10.2307/1938700; Fiedler L.A., 1988, P35; Heesterbeek J. A. P., 1995, P90, DOI 10.1017/CBO9780511629396.004; LEIRS H, 1990, AFR J ECOL, V28, P298, DOI 10.1111/j.1365-2028.1990.tb01164.x; Leirs H, 1996, J APPL ECOL, V33, P937, DOI 10.2307/2404675; Leirs H, 1997, NATURE, V389, P176; LEIRS H, 1993, OIKOS, V68, P53, DOI 10.2307/3545308; Machangu RS, 1997, BELG J ZOOL, V127, P97; Meites E, 2004, EMERG INFECT DIS, V10, P406, DOI 10.3201/eid1003.030431; Murray CJL, 2003, HUM LEPT GUID DIAGN, P109; ROBERTS MG, 1995, VET PARASITOL, V56, P67, DOI 10.1016/0304-4017(94)00655-V; Sauvage F, 2003, J ANIM ECOL, V72, P1, DOI 10.1046/j.1365-2656.2003.00675.x; Swinton J., 2002, P83; Ward MP, 2002, PREV VET MED, V56, P203, DOI 10.1016/S0167-5877(02)00183-6	20	31	33	3	16	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0001-706X			ACTA TROP	Acta Trop.	OCT	2006	99	2-3					218	225		10.1016/j.actatropica.2006.08.003				8	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	122GH	WOS:000243213200013	16996018				2019-03-26	
J	Van de Vijver, KK; Colpaert, CG; Jacobs, W; Kuypers, K; Hokke, CH; Deelder, AM; Van Marck, EA				de Vijver, Koen K. Van; Colpaert, Cecile G.; Jacobs, Werner; Kuypers, Kristel; Hokke, Cornelis H.; Deelder, Andre M.; Van Marck, Eric A.			The host's genetic background determines the extent of angiogenesis induced by schistosome egg antigens	ACTA TROPICA			English	Article						schistosomiasis; soluble egg antigens; angiogenesis; granuloma; fibrosis; inbred mice	HEPATIC GRANULOMA-FORMATION; ENDOTHELIAL GROWTH-FACTOR; MURINE SCHISTOSOMIASIS; EXTRACELLULAR-MATRIX; MANSONI INFECTION; TH1 POLARIZATION; IN-VIVO; FIBROSIS; INFLAMMATION; CELLS	Schistosomiasis is characterised by periovular granuloma, formation within the portal tract and presinusoidal venules. As inflammation wanes, continued attempts to wall off and repair hepatic injury, lead to the development of extensive fibrosis. The codependence of chronic inflammation and angiogenesis is a well-known phenomenon. Neovascularisation is a complex process of endothelial cell proliferation and remodelling of the extracellular matrix. Previous studies demonstrated the ability of schistosome soluble egg antigens (SEAs) to stimulate endothelial cell activation in vitro. In the present study, we investigated the angiogenic potential of SEA in Swiss and BALb/c mice, after infection with Schistosoma mansoni or S. haematobium and by implanting SEA-coated beads into the murine liver. Anti-CD34 and anti-Ki-67 immunohistochemical stainings demonstrated newly formed blood vessels within and at the periphery of the granulomas. However, in one third of the granulomas the pre-existing portal stroma was not destroyed by the granulomatous inflammation, angiogenesis was minimal or absent and further growth of the granuloma was prevented. In C57BL/6J and C3H/HeN inbred mice, this polarisation was even more pronounced. In 91% of the granulomas in C57BL6/J mice the portal stroma was preserved. These mice had significantly smaller granulomas, less fibrosis and less mortality as compared to the high pathology C3H/HeN mice, where 87% of the granulomas were of the angiogenic type with destruction of the pre-existing stroma, leading to more severe chronic pathology. Thus, host's genetic mechanisms regulating the degree of angiogenesis and fibrosis, determine the severity of schistosome-induced pathology. (c) 2006 Elsevier B.V. All rights reserved.	Univ Antwerp, Dept Pathol, B-2610 Antwerp, Belgium; Leiden Univ, Med Ctr, Dept Parasitol, Ctr Infect Dis, NL-2300 RC Leiden, Netherlands	Van Marck, EA (reprint author), Univ Antwerp, Dept Pathol, Univ Pl 1, B-2610 Antwerp, Belgium.	eric.van.marck@uza.be	Jacobs, Werner/B-5723-2017	Jacobs, Werner/0000-0002-2001-6507			Baptista AP, 2005, MEM I OSWALDO CRUZ, V100, P183, DOI 10.1590/S0074-02762005000200012; BERGMAN I, 1963, ANAL CHEM, V35, P1961, DOI 10.1021/ac60205a053; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; CHEEVER AW, 1987, AM J TROP MED HYG, V37, P85, DOI 10.4269/ajtmh.1987.37.85; Cummings RD, 1999, BBA-MOL BASIS DIS, V1455, P363, DOI 10.1016/S0925-4439(99)00063-0; de Vijver KKV, 2004, INT J PARASITOL, V34, P951, DOI 10.1016/j.ijpara.2004.04.009; Deelder A M, 1983, Contrib Microbiol Immunol, V7, P3; Dessein AJ, 1999, AM J HUM GENET, V65, P709, DOI 10.1086/302526; El-Awady MK, 2001, WORLD J UROL, V19, P263, DOI 10.1007/s003450100217; ELMENEZA S, 1989, HEPATOLOGY, V9, P50; FREEDMAN DO, 1988, J INFECT DIS, V158, P556, DOI 10.1093/infdis/158.3.556; GRIMAUD J-A, 1987, Memorias do Instituto Oswaldo Cruz, V82, P55; Hokke CH, 2005, PARASITE IMMUNOL, V27, P257, DOI 10.1111/j.1365-3024.2005.00781.x; Hokke CH, 2001, GLYCOCONJUGATE J, V18, P573, DOI 10.1023/A:1020634602161; Jackson JR, 1997, FASEB J, V11, P457; Jacobs W, 1998, PARASITE, V5, P299, DOI 10.1051/parasite/1998054299; Jacobs W, 1998, CELL TISSUE RES, V292, P101, DOI 10.1007/s004410051039; Jacobs W, 1997, AM J PATHOL, V150, P2033; Kanse SM, 2005, MOL BIOCHEM PARASIT, V144, P76, DOI 10.1016/j.molbiopara.2005.08.001; LENZI HL, 1988, BRAZ J MED BIOL RES, V21, P999; Libby P, 2001, CIRC RES, V89, P195, DOI 10.1161/res.89.3.195; Loeffler DA, 2002, J INFECT DIS, V185, P1650, DOI 10.1086/340416; Mor F, 2004, J IMMUNOL, V172, P4618, DOI 10.4049/jimmunol.172.7.4618; Pearce EJ, 2002, NAT REV IMMUNOL, V2, P499, DOI 10.1038/nri843; Pusztaszeri MP, 2006, J HISTOCHEM CYTOCHEM, V54, P385, DOI 10.1369/jhc.4A6514.2005; Rodrigues V, 1999, INFECT IMMUN, V67, P4689; Rutitzky LI, 2005, J IMMUNOL, V174, P435, DOI 10.4049/jimmunol.174.1.435; Silva LM, 2006, ACTA TROP, V98, P34, DOI 10.1016/j.actatropica.2006.01.011; Silvestre JS, 2001, CIRC RES, V89, P259, DOI 10.1161/hh1501.094269; Smithers S.R., 1976, Advances Parasit, V14, P399, DOI 10.1016/S0065-308X(08)60518-7; Stadecker MJ, 1999, MICROBES INFECT, V1, P505, DOI 10.1016/S1286-4579(99)80089-6; Stadecker MJ, 2004, IMMUNOL REV, V201, P168, DOI 10.1111/j.0105-2896.2004.00197.x; Stavitsky AB, 2004, INFECT IMMUN, V72, P1, DOI 10.1128/IAI.72.1.1-12.2004; Szekanecz Zoltan, 2005, Current Drug Targets - Inflammation and Allergy, V4, P319, DOI 10.2174/1568010054022187; Theuerkauf I, 2001, VIRCHOWS ARCH, V438, P498, DOI 10.1007/s004280000364; Van de Vijver KK, 2006, GLYCOBIOLOGY, V16, P237, DOI 10.1093/glycob/cwj058; VANMARCK EAE, 1980, EXPERIENTIA, V36, P1116; Vermeulen PB, 2002, EUR J CANCER, V38, P1564, DOI 10.1016/S0959-8049(02)00094-1; WEISS JB, 1987, EXP PARASITOL, V64, P228, DOI 10.1016/0014-4894(87)90147-0; WYLER DJ, 1987, J INFECT DIS, V155, P728, DOI 10.1093/infdis/155.4.728	40	11	11	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0001-706X	1873-6254		ACTA TROP	Acta Trop.	OCT	2006	99	2-3					243	251		10.1016/j.actatropica.2006.08.011				9	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	122GH	WOS:000243213200016	17007805				2019-03-26	
J	Sagara, I; Dicko, A; Djimde, A; Guindo, O; Kone, M; Tolo, Y; Thera, MA; Sogoba, M; Fofana, M; Ouattara, A; Sissoko, M; Jansen, HF; Doumbo, OK				Sagara, Issaka; Dicko, Alassane; Djimde, Abdoulaye; Guindo, Ousmane; Kone, Mamady; Tolo, Youssouf; Thera, Mahamadou A.; Sogoba, Moussa; Fofana, Moussa; Ouattara, Amed; Sissoko, Mady; Jansen, Herwig F.; Doumbo, Ogobara K.			A randomized trial of artesunate-sulfamethoxypyrazine-pyrimethamine versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Mali	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							CGP 56697 ARTEMETHER; AFRICAN CHILDREN; DOUBLE-BLIND; EFFICACY; BENFLUMETOL; ANTIMALARIAL; CHLOROQUINE; POPULATION; MEFLOQUINE; THAILAND	The choice of artemisinin-based combination that is being adopted for malaria treatment in sub-Saharan Africa may depend on several factors, including cost, efficacy, side effects, and simplicity of administration. We tested the hypothesis that artesunate-sulfamethoxypyrazine-pyrimethamine is as efficacious as the four-dose regimen of artemether-lumefantrine for treatment of Plasmodium fulciparum malaria. The study was carried out during two transmission seasons (2003 and 2004) in Sotuba, Mali. Participants at least 6 months of age with uncomplicated P. falciparum malaria were randomly assigned to receive artesunate-sulfamethoxypyrazine-pyrimethamine or artemether-lumefantrine. Treatment efficacy was assessed using the World Health Organization 28-day protocol. A total of 606 (303 in each arm) patients were enrolled. The cure rate was higher for artesunate-sulfamethoxypyrazine-pyrimethamine than for artemether-lumefantrine (98.7% versus 89.6%; P < 0.0001). After correction for cases of re-infection, the cure rates were 100% and 99.0%, respectively (P = 0.08). No serious adverse events occurred. Artesunate-sulfamethoxypyrazine-pyrimethamine is well-tolerated and effective against P. falciparum malaria. It showed an additional benefit of preventing new infections.	Univ Bamako, Malaria Res & Training Ctr, Dept Epidemiol & Parasit Dis, Fac Med Pharm & Odonto Stomatol, Bamako, Mali; Dafra Pharma, Turnhout, Belgium	Doumbo, OK (reprint author), Univ Bamako, Malaria Res & Training Ctr, Dept Epidemiol & Parasit Dis, Fac Med Pharm & Odonto Stomatol, POB 1805,Point G, Bamako, Mali.	isagara@mrtcbko.org; adicko@mrtcbko.org; adjimde@mrtcbko.org; guindoous@mrtcbko.org; tolo@mrtcbko.org; mthera@mrtcbko.org; msogoba@mrtcbko.org; moussaf@mrtcbko.org; amed@mrtcbko.org; mady@mrtcbko.org; fhj@dafra.be; okd@mrtcbko.org		Thera, Mahamadou A/0000-0002-2679-035X			Adjuik M, 2002, LANCET, V359, P1365, DOI 10.1016/S0140-6736(02)08348-4; [Anonymous], 2001, WHOCDSRBM200135; [Anonymous], 2001, WHOCDSRBM200133; BORRE MB, 1991, MOL BIOCHEM PARASIT, V49, P119, DOI 10.1016/0166-6851(91)90135-S; Brockman A, 2000, T ROY SOC TROP MED H, V94, P537, DOI 10.1016/S0035-9203(00)90080-4; DEVRIEND.A, 1970, EUR J CLIN PHARMACOL, V3, P36, DOI 10.1007/BF00560289; Djimde A, 2001, NEW ENGL J MED, V344, P257, DOI 10.1056/NEJM200101253440403; DONNO L, 1974, B WORLD HEALTH ORGAN, V50, P223; Dua VK, 1998, J CHROMATOGR B, V714, P390, DOI 10.1016/S0378-4347(98)00222-9; Ezzet F, 1998, BRIT J CLIN PHARMACO, V46, P553, DOI 10.1046/j.1365-2125.1998.00830.x; Falade C, 2005, T ROY SOC TROP MED H, V99, P459, DOI 10.1016/j.trstmh.2004.09.013; HAGOS B, 1993, E AFR MED J, V70, P620; Hatz C, 1998, TROP MED INT HEALTH, V3, P498, DOI 10.1046/j.1365-3156.1998.00250.x; Lefevre G, 2001, AM J TROP MED HYG, V64, P247, DOI 10.4269/ajtmh.2001.64.247; Looareesuwan S, 1999, AM J TROP MED HYG, V60, P238, DOI 10.4269/ajtmh.1999.60.238; Omari AA, 2004, TROP MED INT HEALTH, V9, P192, DOI 10.1046/j.1365-3156.2003.01186.x; PETERSON MG, 1988, MOL CELL BIOL, V8, P2664, DOI 10.1128/MCB.8.6.2664; Picq J.J., 1975, Bulletin Soc Path Exot, V68, P61; Picq J.-J., 1972, Medecine trop, V32, P527; Ranford-Cartwright LC, 1997, T ROY SOC TROP MED H, V91, P719, DOI 10.1016/S0035-9203(97)90539-3; STOREY J, 1973, B WORLD HEALTH ORGAN, V49, P275; TANABE K, 1987, J MOL BIOL, V195, P273, DOI 10.1016/0022-2836(87)90649-8; Triglia T, 1997, P NATL ACAD SCI USA, V94, P13944, DOI 10.1073/pnas.94.25.13944; van Agtmael M, 1999, INT J ANTIMICROB AG, V12, P159, DOI 10.1016/S0924-8579(99)00070-9; van Vugt M, 1998, ANTIMICROB AGENTS CH, V42, P135, DOI 10.1128/AAC.42.1.135; van Vugt M, 1999, AM J TROP MED HYG, V60, P936, DOI 10.4269/ajtmh.1999.60.936; von Seidlein L, 2000, LANCET, V355, P2080; Von Seidlein L, 1998, AM J TROP MED HYG, V58, P638; von Seidlein L, 2000, LANCET, V355, P352, DOI 10.1016/S0140-6736(99)10237-X; White NJ, 1999, CLIN PHARMACOKINET, V37, P105, DOI 10.2165/00003088-199937020-00002; *WHO, 2003, WHOHTMRBM200350; [World Health Organization Severe falciparum malaria], 2000, T R SOC TROP MED S1, V94, pS1, DOI DOI 10.1016/S0035-9203(00)90300-6	32	28	28	0	1	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637	1476-1645		AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	OCT	2006	75	4					630	636		10.4269/ajtmh.2006.75.630				7	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	094BM	WOS:000241214100009	17038684				2019-03-26	
J	Nackers, F; Dramaix, M; Johnson, RC; Zinsou, C; Robert, A; Bakedano, ED; Glynn, JR; Portaels, F; Tonglet, R				Nackers, Fabienne; Dramaix, Michele; Johnson, Roch Christian; Zinsou, Claude; Robert, Annie; Bakedano, Elisa de Biurrun; Glynn, Judith R.; Portaels, Francoise; Tonglet, Rene			BCG vaccine effectiveness against Buruli ulcer: A case-control study in Benin	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							SOUTHERN BENIN; DISEASE; EFFICACY; GHANA; TUBERCULOSIS; OSTEOMYELITIS; SENSITIVITY; INFECTION; CHILDREN; MALAWI	BCG remains the only possible prophylactic intervention against Buruli ulcer (BU). Estimating its public health impact on BU control is an important issue. We conducted a case-control study to investigate the vaccine effectiveness of routine BCG vaccine against BU in southern Benin. From August 2002 to August 2003, BCG vaccination status was obtained for 279 clinically diagnosed BU cases and 988 age- and sex-matched neighborhood controls. BCG coverage, which was estimated by the presence of a scar or a vaccination record, was 64.5% in cases and 67.2% in controls. There was no evidence of a protective effect of routine BCG vaccination against BU in southern Benin (vaccine effectiveness adjusted for socioeconomic status = 12%, 95% confidence interval = -24% to 37%).	Univ Catholique Louvain, Ecole Sante Publ, Unite Epidemiol, B-1200 Brussels, Belgium; Univ Catholique Louvain, Lab Stat Med, B-1200 Brussels, Belgium; Programme Natl Lutte Contre Ulcere Buruli, Cotonou, Benin; Ctr Depistage & Traitement Ulcere Buruli, Lalo, Benin; Ctr Sanit & Nutr Gbemoten, Zagnanado, Benin; Univ London London Sch Hyg & Trop Med, Infect Dis Epidemiol Unit, London WC1E 7HT, England; Inst Trop Med, Dept Microbiol, B-2000 Antwerp, Belgium	Nackers, F (reprint author), Univ Catholique Louvain, Ecole Sante Publ, Unite Epidemiol, Clos Chapelle Champs 30,EPID3058,1200 Woluwe St L, B-1200 Brussels, Belgium.	Fabienne.Nackers@epid.ucl.ac.be; miwilmet@ulb.ac.be; rochjohnson@yahoo.fr; Annie.Robert@epid.ucl.ac.be; ebiurrun@isciii.es; Judith.Glynn@lshtm.ac.uk; portaels@itg.be					Amofah G, 2002, EMERG INFECT DIS, V8, P167, DOI 10.3201/eid0802.010119; AMOFAH GK, 1993, T ROY SOC TROP MED H, V87, P644, DOI 10.1016/0035-9203(93)90272-R; Asiedu K, 1998, AM J TROP MED HYG, V59, P1015, DOI 10.4269/ajtmh.1998.59.1015; Aujoulat I, 2003, TROP MED INT HEALTH, V8, P750, DOI 10.1046/j.1365-3156.2003.01089.x; COMSTOCK GW, 1994, EPIDEMIOL REV, V16, P77, DOI 10.1093/oxfordjournals.epirev.a036147; Debacker M, 2004, EMERG INFECT DIS, V10, P1391, DOI 10.3201/eid1008.030886; DEBACKER M, 2006, EMERG INFECT DIS; Fine PEM, 1996, LANCET, V348, P17; Floyd S, 2000, INT J TUBERC LUNG D, V4, P1133; *INSAE, 2002, ENQ DEM SANT BEN 200; Johnson RC, 2005, EMERG INFECT DIS, V11, P500, DOI 10.3201/eid1103.040597; MANCHIN DCM, 1997, SAMPLE SIZE TABLES C; MARSTON BJ, 1995, AM J TROP MED HYG, V52, P219, DOI 10.4269/ajtmh.1995.52.219; Pereira SM, 2001, INT J TUBERC LUNG D, V5, P1067; Portaels F., 2003, Bulletin des Seances, Academie Royale des Sciences d'Outre- Mer, V49, P161; Portaels F, 2004, INFECT IMMUN, V72, P62, DOI 10.1128/IAI.72.1.62-65.2004; Portaels F, 2002, CLIN DIAGN LAB IMMUN, V9, P1389, DOI 10.1128/CDLI.9.6.1389-1391.2002; Portaels F, 2001, BURULI ULCER DIAGNOS; Raghunathan PL, 2005, CLIN INFECT DIS, V40, P1445, DOI 10.1086/429623; Rodrigues LC, 2005, LANCET, V366, P1290, DOI 10.1016/S0140-6736(05)67145-0; Rodrigues LC, 1999, EPIDEMIOL REV, V21, P56, DOI 10.1093/oxfordjournals.epirev.a017988; SMITH PG, 1982, TUBERCLE, V63, P23, DOI 10.1016/S0041-3879(82)80006-8; SMITH PG, 1988, BRIT MED BULL, V44, P679, DOI 10.1093/oxfordjournals.bmb.a072276; SMITH PG, 1977, T R SOC TROP MED HYG, V70, P449; Sterne JAC, 1998, INT J TUBERC LUNG D, V2, P200; Stoffel V, 2005, Sante Publique, V17, P191; *UNAIDS WHO, 2004, UNAIDS WHO EP FACT S; van der Werf TS, 1999, LANCET, V354, P1013, DOI 10.1016/S0140-6736(99)01156-3; *WHO, 2006, YAM DECL BUR ULC; 1969, LANCET, V1, P111; 2004, WKLY EPIDEMIOL REC, V79, P194	31	33	33	0	2	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637	1476-1645		AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	OCT	2006	75	4					768	774		10.4269/ajtmh.2006.75.768				7	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	094BM	WOS:000241214100034	17038709	Green Published			2019-03-26	
J	Bermudez, H; Rojas, E; Garcia, L; Desjeux, P; Dujardin, JC; Boelaert, M; Chappuis, F				Bermudez, H.; Rojas, E.; Garcia, L.; Desjeux, P.; Dujardin, J. -C.; Boelaert, M.; Chappuis, F.			Generic sodium stibogluconate is as safe and effective as branded meglumine antimoniate, for the treatment of tegumentary leishmaniasis in Isiboro Secure Park, Bolivia	ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY			English	Article							COLOMBIAN CUTANEOUS LEISHMANIASIS; VISCERAL LEISHMANIASIS; MUCOSAL LEISHMANIASIS; NEW-WORLD; PENTAVALENT ANTIMONY; CLINICAL-TRIAL; EFFICACY; PENTOSTAM; CARDIOTOXICITY; ALLOPURINOL	Human cutaneous leishmaniasis (CL) and mucous leishmaniasis (ML) are highly endemic in Isiboro Secure Park, which lies in the Bolivian department of Cochabamba-an area where branded meglumine antimoniate (Glucantim (R)) is expensive and poorly distributed. The safety and efficacy of generic sodium stibogluconate (SSG), from Albert David Ltd, was therefore explored, in CL and ML cases from the park, who were treated with 20 mg/kg.day for 20 and 30 days, respectively. A questionnaire recording adverse effects was completed by a physician in each treatment centre. Efficacy of treatment was assessed at the end of treatment and at follow-ups 1 month and 3, 6 and 12 months later. Overall, 146 patients completed treatment with SSG in 2003-2004. No fatalities or severe adverse effects were reported but mild to moderate adverse effects were noted in 41 (28%) of the patients. The incidence of adverse effects was significantly higher among the cases of ML than among the cases of CL. Of the 86 patients with CL who completed 6 months of follow-up, 81 (94.2%) were considered to have been clinically cured; a comparable cohort of 69 CL cases who had been treated with Glucantime in 2001-2002 showed a similar frequency of clinical cure (90%). Generic SSG was shown to be safe and efficacious for the treatment of tegumentary leishmaniasis in Bolivia. Being several times cheaper than Glucantime, it could contribute to improving the access of CL and ML patients to treatment, not only in Bolivia but also in other countries of Latin America.	Univ Hosp Geneva, Travel & Migrat Med Unit, CH-1211 Geneva 14, Switzerland; Inst Trop Med Prince Leopold, Dept Publ Hlth, B-2000 Antwerp, Belgium; Inst Trop Med Prince Leopold, Dept Parasitol, B-2000 Antwerp, Belgium; WHO, CH-1211 Geneva 27, Switzerland; Univ Mayor San Simon, Fac Med, Cochabamba, Bolivia	Chappuis, F (reprint author), Univ Hosp Geneva, Travel & Migrat Med Unit, Rue Micheli Du Crest 24, CH-1211 Geneva 14, Switzerland.	francois.chappuis@hcuge.ch	Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776			Andersen EM, 2005, AM J TROP MED HYG, V72, P133, DOI 10.4269/ajtmh.2005.72.133; Aronson NE, 1998, CLIN INFECT DIS, V27, P1457, DOI 10.1086/515027; BALLOU WR, 1987, LANCET, V2, P13; Berman JD, 1997, CLIN INFECT DIS, V24, P684, DOI 10.1093/clind/24.4.684; Deps P D, 2000, Rev Soc Bras Med Trop, V33, P535, DOI 10.1590/S0037-86822000000600004; DESJEUX P, 1987, T ROY SOC TROP MED H, V81, P742, DOI 10.1016/0035-9203(87)90014-9; FRANKE ED, 1994, AM J TROP MED HYG, V51, P77, DOI 10.4269/ajtmh.1994.51.77; FRANKE ED, 1990, ANN INTERN MED, V113, P934, DOI 10.7326/0003-4819-113-12-934; Garcia L, 2004, J CLIN MICROBIOL, V42, P2294, DOI 10.1128/JCM.42.5.2294-2297.2004; GRIMALDI G, 1989, AM J TROP MED HYG, V41, P687, DOI 10.4269/ajtmh.1989.41.687; GUDERIAN RH, 1991, AM J TROP MED HYG, V45, P92, DOI 10.4269/ajtmh.1991.45.92; HEPBURN NC, 1994, T ROY SOC TROP MED H, V88, P700, DOI 10.1016/0035-9203(94)90237-2; HERWALDT BL, 1992, AM J TROP MED HYG, V46, P296, DOI 10.4269/ajtmh.1992.46.296; Herwaldt BL, 1999, LANCET, V354, P1191, DOI 10.1016/S0140-6736(98)10178-2; LlanosCuentas A, 1997, CLIN INFECT DIS, V25, P677, DOI 10.1086/513776; Martinez E, 1998, ACTA TROP, V71, P97, DOI 10.1016/S0001-706X(98)00049-7; Martinez E, 2001, T ROY SOC TROP MED H, V95, P375, DOI 10.1016/S0035-9203(01)90185-3; Moore E, 2001, B WORLD HEALTH ORGAN, V79, P388; NAVIN TR, 1992, J INFECT DIS, V165, P528, DOI 10.1093/infdis/165.3.528; NETTO EM, 1990, T ROY SOC TROP MED H, V84, P367, DOI 10.1016/0035-9203(90)90321-5; Oliveira GB, 2000, CYTOMETRY, V42, P321; Palacios R, 2001, AM J TROP MED HYG, V64, P187, DOI 10.4269/ajtmh.2001.64.187; Rijal S, 2003, T ROY SOC TROP MED H, V97, P597, DOI 10.1016/S0035-9203(03)80043-3; Ritmeijer K, 2001, T ROY SOC TROP MED H, V95, P668, DOI 10.1016/S0035-9203(01)90110-5; Romero GAS, 2001, AM J TROP MED HYG, V65, P456, DOI 10.4269/ajtmh.2001.65.456; SAENZ RE, 1991, AM J TROP MED HYG, V44, P394, DOI 10.4269/ajtmh.1991.44.394; SAMPAIO S A P, 1971, International Journal of Dermatology, V10, P179; Soto J, 2004, CLIN INFECT DIS, V38, P1266, DOI 10.1086/383321; Soto J, 2005, AM J TROP MED HYG, V72, P421, DOI 10.4269/ajtmh.2005.72.421; Soto J, 2004, AM J TROP MED HYG, V71, P577, DOI 10.4269/ajtmh.2004.71.577; Sundar S, 1998, AM J TROP MED HYG, V59, P139, DOI 10.4269/ajtmh.1998.59.139; Veeken H, 2000, TROP MED INT HEALTH, V5, P312, DOI 10.1046/j.1365-3156.2000.00555.x; Velez I, 1997, ANN INTERN MED, V126, P232, DOI 10.7326/0003-4819-126-3-199702010-00010	33	25	27	0	0	MANEY PUBLISHING	LEEDS	STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND	0003-4983			ANN TROP MED PARASIT	Ann. Trop. Med. Parasitol.	OCT	2006	100	7					591	600		10.1179/136485906X118495				10	Public, Environmental & Occupational Health; Parasitology; Tropical Medicine	Public, Environmental & Occupational Health; Parasitology; Tropical Medicine	091UK	WOS:000241053600005	16989685				2019-03-26	
J	Fryland, M; Chaillet, P; Zachariah, R; Barnaba, A; Bonte, L; Andereassen, R; Charrondiere, S; Teck, R; Didakus, O				Fryland, M.; Chaillet, P.; Zachariah, R.; Barnaba, A.; Bonte, L.; Andereassen, R.; Charrondiere, S.; Teck, R.; Didakus, O.			The Partec CyFlow Counter (R) could provide an option for CD4+T-cell monitoring in the context of scaling-up antiretroviral treatment at the district level in Malawi	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						HIV; CD4; antiretroviral therapy; ART; CyFlow Counter (R); Malawi	FLOW-CYTOMETRY; HIV-INFECTION; T-LYMPHOCYTES; CD4(+); ENUMERATION; FACSCOUNT; COUNTS; BLOOD; IMPLEMENTATION; SETTINGS	A study was conducted in rural Malawi to verify (a) whether the Partec CyFtow Counter((R)) for CD4+ T-cell lymphocyte counting in HIV-positive individuals could be introduced into a district hospital. laboratory and (b) whether it would produce CD4 counts of acceptable quality. CD4+ cell, counting was performed using the Partec CyFtow Counter and the results were compared with a reference method (FACsCount). A total of 311 blood samples were analysed and the correlation coefficient for the CyFlow Counter was 0.92 (95% CI 0.89-0.95). Mean CD4 counts using the Partec and the reference methods were 308.2cells/mu l and 316.9cells/mu l, respectively. The mean difference in CD4 count values was -8.68cells/mu l (95% CI -18.8 to 1.4). Mean intra-run variation was -6.84cells/mu l (95% CI -12.9 to 0.79). In the district laboratory setting, the instrument could accommodate up to 75 blood samples per technician per day. After being trained, local laboratory staff found the CyFlow Counter procedures simple to run and the instrument easy to manipulate. The Partec CyFtow Counter produces sufficiently reliable results and the instrument appears robust under field conditions. It could provide a new option for introducing routine CD4+ cell monitoring at the district level. in the context of scaling-up antiretroviral. therapy in Malawi. (c) 2006 Royal. Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.	Medecins Frontieres, Dept Med, Brussels Operat Ctr, Brussels, Belgium; Medecins Frontieres, Dept Med, Brussels Operat Ctr, HIV TB, Brussels, Belgium; Minist Hlth & Populat, Reference Lab Unit, Lilongwe, Malawi; Med Frontieres France, Dept Med, Paris, France	Zachariah, R (reprint author), Brussels Operat Ctr, HIV TB, Dept Med, Medecins Frontieres, 68 Rue Gasperich, L-1617 Luxembourg, Luxembourg.	zachariah@internet.lu					BLAND JM, 1986, LANCET, V1, P307; Cassens U, 2004, ANTIVIR THER, V9, P395; *CDC, 1997, MMWR-MORBID MORTAL W, V46, P1; Diagbouga S, 2003, AIDS, V17, P2201, DOI 10.1097/01.aids.0000088198.77946.5e; Didier JM, 2001, J ACQ IMMUN DEF SYND, V26, P193, DOI 10.1097/00126334-200102010-00017; Dieye TN, 2005, JAIDS-J ACQ IMM DEF, V39, P32, DOI 10.1097/01.qai.0000160515.20581.ad; Greve B, 2003, TRANSFUS MED HEMOTH, V30, P8, DOI 10.1159/000069339; Janossy G, 2000, BRIT J HAEMATOL, V111, P1198, DOI 10.1046/j.1365-2141.2000.02433.x; Kober K, 2004, LANCET, V364, P103, DOI 10.1016/S0140-6736(04)16597-5; LANDAY A, 1990, AIDS, V4, P479, DOI 10.1097/00002030-199006000-00001; Lopez A, 1999, CYTOMETRY, V38, P231, DOI 10.1002/(SICI)1097-0320(19991015)38:5<231::AID-CYTO5>3.0.CO;2-Y; Lyamuya EF, 1996, J IMMUNOL METHODS, V195, P103, DOI 10.1016/0022-1759(96)00094-4; Mandy F, 2002, CYTOMETRY, V50, P39, DOI 10.1002/cyto.10097; *MOHP, 2003, STAT HUM CAP DEV EFF; *MOHP, 2003, NAT EST HIV AIDS MAL; *MOHP, 2003, GUID US ANT RETR THE; *MOHP, 2003, TREATM AIDS 2 YEAR P; Mwaba P, 2003, LANCET, V362, P1459, DOI 10.1016/S0140-6736(03)14693-4; Saravolatz L, 1996, CLIN INFECT DIS, V22, P513, DOI 10.1093/clinids/22.3.513; Sherman GG, 1999, J IMMUNOL METHODS, V222, P209, DOI 10.1016/S0022-1759(98)00172-0; *WHO, 2003, QV2685 WHO; World Health Organisation, 2004, RAP HIV TESTS GUID U; Young NL, 1997, CLIN DIAGN LAB IMMUN, V4, P783	23	22	23	0	2	ROYAL SOC TROPICAL MEDICINE	LONDON	MANSON HOUSE 26 PORTLAND PLACE, LONDON W1N 1EY, ENGLAND	0035-9203			T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	OCT	2006	100	10					980	985		10.1016/j.trstmh.2005.11.014				6	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	079LN	WOS:000240177900012	16542690				2019-03-26	
J	De Vos, P; De Ceukelaire, W; Van der Stuyft, P				De Vos, Pol; De Ceukelaire, Wim; Van der Stuyft, Patrick			Colombia and Cuba, contrasting models in Latin America's health sector reform	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						Latin America; Cuba; Colombia; health sector reform; privatization; national health system	MANAGED CARE; UNITED-STATES; TRANSFORMATION; SYSTEM; POLICY; COSTS	Latin American national health systems were drastically overhauled by the health sector reforms the 1990s. Governments were urged by donors and by the international financial institutions to make major institutional changes, including the separation of purchaser and provider functions and privatization. This article first analyses a striking paradox of the far-reaching reform measures: contrary to what is imposed on public health services, after privatization purchaser and provider functions are reunited. Then we compare two contrasting examples: Colombia, which is internationally promoted as a successful - and radical - example of 'market-oriented' health care reform, and Cuba, which followed a highly 'conservative' path to adapt its public system to the new conditions since the 1990s, going against the model of the international institutions. The Colombian reform has not been able to materialize its promises of universality, improved equity, efficiency and better quality, while Cuban health care remains free, accessible for everybody and of good quality. Finally, we argue that the basic premises of the ongoing health sector reforms in Latin America are not based on the people's needs, but are strongly influenced by the needs of foreign - especially North American - corporations. However, an alternative model of health sector reform, such as the Cuban one, can probably not be pursued without fundamental changes in the economic and political foundations of Latin American societies.	Inst Trop Med, Dept Publ Hlth, Epidemiol Unit, B-2000 Antwerp, Belgium; INTAL, Dept Hlth, Brussels, Belgium	De Vos, P (reprint author), Inst Trop Med, Dept Publ Hlth, Epidemiol Unit, Natl Str 155, B-2000 Antwerp, Belgium.	pdevos@itg.be	De Vos, Pol/D-3370-2009				Armada F, 2001, INT J HEALTH SERV, V31, P729, DOI 10.2190/70BE-TJ0Q-P7WJ-2ELU; Baker D., 2002, ROLE SOCIAL SECURITY; Bossert T, 1998, HEALTH POLICY PLANN, V13, P59, DOI 10.1093/heapol/13.1.59; BRAVEMAN P, 1987, INT J HEALTH SERV, V17, P169, DOI 10.2190/DB43-MWPL-2V12-WGXY; Brenner R., 2002, BOOM BUBBLE US WORLD; Cerna C. A., 2002, Cadernos de Saude Publica, V18, P1771, DOI 10.1590/S0102-311X2002000600032; CROCCO P, 2000, REV PANAM SALUD PUBL, V8, P126; De Vos P, 2005, INT J HEALTH SERV, V35, P189, DOI 10.2190/M72R-DBKD-2XWV-HJWB; De Vos P, 2004, INT J HEALTH SERV, V34, P255, DOI 10.2190/PURT-1LY9-F0BG-RRUD; DECARVALHO FJC, 2000, BRAZILIAN J POLITICA, V20, P15; DELGADO G, 1998, REV CUB SALUD PUBLIC, V24, P110; ERIKSON D, 2002, CUBAS SOCIAL SERVICE; ESTRDA A, 1998, ATNECION GERENCIADA; Feinsilver J. M., 1993, HEALING MASSES CUBAN; FRANCOAGULEDO S, 2002, REV SALUD PUBLICA, V3; FRANCOAGULEDO S, 1998, MANIFESTO COMITE GES, V3; FRANCOAGULEDO S, 2003, GERENCIA POLITICAS S, V4, P58; GARFIELD R, 1993, JAMA-J AM MED ASSOC, V270, P989, DOI 10.1001/jama.270.8.989; Garfield Richard, 1992, HLTH CARE NICARAGUA; Geyman JP, 2003, J AM BOARD FAM PRACT, V16, P443, DOI 10.3122/jabfm.16.5.443; Ginzberg E, 1997, NEW ENGL J MED, V336, P1018, DOI 10.1056/NEJM199704033361411; GONZALEZROSSETT.A, 2000, LATIN AM CARIBBEAN H, V39; GRANADOS RT, 2000, REV SALUD PUBLICA, V8, P13; HERNANDEZ M, 2000, SALUD ESTA GRAVE PLA, P133; Hernández Mario, 2002, Cad. Saúde Pública, V18, P991, DOI 10.1590/S0102-311X2002000400007; IGLESIAS GR, 2003, LANCET, V362, P1385; *IMF, 2000, 0084 IMF; INFANTE A, 2000, REV ADM SANITARIA, V4, P29; Iriart C, 2000, Cad Saude Publica, V16, P95, DOI 10.1590/S0102-311X2000000100010; Iriart C, 2001, SOC SCI MED, V52, P1243, DOI 10.1016/S0277-9536(00)00243-4; IRIART C, 1998, ATENCION GERENCIADA; Kroeger Axel, 2002, Malar J, V1, P15, DOI 10.1186/1475-2875-1-15; LEWIS JC, 1996, 8 C ASS LAT AM PREP; LIPSON D, 2001, CMH WORKING PAPER WG, V4, P7; Lopez-Acuna D, 2000, Rev Panam Salud Publica, V8, P147, DOI 10.1590/S1020-49892000000700020; MALAGA H, 2000, REV SALUD PUBLICA, V12; *MIN SAL PUBL, 2002, EST SAL CUB; Mosquera M, 2001, HEALTH POLICY PLANN, V16, P52, DOI 10.1093/heapol/16.suppl_2.52; Navarro V, 2000, LANCET, V356, P1598, DOI 10.1016/S0140-6736(00)03139-1; NAVARRO V, 1989, SOC SCI MED, V28, P887, DOI 10.1016/0277-9536(89)90313-4; NIGENDA G, 2002, HLTH POLICY PLANNING, V15, P312; *PAHO, 1998, HLTH AM, P181; *PAHO, 2001, SIT SAL AM IND BAS 2; *PAHO, 2002, HLTH AM, P198; Shutt H., 1998, TROUBLE CAPITALISM E; Stocker K, 1999, NEW ENGL J MED, V340, P1131, DOI 10.1056/NEJM199904083401425; UNCTAD -United Nations Conference on Trade and Development, 2002, WORLD INV REP; *UNDP, 2000, INF DEARR HUM COL; UNITED NATIONS DEVELOPMENT PROGRAMME UNDP, 2002, HUM DEV REP 2002; Waitzkin H, 2001, INT J HEALTH SERV, V31, P495, DOI 10.2190/BQDD-59K2-3PQD-RE9Q; Woolhandler S, 1999, NEW ENGL J MED, V341, P444, DOI 10.1056/NEJM199908053410611; *WORLD BANK, 2001, WORLD DEV REP 2001; World Bank, 1993, WORLD DEV REP 1993 I; World Bank, 2002, WORLD DEV REP 2001; World Health Organization, 2000, WORLD HLTH REP 2000; World Health Organization (WHO), 2003, WORLD HLTH REP 2003	56	16	18	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2006	11	10					1604	1612		10.1111/j.1365-3156.2006.01702.x				9	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	086NU	WOS:000240681100015	17002735	Bronze			2019-03-26	
J	Rijal, S; Koirala, S; Van der Stuyft, P; Boelaert, M				Rijal, S.; Koirala, S.; Van der Stuyft, P.; Boelaert, M.			The economic burden of visceral leishmaniasis for households in Nepal	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						visceral leishmaniasis; economic burden; poverty; health care; Nepal	KALA-AZAR; DISEASE; INFECTION	Visceral leishmaniasis (VL) affects persons from the lowest socioeconomic strata of the community, but its economic impact is not precisely known. An exploratory survey to document the economic costs of VL to households was conducted in an endemic focus in eastern Nepal. Data were collected from the 20 households in this cluster. Cases of VL over the last 3 years were elicited and information on direct and indirect costs incurred due to the disease as well as income of the households over the last year was estimated. It was reported that 15.0% (16/107) of the residents had suffered from VL and that almost all of the patients had preferred, in the first instance, to visit the private services or local faith heaters instead of visiting the local public health facility. Average total costs incurred per episode of VL were above the median annual per capita income, and six of the seven affected households either had to sell part of their livestock or to take a loan to cover the costs. Direct costs consisted of 53% of the total cost, with 75% of this cost incurred before the patients actually received any treatment for VL. This study demonstrates how VL can lead to catastrophic expenditure for affected households. (C) 2005 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.	BP Koirala Inst Hlth Sci, Dept Med, Dharan, Nepal; Inst Trop Med Prince Leopold, Dept Publ Hlth, Epidemiol Unit, B-2000 Antwerp, Belgium	Rijal, S (reprint author), BP Koirala Inst Hlth Sci, Dept Med, Dharan, Nepal.	sumanrijal2@yahoo.com	Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776			Adhikari SR, 2003, ACTA TROP, V88, P1, DOI 10.1016/S0001-706X(03)00156-6; Ahluwalia IB, 2003, AM J TROP MED HYG, V69, P624, DOI 10.4269/ajtmh.2003.69.624; ALI A, 1994, ANN TROP MED PARASIT, V88, P289, DOI 10.1080/00034983.1994.11812869; Bista MB, 1998, KALA AZAR NEPAL PRIN, P1; Boelaert M, 2004, AM J TROP MED HYG, V70, P72, DOI 10.4269/ajtmh.2004.70.72; Boelaert M, 2000, T ROY SOC TROP MED H, V94, P465, DOI 10.1016/S0035-9203(00)90055-5; Desjeux P, 1996, CLIN DERMATOL, V14, P417, DOI 10.1016/0738-081X(96)00057-0; DESJEUX P, 1991, INFORMATION EPIDEMIO; Hotchkiss DR, 1998, HEALTH POLICY PLANN, V13, P371, DOI 10.1093/heapol/13.4.371; Koirala S, 1998, B WORLD HEALTH ORGAN, V76, P485; Meessen B, 2003, TROP MED INT HEALTH, V8, P581, DOI 10.1046/j.1365-3156.2003.01081.x; Sundar S, 1998, LANCET, V351, P563, DOI 10.1016/S0140-6736(97)04350-X; Thakur CP, 2000, T ROY SOC TROP MED H, V94, P156, DOI 10.1016/S0035-9203(00)90255-4; Trouiller P, 2002, LANCET, V359, P2188, DOI 10.1016/S0140-6736(02)09096-7; *UNDP WORLD BANK W, 1997, TROP DIS RES PROGR 1; Van Damme W, 2004, TROP MED INT HEALTH, V9, P273, DOI 10.1046/j.1365-3156.2003.01194.x; WIJEYARATNE PM, 1994, ACTA TROP, V56, P349, DOI 10.1016/0001-706X(94)90106-6; ZIJLSTRA EE, 1994, AM J TROP MED HYG, V51, P826, DOI 10.4269/ajtmh.1994.51.826	18	43	44	0	4	ROYAL SOC TROPICAL MEDICINE	LONDON	MANSON HOUSE 26 PORTLAND PLACE, LONDON W1N 1EY, ENGLAND	0035-9203			T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	SEP	2006	100	9					838	841		10.1016/j.trstmh.2005.09.017				4	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	072BW	WOS:000239648600007	16406035				2019-03-26	
J	Mulenga, M; Van Geertruyden, JP; Mwananyanda, L; Chalwe, V; Moerman, F; Chilengi, R; Van Overmeir, C; Dujardin, JC; D'Alessandro, U				Mulenga, Modest; Van geertruyden, Jean-Pierre; Mwananyanda, Lawrence; Chalwe, Victor; Moerman, Filip; Chilengi, Roma; Van Overmeir, Chantal; Dujardin, Jean-Claude; D'Alessandro, Umberto			Safety and efficacy of lumefantrine-artemether (Coartem (R)) for the treatment of uncomplicated Plasmodium falciparum malaria in Zambian adults	MALARIA JOURNAL			English	Article							PLUS SULFADOXINE-PYRIMETHAMINE; TANZANIAN CHILDREN; ARTESUNATE; TRIAL; CHLOROQUINE; COMBINATION; AMODIAQUINE; UGANDA; HIV-1; INFECTIONS	Background: In Zambia, unacceptably high resistance to commonly used antimalarial drugs prompted the choice of artemether-lumefantrine (AL) as first line treatment for uncomplicated Plasmodium falciparum malaria. Although the safety and efficacy of AL have been extensively documented, no clinical trials had been carried out in Zambia. Methods: Nine hundred seventy one adult patients with uncomplicated malaria were randomized to either sulfadoxine-pyrimethamine (SP)( 486) or AL ( 485) and followed up for 45 days. Outcome of treatment was defined according to the standard WHO classification. Recurrent parasitaemia were genotyped to distinguish between recrudescence and new infection. Results: Fever at day 3 was significantly lower ( AL: 0.9%; 4/455; SP: 3,5%; 15/433; p = 0.007) and the mean haemoglobin at day 45 significantly higher ( AL: 134 g/l; SP 130 g/l; p = 0.02) in the AL group. Almost all clinical symptoms cleared faster with AL. Early treatment failure was significantly higher in the SP (25/464) than in the AL (2/463) ( OR: 13.1 95% CI: 3.08 - 55.50; P < 0.001). The rate of new infections was similar in both groups ( 18 with SP and 19 with AL). Late clinical failure ( OR: 2.55; 95% CI: 1.34 - 4.84; P = 0.004) and late parasitological failure ( OR: 3.18; 95% CI: 1.25 - 8.09; P = 0.02) were significantly higher in the SP group. Total treatment failure was significantly higher in the SP group (96/393; 19.3%) as compared to the AL (22/403; 5.4%) group ( OR: 4.15; 95% CI: 2.52 6.83; P < 0.001). Conclusion: In Zambia, the new first line regimen AL is far more efficacious than SP in treating uncomplicated P. falciparum malaria in adults. Data on safety and efficacy of AL in pregnant women are urgently needed.	Inst Trop Med, Dept Parasitol, B-2000 Antwerp, Belgium; Inst Trop Med, Clin Dept, B-2000 Antwerp, Belgium; Trop Dis Res Ctr, Dept Clin Sci, Ndola, Zambia	Van Geertruyden, JP (reprint author), Inst Trop Med, Dept Parasitol, Natl Str 155, B-2000 Antwerp, Belgium.	clinsciences@zamtel.zm; jpvangeertruyden@itg.be; lmwananyanda@bhp.org.bw; victorchalwe@yahoo.com; fmoerman@itg.be; chilengi@amanet-trust.org; cvoverm@itg.be; jcdujard@itg.be; UDAlessandro@itg.be	Van geertruyden, Jean-Pierre/K-6425-2014; D'Alessandro, Umberto/D-3457-2015	Van geertruyden, Jean-Pierre/0000-0001-5006-6364; D'Alessandro, Umberto/0000-0001-6341-5009; Mwananyanda, Lawrence/0000-0002-3034-749X			Adjuik M, 2002, LANCET, V359, P1365, DOI 10.1016/S0140-6736(02)08348-4; ATZORI C, 1993, ANN TROP MED PARASIT, V87, P585, DOI 10.1080/00034983.1993.11812814; Bakshi R, 2000, T ROY SOC TROP MED H, V94, P419, DOI 10.1016/S0035-9203(00)90126-3; Chilengi R, 2004, AM J TROP MED HYG, V71, P92; Depoortere E, 2004, ANN TROP MED PARASIT, V98, P635, DOI 10.1179/000349804225021271; *GOV REP ZAMB MIN, 2004, ANT CLIN SENT SURV S; Hastings IM, 2005, J INFECT DIS, V192, P1303, DOI 10.1086/432554; Irion A, 1998, TROP MED INT HEALTH, V3, P490, DOI 10.1046/j.1365-3156.1998.00253.x; Martensson A, 2005, CLIN INFECT DIS, V41, P1079, DOI 10.1086/444460; Mayxay M, 2004, CLIN INFECT DIS, V39, P1139, DOI 10.1086/424512; Mutabingwa TK, 2005, LANCET, V365, P1474, DOI 10.1016/S0140-6736(05)66417-3; *NAT MAL CONTR CTR, NAT MAL SIT AN 2000; Nathoo S, 2003, LANCET, V362, P1039, DOI 10.1016/S0140-6736(03)14414-5; Obonyo CO, 2003, T ROY SOC TROP MED H, V97, P585, DOI 10.1016/S0035-9203(03)80038-X; Piola P, 2005, LANCET, V365, P1467, DOI 10.1016/S0140-6736(05)66416-1; Robert V, 2000, AM J TROP MED HYG, V62, P210, DOI 10.4269/ajtmh.2000.62.210; Sisowath C, 2005, J INFECT DIS, V191, P1014, DOI 10.1086/427997; Staedke SG, 2004, LANCET, V364, P1950, DOI 10.1016/S0140-6736(04)17478-3; STOHRER JM, 2004, TROP MED INT HEALTH, V11, P1175; Targett G, 2001, J INFECT DIS, V183, P1254, DOI 10.1086/319689; van Vugt M, 1998, ANTIMICROB AGENTS CH, V42, P135, DOI 10.1128/AAC.42.1.135; Whitworth J, 2000, LANCET, V356, P1051, DOI 10.1016/S0140-6736(00)02727-6; WHO, 2003, ASS MON ANT DRUG EFF; Zurovac D, 2005, BRIT MED J, V331, P734, DOI 10.1136/bmj.331.7519.734	24	32	32	0	3	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1475-2875			MALARIA J	Malar. J.	AUG 21	2006	5								73	10.1186/1475-2875-5-73				7	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	088MD	WOS:000240814900001	16923176	DOAJ Gold, Green Published			2019-03-26	
J	Okello, PE; Van Bortel, W; Byaruhanga, AM; Correwyn, A; Roelants, P; Talisuna, A; D'Alessandro, U; Coosemans, M				Okello, Paul Edward; Van Bortel, Wim; Byaruhanga, Anatol Maranda; Correwyn, Anne; Roelants, Patricia; Talisuna, Ambrose; D'Alessandro, Umberto; Coosemans, Marc			Variation in malaria transmission intensity in seven sites throughout Uganda	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							PLASMODIUM-FALCIPARUM MALARIA; ANOPHELES-GAMBIAE COMPLEX; TREATED BED NETS; INOCULATION RATES; KENYAN COAST; EL-NINO; AFRICA; CULICIDAE; DIPTERA; IMPACT	Knowledge of the baseline malaria transmission in a given environment is important to guide malaria control interventions. However, in Uganda, recent information on malaria transmission intensity is lacking. Therefore, a 1-year entomological study was conducted in seven ecologically different sites throughout the country to assess spatial and temporal patterns in malaria transmission intensity. Anopheles gambiae sensu stricto was the main vector in five of the seven study sites, and An. funestus was the most important vector in the two other sites. In a peri-urban village, An. arabiensis contributed substantially to malaria transmission. Clear differences in annual entomological inoculation rates (AEIR) were observed between the study sites, ranging from 4 infective bites per person per year in the southwestern part of the country to > 1,500 infective bites per person per year in a swampy area near the Nile River. Between villages with parasite prevalences of >= 80% in children between 1 and 9 years old, a 4-fold difference in AEIR was observed. Based on the observed behavior of the vectors, insecticide-treated bed nets will be highly effective in controlling malaria. However, in the high transmission areas, additional measures will be needed to reduce the malaria burden to acceptable levels.	Inst Trop Med Prince Leopold, Dept Parasitol, B-2000 Antwerp, Belgium; Minist Hlth, Epidemiol Surveillance Div, Kampala, Uganda; Sch Med Entomol, Kampala, Uganda	Coosemans, M (reprint author), Inst Trop Med Prince Leopold, Dept Parasitol, Natl Str 155, B-2000 Antwerp, Belgium.	okellopaul2000@yahoo.co.uk; wvbortel@itg.be; atalisuna@yahoo.com; udalessandro@itg.be; mcoosemans@itg.be	D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009			Beier JC, 1999, AM J TROP MED HYG, V61, P109, DOI 10.4269/ajtmh.1999.61.109; Charlwood JD, 1998, AM J TROP MED HYG, V59, P243, DOI 10.4269/ajtmh.1998.59.243; COLUZZI M, 1979, T ROY SOC TROP MED H, V73, P483, DOI 10.1016/0035-9203(79)90036-1; COOSEMANS M, 1989, Parassitologia (Rome), V31, P113; Fontenille D, 2001, J MED ENTOMOL, V38, P451, DOI 10.1603/0022-2585-38.3.451; GIBBENS EG, 1932, ANN TROP MED PARASIT, V26, P266; Gimnig JE, 2003, AM J TROP MED HYG, V68, P16, DOI 10.4269/ajtmh.2003.68.16; Guillet P, 2001, B WORLD HEALTH ORGAN, V79, P998; Hay SI, 2000, T ROY SOC TROP MED H, V94, P113, DOI 10.1016/S0035-9203(00)90246-3; HIGHTON RB, 1979, B ENTOMOL RES, V69, P43, DOI 10.1017/S0007485300017879; Keating J, 2005, J MED ENTOMOL, V42, P241, DOI 10.1603/0022-2585(2005)042[0241:AGSAAF]2.0.CO;2; Kilian AHD, 1999, T ROY SOC TROP MED H, V93, P22, DOI 10.1016/S0035-9203(99)90165-7; Killeen GF, 2000, AM J TROP MED HYG, V62, P545, DOI 10.4269/ajtmh.2000.62.545; Lengeler C, 1998, TROP MED INT HEALTH, V3, P286, DOI 10.1046/j.1365-3156.1998.00236.x; LENGELER C, 2006, COCHRANE REV, V1, P363; Lindblade KA, 2000, TROP MED INT HEALTH, V5, P263, DOI 10.1046/j.1365-3156.2000.00551.x; Lindblade KA, 1999, T ROY SOC TROP MED H, V93, P480, DOI 10.1016/S0035-9203(99)90344-9; Macdonald G., 1957, EPIDEMIOLOGY CONTROL; Mouchet J, 1998, J AM MOSQUITO CONTR, V14, P121; Mouchet J, 2004, BIODIVERSITE PALUDIS; Mugisha F, 2003, MALARIA J, V2, DOI 10.1186/1475-2875-2-40; Ndymugyenyi R, 2004, ANN TROP MED PARASIT, V98, P315, DOI 10.1179/000349804225003433; Nevill CG, 1996, TROP MED INT HEALTH, V1, P139; Phillips-Howard PA, 2003, AM J TROP MED HYG, V68, P38; SCOTT JA, 1993, AM J TROP MED HYG, V49, P520, DOI 10.4269/ajtmh.1993.49.520; Smith DL, 2004, MALARIA J, V3, DOI 10.1186/1475-2875-3-13; Smith T, 1998, AM J TROP MED HYG, V59, P252, DOI 10.4269/ajtmh.1998.59.252; Smith TA, 2001, TRENDS PARASITOL, V17, P145, DOI 10.1016/S1471-4922(00)01814-6; Smits A, 1996, J MED ENTOMOL, V33, P545, DOI 10.1093/jmedent/33.4.545; STEYN J J, 1946, East Afr Med J, V23, P163; Takken W, 2003, WAG UR FRON, V2, P75; Talisuna AO, 2003, INT J PARASITOL, V33, P1051, DOI 10.1016/S0020-7519(03)00156-5; Talisuna AO, 2002, T ROY SOC TROP MED H, V96, P310, DOI 10.1016/S0035-9203(02)90108-2; Talisuna AO, 2002, T ROY SOC TROP MED H, V96, P551, DOI 10.1016/S0035-9203(02)90439-6; TALISUNA AO, 2004, INTENSITY MALARIA TR; WHITE GB, 1985, SYST ENTOMOL, V10, P501, DOI 10.1111/j.1365-3113.1985.tb00155.x; WIRTZ RA, 1987, B WORLD HEALTH ORGAN, V65, P39; ZAHAR AR, 1985, VECTOR BIONOMICS E 1	38	174	175	0	12	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637	1476-1645		AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	AUG	2006	75	2					219	225		10.4269/ajtmh.2006.75.219				7	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	072ND	WOS:000239679200007	16896122				2019-03-26	
J	Phanzu, DM; Bafende, EA; Dunda, BK; Imposo, DB; Kibadi, AK; Nsiangana, SZ; Singa, JN; Meyers, WM; Suykerbuyk, P; Portaels, F				Phanzu, Delphin M.; Bafende, Eric A.; Dunda, Barthelemy K.; Imposo, Desire B.; Kibadi, Anatole K.; Nsiangana, Samuel Z.; Singa, Jackie N.; Meyers, Wayne M.; Suykerbuyk, Patrick; Portaels, Francoise			Mycobacterium ulcerans disease (Buruli ulcer) in a rural hospital in Bas-Congo, Democratic Republic of Congo, 2002-2004	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							EPIDEMIOLOGY; INFECTION; SPECIMENS; BENIN	Buruli ulcer (BU), which is caused by Mycobacterium ulcerans, is an important disabling skin disease. Its prevalence is highest in west and central Africa. We report an apparent resurgence of BU in the Bas-Congo Province, Democratic Republic of Congo. During a 28-month period in 2002-2004, the rural hospital of the Institut Medical Evangelique at Kimpese admitted 51 patients suspected of having BU. Bacteriologic, molecular biologic, and histopathologic studies confirmed BU in 36 of these patients. Extensive clinical data, treatment outcomes, and socioeconomic correlations are summarized. Osteomyelitis was an important complication. A multidisciplinary approach to BU control in the Bas-Congo is proposed, aimed primarily at active case detection.	Inst Trop Med, Dept Microbiol, Mycobacteriol Unit, B-2000 Antwerp, Belgium; Kimpese Hosp, Inst Med Evangel, Kimpese, BAS Congo, DEM REP CONGO; Programme Natl Lutte Contre Ulcere Buruli, Kinshasa, DEM REP CONGO; Armed Forces Inst Pathol, Washington, DC 20306 USA; Inst Trop Med, Dept Microbiol, Mycobacteriol Unit, B-2000 Antwerp, Belgium	Portaels, F (reprint author), Inst Trop Med, Dept Microbiol, Mycobacteriol Unit, B-2000 Antwerp, Belgium.	portaels@itg.be					ANDERSEN F O, 1965, Cent Afr J Med, V11, P131; Bafende AE, 2004, TROP DOCT, V34, P82, DOI 10.1177/004947550403400207; Bafende AE, 2002, SAMJ S AFR MED J, V92, P437; Bar W, 1998, TROP MED INT HEALTH, V3, P189; Debacker M, 2005, EMERG INFECT DIS, V11, P584, DOI 10.3201/eid1104.041000; Debacker M, 2004, TROP MED INT HEALTH, V9, P1297, DOI 10.1111/j.1365-3156.2004.01339.x; Debacker M, 2004, EMERG INFECT DIS, V10, P1391, DOI 10.3201/eid1008.030886; JANSSENS PG, 1972, ESSAYS DERMATOLOGY, V2, P264; KIBADI K, 2003, CAHIERS SANTE, V13, P39; Kibadi K, 2002, MED AFR NOIRE, V49, P239; Meyers W M, 1974, Ann Soc Belg Med Trop, V54, P147; PETTIT JHS, 1966, BRIT J DERMATOL, V78, P187, DOI 10.1111/j.1365-2133.1966.tb12204.x; PORTAELS F, 1989, ANN SOC BELG MED TR, V69, P91; Portaels F., 2003, Bulletin des Seances, Academie Royale des Sciences d'Outre- Mer, V49, P161; Portaels F, 1997, J CLIN MICROBIOL, V35, P1097; Pszolla N, 2003, CLIN INFECT DIS, V37, pE78, DOI 10.1086/377170; SMITH JH, 1970, AM J TROP MED HYG, V19, P657, DOI 10.4269/ajtmh.1970.19.657; SUYKERBUYK P, 2004, 8 MAASTR MED STUD RE; van OYE E, 1950, Ann Soc Belg Med Trop (1920), V30, P619; *WHO, 2001, WHOCDSCPEGBUI20014; *WHO, 2000, WHOCDSCPEGUI20011; Yeboah-Manu D, 2004, J CLIN MICROBIOL, V42, P5875, DOI 10.1128/JCM.42.12.5875-5876.2004; 2004, WKLY EPIDEMIOL REC, V79, P194	23	39	39	0	0	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637	1476-1645		AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	AUG	2006	75	2					311	314		10.4269/ajtmh.2006.75.311				4	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	072ND	WOS:000239679200024	16896139				2019-03-26	
J	Proano-Perez, F; Rigouts, L; Brandt, J; Dorny, P; Ron, J; Chavez, MA; Rodriguez, R; Fissette, K; Van Aerde, A; Portaels, F; Benitez-Ortiz, W				Proano-Perez, Freddy; Rigouts, Leen; Brandt, Jef; Dorny, Pierre; Ron, Jorge; Chavez, Maria-Augusta; Rodriguez, Richar; Fissette, Krista; Van Aerde, Anita; Portaels, Francoise; Benitez-Ortiz, Washington			Preliminary observations on Mycobacterium spp. in dairy cattle in Ecuador	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							BOVIS INFECTION; TUBERCULOSIS COMPLEX; IDENTIFICATION; ANIMALS; PCR	This study evaluated bovine tuberculosis in Mejia canton, a major dairy cattle production region in Ecuador. Randomly selected cattle (1,012 from 59 farms) classified according to herd size were tested by the single tuberculin test (STT). Sixty days later, positive reactors were tested again by the comparative tuberculin test (CTT). In addition, tissue samples from two STT-CTT-positive reactors detected on a farm were obtained in a local slaughterhouse and analyzed bacteriologically. A total of 4.24% of the cattle were positive in the STT and 3.85% were positive in the CTT, with the highest number (7.95%) in large herds versus 3.4% in medium herds and 0.3% in small herds. Mycobacterium bovis was isolated from mesenteric lymph nodes and lungs of one animal. A 16S ribosomal RNA-based polymerase chain reaction confirmed culture results and differentiated mycobacteria other than M. tuberculosis. This study confirms the zoonotic importance of tuberculosis in Ecuadorian dairy cattle with herd size likely to be a crucial parameter in the prevalence of the disease. The implementation of a national control program is necessary and should be based on the detection of positive cattle by STT in combination with CTT.	Inst Trop Med, Unit Mycobacteriol, Dept Microbiol, B-2000 Antwerp, Belgium; Inst Trop Med, Dept Anim Hlth, B-2000 Antwerp, Belgium; Cent Univ Ecuador, Int Ctr Zoonoses, Quito, Ecuador	Portaels, F (reprint author), Inst Trop Med, Unit Mycobacteriol, Dept Microbiol, 155 Natl Str, B-2000 Antwerp, Belgium.	fproanio-ciz@ac.uce.edu.ec; lrigouts@itg.be; jbrandt@itg.be; pdorny@itg.be; jron-ciz@uce.edu.ec; mchavez-ciz@ac.uce.edu.ec; rrodriguez-ciz@ac.uce.edu.ec; kfissette@itg.be; avaerde@itg.be; portaels@itg.be; wbenitez-ciz@ac.uce.edu.ec	Rodriguez-Hidalgo, Richar/P-8877-2015	Rodriguez-Hidalgo, Richar/0000-0002-9338-1062			Acha P, 2001, SCI TECHNICAL PUBLIC, P283; Adams LG, 2001, REV SCI TECH OIE, V20, P304, DOI 10.20506/rst.20.1.1267; BIBERSTEIN EL, 1999, VET MICROBIOL, P158; BODDINGHAUS B, 1990, J CLIN MICROBIOL, V28, P1751; Cosivi O, 1998, EMERG INFECT DIS, V4, P59, DOI 10.3201/eid0401.980108; FREIRE F, 2001, CASOS TASAS TENDENCI; Gil A, 2001, 2 FOOD AGR ORG, P16; GROOMS D, 2000, EXTENSION B E, V2731; KRAUSS H, 2003, ZOONOSES INFECT DIS, P210; LATINI O, 1997, ARCH MED VET, V29, P1; LESLIE IW, 1975, VET REC, V96, P332; LEVYFREBAULT VV, 1992, INT J SYST BACTERIOL, V42, P315; MONAGHAN ML, 1994, VET MICROBIOL, V40, P111, DOI 10.1016/0378-1135(94)90050-7; *OIE, 2000, BOV TUB MAN STAND DI; Parks L.C., 1997, MICROBIOLOGICAL MEDI, P774; Phillips CJC, 2003, RES VET SCI, V74, P1, DOI 10.1016/S0034-5288(02)00145-5; PORTAELS F, 1988, INT J LEPROSY, V56, P580; Portaels F, 1996, J CLIN MICROBIOL, V34, P319; Portaels F, 1997, J CLIN MICROBIOL, V35, P1097; PORTAELS F, 2001, WHOCDSGBUI2001; QUINN PJ, 1999, CLIN VET MICROBIOLOG, P156; Rigouts L, 1996, TUBERCLE LUNG DIS, V77, P264, DOI 10.1016/S0962-8479(96)90011-8; SHAKESPEARE M, 2002, ZOONOSES, P98; Sreevatsan S, 2000, J CLIN MICROBIOL, V38, P2602; Suazo FM, 2003, PREV VET MED, V58, P1, DOI 10.1016/S0167-5877(03)00003-5; Vitale F, 1998, J CLIN MICROBIOL, V36, P1050; WORTHINGTON R. W., 1967, ONDERSTEPOORT J VET RES, V34, P345	27	13	14	1	2	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637	1476-1645		AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	AUG	2006	75	2					318	323		10.4269/ajtmh.2006.75.318				6	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	072ND	WOS:000239679200026	16896141				2019-03-26	
J	Meessen, B; Musango, L; Kashala, JPI; Lemlin, J				Meessen, Bruno; Musango, Laurent; Kashala, Jean-Pierre I.; Lemlin, Jackie			Reviewing institutions of rural health centres: The performance initiative in Butare, Rwanda	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						contracting; fee-for-service; health services; developing countries; millennium development goals	DEVELOPING-COUNTRIES; CARE; SERVICES; AFRICA; INFORMATION; MANAGEMENT; GOVERNMENT; CAMBODIA; QUALITY; SYSTEMS	In many low-income countries, performance of pyramidal health systems with a public purpose is not meeting the expectations and needs of the populations they serve. A question that has not been studied and tested sufficiently is, 'What is the right package of institutional mechanisms required for organisations and individuals working in these health systems?' This paper presents the experience of the Performance Initiative, an innovative contractual approach that has reshaped the incentive structure in place in two rural districts of Rwanda. It describes the general background, the initial analysis, the institutional arrangement and the results after 3 years of operations. At this stage of the experience, it shows that 'output-based payment + greater autonomy' is a feasible and effective strategy for improving the performance of public health centres. As part of a more global package of strategies, contracting-in approaches could be an interesting option for governments, donors and non-governmental organisations in their effort to achieve some of the Millennium Development Goals.	Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium; Univ Catholique Louvain, Dept Econ, Louvain, Belgium; Sch Publ Hlth, Kigali, Rwanda; HealthNet Int, Amsterdam, Netherlands	Meessen, B (reprint author), Inst Trop Med, Dept Publ Hlth, Natl Str 155, B-2000 Antwerp, Belgium.	bmeessen@itg.be		Meessen, Bruno/0000-0002-0359-8621			ALCHIAN AA, 1972, AM ECON REV, V62, P777; Andre C, 1998, J ECON BEHAV ORGAN, V34, P1, DOI 10.1016/S0167-2681(97)00045-0; BARNUM H, 1995, INT J HEALTH PLAN M, V10, P23, DOI 10.1002/hpm.4740100104; Blaise P, 2004, INT J HEALTH PLAN M, V19, P337, DOI 10.1002/hpm.769; Carrin G, 2005, TROP MED INT HEALTH, V10, P799, DOI 10.1111/j.1365-3156.2005.01455.x; Casalino LP, 1999, NEW ENGL J MED, V341, P1147, DOI 10.1056/NEJM199910073411511; Commission on Macroeconomics and Health, 2001, MACR HLTH INV HLTH E; *EC SANT PUB, 2003, IN PERF ENQ CONTR DI; *EC SANT PUB, 2003, ENQ CONTR PERF FORM; FERINHO P, 2000, STUDIES HLTH SERVICE, V16, P1; FOULON G, 2004, FINANCEMENT SYSTEMS; Franco LM, 2002, SOC SCI MED, V54, P1255, DOI 10.1016/S0277-9536(01)00094-6; Freidson E, 2001, PROFESSIONALISM 3 LO; Gilson L, 1997, HEALTH POLICY PLANN, V12, P273; Gilson L, 2000, INT J HEALTH PLAN M, V15, P291, DOI 10.1002/hpm.599; Graham W., 2001, STUDIES HLTH SERVICE, V17, P97; Green A, 2002, INT J HEALTH PLAN M, V17, P333, DOI 10.1002/hpm.685; GRIFFIN CC, 1995, FINANCING HLTH SERVI; GRUENAIS ME, 2004, AUTREPART, V29, P29; Hardeman W, 2004, HEALTH POLICY PLANN, V19, P22, DOI 10.1093/heapol/czh003; Jaffre Y., 2003, MED INHOSPITALIERE D; Jahn A., 2001, STUD HLTH SERVICES O, V17, P229; JARRETT SW, 1992, HEALTH POLICY PLANN, V7, P164, DOI 10.1093/heapol/7.2.164; Kalk A, 2005, TROP MED INT HEALTH, V10, P872, DOI 10.1111/j.1365-3156.2005.01464.x; Landon BE, 2003, JAMA-J AM MED ASSOC, V290, P1183, DOI 10.1001/jama.290.9.1183; Leonard KL, 2002, INT REV LAW ECON, V22, P61, DOI 10.1016/S0144-8188(02)00069-8; LevyBruhl D, 1997, INT J HEALTH PLAN M, V12, pS49, DOI 10.1002/(SICI)1099-1751(199706)12:1+<S49::AID-HPM466>3.3.CO;2-G; Loevinsohn B, 2005, LANCET, V366, P676, DOI 10.1016/S0140-6736(05)67140-1; MARTENS B, 2002, I EC FOREIGN AIDS; McDonagh M, 1996, HEALTH POLICY PLANN, V11, P1, DOI 10.1093/heapol/11.1.1; Meessen B, 2004, INITIATIVE PERFORMAN; Musango L., 2004, Cahiers d'Etudes et de Recherches Francophones/Sante, V14, P93; NORTH D, 1990, I I CHANGE C PERFORM; North D.C., 1996, EMPIRICAL STUDIES I, P342; Ovretveit J., 1998, EVALUATING HLTH INTE; Pawson R, 1997, REALISTIC EVALUATION; PAWSOW R, 1997, REALISTIC EVALUATION; PORIGNON D, 2003, ADEQUATION SYSTEMES; Preker A, 2004, HLTH FINANCING POOR; PREKER A. S., 2005, SPENDING WISELY BUYI; SALANIE B, 1999, EC CONTRACTS, P1; Schneider P., 2001, 66 ABT ASS; Soeters R, 2003, HEALTH POLICY PLANN, V18, P74, DOI 10.1093/heapol/18.1.74; VANDAMME W, 2001, SOTNIKUM NEW DEAL 1; WHO, 2000, HLTH SYST IMPR PERF; Williamson O. E, 1996, MECH GOVT; World Bank, 2003, WORLD DEV REP 2004 M; World Bank, 1993, WORLD DEV REP 1993 I	48	63	63	0	10	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	AUG	2006	11	8					1303	1317		10.1111/j.1365-3156.2006.01680.x				15	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	065XS	WOS:000239194100017	16903893	Bronze			2019-03-26	
J	Bottieau, E; Clerinx, J; Van Den Enden, E; Van Esbroeck, M; Colebunders, R; Van Gompel, A; Van Den Ende, J				Bottieau, Emmanuel; Clerinx, Jan; Van Den Enden, Erwin; Van Esbroeck, Marian; Colebunders, Robert; Van Gompel, Alfons; Van Den Ende, Jef			Imported non-Plasmodium falciparum malaria: A five-year prospective study in a European referral center	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							SENTINEL SURVEILLANCE DATA; VIVAX MALARIA; PRIMAQUINE THERAPY; CLINICAL-FEATURES; NONIMMUNE TRAVELERS; OVALE MALARIA; EPIDEMIOLOGY; DIAGNOSIS; ACCURACY; DISEASES	From 2000 to 2005, we investigated prospectively 98 cases of imported non-Plasmodium falciparum malaria (48 Plasmodium vivax, 34 P. ovate, and 16 P. malariae). Latency period between return and clinical attack exceeded three months in 40% of the patients. It was longer in travelers who had taken chemoprophylaxis. Time to diagnosis was longer in patients with P. malariae infection and in those with late-onset first attack. Parasite density was often lower than 500/mu L, especially in P. ovale malaria. Relapses were diagnosed in 18% of all malaria episodes. Eight (17%) P. vivax and 2 (6%) P. ovale malaria episodes were due to relapse despite standard primaquine therapy. Diagnosis of imported non-falciparum malaria is often challenged by long latency period and low parasite density. In addition, the substantial relapse rate despite standard primaquine therapy supports the use of a higher dose of primaquine to eradicate P. vivax and P. ovate malaria effectively.	Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium; Univ Antwerp Hosp, Dept Trop Dis, Antwerp, Belgium	Bottieau, E (reprint author), Inst Trop Med, Dept Clin Sci, Nationalestr 155, B-2000 Antwerp, Belgium.	ebottieau@itg.be					Baird JK, 2004, CLIN INFECT DIS, V39, P1336, DOI 10.1086/424663; Bigaillon C, 2005, J CLIN MICROBIOL, V43, P1011, DOI 10.1128/JCM.43.2.1011.2005; Bottieau E, 2005, CLIN INFECT DIS, V41, P1544, DOI 10.1086/497378; *CDCP, 2005, TREATM MAL GUID CL 2; Doherty JF, 1997, T ROY SOC TROP MED H, V91, P76, DOI 10.1016/S0035-9203(97)90403-X; ELIADES MJ, 2003, MMWR SURVEILL SUMM, V54, P25; Elliott JH, 2004, J TRAVEL MED, V11, P213; Grobusch MP, 2002, EUR J CLIN MICROBIOL, V21, P818, DOI 10.1007/s10096-002-0831-0; JELINEK T, 1995, AM J TROP MED HYG, V52, P322, DOI 10.4269/ajtmh.1995.52.322; Jelinek T, 2002, CLIN INFECT DIS, V34, P572, DOI 10.1086/338235; Kain KC, 1998, INFECT DIS CLIN N AM, V12, P267, DOI 10.1016/S0891-5520(05)70005-2; Leder K, 2004, CLIN INFECT DIS, V39, P1104, DOI 10.1086/424510; Maguire JD, 2002, LANCET, V360, P58, DOI 10.1016/S0140-6736(02)09336-4; Marx A, 2005, ANN INTERN MED, V142, P836, DOI 10.7326/0003-4819-142-10-200505170-00009; MILNE LM, 1994, J CLIN PATHOL, V47, P740, DOI 10.1136/jcp.47.8.740; Moody A, 2000, BRIT J HAEMATOL, V109, P891, DOI 10.1046/j.1365-2141.2000.01974.x; Muhlberger N, 2004, MALARIA J, V3, DOI 10.1186/1475-2875-3-5; NATHWANI D, 1991, J INFECTION, V23, P343, DOI 10.1016/0163-4453(91)93548-Q; Robinson P, 2001, J TRAVEL MED, V8, P76; ROMBO L, 1987, TROP MED PARASITOL, V38, P49; Rougemont M, 2004, J CLIN MICROBIOL, V42, P5636, DOI 10.1128/JCM.42.12.5636-5643.2004; Schwartz E, 2000, AM J TROP MED HYG, V62, P393, DOI 10.4269/ajtmh.2000.62.393; Schwartz E, 2003, NEW ENGL J MED, V349, P1510, DOI 10.1056/NEJMoa021592; Singh K, 2003, ARCH INTERN MED, V163, P2027, DOI 10.1001/archinte.163.17.2027; WARRELL DA, 2000, T R SOC TROP MED HYG, V94, P1	25	38	38	0	1	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	JUL	2006	75	1					133	138		10.4269/ajtmh.2006.75.133				6	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	061WA	WOS:000238902600022	16837719				2019-03-26	
J	Cohuet, S; Bonnet, M; Van Herp, M; Van Overmeir, C; D'Alessandro, U; Guthmann, JP				Cohuet, Sandra; Bonnet, Maryline; Van Herp, Michel; Van Overmeir, Chantal; D'Alessandro, Umberto; Guthmann, Jean-Paul			Short report: Molecular markers associated with Plasmodium falciparum resistance to sulfadoxine-pyrimethamine in the Democratic Republic of Congo	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							CHLORPROGUANIL-DAPSONE TREATMENT; DIHYDROFOLATE-REDUCTASE; IN-VIVO; DIHYDROPTEROATE SYNTHETASE; MALARIA; MUTATIONS; SURVEILLANCE; EFFICACY; SULFADOXINE/PYRIMETHAMINE; SYNTHASE	Sulfadoxine-pyrimethamine (SP) is the first line antimalarial treatment in the Democratic Republic of Congo. Using polymerase chain reaction, we assessed the prevalence of mutations in the dihydrofolate reductase (dhfr) (codons 108, 51, 59) and dihydropteroate synthase (dhps) (codons 437, 540) genes of Plasmodium falciparum, which have been associated with resistance to pyrimethamine and sulfadoxine, respectively. Four hundred seventy-four patients were sampled in Kilwa (N = 138), Kisangani (N = 112), Boende (N = 106), and Basankusu (N = 118). The proportion of triple mutations dhfr varied between sites but was always > 50%. The proportion of dhps double mutations was < 20%, with some sites as low as 0.9%. A quintuple mutation was present in 12.8% (16/125) samples in Kilwa; 11.9% (13/109) in Kisangani, 2.9% (3/102) in Boende, and 0.9% (1/112) in Basankusu. These results suggest high resistance to pyrimethamine alone or combined with sulfadoxine. Adding artesunate to SP does not seem a valid alternative to the current monotherapy.	Epictr, F-75011 St Sabin, France; Med Frontieres, Brussels, Belgium; Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium	Guthmann, JP (reprint author), Epictr, 8 Rue St Sabin, F-75011 St Sabin, France.	jguthmann@epicentre.msf.org	D'Alessandro, Umberto/D-3457-2015; Bonnet, Maryline/E-8536-2013	D'Alessandro, Umberto/0000-0001-6341-5009; 			Alifrangis M, 2003, AM J TROP MED HYG, V69, P601, DOI 10.4269/ajtmh.2003.69.601; Basco LK, 2003, AM J TROP MED HYG, V69, P174, DOI 10.4269/ajtmh.2003.69.174; Curtis J, 1998, J INFECT DIS, V177, P1429, DOI 10.1086/517831; Kazadi WM, 2003, TROP MED INT HEALTH, V8, P868, DOI 10.1046/j.1365-3156.2003.01098.x; Kublin JG, 1998, LANCET, V351, P1629, DOI 10.1016/S0140-6736(98)24022-0; Kublin JG, 2002, J INFECT DIS, V185, P380, DOI 10.1086/338566; MacArthur JR, 2001, AM J TROP MED HYG, V65, P679, DOI 10.4269/ajtmh.2001.65.679; Nagesha HS, 2001, T ROY SOC TROP MED H, V95, P43, DOI 10.1016/S0035-9203(01)90329-3; Nsimba B, 2004, AM J TROP MED HYG, V70, P133, DOI 10.4269/ajtmh.2004.70.133; Nzila AM, 2000, ANTIMICROB AGENTS CH, V44, P991, DOI 10.1128/AAC.44.4.991-996.2000; Olliaro P, 1996, LANCET, V348, P1196, DOI 10.1016/S0140-6736(96)06217-4; Piola P, 2005, LANCET, V365, P1467, DOI 10.1016/S0140-6736(05)66416-1; PLOWE CV, 1995, AM J TROP MED HYG, V52, P565, DOI 10.4269/ajtmh.1995.52.565; Plowe CV, 1997, J INFECT DIS, V176, P1590, DOI 10.1086/514159; Ronn AM, 1996, T ROY SOC TROP MED H, V90, P179, DOI 10.1016/S0035-9203(96)90129-7; Talisuna AO, 2004, INFECT GENET EVOL, V4, P321, DOI 10.1016/j.meegid.2004.04.002; Terlouw DJ, 2003, ANTIMICROB AGENTS CH, V47, P2929, DOI 10.1128/AAC.47.9.2929-2932.2003; Wang P, 1999, MOL MICROBIOL, V32, P1254, DOI 10.1046/j.1365-2958.1999.01437.x; *WHO, 2003, POS WHOS ROLL BACK M	19	18	18	0	0	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	JUL	2006	75	1					152	154		10.4269/ajtmh.2006.75.152				3	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	061WA	WOS:000238902600026	16837723				2019-03-26	
J	Stoute, JA; Heppner, DG; Mason, CJ; Siangla, J; Opollo, MO; Kester, KE; Vigneron, L; Voss, G; Walter, MJ; Tornieporth, N; Cohen, JD; Ballou, WR				Stoute, Jose A.; Heppner, D. Gray, Jr.; Mason, Carl J.; Siangla, Joram; Opollo, Malachi O.; Kester, Kent E.; Vigneron, Laurence; Voss, Gerald; Walter, Michael J.; Tornieporth, Nadia; Cohen, Joe D.; Ballou, W. Ripley			Phase 1 safety and immunogenicity trial of malaria vaccine RTS,S/AS02A in adults in a hyperendemic region of western Kenya	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							PLASMODIUM-FALCIPARUM MALARIA; CIRCUMSPOROZOITE PROTEIN VACCINE; RANDOMIZED CONTROLLED-TRIAL; EFFICACY; INFECTION; CHILDREN; DISEASE; BURDEN; GAMBIA	We conducted a phase 1 trial of candidate malaria vaccine RTS,S/AS02A in western Kenya to determine its safety and immunogenicity in healthy adults in an area hyperendemic for malaria. Twenty adults were enrolled and received RTS,S/AS02A (50 mu g of RTS,S in 0.5 mL of AS02A) by intramuscular injection on a 0-, 28-, and 178-day schedule. All 60 scheduled immunizations were given, and 18 of 20 volunteers completed the last study visit on day 210. The vaccine was safe and well-tolerated. There were no vaccine-related severe adverse events. The most common solicited adverse events associated with immunization were injection site pain and headache. The geometric mean concentration of antibodies to circumsporozoite protein was 1.9 mu g/mL at baseline and it increased 2-4 weeks after each dose to 16, 17.8, and 36.6 mu g/mL, respectively. These safety and immunogenicity data from adults in hyperendemic Kenya are comparable to data reported earlier from two trials in west African adults in hypo-endemic and meso-endemic areas of The Gambia. We conclude that in this small study, RTS,S/AS02A is safe and similarly immunogenic in malaria-exposed African adults of different ethnicity in different transmission settings.	Walter Reed Army Inst Res, Malaria Vaccine Program, Silver Spring, MD 20910 USA; GlaxoSmithKlilne Biol, Kenya Med Res Inst, Rixensart, Belgium; USA, Med Res Unit, Nairobi, Kenya	Heppner, DG (reprint author), Walter Reed Army Inst Res, Malaria Vaccine Program, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.	donald.heppner@na.amedd.army.mil	Kester, Kent/A-2114-2011	Kester, Kent/0000-0002-5056-0802; MASON, CARL/0000-0002-3676-2811			Alonso PL, 2005, LANCET, V366, P2012, DOI 10.1016/S0140-6736(05)67669-6; Alonso PL, 2004, LANCET, V364, P1411, DOI 10.1016/S0140-6736(04)17223-1; [Anonymous], 1991, MMWR Recomm Rep, V40, P1; BEIER JC, 1994, AM J TROP MED HYG, V50, P529, DOI 10.4269/ajtmh.1994.50.529; Bojang KA, 2001, LANCET, V358, P1927, DOI 10.1016/S0140-6736(01)06957-4; Bojang KA, 2005, VACCINE, V23, P4148, DOI 10.1016/j.vaccine.2005.03.019; Breman JG, 2001, AM J TROP MED HYG, V64, P1; *CDCP, 1999, MMWR-MORBID MORTAL W, V48, P1; Doherty JF, 1999, AM J TROP MED HYG, V61, P865, DOI 10.4269/ajtmh.1999.61.865; Garcon Nathalie, 2003, Expert Rev Vaccines, V2, P231, DOI 10.1586/14760584.2.2.231; Ghosh K, 2006, J INFECT DIS, V193, P155, DOI 10.1086/498528; GORDON DM, 1995, J INFECT DIS, V171, P1576, DOI 10.1093/infdis/171.6.1576; Heppner DG, 2005, VACCINE, V23, P2243, DOI 10.1016/j.vaccine.2005.01.042; Kester KE, 2001, J INFECT DIS, V183, P640, DOI 10.1086/318534; Mills KHG, 2004, NAT REV IMMUNOL, V4, P841, DOI 10.1038/nri1485; Sachs J, 2002, NATURE, V415, P680, DOI 10.1038/415680a; Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342; Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202	18	26	26	0	0	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	JUL	2006	75	1					166	170		10.4269/ajtmh.2006.75.166				5	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	061WA	WOS:000238902600029	16837726				2019-03-26	
J	Kabura, L; Ilibagiza, D; Menten, J; Van den Ende, J				Kabura, L.; Ilibagiza, D.; Menten, J.; Van den Ende, J.			Intrathecal vs. intramuscular administration of human antitetanus immunoglobulin or equine tetanus antitoxin in the treatment of tetanus: a meta-analysis	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						tetanus; intrathecal; equine tetanus antitoxin; human antitetanus immunoglobulin	DAR-ES-SALAAM; NEONATAL TETANUS; SERUM HORSE; MANAGEMENT; SEROTHERAPY; EXPERIENCE; MAGNESIUM; THERAPY; TRIAL	BACKGROUND Mortality caused by tetanus is still a serious health problem in developing countries. Apart from immunization, early treatment with equine antitetanus serum ( ATS) or human tetanus immunoglobulin (TIG) is the real treatment that can avoid death. On pathophysiological grounds intrathecal administration would be preferred because of high concentrations of the antiserum in cerebrospinal fluid and thus around the nerve roots. Many studies concluded on its effectiveness whereas others did not find any superiority of this method. However, most of those studies were not random and/or had no sufficient weight. OBJECTIVE To assess the efficacy of intrathecal therapy with ATS in neonates and adults. methods Meta-analysis: Clinical trials were identified by searching Medline, the Cochrane library and Current Contents. Published randomized studies in English or French comparing intrathecal therapy and intramuscular therapy (IMS) were analysed with Revman, R, and Stata software. Treatment effects were evaluated by relative risk (RR) between intrathecal vs. intramuscular administration. RESULTS A total of 942 patients were included in 12 trials, 484 in the intrathecal group and 458 in the intramuscular one. The combined RR of mortality for intrathecal vs. IMS was 0.71 (95% CI, 0.62-0.81). The superiority of intrathecal therapy also emerged when the analysis was performed in subcategories of both adults and neonates and for high and low dose of intrathecal serotherapy. CONCLUSION Intrathecal administration of ATS or TIG is more beneficial than intramuscular administration in the treatment of tetanus.	Inst Trop Med, B-2000 Antwerp, Belgium; Univ Hosp Ctr Kigali, Kigali, Rwanda	Van den Ende, J (reprint author), Inst Trop Med, Natl Str 155, B-2000 Antwerp, Belgium.	jvdende@itg.be					ABRUTYN E, 1991, JAMA-J AM MED ASSOC, V266, P2262, DOI 10.1001/jama.266.16.2262; Agarwal M, 1998, NATL MED J INDIA, V11, P209; Attygalle D, 2002, ANAESTHESIA, V57, P811; Attygalle Deepthi, 2004, Expert Rev Anti Infect Ther, V2, P73, DOI 10.1586/14787210.2.1.73; BHANDARI B, 1980, INDIAN J MED RES, V72, P685; CHOPRA K, 1986, Indian Pediatrics, V23, P775; CUCHERAT M, 1997, META ANAL ESSAIES TH; DEVILLE WL, 1997, BMC MED RES METHODOL, V2, P9; DIOPMAR I, 1975, 4 C INT TET DAK SEN, P641; GUPTA PS, 1980, LANCET, V2, P439; ILDRIRIM I, 1967, TURKISH J PEDIAT, V9, P89; LEVIN ASS, 1987, REV I MED TROP, V29, P255, DOI 10.1590/S0036-46651987000500001; MBISE RL, 1984, E AFR MED J, V61, P892; MEON J, 2002, INDIAN PEDIATR, V39, P654; MONGI PS, 1987, ANN TROP PAEDIATR, V7, P27, DOI 10.1080/02724936.1987.11748469; Reddy Venu Gopal, 2002, Middle East Journal of Anesthesiology, V16, P419; RIBERO R, 2000, MED AFRIQUE NOIRE, V47, P141; ROBERT R, 1984, PRESSE MED, V13, P1947; SANDERS RKM, 1977, LANCET, V1, P974; SEDAGHATIAN MR, 1979, ARCH DIS CHILD, V54, P623, DOI 10.1136/adc.54.8.623; SINGH AK, 1980, ARCH DIS CHILD, V55, P527, DOI 10.1136/adc.55.7.527; SUTTON DN, 1990, INTENS CARE MED, V16, P75; Thwaites CL, 2004, T ROY SOC TROP MED H, V98, P671, DOI 10.1016/j.trstmh.2004.01.008; VAKIL BJ, 1979, T ROY SOC TROP MED H, V73, P579, DOI 10.1016/0035-9203(79)90058-0; VANHOUWELINGEN HC, 2002, ACTA GENETICA STAT M, V21, P589	25	22	26	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	JUL	2006	11	7					1075	1081		10.1111/j.1365-3156.2006.01659.x				7	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	060FQ	WOS:000238788300011	16827708	Bronze			2019-03-26	
J	Talisuna, AO; Staedke, SG; D'Alessandro, U				Talisuna, Ambrose O.; Staedke, Sarah G.; D'Alessandro, Umberto			Pharmacovigilance of antimalarial treatment in Africa: is it possible?	MALARIA JOURNAL			English	Editorial Material							UNCOMPLICATED FALCIPARUM-MALARIA; RANDOMIZED-TRIAL; ARTESUNATE; UGANDA; COMBINATION; AMODIAQUINE; RESISTANCE; CHILDREN; KENYA	Pharmacovigilance, defined as "the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other possible drug related problem", is increasingly being recognized in Africa. Many African countries have simultaneously adopted artemisinin derivative based combination therapy ( ACT) as first-line treatment for uncomplicated malaria, offering an opportunity to assess the safety of these drugs when used widely. While ACTs appear to be safe and well-tolerated, there is little experience with these medicines in Africa, outside clinical trials. Pharmacovigilance for ACTs and other combination treatments in Africa is essential. Malaria transmission intensity is high and antimalarial medicines are used frequently. Presumptive treatment of fever with antimalarials is common, often in the absence of a confirmed diagnosis, using drugs obtained without a prescription. Informal use of antimalarial drugs may increase the risk of incorrect dosing, inappropriate treatment, and drug interactions, which may impact negatively on drug safety. Furthermore, the administration of antimalarial treatments in patients with a concomitant illness, including HIV/AIDs, tuberculosis and malnutrition, is a concern. African countries are being encouraged to establish pharmacovigilance systems as ACTs are rolled out. However, pharmacovigilance is difficult, even in countries with a well-developed health care system. The rationale for pharmacovigilance of antimalarial drugs is discussed here, outlining the practical challenges and proposing approaches that could be adopted in Africa.	Minist Hlth, Epidemiol Surveillance Div, Kampala, Uganda; Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium; Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, San Francisco, CA USA	Talisuna, AO (reprint author), Minist Hlth, Epidemiol Surveillance Div, POB 7272, Kampala, Uganda.	atalisuna@afsat.com; sstaedke@medsfgh.ucsf.edu; udalessandro@itg.be	D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009			Adjuik M, 2004, LANCET, V363, P9; Alloueche A, 2004, LANCET, V363, P1843, DOI 10.1016/S0140-6736(04)16350-2; Dorsey G, 2002, LANCET, V360, P2031, DOI 10.1016/S0140-6736(02)12021-6; FOSTER S, 1995, J TROP MED HYG, V98, P29; *ICH, 1996, GUID IND GOOD CLIN P; Marsh VM, 1999, TROP MED INT HEALTH, V4, P383, DOI 10.1046/j.1365-3156.1999.00403.x; McCombie SC, 1996, SOC SCI MED, V43, P933, DOI 10.1016/0277-9536(95)00446-7; McNabb SJN, 2002, BMC PUBLIC HEALTH, V2, DOI 10.1186/1471-2458-2-2; MUTABINGWA TK, 2005, LANCET, V365, P1441; MWENESI H, 1995, SOC SCI MED, V40, P1271, DOI 10.1016/0277-9536(94)00250-W; Nolen LB, 2005, B WORLD HEALTH ORGAN, V83, P597; Nosten F, 2000, LANCET, V356, P297, DOI 10.1016/S0140-6736(00)02505-8; Piola P, 2005, LANCET, V365, P1467, DOI 10.1016/S0140-6736(05)66416-1; Rwagacondo CE, 2004, TROP MED INT HEALTH, V9, P1091, DOI 10.1111/j.1365-3156.2004.01316.x; Setel PW, 2005, B WORLD HEALTH ORGAN, V83, P611; Simooya O, 2005, DRUG SAFETY, V28, P277, DOI 10.2165/00002018-200528040-00001; Staedke SG, 2004, LANCET, V364, P1950, DOI 10.1016/S0140-6736(04)17478-3; Talisuna AO, 2002, T ROY SOC TROP MED H, V96, P310, DOI 10.1016/S0035-9203(02)90108-2; White N J, 1998, Med Trop (Mars), V58, P54; WHO, 2002, IMP PHARM SAF MON ME	20	51	51	1	1	BIOMED CENTRAL LTD	LONDON	MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND	1475-2875			MALARIA J	Malar. J.	JUN 16	2006	5								50	10.1186/1475-2875-5-50				8	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	069PL	WOS:000239460600001	16780575	DOAJ Gold, Green Published			2019-03-26	
J	Tinto, H; Rwagacondo, C; Karema, C; Mupfasoni, D; Vandoren, W; Rusanganwa, E; Erhart, A; Van Overmeir, C; Van Marck, E; D'Alessandro, U				Tinto, H; Rwagacondo, C; Karema, C; Mupfasoni, D; Vandoren, W; Rusanganwa, E; Erhart, A; Van Overmeir, C; Van Marck, E; D'Alessandro, U			In-vitro susceptibility of Plasmodium falciparum to monodesethylamodiaquine, dihydroartemisinin and quinine in an area of high chloroquine resistance in Rwanda	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						malaria; Plasmodium falciparum; chloroquine; monodesethylamodiaquine; dihydroartemisinin; quinine; Rwanda	AFRICAN ISOLATES SENEGAL; SULFADOXINE-PYRIMETHAMINE; UNCOMPLICATED MALARIA; BETA-ARTEETHER; AMODIAQUINE; EFFICACY; ARTESUNATE; METABOLISM; ARTEMETHER; CHILDREN	Plasmodium falciparum in-vitro susceptibility to chloroquine (CQ), monodesethylamodiaquine, quinine and dihydroartemisinin was investigated in Rwandan patients with a parasitaemia of at least >= 4000/mu l. The study was carried out in November-December 2003. Dihydroartemisinin was the most potent (GM IC50 = 2.6 nmol/l, 95% Cl 2.2-3.2) among the drugs tested. Resistance to chloroquine was 45% (33/74) and that to monodesethylamodiaquine 7% (5/74). All the tested isolates were susceptible to quinine. The mean IC50 of monodesethylamodiaquine, quinine and dihydroartemisinin was significantly higher for chloroquine-resistant than for chloroquine-sensitive strains (P<0.05). The IC50 of each drug was significantly and positively correlated to that of the other three drugs (P<0.005), and this correlation was higher between CQ and monodesethylamodiaquine (r=0.8). In-vitro CQ resistance is linked to that of the other drugs tested. Most worrying is the positive correlation between the IC50 Of dihydroartemisinin and the other drugs, more particularly with CQ, suggesting an increased tolerance of the parasites to all drugs. (C) 2005 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.	Inst Rech Sci Sante, Ctr Muraz, Bobo Dioulasso, Burkina Faso; Natl Malaria Control Program, Kigali, Rwanda; Lab Natl Sante Publ, Kigali, Rwanda; Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium; Univ Antwerp, B-2020 Antwerp, Belgium	D'Alessandro, U (reprint author), Inst Trop Med, Nationalestr 155, B-2000 Antwerp, Belgium.	tintohalidou@yahoo.fr; udalessandro@itg.be	D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009; Tinto, Halidou/0000-0002-0472-3586			Adjuik M, 2002, LANCET, V359, P1365, DOI 10.1016/S0140-6736(02)08348-4; Aubouy A, 2004, AM J TROP MED HYG, V71, P294, DOI 10.4269/ajtmh.2004.71.294; Basco LK, 2002, AM J TROP MED HYG, V66, P117, DOI 10.4269/ajtmh.2002.66.117; Batty KT, 1998, BRIT J CLIN PHARMACO, V45, P123, DOI 10.1046/j.1365-2125.1998.00655.x; Bloland PB, 1996, LANCET, V348, P1659, DOI 10.1016/S0140-6736(05)65723-6; Brasseur P, 1999, T ROY SOC TROP MED H, V93, P645, DOI 10.1016/S0035-9203(99)90083-4; DESJARDINS RE, 1979, ANTIMICROB AGENTS CH, V16, P710, DOI 10.1128/AAC.16.6.710; Goldstein JA, 2001, BRIT J CLIN PHARMACO, V52, P349, DOI 10.1046/j.0306-5251.2001.01499.x; Gonzalez IJ, 2003, T ROY SOC TROP MED H, V97, P318, DOI 10.1016/S0035-9203(03)90160-X; Gorissen E, 2000, TROP MED INT HEALTH, V5, P459, DOI 10.1046/j.1365-3156.2000.00570.x; Grace JM, 1998, DRUG METAB DISPOS, V26, P313; KILIMALI VAEB, 1990, E AFR MED J, V67, P336; LEE IS, 1990, PHARMACOL THERAPEUT, V48, P345, DOI 10.1016/0163-7258(90)90053-5; Li XQ, 2002, J PHARMACOL EXP THER, V300, P399, DOI 10.1124/jpet.300.2.399; MCINTOSH HM, 2003, COCHRANE DATABASE SY; Mutanda LN, 1999, E AFR MED J, V76, P421; Noedl H, 2001, AM J TROP MED HYG, V65, P696, DOI 10.4269/ajtmh.2001.65.696; Ouedraogo JB, 1998, TROP MED INT HEALTH, V3, P381; Pettinelli FO, 2004, AM J TROP MED HYG, V70, P635, DOI 10.4269/ajtmh.2004.70.635; Pradines B, 1998, AM J TROP MED HYG, V58, P354, DOI 10.4269/ajtmh.1998.58.354; Pradines B, 1998, PARASITOLOGY, V117, P541, DOI 10.1017/S0031182098003400; Pradines B, 1998, J ANTIMICROB CHEMOTH, V42, P333, DOI 10.1093/jac/42.3.333; Ringwald P, 1999, J CLIN MICROBIOL, V37, P700; Ringwald P, 1999, AM J TROP MED HYG, V61, P187, DOI 10.4269/ajtmh.1999.61.187; Rwagacondo CE, 2004, TROP MED INT HEALTH, V9, P1091, DOI 10.1111/j.1365-3156.2004.01316.x; Rwagacondo CE, 2003, AM J TROP MED HYG, V68, P743, DOI 10.4269/ajtmh.2003.68.743; Schellenberg D, 2002, AM J TROP MED HYG, V67, P17, DOI 10.4269/ajtmh.2002.67.17; SHMUKLARSKY MJ, 1993, AM J TROP MED HYG, V48, P377, DOI 10.4269/ajtmh.1993.48.377; Shretta R, 2000, TROP MED INT HEALTH, V5, P755, DOI 10.1046/j.1365-3156.2000.00643.x; Staedke SG, 2001, LANCET, V358, P368, DOI 10.1016/S0140-6736(01)05557-X; Tinto H, 2001, Bull Soc Pathol Exot, V94, P188; Trape JF, 2001, AM J TROP MED HYG, V64, P12, DOI 10.4269/ajtmh.2001.64.12; van Dillen J, 1999, T ROY SOC TROP MED H, V93, P185, DOI 10.1016/S0035-9203(99)90304-8; WHITE NJ, 1994, T ROY SOC TROP MED H, V88, P1, DOI 10.1016/0035-9203(94)90458-8; White NJ, 1998, ANN TROP MED PARASIT, V92, P449	35	27	29	0	2	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0035-9203	1878-3503		T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	JUN	2006	100	6					509	514		10.1016/j.trstmh.2005.09.018				6	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	037JP	WOS:000237143200003	16337665				2019-03-26	
J	Koffi, M; Solano, P; Denizot, M; Courtin, D; Garcia, A; Lejon, V; Buscher, P; Cuny, G; Jamonneau, V				Koffi, M.; Solano, P.; Denizot, M.; Courtin, D.; Garcia, A.; Lejon, V.; Buscher, P.; Cuny, G.; Jamonneau, V.			Aparasitemic serological suspects in Trypanosoma brucei gambiense human African trypanosomiasis: A potential human reservoir of parasites?	ACTA TROPICA			English	Article						Trypanosoma brucei gambiense; human African trypanosomiasis; PCR; serological suspects; human reservoir; Cote d'Ivoire	POLYMERASE-CHAIN-REACTION; SLEEPING-SICKNESS SUSPECTS; CARD-AGGLUTINATION-TEST; COTE-DIVOIRE; ANIMAL RESERVOIR; GAMBIAN TRYPANOSOMIASIS; DNA AMPLIFICATION; DIAGNOSIS; CATT; CONGO	The serological and parasitological tests used for Trypanosoma brucei gambiense human African trypanosomiasis (HAT) diagnosis have low specificity and sensitivity, respectively, and in the field, control program teams are faced with subjects with positive serology but negative parasitology who remain untreated. The aim of this work was to explore, using PCR tool, the significance of these aparasitemic serological suspects. Since discordant PCR results have been observed earlier with different extraction methods, two DNA extraction methods were compared (the Chelex 100((R)) resin and the DNeasy((R)) Tissue kit). The study was conducted on 604 blood samples: 574 from parasitologically confirmed patients, aparasitemic serological suspects and endemic controls collected in Me d'lvoire and 30 from healthy volunteers collected in France. No significant differences were observed between the PCR results obtained with the two extraction methods. Concerning PCR, problems of reproducibility and discordances with both serological and parasitological test results were observed, mainly for the aparasitemic scrological suspects. In addition to previous results that pointed to the existence of non-virulent or non-pathogenic trypanosome strains and of individual susceptibility leading to long term seropositivity without detectable parasitaemia but positive PCR, the results of this study support the notion of a long lasting human reservoir that may contribute to the maintenance or periodic resurgences of HAT in endemic foci. (c) 2006 Elsevier B.V. All rights reserved.	Inst Rech Dev, Unite Rech 177, Programme Sante Anim, TA 207G, F-34398 Montpellier 5, France; Inst Pierre Richet, Unite Rech 177, Inst Rech Dev, Abidjan 04, Cote Ivoire; Fac Pharm, Inst Rech Dev, Unite Rech 010, F-75270 Paris, France; ITMA, Dept Parasitol, B-2000 Antwerp, Belgium	Jamonneau, V (reprint author), Inst Rech Dev, Unite Rech 177, Programme Sante Anim, TA 207G, Campus Int Baillarguet, F-34398 Montpellier 5, France.	vincent.jamonneau@mpl.ird.fr	Garcia, Andre/S-2959-2016; Jamonneau, Vincent/K-1124-2016; Solano, Philippe/B-2328-2010; Buscher, Philippe/B-9956-2012	Garcia, Andre/0000-0002-1808-472X; Buscher, Philippe/0000-0002-1926-7472; solano, philippe/0000-0002-4351-3506; Courtin, David/0000-0002-5263-4430; Lejon, Veerle/0000-0002-6795-0962			[Anonymous], 1998, WHO TECHN REP SER, V881; Becker S, 2004, DIAGN MICR INFEC DIS, V50, P193, DOI 10.1016/j.diagmicrobio.2004.07.001; Chappuis F, 2005, CLIN MICROBIOL REV, V18, P133, DOI 10.1128/CMR.18.1.133-146.2005; Diallo PB, 1996, B SOC PATHOL EXOT, V89, P262; DUKES P, 1984, TROPENMED PARASITOL, V35, P141; Enyaru JCK, 1998, ANN TROP MED PARASIT, V92, P845; Garcia A, 2000, TROP MED INT HEALTH, V5, P786, DOI 10.1046/j.1365-3156.2000.00623.x; Jamonneau V, 2004, ANN TROP MED PARASIT, V98, P329, DOI 10.1179/000349804225003406; Jamonneau V, 2003, TROP MED INT HEALTH, V8, P589, DOI 10.1046/j.1365-3156.2003.01079.x; Jamonneau V, 2002, TROP MED INT HEALTH, V7, P610, DOI 10.1046/j.1365-3156.2002.00905.x; Jamonneau V, 2000, ANN TROP MED PARASIT, V94, P831, DOI 10.1080/00034980020028004; JANNIN J, 1993, B WORLD HEALTH ORGAN, V71, P215; Kabiri M, 1999, TROP MED INT HEALTH, V4, P658, DOI 10.1046/j.1365-3156.1999.00465.x; Kanmogne GD, 1996, ANN TROP MED PARASIT, V90, P475, DOI 10.1080/00034983.1996.11813072; Kyambadde JW, 2000, B WORLD HEALTH ORGAN, V78, P119; Lambrechts L, 2006, TRENDS PARASITOL, V22, P12, DOI 10.1016/j.pt.2005.11.008; Legros D, 2002, LANCET INFECT DIS, V2, P437, DOI 10.1016/S1473-3099(02)00321-3; Lejon V, 2003, LANCET INFECT DIS, V3, P804, DOI 10.1016/S1473-3099(03)00834-X; LUMSDEN WHR, 1979, T ROY SOC TROP MED H, V73, P312, DOI 10.1016/0035-9203(79)90092-0; MAGNUS E, 1978, ANN SOC BELG MED TR, V58, P169; MEHLITZ D, 1982, TROPENMED PARASITOL, V33, P113; MOSER DR, 1989, PARASITOLOGY, V99, P57, DOI 10.1017/S0031182000061023; Njiokou F, 2006, INFECT GENET EVOL, V6, P147, DOI 10.1016/j.meegid.2005.04.003; NOIREAU F, 1986, ANN SOC BELG MED TR, V66, P63; NOIREAU F, 1986, TROP MED PARASITOL, V37, P393; NOIREAU F, 1987, B SOC PATHOL EXOT, V80, P797; PENCHENIER L, 1991, ANN SOC BELG MED TR, V71, P221; Penchenier L, 2000, T ROY SOC TROP MED H, V94, P392, DOI 10.1016/S0035-9203(00)90116-0; Penchenier L, 1996, PARASITE, V4, P387; Radwanska M, 2002, AM J TROP MED HYG, V67, P289, DOI 10.4269/ajtmh.2002.67.289; Ravel S, 2004, PARASITE, V11, P107, DOI 10.1051/parasite/2004111107; Solano P, 2002, ACTA TROP, V82, P349, DOI 10.1016/S0001-706X(02)00029-3; Sternberg JM, 2004, PARASITE IMMUNOL, V26, P469, DOI 10.1111/j.0141-9838.2004.00731.x; TRUC P, 1994, T ROY SOC TROP MED H, V88, P419, DOI 10.1016/0035-9203(94)90410-3; Yera H, 2003, EUR J PROTISTOL, V39, P435, DOI 10.1078/0932-4739-00017	35	39	39	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0001-706X	1873-6254		ACTA TROP	Acta Trop.	MAY	2006	98	2					183	188		10.1016/j.actatropica.2006.04.001				6	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	055PB	WOS:000238461500010	16723098				2019-03-26	
J	Grandesso, F; Bachy, C; Donam, I; Ntambi, J; Habimana, J; D'Alessandro, U; Maikere, J; Vanlerberghe, V; Kerah, CH; Guthmann, JP				Grandesso, F; Bachy, C; Donam, I; Ntambi, J; Habimana, J; D'Alessandro, U; Maikere, J; Vanlerberghe, V; Kerah, CH; Guthmann, JP			Efficacy of chloroquine, sulfadoxine-pyrimethamine and amodiaquine for treatment of uncomplicated Plasmodium falciparum malaria among children under five in Bongor and Koumra, Chad	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						malaria; Plasmodium falciparum; chloroquine; sulfadoxine-pyrimethamine; amodiaquine; resistance; Chad	ARTEMETHER-LUMEFANTRINE; IN-VIVO; RESISTANCE; COMBINATION; AFRICA; UGANDA; ARTESUNATE; DISASTER; TRIAL; SUDAN	We report two 28-day in-vivo antimalarial efficacy studies carried out in the urban centres of Bongor and Koumra, southern Chad. We assess chloroquine (CQ), sulfadoxine-pyrimethamine (SP) and amodiaquine (AQ) to treat Plasmodium falciparum uncomplicated malaria. Methods and outcome classification complied with latest WHO guidelines. Out of the 301 and 318 children aged 6-59 months included in Bangor and Koumra, respectively, 246 (81.7%) and 257 (80.8%) were eligible for analysis. In Bangor and Koumra, the 28-day PCR-adjusted failure rates for CQ were 23.7% (95% CI 14.7-34.8%) and 32.9% (95% CI 22.1-45.1%), respectively, and those for SP were 16.3% (95% CI 9.4-25.5%) and 4.3% (95% CI 1.2-10.5%). AQ failure rates were 6.4% (95% CI 2.1-14.3%) and 2.2% (95% Cl 0.3-7.6%). The current use of CQ in Bongor and Koumra is questionable, and a more efficacious treatment is needed. Considering the reduced efficacy of SP in Bongor, AQ seems to be the best option for the time being. Following WHO recommendations that prioritize the use of artemisinin-based combinations, artesunate plus amodiaquine could be a potential first-tine treatment. Nevertheless, the efficacy of this combination should be evaluated and the change carefully prepared, implemented and monitored. (c) 2005 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.	Epictr, F-75011 Paris, France; Programme Natl Lutte Contre Malaria, Ndjamena, Chad; Med Sans Frontieres, B-1090 Brussels, Belgium; Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium	Grandesso, F (reprint author), Epictr, 8 Rue St Sabin, F-75011 Paris, France.	francesco.grandesso@epicentre.msf.org	D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009; Grandesso, Francesco/0000-0001-9909-0285			[Anonymous], 2001, WHOCDSRBM200135; BAYOUMI RA, 1989, ACTA TROP, V46, P157, DOI 10.1016/0001-706X(89)90032-6; Bloland PB, 2001, WHOCDSCSRDRS20014; Checchi F, 2004, TROP MED INT HEALTH, V9, P445, DOI 10.1111/j.1365-3156.2004.01217.x; Checchi F, 2002, T ROY SOC TROP MED H, V96, P664, DOI 10.1016/S0035-9203(02)90346-9; EKANEM OJ, 1990, B WORLD HEALTH ORGAN, V68, P45; Marsh K, 1998, LANCET, V352, P924, DOI 10.1016/S0140-6736(05)61510-3; Mutabingwa TK, 2005, LANCET, V365, P1474, DOI 10.1016/S0140-6736(05)66417-3; Nosten F, 2002, DRUGS, V62, P1315, DOI 10.2165/00003495-200262090-00003; Piola P, 2005, LANCET, V365, P1467, DOI 10.1016/S0140-6736(05)66416-1; RANFORDCARTWRIGHT LC, 1993, PARASITOLOGY, V107, P11, DOI 10.1017/S003118200007935X; Rapuoda B, 2003, TROP MED INT HEALTH, V8, P860; Ringwald P, 2000, TROP MED INT HEALTH, V5, P620, DOI 10.1046/j.1365-3156.2000.00614.x; Ronn AM, 1996, T ROY SOC TROP MED H, V90, P179, DOI 10.1016/S0035-9203(96)90129-7; Rwagacondo CE, 2004, TROP MED INT HEALTH, V9, P1091, DOI 10.1111/j.1365-3156.2004.01316.x; Snounou Georges, 2002, Methods Mol Med, V72, P103, DOI 10.1385/1-59259-271-6:103; Sowunmi A, 2001, ANN TROP MED PARASIT, V95, P549, DOI 10.1080/00034980120092507; Stepniewska K, 2004, ANTIMICROB AGENTS CH, V48, P4271, DOI 10.1128/AAC.48.11.4271-4280.2004; Stivanello E, 2004, TROP MED INT HEALTH, V9, P975, DOI 10.1111/j.1365-3156.2004.01290.x; Talisuna AO, 2002, T ROY SOC TROP MED H, V96, P310, DOI 10.1016/S0035-9203(02)90108-2; Terlouw DJ, 2003, ANTIMICROB AGENTS CH, V47, P2929, DOI 10.1128/AAC.47.9.2929-2932.2003; Trape JF, 2001, AM J TROP MED HYG, V64, P12, DOI 10.4269/ajtmh.2001.64.12; White NJ, 1996, PARASITOL TODAY, V12, P399, DOI 10.1016/0169-4758(96)10055-7; White NJ, 1999, LANCET, V353, P1965, DOI 10.1016/S0140-6736(98)07367-X; *WHO, 1996, WHOMAL961077 DIV CON; *WHO, 2002, WHOCDSCSREPH200217; *WHO, 2003, WHOHTMRBM200350	27	9	10	1	3	ROYAL SOC TROPICAL MEDICINE	LONDON	MANSON HOUSE 26 PORTLAND PLACE, LONDON W1N 1EY, ENGLAND	0035-9203			T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	MAY	2006	100	5					419	426		10.1016/j.trstmh.2005.07.017				8	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	029LI	WOS:000236563600004	16297419	Green Published			2019-03-26	
J	Fanello, CI; Karema, C; van Doren, W; Rwagacondo, CE; D'Alessandro, U				Fanello, CI; Karema, C; van Doren, W; Rwagacondo, CE; D'Alessandro, U			Tolerability of amodiaquine and sulphadoxine-pyrimethamine, alone or in combination for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan adults	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						Plasmodium falciparum malaria; Rwanda; amodiaquine; sulphadoxine-pyrimethamine; tolerability	EFFICACY; ARTESUNATE; CHILDREN; RAT	Objective: To assess the tolerability and efficacy of amodiaquine (AQ) + sulphadoxine-pyrimethamine (SP), the first-line malaria treatment in Rwanda. Method: Randomized, double-blind trial in 2003 in Kigali town. A total of 351 adult patients with uncomplicated Plasmodium falciparum malaria were randomly allocated to one of the following treatments: AQ + SP, AQ or SP. We followed patients until day 14 after treatment and recorded adverse events (AEs) and clinical and parasitological outcomes. Results: One hundred and eighteen patients reported at least one AE: 40% in the AQ, 39% in the AQ + SP and 21% in the SP groups. The AE was classified as possibly related to the antimalarial treatment for 86 patients. The Risk Ratio for at least one AE after treatment was significantly and about fourfold higher in patients receiving AQ or AQ + SP than in patients receiving SP. Pruritus and fatigue were significantly more frequent in patients treated with AQ or AQ + SP than in those receiving SP. Severe AEs, such as fatigue, nausea, dizziness and vomiting, were observed in four patients treated with AQ, in 10 treated with AQ + SP and in one patient treated with SP. Conclusion: Amodiaquine + SP is not well tolerated and a substantial proportion of patients experienced pruritus and fatigue, thus decreasing their compliance and compromising the first line treatment implementation at national level. This renders AQ-containing regimens sub-optimal; better-tolerated treatments should be identified.	London Sch Hyg & Trop Med, London WC1, England; Natl Malaria Control Program, Kigali, Rwanda; Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium; Belgian Tech Cooperat, Kigali, Rwanda	D'Alessandro, U (reprint author), London Sch Hyg & Trop Med, London WC1, England.	udalessandro@itg.be	D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009; Fanello, Caterina/0000-0003-1932-9562			Basco LK, 2002, B WORLD HEALTH ORGAN, V80, P538; CLARKE JB, 1990, INT ARCH ALLER A IMM, V91, P335, DOI 10.1159/000235138; Estes M L, 1987, Am J Med, V82, P447, DOI 10.1016/0002-9343(87)90444-X; HARRISON AC, 1992, BIOCHEM PHARMACOL, V43, P1421, DOI 10.1016/0006-2952(92)90198-R; HATTON CSR, 1986, LANCET, V1, P411; MACLEHOSE HG, 2003, AMODIAQUINE SYSTEMAT; MAGGS JL, 1988, BIOCHEM PHARMACOL, V37, P305; NEFTEL KA, 1986, BRIT MED J, V292, P721, DOI 10.1136/bmj.292.6522.721; Oduro AR, 2005, TROP MED INT HEALTH, V10, P279, DOI 10.1111/j.1365-3156.2004.01382.x; Olliaro P, 1996, LANCET, V348, P1196, DOI 10.1016/S0140-6736(96)06217-4; Olliaro P, 2003, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858; PHILLIPSHOWARD PA, 1990, J ROY SOC MED, V83, P82, DOI 10.1177/014107689008300208; Rwagacondo CE, 2004, TROP MED INT HEALTH, V9, P1091, DOI 10.1111/j.1365-3156.2004.01316.x; Rwagacondo CE, 2003, AM J TROP MED HYG, V68, P743, DOI 10.4269/ajtmh.2003.68.743; Staedke SG, 2001, LANCET, V358, P368, DOI 10.1016/S0140-6736(01)05557-X; WHO, 2003, ASS MON ANT DRUG EFF; *WHO, 2003, REP WHO EXP COMM SEL; WHO, 2002, REP WHO EXP COMM SEL; WHO, 1996, MAN UNC MAL US ANT D; *WHO, 2002, METH FOODB DIS SURV, P1; YEKA, 2005, PLOS MED, V2, pE190	21	15	15	0	0	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	MAY	2006	11	5					589	596		10.1111/j.1365-3156.2006.01610.x				8	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	036TG	WOS:000237097800004	16640610				2019-03-26	
J	Lejon, V; Jamonneau, V; Solano, P; Atchade, P; Mumba, D; Nkoy, N; Bebronne, N; Kibonja, T; Balharbi, F; Wierckx, A; Boelaert, M; Buscher, P				Lejon, V; Jamonneau, V; Solano, P; Atchade, P; Mumba, D; Nkoy, N; Bebronne, N; Kibonja, T; Balharbi, F; Wierckx, A; Boelaert, M; Buscher, P			Detection of trypanosome-specific antibodies in saliva, towards non-invasive serological diagnosis of sleeping sickness	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						human African trypanosomiasis; antibody detection; saliva; serum; diagnosis; Trypanosoma brucei gambiense	ORAL FLUID; AFRICAN TRYPANOSOMIASIS; CEREBROSPINAL-FLUID; AGGLUTINATION-TEST; SERUM; BRUCEI; ETHIOPIA; DISEASES; RUBELLA	Objective: The detection of trypanosome-specific antibodies in saliva is technically feasible, and, if clinically validated, could become an attractive option for non-invasive diagnosis of sleeping sickness. We wanted to optimize the test format of an enzyme-linked immunosorbent assay (ELISA)-based antibody detection system. Methods: Different ELISA formats for antibody detection in serum and saliva were developed and standardized. Saliva and serum samples were collected from 78 patient and 128 endemic control samples, and sensitivity and specificity of saliva ELISAs, serum ELISAs and the card agglutination test for trypanosomiasis (CATT), were evaluated. Results: All ELISA formats showed sensitivity and specificity above 90%. Saliva ELISAs showed a similar test performance as serum ELISAs and the CATT on whole blood or serum. Conclusions: This study confirms the potential of trypanosome-specific antibody detection in saliva.	Inst Trop Med, Dept Parasitol, Natl Str 155, B-2000 Antwerp, Belgium; Lab Rech & Coordinat Trypanosomoses, Inst Rech Dev, Montpellier, France; Inst Rech Dev, Bobo Dioulasso, Burkina Faso; Programme Natl Lutte Contre Trypanosomiase Humani, Cotonou, Benin; Inst Natl Rech Biomed, Kinshasa, DEM REP CONGO; Programme Natl Lutte Contre Trypanosomiase Humain, Kinshasa, DEM REP CONGO; Katholieke Hogesch St Lieven, Ghent, Belgium; Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium	Lejon, V (reprint author), Inst Trop Med, Dept Parasitol, Natl Str 155, B-2000 Antwerp, Belgium.	vlejon@itg.be	Buscher, Philippe/B-9956-2012; Boelaert, Marleen/E-2698-2012; Solano, Philippe/B-2328-2010; Jamonneau, Vincent/K-1124-2016	Buscher, Philippe/0000-0002-1926-7472; Boelaert, Marleen/0000-0001-8051-6776; solano, philippe/0000-0002-4351-3506; Lejon, Veerle/0000-0002-6795-0962			AVODE G, 1988, B SOC PATHOL EXOT, V81, P513; BAILEY JW, 1992, T ROY SOC TROP MED H, V86, P630, DOI 10.1016/0035-9203(92)90160-E; BEHETS FM, 1991, J ACQ IMMUN DEF SYND, V4, P183; Buscher P, 1999, ACTA TROP, V73, P11, DOI 10.1016/S0001-706X(99)00009-1; BUSCHER P, 1994, B LIAIS DOC OCEAC, V27, P225; Chappuis F, 2005, CLIN MICROBIOL REV, V18, P133, DOI 10.1128/CMR.18.1.133-146.2005; Jacobson RH, 1998, REV SCI TECH OIE, V17, P469, DOI 10.20506/rst.17.2.1119; Lejon V, 2003, TROP MED INT HEALTH, V8, P585, DOI 10.1046/j.1365-3156.2003.01077.x; Lejon V, 1998, ACTA TROP, V69, P151, DOI 10.1016/S0001-706X(97)00137-X; LUMSDEN WHR, 1979, T ROY SOC TROP MED H, V73, P312, DOI 10.1016/0035-9203(79)90092-0; MAGNUS E, 1978, ANN SOC BELG MED TR, V58, P169; McKie A, 2002, LANCET INFECT DIS, V2, P18, DOI 10.1016/S1473-3099(01)00169-4; Nokes DJ, 1998, TROP MED INT HEALTH, V3, P258, DOI 10.1046/j.1365-3156.1998.00227.x; Nokes DJ, 2001, B WORLD HEALTH ORGAN, V79, P588; Vyse AJ, 2001, PUBLIC HEALTH, V115, P201, DOI 10.1016/S0033-3506(01)00444-9; WESTGARD JO, 1981, CLIN CHEM, V27, P493; *WHO, 2001, STAT WORLDS NEWB, P1; WOO P T K, 1971, Acta Tropica, V28, P298; YOUDEN WJ, 1950, CANCER, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3	19	14	14	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	MAY	2006	11	5					620	627		10.1111/j.1365-3156.2006.01620.x				8	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	036TG	WOS:000237097800008	16640614	Bronze			2019-03-26	
J	Torrico, F; Vega, CA; Suarez, E; Tellez, T; Brutus, L; Rodriguez, P; Torrico, MC; Schneider, D; Truyens, C; Carlier, Y				Torrico, F; Vega, CA; Suarez, E; Tellez, T; Brutus, L; Rodriguez, P; Torrico, MC; Schneider, D; Truyens, C; Carlier, Y			Are maternal re-infections with Trypanosoma cruzi associated with higher morbidity and mortality of congenital Chagas disease?	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article; Proceedings Paper	International Colloquium on Congenital Trypanosoma Cruzi Infection - From Mechanisms of Transmission to a Strategy for Diagnosis and Control	NOV 06-08, 2002	COCHABAMBA, BOLIVIA			Trypanosoma cruzi; congenital Chagas disease; vectorial density; maternal residence; parasitaemia	TRIATOMA-INFESTANS HEMIPTERA; TRANSMISSION; REINFECTION; BRAZIL; REDUVIIDAE; ARGENTINA; MICE	Background: Comparing two surveys performed in Bolivia in 1992-1994 and 1999-2001, we reported a significant decrease in the proportions of severe and mortal forms of congenital Chagas disease. This might be due to a reduction of vectorial density (VD) in maternal residence area, raising the question of a possible causal relationship between such VD, maternal parasitaemia and prognosis of congenital infection with Trypanosoma cruzi. Method: Comparisons of haematological and parasitological data obtained from Bolivian mothers infected with T. cruzi, and of clinical and biological data obtained from their infected and uninfected newborns, stratified according to VD in the area of maternal residence. Results: i) Blood hematocrit rates or hemoglobin amounts were within the normal ranges and similar in all the maternal groups, whatever the VD in their areas of residence; ii) mothers living in high VD areas displayed a higher frequency of hemocultures positive for T. cruzi; iii) newborns congenitally infected with T. cruzi, but not uninfected babies born from infected mothers, displayed higher frequencies of very low Apgar scores, low birth weights, prematurity, respiratory distress syndrome or anasarca, as well as higher mortality rates when their mothers lived in areas of high VD. Conclusion: Frequent bites of blood sucking Reduvidae during pregnancy do not induce maternal anaemia, but, likely through multiple maternal re-infections with T. cruzi, increase maternal parasitemia and worsen congenital Chagas disease. Maternal dwelling in areas of high VD is associated with a serious increased risk of severe and mortal congenital Chagas disease.	Univ Libre Bruxelles, Fac Med, Parasitol Lab, B-1070 Brussels, Belgium; Univ Mayor San Simon, Fac Med, Ctr Univ Med Trop, Cochabamba, Bolivia; Univ Libre Bruxelles, Fac Med, Parasitol Lab, La Paz, Bolivia	Carlier, Y (reprint author), Univ Libre Bruxelles, Fac Med, Parasitol Lab, 808 Route Lennik CP 616, B-1070 Brussels, Belgium.	ycarlier@ulb.ac.be	Brutus, Laurent/A-7430-2011	Brutus, Laurent/0000-0002-9967-0666			Carlier Yves, 2003, Rev. Soc. Bras. Med. Trop., V36, P767, DOI 10.1590/S0037-86822003000600024; BALLARD JL, 1991, J PEDIATR-US, V119, P417, DOI 10.1016/S0022-3476(05)82056-6; BASSO B, 1984, MEDICINA-BUENOS AIRE, V44, P41; BRENIERE SF, 1985, TROP GEOGR MED, V37, P231; Bustamante JM, 2002, INT J PARASITOL, V32, P889, DOI 10.1016/S0020-7519(02)00023-1; Cabrine-Santos M, 2001, EXP PARASITOL, V99, P160, DOI 10.1006/expr.2001.4661; CARLIER Y, 2002, ENCY MED CHIR; DIAS JCP, 2000, TRYPANOSOMA CRUZI DO, P48; Hermann E, 2004, J INFECT DIS, V189, P1274, DOI 10.1086/382511; HUTTENLOCKER PR, 1987, NELSON TXB PEDIAT, P1279; LauriaPires L, 1997, J PARASITOL, V83, P819, DOI 10.2307/3284274; Lh A, 2000, AM J CLIN NUTR, V7, P1280; Machado EMM, 2001, AM J TROP MED HYG, V65, P958, DOI 10.4269/ajtmh.2001.65.958; MINTER DM, 1973, T ROY SOC TROP MED H, V67, P290, DOI 10.1016/0035-9203(73)90212-5; MOTT KE, 1978, AM J TROP MED HYG, V27, P1116, DOI 10.4269/ajtmh.1978.27.1116; PIESMAN J, 1985, AM J TROP MED HYG, V34, P866, DOI 10.4269/ajtmh.1985.34.866; RABINOVICH JE, 1990, B WORLD HEALTH ORGAN, V68, P737; REVELLI S, 1990, REV I MED TROP, V32, P260, DOI 10.1590/S0036-46651990000400005; SCHOFIELD CJ, 1981, LANCET, V1, P1316; Torrico F, 2004, AM J TROP MED HYG, V70, P201, DOI 10.4269/ajtmh.2004.70.201; Virreira M, 2003, AM J TROP MED HYG, V68, P574, DOI 10.4269/ajtmh.2003.68.574; WISNIVESKYCOLLI C, 1982, J MED ENTOMOL, V19, P645, DOI 10.1093/jmedent/19.6.645	22	36	40	1	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	MAY	2006	11	5					628	635		10.1111/j.1365-3156.2006.01623.x				8	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	036TG	WOS:000237097800009	16640615	Bronze			2019-03-26	
J	Saizonou, J; Godin, I; Ouendo, EM; Zerbo, R; Dujardin, B				Saizonou, J; Godin, I; Ouendo, EM; Zerbo, R; Dujardin, B			Emergency obstetrical care in Benin referral hospitals: 'near miss' patients' views	TROPICAL MEDICINE & INTERNATIONAL HEALTH			French	Article						emergency obstetric care; 'near miss'; satisfaction; expectations; evaluation; Benin	HEALTH-CARE; QUALITY	Objective: To evaluate emergency obstetric care and the perceptions and expectations of women who experienced 'near miss' events to improve maternal health in Benin. Methods: Qualitative survey in seven hospitals at the three referral levels of the health pyramid from July to October 2003. We used two methods: 557 women with near miss events were interviewed in hospital and a standard questionnaire completed; then semi-structured individual interviews were conducted at home with 42 of these 557 women. Results: Provided care, accommodation, facilities, costs and modalities of recovery, hygiene of the premises, dynamism, expertise, social support, behaviours and attitude of staff were the criteria used to express patients' satisfaction. Most women interviewed in hospital were happy with physical access, organization, functioning and environment. However, excessive costs and coercive recovery of the expenses, failure of the referral system, lack of empathy and discrimination of the nursing staff, lack of resources for emergencies, lack of hygiene and comfort of the premises were criticized by the women interviewed at home. Conclusion: The current maternal care system fails to effectively deal with obstetric complications. It needs to be better resourced, more easily available, cheaper and taking into account the women's needs.	Ctr Rech Reprod Humaine & Demog, Cotonou, Benin; Univ Libre Bruxelles, Ecole Sante Publ, Brussels, Belgium; Inst Reg Sante Publ, Ouidah, Benin	Saizonou, J (reprint author), Ctr Rech Reprod Humaine & Demog, Cotonou, Benin.	saizonoujacques@yahoo.fr					Beraud C, 1998, REV EPIDEMIOL SANTE, V46, P345; Briancon S, 2000, REV EPIDEMIOL SANTE, V48, P541; CLERGUE F, 2003, REANIMATION, V12, pS49; Daouas F, 2002, Sante Publique, V14, P135; Dujardin A, 1993, THESIS I MED TROPICA, P198; Filippi V, 2004, HEALTH POLICY PLANN, V19, P57, DOI 10.1093/heapol/czh007; Grossmann-Kendall F, 2001, REPROD HEALTH MATTER, V9, P90, DOI 10.1016/S0968-8080(01)90095-3; HADDAD S, 1995, SOC SCI MED, V40, P743, DOI 10.1016/0277-9536(94)00134-F; JAFERY SN, 1993, SOC SCI MED, V36, P371; JAFFRE Y, 1994, SOC SCI MED, V38, P1069, DOI 10.1016/0277-9536(94)90224-0; JAFFRE Y, 2003, MED INHOSPITALIERE D, P461; Jahn A, 2000, TROP MED INT HEALTH, V5, P657, DOI 10.1046/j.1365-3156.2000.00611.x; Kowalewski M, 2000, Afr J Reprod Health, V4, P100, DOI 10.2307/3583247; Landais P, 2003, REV EPIDEMIOL SANTE, V51, P185; MAHLER H, 1987, LANCET, V1, P668; *MIN SANT BEN, 2002, PROGR NAT SANT REPR; PARIZOT I, 2003, REV EPIDEMIOL SANTE, V51, P557; *PMM NETW, 1995, SOC SCI MED, V40, P657; Prual A, 1999, Sante Publique, V11, P155; Prual A, 1999, Sante Publique, V11, P167; Prual A, 2000, B WORLD HEALTH ORGAN, V78, P593; RACHEL J, 1998, SOC SCI MED, V47, P1781; Richard F, 2003, REV EPIDEMIOL SANTE, V51, P39; Sitzia J, 1997, SOC SCI MED, V45, P1829, DOI 10.1016/S0277-9536(97)00128-7; THADDEUS S, 1994, SOC SCI MED, V38, P1091, DOI 10.1016/0277-9536(94)90226-7; van den Broek NR, 2003, BJOG-INT J OBSTET GY, V110, P902, DOI 10.1016/S1470-0328(03)02902-1; *WHO, 2004, RAPP SANT MOND 2004; [World Health Organization (WHO) Maternal Health and Safe Motherhood Programme], 1994, MOTH BAB PACK IMPL S	28	7	7	0	3	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	MAY	2006	11	5					672	680		10.1111/j.1365-3156.2006.01602.x				9	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	036TG	WOS:000237097800014	16640620				2019-03-26	
J	Callens, SFJ; Kitetele, F; Lukun, P; Lelo, P; Van Rie, A; Behets, F; Colebunders, R				Callens, SFJ; Kitetele, F; Lukun, P; Lelo, P; Van Rie, A; Behets, F; Colebunders, R			Pulmonary Sporothrix schenckii infection in a HIV positive child	JOURNAL OF TROPICAL PEDIATRICS			English	Article							SPOROTRICHOSIS; AIDS; EPIDEMIOLOGY; RIFAMPICIN	Sporothrix schenckii is a ubiquitous fungus, causing mostly non life-threatening localized infections of the skin and subcutaneous tissues that can be treated with oral antifungal agents. Meningeal, pulmonary and osteoarticular dissemination occur mainly in immunosuppressed patients. Pulmonary sporothricosis is rare and responds poorly to treatment. Cases of disseminated sporotrichosis have most frequently been reported in patients residing in South America and Asia, and have increasingly been reported in AIDS patients. The distribution and pathogenicity of S. schenckii in Sub-Saharan Africa is not well known. We report a case of invasive pulmonary sporothrichosis in an eleven year old HIV-infected boy in Kinshasa, Democratic Republic of the Congo, successfully treated with oral fluconazole.	Pediat Hosp Kalembe Lembe, Kinshasa, Zaire; Univ Kinshasa, Sch Publ Hlth, Kinshasa, Zaire; Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC USA; Univ Antwerp, B-2020 Antwerp, Belgium; Inst Trop Med, Antwerp, Belgium	Callens, SFJ (reprint author), Natl Str 155, B-2000 Antwerp, Belgium.	callens@email.unc.edu	Van Rie, Annelies/C-2082-2017	Van Rie, Annelies/0000-0001-7666-3263; Callens, Steven/0000-0002-7245-527X			Aarestrup FM, 2001, ORAL DIS, V7, P134, DOI 10.1034/j.1601-0825.2001.0070213.x; AUTAR R, 2004, EJIAS           0711, P1; Ayudhya DPN, 2004, CLIN PHARMACOKINET, V43, P725, DOI 10.2165/00003088-200443110-00003; Bangsberg DR, 2003, AIDS, V17, P1925, DOI 10.1097/01.aids.0000076320.42412.fd; da Rosa ACM, 2005, J AM ACAD DERMATOL, V52, P451, DOI 10.1016/j.jaad.2004.11.046; GEEL J, 2004, EJIAS           0711, P1; GUMAA SA, 1978, T ROY SOC TROP MED H, V72, P637, DOI 10.1016/0035-9203(78)90020-2; Kauffman CA, 2000, CLIN INFECT DIS, V30, P684, DOI 10.1086/313751; Madhivanan Purnima, 2003, Indian Journal of Pediatrics, V70, P615, DOI 10.1007/BF02724249; MAHGOUB ES, 1968, J TROP MED HYG, V71, P313; Marques SA, 2000, MED MYCOL, V38, P269, DOI 10.1080/744118724; Ribera E, 2001, J ACQ IMMUN DEF SYND, V28, P450; Torrealba JR, 2005, OTOLARYNG HEAD NECK, V132, P339, DOI 10.1016/j.otohns.2004.05.003; Vismer HF, 1997, MYCOPATHOLOGIA, V137, P137, DOI 10.1023/A:1006830131173	14	19	22	0	4	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0142-6338			J TROP PEDIATRICS	J. Trop. Pediatr.	APR	2006	52	2					144	146		10.1093/tropej/fmi101				3	Pediatrics; Tropical Medicine	Pediatrics; Tropical Medicine	030DT	WOS:000236614200016	16291829	Bronze			2019-03-26	
J	Lutumba, P; Robays, J; Miaka, C; Kande, V; Mumba, D; Buscher, P; Dujardin, B; Boelaert, M				Lutumba, P; Robays, J; Miaka, C; Kande, V; Mumba, D; Buscher, P; Dujardin, B; Boelaert, M			Validity, cost and feasibility of the mAECT and CTC as the tests of confirmation in the detection of the African Human Trypanosomiasis.	TROPICAL MEDICINE & INTERNATIONAL HEALTH			French	Article						Human African Trypanosomiasis; diagnostic accuracy; D. R. Congo; sensitivity and specificity; Trypanosoma brucei gambiense; screening; mini anion-exchange centrifugation technique; capillary tube centrifugation; card agglutination test for trypanosomiasis titration	CARD-AGGLUTINATION-TEST; CEREBROSPINAL-FLUID; BRUCEI-GAMBIENSE; COTE-DIVOIRE; DIAGNOSIS; CATT; CENTRIFUGATION; INDIVIDUALS; POPULATION; FIELD		Programme Natl Lutte Trypanosomiase Humaine Afric, Kinshasa, Zaire; Inst Trop Med, Dept Sante Publ, Antwerp, Belgium; Inst Natl Rech Biomed, Kinshasa, Zaire; Inst Trop Med, Dept Parasitol, Antwerp, Belgium; Univ Libre Bruxelles, Ecole Sante Publ, Brussels, Belgium	Boelaert, M (reprint author), Inst Trop Med, Unite Epidemiol & Controle Maladie, Nationalestr 155, B-2000 Antwerp, Belgium.	mboelaert@itg.be	Buscher, Philippe/B-9956-2012; Boelaert, Marleen/E-2698-2012	Buscher, Philippe/0000-0002-1926-7472; Boelaert, Marleen/0000-0001-8051-6776			Alonzo TA, 1999, STAT MED, V18, P2987, DOI 10.1002/(SICI)1097-0258(19991130)18:22<2987::AID-SIM205>3.3.CO;2-2; BAILEY JW, 1994, TROP DOCT, V24, P54, DOI 10.1177/004947559402400204; Blum J, 2001, TROP MED INT HEALTH, V6, P390, DOI 10.1046/j.1365-3156.2001.00710.x; *BUR CENTR TRYP, 1995, GUID TECHN PROGR NAT; *BUR CENTR TRYP, 2002, DECL POL NAT LUTT CO; CATTAND P, 1988, B WORLD HEALTH ORGAN, V66, P83; Chappuis F, 2004, AM J TROP MED HYG, V71, P313, DOI 10.4269/ajtmh.2004.71.313; Garcia A, 2000, TROP MED INT HEALTH, V5, P786, DOI 10.1046/j.1365-3156.2000.00623.x; GOODMAN LA, 1974, BIOMETRIKA, V61, P215, DOI 10.1093/biomet/61.2.215; HENRY MC, 1981, ANN SOC BELG MED TR, V61, P79; LUMSDEN WHR, 1979, T ROY SOC TROP MED H, V73, P312, DOI 10.1016/0035-9203(79)90092-0; Lutumba P, 2005, TROP MED INT HEALTH, V10, P347, DOI 10.1111/j.1365-3156.2005.01391.x; MAGNUS E, 1978, ANN SOC BELG MED TR, V58, P169; Miezan TW, 2000, T ROY SOC TROP MED H, V94, P293, DOI 10.1016/S0035-9203(00)90327-4; MIEZAN TW, 1994, B SOC PATHOL EXOT, V87, P101; *OMS, 1993, PAR MED TECHN BAS LA; Robays J, 2004, TROP MED INT HEALTH, V9, P542, DOI 10.1111/j.1365-3156.2004.01240.x; Simarro PP, 1999, TROP MED INT HEALTH, V4, P858, DOI 10.1046/j.1365-3156.1999.00494.x; TRUC P, 1994, T ROY SOC TROP MED H, V88, P419, DOI 10.1016/0035-9203(94)90410-3; VanMeirvenne N, 1995, ACTA TROP, V60, P189, DOI 10.1016/0001-706X(95)00127-Z; VANNIEUWENHOVE S, 1984, S DIAGN AFR SLEEP SI, P71; VERMUNT JK, 2000, LATENT GOLD 2 0; Whiting Penny, 2003, BMC Med Res Methodol, V3, P25, DOI 10.1186/1471-2288-3-25; *WHO EXP COMM, 1998, CONTR SURV AFR TRYP; Woo P. T. K., 1970, Acta trop., V27, P384	25	22	22	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	APR	2006	11	4					470	478		10.1111/j.1365-3159.2006.01591.x				9	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	024TY	WOS:000236220300010	16553930				2019-03-26	
J	Mboera, LEG; Fanello, CI; Malima, RC; Talbert, A; Fogliati, P; Bobbio, F; Molteni, F				Mboera, LEG; Fanello, CI; Malima, RC; Talbert, A; Fogliati, P; Bobbio, F; Molteni, F			Comparison of the Paracheck-Pf (R) test with microscopy, for the confirmation of Plasmodium falciparum malaria in Tanzania	ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY			English	Article							RAPID DIAGNOSTIC-TEST; INDIA MADHYA-PRADESH; IMMUNOCHROMATOGRAPHIC TEST; FOREST VILLAGES; FIELD; INFECTION; PF	Paracheck-Pf is a rapid, qualitative immuno-assay for the detection of Plasmodium falciparum-specific histidine-rich protein-2 in samples of human blood. The assay has now been evaluated, against the usual 'gold standard', microscopy, using blood samples from 1655 individuals in five districts of Tanzania, four of which experience frequent malaria outbreaks. The aim was to verify whether Paracheck-Pf could be a reliable tool for the confirmation of malaria outbreaks in such areas. The overall measurements of the assay's performance were good, with a sensitivity of 90.0%, a specificity of 96.6%, a positive predictive value of 88.9%, and a negative predictive value of 97.0% (with an estimated malaria prevalence of 23.3%). There was, however, marked variation between the study districts, the assay's performance being relatively poor where the test had been stored for 12 months at room temperature (23.5 +/- 3.5 degrees C). The assay was easy to perform in the field and could clearly be a valuable tool in remote areas and in emergency situations, such as the early detection of malaria outbreaks. The cost of the assay (U.S.$0.62/test at the time of the present study) is sufficiently low that its routine use in the confirmation of P. falciparum malaria might also be cost-effective, particularly in areas where there are no facilities for microscopy and/or where the first-line treatment of malaria is based on relatively expensive artemisinin-based combinations.	Natl Inst Med Res, Dar Es Salaam, Tanzania; Minist Hlth, Natl Malaria Control Programme, Dar Es Salaam, Tanzania; Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium; Mvumi Hosp, Dodoma, Tanzania	Mboera, LEG (reprint author), Natl Inst Med Res, POB 9653, Dar Es Salaam, Tanzania.	lmboera@nimr.or.tz		bobbio, flavio/0000-0001-8850-8543; Fanello, Caterina/0000-0003-1932-9562			BEADLE C, 1994, LANCET, V343, P564, DOI 10.1016/S0140-6736(94)91520-2; Bojang KA, 1999, ANN TROP MED PARASIT, V93, P685, DOI 10.1080/00034989957925; Garay J, 1998, EPIDEMIOLOGICAL SURV; Grobusch MP, 1999, LANCET, V353, P297, DOI 10.1016/S0140-6736(05)74930-8; Guthmann JP, 2002, T ROY SOC TROP MED H, V96, P254, DOI 10.1016/S0035-9203(02)90091-X; Laferi H, 1997, NEW ENGL J MED, V337, P1635, DOI 10.1056/NEJM199711273372219; Makler MT, 1998, ANN TROP MED PARASIT, V92, P419; Mason DP, 2002, ACTA TROP, V82, P51, DOI 10.1016/S0001-706X(02)00031-1; Mboera LEG, 2004, TANZANIA HLTH RES B, V6, P11; Mboera LEG, 2001, AFR J HLTH SCI, V8, P14; MBORRA LEG, 2001, MALARIA EPIDEMIOLOGI; Moody AH, 2000, CLIN LAB HAEMATOL, V22, P189, DOI 10.1046/j.1365-2257.2000.00318.x; Proux S, 2001, TROP MED INT HEALTH, V6, P99, DOI 10.1046/j.1365-3156.2001.00694.x; Reyburn H, 2004, BRIT MED J, V329, P1212, DOI 10.1136/bmj.38251.658229.55; SHIFF CJ, 1993, T ROY SOC TROP MED H, V87, P646, DOI 10.1016/0035-9203(93)90273-S; Singer LM, 2004, AM J TROP MED HYG, V70, P481; Singh N, 1997, CURR SCI INDIA, V73, P686; Singh N, 1997, T ROY SOC TROP MED H, V91, P396, DOI 10.1016/S0035-9203(97)90254-6; Singh N, 2001, BMC INFECT DIS, V1, DOI 10.1186/1471-2334-1-10; Singh N, 2000, ANN TROP MED PARASIT, V94, P421, DOI 10.1080/00034983.2000.11813560; Wakibara JV, 1997, E AFR MED J, V74, P69; *WHO, 2000, MAL DIAGN NEW PERSP	22	44	44	0	2	MANEY PUBLISHING	LEEDS	HUDSON RD, LEEDS LS9 7DL, ENGLAND	0003-4983			ANN TROP MED PARASIT	Ann. Trop. Med. Parasitol.	MAR	2006	100	2					115	122		10.1179/136485906X78571				8	Public, Environmental & Occupational Health; Parasitology; Tropical Medicine	Public, Environmental & Occupational Health; Parasitology; Tropical Medicine	022CB	WOS:000236031200003	16492359				2019-03-26	
J	Poovorawan, Y; Hutagalung, Y; Chongsrisawat, V; Boudville, I; Bock, HL				Poovorawan, Y; Hutagalung, Y; Chongsrisawat, V; Boudville, I; Bock, HL			Dengue virus infection: a major cause of acute hepatic failure in Thai children	ANNALS OF TROPICAL PAEDIATRICS			English	Article							ACUTE LIVER-FAILURE; FULMINANT-HEPATITIS; MOLECULAR CHARACTERIZATION; CLINICAL-FEATURES; VIRAL-HEPATITIS; PROGNOSIS; VACCINES	Background: Acute hepatic failure (AHF) can be caused by a variety of viruses, drugs, toxins and metabolic disorders. Aims: A prospective study was conducted to determine the aetiology and outcome of AHF in Thai children aged 1-15 years. Methods: All serum samples were tested for anti-HAV IgM, HBsAg, anti-HBc IgM, anti-HCV, anti-HEV IgM and anti-dengue IgG and IgM. Further individual investigations were done according to the clinical impression. Results: Forty subjects were enrolled from 14 centres during February 2000 to December 2001. Five cases were excluded owing to a lack of evidence of encephalopathy. The causes of AHF were dengue infection in 12 (34.3%), Wilson disease in 2 (5.7%), T-cell lymphoma in 2 (5.7%), ischaemic hepatitis in two (5.7%), haemophagocytic syndrome in one (2.8%), CMV in 2 (5.7%), Reye syndrome in one (2.8%) and unknown in 13 (37.1%) patients. The fatality rate was 68.6%. Eight of 24 (33.3%) deaths were caused by dengue infection. Conclusions: Improvements in sanitation and socio-economic status as well as the implementation of hepatitis B vaccine in the Extended Programme on Immunization (EPI) are likely to be the reasons for the observed absence of AHF caused by hepatitis A and B. The study showed that dengue infection, on the other hand, was a major cause of AHF in Thailand.	Chulalongkorn Univ & Hosp, Ctr Excellence Viral Hepatitis Res, Dept Pediat, Fac Med, Bangkok 10330, Thailand; GlaxoSmithKline Biol, Rixensart, Belgium	Poovorawan, Y (reprint author), Chulalongkorn Univ & Hosp, Ctr Excellence Viral Hepatitis Res, Dept Pediat, Fac Med, Rama IV Rd, Bangkok 10330, Thailand.	Yong.P@chula.ac.th		Poovorawan, Yong/0000-0002-2337-6807			Acharya SK, 1996, HEPATOLOGY, V23, P1448, DOI 10.1002/hep.510230622; ALVEREZ ME, 1985, AM J MED, V79, P670; BERNUAU J, 1986, SEMIN LIVER DIS, V6, P97, DOI 10.1055/s-2008-1040593; Ciocca M, 2000, VACCINE, V18, pS71, DOI 10.1016/S0264-410X(99)00470-3; Debray D, 1997, HEPATOLOGY, V26, P1018, DOI 10.1002/hep.510260433; DeRoeck D, 2003, VACCINE, V22, P121, DOI 10.1016/S0264-410X(03)00533-4; DEVICTOR D, 1992, HEPATOLOGY, V16, P1156, DOI 10.1002/hep.1840160509; Edelman R, 2005, J INFECT DIS, V191, P650, DOI 10.1086/427784; FRIEDLAND IR, 1992, ANN TROP PAEDIATR, V11, P207; Gill RQ, 2001, J CLIN GASTROENTEROL, V33, P191, DOI 10.1097/00004836-200109000-00005; HALSTEAD SB, 1988, SCIENCE, V239, P476, DOI 10.1126/science.3277268; INNIS BL, 1989, AM J TROP MED HYG, V40, P418, DOI 10.4269/ajtmh.1989.40.418; LAWN SD, 2003, CLIN INFECT DIS, V37, P1; Lee WM, 1996, HEPATOLOGY, V24, P270, DOI 10.1002/hep.510240143; LEVIN ASS, 1989, REV I MED TROP, V31, P213, DOI 10.1590/S0036-46651989000400002; LUM LC, 1993, SE ASIAN J TROP MED, V24, P46; MOREIRASILVA SF, 1998, REV SOC BRAS MED TRO, V31, P87; OGRADY JG, 1993, LANCET, V342, P273; OGRADY JG, 1989, GASTROENTEROLOGY, V97, P439, DOI 10.1016/0016-5085(89)90081-4; Pancharoen Chitsanu, 2001, Southeast Asian Journal of Tropical Medicine and Public Health, V32, P341; Poddar U, 2002, J TROP PEDIATRICS, V48, P210, DOI 10.1093/tropej/48.4.210; Poovorawan Y, 2005, J CLIN VIROL, V32, P24, DOI 10.1016/j.jcv.2004.04.008; Poovorawan Y, 2000, ASIAN PAC J ALLERGY, V18, P249; Shah U, 2000, PEDIATRICS, V105, P436, DOI 10.1542/peds.105.2.436; TAKAHASHI Y, 1991, J GASTROEN HEPATOL, V6, P159, DOI 10.1111/j.1440-1746.1991.tb01458.x; Tandon B, 1999, J GASTROEN HEPATOL, V14, P403; Tapia-Conyer R, 1999, AM J TROP MED HYG, V61, P825, DOI 10.4269/ajtmh.1999.61.825; Theamboonlers A, 2002, ANN TROP MED PARASIT, V96, P727, DOI 10.1179/000349802125001898; Thisyakom U, 1994, JAMA SEA, V10, P102; TREY C, 1970, PROGR LIVER DISEASE, V3, P292; *WHO REG OFF SE AS, SIT DENQ DENG HAEM F; Wichmann O, 2004, TROP MED INT HEALTH, V9, P1022, DOI 10.1111/j.1365-3156.2004.01295.x; World Health Organization, 1997, DENG HAEM FEV DIAGN; ZACARIAS J, 1987, PEDIATR INFECT DIS J, V6, P686, DOI 10.1097/00006454-198707000-00015	34	41	44	0	1	MANEY PUBLISHING	LEEDS	STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND	0272-4936	1465-3281		ANN TROP PAEDIATR	Ann. Trop. Paediatr.	MAR	2006	26	1					17	23		10.1179/146532806X90565				7	Pediatrics; Tropical Medicine	Pediatrics; Tropical Medicine	023ET	WOS:000236109200002	16494700				2019-03-26	
J	Jansen, FH				Jansen, FH			The herbal tea approach for artemisinin as a therapy for malaria?	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Letter							L. ANNUAL WORMWOOD; TRADITIONAL PREPARATION		Dafra Pharma NV, B-2300 Turnhout, Belgium	Jansen, FH (reprint author), Dafra Pharma NV, Slachthuisstr 30-7, B-2300 Turnhout, Belgium.	fhj@dafra.be					[Anonymous], 2003, INT PHARM, V5, P187; ELFORD BC, 1987, T ROY SOC TROP MED H, V81, P434, DOI 10.1016/0035-9203(87)90161-1; Francois G., 1993, Planta Medica, V59, pA677, DOI 10.1055/s-2006-959956; HASSAN AM, 1996, T R SOC TROP MED HYG, V90, P61; Mueller MS, 2004, T ROY SOC TROP MED H, V98, P318, DOI 10.1016/j.trstmh.2003.09.001; Rath K, 2004, AM J TROP MED HYG, V70, P128, DOI 10.4269/ajtmh.2004.70.128; SY ND, 1993, AM J TROP MED HYG, V48, P398, DOI 10.4269/ajtmh.1993.48.398	7	28	29	0	2	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0035-9203	1878-3503		T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	MAR	2006	100	3					285	286		10.1016/j.trstmh.2005.08.004				2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	011JQ	WOS:000235264800015	16274712				2019-03-26	
J	Unger, JP; d'Alessandro, U; De Paepe, P; Green, A				Unger, JP; d'Alessandro, U; De Paepe, P; Green, A			Can malaria be controlled where basic health services are not used?	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						health policy; international cooperation; public sector; disease control integration	CASE-MANAGEMENT; CARE SERVICES; CHILDREN; REGION; INTEGRATION; STRATEGIES; DIAGNOSIS; PROGRAMS; TANZANIA; DELIVERY	To assess the potential of integrating malaria control interventions in underused health services. Using the Piot predictive model, we estimated malaria cure rates by deriving parameters influencing treatment at home and in health facilities from the best-performing African malaria programmes and applying them to Yanfolila district, Mali. Without any malaria control intervention, the population cure rate is 8.4% with home treatment, but would be 13% if access to timely treatment were improved (as in Kenya). A further 3.2% of malaria patients could be cured in institutional settings with more sensitive diagnosis, timely start of treatment, better compliance (as in Uganda, Tanzania, Ghana) and 80% chloroquine efficacy. Applied in a setting where 7.6% of malaria patients seek institutional care, these assumptions would result in a total population cure rate of 14.5%. Increasing the health service user rate from 0.17 in Yanfolila to 0.95 new cases/inhabitant/year (as in Namibia) would result in half of all malaria patients attending professional services, raising the cure rate to 26.1%. If malaria patients are to be treated and followed-up early and appropriately, basic health services need to deliver integrated care and be attended by an adequate pool of users. Improved service user rates and case management can increase malaria cure rates far more than isolated control interventions can. This has implications for international policies endorsing a narrow disease-based approach.	Inst Trop Med Prince Leopold, Dept Publ Hlth, B-2000 Antwerp, Belgium; Inst Trop Med Prince Leopold, Dept Parasitol, B-2000 Antwerp, Belgium; Univ Leeds, Nuffield Inst Hlth, Leeds, W Yorkshire, England	De Paepe, P (reprint author), Inst Trop Med Prince Leopold, Dept Publ Hlth, Natl Str 155, B-2000 Antwerp, Belgium.	pdpaepe@itg.be	D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009			Ageel ARM, 1997, ANN TROP MED PARASIT, V91, P907, DOI 10.1080/00034983.1997.11813218; AGHA S, 1997, EVALUATION GREEN STA; Agyepong IA, 2002, SOC SCI MED, V55, P2215, DOI 10.1016/S0277-9536(01)00366-5; Attaran A, 2004, LANCET, V363, P237, DOI 10.1016/S0140-6736(03)15330-5; Belsky L, 2004, HEALTH AFFAIR, V23, P137, DOI 10.1377/hlthaff.23.3.137; Berkley JA, 2005, NEW ENGL J MED, V352, P39, DOI 10.1056/NEJMoa040275; Bossyns P, 1997, LANCET, V350, P1783, DOI 10.1016/S0140-6736(05)63621-5; Brugha R, 1998, HEALTH POLICY PLANN, V13, P107, DOI 10.1093/heapol/13.2.107; Buve A, 2003, INT J HEALTH PLAN M, V18, pS41, DOI 10.1002/hpm.725; Buve A, 2001, TROP MED INT HEALTH, V6, P971, DOI 10.1046/j.1365-3156.2001.00809.x; Coleman PG, 2004, AM J TROP MED HYG, V71, P196, DOI 10.4269/ajtmh.2004.71.196; *COMM EUR COMM, 2002, 129 COM EUR COMM; ELOBEID S, 2001, HLTH NAMIBIA PROGRES, pCH3; Font F, 2001, TROP MED INT HEALTH, V6, P423, DOI 10.1046/j.1365-3156.2001.00727.x; *GLOB FUND, 2003, SCAL FIGHT HIV AIDS; Goodman CA, 1999, LANCET, V354, P378, DOI 10.1016/S0140-6736(99)02141-8; JACOBS B, 1999, FEASIBILITY ACCEPTAB; Jong-wook Lee, 2003, Lancet (North American Edition), V362, P2083, DOI 10.1016/S0140-6736(03)15107-0; Krause G, 2000, ANN TROP PAEDIATR, V20, P273, DOI 10.1080/02724936.2000.11748147; LevyBruhl D, 1997, INT J HEALTH PLAN M, V12, pS49, DOI 10.1002/(SICI)1099-1751(199706)12:1+<S49::AID-HPM466>3.3.CO;2-G; Lonnroth K, 1999, INT J TUBERC LUNG D, V3, P992; LORETTI A, 1989, LEPROSY REV, V60, P306; Lubanga RGN, 1997, ACTA TROP, V68, P53, DOI 10.1016/S0001-706X(97)00071-5; Mahendradhata Y, 2003, INT J HEALTH PLAN M, V18, pS53, DOI 10.1002/hpm.724; Marsh VM, 1999, TROP MED INT HEALTH, V4, P383, DOI 10.1046/j.1365-3156.1999.00403.x; Moerman F, 2003, LANCET INFECT DIS, V3, P99, DOI 10.1016/S1473-3099(03)00518-8; Mulholland EK, 2005, NEW ENGL J MED, V352, P75, DOI 10.1056/NEJMe048306; Mumba M, 2003, TROP MED INT HEALTH, V8, P544, DOI 10.1046/j.1365-3156.2003.01064.x; *OXF, 2003, 24 OXF; Paredes P, 1996, SOC SCI MED, V42, P1141, DOI 10.1016/0277-9536(95)00387-8; Piot MA, 1967, SIMULATION MODEL CAS; ROBAYS J, 2004, TROP MED INT HEALTH, V5, P542; Thera MA, 2000, TROP MED INT HEALTH, V5, P876, DOI 10.1046/j.1365-3156.2000.00652.x; TULLOCH J, 1999, LANCET S2, V354, P16; UNGER HP, 2003, INT J HLGH PLANNING, V18, pS79; Unger JP, 2002, INT J HEALTH SERV, V32, P799, DOI 10.1092/FN20-AGDQ-GYCP-P8R6; WEBB D, 2004, M CHALLENGE COMPREHE; *WHO, 2000, WORLD HLTH REP 1999; WHO, 1999, WORLD HLTH REP 1999; *WHO, 2003, ROLL BACK MAL TECHN; *WORLD BANK, 1994, BETT HLTH AFR EXP LE; *WORLD BANK, 1995, BETT HLTH AFR EXP LE	42	17	17	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	MAR	2006	11	3					314	322		10.1111/j.1365-3156.2006.01576.x				9	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	019NG	WOS:000235843200008	16553911	Bronze			2019-03-26	
J	Verhaeghen, K; Van Bortel, W; Roelants, P; Backeljau, T; Coosemans, M				Verhaeghen, K; Van Bortel, W; Roelants, P; Backeljau, T; Coosemans, M			Detection of the East and West African kdr mutation in Anopheles gambiae and Anopheles arabiensis from Uganda using a new assay based on FRET/Melt Curve analysis	MALARIA JOURNAL			English	Article							KNOCKDOWN RESISTANCE; IDENTIFICATION; PYRETHROIDS; DDT	Background: Appropriate monitoring of vector resistance to insecticides is an integral component of planning and evaluation of insecticide use in malaria control programmes. The malaria vectors Anopheles gambiae s.s. and Anopheles arabiensis have developed resistance to pyrethroid insecticides as a result of a mechanism conferring reduced nervous system sensitivity, better known as knockdown resistance (kdr). In An. gambiae s.s. and An. arabiensis, two different substitutions in the para-type sodium channel, a L1014F substitution common in West Africa and a L1014S replacement found in Kenya, are linked with kdr. Two different allele- specific polymerase chain reactions (AS-PCR) are needed to detect these known kdr mutations. However, these AS-PCR assays rely on a single nucleotide polymorphism mismatch, which can result in unreliable results. Methods: Here, a new assay for the detection of knockdown resistance in An. gambiae s.s. and An. arabiensis based on Fluorescence Resonance Energy Transfer/Melt Curve analysis (FRET/MCA) is presented and compared with the existing assays. Results: The new FRET/MCA method has the important advantage of detecting both kdr alleles in one assay. Moreover, results show that the FRET/MCA is more reliable and more sensitive than the existing AS-PCR assays and is able to detect new genotypes. By using this technique, the presence of the East African kdr mutation ( L1014S) is shown for the first time in An. arabiensis specimens from Uganda. In addition, a new kdr genotype is reported in An. gambiae s.s. from Uganda, where four An. gambiae s.s. mosquitoes possess both, the West ( L1014F) and East ( L1014S) African kdr allele, simultaneously. Conclusion: The presence of both kdr mutations in the same geographical region shows the necessity of a reliable assay that enables to detect both mutations in one single assay. Hence, this new assay based on FRET/MCA will improve the screening of the kdr frequencies in An. gambiae s.s. and An. arabiensis.	Inst Trop Med Prince Leopold, Dept Parasitol, B-2000 Antwerp, Belgium; Royal Belgian Inst Nat Sci, Dept Invertebrates, B-1000 Brussels, Belgium; Univ Antwerp, Evolutionary Biol Grp, B-2020 Antwerp, Belgium	Verhaeghen, K (reprint author), Inst Trop Med Prince Leopold, Dept Parasitol, Natl Str 155, B-2000 Antwerp, Belgium.	kverhaeghen@itg.be; wvbortel@itg.be; proelants@itg.be; thierry.backeljau@naturalsciences.be; mcoosemans@itg.be		Van Bortel, Wim/0000-0002-6644-518X			Diabate A, 2004, J AM MOSQUITO CONTR, V20, P195; GILLIES MT, 1987, PUBLICATIONS S AFRIC, V55; LUND AE, 1983, PESTIC BIOCHEM PHYS, V20, P203, DOI 10.1016/0048-3575(83)90025-1; Lynd A, 2005, MALARIA J, V4, DOI 10.1186/1475-2875-4-16; Martinez-Torres D, 1998, INSECT MOL BIOL, V7, P179, DOI 10.1046/j.1365-2583.1998.72062.x; Ranson H, 2000, INSECT MOL BIOL, V9, P491, DOI 10.1046/j.1365-2583.2000.00209.x; Schutz E, 1999, BIOTECHNIQUES, V27, P1218, DOI 10.2144/99276bc04; SCOTT JA, 1993, AM J TROP MED HYG, V49, P520, DOI 10.4269/ajtmh.1993.49.520; Soderlund DM, 2003, INSECT BIOCHEM MOLEC, V33, P563, DOI 10.1016/S0965-1748(03)00023-7; Stump AD, 2004, AM J TROP MED HYG, V70, P591, DOI 10.4269/ajtmh.2004.70.591; Vythilingam I., 1999, Southeast Asian Journal of Tropical Medicine and Public Health, V30, P631; WIRTZ RA, 1992, J MED ENTOMOL, V29, P854, DOI 10.1093/jmedent/29.5.854	12	84	88	0	7	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1475-2875			MALARIA J	Malar. J.	FEB 22	2006	5								16	10.1186/1475-2875-5-16				9	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	024HF	WOS:000236185400001	16504072	DOAJ Gold, Green Published			2019-03-26	
J	Zachariah, R; Teck, R; Buhendwa, L; Labana, S; Chinji, C; Humblet, P; Harries, AD				Zachariah, R; Teck, R; Buhendwa, L; Labana, S; Chinji, C; Humblet, P; Harries, AD			How can the community contribute in the fight against HIV/AIDS and tuberculosis? An example from a rural district in Malawi	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						TB; HIV; community; volunteers; human resources; Malawi	COTRIMOXAZOLE PROPHYLAXIS; HIV; THYOLO; CARE	This paper describes (a) the experience of initiating community involvement in HIV/AIDS and tuberculosis (TB) activities in a rural district in Malawi and (b) some of the different ways in which the community is contributing in the fight against these two diseases and the outcomes of their involvement. During a 2-year period, a total of 21358 (41%) of 52510 HIV tests performed at voluntary counselling and HIV testing (VCT) sites in the district were conducted by lay community counsellors. A team of 465 community volunteers, 1362 trained family caregivers and 9 community nurses provided care and support to 5106 HIV-positive individuals, of whom 2006 (39%) were in WHO stage III or IV. All those in WHO stage III or IV were on co-trimoxazole prophylaxis and 895 (45%) of these were also on antiretroviral treatment. A total of 2714 _B patients, of whom 1627 (60%) were HIV-positive, also received care and support. A total of 1694 orphans were trained in vocational skills. Twelve vegetable gardens and three maize farms were set up, and pre-school activities were organised for 900 orphans. Communities can play an important contributory rote in reducing the burden of HIV/AIDS and TB and in mitigating its impact. Despite this, community resources in most settings are often under-exploited and their role remains undefined. (C) 2005 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.	Med Sans Frontieres, Med Dept Operat Res, Brussels Operat Ctr, Brussels, Belgium; Med Sans Frontieres Luxembourg, Blantyre, Thyolo District, Malawi; Minist Hlth & Populat, Lilongwe, Malawi; London Sch Hyg & Trop Med, London WC1, England; Family Hlth Int, Arlington, VA USA	Zachariah, R (reprint author), Med Sans Frontieres, Dept Med, Brussels Operat Ctr HIV TB Operat Res, 68 Rue Gasperich, L-1617 Luxembourg, Luxembourg.	zachariah@internet.lu					Floyd K, 2003, INT J TUBERC LUNG D, V7, pS29; Harries AD, 2002, T ROY SOC TROP MED H, V96, P34, DOI 10.1016/S0035-9203(02)90231-2; KNIPPENBERG R, 1997, INT J HEALTH PLAN MA, V12, P29; KWANJANA JH, 2001, MALAWI MED J, V13, P7; Lewis DK, 2003, T ROY SOC TROP MED H, V97, P91, DOI 10.1016/S0035-9203(03)90035-6; *MOH, 2003, GUID US ANT THER MAL; *MOH, 1999, MAL NAT HLTH PLAN 19, V2; *MOH, 2003, STAT HUM CAP DEV EFF; *MOH, 2003, MAL HLTH FAC SURV RE; *NACP, 2003, NAT EST HIV AIDS MAL; NSO, 1998, POP HOUS CENS; *NTP, 2001, NAT TUB CONTR PROGR; Salaniponi FM, 2003, INT J TUBERC LUNG D, V7, pS38; UNAIDS World Health Organization, 1997, WKLY EPIDEMIOL REC, V72, P81; Verver S, 2004, LANCET, V363, P212, DOI 10.1016/S0140-6736(03)15332-9; Zachariah R, 2003, AIDS, V17, P1053, DOI [10.1097/00002030-200305020-00015, 10.1097/01.aids.0000060355.78202.b7]; Zachariah R, 2001, INT J TUBERC LUNG D, V5, P843; Zachariah R, 2004, INT J TUBERC LUNG D, V8, P1058; Zachariah R, 2002, INT J TUBERC LUNG D, V6, P1046	19	38	38	1	2	ROYAL SOC TROPICAL MEDICINE	LONDON	MANSON HOUSE 26 PORTLAND PLACE, LONDON W1N 1EY, ENGLAND	0035-9203			T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	FEB	2006	100	2					167	175		10.1016/j.trstmh.2005.07.008				9	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	002RA	WOS:000234627700011	16214192	Green Published			2019-03-26	
J	Kelly-Hope, LA; Diggle, PJ; Rowlingson, BS; Gyapong, JO; Kyelem, D; Coleman, M; Thomson, MC; Obsomer, V; Lindsay, SW; Hemingway, J; Molyneux, DH				Kelly-Hope, LA; Diggle, PJ; Rowlingson, BS; Gyapong, JO; Kyelem, D; Coleman, M; Thomson, MC; Obsomer, V; Lindsay, SW; Hemingway, J; Molyneux, DH			Short communication: Negative spatial association between lymphatic filariasis and malaria in West Africa	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						Anopheles; lymphatic filariasis; malaria; West Africa; epidemiology; transmission; climate; environment; geographical information systems; statistical modelling	ANOPHELES-GAMBIAE; BANCROFTIAN FILARIASIS; PLASMODIUM-FALCIPARUM; INCIPIENT SPECIATION; INFECTIONS; DISEASE; GHANA; IRRIGATION; ELIMINATION; COMMUNITIES	To determine the relationship between human lymphatic filariasis, caused by Wuchereria bancrofti, and falciparum malaria, which are co-endemic throughout West Africa. We used geographical information systems and spatial statistics to examine the prevalence of lymphatic filariasis in relation to malaria prevalence, mosquito species distributions, vegetation and climate. A negative spatial association between W. bancrofti and falciparum malaria prevalence exists. Interspecies competition between parasites, seasonality, differences in the distribution and vector competence of Anopheles vectors, agricultural practices and insecticide resistance may be factors driving current (and potentially future) spatial distributions. Further investigating these factors will become crucial as large-scale lymphatic filariasis and malaria control programmes are implemented in West Africa that may influence the epidemiology of both diseases.	Univ Liverpool Liverpool Sch Trop Med, Vector Res Grp, Liverpool L3 5QA, Merseyside, England; Univ Lancaster, Dept Math & Stat, Lancaster, England; Ghana Hlth Serv, Minist Hlth, Hlth Res Unit, Accra, Ghana; Minist Hlth, Div Prevent Med, Ouagadougou, Burkina Faso; Columbia Univ, Int Res Inst Climate Predict, Earth Inst, New York, NY USA; Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium; Univ Durham, Sch Biol & Biomed Sci, Durham DH1 3HP, England; Univ Liverpool Liverpool Sch Trop Med, Lymphat Filariasis Support Ctr, Liverpool, Merseyside, England	Kelly-Hope, LA (reprint author), Univ Liverpool Liverpool Sch Trop Med, Vector Res Grp, Pembroke Pl, Liverpool L3 5QA, Merseyside, England.	kellyhopel@mail.nih.gov	Diggle, Peter/A-3025-2009	Gyapong, John/0000-0002-8415-1468; Diggle, Peter/0000-0003-3521-5020; Rowlingson, Barry/0000-0002-8586-6625; Hemingway, Janet/0000-0002-3200-7173; Coleman, Michael/0000-0003-4186-3526	NIEHS NIH HHS [R01 ES012054]		ALBUQUERQUE CMR, 1995, PARASITOLOGY, V110, P1, DOI 10.1017/S0031182000080987; Amexo M, 2004, LANCET, V364, P1896, DOI 10.1016/S0140-6736(04)17446-1; Appawu MA, 2001, TROP MED INT HEALTH, V6, P511, DOI 10.1046/j.1365-3156.2001.00737.x; APPAWU MA, 1994, ACTA TROP, V56, P15, DOI 10.1016/0001-706X(94)90036-1; Bayoh MN, 2001, MED VET ENTOMOL, V15, P267, DOI 10.1046/j.0269-283x.2001.00298.x; BRENGUES J, 1975, THESIS ORSTOM PARIS; BURKOT TR, 1990, PARASITOLOGY, V100, P369, DOI 10.1017/S003118200007863X; Carnevale P, 1999, PARASSITOLOGIA, VOL 41, NOS 1-3, SEPTEMBER 1999, P273; Coetzee M, 2004, INSECT BIOCHEM MOLEC, V34, P599, DOI 10.1016/j.ibmb.2004.03.012; COLUZZI M, 1985, B ZOOL, V52, P45, DOI 10.1080/11250008509440343; Coluzzi M., 1993, Parassitologia (Rome), V35, P23; della Torre A, 2001, INSECT MOL BIOL, V10, P9, DOI 10.1046/j.1365-2583.2001.00235.x; Diggle PJ, 1998, J R STAT SOC C-APPL, V47, P299, DOI 10.1111/1467-9876.00113; Dzodzomenyo M, 1999, TROP MED INT HEALTH, V4, P13, DOI 10.1046/j.1365-3156.1999.00354.x; Graham AL, 2005, J INFECT DIS, V191, P410, DOI 10.1086/426871; Gyapong JO, 2001, T ROY SOC TROP MED H, V95, P681, DOI 10.1016/S0035-9203(01)90115-4; Gyapong JO, 2002, ANN TROP MED PARASIT, V96, P695, DOI 10.1179/000349802125001735; Hemingway J, 2000, ANNU REV ENTOMOL, V45, P371, DOI 10.1146/annurev.ento.45.1.371; HUNTER JM, 1992, SOC SCI MED, V35, P627, DOI 10.1016/0277-9536(92)90001-7; Ijumba JN, 2001, MED VET ENTOMOL, V15, P1, DOI 10.1046/j.1365-2915.2001.00279.x; Kleinschmidt I, 2001, TROP MED INT HEALTH, V6, P779, DOI 10.1046/j.1365-3156.2001.00790.x; Lamontellerie M, 1972, Ann Parasitol Hum Comp, V47, P783; Lindsay SW, 1998, P ROY SOC B-BIOL SCI, V265, P847, DOI 10.1098/rspb.1998.0369; Lindsay SW, 2000, T ROY SOC TROP MED H, V94, P37, DOI 10.1016/S0035-9203(00)90431-0; McCarroll L, 2000, NATURE, V407, P961, DOI 10.1038/35039671; Molyneux DH, 2002, ANN TROP MED PARASIT, V96, pS15, DOI 10.1179/000349802125002374; MUIRHEADTHOMSON RC, 1953, NATURE, V172, P352, DOI 10.1038/172352a0; Petney TN, 2001, INT J PARASITOL, V31, P919, DOI 10.1016/S0020-7519(01)00196-5; Petney TN, 1998, INT J PARASITOL, V28, P377, DOI 10.1016/S0020-7519(97)00189-6; Power E, 1999, CRIT-Q LIT ART, V41, P101; SCHMIDT LH, 1981, AM J TROP MED HYG, V30, P5, DOI 10.4269/ajtmh.1981.30.5; Spiegel A, 2003, T ROY SOC TROP MED H, V97, P198, DOI 10.1016/S0035-9203(03)90117-9; Weil GJ, 1997, PARASITOL TODAY, V13, P401, DOI 10.1016/S0169-4758(97)01130-7; *WHO, 2005, WHOHTMMAL20051102; *WHO UNICEF, 2003, WHOCDCMAL20031093; Zagaria N, 2002, ANN TROP MED PARASIT, V96, pS3, DOI [10.1179/00034980215002347, 10.1179/0034980215002347]	36	29	29	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	FEB	2006	11	2					129	135		10.1111/j.1365-3156.2005.01558.x				7	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	008TW	WOS:000235064600002	16451336				2019-03-26	
J	Zachariah, R; Teck, R; Ascurra, O; Humblet, P; Harries, AD				Zachariah, R; Teck, R; Ascurra, O; Humblet, P; Harries, AD			Targeting CD4 testing to a clinical subgroup of patients could limit unnecessary CD4 measurements, premature antiretroviral treatment and costs in Thyolo District, Malawi	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						HIV; CD4; ART; Malawi	HIV-INFECTION; IMPLEMENTATION; RESISTANCE; AFRICA	Malawi offers antiretroviral treatment (ART) to all HIV-positive adults who are clinically classified as being in WHO clinical stage III or IV without 'universal' CD4 testing. This study was conducted among such adults attending a rural district hospital HIV/AIDS clinic (a) to determine the proportion who have CD4 counts >= 350 cells/mu l, (b) to identify risk factors associated with such CD4 counts and (c) to assess the validity and predictive values of possible clinical markers for CD4 counts >= 350cells/mu l. A CD4 count >= 350cells/mu l was found in 36 (9%) of 401 individuals who are thus at risk of being placed prematurely on ART. A body mass index (BMI) > 22kg/m(2), the absence of an active WHO indicator disease at the time of presentation for ART, and a total lymphocyte count > 1200cells/mu l were significantly associated with such a CD4 count. The first two of these variables could serve as clinical markers for selecting subgroups of patients who should undergo CD4 testing. In a resource-limited district setting, assessing the BMI and checking for active opportunistic infections are routine clinical procedures that could be used to target CD4 measurements, thereby minimising unnecessary CD4 measurements, unnecessary (too early) treatment and costs. (c) 2005 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.	Brussels Operat Ctr, Medecins Sans Frontieres, Med Dept Operat Res HIV TB, Brussels, Belgium; Medecins Sans Frontieres Luxembourg, Thyolo District, Malawi; Minist Hlth & Populat, HIV Care & Support, Lilongew, Madagascar; London Sch Hyg & Trop Med, London WC1, England	Zachariah, R (reprint author), Medecins Sans Frontieres Brussels Operat Ctr, Med Dept Operat Res HIV TB, 68 Rue Gasperich, L-1617 Gasperich, Luxembourg.	zachariah@internet.lu					Coetzee D, 2004, AIDS, V18, P887, DOI [10.1097/01.aids.0000125925.87797.38, 10.1097/00002030-200406003-00006]; Diagbouga S, 2003, AIDS, V17, P2201, DOI 10.1097/01.aids.0000088198.77946.5e; JOHNSON MA, 1995, SOFTWARE QUAL J, V4, P15, DOI 10.1007/BF00404647; Kober K, 2004, LANCET, V364, P103, DOI 10.1016/S0140-6736(04)16597-5; Mermin J, 2004, LANCET, V364, P1428, DOI 10.1016/S0140-6736(04)17225-5; *MOH, 2003, GUID US ANT THER MAL; *MOH, 2003, NAT AIDS COMM MAL NA; *MOH, 2003, TREATM AIDS 2 YEAR P; *MOH, 2003, STAT HUM CAP DEV EFF; *MOH, 1999, NAT HLTH PLAN 1999 2, V2; Richard N, 2004, AIDS RES HUM RETROV, V20, P355, DOI 10.1089/088922204323048104; Sherman GG, 1999, J IMMUNOL METHODS, V222, P209, DOI 10.1016/S0022-1759(98)00172-0; UNAIDS World Health Organization, 1997, WKLY EPIDEMIOL REC, V72, P81; Vergne L, 2002, J ACQ IMMUN DEF SYND, V29, P165; *WHO, 2004, QV2685 WHO; ZACHARIAH R, 2002, T R SOC TROP MED HYG, V92, P291	16	13	13	1	1	ROYAL SOC TROPICAL MEDICINE	LONDON	MANSON HOUSE 26 PORTLAND PLACE, LONDON W1N 1EY, ENGLAND	0035-9203			T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	JAN	2006	100	1					24	31		10.1016/j.trstmh.2005.06.018				8	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	990ST	WOS:000233764200006	16202436	Green Published			2019-03-26	
J	Chappuis, F; Rijal, S; Jha, UK; Desjeux, P; Karki, BMS; Koirala, S; Loutan, L; Boelaert, M				Chappuis, F; Rijal, S; Jha, UK; Desjeux, P; Karki, BMS; Koirala, S; Loutan, L; Boelaert, M			Field validity, reproducibility and feasibility of diagnostic tests for visceral leishmaniasis in rural Nepal	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						kala-azar; visceral leishmaniasis; diagnosis; serology; antigen detection; Nepal	DIRECT AGGLUTINATION-TEST; KALA-AZAR; DIPSTICK TEST; K-39 ANTIGEN; STRIP-TEST; SERODIAGNOSIS; ANTIBODY; SUDAN; DAT	OBJECTIVES To assess the field accuracy, reproducibility and feasibility of the formol gel test (FGT), the urine latex agglutination test (KAtex) and a rK39 antigen-based dipstick for the diagnosis of visceral leishmaniasis (VL) in rural Nepal. METHOD Patients with clinical suspicion of VL were recruited at Rangeli District Hospital (DH), a 15-bed government hospital located in south-eastern Nepal. FGT, KAtex and rK39 dipstick tests were performed on site and later repeated at a reference kala-azar diagnostic laboratory to assess reproducibility. Diagnosis of VL was confirmed by either a positive bone marrow aspirate examination or a positive direct agglutination test (DAT titre >= 1:3200) in patients who later responded to anti-leishmanial therapy. RESULTS Of 155 patients initially recruited, 142 (85 with VL and 57 with another diagnosis) were included in the study. The sensitivity of the rK39 dipstick [89%; 95% confidence interval (CI): 81-94] was significantly higher than that of the KAtex (57%; 95% CI: 46-67) and the FGT (52%; 95% CI: 41-62). All three tests had a specificity of at least 90%. Agreement was higher for the rK39 dipstick (kappa = 0.87) than for the FGT (0.68) and the KAtex (0.43). All tests required <= 20 min of actual work and <= 40 min to obtain the results. CONCLUSION The rK39 dipstick was easy to do, more accurate and reproducible than other rapid diagnostic tests for VL in a DH of rural Nepal. It should be integrated into the field diagnostic algorithm of VL in this region and mechanisms to secure its availability should be found.	Univ Hosp Geneva, Travel & Migrat Med Unit, CH-1211 Geneva 14, Switzerland; BP Koirala Inst Hlth Sci, Dept Med, Dharan, Nepal; Rangeli Dist Hosp, Rangeli, Nepal; WHO, CH-1211 Geneva, Switzerland; BP Koirala Inst Hlth Sci, Dept Microbiol, Dharan, Nepal; Inst Trop Med, B-2000 Antwerp, Belgium	Chappuis, F (reprint author), Univ Hosp Geneva, Travel & Migrat Med Unit, CH-1211 Geneva 14, Switzerland.	francois.chappuis@hcuge.ch	Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776			Abdallah KAA, 2004, TROP MED INT HEALTH, V9, P1127, DOI 10.1111/j.1365-3156.2004.01308.x; ABELE DC, 1965, AM J TROP MED HYG, V14, P191, DOI 10.4269/ajtmh.1965.14.191; Attar ZJ, 2001, ACTA TROP, V78, P11, DOI 10.1016/S0001-706X(00)00155-8; Bern C, 2000, AM J TROP MED HYG, V63, P153, DOI 10.4269/ajtmh.2000.63.153; Boelaert M, 2004, AM J TROP MED HYG, V70, P72, DOI 10.4269/ajtmh.2004.70.72; Boelaert M, 1999, TROP MED INT HEALTH, V4, P395, DOI 10.1046/j.1365-3156.1999.00421.x; Boelaert M, 1999, AM J TROP MED HYG, V60, P129, DOI 10.4269/ajtmh.1999.60.129; Boelaert M, 1999, TROP MED INT HEALTH, V4, P31, DOI 10.1046/j.1365-3156.1999.00348.x; Boelaert M, 1999, B WORLD HEALTH ORGAN, V77, P667; Brandonisio O, 2002, EUR J CLIN MICROBIOL, V21, P461, DOI 10.1007/s10096-002-0739-8; Carvalho SFG, 2003, AM J TROP MED HYG, V68, P321; Chappuis F, 2003, TROP MED INT HEALTH, V8, P277, DOI 10.1046/j.1365-3156.2003.01026.x; CHOWDHURY MAJ, 1992, TROP DOCT, V22, P185, DOI 10.1177/004947559202200432; Delgado O, 2001, PARASITE, V8, P355, DOI 10.1051/parasite/2001084355; Desjeux P, 1996, CLIN DERMATOL, V14, P417, DOI 10.1016/0738-081X(96)00057-0; HAILU A, 1990, T ROY SOC TROP MED H, V84, P673, DOI 10.1016/0035-9203(90)90141-Z; HARITH AE, 1987, T ROY SOC TROP MED H, V81, P603, DOI 10.1016/0035-9203(87)90423-8; HARITH AE, 1986, T ROY SOC TROP MED H, V80, P583, DOI 10.1016/0035-9203(86)90149-5; Iqbal J, 2002, J CLIN MICROBIOL, V40, P475, DOI 10.1128/JCM.40.2.475-479.2002; LANDIS JR, 1977, BIOMETRICS, V33, P174; Mabey D, 2004, NAT REV MICROBIOL, V2, P231, DOI 10.1038/nrmicro841; Riera C, 2004, EUR J CLIN MICROBIOL, V23, P899, DOI 10.1007/s10096-004-1249-7; Rijal S, 2004, TROP MED INT HEALTH, V9, P724, DOI 10.1111/j.1365-3156.2004.01251.x; Schallig HDFH, 2002, MEM I OSWALDO CRUZ, V97, P1015, DOI 10.1590/S0074-02762002000700015; Sundar S, 1998, LANCET, V351, P563, DOI 10.1016/S0140-6736(97)04350-X; Sundar S, 2002, CLIN INFECT DIS, V35, P581, DOI 10.1086/342057; Sundar S, 2002, ANN TROP MED PARASIT, V96, P19, DOI 10.1179/000349802125000466; Sundar S, 2000, CLIN INFECT DIS, V31, P1104, DOI 10.1086/318121; SUNDAR S, 2003, ASTMH 52 ANN M PHIL; Veeken H, 2003, TROP MED INT HEALTH, V8, P164, DOI 10.1046/j.1365-3156.2003.00996.x; ZIJLSTRA EE, 1992, T ROY SOC TROP MED H, V86, P505, DOI 10.1016/0035-9203(92)90086-R; Zijlstra EE, 2001, TROP MED INT HEALTH, V6, P108, DOI 10.1046/j.1365-3156.2001.00680.x; ZIJLSTRA EE, 1991, T ROY SOC TROP MED H, V85, P474, DOI 10.1016/0035-9203(91)90224-M	33	34	34	0	2	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	JAN	2006	11	1					31	40		10.1111/j.1365-3156.2005.01533.x				10	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	001QZ	WOS:000234552700005	16398753	Bronze			2019-03-26	
J	Somers, R; Dorny, P; Nguyen, VK; Dang, TCT; Goddeeris, B; Craig, PS; Vercruysse, J				Somers, R; Dorny, P; Nguyen, VK; Dang, TCT; Goddeeris, B; Craig, PS; Vercruysse, J			Taenia solium taeniasis and cysticercosis in three communities in north Vietnam	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						cysticercosis; taeniasis; epidemiology; northern Vietnam	RISK-FACTORS; PREVALENCE; VILLAGE; MEXICO; NEUROCYSTICERCOSIS; SEROPREVALENCE; EPIDEMIOLOGY; INFECTION; EPILEPSY; PERU	OBJECTIVES (1) To investigate the response to a serum antigen-detecting ELISA for cysticercosis and a stool coproantigen test for taeniasis in two rural communities (mountainous and coastal areas) and one group of (peri-)urban factory workers; and (2) to examine clinical features of human cysticercosis in northern Vietnam. METHODS Villagers and factory workers and their families were informed and invited to participate in the study. Blood and faecal samples were collected from the participants and a simple questionnaire on taeniasis/cysticercosis completed. Serum was examined for the presence of circulating cysticercus antigen by a monoclonal-based sandwich ELISA. Ag-ELISA positive persons underwent a clinical examination and a computed tomography (CT) scan. Stool samples were examined microscopically for the presence of Taenia eggs and for copro-antigens. Tapeworms were identified following therapeutic expulsion using morphology and PCR-RFLP. RESULTS Circulating cysticercus antigens, suggesting active infection, were detected in 5.3% (16/303), 0.6% (1/175) and 0.0% (0/229) of the sampled individuals from the mountainous, coastal and urban regions, respectively. Clinical examination and CT scan of the cysticercus antigen positive persons showed that active cysticercosis did not cause severe disease in most cases. Taenia copro-antigens were found in 0.3% (1/297), 1.8% (3/166) and 0.0% (0/228) of the stool samples from the mountainous, coastal and urban communities, respectively. Three tapeworms were expelled after treatment: two Taenia solium and one Taenia saginata. CONCLUSION This survey points to a focal distribution of taeniasis/cysticercosis and suggests that human cysticercosis is rather acquired due to close contact with a T. solium carrier and self-infection, than through infection from the environment.	Inst Trop Med Antwerp, Dept Anim Hlth, B-2000 Antwerp, Belgium; Univ Ghent, Fac Vet Med, Parasitol Lab, Merelbeke, Belgium; Natl Inst Vet Res, Hanoi, Vietnam; Natl Inst Malariol Parasitol & Entomol, Hanoi, Vietnam; Katholieke Univ Leuven, Fac Agr & Appl Biol Sci, Lab Physiol & Immunol Domest Anim, Louvain, Belgium; Univ Salford, Biosci Res Inst, Salford M5 4WT, Lancs, England	Dorny, P (reprint author), Inst Trop Med Antwerp, Dept Anim Hlth, Natl Str 155, B-2000 Antwerp, Belgium.	pdorny@itg.be	Goddeeris, Bruno/L-2440-2015; Marra, Giulia/L-8303-2014	Goddeeris, Bruno/0000-0003-3729-7592; 			ALLAN JC, 1990, PARASITOLOGY, V101, P473, DOI 10.1017/S0031182000060686; Allan JC, 1996, AM J TROP MED HYG, V54, P352, DOI 10.4269/ajtmh.1996.54.352; ArandaAlvarez JG, 1995, ANN TROP MED PARASIT, V89, P689, DOI 10.1080/00034983.1995.11813004; Craig PS, 1996, ADV PARASIT, V38, P169, DOI 10.1016/S0065-308X(08)60035-4; DE NV, 2001, J CONTROL MALARIA OT, V3, P87; DE NV, 1999, J MALARIOLOGY PARASI, V2, P73; Dorny P, 2004, TRENDS PARASITOL, V20, P259, DOI 10.1016/j.pt.2004.04.001; Dorny P, 2003, ACTA TROP, V87, P79, DOI 10.1016/S0001-706X(03)00058-5; Dorny P, 2002, VET PARASITOL, V104, P211, DOI 10.1016/S0304-4017(01)00634-3; Dorny P, 2004, SE ASIAN J TROP MED, V35, P223; Erhart A, 2002, T ROY SOC TROP MED H, V96, P270, DOI 10.1016/S0035-9203(02)90095-7; Fleury A, 2003, NEUROEPIDEMIOLOGY, V22, P139, DOI 10.1159/000068748; Garcia HH, 2001, AM J TROP MED HYG, V65, P31, DOI 10.4269/ajtmh.2001.65.31; GARCIA HH, 1993, LANCET, V341, P197, DOI 10.1016/0140-6736(93)90064-N; Garcia HH, 2003, AM J TROP MED HYG, V68, P268, DOI 10.4269/ajtmh.2003.68.268; Garcia-Noval J, 2001, ANN TROP MED PARASIT, V95, P167, DOI 10.1080/00034980120050260; MORGAN B, 1949, VET HELMINTHOLOGY, P400; NGUYEN VK, 2003, 4 SEM FOOD WAT BORN, P201; Prabhakar Sudesh, 2002, P169; Rajshekhar V, 2003, ACTA TROP, V87, P53, DOI 10.1016/S0001-706X(03)00055-X; Rodriguez V, 2002, PHYSICA E, V12, P88, DOI 10.1016/S1386-9477(01)00249-1; Sanchez AL, 1999, ANN TROP MED PARASIT, V93, P247, DOI 10.1080/00034983.1999.11813420; SARTI E, 1992, AM J TROP MED HYG, V46, P677, DOI 10.4269/ajtmh.1992.46.677; Schantz P M, 1993, Bull Pan Am Health Organ, V27, P397; Schantz Peter M., 2002, P63, DOI 10.1079/9780851996288.0063; Sokal RR, 1981, BIOMETRY, P859; Thienpont D., 1986, Diagnosing helminthiasis by coprological examination.; Verle P, 2003, TROP MED INT HEALTH, V8, P961, DOI 10.1046/j.1365-3156.2003.01123.x; *VIETN ADM, 2003, VIETN ADM ATL; Willingham A Lee 3rd, 2003, Southeast Asian J Trop Med Public Health, V34 Suppl 1, P35	30	31	33	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	JAN	2006	11	1					65	72		10.1111/j.1365-3156.2005.01537.x				8	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	001QZ	WOS:000234552700009	16398757	Bronze			2019-03-26	
J	Bitwe, R; Dramaix, M; Hennart, P				Bitwe, R; Dramaix, M; Hennart, P			Simplified prognostic model of overall intrahospital mortality of children in central Africa	TROPICAL MEDICINE & INTERNATIONAL HEALTH			French	Article						predictors; prognostic score; intrahospital mortality; children; care evaluation; central Africa	RESPIRATORY-INFECTIONS; CLINICAL PREDICTORS; NUTRITIONAL-STATUS; RISK-FACTORS; WEST-AFRICA; DISEASES; GAMBIA; DEATH; MANAGEMENT; INDEXES	OBJECTIVES To find a simple mortality prediction model based on nutritional and infection indicators for the assessment of the care of children admitted to hospital in central Africa. METHOD Cohort study of 414 children admitted at Goma Hospital between 1.4.2003 and 31.3.2004. We conducted univariate analysis and logistic regression, computed adjusted odds ratios and constructed a prognostic score from the coefficients of logistic regression. The performance of logistic model and score were evaluated by the calculation of areas under the ROC curves. RESULTS The intrahospital mortality rate reached 15.9%. In univariate analysis, age, WAZ, arm circumference, neurological status (Blantyre coma score), stiff neck, subcostal indrawning, and infection were significantly associated with mortality. Logistic regression model analysis and adjusted odds ratios (AOR) confirmed higher risks of death for young ( AOR 3.4 ( 1.4 - 8.8) and underweight children (WAZ) 2->- 3 and WAZ < = -3, AOR 3.2 (1.4-7.6) and AOR 4.4 (1.7 - 11.2)), for children with arm circumference under 115 mm ( AOR 3.4 (1.5 - 7.3)), impaired consciousness ( AOR 9.6 (3.1 - 29.9)) and bloodstream infections ( AOR 6.6 (2.1 - 21.1)). The area under the ROC curve of the prognostic model is 0.83 (0.78 - 0.88), that of the pronostic score, 0.80 (0.75 - 0.86). CONCLUSION: This study provides a simple mortality prediction model for hospitalised children in central Africa, based on age, weight for age or arm circumference, neurological status ( Blantyre coma score), and infection. This model and scoring system can be used to evaluate programs set up to reduce intrahospital mortality in this region.	Univ Libre Bruxelles, Ecole Sante Publ, Brussels, Belgium		bitwe@yahoo.com					Berkley JA, 2003, BRIT MED J, V326, P361, DOI 10.1136/bmj.326.7385.361; BREWSTER DR, 1993, ANN TROP PAEDIATR, V13, P133, DOI 10.1080/02724936.1993.11747637; Chandra RK, 2002, EUR J CLIN NUTR, V56, pS73, DOI 10.1038/sj.ejcn.1601492; da Cunha A J, 2000, Indian Pediatr, V37, P296; Demers AM, 2000, PEDIATR INFECT DIS J, V19, P424, DOI 10.1097/00006454-200005000-00007; Djelantik IGG, 2003, J TROP PEDIATRICS, V49, P327, DOI 10.1093/tropej/49.6.327; DRAMAIX M, 1993, BRIT MED J, V307, P710, DOI 10.1136/bmj.307.6906.710; Dramaix M, 1996, AM J EPIDEMIOL, V143, P1235; Man WDC, 1998, TROP MED INT HEALTH, V3, P678, DOI 10.1046/j.1365-3156.1998.00283.x; Mitra AK, 2000, J HEALTH POPUL NUTR, V18, P151; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Nolan T, 2001, LANCET, V357, P106, DOI 10.1016/S0140-6736(00)03542-X; Norton EB, 2004, PEDIATR INFECT DIS J, V23, P145, DOI 10.1097/01.inf.0000109258.82988.40; PAXTON LA, 1996, WHO B OMS, V74, P66613; Pepin J, 2001, T ROY SOC TROP MED H, V95, P410, DOI 10.1016/S0035-9203(01)90199-3; Planche T, 2003, CLIN INFECT DIS, V37, P890, DOI 10.1086/377536; Prudhon C, 1996, AM J EPIDEMIOL, V144, P116, DOI 10.1093/oxfordjournals.aje.a008898; Savadogo LGB, 2002, REV EPIDEMIOL SANTE, V50, P441; Victora CG, 2003, LANCET, V362, P233, DOI 10.1016/S0140-6736(03)13917-7; Weber MW, 2002, TROP MED INT HEALTH, V7, P722, DOI 10.1046/j.1365-3156.2002.00926.x; *WHO, 1990, WHOCDDSER802; *WHO, 1991, WHOARI9120; Zucker JR, 1996, AM J TROP MED HYG, V55, P655, DOI 10.4269/ajtmh.1996.55.655	23	3	3	0	2	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	JAN	2006	11	1					73	80		10.1111/j.1365-3156.2005.01540.x				8	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	001QZ	WOS:000234552700010	16398758	Bronze			2019-03-26	
J	Garros, C; Van Bortel, W; Trung, HD; Coosemans, M; Manguin, S				Garros, C; Van Bortel, W; Trung, HD; Coosemans, M; Manguin, S			Review of the Minimus Complex of Anopheles, main malaria vector in Southeast Asia: from taxonomic issues to vector control strategies	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						Anopheles minimus s.l; sibling species; distribution; bionomics; malaria; Southeast Asia	RYUKYU ARCHIPELAGO; PHYLOGENETIC-RELATIONSHIPS; CULICIDAE; DIPTERA; THAILAND; IDENTIFICATION; TRANSMISSION; VIETNAM; MOSQUITOS; FUNESTUS	BACKGROUND The Minimus Complex of Anopheles subgenus Cellia is composed of two sibling species, A and C, on the Southeast Asian mainland, and a third allopatric species E that occurs in the Ryukyu Archipelago (Japan), a malaria-free region. Anopheles minimus s.l. is considered to be one of the main malaria vector in the hilly forested regions of Southeast Asia. Despite a large number of studies over its range of distribution, it is difficult to have a global view of the ecological and bionomical characteristics of the individual species as different identification methods were used, generally without specific identification of the sibling species. OBJECTIVES (1) To review the main malaria studies on An. minimus s.l.; (2) to discuss recently published data on the biology and ecology of each sibling species; and (3) to identify gaps in our understanding of the Minimus Complex. REVIEW RESULTS Major biological and ecological trends are addressed, such as the high plasticity of trophic behaviour and the sympatry of species A and C over the Southeast Asian mainland. Despite the availability of rapid molecular identification methods, we still lack important information concerning the biological characteristics of each sibling species. These gaps must be filled in the future because An. minimus species A and C may exhibit different abilities to transmit malaria. CONCLUSION We expect that entomological surveys will employ molecular methods to clearly identify these two species, and thus elucidate the biological characteristics of each species. As a consequence, current vector control strategies will be improved by targeting the most efficient vectors.	Ctr Biol & Management Populat, Inst Dev Res, Montpellier, France; Inst Trop Med Prince Leopold, Dept Parasitol, B-2000 Antwerp, Belgium; Natl Inst Malariol Parasitol & Entomol, Hanoi, Vietnam	Manguin, S (reprint author), Ctr Biol & Gest Populat, Campus Int Baillarguet,CS 30016, F-34988 Montferrier Sur Lez, France.	manguin@mpl.ird.fr	Manguin, Sylvie/G-1787-2015; Garros, Claire/C-2715-2011	Manguin, Sylvie/0000-0002-5925-7164; Van Bortel, Wim/0000-0002-6644-518X			AM NT, 1993, B SOC PATHOL EXOT, V86, P494; Amerasinghe PH, 1999, AM J TROP MED HYG, V60, P421, DOI 10.4269/ajtmh.1999.60.421; Baba K., 1950, Transactions of the Kansai Entomological Society, V15, P1; BAIMAI V, 1989, P 3 C MAL RES BANGK; Barcus MJ, 2002, AM J TROP MED HYG, V66, P287, DOI 10.4269/ajtmh.2002.66.287; Bhatt R. M., 1996, Indian Journal of Malariology, V33, P180; Chareonviriyaphap T, 2003, J MED ENTOMOL, V40, P876, DOI 10.1603/0022-2585-40.6.876; Chareonviriyaphap T, 2003, J VECTOR ECOL, V28, P108; Chareonviriyaphap Theeraphap, 2000, Southeast Asian Journal of Tropical Medicine and Public Health, V31, P225; Chen B, 2002, MED VET ENTOMOL, V16, P253, DOI 10.1046/j.1365-2915.2002.00373.x; Covell G., 1944, JOUR MALARIA INST INDIA, V5, P399; Das N. G., 2000, Indian Journal of Malariology, V37, P88; DAS S C, 1985, Indian Journal of Malariology, V22, P53; Dev V, 1996, B WORLD HEALTH ORGAN, V74, P61; Dev V, 2003, J Assoc Physicians India, V51, P1073; Dieng H, 2003, J AM MOSQUITO CONTR, V19, P67; DONG XS, 1997, ADV MOSQUITO RES YUN, P72; Garros C, 2005, J MED ENTOMOL, V42, P522, DOI 10.1603/0022-2585(2005)042[0522:MAAMPO]2.0.CO;2; Garros C, 2005, J AM MOSQUITO CONTR, V21, P139, DOI 10.2987/8756-971X(2005)21[139:FROAMC]2.0.CO;2; Garros C, 2005, J MED ENTOMOL, V42, P7, DOI 10.1603/0022-2585(2005)042[0007:SABIOT]2.0.CO;2; Garros C, 2004, AM J TROP MED HYG, V70, P583, DOI 10.4269/ajtmh.2004.70.583; Garros C, 2004, AM J TROP MED HYG, V70, P260, DOI 10.4269/ajtmh.2004.70.260; GARROS C, 2005, INT C TROP MED MARS; GREEN CA, 1990, MED VET ENTOMOL, V4, P25, DOI 10.1111/j.1365-2915.1990.tb00256.x; Harbach RE, 2004, B ENTOMOL RES, V94, P537, DOI 10.1079/BER2004321; HARBACH RE, 1987, J AM MOSQUITO CONTR, V3, P296; HARRISON B A, 1980, Contributions of the American Entomological Institute, V17, P1; JANAKARA BR, 1995, J TROP MED HYG, V98, P73; Kengne P, 2001, INSECT MOL BIOL, V10, P427, DOI 10.1046/j.0962-1075.2001.00281.x; KHAI MD, 1975, ANN SCI WORKS, P24; KIRNOWARDOYO S, 1985, Southeast Asian Journal of Tropical Medicine and Public Health, V16, P129; LIEN J-C, 1991, Kaohsiung Journal of Medical Sciences, V7, P207; Lin Khin, 2000, Southeast Asian Journal of Tropical Medicine and Public Health, V31, P444; Maheswary N. P., 1992, Southeast Asian Journal of Tropical Medicine and Public Health, V23, P798; MEEK SR, 1995, ANN TROP MED PARASIT, V89, P135, DOI 10.1080/00034983.1995.11812944; Mungkornasawakul P, 2004, J NAT PROD, V67, P675, DOI 10.1021/np034066u; Nandi J., 2000, Journal of Communicable Diseases, V32, P95; NUTSATHAPANA S, 1986, B ENTOMOL RES, V76, P303; Oo TT, 2004, J VECTOR ECOL, V29, P21; Overgaard HJ, 2002, ENVIRON ENTOMOL, V31, P134, DOI 10.1603/0046-225X-31.1.134; PAING M, 1998, TROPICAL BIOMEDICINE, V5, P161; PARAJULI MB, 1981, T ROY SOC TROP MED H, V75, P603; PHAN V, 1973, ANN SCI WORKS, P60; PHAN VT, 1998, EPIDEMIOLOGIE PALUDI; Phuc HK, 2003, MED VET ENTOMOL, V17, P423, DOI 10.1111/j.1365-2915.2003.00462.x; PHUNG TT, 1997, ANN SCI WORKS, V1, P333; Prakash A, 2004, ANN TROP MED PARASIT, V98, P559, DOI 10.1179/000349804225021361; Prakash Anil, 2000, Indian Journal of Malariology, V37, P74; Rahman W. A., 2002, Southeast Asian Journal of Tropical Medicine and Public Health, V33, P547; RATANATHAM S, 1988, Southeast Asian Journal of Tropical Medicine and Public Health, V19, P283; Rattanarithikul R, 1996, J AM MOSQUITO CONTR, V12, P52; Rueda LM, 2004, J AM MOSQUITO CONTR, V20, P204; Rwegoshora R. Theophil, 2002, Southeast Asian Journal of Tropical Medicine and Public Health, V33, P694; SCHULTZ G W, 1989, Southeast Asian Journal of Tropical Medicine and Public Health, V20, P49; Sharpe RG, 2000, SYST ENTOMOL, V25, P263, DOI 10.1046/j.1365-3113.2000.00118.x; Sharpe RG, 1999, MED VET ENTOMOL, V13, P265, DOI 10.1046/j.1365-2915.1999.00178.x; Soe-Soe, 2001, T ROY SOC TROP MED H, V95, P81, DOI 10.1016/S0035-9203(01)90342-6; Somboon P, 2000, J MED ENTOMOL, V37, P476, DOI 10.1603/0022-2585(2000)037[0476:EOTSSO]2.0.CO;2; Somboon P, 2005, J AM MOSQUITO CONTR, V21, P5, DOI 10.2987/8756-971X(2005)21[5:CEOAMS]2.0.CO;2; Somboon P, 2001, J AM MOSQUITO CONTR, V17, P98; Somboon Pradya, 2003, Southeast Asian Journal of Tropical Medicine and Public Health, V34, P87; SUCHARIT S, 1988, Southeast Asian Journal of Tropical Medicine and Public Health, V19, P717; Trung HD, 2005, TROP MED INT HEALTH, V10, P251, DOI 10.1111/j.1365-3156.2004.01378.x; Trung HD, 2004, TROP MED INT HEALTH, V9, P230, DOI 10.1046/j.1365-3156.2003.01179.x; Tsuda Y, 1999, J MED ENTOMOL, V36, P601, DOI 10.1093/jmedent/36.5.601; Van Bortel W, 1999, TROP MED INT HEALTH, V4, P257; Van Bortel W, 2000, INSECT MOL BIOL, V9, P335, DOI 10.1046/j.1365-2583.2000.00192.x; Van Bortel W, 2004, J MED ENTOMOL, V41, P366, DOI 10.1603/0022-2585-41.3.366; Van Bortel W, 2003, HEREDITY, V91, P487, DOI 10.1038/sj.hdy.6800313; Van Bortel W, 2003, J AM MOSQUITO CONTR, V19, P261; Van Bortel W, 2001, AM J TROP MED HYG, V65, P729, DOI 10.4269/ajtmh.2001.65.729; Vythilingam Indra, 2001, Southeast Asian Journal of Tropical Medicine and Public Health, V32, P83; Walton C, 2004, J AM MOSQUITO CONTR, V20, P331; WOOSTER M T, 1985, Southeast Asian Journal of Tropical Medicine and Public Health, V16, P59; YU Y, 1987, Mosquito Systematics, V19, P143; Yu Yuan, 1984, Journal of Parasitology and Parasitic Diseases, V2, P95	76	52	55	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	JAN	2006	11	1					102	114		10.1111/j.1365-3156.2005.01536.x				13	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	001QZ	WOS:000234552700013	16398761	Bronze			2019-03-26	
J	Erhart, A; Thang, ND; Ky, PV; Tinh, TT; Van Overmeir, C; Speybroeck, N; Obsomer, V; Hung, LX; Thuan, LK; Coosemans, M; D'alessandro, U				Erhart, A; Thang, ND; Ky, PV; Tinh, TT; Van Overmeir, C; Speybroeck, N; Obsomer, V; Hung, LX; Thuan, LK; Coosemans, M; D'alessandro, U			Epidemiology of forest malaria in central Vietnam: a large scale cross-sectional survey	MALARIA JOURNAL			English	Article							RISK-FACTORS; SRI-LANKA; INTERVENTIONS; INFECTION; VECTORS; AREA	In Vietnam, a large proportion of all malaria cases and deaths occurs in the central mountainous and forested part of the country. Indeed, forest malaria, despite intensive control activities, is still a major problem which raises several questions about its dynamics. A large-scale malaria morbidity survey to measure malaria endemicity and identify important risk factors was carried out in 43 villages situated in a forested area of Ninh Thuan province, south central Vietnam. Four thousand three hundred and six randomly selected individuals, aged 10 - 60 years, participated in the survey. Rag Lays (86%), traditionally living in the forest and practising "slash and burn" cultivation represented the most common ethnic group. The overall parasite rate was 13.3% ( range [ 0 - 42.3] while Plasmodium falciparum seroprevalence was 25.5% ( range [2.1 - 75.6]). Mapping of these two variables showed a patchy distribution, suggesting that risk factors other than remoteness and forest proximity modulated the human-vector interactions. This was confirmed by the results of the multivariate-adjusted analysis, showing that forest work was a significant risk factor for malaria infection, further increased by staying in the forest overnight (OR= 2.86; 95% CI [1.62; 5.07]). Rag Lays had a higher risk of malaria infection, which inversely related to education level and socio-economic status. Women were less at risk than men ( OR = 0.71; 95% CI [0.59; 0.86]), a possible consequence of different behaviour. This study confirms that malaria endemicity is still relatively high in this area and that the dynamics of transmission is constantly modulated by the behaviour of both humans and vectors. A well-targeted intervention reducing the "vector/forest worker" interaction, based on long-lasting insecticidal material, could be appropriate in this environment.	Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium; Natl Inst Malariol Parasitol & Entomol, Hanoi, Vietnam; Prov Ctr Malariol Parasitol & Entomol, Phan Rang City, Ninh Thuan Prov, Vietnam	Erhart, A (reprint author), Inst Trop Med Prince Leopold, Natl Str 155, B-2000 Antwerp, Belgium.	aerhart@itg.be; thangnimpevn@yahoo.com; phamvankynt@hotmail.com; tathitinh2411@yahoo.com; cvovermeir@itg.be; nspeybroeck@itg.be; vobsomer@itg.be; lxhung@netnam.org; nimpe@netnam.org.vn; mcoos@itg.be; udalessandro@itg.be	D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009			Amuge Beatrice, 2004, Afr Health Sci, V4, P119; Barat LM, 2004, AM J TROP MED HYG, V71, P174, DOI 10.4269/ajtmh.2004.71.174; Cavanagh DR, 1998, J IMMUNOL, V161, P347; Chaveepojnkamjorn W, 2005, SE ASIAN J TROP MED, V35, P48; Cropley L, 2004, HEALTH PROMOT INT, V19, P445, DOI 10.1093/heapro/dah406; Danis-Lozano R, 1999, EPIDEMIOL INFECT, V122, P461, DOI 10.1017/S0950268899002319; Das N. G., 2004, Journal of Vector Borne Diseases, V41, P5; DEMEDTS P, 1985, ANN SOC BELG MED TR, V65, P89; Erhart A, 2004, AM J TROP MED HYG, V70, P110, DOI 10.4269/ajtmh.2004.70.110; Gadelha P., 1994, Parassitologia (Rome), V36, P175; GAMAGEMENDIS AC, 1991, AM J TROP MED HYG, V45, P77, DOI 10.4269/ajtmh.1991.45.77; *GTZ, 2004, VIETN PROGR POV ALL; Gunawardena DM, 1998, AM J TROP MED HYG, V58, P533, DOI 10.4269/ajtmh.1998.58.533; Klinkenberg E, 2004, ACTA TROP, V89, P215, DOI 10.1016/j.actatropica.2003.08.007; Konradsen F, 2003, AM J TROP MED HYG, V68, P177, DOI 10.4269/ajtmh.2003.68.177; Lansang MAD, 1997, ACTA TROP, V63, P257, DOI 10.1016/S0001-706X(96)00625-0; Lindsay SW, 2003, TROP MED INT HEALTH, V8, P512, DOI 10.1046/j.1365-3156.2003.01059.x; Malaney P, 2004, AM J TROP MED HYG, V71, P141, DOI 10.4269/ajtmh.2004.71.141; MARSH K, 2002, ESSENTIAL MALARIOLOG, V11, P252; NIMPE, 2003, ANN REP NAT MAL CONT; *NIMPE, 2004, ANN REP NAT MAL CONT; Povoa MM, 2003, J MED ENTOMOL, V40, P379, DOI 10.1603/0022-2585-40.4.379; Sachs J, 2002, NATURE, V415, P680, DOI 10.1038/415680a; Safeukui-Noubissi I, 2004, MICROBES INFECT, V6, P572, DOI 10.1016/j.micinf.2004.02.007; SHARMA VP, 1991, FOR MAL SE AS P INF; *TDR, 2000, TDR 15 PROGR REP PRO; Trung HD, 2004, TROP MED INT HEALTH, V9, P230, DOI 10.1046/j.1365-3156.2003.01179.x; TRUNG HD, 2005, TROP MED INT HEALTH, V10, P1; *WHO, 2003, COMB COMM DIS FOC 2; *WHO, 2002, 20 WHO EXP COMM MAL	30	90	91	1	8	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1475-2875			MALARIA J	Malar. J.	DEC 8	2005	4								58	10.1186/1475-2875-4-58				11	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	000UG	WOS:000234487300001	16336671	DOAJ Gold, Green Published			2019-03-26	
J	Zamora, H; Castillo, Y; Garcia, HH; Pretell, J; Rodriguez, S; Dorny, P; Gonzalez, AE; Gilman, RH; Tsang, VW; Brandt, J				Zamora, Humberto; Castillo, Yesenia; Garcia, Hector H.; Pretell, Javier; Rodriguez, Silvia; Dorny, Pierre; Gonzalez, Armando E.; Gilman, Robert H.; Tsang, Victor W.; Brandt, Jef		Cysticercosis Working Grp Peru	Drop in antigen levels following successful treatment of subarachnoid neurocysticercosis	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Meeting Abstract									[Zamora, Humberto; Castillo, Yesenia; Garcia, Hector H.; Pretell, Javier; Rodriguez, Silvia; Gilman, Robert H.] Univ Peruana Cayetano Heredia, Dept Microbiol, Lima, Peru; [Dorny, Pierre; Brandt, Jef] Inst Trop Med, B-2000 Antwerp, Belgium; [Gonzalez, Armando E.] Univ Nacl Mayor San Marcos, Sch Vet Med, Lima 14, Peru; [Tsang, Victor W.] Ctr Dis Control & Prevent, Div Parasit Dis, Atlanta, GA USA; [Cysticercosis Working Grp Peru] Univ Peruana Cayetano Heredia, Lima, Peru								0	9	9	0	1	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	DEC	2005	73	6		S		120	41	41						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	V44GA	WOS:000202990000121					2019-03-26	
J	Robledo, JA; Mejia, GI; Morcillo, N; Chacon, L; Camacho, M; Luna, J; Zurita, J; Velasco, M; Palomino, JC; Martin, A; Portaels, F				Robledo, Jaime A.; Mejia, Gloria I.; Morcillo, Nora; Chacon, Luis; Camacho, Mirta; Luna, Julieta; Zurita, Janeth; Velasco, Maritza; Palomino, Juan C.; Martin, Anandi; Portaels, Francoise			Evaluation of a rapid culture method for tuberculosis diagnosis: A Latin American multi-center study	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Meeting Abstract									[Robledo, Jaime A.; Mejia, Gloria I.] Univ Pontificia Bolivariana, Corp Invest Biol, Bacteriol & Mycobacteriol Unit, Medellin, Antioquia, Colombia; [Robledo, Jaime A.; Mejia, Gloria I.] Univ Pontificia Bolivariana, Escuela Ciencias Salud, Medellin, Antioquia, Colombia; [Morcillo, Nora] Hosp Cetragolo, Mycobacterial Reg Reference Lab, Buenos Aires, DF, Argentina; [Chacon, Luis] Ctr Nacl Diagnost & Referencia, Dept Micobacterias, Minist Salud Nicaragua, Managua, Nicaragua; [Camacho, Mirta] Inst Nacl Labs Salud, INLASA, La Paz, Bolivia; [Luna, Julieta] Inst Politecn Nacl, Escuela Nacl Ciencias Biol, Mexico City, DF, Mexico; [Zurita, Janeth] Hosp Vozandes, Lab Microbiol & Tuberculosis, Quito, Ecuador; [Velasco, Maritza] Inst Salud Publ Chile, Secc Micobacterias, Santiago De Compostela, Spain; [Palomino, Juan C.; Martin, Anandi; Portaels, Francoise] Inst Trop Med, B-2000 Antwerp, Belgium								0	0	0	0	4	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	DEC	2005	73	6		S		166	55	56						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	V44GA	WOS:000202990000167					2019-03-26	
J	Tinto, H; Ouedraogo, JB; Guiguemde, TR; Sanou, B; Dujardin, JC; Dujardin, JC; Van Overmeir, C; Erhart, A; Van Marck, E; D'Alessandro, U				Tinto, Halidou; Ouedraogo, Jean Bosco; Guiguemde, Tinga Robert; Sanou, Boroma; Dujardin, Jean Claude; Dujardin, Jean Claude; Van Overmeir, Chantal; Erhart, Annette; Van Marck, Eric; D'Alessandro, Umberto			Usefulness of the Pfcrt T76 genotype failure index (GFI) for the estimation of in vivo chloroquine resistance in Burkina Faso	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Meeting Abstract									[Tinto, Halidou; Ouedraogo, Jean Bosco; Sanou, Boroma; Dujardin, Jean Claude] IRSS Ctr Muraz, Bobo Dioulasso, Burkina Faso; [Guiguemde, Tinga Robert] Ctr Muraz, Bobo Dioulasso, Burkina Faso; [Dujardin, Jean Claude; Van Overmeir, Chantal; Erhart, Annette; D'Alessandro, Umberto] Inst Trop Med, B-2000 Antwerp, Belgium; [Van Marck, Eric] Univ Antwerp, B-2020 Antwerp, Belgium			D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009				0	0	0	0	0	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	DEC	2005	73	6		S		361	120	120						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	V44GA	WOS:000202990000360					2019-03-26	
J	Angov, E; Brent-Kirk, A; Bowden, SA; Soisson, LA; Stoute, JA; Ockenhouse, CF; Cohen, J; Diggs, CL; Heppner, DG; Lyon, JA				Angov, Evelina; Brent-Kirk, Afiya; Bowden, Scott A.; Soisson, Lorraine A.; Stoute, Jose A.; Ockenhouse, Christian F.; Cohen, Joe; Diggs, Carter L.; Heppner, Donald G.; Lyon, Jeffrey A.			Analysis of antibody specificities detected by an MSP1-42 fragment specific ELISA following vaccination with FMP1/ASO2A in three diverse populations	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Meeting Abstract									[Angov, Evelina; Brent-Kirk, Afiya; Bowden, Scott A.; Ockenhouse, Christian F.; Heppner, Donald G.; Lyon, Jeffrey A.] Walter Reed Army Inst Res, Dept Immunol, Silver Spring, MD USA; [Soisson, Lorraine A.; Diggs, Carter L.] US Agcy Int Dev, Washington, DC 20523 USA; [Stoute, Jose A.] Walter Reed Army Inst Res, Dept Cellular Injury, Silver Spring, MD USA; [Cohen, Joe] GlaxoSmithKline Biol, Rixensart, Belgium								0	0	0	0	0	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	DEC	2005	73	6		S		557	183	184						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	V44GA	WOS:000202990000556					2019-03-26	
J	Ogutu, BR; Withers, MR; Onyango, M; Otieno, A; Waitumbi, JN; Heppner, DG; Tucker, MSK; Milman, J; Leach, A; Spiessens, B; Ballou, R; Diggs, C; Stoute, J				Ogutu, Bernhards R.; Withers, Mark R.; Onyango, Melanie; Otieno, Allan; Waitumbi, John N.; Heppner, Donald G.; Tucker, Kathryn M. S.; Milman, Jessica; Leach, Amanda; Spiessens, Bert; Ballou, Ripley; Diggs, Carter; Stoute, Jose			A longitudinal cohort study of the epidemiology of pediatric malaria in Kombewa division, western Kenya: Update	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Meeting Abstract									[Ogutu, Bernhards R.; Onyango, Melanie; Otieno, Allan; Waitumbi, John N.] Kenya Govt Med Res Ctr, Kisumu, Kenya; [Withers, Mark R.] USAMRU K, Kenya Med Res Inst, Kisumu, Kenya; [Heppner, Donald G.] Walter Reed Army Inst Res, Maryland, MD USA; [Tucker, Kathryn M. S.] Stat Collaborat Inc, Washington, DC USA; [Milman, Jessica] PATH Malaria Vaccine Initiat, Washington, DC USA; [Milman, Jessica] GlaxoSmithKline Biol, Rixensart, Belgium; [Diggs, Carter] US Agcy Int Dev, Malaria Vaccine Dev Project, Washington, DC USA								0	0	0	0	0	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	DEC	2005	73	6		S		850	280	280						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	V44GA	WOS:000202990001273					2019-03-26	
J	McGrath, SM; Bayat, B; Donner, MN; Mettens, P; Collignon, C; Pau, MG; Dubois, P; Goudsmit, J; Cohen, J; Heppner, DG; Stewart, VA				McGrath, Shannon M.; Bayat, Babak; Donner, Marie-Noalle; Mettens, Pascal; Collignon, Catherine; Pau, Maria Grazia; Dubois, Patrice; Goudsmit, Jaap; Cohen, Joe; Heppner, D. Gray; Stewart, V. Ann			Use of 6-color flow cytometry to measure immune response in rhesus macaques immunized with malaria vaccine candidates	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Meeting Abstract									[McGrath, Shannon M.; Heppner, D. Gray; Stewart, V. Ann] Walter Reed Army Inst Res, Silver Spring, MD USA; [Bayat, Babak; Donner, Marie-Noalle; Mettens, Pascal; Collignon, Catherine; Dubois, Patrice; Cohen, Joe] GlaxoSmithKline Biol, Rixensart, Belgium; [Pau, Maria Grazia; Goudsmit, Jaap] Crucell Holland BV, Leiden, Netherlands								0	0	0	0	0	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	DEC	2005	73	6		S		880	290	290						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	V44GA	WOS:000202990001303					2019-03-26	
J	Shott, J; Pau, MG; Demoitia, MA; Custers, JH; McGrath, S; Dubois, P; Ophorst, O; Dubois, MC; Komisar, J; Cohen, J; Goudsmit, J; Heppner, DG; Stewart, VA				Shott, Joseph; Pau, Maria Grazia; Demoitia, Marie-Ange; Custers, Jerome H.; McGrath, Shannon; Dubois, Patrice; Ophorst, Olga; Dubois, Marie-Claude; Komisar, Jack; Cohen, Joe; Goudsmit, Jaap; Heppner, D. Gray; Stewart, V. Ann			Evaluation of immunogenicity of adenovirus-PFCS malaria vaccine candidates in mice	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Meeting Abstract									[Shott, Joseph; McGrath, Shannon; Komisar, Jack; Heppner, D. Gray; Stewart, V. Ann] Walter Reed Army Inst Res, Silver Spring, MD USA; [Pau, Maria Grazia; Custers, Jerome H.; Ophorst, Olga; Goudsmit, Jaap] Crucell Holland BV, Leiden, Netherlands; [Demoitia, Marie-Ange; Dubois, Patrice; Dubois, Marie-Claude; Cohen, Joe] GlaxoSmithKline Biol, Rixensart, Belgium								0	0	0	0	0	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	DEC	2005	73	6		S		881	290	290						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	V44GA	WOS:000202990001304					2019-03-26	
J	Cobb, M; McGrath, S; Dutta, S; Ware, LA; Lalitha, PV; Cohen, J; Lanar, DE; Heppner, DG; Stewart, VA				Cobb, Michelle; McGrath, Shannon; Dutta, Sheetij; Ware, Lisa A.; Lalitha, P. V.; Cohen, Joe; Lanar, David E.; Heppner, D. Gray; Stewart, V. Ann			Interferon-gamma elispot responses to pfama-1/E, a recombinant protein blood-stage Plasmodium falciparum vaccine candidate, in rhesus macaques	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Meeting Abstract									[Cobb, Michelle; McGrath, Shannon; Dutta, Sheetij; Ware, Lisa A.; Lalitha, P. V.; Lanar, David E.; Heppner, D. Gray; Stewart, V. Ann] Walter Reed Army Inst Res, Silver Spring, MD USA; [Cohen, Joe] GlaxoSmithKline Biol, Rixensart, Belgium			Lanar, David/B-3560-2011					0	0	0	0	0	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	DEC	2005	73	6		S		883	291	291						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	V44GA	WOS:000202990001306					2019-03-26	
J	Angov, E; Khan, F; N-Leitner, ESB; Kincaid, R; Heppner, DG; Soisson, L; Cohen, J; Diggs, CL; Lyon, JA				Angov, Evelina; Khan, Farhat; N-Leitner, Elke S. Bergman; Kincaid, Randall; Heppner, Donald G.; Soisson, Lorraine; Cohen, Joe; Diggs, Carter L.; Lyon, Jeffrey A.			Antibodies raised against Plasmodium falciparum MSP1-42 expressed from a fully codon-harmonized gene are significantly more growth inhibitory than those raised against the same antigen expressed from a partially codon-harmonized gene	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Meeting Abstract									[Angov, Evelina; Khan, Farhat; N-Leitner, Elke S. Bergman; Heppner, Donald G.; Lyon, Jeffrey A.] Walter Reed Army Inst Res, Dept Immunol, Silver Spring, MD USA; [Kincaid, Randall] Veritas Inc, Rockville, MD USA; [Soisson, Lorraine; Diggs, Carter L.] US Agcy Int Dev, Washington, DC 20523 USA; [Cohen, Joe] GlaxoSmithKline Biol, Rixensart, Belgium								0	0	0	0	4	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	DEC	2005	73	6		S		887	292	292						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	V44GA	WOS:000202990001310					2019-03-26	
J	Walsh, DS; Gettayacamin, M; Lyon, JA; Leitner, WW; Stewart, A; Pichyangkul, S; Gosi, P; Tongtawe, P; Holland, CA; Kolodny, N; Cohen, J; Voss, G; Ballou, R; Heppner, DG; Heppner, DG				Walsh, Douglas S.; Gettayacamin, Montip; Lyon, Jeffrey A.; Leitner, Wolfgang W.; Stewart, Ann; Pichyangkul, Sathit; Gosi, Panita; Tongtawe, Pongsri; Holland, Carolyn A.; Kolodny, Nelly; Cohen, Joe; Voss, Gerald; Ballou, Ripley; Heppner, D. Gray, Jr.; Heppner, D. Gray			Heterologous prime-boost immunization with epidermal gene gun administered Plasmodium falciparum circumsporozoite protein (CSP) encoding DNA and intramuscular RTS,S/ASO2A in rhesus monkeys generates robust cutaneous delayed-type hypersensitivity responses against CSPC terminus	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Meeting Abstract									[Walsh, Douglas S.; Lyon, Jeffrey A.; Stewart, Ann; Holland, Carolyn A.; Kolodny, Nelly; Heppner, D. Gray, Jr.; Heppner, D. Gray] Walter Reed Army Inst Res, Silver Spring, MD USA; [Gettayacamin, Montip; Pichyangkul, Sathit; Gosi, Panita; Tongtawe, Pongsri] Armed Forces Res Inst Med Sci, US Army Med Component, Bangkok 10400, Thailand; [Leitner, Wolfgang W.] Natl Inst Hlth, Dermatol Branch, Bethesda, MD USA; [Cohen, Joe; Voss, Gerald; Ballou, Ripley] GlaxoSmithKline Biol, Rixensart, Belgium			Leitner, Wolfgang/F-5741-2011	Leitner, Wolfgang/0000-0003-3125-5922				0	0	0	0	0	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	DEC	2005	73	6		S		1089	359	359						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	V44GA	WOS:000202990001512					2019-03-26	
J	Stewart, VA; McGrath, SM; Pau, MG; Mettens, P; Dubois, P; Custers, JHHV; Demoitie, MA; Ophorst, O; Shott, J; Bayat, B; Donner, MN; Dubois, AC; Goudsmit, J; Cohen, J; Heppner, DG				Stewart, V. Ann; McGrath, Shannon M.; Pau, Maria Grazia; Mettens, Pascal; Dubois, Patrice; Custers, Jerome H. H. V.; Demoitie, Marie-Ange; Ophorst, Olga; Shott, Joseph; Bayat, Babak; Donner, Marie-Noelle; Dubois, Arie-Claude; Goudsmit, Jaap; Cohen, Joe; Heppner, D. Gray			Heterologous prime-boost with adenovirus35-vectored CS and recombinant protein RTS,S/ASO1B greatly enhances immune responses to Plasmodium falciparum CS	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Meeting Abstract									[Stewart, V. Ann; McGrath, Shannon M.; Shott, Joseph; Heppner, D. Gray] Walter Reed Army Inst Res, Silver Spring, MD USA; [Pau, Maria Grazia; Custers, Jerome H. H. V.; Ophorst, Olga; Goudsmit, Jaap] Crucell Holland BV, Leiden, Netherlands; [Mettens, Pascal; Dubois, Patrice; Demoitie, Marie-Ange; Bayat, Babak; Donner, Marie-Noelle; Dubois, Arie-Claude; Cohen, Joe] GlaxoSmithKline Biol, Rixensart, Belgium								0	0	0	0	0	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	DEC	2005	73	6		S		1090	360	360						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	V44GA	WOS:000202990001513					2019-03-26	
J	Lambert, ML; Delgado, R; Michaux, G; Volz, A; Speybroeck, N; van der Stuyft, P				Lambert, ML; Delgado, R; Michaux, G; Volz, A; Speybroeck, N; van der Stuyft, P			Delays to treatment and out-of-pocket medical expenditure for tuberculosis patients, in an urban area of South America	ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY			English	Article							PULMONARY TUBERCULOSIS; DIAGNOSIS; HEALTH; SYSTEM	Short delays to treatment are important for the control of tuberculosis ( TB). National Tuberculosis Programmes provide free diagnosis and treatment for smear-positive patients, so that the patients' out-of-pocket medical expenditure could be almost nil. The factors associated with delays in starting treatment, and the pre-treatment out-of-pocket medical expenditure for TB patients, have now been investigated in the Bolivian city of Cochabamba. Bolivia is the Latin American country with the highest incidence of TB. It is covered by a national TB programme that provides free diagnosis and free treatment for smear-positive patients. Structured interviews with 144 smear-positive patients enrolled in this programme revealed median patient, provider and total delays of 3.6, 6.2 and 12.9 weeks, respectively. The total delays were longer for the female patients than for the male, and for patients who consulted private doctors than for the other patients. When the first healthcare provider was a doctor, the median provider delay was 4.9 weeks in the public sector but 7.2 weeks in the private. The median out-of-pocket medical expenditure per patient, which was U.S.$13.2 overall, was much higher for those who consulted a private doctor than for those who did not (U.S.$21.9 v. U.S.$5.4, respectively; P < 0.001). It appears that interventions targeting doctors ( in both the private and public sectors) are likely to have a larger impact on the shortening of delays in TB treatment than interventions targeting patients. They could also reduce unnecessary out-of-pocket expenditure.	Inst Trop Med, B-2000 Antwerp, Belgium; Univ Mayor de San Simon, Fac Med, Biomed Res Inst, Cochabamba, Bolivia; Belgian Tech Corp, B-1000 Brussels, Belgium	Lambert, ML (reprint author), Inst Trop Med, Natl Str 155, B-2000 Antwerp, Belgium.	mllambert@itg.be					Enarson D.A., 2000, MANAGEMENT TUBERCULO; Godfrey-Faussett R, 2002, INT J TUBERC LUNG D, V6, P796; Lambert ML, 2004, INT J TUBERC LUNG D, V8, P1325; Lawn SD, 1998, INT J TUBERC LUNG D, V2, P635; Liam CK, 1997, INT J TUBERC LUNG D, V1, P326; Lienhardt C, 2001, INT J TUBERC LUNG D, V5, P233; Lonnroth K, 1999, INT J TUBERC LUNG D, V3, P992; Needham DM, 1998, INT J TUBERC LUNG D, V2, P811; Rajeswari R, 2002, INT J TUBERC LUNG D, V6, P789; Rieder H, 1999, EPIDEMIOLOGIC BASIS; Steen TW, 1998, INT J TUBERC LUNG D, V2, P627; Uplekar M, 2001, LANCET, V358, P912, DOI 10.1016/S0140-6736(01)06076-7; *WHO, 2004, WHOHTMTB2004331	13	15	15	0	2	MANEY PUBLISHING	LEEDS	STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND	0003-4983	1364-8594		ANN TROP MED PARASIT	Ann. Trop. Med. Parasitol.	DEC	2005	99	8					781	787		10.1179/136485905X65152				7	Public, Environmental & Occupational Health; Parasitology; Tropical Medicine	Public, Environmental & Occupational Health; Parasitology; Tropical Medicine	991JF	WOS:000233808700007	16297291				2019-03-26	
J	Apers, L; Lynen, L; Worodria, W; Colebunders, R				Apers, L; Lynen, L; Worodria, W; Colebunders, R			Review editorial: Prevention of tuberculosis in resource-poor countries with increasing access to highly active antiretroviral treatment	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						tuberculosis; prevention; highly active antiretroviral treatment; human immunodeficiency virus infection; countries with limited resources	HIV-INFECTED PERSONS; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; ISONIAZID PROPHYLAXIS; CONTROLLED-TRIALS; RANDOMIZED-TRIAL; SOUTH-AFRICA; THERAPY; PYRAZINAMIDE; MORTALITY; RELAPSE	The administration of isoniazid (INH) has been proposed, evaluated and implemented to prevent tuberculosis (TB) disease among patients who are infected with the human immunodeficiency virus (HIV). This strategy has been developed in communities where TB is highly endemic and at a time when antiretroviral (ARV) treatment was not, or was rarely available. Although INH prevention programmes were somewhat pushed to the background due to the worldwide advocacy for ARV drugs, prevention of TB remains of paramount importance. The dual HIV-TB infection poses problems, not only for the individual and his/her clinician but also for the programme manager. We review various aspects of TB preventive treatment in countries with a high prevalence of HIV-TB co-infection and limited resources but with increasing access to ARV treatment.	Inst Trop Med, B-2000 Antwerp, Belgium; Makerere Univ, Infect Dis Inst, Kampala, Uganda; Univ Antwerp, B-2020 Antwerp, Belgium	Apers, L (reprint author), Inst Trop Med, Natl Str 155, B-2000 Antwerp, Belgium.	worodria@yahoo.com	Lynen, Lutgarde/A-1212-2014	Lynen, Lutgarde/0000-0001-7183-4895			ACKAH AN, 1995, LANCET, V345, P607, DOI 10.1016/S0140-6736(95)90519-7; AISU T, 1995, AIDS, V9, P267; Badri M, 2002, LANCET, V359, P2059, DOI 10.1016/S0140-6736(02)08904-3; BAILEY WC, 1983, AM REV RESPIR DIS, V127, P790; Bucher HC, 1999, AIDS, V13, P501, DOI 10.1097/00002030-199903110-00009; Casado JL, 2002, CLIN INFECT DIS, V34, P386, DOI 10.1086/324746; CHAISSON RE, 1987, AM REV RESPIR DIS, V136, P570, DOI 10.1164/ajrccm/136.3.570; Churchyard GJ, 2003, AIDS, V17, P2063, DOI 10.1097/01.aids.0000076319.42412.70; Colebunders R, 2000, INT J TUBERC LUNG D, V4, P97; COMSTOCK GW, 1979, AM REV RESPIR DIS, V119, P827; Connolly C, 1999, AIDS, V13, P1543, DOI 10.1097/00002030-199908200-00015; CORBETT EL, 2002, 14 INT AIDS C BARC S, P94; DAVIES PDO, 1998, CLIN TUBERCULOSIS, P397; Fitzgerald DW, 2001, J ACQ IMMUN DEF SYND, V28, P305; Foudraine NA, 1999, AIDS, V13, P177, DOI 10.1097/00002030-199902040-00005; Godfrey-Faussett P, 2003, TUBERCULOSIS, V83, P68, DOI 10.1016/S1472-9792(02)00083-5; Godfrey-Faussett P, 2002, B WORLD HEALTH ORGAN, V80, P939; Gordin FM, 2004, CLIN INFECT DIS, V39, P561, DOI 10.1086/422724; GUELAR A, 1993, AIDS, V7, P1345, DOI 10.1097/00002030-199310000-00007; Halsey NA, 1998, LANCET, V351, P786, DOI 10.1016/S0140-6736(97)06532-X; HOUK VN, 1968, ARCH ENVIRON HEALTH, V16, P46, DOI 10.1080/00039896.1968.10665013; Johnson JL, 2001, AIDS, V15, P2137, DOI 10.1097/00002030-200111090-00009; Kapp C, 2004, LANCET, V363, P1710, DOI 10.1016/S0140-6736(04)16296-X; Lambert ML, 2003, LANCET INFECT DIS, V3, P282, DOI 10.1016/S1473-3099(03)00607-8; LUCAS SB, 1988, BIOL MYCOBACTERIA, P107; Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2; Narita M, 1998, AM J RESP CRIT CARE, V158, P157, DOI 10.1164/ajrccm.158.1.9712001; Navas E, 2002, ARCH INTERN MED, V162, P97, DOI 10.1001/archinte.162.1.97; RODRIGUES LC, 1990, T ROY SOC TROP MED H, V84, P739, DOI 10.1016/0035-9203(90)90172-B; Saukkonen J, 2004, CLIN INFECT DIS, V39, P566, DOI 10.1086/422728; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; Sonnenberg P, 2001, LANCET, V358, P1687, DOI 10.1016/S0140-6736(01)06712-5; Wendel KA, 2001, CHEST, V120, P193, DOI 10.1378/chest.120.1.193; *WHO, 1994, TB GLOB EM LOW PRIOR; *WHO GLOB TUB PROG, 1998, WHOTB98255 UNAIDS GL; Wilkinson D, 1998, BRIT MED J, V317, P625, DOI 10.1136/bmj.317.7159.625; Woldehanna S, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000171.PUB2	37	3	3	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	DEC	2005	10	12					1209	1214		10.1111/j.1365-3156.2005.01516.x				6	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	990AH	WOS:000233715100001	16359399				2019-03-26	
J	Manzi, M; Zachariah, R; Teck, R; Buhendwa, L; Kazima, J; Bakali, E; Firmenich, P; Humblet, P				Manzi, M; Zachariah, R; Teck, R; Buhendwa, L; Kazima, J; Bakali, E; Firmenich, P; Humblet, P			High acceptability of voluntary counselling and HIV-testing but unacceptable loss to follow up in a prevention of mother-to-child HIV transmission programme in rural Malawi: scaling-up requires a different way of acting	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						scaling-up; Voluntary counselling HIV-testing; prevention of mother-to-child HIV transmission; nevirapine; Malawi	TRADITIONAL BIRTH ATTENDANTS; PERINATAL TRANSMISSION; RANDOMIZED-TRIAL; NEVIRAPINE; MORTALITY; STRATEGIES; ZIDOVUDINE; TANZANIA; KENYA	SETTING Thyolo District Hospital, rural Malawi. OBJECTIVES In a prevention of mother-to-child HIV transmission (PMTCT) programme, to determine: the acceptability of offering 'opt-out' voluntary counselling and HIV-testing (VCT); the progressive loss to follow up of HIV-positive mothers during the antenatal period, at delivery and to the 6-month postnatal visit; and the proportion of missed deliveries in the district. DESIGN Cohort study. METHODS Review of routine antenatal, VCT and PMTCT registers. RESULTS Of 3136 new antenatal mothers, 2996 [96%, 95% confidence interval (CI): 95-97] were pre-test counselled, 2965 (95%, CI: 94-96) underwent HIV-testing, all of whom were post-test counselled. Thirty-one (1%) mothers refused HIV-testing. A total of 646 (22%) individuals were HIV-positive, and were included in the PMTCT programme. Two hundred and eighty-eight (45%) mothers and 222 (34%) babies received nevirapine. The cumulative loss to follow up (n = 646) was 358 (55%, CI: 51-59) by the 36-week antenatal visit, 440 (68%, CI: 64-71) by delivery, 450 (70%, CI: 66-73) by the first postnatal visit and 524 (81%, CI: 78-84) by the 6-month postnatal visit. This left just 122 (19%, CI: 16-22) of the initial cohort still in the programme. The great majority (87%) of deliveries occurred at peripheral sites where PMTCT was not available. CONCLUSIONS In a rural district hospital setting, at least 9 out of every 10 mothers attending antenatal services accepted VCT, of whom approximately one-quarter were HIV-positive and included in the PMTCT programme. The progressive loss to follow up of more than three-quarters of this cohort by the 6-month postnatal visit demands a 'different way of acting' if PMTCT is to be scaled up in our setting.	Med Sans Frontieres, Brussels Operat Ctr, Dept Med, Operat Res HIV TB, Luxembourg 1617, Malawi; Med Sans Frontieres, Brussels Operat Ctr, Brussels, Belgium; Minist Hlth & Populat, Thyolo Dist Hlth Serv, Thyolo, Malawi	Zachariah, R (reprint author), Med Sans Frontieres, Brussels Operat Ctr, Dept Med, Operat Res HIV TB, 68 Rue Gasperich, Luxembourg 1617, Malawi.	m.manzi@belgacom.net; zachariah@internet.lu; roger.teck@msf.ch; Leopold.Buhendwa@yahoo.com; kazima@yahoo.com; peter.firmenich@luxembourg.msf.org; Pierre.humbelt@msf.be					Brahmbhatt H, 2003, AIDS, V17, P879, DOI 10.1097/01/aids.0000050828.06065.f2; Bulterys M, 2002, BRIT MED J, V324, P222, DOI 10.1136/bmj.324.7331.222; CABALLEROGORDO A, 1991, J REPROD MED, V36, P717; Coates TJ, 2000, LANCET, V356, P103; Graham SM, 2000, LANCET, V355, P369, DOI 10.1016/S0140-6736(98)11074-7; Graham SM, 2001, INT J TUBERC LUNG D, V5, P12; GREEN EC, 1988, SOC SCI MED, V27, P1125, DOI 10.1016/0277-9536(88)90341-3; Guay LA, 1999, LANCET, V354, P795, DOI 10.1016/S0140-6736(99)80008-7; ISENALUMBE A E, 1990, World Health Forum, V11, P192; *MOHP, 2000, MIN HLTH POP GUID MA; *MOHP, 2003, MIN HLTH POP NAT AID; *MOHP, 1999, MIN HLTH POP MAL NAT, V2; Newell ML, 2003, T ROY SOC TROP MED H, V97, P22, DOI 10.1016/S0035-9203(03)90009-5; Nolan ML, 2002, AIDS, V16, P1991, DOI 10.1097/00002030-200210180-00003; *NSO, 2001, POP HOUS CENS; Stringer JSA, 2004, AIDS, V18, P939, DOI 10.1097/01.aids.0000125907.75228.bc; Sweat M, 2000, LANCET, V356, P113, DOI 10.1016/S0140-6736(00)02447-8; Taha TE, 2004, JAMA-J AM MED ASSOC, V292, P202, DOI 10.1001/jama.292.2.202; Taha TE, 2003, LANCET, V362, P1171, DOI 10.1016/S0140-6736(03)14538-2; UNAIDS World Health Organization, 1997, WKLY EPIDEMIOL REC, V72, P81; Walraven G, 1999, TROP MED INT HEALTH, V4, P527, DOI 10.1046/j.1365-3156.1999.00441.x; *WHO UNAIDS, 2000, PROV WHO UNAIDS SECR; World Health Organisation, 2004, RAP HIV TESTS GUID U; World Health Organization, 2004, ANT DRUGS TREAT PREG; Zachariah R, 2004, INT J TUBERC LUNG D, V8, P1058; ZACHARIAH R, 2002, INT J TUBERC LUNG D, V7, P65	26	163	164	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	DEC	2005	10	12					1242	1250		10.1111/j.1365-3156.2005.01526.x				9	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	990AH	WOS:000233715100006	16359404	Bronze			2019-03-26	
J	Baruch, WA; Contreras, JAA; Fernandez, DHB; Carlier, Y; Coura, JR; Chuit, R; Dias, JCP; Freilij, H; Gascon, J; Prat, JG; Luquetti, A; Manzullo, EC; Cordoba, JRM; Mitelman, J; Prata, A; Rassi, A; Lopez, PAR; Estani, SS; Torres, RM; Torrico, F; Chamikian, YB; Zackiewicz, C; Karunakara, UK; Postigo, KAR; Gonzalez, ME; Vinas, PA; Castel, SM				Baruch, WA; Contreras, JAA; Fernandez, DHB; Carlier, Y; Coura, JR; Chuit, R; Dias, JCP; Freilij, H; Gascon, J; Prat, JG; Luquetti, A; Manzullo, EC; Cordoba, JRM; Mitelman, J; Prata, A; Rassi, A; Lopez, PAR; Estani, SS; Torres, RM; Torrico, F; Chamikian, YB; Zackiewicz, C; Karunakara, UK; Postigo, KAR; Gonzalez, ME; Vinas, PA; Castel, SM			OPS/MSF Regional Technical Consult on Organisation and Structure of Medical Attention for those sick and infected by Trypanosoma cruzi Chagas Disease	REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL			Portuguese	Article									Univ Chile, Santiago, Chile; Univ Republ Uruguay, Montevideo, Uruguay; Univ Libre Bruxelles, Brussels, Belgium; Inst Oswaldo Cruz, Rio De Janeiro, Brazil; Minist Salud, Cordoba, Argentina; Hosp Clin Barcelona, RiVEMTI, RICET, Barcelona, Spain; ICS, Unitat Med Trop & Salut Int Drassanes Barcelona, RiVEMTI, Barcelona, Spain; Univ Fed Goias, Goiania, Go, Brazil; Univ Fed Triangulo Mineiro, Uberaba, Brazil; Univ Fed Minas Gerais, Hosp Clin, Belo Horizonte, MG, Brazil; Inst Oswaldo Cruz, MSF Espana, Rio De Janeiro, Brazil	Baruch, WA (reprint author), Univ Chile, Santiago, Chile.						*ORG PAN SAL, 2004, OPSDPCCD30104; *ORG PAN SAL ORG M, 1998, OPSHCPHCT14099 ORG M; *WHO, 2002, WHO TECHN REP SER, V905	3	4	4	0	1	SOCIEDADE BRASILEIRA MEDICINA TROPICAL	BRASILIA	UNIV BRASILIA, NUCLEO MEDICINA TROPICAL E NUTRICAO, CAIXA POSTAL 4356, BRASILIA, DF 70919-970, BRAZIL	0037-8682			REV SOC BRAS MED TRO	Rev. Soc. Bras. Med. Trop.	NOV-DEC	2005	38	6					538	541						4	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	000KU	WOS:000234461500021		DOAJ Gold			2019-03-26	
J	Roberfroid, D; Kolsteren, P; Hoeree, T; Maire, B				Roberfroid, D; Kolsteren, P; Hoeree, T; Maire, B			Do growth monitoring and promotion programs answer the performance criteria of a screening program? A critical analysis based on a systematic review	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Review						growth chart; monitoring; screening; promotion; malnutrition; prevention	PROTEIN-ENERGY MALNUTRITION; DIRECT RECORDING SCALES; NUTRITIONAL-STATUS; MATERNAL COMPREHENSION; INTEGRATED MANAGEMENT; CHILDHOOD ILLNESS; ANTHROPOMETRIC INDICATORS; SOCIOECONOMIC VARIABLES; DEVELOPING-COUNTRIES; SUBSEQUENT RISK	OBJECTIVE Growth Monitoring and Promotion programs (GMP) have been intensively promoted to improve children's health in developing countries. It has been hoped that regularly weighing children would result in the early detection of growth falterers, and that the growth chart would serve as an educational tool to make that state apparent to both health workers and caretakers in order to trigger improved caring practices. Our objective was to review whether GMP answers the theoretical grounds of a screening and intervention program. METHOD A systematic literature review was performed. The WHO framework developed by Wilson and Jungner for planning and evaluating screening programs guided the analysis. RESULTS Sixty-nine studies were retrieved. Overall, evidence is weak on the performance of GMP as a screening program for malnutrition through early detection of growth falterers. The main results are: (1) malnutrition remains a public health problem, but its importance is context specific; (2) the value of a low weight velocity to predict malnutrition is unknown and likely to vary in different contexts; (3) the performance of GMP for improving nutrition status of children and in reducing mortality and morbidity is unknown; (4) the performance of the screening is affected by the unreliability of weight measurements; (5) the promotional and educational effectiveness of GMP is low, in particular the growth chart is poorly understood by mothers; (6) the acceptability seems low in regards of low attendance rates; (7) evidence is lacking regarding cost-effectiveness. CONCLUSIONS We conclude that there is too little scientific evidence to indiscriminately support international promotion of GMP. However GMP could constitute a valid strategy of public nutrition in specific situations. We indicate paths for further research and how prevention programs could be developed.	Inst Trop Med, Dept Publ Hlth, Nutr Unit, B-2000 Antwerp, Belgium; Inst Rech Dev, Montpellier, France	Kolsteren, P (reprint author), Inst Trop Med, Dept Publ Hlth, Nutr Unit, Natl Str 155, B-2000 Antwerp, Belgium.	droberfroid@itg.be; pkolsteren@itg.be; thoeree@itg.be; bernard.maire@mpl.ird.fr					*ACCSCN, 2000, ACC SCN, V4, P1; Achadi E., 1988, Food and Nutrition Bulletin, V10, P56; Aden A S, 1990, Paediatr Perinat Epidemiol, V4, P340, DOI 10.1111/j.1365-3016.1990.tb00656.x; ALAM N, 1989, AM J CLIN NUTR, V49, P884; ANDRIEN M, 1993, NUTR COMMUNICATION, P1; Argyle J, 2003, ANN HUM BIOL, V30, P499, DOI 10.1080/0301446032000112698; BAIRAGI R, 1993, AM J EPIDEMIOL, V138, P310, DOI 10.1093/oxfordjournals.aje.a116860; BAIRAGI R, 1985, AM J CLIN NUTR, V42, P296; BAIRAGI R, 1994, INT J EPIDEMIOL, V23, P1179, DOI 10.1093/ije/23.6.1179; Baranowski T, 2003, OBES RES, V11, p23S, DOI 10.1038/oby.2003.222; BEHAGUE D, 1993, SOC SCI MED, V37, P1565, DOI 10.1016/0277-9536(93)90191-6; Bern C, 1997, B WORLD HEALTH ORGAN, V75, P87; Black RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8; BRIEND A, 1989, BRIT MED J, V298, P1607, DOI 10.1136/bmj.298.6688.1607; BROWN R, 1993, J TROP PEDIATRICS, V39, P55, DOI 10.1093/tropej/39.1.55; Bryce J, 2004, AM J PUBLIC HEALTH, V94, P406, DOI 10.2105/AJPH.94.3.406; Cape N., 1988, Health Policy and Planning, V3, P167, DOI 10.1093/heapol/3.2.167; Carey VJ, 2004, STAT MED, V23, P509, DOI 10.1002/sim.1578; CHEN LC, 1980, AM J CLIN NUTR, V33, P1836; Chopra M, 1997, S AFR MED J, V87, P875; COETZEE DJ, 1994, S AFR MED J, V84, P413; CONNER M, 1995, PREDICTING HLTH BEHA, P1; De Onis M, 2004, J PEDIATR-US, V144, P461, DOI 10.1016/j.jpeds.2003.12.034; de Onis M, 2003, ACTA PAEDIATR, V92, P413; de Souza ACT, 1999, B WORLD HEALTH ORGAN, V77, P895; DIXON RA, 1994, J TROP PEDIATRICS, V40, P376, DOI 10.1093/tropej/40.6.376; DIXON RA, 1993, LANCET, V342, P317, DOI 10.1016/0140-6736(93)91465-X; DIXON RA, 1991, ANN TROP PAEDIATR, V11, P3, DOI 10.1080/02724936.1991.11747471; Faber M, 1998, Afr J Health Sci, V5, P72; Faber Mieke, 2003, Food and Nutrition Bulletin, V24, P350; FAGBULE D O, 1991, African Journal of Medicine and Medical Sciences, V20, P41; FAGBULE DO, 1990, E AFR MED J, V67, P69; Fawzi WW, 1997, AM J CLIN NUTR, V65, P1062; Forsyth S. J., 1984, Food and Nutrition Bulletin, V6, P22; GARENNE M, 2000, RISQUES DECES ASS DI, P1; Garner P, 2000, ARCH DIS CHILD, V82, P197, DOI 10.1136/adc.82.3.197; GEORGE SM, 1993, LANCET, V342, P348, DOI 10.1016/0140-6736(93)91479-6; GEREIN NM, 1991, SOC SCI MED, V32, P667, DOI 10.1016/0277-9536(91)90145-3; GHOSH S, 1988, Indian Journal of Pediatrics, V55, pS67, DOI 10.1007/BF02810392; GOPALAN C, 1984, J TROP PEDIATRICS, V30, P7, DOI 10.1093/tropej/30.1.7; GOPALAN C, 1988, LINEAR GROWTH RETARD, P265; GOPALAN C, 1989, NUTR FDN INDIA SPECI, V2, P1; GOPALDAS T, 1990, J TROP PEDIATRICS, V36, P322, DOI 10.1093/tropej/36.6.322; GORSTEIN J, 1994, B WORLD HEALTH ORGAN, V72, P273; GRANT JP, 1986, STATE WORLDS CHILDRE; GRANT K, 1986, J TROP PEDIATRICS, V32, P255, DOI 10.1093/tropej/32.5.255; GRIFFITHS M, 1988, Indian Journal of Pediatrics, V55, pS59, DOI 10.1007/BF02810391; Griffiths M, 1996, PROMOTING GROWTH CHI, P1; HABICHT JP, 1990, J NUTR, V120, P1519, DOI 10.1093/jn/120.suppl_11.1519; Hampshire RD, 2004, PUBLIC HEALTH NUTR, V7, P1047, DOI 10.1079/PHN2004641; HENDRATA L, 1988, INDIAN J PEDIAT S, V55, P9; Henry F., 1989, Health Policy and Planning, V4, P295, DOI 10.1093/heapol/4.4.295; HEYWOOD P, 1982, J FOOD NUTR, V39, P13; HODGES MEH, 1991, J TROP PEDIATRICS, V37, P244, DOI 10.1093/tropej/37.5.244; Hossain SMM, 2005, HEALTH POLICY PLANN, V20, P35, DOI 10.1093/heapol/czi004; HUGHSON H C, 1988, Journal of the Medical Association of Thailand, V71, P666; JELLIFFE EFP, 1987, J TROP PEDIATRICS, V33, P290, DOI 10.1093/tropej/33.6.290; Kapil U, 1996, Indian Pediatr, V33, P949; Karim Fazlul, 1994, Food and Nutrition Bulletin, V15, P192; *KAS PROJ TEAM, 1983, J TROPICAL PEDIAT, V29, P69; KATZ J, 1989, AM J EPIDEMIOL, V130, P1219, DOI 10.1093/oxfordjournals.aje.a115450; KIELMANN AA, 1978, LANCET, V1, P1247; Kolsteren P, 1997, Asia Pac J Clin Nutr, V6, P106; KUHN L, 1990, S AFR MED J, V78, P495; LAUNER LJ, 1989, SOC SCI MED, V29, P13, DOI 10.1016/0277-9536(89)90123-8; LINDSKOG U, 1988, ACTA PAEDIATR SCAND, V77, P260, DOI 10.1111/j.1651-2227.1988.tb10640.x; LOTFI M, 1988, Food and Nutrition Bulletin, V10, P3; Lovel H., 1984, Assignment Children, V65/68, P275; Maleta K, 2003, ACTA PAEDIATR, V92, P491; Mapatano MA, 1997, E AFR MED J, V74, P96; MARKS GC, 1989, AM J EPIDEMIOL, V130, P578, DOI 10.1093/oxfordjournals.aje.a115372; Martorell Reynaldo, 1994, Food and Nutrition Bulletin, V15, P185; MCAULIFFE JF, 1993, J TROP PEDIATRICS, V39, P370, DOI 10.1093/tropej/39.6.370; MEEGAN M, 1994, T ROY SOC TROP MED H, V88, P635, DOI 10.1016/0035-9203(94)90202-X; Meegan M, 1999, TROP DOCT, V29, P23, DOI 10.1177/004947559902900109; MELVILLE B, 1995, PUBLIC HEALTH, V109, P111, DOI 10.1016/S0033-3506(05)80004-6; MORLEY D, 1988, Indian Journal of Pediatrics, V55, pS38, DOI 10.1007/BF02810388; Morley D, 1994, S Afr Med J, VSuppl, P15; Morley D., 1988, SEE THEY GROW MONITO; MSEFULA D, 1993, TROP DOCT, V23, P107, DOI 10.1177/004947559302300306; MULL DS, 1991, SOC SCI MED, V32, P175, DOI 10.1016/0277-9536(91)90058-K; Muller O, 2003, TROP MED INT HEALTH, V8, P507, DOI 10.1046/j.1365-3156.2003.01043.x; Musaiger AO, 2001, TROP DOCT, V31, P161, DOI 10.1177/004947550103100316; NABARRO D, 1988, SOC SCI MED, V26, P941, DOI 10.1016/0277-9536(88)90414-5; NDAO I, 1992, EVALUATION FONCTIONN, P1; OWEN MR, 1983, W INDIAN MED J, V32, P176; Owusu W. B., 1992, Food and Nutrition Bulletin, V14, P97; PELLETIER DL, 1994, J NUTR, V124, pS2047; PELLETIER DL, 1994, J NUTR, V124, pS2082; PELLETIER DL, 1994, HEALTH POLICY PLANN, V9, P171, DOI 10.1093/heapol/9.2.171; Pelletier DL, 2003, J NUTR, V133, P107; PYLE D, 1986, WORLD ED REPORT, V25, P15; Qazi Shamim A, 2003, Indian Pediatr, V40, P1043; Rasheed P, 1996, SAUDI MED J, V17, P195; Rice AL, 2000, B WORLD HEALTH ORGAN, V78, P1207; ROHDE J E, 1988, Indian Journal of Pediatrics, V55, pS3, DOI 10.1007/BF02810383; Ross A, 2005, TROP MED INT HEALTH, V10, P404, DOI 10.1111/j.1365-3156.2005.01405.x; RUEL MT, 1992, J NUTR, V122, P1772; RUEL MT, 1990, B WORLD HEALTH ORGAN, V68, P483; RUEL MT, 1992, INT J EPIDEMIOL, V21, P59, DOI 10.1093/ije/21.1.59; *SAV CHILDR UK, 2003, THIN GROUND QUEST EV, P1; SCHROEDER DG, 1994, B WORLD HEALTH ORGAN, V72, P569; Schroeder DG, 1997, AM J CLIN NUTR, V65, P1080; Senanayake MP, 1997, ARCH DIS CHILD, V76, P359, DOI 10.1136/adc.76.4.359; Simoes EAF, 1997, B WORLD HEALTH ORGAN, V75, P43; SMEDMAN L, 1987, AM J CLIN NUTR, V46, P369; Sohal H, 1998, TROP DOCT, V28, P160, DOI 10.1177/004947559802800311; Suelan F, 1992, NCP Bull, P4; Thaver Inayat H., 1993, Southeast Asian Journal of Tropical Medicine and Public Health, V24, P23; Tomkins A., 1989, MALNUTRITION INFECT; Tonglet R, 1999, TROP MED INT HEALTH, V4, P120, DOI 10.1046/j.1365-3156.1999.00366.x; TUAN T, 2002, FOOD NUTR B, V23, P45; Valadez JJ, 1996, INT J EPIDEMIOL, V25, P381, DOI 10.1093/ije/25.2.381; VANDENBROECK J, 1993, LANCET, V341, P1491, DOI 10.1016/0140-6736(93)90632-Q; VANLERBERGHE W, 1986, B WORLD HEALTH ORGAN, V64, P703; Vasundhara M K, 1993, Indian J Matern Child Health, V4, P25; VELLA V, 1992, B WORLD HEALTH ORGAN, V70, P637; VELLA V, 1994, EUR J CLIN NUTR, V48, P189; Victora CG, 1998, J NUTR, V128, P1134; Waterlow J, 1999, LANCET, V354, P1142, DOI 10.1016/S0140-6736(99)00329-3; *WHO, 1995, 849 WHO, P1; *WHO, 1986, GUID PREV CONTR GIAR, P1; Wilson JM, 1968, PRINCIPLES PRACTICE, P1; WIT JM, 1984, TROP DOCT, V14, P34, DOI 10.1177/004947558401400118; YAMBI O, 1991, Food and Nutrition Bulletin, V13, P271; 1992, LANCET, V340, P149	126	11	11	1	8	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	NOV	2005	10	11					1121	1133		10.1111/j.1365-3156.2005.01498.x				13	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	978IW	WOS:000232867800006	16262737				2019-03-26	
J	Van den Ende, J; Mukaminega, M				Van den Ende, J; Mukaminega, M			Untitled	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Letter									CHUK, Kigali, Rwanda	Van den Ende, J (reprint author), IMTA, Antwerp, Belgium.						Dicko A, 2005, TROP MED INT HEALTH, V10, P550, DOI 10.1111/j.1365-3156.2005.01418.x; XIAOHUA Z, 2002, STAT METHODS DIAGNOS, P437; ZWEIG MH, 1993, CLIN CHEM, V39, P561	3	2	2	0	0	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	NOV	2005	10	11					1207	1207		10.1111/j.1365-3156.2005.01508.x				1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	978IW	WOS:000232867800017	16262748	Bronze			2019-03-26	
J	Leang, B; Lynen, L; Schrooten, W; Hines, J				Leang, B; Lynen, L; Schrooten, W; Hines, J			Comparison of albendazole regimen for prophylaxis of strongyloides hyperinfection in nephrotic syndrome patients on long-term steroids in Cambodia	TROPICAL DOCTOR			English	Article								Nephrotic syndrome patients on long-term steroids face the risk of having heavy uncomplicated strongyloidiasis or death from its extreme form, the strongyloides hyperinfection. The risk can be minimized if we eradicate the parasite first. We compare a once daily and twice daily albendazole regimen in preventing this potentially fatal complication in 122 patients with nephrotic syndrome.	Sihanouk Hosp Ctr Hope, Dept Med, Phnom Penh, Cambodia; Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium	Leang, B (reprint author), Sihanouk Hosp Ctr Hope, Dept Med, Phnom Penh, Cambodia.	tmed1shch@online.com.kh	Lynen, Lutgarde/A-1212-2014	Lynen, Lutgarde/0000-0001-7183-4895			deSilva N, 1997, DRUGS, V53, P769, DOI 10.2165/00003495-199753050-00004; Mahmoud AAF, 1996, CLIN INFECT DIS, V23, P949, DOI 10.1093/clinids/23.5.949; Muennig P, 1999, NEW ENGL J MED, V340, P773, DOI 10.1056/NEJM199903113401006; Schaffel R, 2000, CLIN INFECT DIS, V31, P821, DOI 10.1086/314023; Shinozaki F, 1994, Kansenshogaku Zasshi, V68, P539; Siddiqui AA, 2001, CLIN INFECT DIS, V33, P1040, DOI 10.1086/322707	6	2	2	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0049-4755	1758-1133		TROP DOCT	Trop. Dr.	OCT	2005	35	4					212	213		10.1258/004947505774938558				2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	996ZO	WOS:000234215000008	16354470				2019-03-26	
J	Mieke, P; Nisachol, O; Sudrak, L; Koen, F; David, W; Rony, Z				Mieke, P; Nisachol, O; Sudrak, L; Koen, F; David, W; Rony, Z			Offering highly active antiretroviral treatment to children in Thailand: the difficulties	TROPICAL DOCTOR			English	Letter									Med Sans Frontieres, Brussels Operat Ctr, Dept Med, Operat Res HIV TB, Brussels, Belgium; Med Sans Frontieres, Bangkok, Thailand; Camillian Social Ctr, Rayong, Thailand	Rony, Z (reprint author), Med Sans Frontieres, Brussels Operat Ctr, Dept Med, Operat Res HIV TB, Brussels, Belgium.	zachariah@internet.lu					Goode M, 2003, AIDS CARE, V15, P403, DOI 10.1080/0954012031000105450; SUSITA LC, 2003, PERCEPTIONS ILLNESS; WILSON D, 2001, DEVIMON VIRUS TALE; Zachariah R, 2001, INT J TUBERC LUNG D, V5, P843	4	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0049-4755	1758-1133		TROP DOCT	Trop. Dr.	OCT	2005	35	4					251	252		10.1258/004947505774938675				2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	996ZO	WOS:000234215000031	16354493				2019-03-26	
J	Lambert, ML; Van der Stuyft, P				Lambert, ML; Van der Stuyft, P			Editorial: Delays to tuberculosis treatment: shall we continue to blame the victim?	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Editorial Material						tuberculosis; tuberculosis control; treatment delay; health services; health education	HEALTH-SEEKING BEHAVIOR; PULMONARY TUBERCULOSIS; DIAGNOSIS		Inst Trop Med, Dept Publ Hlth, Unit Epidemiol & Dis Control, B-2000 Antwerp, Belgium	Lambert, ML (reprint author), Inst Trop Med, Dept Publ Hlth, Unit Epidemiol & Dis Control, Natl Str 155, B-2000 Antwerp, Belgium.	PVDS@itg.be					Enwuru CA, 2002, T ROY SOC TROP MED H, V96, P614, DOI 10.1016/S0035-9203(02)90328-7; Godfrey-Faussett R, 2002, INT J TUBERC LUNG D, V6, P796; Jaramillo E, 1998, TROP MED INT HEALTH, V3, P138, DOI 10.1046/j.1365-3156.1998.00202.x; Johansson E, 2000, HEALTH POLICY, V52, P33, DOI 10.1016/S0168-8510(00)00062-2; Liam CK, 1997, INT J TUBERC LUNG D, V1, P326; Liefooghe R, 1995, SOC SCI MED, V41, P1685, DOI 10.1016/0277-9536(95)00129-U; Lienhardt C, 2001, INT J TUBERC LUNG D, V5, P233; Newell J, 2002, B WORLD HEALTH ORGAN, V80, P836; Rajeswari R, 2002, INT J TUBERC LUNG D, V6, P789; Rieder HL, 1999, EPIDEMIOLOGIC BASIS, P17; Steen TW, 1998, INT J TUBERC LUNG D, V2, P627; Thomas Cassie, 2002, J Manag Med, V16, P371, DOI 10.1108/02689230210446544; *WHO, 2004, WHOHTMTB2004331; World Health Organisation, 2003, WHOCDSTB2003313	14	34	34	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2005	10	10					945	946		10.1111/j.1365-3156.2005.01485.x				2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	967OP	WOS:000232101000001	16185227				2019-03-26	
J	Van den Bossche, P; Ky-Zerbo, A; Brandt, J; Marcotty, T; Geerts, S; De Deken, R				Van den Bossche, P; Ky-Zerbo, A; Brandt, J; Marcotty, T; Geerts, S; De Deken, R			Transmissibility of Trypanosoma brucei during its development in cattle	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						trypanosomiasis; cattle; sleeping sickness; Trypanosoma brucei; reservoir; transmission	TSETSE	Recent outbreaks of Trypanosoma brucei rhodesiense sleeping sickness in Soroti District of eastern Uganda have demonstrated the important role cattle can play as reservoirs of this parasite. To clarify the epidemiological importance of the cattle reservoir, experiments were conducted to determine the ease with which T. brucei is transmitted during the course of its development in Friesian cattle. The development of T. brucei in cattle is characterized by an acute phase with high levels of parasitaemia and a decline in PCV. The acute phase is followed by a chronic phase during which the PCV remains low but stable and the parasitaemia is low. Parasites are often difficult to detect using parasitological diagnostic tools during this chronic phase. Challenge of chronically infected cattle with T. congolense results in a sudden increase in the T. brucei parasitaemia. Despite significant differences in parasitaemia, the proportion of tsetse flies that developed metacyclic infections after a first bloodmeal on the infected cattle did not differ significantly between the acute and chronic phases or the phase of mixed T. b. brucei/T. congolense infection. This suggests that, throughout the observation period, the parasitaemia was above the threshold above which infection rates of tsetse are independent of the parasitaemia. The repercussions of the research findings for the understanding of the epidemiology, spread and the control of T. b. rhodesiense sleeping sickness are discussed.	Inst Trop Med, Dept Anim Hlth, B-2000 Antwerp, Belgium	Van den Bossche, P (reprint author), Inst Trop Med, Dept Anim Hlth, Natl Str 155, B-2000 Antwerp, Belgium.	pvdbossche@itg.be; zonguy_axkz@hotmail.com; jbrandt@itg.be; tmarcotty@itg.be; sgeerts@itg.be; rdeken@itg.be		Geerts, Stanny/0000-0001-9885-8846			Doko A, 1997, VET PARASITOL, V69, P151, DOI 10.1016/S0304-4017(96)01097-7; Doko A., 1997, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V50, P23; Elsen Pierre, 1993, Journal of African Zoology, V107, P439; Fevre EM, 2001, LANCET, V358, P625, DOI 10.1016/S0140-6736(01)05778-6; GEIGY R, 1973, Acta Tropica, V30, P12; LERAY D, 1989, ANN SOC BELG MED TR, V69, P165; Lloyd LL, 1924, B ENTOMOL RES, V14, P225; MAUDLIN I, 1989, ANN TROP MED PARASIT, V83, P431, DOI 10.1080/00034983.1989.11812368; PARIS J, 1982, ACTA TROP, V39, P307; Picozzi K., 2002, African Journal of Biotechnology, V1, P39; *STAT CORP, 2000, STAT STAT SOFTW REL; Swallow BM, 2000, PAAT TECHNICAL SCI S, V2; Van den Bossche P, 2004, VET PARASITOL, V121, P79, DOI 10.1016/j.vetpar.2004.02.011; Van den Bossche P, 2004, VET PARASITOL, V119, P147, DOI 10.1016/j.vetpar.2003.11.008; Van den Bossche P, 2001, INT J PARASITOL, V31, P592, DOI 10.1016/S0020-7519(01)00146-1; van Meirvenne N., 1975, Annales Soc belge Med trop, V55, P1; VANDENABBEELE J, 2001, THESIS ANTWERP U ANT; Welburn SC, 1995, EXP PARASITOL, V81, P404, DOI 10.1006/expr.1995.1131; WELLDE BT, 1989, ANN TROP MED PARASIT, V83, P151, DOI 10.1080/00034983.1989.11812419; WILDE JKH, 1945, J COMP PATHOL THERAP, V55, P206, DOI 10.1016/S0368-1742(45)80021-8	20	26	26	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	SEP	2005	10	9					833	839		10.1111/j.1365-3156.2005.01467.x				7	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	959II	WOS:000231511000004	16135189	Bronze			2019-03-26	
J	Buscher, P; Shamamba, SKB; Ngoyi, DM; Pyana, P; Baelmans, R; Magnus, E; Overmeir, CV				Buscher, P; Shamamba, SKB; Ngoyi, DM; Pyana, P; Baelmans, R; Magnus, E; Overmeir, CV			Susceptibility of Grammomys surdaster thicket rats to Trypanosoma brucei gambiense infection	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						Trypanosoma brucei gambiense; isolation; rodent; Grammomys surdaster	HUMAN AFRICAN TRYPANOSOMIASIS; STOCKS	Human African Trypanosomiasis is caused by Trypanosoma brucei gambiense and T. b. rhodesiense. Historically, a treatment relapse rate of about 5% is observed in patients treated with melarsoprol, an arsenical derivative used for treatment of both gambiense and rhodesiense second stage sleeping sickness. More recently, relapse rates up to 30% are noted in gambiense sleeping sickness foci in Angola, Sudan and Uganda. Therefore, WHO established a Network on Treatment Failure and Drug Resistance in Sleeping Sickness. One of its objectives is to improve isolation of T. b. gambiense from relapsing cases for research on drug resistance mechanisms. Trypanosoma b. gambiense isolation techniques suffer from low success rates and long periods needed to adapt the parasite to its new host. Usually, rodents are inoculated with patient's blood or cerebrospinal fluid and sub-passaged until the strain becomes sufficiently adapted to yield high parasitaemia within few days after inoculation. Until now, the best recipient for T. b. gambiense is Mastomys natalensis, with a success rate of about 50%. In this study, Grammomys surdaster (former Thamnomys surdaster) was investigated as a potential recipient for isolation of T. b. gambiense. Comparative experimental infections of Swiss mice, Wistar rats and G. surdaster thicket rats with T. b. gambiense clearly show that this trypanosome grows faster in G. surdaster. Inoculation of the same rodent species with patient's blood and cerebrospinal fluid in Kinshasa (R.D. Congo) confirms the observation that the thicket rats are more susceptible to T. b. gambiense infection than typical laboratory rodents.	Inst Trop Med, Dept Parasitol, B-2000 Antwerp, Belgium; Inst Natl Rech Biomed, Kinshasa, Zaire; Inst Trop Med, Appl Technol & Prod Unit, B-2000 Antwerp, Belgium	Buscher, P (reprint author), Inst Trop Med, Dept Parasitol, Natl Str 155, B-2000 Antwerp, Belgium.	pbuscher@itg.be; stomy_karhem@yahoo.fr; mumbadieudonne@yahoo.fr; ppyana@yahoo.fr; rbaelmans@itg.be; emagnus@itg.be; cvoverm@itg.be	Buscher, Philippe/B-9956-2012	Buscher, Philippe/0000-0002-1926-7472			BABIKER EA, 1981, ANN SOC BELG MED TR, V61, P15; Barrett MP, 2001, LANCET, V358, P603, DOI 10.1016/S0140-6736(01)05817-2; Brun R, 2001, TROP MED INT HEALTH, V6, P906, DOI 10.1046/j.1365-3156.2001.00775.x; CHATTERJEE S, 2001, AFRICAN J MED MED SC, V30, pS25; FREZIL J-L, 1976, Cahiers O.R.S.T.O.M. (Office de la Recherche Scientifique et Technique Outre-Mer) Serie Entomologie Medicale et Parasitologie, V14, P307; HERBERT WJ, 1976, EXP PARASITOL, V40, P427, DOI 10.1016/0014-4894(76)90110-7; LANHAM SM, 1970, EXP PARASITOL, V28, P521, DOI 10.1016/0014-4894(70)90120-7; Legros D, 2002, LANCET INFECT DIS, V2, P437, DOI 10.1016/S1473-3099(02)00321-3; MEHLITZ D, 1978, TROPENMED PARASITOL, V29, P101; Radwanska M, 2002, AM J TROP MED HYG, V67, P289, DOI 10.4269/ajtmh.2002.67.289; Van Nieuwenhove S, 2000, B WORLD HEALTH ORGAN, V78, P1283; World Health Organization, 1998, WHO TECH REP SER, P1; YOELI M, 1963, SCIENCE, V142, P1585, DOI 10.1126/science.142.3599.1585; ZILLMANN U, 1984, TROPENMED PARASITOL, V35, P105	14	11	11	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	SEP	2005	10	9					850	855		10.1111/j.1365-3156.2005.01468.x				6	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	959II	WOS:000231511000006	16135191	Bronze			2019-03-26	
J	Johnson, RC; Sopoh, GE; Boko, M; Zinsou, C; Gbovi, J; Makoutode, M; Portaels, F				Johnson, RC; Sopoh, GE; Boko, M; Zinsou, C; Gbovi, J; Makoutode, M; Portaels, F			Distribution of the infection Mycobacterium ulcerans (Buruli ulser) in the villages of Lalo in Benin	TROPICAL MEDICINE & INTERNATIONAL HEALTH			French	Article						Mycobacterium ulcerans; Buruli ulcer; distribution; prevalence; Benin	SOUTHERN BENIN; DISEASE; GHANA	This study aimed to determine the distribution of Buruli ulcer (BU) in Lalo, one of the endemic districts of the Couffo department in Benin. A total of 752 BU patients were detected in this district with 160 active and 592 inactive cases. The overall prevalence of BU in this district is 86.6 per 10 000 inhabitants, varying from 0 to 249/10 000 between sub-districts. At village level the prevalence varies between 0 and 561 cases per 10 000 inhabitants. Our findings confirm the large variation of distribution of the disease at the village level in endemic area. Children under 15 years are frequently affected. We also found a significant association between age and location of Buruli lesions. Further epidemiological and environmental studies are needed to identify the reasons for the extraordinary variation in BU distribution between villages from the same sub-district, and to confirm if it is associated with temporal variations.	Inst Trop Med, B-2000 Antwerp, Belgium; Programme Natl Lutte UB, Cotonou, Benin; Univ Abomey Calavi, Inst Reg Sante Publ, Cotonou, Benin; Univ Abomey Calavi, Ecole Doctorale Pluridisciplinaire, Cotonou, Benin	Portaels, F (reprint author), Inst Trop Med, Natl Str 155, B-2000 Antwerp, Belgium.	rochjohnson@yahoo.fr; mboko47@intnet.bj; makoutod@hotmail.com; portaels@itg.be					Aguiar J, 1997, Med Trop (Mars), V57, P83; AGUIAR J, 1997, B SEANCES ACAD ROYAL, V43, P325; Amofah G, 2002, EMERG INFECT DIS, V8, P167, DOI 10.3201/eid0802.010119; Aujoulat I, 2003, TROP MED INT HEALTH, V8, P750, DOI 10.1046/j.1365-3156.2003.01089.x; Debacker M, 2004, TROP MED INT HEALTH, V9, P1297, DOI 10.1111/j.1365-3156.2004.01339.x; Debacker M, 2004, EMERG INFECT DIS, V10, P1391, DOI 10.3201/eid1008.030886; Ellen DE, 2003, TROP MED INT HEALTH, V8, P90, DOI 10.1046/j.1365-3156.2003.00976.x; Johnson R C, 2004, Med Trop (Mars), V64, P145; Johnson RC, 2005, EMERG INFECT DIS, V11, P500, DOI 10.3201/eid1103.040597; Lagarrigue V, 2000, Med Trop (Mars), V60, P262; MARSTON BJ, 1995, AM J TROP MED HYG, V52, P219, DOI 10.4269/ajtmh.1995.52.219; Muelder K, 1988, Trop Doct, V18, P53; Portaels F., 2003, Bulletin des Seances, Academie Royale des Sciences d'Outre- Mer, V49, P161; Stienstra Y, 2002, AM J TROP MED HYG, V67, P207, DOI 10.4269/ajtmh.2002.67.207; Uganda Buruli Group, 1971, T R SOC TROP MED HYG, V65, P763; World Health Organization (WHO), 2000, MAN CHILD SER INF SE, P55	16	17	17	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	SEP	2005	10	9					863	871		10.1111/j.1365-3156.2005.01465.x				9	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	959II	WOS:000231511000008	16135193	Bronze			2019-03-26	
J	Bossyns, P; Abache, R; Abdoulaye, MS; Van Lerberghe, W				Bossyns, P; Abache, R; Abdoulaye, MS; Van Lerberghe, W			Unaffordable or cost-effective? introducing an emergency referral system in rural Niger	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						referral system; emergency transport; accessibility; cost-effectiveness; communication	MATERNAL MORTALITY; CARE	OBJECTIVES An important investment was made in two health districts in Niger to organize an emergency referral system. This study estimates its impact and cost-effectiveness in relation with external determinants. METHODS After installing a solar radio network in the health centres, emergency calls and related data were monitored over 7 years and investment and recurrent costs for the system were estimated. RESULTS The number of emergency calls increased significantly in both districts. In 2003, the total yearly cost for the district amounted to US$ 14 147, the cost per useful and successful call was US$ 49 and the cost per inhabitant and per year was about US$ 0.06. CONCLUSION The impressive and immediate impact on the health system, the relatively low recurrent cost and the minimal management requirements for the health service make the investment very worthwhile. Organizing emergency evacuation systems should be a priority for any health district in the world.	Belgian Tech Cooperat Agcy, Brussels, Belgium; Minist Hlth, Niamey, Niger; Minist Sante Publ, Dist Format Ouallam, Ouallam, Niger; WHO, CH-1211 Geneva, Switzerland	Bossyns, P (reprint author), Missestr 47, B-2570 Duffel, Belgium.	paul.bossyns@pandora.be; aranaoudf@yahoo.fr; abdoulayemsani@yahoo.fr; vanlerberghew@who.int		Van Lerberghe, Wim/0000-0001-9966-6563			ABOUZAHR C, 2003, MATERNAL MORTALITY 2, P1; Banerjee A, 2001, TROP DOCT, V31, P34, DOI 10.1177/004947550103100113; BLAISE P, 1997, STUDIES HLTH SERVICE, V5, P1; BOSSYNS P, 2004, HUM RESOUR HEALTH, V2, P1, DOI DOI 10.1186/1478-4491-2-1; Casterline JB, 1997, STUD FAMILY PLANN, V28, P173, DOI 10.2307/2137886; *COORD RES SYST NA, 2002, COMB PAUVR DEF MILL, P1; COULIBALY A, 2000, ANAL SYSTEME REFEREN, P1; Creese A, 1994, COST ANAL PRIMARY HL; ESSIEN E, 1997, INT J GYNECOL OBS S2, V59, P237; Fawcus S, 1996, STUD FAMILY PLANN, V27, P319, DOI 10.2307/2138027; Kipp W, 2001, B WORLD HEALTH ORGAN, V79, P1032; Koblinsky MA, 1999, B WORLD HEALTH ORGAN, V77, P399; Krasovec K, 2004, INT J GYNECOL OBSTET, V85, pS14, DOI 10.1016/ijgo.2004.02.007; LeBacq F, 1997, INT J EPIDEMIOL, V26, P357, DOI 10.1093/ije/26.2.357; Maine D, 1996, STUD FAMILY PLANN, V27, P179, DOI 10.2307/2137952; Ministerio da Saude, 2001, BUDG POL STAT 2002, V2, P1; Nkyekyer K, 2000, TROP MED INT HEALTH, V5, P811, DOI 10.1046/j.1365-3156.2000.00640.x; Nordberg E, 1996, TROP MED INT HEALTH, V1, P107, DOI 10.1046/j.1365-3156.1996.d01-2.x; SAMAI O, 1997, INT J GYNECOL OBS S2, V59, P157; Shehu D., 1997, INT J GYNECOL OBS S2, V59, P173; SHEPARD SD, 2000, ANAL HOSP COSTS MANU; THADDEUS S, 1994, SOC SCI MED, V38, P1091, DOI 10.1016/0277-9536(94)90226-7; Urassa E, 1997, HEALTH POLICY PLANN, V12, P50, DOI 10.1093/heapol/12.1.50; VANBALEN H, 1997, B SEANCES ACAD ROYAL, V43, P153; *WHO, 1992, TECHN REP SER WHO, V819; Who, 2005, WHO TECH REP SER, P1, DOI 10.1016/0004-6981(88)90109-6; *WHO EXP COMM, 1987, HOSP HLTH ALL, P1; WILSON JB, 1997, INT J GYNECOL OBSTET, V59, P165	28	13	13	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	SEP	2005	10	9					879	887		10.1111/j.1365-3156.2005.01459.x				9	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	959II	WOS:000231511000010	16135195	Bronze			2019-03-26	
J	Yardley, V; Croft, SL; De Doncker, S; Dujardin, JC; Koirala, S; Rijal, S; Miranda, C; Llanos-Cuentas, A; Chappuis, F				Yardley, V; Croft, SL; De Doncker, S; Dujardin, JC; Koirala, S; Rijal, S; Miranda, C; Llanos-Cuentas, A; Chappuis, F			The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							HEXADECYLPHOSPHOCHOLINE MILTEFOSINE; DONOVANI PROMASTIGOTES; RESISTANT; PARASITE; TROPICA; GENES	Clinical isolates of Leishmania, from visceral leishmaniasis (VL) cases in Nepal and from cutaneous leishmaniasis (CL) cases in Peru, were cultured using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) to type species and strain. Promastigotes from 38 isolates, within eight passages from isolation, were used to infect mouse peritoneal macrophage cultures in vitro, and the amastigote sensitivity to miltefosine was determined. The concentration required to kill 50% of intracellular amastigotes from Nepalese VL isolates, all typed as Leishmania (L.) donovani (N = 24) from both Sb-v responders and nonresponders, ranged from 8.7 to 0.04 mu g/mL. In contrast, the concentration required to kill 50% intracellular amastigotes from isolates from Peru, typed as L.(V.) braziliensis (N = 8), was > 30 to 8.4 mu g/mL, L. (V.) guyanensis (N = 2) > 30 to 1.9 mu g/mL, L. (L.) mexicana (N = 1) > 30 mu g/mL, and L. (V.) lainsoni (N = 4) was 3.4 to 1.9 mu g/mL. This demonstrates a notable difference in the intrinsic sensitivity of Leishmania species to miltefosine in vitro. If this model can be correlated to therapeutic outcome, it may have implications for the interpretation of clinical trials.	LSHTM, ITD, Dept Infect & Trop Dis, London WC1E 7HT, England; Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium; BP Koirala Inst Hlth Sci, Dharan, Nepal; Inst Trop Alexander von Humbold, Lima, Peru; Hop Univ Geneve, Geneva, Switzerland	Yardley, V (reprint author), LSHTM, ITD, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.	Vanessa.Yardley@lshtm.ac.uk; scroft@dndi.org; SDoncker@proto.itg.be; jcdujard@itg.be; siddharthakoirala2001@yahoo.com; sumanrijal2@yahoo.com; cesar.miranda@mail.mcgill.ca; allanos@upch.edu.pe; francois.chappuis@hcuge.ch					Aubouy A, 2003, ANTIMICROB AGENTS CH, V47, P231, DOI 10.1128/AAC.47.1.231-237.2003; BURROUGHS P, 2004, AETERNA ITS SUBSIDIA; CODERRE JA, 1983, P NATL ACAD SCI-BIOL, V80, P2132, DOI 10.1073/pnas.80.8.2132; Croft Simon L, 2002, Trans R Soc Trop Med Hyg, V96 Suppl 1, pS127, DOI 10.1016/S0035-9203(02)90063-5; Croft SL, 2003, TRENDS PARASITOL, V19, P502, DOI 10.1016/j.pt.2003.09.008; Croft SL, 2003, MOL BIOCHEM PARASIT, V126, P165, DOI 10.1016/S0166-6851(02)00283-9; Dey T, 2002, J EUKARYOT MICROBIOL, V49, P270, DOI 10.1111/j.1550-7408.2002.tb00369.x; Escobar P, 2002, ACTA TROP, V81, P151, DOI 10.1016/S0001-706X(01)00197-8; EVANS SF, 1993, BONE MINER, V21, P29, DOI 10.1016/S0169-6009(08)80118-3; GARCIA AL, 2005, INFECT GENETICS EVOL, V8, P109; Garcia L, 2004, J CLIN MICROBIOL, V42, P2294, DOI 10.1128/JCM.42.5.2294-2297.2004; Perez-Victoria JM, 2001, ANTIMICROB AGENTS CH, V45, P2468, DOI 10.1128/AAC.45.9.2468-2474.2001; Seifert K, 2003, INT J ANTIMICROB AG, V22, P380, DOI 10.1016/S0924-8579(03)00125-0; Soto J, 2004, CLIN INFECT DIS, V38, P1266, DOI 10.1086/383321; SOTO J, 2001, CLIN INFECT DIS, V33, P57; Sundar S, 2002, NEW ENGL J MED, V347, P1739, DOI 10.1056/NEJMoa021556; Tintaya KWQ, 2004, J INFECT DIS, V189, P1035, DOI 10.1086/382049; Victoir K, 2003, T ROY SOC TROP MED H, V97, P80, DOI 10.1016/S0035-9203(03)90031-9	18	80	81	0	1	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637	1476-1645		AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	AUG	2005	73	2					272	275		10.4269/ajtmh.2005.73.272				4	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	956BA	WOS:000231272700010	16103588	Green Published			2019-03-26	
J	Walsh, DS; Meyers, WM; Portaels, F; Lane, JE; Mongkolsirichaikul, D; Hussem, K; Gosi, P; Myint, KSA				Walsh, DS; Meyers, WM; Portaels, F; Lane, JE; Mongkolsirichaikul, D; Hussem, K; Gosi, P; Myint, KSA			High rates of apoptosis in human Mycobacterium ulcerans culture-positive Buruli ulcer skin lesions	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							LEPROSY LESIONS; CELL-DEATH; INCREASED EXPRESSION; IMMUNE EVASION; FAS LIGAND; TOXIN; INFECTION; IDENTIFICATION; TUBERCULOSIS; MYCOLACTONE	Buruli ulcer, a disease caused by Mycobacterium ulcerans, causes ulcerative skin disease likely generated by a toxin that mediates apoptosis. We analyzed paraffin-embedded sections of surgically excised Buruli ulcer lesions (two ulcers and one edematous plaque) and adjacent non-lesional skin samples (n = 9) for apoptosis by an indirect immunofluorescent terminal deoxynucleotide transferase-mediated dUTP-digoxigenin nick end labeling (TUNEL) assay. All samples were stained for acid-fast bacilli (AFB) and cultured for mycobacteria, and most were analyzed with an M. ulcerans-specific diagnostic polymerase chain reaction (PCR). TUNEL (+) bodies were numerous in both ulcers and the plaque, and sparse or absent in adjacent non-lesional skin. The AFB tissue stains and cultures for M. ulcerans were positive only in the three lesions. The result of the PCR for M. ulcerans was positive in all three lesions and in four of six non-lesional tissue samples; three contained sparse TUNEL (+) bodies. An abundance of TUNEL (+) bodies in the three AFB stain (+), culture (+), and PCR (+) Buruli ulcer lesional samples, but not in nearby AFB stain (-), culture (-), and PCR (+) non-lesional skin samples, strengthen the evidence that apoptosis is an important tissue destruction mechanism in human lesions closely associated with viable M. ulcerans.	Eisenhower Army Med Ctr, Dermatol Serv, Ft Gordon, GA 30905 USA; Armed Forces Inst Pathol, Dept Microbiol, Washington, DC 20306 USA; Inst Trop Med, Mycobacteriol Unit, B-2000 Antwerp, Belgium; Med Coll Georgia, Dept Med, Dermatol Sect, Augusta, GA 30912 USA; Armed Forces Res Inst Med Sci, USA Med Component, Dept Immunol & Med, Bangkok 10400, Thailand; Armed Forces Res Inst Med Sci, Dept Virol, Bangkok 10400, Thailand	Walsh, DS (reprint author), Eisenhower Army Med Ctr, Dermatol Serv, Ft Gordon, GA 30905 USA.	douglas.walsh@se.amedd.army.mil; wmekmeyers@erols.com; portaels@itg.be; joshua.lane@lycos.com; GosiP@afrims.org; MyintK@afrims.org					Abalos F M, 2000, Ann Diagn Pathol, V4, P386, DOI 10.1053/adpa.2000.19372; Chemlal K, 2001, AM J TROP MED HYG, V64, P270, DOI 10.4269/ajtmh.2001.64.270; CREE IA, 1986, INT J LEPROSY, V54, P607; CREE IA, 1987, J CLIN PATHOL, V40, P1314, DOI 10.1136/jcp.40.11.1314; Dobos KM, 2001, INFECT IMMUN, V69, P7182, DOI 10.1128/IAI.69.11.7182-7186.2001; Dockrell DH, 2001, J INFECTION, V42, P227, DOI 10.1053/jinf.2001.0836; Fratazzi C, 1999, J LEUKOCYTE BIOL, V66, P763; Fujita J, 2002, MICROBIOL IMMUNOL, V46, P67, DOI 10.1111/j.1348-0421.2002.tb02660.x; George KM, 1998, INFECT IMMUN, V66, P587; George KM, 1999, SCIENCE, V283, P854, DOI 10.1126/science.283.5403.854; George KM, 2000, INFECT IMMUN, V68, P877, DOI 10.1128/IAI.68.2.877-883.2000; Guarner J, 2003, EMERG INFECT DIS, V9, P651; Hande S, 1998, IMMUNITY, V8, P189, DOI 10.1016/S1074-7613(00)80471-9; HAYMAN J, 1985, Australasian Journal of Dermatology, V26, P67, DOI 10.1111/j.1440-0960.1985.tb01819.x; Hetts SW, 1998, JAMA-J AM MED ASSOC, V279, P300, DOI 10.1001/jama.279.4.300; HOCKMEYER WT, 1978, INFECT IMMUN, V21, P124; KRIEG RE, 1974, ARCH DERMATOL, V110, P783, DOI 10.1001/archderm.110.5.783; MEYERS WM, 1974, AM J TROP MED HYG, V23, P919, DOI 10.4269/ajtmh.1974.23.919; Motoyama S, 1998, GASTROENTEROLOGY, V114, P153, DOI 10.1016/S0016-5085(98)70643-2; Mustafa T, 1999, INFLAMMATION, V23, P507; Mustafa T, 2001, SCAND J IMMUNOL, V54, P630, DOI 10.1046/j.1365-3083.2001.01020.x; Pahlevan AA, 1999, J IMMUNOL, V163, P3928; PIMSLER M, 1988, J INFECT DIS, V157, P577, DOI 10.1093/infdis/157.3.577; Portaels F, 1997, J CLIN MICROBIOL, V35, P1097; READ JK, 1974, INFECT IMMUN, V9, P1114; Stinear T, 1999, J CLIN MICROBIOL, V37, P1018; van der Werf TS, 1999, LANCET, V354, P1013, DOI 10.1016/S0140-6736(99)01156-3; van der Werf TS, 2003, LANCET, V362, P1062, DOI 10.1016/S0140-6736(03)14417-0; Villahermosa LG, 1997, CLIN EXP DERMATOL, V22, P134, DOI 10.1111/j.1365-2230.1997.tb01041.x; Walsh DS, 2004, FEMS IMMUNOL MED MIC, V41, P265, DOI 10.1016/j.femsim.2004.04.002; *WHO, 2001, BUR ULC DIAGN MYC UL	31	22	22	0	0	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637	1476-1645		AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	AUG	2005	73	2					410	415		10.4269/ajtmh.2005.73.410				6	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	956BA	WOS:000231272700035	16103613				2019-03-26	
J	Sacy, RG; Haddad, M; Baasiri, G; Khoriati, A; Gerbaka, BJ; Abu-Elyazeed, R				Sacy, RG; Haddad, M; Baasiri, G; Khoriati, A; Gerbaka, BJ; Abu-Elyazeed, R			Hepatitis A in Lebanon: A changing epidemiological pattern	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							PROGRAM; VACCINE; CHILDREN; HAV	In this multicenter study in Lebanon, hepatitis A virus (HAV) seroprevalence rates were surveyed by age, gender, and socioeconomic factors. Blood samples collected from 606 subjects aged 1 to 30 years were analyzed for anti-HAV IgG. Age was the most important factor influencing HAV seroprevalence. HAV seroprevalence rates in the current study were about 78% in the >= 21 years age group, 28% in the 6-10 years age group, and 11% in the 1-5 years age group as compared with 97.7% in adults, 85% in children aged 6-12 years, and 40% in children aged 1 to 5 years in previous studies, demonstrating a shift in HAV seroprevalence from the younger to the higher age groups. In light of the severity of the disease in adults and availability of safe and effective vaccines against HAV infection, introduction of HAV vaccination into the national immunization schedule of Lebanon should be considered.	GlaxoSmithKline Biol, Rixensart, Belgium; St George Hosp, Beirut, Lebanon; France Hosp, Hotel Dieu, Beirut, Lebanon; Hammoud Hosp, Saida, Lebanon; Nini Hosp, Tripoli, Lebanon	Abu-Elyazeed, R (reprint author), GlaxoSmithKline Biol, 150 Beach Rd,22-00 Gateway W, Singapore 189720, Singapore.	rsacy@lb.refer.org; germanos@inco.com.lb; khorina@dm.net.lb; pedhdf@usj.edu.lb; remon.abu-elyazeed@gsk.com					ANDRE F, 2000, EXPERT REV VACCINES, V1, P9; ANDRE FE, 1992, VACCINE S1, V10, P160; [Anonymous], 2000, Wkly Epidemiol Rec, V75, P38; Battegay M, 1995, PRINCIPLES PRACTICE, P1636; Demicheli V, 2003, VACCINE, V21, P2250, DOI 10.1016/S0264-410X(03)00136-1; Dominguez A, 2003, VACCINE, V21, P698, DOI 10.1016/S0264-410X(02)00583-2; FISHMAN RH, 1998, LANCET, V352, P88846; GAY NJ, 1994, EPIDEMIOL INFECT, V113, P113, DOI 10.1017/S0950268800051529; GERMINARIO C, 2000, VACCINE, V18, P83; Ginsberg GM, 2001, J HEPATOL, V34, P92, DOI 10.1016/S0168-8278(00)00007-6; Green MS, 2001, ISRAEL MED ASSOC J, V3, P347; GUST ID, 1992, VACCINE S1, V10, P56; HADLER SC, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P14; HALLIDAY ML, 1991, J INFECT DIS, V164, P852, DOI 10.1093/infdis/164.5.852; INNIS BL, 1994, JAMA-J AM MED ASSOC, V271, P1328, DOI 10.1001/jama.271.17.1328; Kalaajieh W, 2000, MED MALADIES INFECT, V30, P757, DOI 10.1016/S0399-077X(01)80031-7; KANE M, 1995, B WORLD HEALTH ORGAN, V73, P15; McMahon BJ, 1996, ARCH PEDIAT ADOL MED, V150, P733, DOI 10.1001/archpedi.1996.02170320079014; Poovorawan Y, 2000, ASIAN PAC J ALLERGY, V18, P249; SALLERAS L, 2000, VACCINE S, V18, P80; SHAMMAA MH, 1982, INT J EPIDEMIOL, V11, P406, DOI 10.1093/ije/11.4.406; Tanaka J, 2000, VACCINE, V18, P57; TUFENKEJI H, 2000, VACCINE S1, V18, P65; WERZBERGER A, 1992, NEW ENGL J MED, V327, P453, DOI 10.1056/NEJM199208133270702	24	26	29	0	2	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637	1476-1645		AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	AUG	2005	73	2					453	456		10.4269/ajtmh.2005.73.453				4	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	956BA	WOS:000231272700043	16103621				2019-03-26	
J	Carrin, G; Waelkens, MP; Criel, B				Carrin, G; Waelkens, MP; Criel, B			Community-based health insurance in developing countries: a study of its contribution to the performance of health financing systems	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						performance of financing health systems; health financing; community health insurance; developing countries	HOSPITAL-CARE; SCHEMES; ORGANIZATION; SERVICES; AFRICA; ZAIRE	We studied the potential of community-based health insurance (CHI) to contribute to the performance of health financing systems. The international empirical evidence is analysed on the basis of the three health financing subfunctions as outlined in the World Health Report 2000: revenue collection, pooling of resources and purchasing of services. The evidence indicates that achievements of CHI in each of these subfunctions so far have been modest, although many CHI schemes still are relatively young and would need more time to develop. We present an overview of the main factors influencing the performance of CHI on these financing subfunctions and discuss a set of proposals to increase CHI performance. The proposals pertain to the demand for and the supply of health care in the community; to the technical, managerial and institutional set-up of CHI; and to the rational use of subsidies.	Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium; WHO, Dept Hlth Financing Expenditure & Resource Alloca, CH-1211 Geneva, Switzerland	Criel, B (reprint author), Inst Trop Med, Dept Publ Hlth, 155 Natl Str, B-2000 Antwerp, Belgium.	carring@who.int; mpwaelkens@itg.be; bcriel@itg.be					Atim C, 1999, SOC SCI MED, V48, P881, DOI 10.1016/S0277-9536(98)00390-6; Atim C., 1998, 18 ABT ASS; Baeza C, 2002, EXTENDING SOCIAL PRO; Bennett S, 2004, HEALTH POLICY PLANN, V19, P147, DOI 10.1093/heapol/czh018; Bennett S, 1998, WHOARACC981; BOSE A, 1983, STUDIES SOCIAL DYNAM; Carrin G, 1999, SOC SCI MED, V48, P961, DOI 10.1016/S0277-9536(98)00396-7; CARRIN G, 2003, 1 WHO DEP HLTH FER; Carrin G, 2001, BUILDING SOCIAL SECU, P125; Criel B, 1997, TROP MED INT HEALTH, V2, P654, DOI 10.1046/j.1365-3156.1997.d01-349.x; Criel B, 2003, SOC SCI MED, V57, P1205, DOI 10.1016/S0277-9536(02)00495-1; Criel B, 1999, TROP MED INT HEALTH, V4, P155, DOI 10.1046/j.1365-3156.1999.43385.x; CRIEL B, 1998, STUDIES HLTH SERVICE, V10; CUTLER DM, 1910, HDB HLTH EC A, V1, DOI ARTN 11; Davies P, 2001, B WORLD HEALTH ORGAN, V79, P587; Desmet M, 1999, SOC SCI MED, V48, P925, DOI 10.1016/S0277-9536(98)00393-1; DEWEERDT J, 2002, THESIS KATHOLIEKE U; Dror D., 1999, MICROINSURANCE EXTEN; Dror DM, 2001, B WORLD HEALTH ORGAN, V79, P672; Ekman B, 2004, HEALTH POLICY PLANN, V19, P249, DOI 10.1093/heapol/czh031; HARDING R, 1996, UNPUB LATITPUR MED I; ILO, 2001, SOC SEC NEW CONS; Jakab M, 2001, SOCIAL INCLUSION FIN; Jutting JP, 2001, IMPACT HLTH INSURANC; Kawabata K, 2002, B WORLD HEALTH ORGAN, V80, P612; KRAUSE P, 2000, 24E GTZ DTSCH GES TE; LAUTIER B, 2003, INT S SOL SOC PROT D; LICHTENBERGER J, 2003, INT S SOL SOC PROT D; McCord M, 2003, REDUCING VULNERABILI; MCPAKE B, 1993, SOC SCI MED, V36, P1397, DOI 10.1016/0277-9536(93)90382-E; MEESSEN B, 2002, INT SOCIAL SECURITY, V55, P71; MILLS A, 1998, ACHIEVING UNIVERSAL, P283; MOENS F, 1990, SOC SCI MED, V30, P1319, DOI 10.1016/0277-9536(90)90312-G; MUSAU S, 1999, 34 ABT ASS PARTN HLT; OUATTARA O, 2002, FOR 2002 CONC DAK 16; Palmer N, 2004, LANCET, V364, P1365, DOI 10.1016/S0140-6736(04)17195-X; PERROT J, 2000, APPL CONTRACTUAL APP; PERROT J, 2002, ANAL ALLOCATION FINA; PRITI D, 1990, HLTH FIN VOL SECT RE, P8; Ranson MK, 2002, B WORLD HEALTH ORGAN, V80, P613; Ray D., 1998, DEV EC; Ron A, 1999, SOC SCI MED, V48, P939, DOI 10.1016/S0277-9536(98)00394-3; Schneider P, 2001, IMPACT PREPAYMENT PI; SCHNEIDER P, 2001, 66 ABT ASS PARTN HLT; SCHNEIDER P, 2000, 45 ABT ASS PARTN HLT; Schneider P, 2001, PAYING HIV AIDS SERV; Soeters R, 2003, HEALTH POLICY PLANN, V18, P74, DOI 10.1093/heapol/18.1.74; STEINWACHS L, 2002, 7 ILO SOC SEC POL DE; Van Ginneken W., 1999, SOCIAL SECURITY EXCL; VANDENHEEVER A, 1997, PRIVATE HLTH PROVIDE, P158; VANGINNEKEN W, 1999, INT SOCIAL SECURITY, V52, P49, DOI DOI 10.1111/1468-246X.00033; WALEKENS MP, 2004, MUTUELLES SANTE AFRI; WALFORD V, 2000, UGANDA COMMUNITY HLT; WHO, 2000, HLTH SYST IMPR PERF; World Bank, 2003, WORLD DEV REP 2004 M; ZETT J, 2001, ACTUALISATION INVENT	56	112	113	0	21	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	AUG	2005	10	8					799	811		10.1111/j.1365-3156.2005.01455.x				13	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	948PF	WOS:000230727500012	16045467				2019-03-26	
J	Tinto, H; Sanou, B; Dujardin, JC; Ouedragogo, JB; Van Overmeir, C; Erhart, A; Van Marck, E; Guiguemde, TR; D'Alessandro, U				Tinto, H; Sanou, B; Dujardin, JC; Ouedragogo, JB; Van Overmeir, C; Erhart, A; Van Marck, E; Guiguemde, TR; D'Alessandro, U			Short report: Usefulness of the Plasmodium falciparum chloroquine resistance transporter T76 genotype failure index for the estimation of in vivo chloroquine resistance in Burkina Faso	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							MALARIA TRANSMISSION; MOLECULAR MARKERS; BOBO-DIOULASSO; PFCRT; VITRO; PYRIMETHAMINE; POLYMORPHISMS; SURVEILLANCE; SENSITIVITY; MUTATIONS	The prevalence of chloroquine (CQ) treatment failure and the genotype failure index was determined in four sentinel sites in Burkina Faso. In three sites, the genotype failure index varied between 1.7 and 3, a result confirming the relationship between the Plasmodium falciparum CQ resistance transporter (Pfcrt) T76 mutation and CQ resistance. In the remaining site, the genotype failure index was unusually low, 1.1, which was significantly different than that in the other sites (P < 0.00001). These findings are discussed. Often but not always, the prevalence of CQ resistance can be correctly estimated by the Pfcrt T76 genotype failure index.	Inst Trop Med, B-2000 Antwerp, Belgium; Inst Rech Sci Sante, Ctr Muraz, Bobo Dioulasso, Burkina Faso; Univ Antwerp, Fac Med, B-2610 Antwerp, Belgium	D'Alessandro, U (reprint author), Inst Trop Med, Natl Str 155, B-2000 Antwerp, Belgium.	Ei-ic.Van.Marck@uza.be; udalessandro@itg.be	D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009; Tinto, Halidou/0000-0002-0472-3586			Abdel-Muhsin AMA, 2004, J INFECT DIS, V189, P1239, DOI 10.1086/382509; Abdoulaye D, 2003, J MED ENTOMOL, V40, P195, DOI 10.1603/0022-2585-40.2.195; Babiker HA, 2001, J INFECT DIS, V183, P1535, DOI 10.1086/320195; Basco LK, 2001, J INFECT DIS, V183, P1828, DOI 10.1086/320726; Chen N, 2001, J INFECT DIS, V183, P1543, DOI 10.1086/320206; Djimde A, 2001, NEW ENGL J MED, V344, P257, DOI 10.1056/NEJM200101253440403; Djimde A, 2001, LANCET, V358, P890, DOI 10.1016/S0140-6736(01)06040-8; Jelinek T, 2002, AM J TROP MED HYG, V67, P449, DOI 10.4269/ajtmh.2002.67.449; MBOUP S, 2002, AM J TROP MED HYG, V66, P474; Ouedraogo JB, 1998, TROP MED INT HEALTH, V3, P381; Pillai DR, 2001, J INFECT DIS, V183, P789, DOI 10.1086/318836; PLOWE CV, 1995, AM J TROP MED HYG, V52, P565, DOI 10.4269/ajtmh.1995.52.565; Rason MA, 2002, PARASITE, V9, P247, DOI 10.1051/parasite/2002093247; Talisuna AO, 2002, T ROY SOC TROP MED H, V96, P310, DOI 10.1016/S0035-9203(02)90108-2; Tinto H, 2002, TROP MED INT HEALTH, V7, P925, DOI 10.1046/j.1365-3156.2002.00952.x; Tinto H, 2003, INFECT GENET EVOL, V3, P287, DOI 10.1016/j.meegid.2003.08.002; *WHO, 2002, MON ANT RES GEN WHO	17	14	15	0	0	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637	1476-1645		AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	JUL	2005	73	1					171	173		10.4269/ajtmh.2005.73.171				3	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	944TH	WOS:000230451900032	16014853				2019-03-26	
J	Nyachieo, A; Van Overmeir, C; Laurent, T; Dujardin, JC; D Alessandro, U				Nyachieo, A; Van Overmeir, C; Laurent, T; Dujardin, JC; D Alessandro, U			Plasmodium falciparum genotyping by microsatellites as a method to distinguish between recrudescent and new infections	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							NATURAL-SELECTION; MALARIA; REINFECTION; EFFICACY; REPEATS; MARKERS; PCR	In vivo tests for susceptibility to antimalarial drugs require molecular methods to distinguish recrudescence from new infection. The most commonly used DNA markers (merozoite surface proteins [MSPs]) are under immune selective pressure, which might lead to misclassification. We evaluated immunologically neutral microsatellite markers in blood samples collected during a drug efficacy trial in Rwanda. Fifty percent of the infections classified as recrudescent by MSP were classified as new by microsatellite markers. Reciprocally, 23.3% of infections classified as recrudescent by microsatellite markers were identified as new by MSP. In drug efficacy studies, microsatellite markers should complement MSP genotyping to distinguish a recrudescence from a new infection.	Inst Trop Med Prince Leopold, Dept Parasitol, B-2000 Antwerp, Belgium	D Alessandro, U (reprint author), Inst Trop Med Prince Leopold, Dept Parasitol, Natl Str 155, B-2000 Antwerp, Belgium.	udalessandro@itg.be	D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009			Anderson TJC, 2000, MOL ECOL, V9, P1599, DOI 10.1046/j.1365-294x.2000.01057.x; Anderson TJC, 1999, PARASITOLOGY, V119, P113, DOI 10.1017/S0031182099004552; Cattamanchi A, 2003, AM J TROP MED HYG, V68, P133, DOI 10.4269/ajtmh.2003.68.133; Escalante AA, 1998, GENETICS, V149, P189; HUGHES MK, 1995, MOL BIOCHEM PARASIT, V71, P99, DOI 10.1016/0166-6851(95)00037-2; Joshi Hema, 2003, Journal of Vector Borne Diseases, V40, P78; Nair S, 2003, MOL BIOL EVOL, V20, P1526, DOI 10.1093/molbev/msg162; Rich SM, 2000, P NATL ACAD SCI USA, V97, P6994, DOI 10.1073/pnas.97.13.6994; Rwagacondo CE, 2004, TROP MED INT HEALTH, V9, P1091, DOI 10.1111/j.1365-3156.2004.01316.x; Snounou G, 1998, PARASITOL TODAY, V14, P462, DOI 10.1016/S0169-4758(98)01340-4; Su XZ, 1996, GENOMICS, V33, P430, DOI 10.1006/geno.1996.0218; WEBER JL, 1993, HUM MOL GENET, V2, P1123, DOI 10.1093/hmg/2.8.1123; *WHO, 2003, WHOHTMRBM200350; WOODEN J, 1993, PARASITOL TODAY, V9, P303, DOI 10.1016/0169-4758(93)90131-X; Wootton JC, 2002, NATURE, V418, P320, DOI 10.1038/nature00813	15	15	15	0	1	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637	1476-1645		AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	JUL	2005	73	1					210	213		10.4269/ajtmh.2005.73.210				4	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	944TH	WOS:000230451900040	16014861				2019-03-26	
J	Guthmann, JP; Ampuero, J; Fortes, F; van Overmeir, C; Gaboulaud, V; Tobback, S; Dunand, J; Saraiva, N; Gillet, P; Franco, J; Denoncin, A; van Herp, M; Balkan, S; Dujardin, JC; D'Alessandro, U; Legros, D				Guthmann, JP; Ampuero, J; Fortes, F; van Overmeir, C; Gaboulaud, V; Tobback, S; Dunand, J; Saraiva, N; Gillet, P; Franco, J; Denoncin, A; van Herp, M; Balkan, S; Dujardin, JC; D'Alessandro, U; Legros, D			Antimalarial efficacy of chloroquine, amodiaquine, sulfadoxine-pyrimethamine, and the combinations of amodiaquine plus artesunate and sulfadoxine-pyrimethamine plus artesunate in Huambo and Bie provinces, central Angola	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						Plasmodium falciparum; chloroquine; amodiaquine; sulfadoxine-pyrimethamine; artemisinin-based combinations; Angola	PLASMODIUM-FALCIPARUM MALARIA; RESISTANT MALARIA; DRUG EFFICACY; TRIAL	We studied three antimalarial treatments in Caala and Kuito, Angola, in 2002 and 2003. We tested chloroquine (CQ), amodiaquine (AQ) and sulfadoxine-pyrimethamine (SP) in Caala, and AQ, SP and the combinations AQ + artesunate (AQ + AS) and SP + artesunate (SP + AS) in Kuito. A total of 619 children (240 in Caala, 379 in Kuito) with uncomplicated Plasmodium falciparum malaria were followed-up for 28 days, with PCR genotyping to distinguish recrudescence from reinfection. PCR-corrected failure proportions at day 28 were very high in the CQ group (83.5%, 95% CI 74.1-90.5), high in the SP groups (Caala: 25.3%, 95% CI 16.7-35.8; Kuito: 38.8%, 95% CI 28.4-50.0), around 20% in the AQ groups (Caala: 17.3%, 95% CI 10.0-27.2; Kuito: 21.6%, 95% CI 14.3-30.6) and very low in the artemisinin-based combination groups (1.2%, 95% CI 0.0-6.4 for each combination AQ +AS and SP +AS), These results show that CQ and SP are no longer efficacious in Caala and Kuito and that the moderate efficacy of AQ is likely to be compromised in the short term if used as monotherapy. We recommend the use of AQ with AS, though this combination might not have a tong useful therapeutic life because of AQ resistance. (c) 2005 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.	Epictr, F-75011 Paris, France; Med Sans Frontieres, F-75011 Paris, France; Med Sans Frontieres, B-1090 Brussels, Belgium; Ministerio Saude, Programa Nacl Controlo Malaria, Luanda, Angola; Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium; Hop Ambroise Pare, Serv Parasitol, Boulogne, France	Guthmann, JP (reprint author), Epictr, 8 Rue St Sabin,42 Bis,Blvd Richard Lenoir, F-75011 Paris, France.	jguthmann@epicentre.msf.org	D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009			Bloland PB, 2000, B WORLD HEALTH ORGAN, V78, P1378; BLOLAND PB, 2001, WHOCDSCDRDRS20014; BRABIN B, 2001, J NUTR, V31, pS636; Checchi F, 2004, TROP MED INT HEALTH, V9, P445, DOI 10.1111/j.1365-3156.2004.01217.x; D'Alessandro U, 2001, TROP MED INT HEALTH, V6, P845, DOI 10.1046/j.1365-3156.2001.00819.x; Dorsey G, 2002, LANCET, V360, P2031, DOI 10.1016/S0140-6736(02)12021-6; Irion A, 1998, TROP MED INT HEALTH, V3, P490, DOI 10.1046/j.1365-3156.1998.00253.x; KYRONSEPPA H, 1984, LANCET, V1, P1244; LAUREILLARD D, 1996, ETUDE RESISTANCE PLA; LINDBERG J, 1985, LANCET, V1, P765; Martinez Rodriguez R, 1985, Rev Cubana Med Trop, V37, P2; *MINSA, 2001, PROGR NAC CONTR MAL; NOSTEN F, 2002, DRUGS, V69, P1315; Pena Molina E, 1988, Rev Cubana Med Trop, V40, P82; Stepniewska K, 2004, ANTIMICROB AGENTS CH, V48, P4271, DOI 10.1128/AAC.48.11.4271-4280.2004; Stivanello E, 2004, TROP MED INT HEALTH, V9, P975, DOI 10.1111/j.1365-3156.2004.01290.x; Suleimanov S D, 1994, Med Parazitol (Mosk), P8; White NJ, 2002, TRENDS PARASITOL, V18, P458, DOI 10.1016/S1471-4922(02)02373-5; *WHO, 1991, BAS MAL MICR 1; *WHO, 2002, WHOCDSRBM200239; WHO, 2003, WHOHTMRBM20035; *WHO, 2000, T R SOC TROP MED S1, V94; *WHO RBM, 2003, POS WHOS ROLL BACK M	23	36	36	0	2	ROYAL SOC TROPICAL MEDICINE	LONDON	MANSON HOUSE 26 PORTLAND PLACE, LONDON W1N 1EY, ENGLAND	0035-9203			T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	JUL	2005	99	7					485	492		10.1016/j.trstmh.2004.11.010				8	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	934NB	WOS:000229714400003	15876443	Green Published			2019-03-26	
J	Van Geertruyden, JP; Ntakirutimana, D; Erhart, A; Rwagacondo, C; Kabano, A; D'Alessandro, U				Van Geertruyden, JP; Ntakirutimana, D; Erhart, A; Rwagacondo, C; Kabano, A; D'Alessandro, U			Malaria infection among pregnant women attending antenatal clinics in six Rwandan districts	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						malaria; pregnancy; cross-sectional; anaemia; bed nets; Rwanda; KAP survey	LOW BIRTH-WEIGHT; PLASMODIUM-FALCIPARUM; AFRICA; ANEMIA; DETERMINANTS; TRANSMISSION; MORTALITY; BEDNETS; BURDEN; KENYA	OBJECTIVES The aim of the study was to assess the knowledge, attitude and practices of pregnant women towards malaria and their association with malaria morbidity. METHODS Cross-sectional malaria survey of 1432 pregnant women attending six health centres, each of them situated in a specific health district in Rwanda from September to October 2002. RESULTS The overall prevalence of malaria infection was 13.6% and all infections but two were caused by Plasmodium falciparum. The six health districts were significantly different in terms of malaria prevalence, which varied between 11.5% and 15.4% in four and was < 5% in the other two districts. The prevalence of anaemia and splenomegaly mirrored that of malaria infection. In three districts, the prevalence of infection was significantly higher in primigravidae than in secundigravidae and multigravidae (P = 0.01), while in two others it did not vary with parity. Bed net use was low - only 13.1% of the women had at least one bed net at home and 8.3% of them slept under it - and significantly different between districts. Most women knew that malaria might have serious consequences for their pregnancy and that insecticide-treated bed nets are useful for malaria prevention. However, the bed net market price [1525 Rwandan Francs (RFr), approximately 1.6e] was much higher than that considered as affordable and acceptable (389 RFr, approximately 0.3e). CONCLUSION Malaria in pregnancy is a major problem in Rwanda, even in the districts of low transmission. Bed net use among pregnant women is low. The option of providing free insecticide-treated bed nets to pregnant women should be explored and possibly implemented; it could rapidly increase bed net use and earlier attendance to antenatal clinics with clear benefits for the women's health.	Inst Trop Med Prince Leopold, Dept Parasitol, B-2000 Antwerp, Belgium; Programme Natl Lutte Tuberculose, Bujumbura, Burundi; Programme Natl Lutte Integree Paludisme, Kigali, Rwanda; UNICEF, Kigali, Rwanda	Van Geertruyden, JP (reprint author), Inst Trop Med Prince Leopold, Dept Parasitol, Nationalestr 155, B-2000 Antwerp, Belgium.	jpvangeertruyden@itg.be; dorotakirutimana2002@yahoo.fr; crwagacondo@rwanda1.com; akabano@unicef.org	D'Alessandro, Umberto/D-3457-2015; Van geertruyden, Jean-Pierre/K-6425-2014	D'Alessandro, Umberto/0000-0001-6341-5009; Van geertruyden, Jean-Pierre/0000-0001-5006-6364			BRABIN BJ, 1983, B WORLD HEALTH ORGAN, V61, P1005; D'Alessandro U, 2003, LANCET, V362, P1515, DOI 10.1016/S0140-6736(03)14778-2; FLEMING AF, 1989, T ROY SOC TROP MED H, V83, P441, DOI 10.1016/0035-9203(89)90241-1; Fried M, 1996, SCIENCE, V272, P1502, DOI 10.1126/science.272.5267.1502; Guyatt H, 2003, LANCET, V362, P1549, DOI 10.1016/S0140-6736(03)14744-7; Guyatt HL, 2002, TROP MED INT HEALTH, V7, P409, DOI 10.1046/j.1365-3156.2002.00879.x; Hammerich A, 2002, TROP MED INT HEALTH, V7, P573, DOI 10.1046/j.1365-3156.2002.00898.x; KRAMER MS, 1987, B WORLD HEALTH ORGAN, V65, P663; Laxminarayan R, 2004, TROP MED INT HEALTH, V9, P267, DOI 10.1046/j.1365-3156.2003.01171.x; MCCORMICK MC, 1985, NEW ENGL J MED, V312, P82, DOI 10.1056/NEJM198501103120204; McGregor I A, 1987, Parassitologia, V29, P153; MCGREGOR IA, 1983, T ROY SOC TROP MED H, V77, P232, DOI 10.1016/0035-9203(83)90081-0; Murphy SC, 2001, AM J TROP MED HYG, V64, P57, DOI 10.4269/ajtmh.2001.64.57; Mushi AK, 2003, HEALTH POLICY PLANN, V18, P163, DOI 10.1093/heapol/czg021; Newman RD, 2003, J INFECT DIS, V187, P1765, DOI 10.1086/374878; Newman RD, 2003, TROP MED INT HEALTH, V8, P488, DOI 10.1046/j.1365-3156.2003.01066.x; Nosten F, 1999, LANCET, V354, P546, DOI 10.1016/S0140-6736(98)09247-2; Rwagacondo CE, 2003, AM J TROP MED HYG, V68, P743, DOI 10.4269/ajtmh.2003.68.743; Shulman CE, 2003, T ROY SOC TROP MED H, V97, P30, DOI 10.1016/S0035-9203(03)90012-5; Steketee RW, 2001, AM J TROP MED HYG, V64, P28, DOI 10.4269/ajtmh.2001.64.28; ter Kuile FO, 2003, AM J TROP MED HYG, V68, P50, DOI 10.4269/ajtmh.2003.68.50; Van den Broek NR, 1998, AM J TROP MED HYG, V59, P1004, DOI 10.4269/ajtmh.1998.59.1004; Van Geertruyden JP, 2004, AM J TROP MED HYG, V71, P35, DOI 10.4269/ajtmh.2004.71.35; Verhoeff FH, 1999, ANN TROP MED PARASIT, V93, P119	24	13	13	1	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	JUL	2005	10	7					681	688						8	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	936DZ	WOS:000229837000008	15960707	Bronze			2019-03-26	
J	Mesia, GK; Tona, GL; Penge, O; Lusakibanza, M; Nanga, TM; Cimanga, RK; Apers, S; Van Miert, S; Totte, J; Pieters, L; Vlietinck, AJ				Mesia, GK; Tona, GL; Penge, O; Lusakibanza, M; Nanga, TM; Cimanga, RK; Apers, S; Van Miert, S; Totte, J; Pieters, L; Vlietinck, AJ			Antimalarial activities and toxicities of three plants used as traditional remedies for malaria in the Democratic Republic of Congo: Croton mubango, Nauclea pobeguinii and Pyrenacantha staudtii	ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY			English	Article							VITRO ANTIPLASMODIAL ACTIVITY; MEDICINAL-PLANTS; INDOLE ALKALOIDS; NEOCLERODANE DITERPENOIDS; DIDERRICHII BARK; AQUEOUS EXTRACT; LATIFOLIA SM; IN-VIVO; EUPHORBIACEAE; CONSTITUENTS	The antimalarial activities of crude extracts and 17 fractions from the partition of 80%-methanolic extracts of three plants (the stem bark of Croton mubango, the stem bark of Nauclea pobeguinii and the leaves of Pyrenacantha staudtii) used as antimalarial remedies in the Democratic Republic of Congo were studied both in vitro (against Plasmodium falciparum) and in mice infected with Pl. berghei berghei. The toxic effects of dried aqueous extracts of the plants were also investigated, in uninfected mice. The most active crude extracts in vitro, with median inhibitory concentrations (IC(50)) of < 1 mu g/ml, were found to be the methanolic and dichloromethane extracts of C. mubango, and the dichloromethane extracts of N. pobeguinii and Py. staudtii. The aqueous extract with the most antimalarial activity in vitro was that of C. mubango (IC(50)=3.2 mu g/ml), followed by that of N. probeguinii (IC(50)=5.3 mu g/ml) and then that of Py. staudii (IC(50)=15.2 mu g/ml). Results from the in-vivo tests of antimalarial activity showed that, at a daily oral dose of 200 mg/kg, all the dichloromethane extracts, the petroleum-ether, chloroformic, ethyl-acetate and residual water-soluble fractions from C. mubango, and the chloroformic, ethyl-acetate and n-butanolic fractions from Py. staudtii produced > 80% chemosuppression of the parasitaemias by day 4. The aqueous extracts of C. mubango and M probeguinii produced a slightly lower but still significant inhibition of parasitaemia (60%-80%) whereas that of Py. staudtii only suppressed the day-4 parasitaemias by 37%. The dried aqueous extract of the stem bark of C. mubango showed some signs of toxicity in mice, with median lethal doses (LD(50)) of 350 mg/kg in the female mice and 900 mg/kg in the male. The extract significantly increased the serum concentrations of glutamate-oxaloacetate transaminase (GOT) and glutamate-pyruvate transaminase (GPT) in mice of both sexes, but had no effect on the blood levels of creatinine or urea. No significant toxic effect was observed for the dried aqueous extracts of N. pobeguinii and Py. staudtii (LD(50) > 5 g/kg). Neither of these extracts affected the serum concentrations of GPT or the blood concentrations of creatinine and urea, although the N. pobeguinii extract did increase the serum concentration of GOT.	Univ Antwerp, Dept Pharmaceut Sci, B-2610 Antwerp, Belgium; Univ Kinshasa, Fac Pharm, Kinshasa 11, Zaire	Cimanga, RK (reprint author), Univ Antwerp, Dept Pharmaceut Sci, Universiteitsplein 1, B-2610 Antwerp, Belgium.	kanyanga.cimanga@ua.ac.be	Pieters, Luc/P-5820-2016; Apers, Sandra/P-6286-2016; /E-9308-2019	Pieters, Luc/0000-0002-8288-4254; /0000-0002-8926-0006			ADEBOWALE O, 1983, PHYTOCHEMISTRY, V22, P975; Aguilar-Guadarrama AB, 2004, J NAT PROD, V67, P914, DOI 10.1021/np030485f; AGUWA CN, 1981, EUR J PHARMACOL, V74, P215, DOI 10.1016/0014-2999(81)90533-1; AGUWA CN, 1986, J ETHNOPHARMACOL, V15, P45, DOI 10.1016/0378-8741(86)90103-0; Amaral ACF, 1998, PHYTOCHEMISTRY, V47, P1445, DOI 10.1016/S0031-9422(97)00764-4; Anam EM, 1997, INDIAN J CHEM B, V36, P54; Barbosa PR, 2003, BIOCHEM SYST ECOL, V31, P307, DOI 10.1016/S0305-1978(02)00145-X; Benoit-Vical F, 1998, J ETHNOPHARMACOL, V61, P173, DOI 10.1016/S0378-8741(98)00036-1; BERNARD S, 1989, BIOCH CLIN INSTRUMEN; Bittner M, 1997, BOL SOC CHIL QUIM, V42, P223; Block S, 2002, PLANTA MED, V68, P647, DOI 10.1055/s-2002-32903; CAI Y, 1991, PHYTOCHEMISTRY, V30, P2033, DOI 10.1016/0031-9422(91)85063-6; Christensen SB, 2001, BIOACTIVE COMPOUNDS FROM NATURAL SOURCES: ISOLATION CHARACTERISATION AND BIOLOGICAL PROPERTIES, P379; Clarkson C, 2004, J ETHNOPHARMACOL, V92, P177, DOI 10.1016/j.jep.2004.02.011; Cotillo HCD, 1996, BIOCHEM SYST ECOL, V24, P463; de Almeida ABA, 2003, EUR J PHARMACOL, V472, P205, DOI 10.1016/S0014-2999(03)01909-5; DEENI YY, 1991, J ETHNOPHARMACOL, V35, P91, DOI 10.1016/0378-8741(91)90137-3; ERDELMEIER CAJ, 1991, PLANTA MED, V57, P149, DOI 10.1055/s-2006-960052; Fattorusso E, 2002, J AGR FOOD CHEM, V50, P5131, DOI 10.1021/jf0203693; Franssen FFJ, 1997, ANTIMICROB AGENTS CH, V41, P1500, DOI 10.1128/AAC.41.7.1500; FRIERE ACG, 2003, PLANTA MED, V60, P67; Gadir WSA, 2003, SMALL RUMINANT RES, V48, P61; HARBORNE JB, 1974, PHYTOCHEMICAL METHOD; HOTELLIER F, 1979, PLANTA MED, V35, P242, DOI 10.1055/s-0028-1097211; LAMIDI M, 1995, J NAT PRODUCTS, V58, P921, DOI 10.1021/np50120a016; Lamidi M, 1996, ADV EXP MED BIOL, V404, P383; LAMIDI M, 1995, PLANTA MED, V61, P280, DOI 10.1055/s-2006-958075; Lamidi M, 1997, PLANTA MED, V63, P284, DOI 10.1055/s-2006-957679; LIN M, 1989, Yaoxue Xuebao, V24, P32; Lin M., 1985, ACTA PHARMACOL SINIC, V20, P902; Melo PS, 2002, HUM EXP TOXICOL, V21, P281, DOI 10.1191/0960327102ht246oa; Murillo RM, 2001, REV BIOL TROP, V49, P259; MUSTOFA VA, 2000, J ETHNOPHARMACOL, V73, P145; Ngadjui BT, 2002, PHYTOCHEMISTRY, V60, P345, DOI 10.1016/S0031-9422(02)00034-1; Ngnokam D, 2003, B CHEM SOC ETHIOPIA, V17, P173; PHILLIPSON JD, 1991, PLANTA MED, V57, pS53, DOI 10.1055/s-2006-960230; Prozesky EA, 2001, J ETHNOPHARMACOL, V76, P239, DOI 10.1016/S0378-8741(01)00245-8; Puebla P, 2003, PHYTOCHEMISTRY, V62, P551, DOI 10.1016/S0031-9422(02)00516-2; RODRIGUEZ JA, 1999, PLANTA MED, V65, P1; Shigemori H, 2003, CHEM PHARM BULL, V51, P58, DOI 10.1248/cpb.51.58; SONG PT, 2000, AUST J CHEM, V56, P11; Suarez AI, 2003, J ETHNOPHARMACOL, V88, P11, DOI 10.1016/S0378-8741(03)00179-X; SUTHIVAIYAKIT S, 2001, PHYTOCHEMISTRY, V56, P811; Takayama H, 2003, CHEM PHARM BULL, V51, P232, DOI 10.1248/cpb.51.232; TANGENYI OH, 1996, THESIS PE LUMUMBA ME; Tona L, 1999, J ETHNOPHARMACOL, V68, P193, DOI 10.1016/S0378-8741(99)00090-2; Tona L, 2001, ANN TROP MED PARASIT, V95, P47, DOI 10.1080/00034980020035915; Traore F, 2000, PHYTOTHER RES, V14, P608, DOI 10.1002/1099-1573(200012)14:8<608::AID-PTR667>3.0.CO;2-D; Traore-Keita F, 2000, PHYTOTHER RES, V14, P45, DOI 10.1002/(SICI)1099-1573(200002)14:1<45::AID-PTR544>3.0.CO;2-C; Vigor C, 2002, J NAT PROD, V65, P1180, DOI 10.1021/np020022u; Vigor C, 2001, PHYTOCHEMISTRY, V57, P1209, DOI 10.1016/S0031-9422(01)00183-2; Wellems T., 2000, J INFECT DIS, V184, P770; Weniger B, 2004, J ETHNOPHARMACOL, V90, P279, DOI 10.1016/j.jep.2003.10.002; ZECHES M, 1985, J NAT PROD, V48, P42, DOI 10.1021/np50037a007; Zhang ZZ, 2001, J NAT PROD, V64, P1001, DOI 10.1021/np010042g	55	20	24	0	11	MANEY PUBLISHING	LEEDS	STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND	0003-4983			ANN TROP MED PARASIT	Ann. Trop. Med. Parasitol.	JUN	2005	99	4					345	357		10.1179/136485905X36325				13	Public, Environmental & Occupational Health; Parasitology; Tropical Medicine	Public, Environmental & Occupational Health; Parasitology; Tropical Medicine	938TW	WOS:000230027300003	15949182				2019-03-26	
J	Lejon, V; Buscher, P				Lejon, V; Buscher, P			Review article: Cerebrospinal fluid in human African trypanosomiasis: a key to diagnosis, therapeutic decision and post-treatment follow-up	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Review						human African trypanosomiasis; central nervous system; cerebrospinal fluid; diagnosis; treatment; diagnostic criteria; review	SLEEPING SICKNESS PATIENTS; NERVOUS-SYSTEM INVOLVEMENT; INTRATHECAL IMMUNE-RESPONSE; GAMBIENSE-INFECTED PATIENTS; POLYMERASE-CHAIN-REACTION; CARD-AGGLUTINATION-TEST; BRUCEI-GAMBIENSE; RISK-FACTORS; TB-GAMBIENSE; ANTIBODIES	Human African trypanosomiasis is a lethal parasitic infection with neurological involvement. Examination of the cerebrospinal fluid (CSF) plays an essential role in diagnosis, selection of treatment and post-treatment follow-up. This paper reviews clinical presentation, diagnosis and treatment of the disease, with emphasis on CSF characteristics and interpretation of the CSF results for therapeutic decision and post-treatment follow-up.	Inst Trop Med, Dept Parasitol, B-2000 Antwerp, Belgium	Lejon, V (reprint author), Inst Trop Med, Dept Parasitol, Natl Str 155, B-2000 Antwerp, Belgium.	vlejon@itg.be	Buscher, Philippe/B-9956-2012	Buscher, Philippe/0000-0002-1926-7472			Apted F. I. C., 1970, P645; APTED FIC, 1970, AFRICAN TRYPANOSOMIA, P661; Ayed Z, 1997, AM J TROP MED HYG, V57, P1; Bisser S, 1997, B SOC PATHOL EXOT, V90, P321; Bisser S, 2000, T ROY SOC TROP MED H, V94, P225, DOI 10.1016/S0035-9203(00)90285-2; Bisser S, 2002, J NEUROL SCI, V193, P127, DOI 10.1016/S0022-510X(01)00655-4; BOA YF, 1988, B SOC PATHOL EXOT, V81, P427; BRODEN A, 1908, B SOC PATHOL EXOT, V1, P496; Burri C, 2000, LANCET, V355, P1419, DOI 10.1016/S0140-6736(00)02141-3; BURRI C, 2003, MANSONS TROPICAL DIS, P1303; Buscher P, 1999, ACTA TROP, V73, P11, DOI 10.1016/S0001-706X(99)00009-1; Buscher P., 2004, The trypanosomiases, P203, DOI 10.1079/9780851994758.0203; CATTAND P, 1988, B WORLD HEALTH ORGAN, V66, P83; COURTIOUX B, 2003, MED TROPICALE, V63, P327; Doua F, 1996, AM J TROP MED HYG, V55, P586, DOI 10.4269/ajtmh.1996.55.586; DUGGAN AJ, 1966, J TROP MED HYG, V69, P124; Dumas M., 1999, PROGR HUMAN AFRICAN, P215; DUMAS M, 1978, HDB CLIN NEUROLOGY I, V35, P67; Edan G, 1979, Med Trop (Mars), V39, P499; GREENWOOD BM, 1976, BRIT MED J, V2, P1291, DOI 10.1136/bmj.2.6047.1291; GREENWOOD BM, 1980, T ROY SOC TROP MED H, V74, P716, DOI 10.1016/0035-9203(80)90184-4; GREENWOOD BM, 1973, LANCET, V2, P525; Jamonneau V, 2003, TROP MED INT HEALTH, V8, P589, DOI 10.1046/j.1365-3156.2003.01079.x; JAUBERTEAU MO, 1994, B SOC PATHOL EXOT, V87, P333; Kennedy PGE, 2004, J CLIN INVEST, V113, P496, DOI 10.1172/JCI200421052; Kirchhoff L. V., 1998, Central African Journal of Medicine, V44, P134; KNOBLOCH J, 1984, TROPENMED PARASITOL, V35, P137; Kristensson K., 1999, PROGR HUMAN AFRICAN, P157; Kyambadde JW, 2000, B WORLD HEALTH ORGAN, V78, P119; LAMBERT PH, 1981, J CLIN INVEST, V67, P77, DOI 10.1172/JCI110035; LAVERAN A, 1912, TRYPANOSOMES TRYPANO, P673; Legros D, 2002, LANCET INFECT DIS, V2, P437, DOI 10.1016/S1473-3099(02)00321-3; LEGROS D, 2001, JOURN PHAR 6 8 SEPT; Lejon V, 1999, AM J TROP MED HYG, V60, P94, DOI 10.4269/ajtmh.1999.60.94; Lejon V, 2003, J NEUROIMMUNOL, V144, P132, DOI 10.1016/j.jneuroim.2003.08.033; Lejon V, 2003, EUR J NEUROL, V10, P711, DOI 10.1046/j.1468-1331.2003.00660.x; Lejon V, 2003, J INFECT DIS, V187, P1475, DOI 10.1086/374645; Lejon V, 2002, TROP MED INT HEALTH, V7, P685, DOI 10.1046/j.1365-3156.2002.00917.x; Lejon V, 2002, T ROY SOC TROP MED H, V96, P329, DOI 10.1016/S0035-9203(02)90115-X; Lejon V, 1998, ACTA TROP, V69, P151, DOI 10.1016/S0001-706X(97)00137-X; LEMESRE JL, 1988, B SOC PATHOL EXOT, V81, P506; Lourie E. M., 1942, ANN TROP MED AND PARASITOL, V36, P113; LUCASSE C., 1964, BULL SOC PATHOL EXOTIQUE, V57, P283; LUMSDEN WHR, 1979, T ROY SOC TROP MED H, V73, P312, DOI 10.1016/0035-9203(79)90092-0; MacLean L, 2001, J INFECT DIS, V184, P1086, DOI 10.1086/323479; MAGNUS E, 1978, ANN SOC BELG MED TR, V58, P169; MATTERN P, 1968, B WORLD HEALTH ORGAN, V38, P1; MATTERN P, 1967, SEPT C TECHN OCCGE M, P1053; MATTERN P, 1965, MED AFR NOIRE, V6, P219; Miezan TW, 2000, T ROY SOC TROP MED H, V94, P293, DOI 10.1016/S0035-9203(00)90327-4; Miezan TW, 2003, B SOC PATHOL EXOT, V95, P362; Miezan TW, 1998, TROP MED INT HEALTH, V3, P571, DOI 10.1046/j.1365-3156.1998.00267.x; Moore A, 2001, TROP MED INT HEALTH, V6, P342, DOI 10.1046/j.1365-3156.2001.00714.x; MOTT FW, 1906, REPORT SLEEPING SICK, V7, P3; NANTULYA VM, 1992, T ROY SOC TROP MED H, V86, P42, DOI 10.1016/0035-9203(92)90435-F; NANTULYA VM, 1988, B SOC PATHOL EXOT, V81, P511; Papadopoulos MC, 2004, LANCET, V363, P1358, DOI 10.1016/S0140-6736(04)16046-7; PENTREATH VW, 1990, T ROY SOC TROP MED H, V84, P795, DOI 10.1016/0035-9203(90)90085-S; Pentreath VW, 1997, PARASITOLOGY, V114, P361, DOI 10.1017/S0031182096008530; Pentreath VW, 1996, PARASITOLOGY, V112, P67, DOI 10.1017/S0031182000065082; PENTREATH VW, 1992, ANN TROP MED PARASIT, V86, P29, DOI 10.1080/00034983.1992.11812627; PEPIN J, 1991, T ROY SOC TROP MED H, V85, P222, DOI 10.1016/0035-9203(91)90032-T; PEPIN J, 1994, T ROY SOC TROP MED H, V88, P447, DOI 10.1016/0035-9203(94)90430-8; PEPIN J, 1994, ADV PARASIT, V33, P2; ROFFI J, 1979, MED MALADIES INFECT, V9, P306, DOI 10.1016/S0399-077X(79)80103-1; Ruiz JA, 2002, B WORLD HEALTH ORGAN, V80, P738; Schmid C, 2004, LANCET, V364, P789, DOI 10.1016/S0140-6736(04)16940-7; Scott D., 1970, P614; SMITH DH, 1989, ANN TROP MED PARASIT, V83, P91, DOI 10.1080/00034983.1989.11812412; Stanghellini A, 2001, TROP MED INT HEALTH, V6, P330, DOI 10.1046/j.1365-3156.2001.00724.x; TRUC P, 1999, B WORLD HEALTH ORGAN, V77, P45; Van Nieuwenhove S, 2001, TROP MED INT HEALTH, V6, P335, DOI 10.1046/j.1365-3156.2001.00731.x; VANMEIRVENNE N, 1999, PROGR HUMAN AFRICAN, P235; VANNIEUWENHOVE S, 1999, PROGR HUMAN AFRICAN, P253; WHITTLE HC, 1977, AM J TROP MED HYG, V26, P1129, DOI 10.4269/ajtmh.1977.26.1129; *WHO, 1983, TRYP CONTR MAN, P1; WOO P T K, 1971, Acta Tropica, V28, P298; World Health Organization, 1998, WHO TECH REP SER, P1	78	45	46	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	MAY	2005	10	5					395	403		10.1111/j.1365-3156.2005.01403.x				9	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	921FM	WOS:000228749600002	15860085				2019-03-26	
J	Criel, B; Diallo, AA; Van der Vennet, J; Waelkens, MP; Wiegandt, A				Criel, B; Diallo, AA; Van der Vennet, J; Waelkens, MP; Wiegandt, A			The difficulties in partnership between health professionals and mutual health organizations: the case of Maliando MHO in Guinea-Conarky	TROPICAL MEDICINE & INTERNATIONAL HEALTH			French	Article						Mutual Health Organizations; health care providers; partnership; local health systems; Guinea Conakry	CARE	In 1998, a Mutual Health Organization (MHO) was created in the region of Guinee forestiere in Guinea-Conakry, West Africa, in the context of the action-research project PRIMA (Projet de recherche sur le partage du risque maladie). The aim of the project was to test whether, and under which conditions, an MHO can improve the access to quality health care. The specificity of the model is double-sided: on the one hand, the wish to integrate the organization into the local health system through a partnership between MHO and health services; on the other hand, the systematic efforts by the local research team to involve health professionals, at both the operational and managerial level of the system, in the planning and implementation of the MHO. We present the results of a study that investigates the health professionals' perception of this model. In April 2000, semi-structured interviews were held with 16 health professionals working at the different operational, managerial and administrative levels of the Guinean health system. The professionals perceive the MHO as an effective strategy to overcome financial accessibility problems. However, the interviews highlight the uncertainties and worries of the health professionals, their lack of understanding of the model, their reluctance even to fully accept it. The partnership approach was not internalized. They understand the technical instrument, but are confused and uncomfortable in their dialogue with the population. This study illustrates the difficulties of establishing a real partnership between population and health services, as well as the need for proper training and coaching of the health workers in the set-up of MHOs. The importance of this aspect was insufficiently recognized by the research team, despite its good intentions and its huge investment in organizing exchange between stakeholders. An important lesson of this experience is the need for promoters to conceive and operate MHO systems in which the expectations and fears of the health care providers are better identified and better taken into account.	Inst Trop Med, Dept Sante Publ, B-2000 Antwerp, Belgium; Minist Sante Publ, Conakry, Guinea	Criel, B (reprint author), Inst Trop Med, Dept Sante Publ, Natl Str 155, B-2000 Antwerp, Belgium.	bcriel@itg.be					Atim C, 1998, CONTRIBUTION MUTUAL; BLAISE P, 2001, QUALITY PROFESSIONAL, P25; Criel B, 2003, SOC SCI MED, V57, P1205, DOI 10.1016/S0277-9536(02)00495-1; CRIEL B, 1999, CONTROLLING COSTS ST, P100; DIALLO Y, 2003, CONAKRY CTR SANTE PU; DJAN B, 2002, PROJET PRIMA GUINEE, P112; GALLAND B, 1996, CREATION MUTUELLES S, P1; Haddad S, 1998, SOC SCI MED, V47, P381, DOI 10.1016/S0277-9536(98)00075-6; Holloway KA, 2002, SOC SCI MED, V54, P905, DOI 10.1016/S0277-9536(01)00064-8; LETOURMY A, 1998, ETUDE UNE STRATEGIE; LevyBruhl D, 1997, INT J HEALTH PLAN M, V12, pS49, DOI 10.1002/(SICI)1099-1751(199706)12:1+<S49::AID-HPM466>3.3.CO;2-G; *PROJ PRIMA GUIN C, 2002, UN EXP ORG MUT SANT; SOUCAT A, 1997, INT J HLTH PLANNING, V12, P137; SYLLA MB, 2002, PROJET PRIMA GUINEE, P17	14	16	16	0	4	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	MAY	2005	10	5					450	463		10.1111/j.1365-3156.2005.01410.x				14	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	921FM	WOS:000228749600009	15860092				2019-03-26	
J	Marchal, B; De Brouwere, V; Kegels, G				Marchal, B; De Brouwere, V; Kegels, G			Viewpoint: HIV/AIDS and the health workforce crisis: What are the next steps?	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Editorial Material						AIDS; human resources; health workforce; policy; international agencies	HIV; SETTINGS; ZAMBIA; RISK; CARE	In scaling up antiretroviral treatment (ART), financing is fast becoming less of a constraint than the human resources to ensure the implementation of the programmes. In the countries hardest affected by the acquired immunodeficiency syndrome (AIDS) pandemic, AIDS increases workloads, professional frustration and burn-out. It affects health workers also directly, contributing to rising sick leave and attrition rates. This burden is shouldered by a health workforce weakened already by chronic deficiencies in training, distribution and retention. In these countries, health workforce issues can no longer be analysed from the traditional perspective of human resource development, but should start from the position that entire societies are in a process of social involution of a scale unprecedented in human history. Strategies that proved to be effective and correct in past conditions need be reviewed, particularly in the domains of human resource management and policy-making, education and international aid. True paradigm shifts are thus required, without which the fundamental changes required to effectively strengthen the health workforce are unlikely to be initiated.	Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium	Marchal, B (reprint author), Inst Trop Med, Dept Publ Hlth, Natl Str 155, B-2000 Antwerp, Belgium.	bmarchal@itg.be; udbrouw@itg.be; gkegels@itg.be					*ABT ASS S AFR INC, 2000, IMP HIV AIDS HLTH SE; AITKEN JM, 2003, 12 EQUINET; BUVE A, 1994, AIDS, V8, P396, DOI 10.1097/00002030-199403000-00023; COHEN D, 2002, HUMAN CAPITAL HIV EP; CONSTEN ECJ, 1995, AIDS, V9, P585, DOI 10.1097/00002030-199506000-00009; de Graaf R, 1998, AIDS CARE, V10, P441, DOI 10.1080/09540129850123975; DEWAAL A, IN PRESS HIV AIDS TH; HAACKER M, 2002, 0283 IMF; *HSRC, 2003, REV HUM RES CONT PRS; HUDDART J, 2003, HLTH SECTOR HUMAN RE; *IOE, 2002, EMPL HDB HIV AIDS GU; Kapp C, 2004, LANCET, V363, P1202, DOI 10.1016/S0140-6736(04)15986-2; Karim SSA, 2004, AIDS, V18, P975, DOI [10.1097/00002030-200404300-00004, 10.1097/01.aids.0000125944.42948.56]; Koenig SP, 2004, AIDS, V18, pS21, DOI [10.1097/00002030-200406003-00005, 10.1097/01.aids.0000131308.62828.45]; Marchal B, 2003, INT J HEALTH PLAN M, V18, pS89, DOI 10.1002/hpm.720; Martineau T, 2002, BRIEFING NOTE INT MI; MASINI T, 1993, INT C AIDS JUN 6 11; Narasimhan V, 2004, LANCET, V363, P1469, DOI 10.1016/S0140-6736(04)16108-4; *OECD, 2004, TRENDS INT MIGR; SHISANA O, 2003, IMPACT HIV AIDS HLTH, P1; TAWFIQ L, 2003, IMPACT HIV AIDS HLTH; UNGER A, 2002, IMPACT HIV AIDS HLTH; *WHO, 2004, WHOEIPHRH20042; 2001, MMWR RECOMMENDATIONS, V50, P1	24	57	58	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	APR	2005	10	4					300	304		10.1111/j.1365-3156.2005.01397.x				5	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	912FY	WOS:000228064200003	15807792	Bronze			2019-03-26	
J	Lutumba, P; Robays, J; Miaka, C; Kande, V; Simarro, PP; Shaw, APM; Dujardin, B; Boelaert, M				Lutumba, P; Robays, J; Miaka, C; Kande, V; Simarro, PP; Shaw, APM; Dujardin, B; Boelaert, M			Efficiency of different detection strategies of Human African trypanosomiasis at T-b. gambiense	TROPICAL MEDICINE & INTERNATIONAL HEALTH			French	Article						human African trypanosomiasis; trypanosoma brucei gambiense; cost-effectiveness; decision analysis; screening; democratic Republic of Congo	CARD-AGGLUTINATION-TEST; SLEEPING SICKNESS; BRUCEI-GAMBIENSE; DIAGNOSIS; CONGO; CATT	Introduction Population screening for human African trypanosomiasis (HAT) is often based on a combination of two screening tests: lymph node palpation (LN) and card agglutination test for trypanosomiasis (CATT). This decision analysis compared the efficiency of three alternative detection strategies: screening by LN only, CATT only and their combination (LN and CATT). Method An HAT detection strategy was defined as the sequence of screening and confirmation. Efficacy was evaluated in terms of lives saved. The cost of screening and confirmation tests was estimated in US$. The different parameters in the decision tree were based on published literature and observations of the HAT control programme in the Democratic Republic of Congo. A sensitivity analysis was carried out on those parameters subject to uncertainty. Results The cost-effectiveness of a detection strategy based on CATT was US$125 per life saved, compared with US$517 for LN and US$452 for the combined. Marginal cost to add LN to CATT only was between US$1225 and US$5000 per life saved. Sensitivity analysis shows that these results are robust to variation. Discussion The CATT strategy was the most efficient. None of the strategies was able to avoid more than 60% of HAT deaths. This moderate efficacy is due to the low sensitivity of the confirmatory ( diagnostic) tests. Substantial efficiency gains can be obtained by adopting a CATT only strategy and resources can be better allocated to more sensitive confirmatory tests or to increasing the coverage of populations at risk.	Inst Trop Med Prince Leopold, Unite Epidemiol, Dept Sante Publ, B-2000 Antwerp, Belgium; Programme Natl Lutte Trupanosomiase Humaine Afric, Kinshasa, Congo; OMS, CDS, CPE, ZFK, Yaounde, Cameroon; AP Consultants, Andover SP11 7BA, England; Free Univ Brussels, Ecole Sante Publ, Brussels, Belgium	Boelaert, M (reprint author), Inst Trop Med Prince Leopold, Unite Epidemiol, Dept Sante Publ, Natl Str 155, B-2000 Antwerp, Belgium.	plutumba@itg.be; jrobays@itg.be; tshimbadi@yahoo.fr; bctrdc@ic.cs; simarrop_who@yahoo.fr; alexandrashaw@compuserve.com; bruno.dujardin@ulb.ac.be; boelaert@itg.be	Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776			ARBYN M, 1993, THESIS I MED TROP PR; BISSER S, 2001, THESIS U LIMOGES; BONE G J, 1975, Annales de la Societe Belge de Medecine Tropicale, V55, P559; *BUR CENTR TRYP, 1995, GUID TECHN PROGR NAT; *BUR CENTR TRYP, 2002, DECL POL NAT LUTT CO; BURKE J, 1992, MED HYGIENE AFRIQUE, P1489; DEMUYNCK A, 1990, ETUDE EPIDEMIOLOGIQU, P19; DOUA F, 1993, ACTA TROP, V54, P163, DOI 10.1016/0001-706X(93)90090-X; DRUMMOND MF, 1977, METHODS EC EVALUATIO, P52; DUTTON JE, 2006, GLAND PALPATION HUMA, V18; JOHN M, 1995, THESIS LONDON SCH HY; KEGELS G, 1995, THESIS U ANVERS BELG; Magnus E, 2002, ACTA TROP, V81, P7, DOI 10.1016/S0001-706X(01)00184-X; MAGNUS E, 1978, ANN SOC BELG MED TR, V58, P169; MARTIN G, 1908, B SOC PATHOL EXOT, V1, P221; MIEZAN TW, 1994, B SOC PATHOL EXOT, V87, P101; Nantulya VM, 1997, T ROY SOC TROP MED H, V91, P551, DOI 10.1016/S0035-9203(97)90023-7; NOIREAU F, 1991, J TROP MED HYG, V94, P251; NOIREAU F, 1988, T ROY SOC TROP MED H, V82, P237, DOI 10.1016/0035-9203(88)90430-0; NOIREAU F, 1987, B SOC PATHOL EXOT, V80, P797; PEPIN J, 1991, T ROY SOC TROP MED H, V85, P222, DOI 10.1016/0035-9203(91)90032-T; Robays J, 2004, TROP MED INT HEALTH, V9, P542, DOI 10.1111/j.1365-3156.2004.01240.x; STANGHELLINI A, 1999, PROGR HUMAN AFRICAN, P301; THIROUX A, 1909, B SOC PATHOL EXOT, V2, P135; TODD JL, 1910, B SOC PATHOL EXOT, V3, P438; TODD JL, 1908, J TROPICAL MED HYG, V11, P229; VANNIEUWENHOVE S, 1984, S DIAGN AFR SLEEP SI, P71; WEINSTEIN MC, 1980, CLIN DECISION ANAL, P1; WERY M, 1970, Annales des Societes Belges de Medecine Tropicale de Parasitologie et de Mycologie, V50, P613; *WHO EXP COMM, 1998, CONTR SURV AFR TRYP	30	19	19	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	APR	2005	10	4					347	356		10.1111/j.1365-3156.2005.01391.x				10	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	912FY	WOS:000228064200010	15807799	Bronze			2019-03-26	
J	Faye, D; Fall, A; Leak, S; Losson, B; Geerts, S				Faye, D; Fall, A; Leak, S; Losson, B; Geerts, S			Influence of an experimental Trypanosoma congolense infection and plane of nutrition on milk production and some biochemical parameters in West African Dwarf goats	ACTA TROPICA			English	Article						Trypanosoma congolense; nutrition; milk; West African Dwarf goats; biochemistry; lactation	LISTERIA-MONOCYTOGENES INFECTION; SCOTTISH BLACKFACE SHEEP; DJALLONKE EWE LAMBS; VIVAX INFECTION; NITROGEN-METABOLISM; DIETARY LIPIDS; NDAMA CATTLE; COTTON SEED; FEED-INTAKE; SUSCEPTIBILITY	The interactions of trypanosomosis and plane of nutrition on health and productivity of multiparous and primiparous West African Dwarf (WAD) does were studied in a multi-factorial experiment including diet (supplementation or basal diet) and infection (infected or control). Experimental does were infected with Trypanosoma congolense at the beginning of the second week post-kidding and monitored for 16 weeks after infection. Trypanosome infection significantly reduced packed cell volume (PCV) (control: 30.1 +/- 0.3% versus infected: 22.2 +/- 0.3%; P < 0.0001). Regardless of infection, the drop in PCV from the pre-infection period to the end of the experiment was more severe in animals under restricted diet (interaction diet x period, P < 0.001). Trypanosome parasitaemia tended to be higher in the supplemented group than in the basal diet group (P > 0.05) and multiparous animals had a higher parasitaemia (score: 2.6 +/- 0.1) than primiparous animals (score: 2.2 +/- 0.1) (P < 0.05). Trypanosome infection as well as dietary supplement had a significant effect on lactation length. Milk off-take from trypanosome-infected does was significantly lower than that from the uninfected control group (17.5 +/- 3.21 versus 35.5 +/- 3.21, P < 0.001) and there was a positive effect of plane of nutrition (supplemented: 32.8 +/- 3.21 and basal diet: 20.2 +/- 3.51, P = 0.01). The drop in milk off-take due to trypanosome infection was more severe in the supplemented group (control: 46.7 +/- 4.71 versus infected: 18.9 +/- 4.21) than in the group receiving a basal diet (control: 24.2 +/- 5.01 versus infected: 16.1 +/- 4.71) (interaction infection x diet, P = 0.04) due to the number of does from the supplemented group that were withdrawn from the experiment. The effect of trypanosome infection on doe's live-weight was only noticeable during the first 8 weeks of lactation and there was no significant effect on offspring growth rate unless the mother died. Plasma total protein (TP), albumin and cholesterol concentrations were significantly reduced by the infection but were significantly increased by supplementation. Supplemented does had a higher level of cholesterol and a tendency for a higher parasitaemia. Does of high parity also had a higher cholesterol level than primiparous does and, based on the number of animals that were withdrawn from the experiment, they showed a lower resistance to the infection. (c) 2005 Elsevier B.V. All rights reserved.	Inst Trop Med, Dept Anim Hlth, B-2000 Antwerp, Belgium; Int Trypanotolerance Ctr, Banjul, Gambia; Univ Liege, Fac Vet Med, Dept Parasitol, B-4000 Cointe Ougree, Belgium	Geerts, S (reprint author), Inst Trop Med, Dept Anim Hlth, Natl Str 155, B-2000 Antwerp, Belgium.	sgeerts@itg.be		Geerts, Stanny/0000-0001-9885-8846			ADAH MI, 1993, VET PARASITOL, V47, P177, DOI 10.1016/0304-4017(93)90020-N; AGYEMANG K, 1990, ANIM PROD, V50, P383, DOI 10.1017/S0003356100004864; AGYEMANG K, 1991, ACTA TROP, V50, P91, DOI 10.1016/0001-706X(91)90001-Z; AKINBAMIJO OO, 1992, VET QUART, V14, P95, DOI 10.1080/01652176.1992.9694341; AKINBAMIJO OO, 1994, J AGR SCI, V123, P387, DOI 10.1017/S0021859600070404; ALBRIGHT JW, 1994, IMMUNOL LETT, V40, P279, DOI 10.1016/0165-2478(94)00066-2; Andrianarivo AG, 1996, EXP PARASITOL, V82, P104, DOI 10.1006/expr.1996.0014; ANOSA VO, 1976, TROP ANIM HLTH PROD, V8, P11; BELIBASAKIS NG, 1995, ANIM FEED SCI TECH, V52, P227, DOI 10.1016/0377-8401(94)00725-O; BENNISON JJ, 1997, THESIS WYE COLL U LO; Calder PC, 2001, NUTR RES, V21, P309, DOI 10.1016/S0271-5317(00)00287-6; Chaudhary ZI, 2000, ACTA TROP, V77, P209, DOI 10.1016/S0001-706X(00)00142-X; Fall A, 1999, VET PARASITOL, V81, P235, DOI 10.1016/S0304-4017(98)00213-1; Goossens B, 1998, VET PARASITOL, V79, P283, DOI 10.1016/S0304-4017(98)00171-X; Goossens B, 1997, RES VET SCI, V63, P169, DOI 10.1016/S0034-5288(97)90013-8; GRIFFIN L, 1979, VET PARASITOL, V5, P97, DOI 10.1016/0304-4017(79)90001-3; Hudson J. R., 1944, JOUR COMP PATH AND THERAP, V54, P108; *INT COMM AN REC, 2001, ICAR RUL STAND GUID; JARRIGE R, 1988, ALIMENTATION BOVINS; KALU AU, 1991, TROP ANIM HEALTH PRO, V23, P215, DOI 10.1007/BF02357102; Kanyari P. W. N., 1986, Bulletin of Animal Health and Production in Africa, V34, P93; Katunguka-Rwakishaya E, 1999, VET PARASITOL, V84, P1, DOI 10.1016/S0304-4017(99)00088-6; KATUNGUKARWAKISHAYA E, 1993, VET PARASITOL, V47, P189, DOI 10.1016/0304-4017(93)90021-E; KATUNGUKARWAKISHAYA E, 1995, VET PARASITOL, V59, P207, DOI 10.1016/0304-4017(94)00748-2; KatungukaRwakishaya E, 1997, VET PARASITOL, V70, P67, DOI 10.1016/S0304-4017(96)01136-3; KATUNGUKARWAKISHAYA E, 1992, VET PARASITOL, V45, P17, DOI 10.1016/0304-4017(92)90024-4; LEAK S, 2002, ICPTV NEWSLETT, P36; Leak SGA, 1998, TSETSE BIOL ECOLOGY; MCDONALD P, 1978, ANIMAL NUTR; MURRAY M, 1977, T ROY SOC TROP MED H, V71, P325, DOI 10.1016/0035-9203(77)90110-9; MURRAY M, 1982, ADV PARASIT, V21, P1, DOI 10.1016/S0065-308X(08)60274-2; OKELLY JC, 1984, VET PARASITOL, V15, P151, DOI 10.1016/0304-4017(84)90030-X; Osaer S, 1999, VET PARASITOL, V80, P215, DOI 10.1016/S0304-4017(98)00193-9; OSAER S, 1994, VET PARASITOL, V51, P191, DOI 10.1016/0304-4017(94)90156-2; Osaer S, 1998, RES VET SCI, V65, P65, DOI 10.1016/S0034-5288(98)90029-7; Osaer S, 2000, ACTA TROP, V75, P229, DOI 10.1016/S0001-706X(00)00060-7; PARIS J, 1982, ACTA TROP, V39, P307; PAYNE JM, 1989, METABOLIC NUTR DIS C; Puertollano MA, 2003, CLIN NUTR, V22, P313, DOI 10.1016/S0261-5614(03)00031-1; Puertollano MA, 2001, FEMS IMMUNOL MED MIC, V32, P47, DOI 10.1016/S0928-8244(01)00270-X; *STAT AN SYST I SA, 1999, VERS 8 1; VANDAM JTP, 1996, THESIS WAGENINGEN AG; VERSTEGEN MWA, 1991, J ANIM SCI, V69, P1667; WHITELAW DD, 1985, TROP ANIM HEALTH PRO, V17, P155, DOI 10.1007/BF02355876; ZWART D, 1991, J ANIM SCI, V69, P3780	45	11	12	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0001-706X	1873-6254		ACTA TROP	Acta Trop.	MAR	2005	93	3					247	257		10.1016/j.actatropica.2004.10.008				11	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	910JG	WOS:000227926700004	15715994				2019-03-26	
J	Lambert, ML; Delgado, R; Michaux, G; Vols, A; Speybroeck, N; Van der Stuyft, P				Lambert, ML; Delgado, R; Michaux, G; Vols, A; Speybroeck, N; Van der Stuyft, P			Collaboration between private pharmacies and national tuberculosis programme: an intervention in Bolivia	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						tuberculosis; tuberculosis control private sector; public-private partnership pharmacies; Bolivia	CHI-MINH-CITY; PARTNERSHIP; VIETNAM; NEPAL	Background Public-private partnerships are felt to be necessary for tuberculosis (TB) control in some developing countries. objectives To evaluate the potential of a collaboration between the National TB Programme (NTP) and private pharmacies in Bolivia, the country with the highest TB incidence in Latin America. Methods We contacted the local Pharmacists' Association in the city of Cochabamba, and designed a two phase intervention. The objectives of the first phase were to decrease the availability of TB drugs in private pharmacies on a voluntary basis, and to improve referral of clients seeking TB drugs to the NTP. A survey of all pharmacies allowed for a before-after comparison with a baseline survey. The objectives of the second phase were to obtain referral of pharmacy clients with chronic cough for TB screening in the NTP. This phase was started in 70 pharmacies and evaluated after 2 months using the referral slips issued by the pharmacists. Results The proportion of pharmacies selling TB drugs decreased (rifampicin: 23 - 11.5%; isoniazid: 16 - 3.1%; P < 0.001) and the proportion of pharmacies referring to the NTP clients seeking TB drugs increased (22 - 58%; P < 0.0001). In the second phase, 26 of 70 pharmacies (38%) referred a total of 41 clients for screening in the NTP (i.e. an average of 0.29 clients per pharmacy and per month); 11 of 41 (27%) were screened and three of 11 ( 27%) diagnosed with smear-positive TB. Conclusion The first phase of the intervention proved effective in reducing the availability of the main TB drugs in pharmacies, and in improving referral of clients seeking TB drugs. Key factors in this success were not specific to Bolivia, and collaboration between private pharmacies and public services appears possible in that respect. However, collaboration with pharmacies does not seem an efficient way to increase the number of patients screened for TB, and to shorten delays to TB diagnosis and treatment.	Inst Trop Med, Epidemiol & Dis Control Unit, Dept Publ Hlth, B-2000 Antwerp, Belgium; Univ Mayor Simon, Fac Med, Inst Invest Biomed, Cochabamba, Bolivia; Belgian Tech Cooperat, Brussels, Belgium; Inst Trop Med, Vet Dept, B-2000 Antwerp, Belgium	Lambert, ML (reprint author), Inst Trop Med, Epidemiol & Dis Control Unit, Dept Publ Hlth, Natl Str 155, B-2000 Antwerp, Belgium.	mllambert@itg.be; incotb@med.umss.edu.bo; gmmichaux@yahoo.com; speybroeck@who.int; pvds@itg.be					Al-Hajjaj M S, 2001, Respirology, V6, P317, DOI 10.1046/j.1440-1843.2001.00344.x; Goel P, 1996, SOC SCI MED, V42, P1155, DOI 10.1016/0277-9536(95)00388-6; Hurtig AK, 2000, INT J TUBERC LUNG D, V4, P730; Lambert ML, 2004, INT J TUBERC LUNG D, V8, P1325; Lonnroth K, 2003, INT J TUBERC LUNG D, V7, P1147; Lonnroth K, 2000, INT J TUBERC LUNG D, V4, P1052; Murthy KJR, 2001, INT J TUBERC LUNG D, V5, P354; Newell JN, 2004, B WORLD HEALTH ORGAN, V82, P92; Rajeswari R, 2002, INT J TUBERC LUNG D, V6, P171; *WHO, 2004, WHOHTMTB2004331; World Health Organization (WHO), 2001, INV PRIV PRACT TUB C	11	15	16	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	MAR	2005	10	3					246	250		10.1111/j.1365-3156.2004.01383.x				5	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	900AT	WOS:000227188500008	15730509				2019-03-26	
J	Trung, HD; Van Bortel, W; Sochantha, T; Keokenchanh, K; Briet, OJT; Coosemans, M				Trung, HD; Van Bortel, W; Sochantha, T; Keokenchanh, K; Briet, OJT; Coosemans, M			Behavioural heterogeneity of Anopheles species in ecologically different localities in Southeast Asia: a challenge for vector control	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						malaria control; behaviour; Anopheles; Southeast Asia	MALARIA TRANSMISSION; FOREST MALARIA; COMPLEX; AREA; IDENTIFICATION; CULICIDAE; VIETNAM; DIPTERA; MEMBERS; DIRUS	In Southeast Asia the biodiversity of Anopheles species in the domestic environment is very high. Only few species are considered major vectors throughout the region, whereas the vector status of other species varies from area to area. Often it is difficult to identify an Anopheles species as a malaria vector in areas with low malaria incidence. The behaviour of Anopheles species largely determines their vector status, and insights into their behaviour are essential to evaluate the appropriateness of vector control measures. This study was conducted in six ecologically different localities in Southeast Asia to rank the different Anopheles species in terms of anthropophily and endophagy in order to estimate their current epidemiological importance. Concurrently, the biting and resting behaviour of the vectors was analysed to evaluate the appropriateness of insecticide-impregnated bed nets and residual house spraying in vector control. Anopheles dirus A was highly anthropophilic at all sites where it occurred. By contrast, the degree of anthropophily exhibited by An. minimus A depended on availability of cattle. Anopheles campestris, An. nimpe, An. sinensis, An. maculatus, An. aconitus showed a high degree of anthropophily in certain villages, indicating their potential of participating in malaria transmission, although the actual incidence of malaria in the study villages can be fully explained by transmission of the major vectors (An. dirus A, An. minimus A and An. sundaicus). Late biting of An. minimus A and biting activity throughout the night of An. sundaicus favour bed nets as a control method for these species, whilst exophilic and outdoor biting in combination with early feeding behaviour of An. dirus A will make both insecticide-impregnated bed nets and indoor residual spraying less suitable for controlling this species. Spatial variation in biting and resting behaviour was observed within almost all Anopheles species. These heterogeneities may result in the differences in epidemiological importance and in response to vector control of Anopheles species in different areas. Moreover, environmental changes and changes in human practice are expected to influence the behaviour, hence the role of the different species in malaria transmission. The effect of environmental changes on vector behaviour should be followed up carefully.	Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium; Natl Inst Malariol Parasit & Entomol, Hanoi, Vietnam; Natl Ctr Malaria Control Parasitol & Entomol, Phnom Penh, Cambodia; Int Water Management Inst, Colombo, Sri Lanka	Coosemans, M (reprint author), Inst Trop Med Prince Leopold, Natl Str 155, B-2000 Antwerp, Belgium.	entomology@fpt.vn; wvbortel@itg.be; sochanthat@cnm.gov.kh; kalou@laomails.com; o.briet@cgiar.org; mcoosemans@itg.be	Briet, Olivier/K-1917-2015	Briet, Olivier/0000-0003-1186-2688			AM NT, 1993, B SOC PATHOL EXOT, V86, P494; AMERASINGHE FP, 1991, AM J TROP MED HYG, V45, P226, DOI 10.4269/ajtmh.1991.45.226; BRUCECHWATT LJ, 1966, B WORLD HEALTH ORGAN, V35, P405; Costantini C, 1999, PARASSITOLOGIA, VOL 41, NOS 1-3, SEPTEMBER 1999, P209; Covell G., 1944, JOUR MALARIA INST INDIA, V5, P399; ELLIOTT R, 1968, B WORLD HEALTH ORGAN, V38, P239; Erhart A, 2004, TROP MED INT HEALTH, V9, P1081, DOI 10.1111/j.1365-3156.2004.01310.x; Erhart A, 2004, AM J TROP MED HYG, V70, P110, DOI 10.4269/ajtmh.2004.70.110; GIGLIOLI G, 1963, B WORLD HEALTH ORGAN, V29, P131; Gillies M. T., 1988, Malaria: principles and practice of malariology. Volume 1., P453; HARRISON B A, 1980, Contributions of the American Entomological Institute, V17, P1; HIHN TD, 1997, ANN SCI WORKS, V1, P287; HINH TD, 1987, ANN SCI WORKS, V1, P199; HINH TD, 2000, MEKONG MALARIA FORUM, V6, P64; *IMPE, 1987, KEYS AN VIETN AD PUP; Klowden Marc J., 1996, P34; Maheswary N. P., 1992, Southeast Asian Journal of Tropical Medicine and Public Health, V23, P798; Manguin S, 2002, MED VET ENTOMOL, V16, P46, DOI 10.1046/j.0269-283x.2002.00344.x; PHAN VT, 1998, EPIDEMIOLOGIE PALUDI; PHAN VT, 1936, ANN SCI WORKDS, P194; ROSENBERG R, 1982, AM J TROP MED HYG, V31, P183, DOI 10.4269/ajtmh.1982.31.183; SCANLON JOHN E., 1965, J MED ENTOMOL, V2, P61; Service MW, 1993, MOSQUITO ECOLOGY FIE; THUAN LK, 1997, ANN SCI WORKS, V1, P316; Trung HD, 2004, TROP MED INT HEALTH, V9, P230, DOI 10.1046/j.1365-3156.2003.01179.x; Van Bortel W, 2000, INSECT MOL BIOL, V9, P335, DOI 10.1046/j.1365-2583.2000.00192.x; Van Bortel W, 2004, J MED ENTOMOL, V41, P366, DOI 10.1603/0022-2585-41.3.366; Verle P., 1998, Research and Reviews in Parasitology, V58, P169; VIEN NT, 1974, ANN SCI WORKS, V2, P12; WILKINSON RN, 1978, J MED ENTOMOL, V14, P666, DOI 10.1093/jmedent/14.6.666	30	100	103	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	MAR	2005	10	3					251	262		10.1111/j.1365-3156.2004.01378.x				12	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	900AT	WOS:000227188500009	15730510	Bronze			2019-03-26	
J	Donnelly, MJ; McCall, PJ; Lengeler, C; Bates, I; D'Alessandro, U; Barnish, G; Konradsen, F; Klinkenberg, E; Townson, H; Trape, JF; Hastings, IM; Mutero, C				Donnelly, MJ; McCall, PJ; Lengeler, C; Bates, I; D'Alessandro, U; Barnish, G; Konradsen, F; Klinkenberg, E; Townson, H; Trape, JF; Hastings, IM; Mutero, C			Malaria and urbanization in sub-Saharan Africa	MALARIA JOURNAL			English	Article							URBAN; MANAGEMENT	There are already 40 cities in Africa with over 1 million inhabitants and the United Nations Environmental Programme estimates that by 2025 over 800 million people will live in urban areas. Recognizing that malaria control can improve the health of the vulnerable and remove a major obstacle to their economic development, the Malaria Knowledge Programme of the Liverpool School of Tropical Medicine and the Systemwide Initiative on Malaria and Agriculture convened a multi-sectoral technical consultation on urban malaria in Pretoria, South Africa from 2nd to 4th December, 2004. The aim of the meeting was to identify strategies for the assessment and control of urban malaria. This commentary reflects the discussions held during the meeting and aims to inform researchers and policy makers of the potential for containing and reversing the emerging problem of urban malaria.	Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England; Swiss Trop Inst, CH-4002 Basel, Switzerland; Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium; Int Water Management Inst Sri Lanka 127, Pelawatte, Battaramulla, Sri Lanka; Univ Copenhagen, Inst Publ Hlth, Dept Int Hlth, DK-32200 Copenhagen, Denmark; Int Water Management Inst W Africa, Cantonments, Accra, Ghana; Inst Rech Dev, Dakar, Senegal; Int Water Management Inst, Syst Wide Initiat Malaria & Agr, ZA-0127 Silverton, South Africa	Donnelly, MJ (reprint author), Univ Liverpool, Liverpool Sch Trop Med, Pembroke Pl, Liverpool L3 5QA, Merseyside, England.	m.j.donnelly@liv.ac.uk; mccall@liv.ac.uk; Christian.Lengeler@unibas.ch; ibates@liverpool.ac.uk; udalessandro@itg.be; gbarnish@liv.ac.uk; f.konradsen@pubhealth.ku.dk; e.klinkenberg@cgiar.org; htownson@liv.ac.uk; Jean-Francois.Trape@ird.sn; hastings@liv.ac.uk; c.mutero@cgiar.org	D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009; Donnelly, Martin/0000-0001-5218-1497; McCall, Philip/0000-0002-0007-3985; Konradsen, Flemming/0000-0003-1036-6949			Amexo M, 2004, LANCET, V364, P1896, DOI 10.1016/S0140-6736(04)17446-1; Bates I, 2004, LANCET INFECT DIS, V4, P267, DOI 10.1016/S1473-3099(04)01002-3; COENE J, 1993, MED VET ENTOMOL, V7, P127, DOI 10.1111/j.1365-2915.1993.tb00665.x; Conteh L, 2004, TROP MED INT HEALTH, V9, P125, DOI 10.1046/j.1365-3156.2003.01150.x; D'Alessandro U, 2005, TROP MED INT HEALTH, V10, P1, DOI 10.1111/j.1365-3156.2004.01375.x; FEILDEN RM, 1996, EXPERIENCES IMPLEMEN; Holtz TH, 2002, TROP MED INT HEALTH, V7, P220, DOI 10.1046/j.1365-3156.2002.00846.x; Keiser J, 2004, AM J TROP MED HYG, V71, P118, DOI 10.4269/ajtmh.2004.71.118; KLINKENBERG E, 2004, AM J TROP MED HYG, P9; Konradsen F, 1998, ACTA TROP, V71, P131, DOI 10.1016/S0001-706X(98)00060-6; McCombie SC, 1996, SOC SCI MED, V43, P933, DOI 10.1016/0277-9536(95)00446-7; Robert V, 2003, AM J TROP MED HYG, V68, P169, DOI 10.4269/ajtmh.2003.68.169; Sharp B, 2002, TROP MED INT HEALTH, V7, P732, DOI 10.1046/j.1365-3156.2002.00928.x; WARREN M, 1999, 71 EHP; World Health Organization (WHO), 2001, MACR HLTH INV HLTH E	15	74	77	0	15	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1475-2875			MALARIA J	Malar. J.	FEB 18	2005	4								12	10.1186/1475-2875-4-12				5	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	910RV	WOS:000227950800001	15720713	DOAJ Gold, Green Published			2019-03-26	
J	Van Benthem, BHB; Vanwambeke, SO; Khantikul, N; Burghoorn-Maas, C; Panart, K; Oskam, L; Lambin, EF; Somboon, P				Van Benthem, BHB; Vanwambeke, SO; Khantikul, N; Burghoorn-Maas, C; Panart, K; Oskam, L; Lambin, EF; Somboon, P			Spatial patterns of and risk factors for seropositivity for dengue infection	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							PRIMARY-SCHOOL CHILDREN; AEDES-ALBOPICTUS; HEMORRHAGIC-FEVER; VIRUS-INFECTION; KAMPHAENG PHET; THAILAND; LARVAE; EPIDEMIOLOGY; VECTORS; AEGYPTI	Spatial patterns of and risk factors for seropositivity of dengue infection were studied in three sites in northern Thailand. A survey was conducted in 2001 among 1,750 persons. Potential risk factors for dengue infection were measured by questionnaire and IgM antibodies against dengue were detected by an enzyme-linked immunosorbent assay. The role of landscape as a risk factor was studied using land cover maps and a geographic information system. Logistic regression identified risk factors for dengue seropositivity. Spatial patterns of seropositive cases were determined by cluster analyses. Six percent of the study population was seropositive. Risk factors for dengue seropositivity differed per site. demonstrating variation in local infection patterns. In the periurban site, seropositivity depended on human behavior and factors related to housing quality rather than environmental factors. In both rural sites, older persons had a higher risk of seropositivity and persons living in houses surrounded by natural and agricultural land covers had a lower risk of seropositivity.	Koninklijk Inst Tropen Royal Inst, Biomed Res, Amsterdam, Netherlands; Catholic Univ Louvain, Dept Geog, Louvain, Belgium; Off Vecotr Borne Dis Control 2, Chiang Mai, Thailand; Erasmus Univ, Inst Virol, Rotterdam, Netherlands; Chiang Mai Univ, Fac Med, Dept Parasitol, Chiang Mai 50000, Thailand	Van Benthem, BHB (reprint author), Koninklijk Inst Tropen Royal Inst, Biomed Res, Amsterdam, Netherlands.	b.v.benthem@kit.nl; vanwambeke@gorg.ucl.ae.be; ornardlada@hotmail.com; c.maas@erasmusmc.nl; malar@chmai.loxinfo.co.th; l.oskam@kit.nl; lambin@geog.ucl.ac.be; psomboon@mail.med.cmu.ac.th		Vanwambeke, Sophie/0000-0001-6620-6173; Somboon, Pradya/0000-0002-0760-4363			Bartley LM, 2002, EPIDEMIOL INFECT, V128, P213, DOI 10.1017/S0950268801006495; BURKE DS, 1988, AM J TROP MED HYG, V38, P172, DOI 10.4269/ajtmh.1988.38.172; CHAN YC, 1971, B WORLD HEALTH ORGAN, V44, P651; Chareonsook O, 1999, EPIDEMIOL INFECT, V122, P161, DOI 10.1017/S0950268898001617; Cummings DAT, 2004, NATURE, V427, P344, DOI 10.1038/nature02225; DeRoeck D, 2003, VACCINE, V22, P121, DOI 10.1016/S0264-410X(03)00533-4; Endy TP, 2002, AM J EPIDEMIOL, V156, P52, DOI 10.1093/aje/kwf006; Endy TP, 2002, AM J EPIDEMIOL, V156, P40, DOI 10.1093/aje/kwf005; Groen J, 2000, CLIN DIAGN LAB IMMUN, V7, P867, DOI 10.1128/CDLI.7.6.867-871.2000; Gubler DJ, 2003, LANCET INFECT DIS, V3, P751, DOI 10.1016/S1473-3099(03)00826-0; Hay SI, 1997, INT J REMOTE SENS, V18, P2899, DOI 10.1080/014311697217125; KITTAYAPONG P, 1993, J MED ENTOMOL, V30, P601, DOI 10.1093/jmedent/30.3.601; Kuldorff M, 1995, STAT MED, V14, P799; Lounibos LP, 2003, ECOL ENTOMOL, V28, P551, DOI 10.1046/j.1365-2311.2003.00543.x; *MIN PUBL HLTH DEP, 2000, COMM DIS CONTR THAIL; *MIN PUBL HLTH DIV, 1989, ANN EP SURV REP, P67; Muttitanon W., 1997, SPATIAL TEMPORAL DYN; Reiskind MH, 2001, TROP MED INT HEALTH, V6, P212, DOI 10.1046/j.1365-3156.2001.00703.x; Strickman D, 2002, AM J TROP MED HYG, V67, P247, DOI 10.4269/ajtmh.2002.67.247; Strickman D, 2000, AM J TROP MED HYG, V63, P27, DOI 10.4269/ajtmh.2000.63.27; van Benthem BHB, 2002, TROP MED INT HEALTH, V7, P993, DOI 10.1046/j.1365-3156.2002.00950.x; Vazeille M, 2003, AM J TROP MED HYG, V68, P203, DOI 10.4269/ajtmh.2003.68.203; WELLMER H, 1983, DENGUE HAEMORRHAGIC, P1; World Health Organization, 1997, DENG HAEM FEV DIAGN; Zeller HG, 1998, B SOC PATHOL EXOT, V91, P56	25	59	60	0	7	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637	1476-1645		AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	FEB	2005	72	2					201	208		10.4269/ajtmh.2005.72.201				8	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	903CE	WOS:000227402200016	15741558				2019-03-26	
J	Checchi, F; Roddy, P; Kamara, S; Williams, A; Morineau, G; Wurie, AR; Hora, B; de Lamotte, N; Baerwaldt, T; Heinzelmann, A; Danks, A; Pinoges, L; Oloo, A; Durand, M; Ranford-Cartwright, L; de Smet, M				Checchi, F; Roddy, P; Kamara, S; Williams, A; Morineau, G; Wurie, AR; Hora, B; de Lamotte, N; Baerwaldt, T; Heinzelmann, A; Danks, A; Pinoges, L; Oloo, A; Durand, M; Ranford-Cartwright, L; de Smet, M		Sierra Leone Antimalarial	Evidence basis for antimalarial policy change in Sierra Leone: five in vivo efficacy studies of chloroquine, sulphadoxine-pyrimethamine and amodiaquine	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						Plasmodium falciparum; malaria; Sierra Leone; efficacy; chloroquine; sulphidoxine-pyrimethamine amodiaquine; artesunate; policy	PLASMODIUM-FALCIPARUM MALARIA; COMBINATION THERAPY; WESTERN KENYA; RESISTANCE; CHILDREN; ARTESUNATE; AFRICA; LIBERIA; HARPER	OBJECTIVES To provide nationally relevant information on the antimalarial efficacy of chloroquine (CQ), sulphadoxine-pyrimethamine (SP) and amodiaquine (AQ) in Sierra Leone, with a view to updating antimalarial policy in the country. METHODS Between October 2002 and May 2003, standard WHO methodology for in vivo efficacy assessment was used in five sites to study the therapeutic response of 6-59 months old uncomplicated Plasmodium falciparum malaria cases treated with CQ (n - 247), SP (it - 353) or AQ (n - 434). Follow-up was of 28 days, with polymerase chain reaction genotyping to distinguish late recrudescences from re-infections. RESULTS Overall 85.3% of patients reached an analysable endpoint. CQ failure proportions were very high, ranging from 39.5% (95%, CI: 25.0-5-5.6) in Kabala to 78.8% (65.3-88.9) in Kailahun. Early failures under CQ were frequent. SP efficacy was also disappointing, with failure from 23.2% (13.9-34.9) in Kabala to 46.1 %, (35.4-57.0) in Kailahun. AQ resistance was more moderate, ranging from 5.4% (1.8-12.1) in Makeni to 29.8% (20.3-40.8) in Kailahun, with almost no early failures. AQ also provided more rapid fever and parasite clearance. CONCLUSION In a consensus meeting organized by the Ministry of Health and Sanitation, and based on these findings, artesunate (AS) + AQ and artemether-lumefantrine (Coartem(TM)) were identified as the only options to rapidly replace CQ. The choice fell on AS + AQ because of expected high efficacy, lower cost in a blister presentation, and the absence of safety data on artemether-lumefantrine in pregnancy. Donor support is required to support this policy change. Throughout Africa, as SP resistance increases, these two regimens are probably the only options available while newer combinations are developed. Efficacy studies should focus on testing AQ and AS + AQ.	EpiCtr, Paris, France; Med Sans Frontieres Belgium, Brussels, Belgium; Med Sans Frontieres Holland, Amsterdam, Netherlands; Med Sans Frontieres France, Paris, France; Minist Hlth & Sanitat, Freetown, Sierra Leone; WHO, Freetown, Sierra Leone; Concern Worldwide, Freetown, Sierra Leone; WHO Reg Off Africa, Harare, Zimbabwe; Hop Xavier Bichat, Lab Parasitol Mycol, Paris, France; Univ Glasgow, Inst Biomed & Life Sci, Div Infect & Immun, Glasgow G12 8QQ, Lanark, Scotland; Med Sans Frontieres, Malaria Working Grp, Brussels, Belgium	Checchi, F (reprint author), EpiCtr, Paris, France.	francesco.checchi@lshtm.ac.uk; roddypd@yahoo.com; guy.morineau@laposte.net; wuriear@who-sl.org; bonahora@who-sl.org; nadine.de.lamotte@brussels.msf.org; msfh-sl-cm@amsterdam.msf.org; annette.heinzelmann@paris.msf.org; alisonnamu@hotmail.com; lpinoges@epicentre.msf.org; olooa@afro.who.int; remy.durand@avc.ap-hop-paris.fr; l.cranford-cartwright@bio.gla.ac.uk; martin.de.smet@brussels.msf.org	Ranford-Cartwright, Lisa/H-4701-2013	Ranford-Cartwright, Lisa/0000-0003-1992-3940			Adjuik M, 2004, LANCET, V363, P9; Adjuik M, 2002, LANCET, V359, P1365, DOI 10.1016/S0140-6736(02)08348-4; BACHY C, 2002, VIVO STUDY EFFICACY; BAKSHI R, 2000, T ROY SOC TROP MED H, V96, P418; BARNISH G, 1993, ANN TROP MED PARASIT, V87, P137, DOI 10.1080/00034983.1993.11812747; Barnish G, 1993, Parassitologia, V35 Suppl, P1; Bjorkman A, 2002, INT J PARASITOL, V32, P1637, DOI 10.1016/S0020-7519(02)00192-3; Bousema JT, 2003, TROP MED INT HEALTH, V8, P427, DOI 10.1046/j.1365-3156.2003.01047.x; Checchi F, 2002, T ROY SOC TROP MED H, V96, P670, DOI 10.1016/S0035-9203(02)90348-2; Checchi F, 2002, T ROY SOC TROP MED H, V96, P664, DOI 10.1016/S0035-9203(02)90346-9; *MIN HLTH SAN PART, 2004, NAT STRAT PLAN ROLL; Nosten F, 2002, DRUGS, V62, P1315, DOI 10.2165/00003495-200262090-00003; Olliaro PL, 2003, J EXP BIOL, V206, P3753, DOI 10.1242/jeb.00653; Olumese PE, 2002, T ROY SOC TROP MED H, V96, P418, DOI 10.1016/S0035-9203(02)90378-0; Ranford-Cartwright LC, 1997, T ROY SOC TROP MED H, V91, P719, DOI 10.1016/S0035-9203(97)90539-3; Rapuoda B, 2003, TROP MED INT HEALTH, V8, P860; Rwagacondo CE, 2004, TROP MED INT HEALTH, V9, P1091, DOI 10.1111/j.1365-3156.2004.01316.x; Snounou G, 1999, T ROY SOC TROP MED H, V93, P369, DOI 10.1016/S0035-9203(99)90120-7; Stepniewska K, 2004, ANTIMICROB AGENTS CH, V48, P4271, DOI 10.1128/AAC.48.11.4271-4280.2004; Talisuna AO, 2002, T ROY SOC TROP MED H, V96, P310, DOI 10.1016/S0035-9203(02)90108-2; Talisuna AO, 2004, CLIN MICROBIOL REV, V17, P235, DOI 10.1128/CMR.17.1.235-254.2004; Trape JF, 2001, AM J TROP MED HYG, V64, P12, DOI 10.4269/ajtmh.2001.64.12; van Vugt M, 1999, AM J TROP MED HYG, V60, P936, DOI 10.4269/ajtmh.1999.60.936; WHO, 2003, ASS MON ANT DRUG EFF; *WHO, 2003, POS WHOS ROLL BACK M; Zucker JR, 2003, AM J TROP MED HYG, V68, P386, DOI 10.4269/ajtmh.2003.68.386	26	30	31	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	FEB	2005	10	2					146	153		10.1111/j.1365-3156.2004.01367.x				8	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	897OB	WOS:000227013400005	15679557	Bronze			2019-03-26	
J	Getahun, H; Lambein, F; Vanhoorne, M; Van der Stuyft, P				Getahun, H; Lambein, F; Vanhoorne, M; Van der Stuyft, P			Neurolathyrism risk depends on type of grass pea preparation and on mixing with cereals and antioxidants	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						lathyrism; Ethiopia; grass pea; antioxidants	LATHYRUS-SATIVUS; ETHIOPIA; BRAIN; EPIDEMIC; DISEASE; BOAA	OBJECTIVE To study an array of household individual and dietary risk factors for neurolathyrism. METHOD Case-control stud), using recent cases in a district highly affected by the recent neurolathyrism epidemic in Ethiopia: 108 households with cases and 404 households with no cases; 170 neurolathyrism cases, 370 intra-family controls and 170 community controls frequency matched for age and sex. RESULTS A history of acute illness was associated with a two- and threefold increased risk of paralysis in community and intra-family controls, respectively. Soaking grass pea in water before cooking roughly halved the risk of neurolathyrism but cooking in clay utensils more than quadrupled it. Consumption of grass pea in the green unripe and boiled forms increased the risk 10 times or more. Mixing the food with gravy that contains condiments with antioxidant activity reduced it by a factor of 4. The consumption of grass pea mixed with cereals rich in sulphur amino acids was also highly protective, but the magnitude of the effect depended on the grass pea preparation consumed. CONCLUSION Consumption of pure grass pea, especially in the green unripe and boiled forms, should be avoided. Communities at risk of neurolathyrism during famine crises should be encouraged to combine and use grass pea with cereals before the household cereal stock is fully depleted. Breeding programmes, alongside traditional attempts to reduce the toxin content, should enhance the content of sulphur amino acids and antioxidants in grass pea.	State Univ Ghent, Fac Med & Hlth Sci, Physiol Chem Lab, B-9000 Ghent, Belgium; State Univ Ghent, Fac Med & Hlth Sci, Dept Publ Hlth, B-9000 Ghent, Belgium; Inst Trop Med, Epidemiol Unit, B-2000 Antwerp, Belgium; S Gondar Hlth Dept, Debre Tabor, Ethiopia	Getahun, H (reprint author), Rue Liotard 48, CH-1202 Geneva, Switzerland.	getahunh@who.int; fernand.lambein@ugent.be; Michael.vanhoorne@ugent.be; pvds@itg.be					AMARA A, 1995, NEUROSCI LETT, V185, P147, DOI 10.1016/0304-3940(95)11246-S; Chu YF, 2002, J AGR FOOD CHEM, V50, P6910, DOI 10.1021/jf020665f; FALCO E, 2000, LATHYRUS LATHYRISM N, V1, P27; Gebre-ab T, 1978, Ethiop Med J, V16, P1; Getahun H, 2002, TROP MED INT HEALTH, V7, P118, DOI 10.1046/j.1365-3156.2002.00836.x; Getahun H, 1999, LANCET, V354, P306, DOI 10.1016/S0140-6736(99)02532-5; Getahun H, 1998, ETHIOPIAN MED J, V36, P9; HAIMANOT RT, 1990, INT J EPIDEMIOL, V19, P664, DOI 10.1093/ije/19.3.664; Haque A, 1996, NEUROEPIDEMIOLOGY, V15, P83, DOI 10.1159/000109893; KESSLER A, 1947, MONATSCHRIFT PSYCHIA, V113, P41; Kleinbaum DG, 1998, APPL REGRESSION ANAL; KUO YH, 1995, J SCI FOOD AGR, V69, P81, DOI 10.1002/jsfa.2740690113; LAMBEIN F, 1994, TOXICON, V32, P461, DOI 10.1016/0041-0101(94)90298-4; McCracken KJ, 2002, BRIT POULTRY SCI, V43, P253, DOI 10.1080/00071660120121472; MERA M, 2000, LATHYRUS LATHYRISM N, V1, P31; MILCZAK M, 2001, LATHYRUS LATHYRISM N, V2, P85; PAI KS, 1993, BRAIN RES, V621, P215, DOI 10.1016/0006-8993(93)90109-Z; ROLDAN SG, 1994, NUTRITION NEUROTOXIN; ROSS SM, 1987, BRAIN RES, V425, P120, DOI 10.1016/0006-8993(87)90490-2; SPENCER PS, 1986, LANCET, V2, P1066, DOI 10.1016/S0140-6736(86)90468-X; SPENCER PS, 1983, NEUROBEH TOXICOL TER, V5, P625; Sriram K, 1998, J NEUROSCI, V18, P10287; STREIFLER M, 1977, NEUROLOGY, V27, P1176; 2001, HAZARAJAT ASSISTANCE, V2, P14	24	30	31	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	FEB	2005	10	2					169	178		10.1111/j.1365-3156.2004.01370.x				10	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	897OB	WOS:000227013400008	15679560				2019-03-26	
J	Ouendo, EM; Makoutode, M; Paraiso, MN; Wilmet-Dramaix, M; Dujardin, B				Ouendo, EM; Makoutode, M; Paraiso, MN; Wilmet-Dramaix, M; Dujardin, B			Therapeutic itinerary of indigent patients in Benin - Poverty and health care	TROPICAL MEDICINE & INTERNATIONAL HEALTH			French	Article						indigents; type of instance; therapeutic itinerary; Benin		OBJECTIVE There is great risk of excluding the poor in a system where patients are charged for medical care. Our objective was to identify the stages of the therapeutic itinerary of poor and nonpoor patients in case of illness. METHOD Prospective study over 12 months, in 16 sites selected randomly after dividing the territory of Benin into four strata. The sample included 1312 households (668 poor and 644 nonpoor) and 9554 people. Those who were ill during the study period were interviewed on the therapeutic itinerary chosen. RESULTS A total of 1959 (20.5%, of whom 1091 were poor) of the 9554 people in our sample experienced at least one episode of illness. The nonpoor chose the health centres in the first instance more frequently than the poor (26.3% us. 20%; P < 0.001); but the first choice of most patients (66.4% of poor and 63.9% of the nonpoor patients) was modern or traditional self-medication. Within the strata (regions), indigents and nonpoor in the urban region and the north chose different treatments in the first instance (P < 0.001). Apart from the first treatment chosen, no significant difference was observed between the therapeutic satisfaction of both groups. Patients unsatisfied with the first step of treatment were essentially those who used traditional or modern self-medication. Despite this, modern and traditional self-medication remain the most frequent second step choice for both poor and nonpoor patients. CONCLUSION The main difference between poor and nonpoor people's therapeutic itinerary is that nonpoor people more often use state health facilities first than the poor.	Inst Reg Sante Publ, Unite Rech, Ouidah, Benin; Free Univ Brussels, Ecole Sante Publ, Dept Biostat, B-1050 Brussels, Belgium; Free Univ Brussels, Ecole Sante Publ, Unite Polit & Programmes Sante Pays Dev, B-1050 Brussels, Belgium	Ouendo, EM (reprint author), Inst Reg Sante Publ, Unite Rech, Ouidah, Benin.	eouendo@vahoo.fr; miwilmer@u1b.ac.be; bruno.dujardin@ulb.ac.be					BENNETT S, 2001, HLTH FINANCING DESIG; BLUNDO G., 2001, POLITIQUE AFRICAINE, V83, P8; DELAROQUE M, 1996, CAHIERS SANTE, V6, P341; Fourn L, 2001, Sante Publique, V13, P161; GILSON L, 1999, PROMOTING EQUITY COM; *INSAE, 2002, ENQUETE DEMOGRAPHIQU; JAFFRE Y, 2001, DYSFONCTIONNEMENTS S; Jaffre Y., 2003, MED INHOSPITALIERE D; MONITEILLET N, 1999, LIT APAD B, V17, P95; *ORG MOND SANT, 1978, SOINS SANT PRIM RAPP; *ORG MOND SANT, 1988, ID DIR MIS OEUVR IN; OUENDO EM, 2003, FINANCEMENT SANTE PA, P119; *PROGR NAT UN DEV, 1997, RAPP DEV HUM BEN; SODOGANDJI TH, 1988, PUBLICATIONS MINISTE, P1; TOVO M, 1995, RED PAUV BEN VERS ST; VISSOH G, 1995, ENQUETE PERCEPTION S; WAELKENS MP, 1999, EXEMPTIONS COST RECO	17	8	8	1	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	FEB	2005	10	2					179	186		10.1111/j.1365-3156.2004.01371.x				8	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	897OB	WOS:000227013400009	15679561				2019-03-26	
J	Alain, N; Anneitte, E; Dorothee, G; Carine, A; Aurore, O; Chantal, O; Martin, A; Achille, M; Umberto, D				Alain, N.; Anneitte, E.; Dorothee, G.; Carine, A.; Aurore, O.; Chantal, O.; Martin, A.; Achille, M.; Umberto, D.			Evolution du paludisme simple a P. falciparu sous 3 traitements chez les enfants d'une cohorte en milieu cotier lagunaire an Benin [MIM-NA-38313]	ACTA TROPICA			English	Meeting Abstract									Ctr Rech Entomol Cotonou, Cotonou, Benin; Univ Abomey Calavi, Fac Sci Sante, Unite Enseignement & Rech Parasitol Mycol, Cotonou, Benin; Inst Med Trop Anvers, Antwerp, Belgium								0	0	0	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0001-706X			ACTA TROP	Acta Trop.		2005	95						S337	S337						1	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	V80CY	WOS:000205415600541					2019-03-26	
J	Atemnkeng, M; Plazier-Vercammen, J				Atemnkeng, M.; Plazier-Vercammen, J.			Underdosage of artemisinin-derivative antimalarials in Kenya and Congo DR [MIM-MA-219240]	ACTA TROPICA			English	Meeting Abstract									[Atemnkeng, M.; Plazier-Vercammen, J.] Vrije Univ Brussels, Dept Pharmaceut Technol & Phys Pharm, Inst Pharmaceut, Brussels, Belgium								0	0	0	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0001-706X			ACTA TROP	Acta Trop.		2005	95						S339	S339						1	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	V80CY	WOS:000205415600544					2019-03-26	
J	Baza, D; Karenzo, J; Protopopoff, N; Maes, P; Coosemans, M				Baza, D.; Karenzo, J.; Protopopoff, N.; Maes, P.; Coosemans, M.			Prevention of malaria outbreaks in Burundi Highlands, Karuzi Province [MIM-DB-2502500]	ACTA TROPICA			English	Meeting Abstract									Programme Lutte Malad Transmissibles & Carentiell, Bujumbura, Burundi; Inst Trop Med, Dept Parasitol, B-2000 Antwerp, Belgium; Med Sans Frontieres, B-1090 Brussels, Belgium		bazadismas@yahoo.fr; karenzoj@yahoo.fr; nprotopopoff@itg.be; peter.maes@msf.be; mcoosemans@itg.be						0	0	0	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0001-706X			ACTA TROP	Acta Trop.		2005	95						S125	S125						1	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	V80CY	WOS:000205415600190					2019-03-26	
J	Geertruyden, J; Mwananyanda, L; Chalwe, V; Moerman, F; Chilengi, R; Kestens, L; D'alessandro, U				Geertruyden, J.; Mwananyanda, L.; Chalwe, V.; Moerman, F.; Chilengi, R.; Kestens, L.; D'alessandro, U.			Higher risk of antimalarial treatment failure in HIV positive than in HIV negative individuals with clinical malaria [MIM-LM-234960]	ACTA TROPICA			English	Meeting Abstract									Trop Dis Res Ctr, Ndola, Zambia; Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium			D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009				0	1	1	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0001-706X			ACTA TROP	Acta Trop.		2005	95						S253	S253						1	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	V80CY	WOS:000205415600403					2019-03-26	
J	Gies, S; Coulibaly, S; Dalessandro, U				Gies, S.; Coulibaly, S.; Dalessandro, U.			The burden of malaria in primi- and secundigravidae in Boromo health district, Burkina Faso [MIM-sg-222015]	ACTA TROPICA			English	Meeting Abstract									Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium; Lab Natl Sante Publ, Ouagadougou, Burkina Faso								0	0	0	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0001-706X			ACTA TROP	Acta Trop.		2005	95						S103	S103						1	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	V80CY	WOS:000205415600158					2019-03-26	
J	Karema, C; Fanello, C; Doren, W; Rwagacondo, C; Overmeir, C; Dujardin, J; Alessandro, U				Karema, C.; Fanello, C.; Doren, W.; Rwagacondo, C.; Overmeir, C.; Dujardin, J.; Alessandro, U.			Safety and efficacy of dihydroartemisinin-piperaquine in Rwandan children with uncomplicated P-falciparum malaria [MIM-CK-70620]	ACTA TROPICA			English	Meeting Abstract									Programme Natl Integre Lutte Paludisme, Kigali, Rwanda; Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium								0	0	0	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0001-706X			ACTA TROP	Acta Trop.		2005	95						S243	S244						2	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	V80CY	WOS:000205415600387					2019-03-26	
J	Kilian, A; Byamukama, W; Pigeon, O; Atieli, F; Rubaale, T				Kilian, A.; Byamukama, W.; Pigeon, O.; Atieli, F.; Rubaale, T.			Field performance of the improved, second generation PermaNet (R), a polyester based long-lasting insecticidal mosquito net [MIM-AK-20898]	ACTA TROPICA			English	Meeting Abstract									USAID, Kampala, Uganda; Ctr Dis Control, Kampala, Uganda; Kabarole Dist Hlth Serv, Ft Portal, Uganda; Agr Res Ctr, Gembloux, Belgium; Ctr Dis Control, Atlanta, GA 30333 USA; GTZ Basic Hlth Serv, Ft Portal, Uganda								0	0	0	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0001-706X			ACTA TROP	Acta Trop.		2005	95						S493	S494						2	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	V80CY	WOS:000205415600797					2019-03-26	
J	Talisuna, A; Erhart, A; Samarasinghe, S; Overmeir, C; Speybroeck, N; Alessandro, U				Talisuna, A.; Erhart, A.; Samarasinghe, S.; Overmeir, C.; Speybroeck, N.; Alessandro, U.			Malaria transmission intensity and the evolution of chloroquine resistant Plasmodium falciparum: Why have theoretical models generated conflicting results? [MIM-UD-103581]	ACTA TROPICA			English	Meeting Abstract									Minist Hlth, Epidemiol Surveillance Div, Kampala, Uganda; Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium								0	0	0	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0001-706X			ACTA TROP	Acta Trop.		2005	95						S340	S341						2	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	V80CY	WOS:000205415600547					2019-03-26	
J	Thera, M; Doumbo, O; Coulibaly, D; Diallo, D; Sagara, I; Heppner, G; Soisson, L; Leach, A; Lyke, K; Plowe, C				Thera, M.; Doumbo, O.; Coulibaly, D.; Diallo, D.; Sagara, I.; Heppner, G.; Soisson, L.; Leach, A.; Lyke, K.; Plowe, C.			Safety and immunogenicity of the WRAIR and GSK biologicals' malaria vaccine candidate AMA-1/AS02A versus rabies vaccine in adults in Bandiagara, Mali [MIM-MT-9315]	ACTA TROPICA			English	Meeting Abstract									Univ Bamako, Malaria Res & Training Ctr, Bamako, Mali; Walter Reed Army Inst Res, Silver Spring, MD USA; USAID, Washington, DC USA; GlaxoSmithKline Biol, Rixensart, Belgium; Univ Maryland, Sch Med, Baltimore, MD 21201 USA								0	0	0	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0001-706X			ACTA TROP	Acta Trop.		2005	95						S85	S85						1	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	V80CY	WOS:000205415600129					2019-03-26	
J	Tinto, H; Rwagacondo, C; Karema, C; Mupfasoni, D; Rusanganwa, E; Vandoren, W; Erhart, A; Overmeir, C; Marck, E; D'alessandro, U				Tinto, H.; Rwagacondo, C.; Karema, C.; Mupfasoni, D.; Rusanganwa, E.; Vandoren, W.; Erhart, A.; Overmeir, C.; Marck, E.; D'alessandro, U.			In vitro susceptibility of Plasmodium falciparum to monodesethylamodiaquin, dihydroartemisinin and quinine in an area of high chloroquine resistance in Rwanda [MIM-HT-263384]	ACTA TROPICA			English	Meeting Abstract									Ctr Muraz, Inst Rech Sci Sante, Bobo Dioulasso, Burkina Faso; Natl Malaria Control Program, Kigali, Rwanda; Lab Natl Sante Publ, Kigali, Rwanda; Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium; Univ Antwerp, Antwerp, Belgium			D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009				0	0	0	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0001-706X			ACTA TROP	Acta Trop.		2005	95						S375	S375						1	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	V80CY	WOS:000205415600604					2019-03-26	
J	Torrico, F; Alonso-Vega, C; Suarez, E; Rodriguez, P; Torrico, MC; Dramaix, M; Truyens, C; Carlier, Y				Torrico, F; Alonso-Vega, C; Suarez, E; Rodriguez, P; Torrico, MC; Dramaix, M; Truyens, C; Carlier, Y			Endemic level of infection by Trypanosoma cruzi in the mother's place of residence and development of congenital Chagas disease in Bolivia	REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL			Spanish	Article; Proceedings Paper	International Colloquium on Congenital Trypanosoma Cruzi Infection - From Mechanisms of Transmission to a Strategy for Diagnosis and Control	NOV 06-08, 2002	COCHABAMBA, BOLIVIA			congenital chagas; level of endemia; clinical; control; newborn; risk epidemiologist; morbidity; mortality	POLYMERASE-CHAIN-REACTION	In Bolivia, the prevalence of infection by T. cruzi in women in fertile age can vary between 20 and 60%. The present study, made in the Maternity German Urquidi of Cochabamba - Bolivia, it has demonstrated, that 19.9% of the mothers who go to this hospitable center to betaken care of in the childbirth, they are carrying of the infection and that 4.6% of them, they are going to transmit, by transplacentaria route, the infection to its babies. Of the 71 children born with congenital Chagas, only 47.8 % present/display some type of alteration or of development(Apgar to 1 minute low, BPN, prematuridad, pathological dismadurez) or signs (SDR, hepatomegalia, esplenomegalia, neurological signs, cardiomegalia, anasarca, petequias). When investigating the effect of the differences in the vectorial density (low, medium and high) of the zone of maternal residence, on the transmission of the infection of the mother infected to the fetus, we concluded that the rate of transmission of the congenital infection of T cruzi is not modified by the level of endemicidad of the zone of maternal residence. By another infected new born sides whose mothers reside in zones of high endemicidad presentl/display most frequently and of significant way, Apgar to 1 minute < to 7, low weight when being born and prematuridad or an association of these alterations with respiratory syndrome of distress or anasarca, when one compares them with new born of resident mothers in the zones of loss or medium endemicidad mortality in this group is greater. These results suggest calls to account it of the mothers, in areas of high endemicidad, she is associate with a serious increase in the risk of Disease of newborn severe and mortal congenital Chagas in.	Univ Mayor San Simon, Fac Med, Ctr Univ Trop Med, CUMETROP,LABIMED, Cochabamba, Bolivia; Univ Libre Bruxelles, Ecole Sante Publ, Lab Stat Med, Brussels, Belgium; Univ Libre Bruxelles, Fac Med, Parasitol Lab, Brussels, Belgium	Torrico, F (reprint author), Univ Mayor San Simon, Fac Med, Ctr Univ Trop Med, CUMETROP,LABIMED, Ave Aniceto Arce 371,Casilla 3023, Cochabamba, Bolivia.	foxtorrico@yahoo.com					Carlier Yves, 2003, Rev. Soc. Bras. Med. Trop., V36, P767, DOI 10.1590/S0037-86822003000600024; AZOGUE E, 1985, T ROY SOC TROP MED H, V79, P176, DOI 10.1016/0035-9203(85)90328-1; BASOMBRLO MA, 1999, MEDICINA B AIRES, P143; Bittencourt A.L., 2000, TRYPANOSOMA CRUZI DO, P16; BITTENCOURT AI, 1976, AM J DIS CHILD, P97; BLANCO SB, 2000, TROP MED INT HEALTH, P293; CARLIER Y, 2002, IN PRESS ENCY MED CH; *CLAP, 2004, CONS OPS ENF CHAG CO; CONTERAS S, 1999, REV SOC BRAS MED TRO, P633; DIAS JCP, 2000, TRYPANOSOMA CRUZI DO, P48; Freilij H., 1983, Journal of Clinical Microbiology, V18, P327; FREILIJ H, 1995, CLIN INFECT DIS, V21, P551, DOI 10.1093/clinids/21.3.551; HERMANN E, 2002, BLOOD, P2153; HOWARD J, 1968, B CHIL PARADITOL, P107; HOWARD JE, 1975, PAN AM HLTH ORG SCI, P212; Moya P., 1997, CLIN TERAPEUTICA DOE, P383; MOYA PR, 1979, REV FAC CIENC MED CO, P21; Remington J. S., 2001, INFECT DIS FETUS NEW, P205; Russomando G, 1998, AM J TROP MED HYG, V59, P487, DOI 10.4269/ajtmh.1998.59.487; SCHMUNIS GA, 1977, MEDICINA B AIRES, P47; STREIGER M, 1995, MEDICINA B AIRES, P125; Virreira M, 2003, AM J TROP MED HYG, V68, P574, DOI 10.4269/ajtmh.2003.68.574; VOTTA RA, 1974, ENFERMEDAD CHAGAS EM, P56	23	14	16	2	3	SOCIEDADE BRASILEIRA MEDICINA TROPICAL	BRASILIA	UNIV BRASILIA, NUCLEO MEDICINA TROPICAL E NUTRICAO, CAIXA POSTAL 4356, BRASILIA, DF 70919-970, BRAZIL	0037-8682			REV SOC BRAS MED TRO	Rev. Soc. Bras. Med. Trop.		2005	38			2			17	20						4	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	993TW	WOS:000233979000003	16482806	DOAJ Gold			2019-03-26	
J	Torrico, MC; Solano, M; Guzman, JM; Parrado, R; Suarez, E; Alonzo-Vega, C; Truyens, C; Carlier, Y; Torrico, F				Torrico, MC; Solano, M; Guzman, JM; Parrado, R; Suarez, E; Alonzo-Vega, C; Truyens, C; Carlier, Y; Torrico, F			Estimation of parasitemia in human infection by Trypanosoma cruzi: high parasitemias associated with severe and fatal congenital Chagas disease	REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL			Spanish	Article; Proceedings Paper	International Colloquium on Congenital Trypanosoma Cruzi Infection - From Mechanisms of Transmission to a Strategy for Diagnosis and Control	NOV 06-08, 2002	COCHABAMBA, BOLIVIA			congenital Chagas' disease; parasitemia; method of the microhematocrit tube		The aim of this study was to validate the method of microhemitocrit tube, as a rapid method to estimate the parasitemia in blood and to associate the parasites concentration with the morbility and mortality of new born-children with congenital Chagas diseases. Our results were determined experimentally and shown that the detection limit of the microhematocrit tube method is 40 parasites/ml when at least one of the four observed tubes is positive. Besides, it was also established that when the four examined tubes are positive the parasitemia in blood reaches more than 100 parasites/ml. It is important to highlight the modification made by our laboratory, in the microscopic observation of the microhematocrit tubes with respect to the methodology used by previous investigators. A positive association exists between a high number of parasites in blood and the morbi-mortality of the newly born children with congenital chagas. The results of positive association between the parasitic load and the morbility and mortality could constitute an argument to understand the possible role of the parasite in the pathology of the disease.	Univ Mayor San Simon, Fac Med, CUMETROP, LABIMED, Cochabamba, Bolivia; Univ Libre Bruxelles, Fac Med, Parasitol Lab, Brussels, Belgium	Torrico, MC (reprint author), Univ Mayor San Simon, Fac Med, CUMETROP, LABIMED, Ave Aniceto Arce 371,Casilla 3023, Cochabamba, Bolivia.	mctorrico@med.umss.edu.bo					BITTENCOURT AL, 1985, J TROP PEDIATRICS, V31, P242, DOI 10.1093/tropej/31.5.242; CARLIER Y, 1987, AM J TROP MED HYG, V37, P534, DOI 10.4269/ajtmh.1987.37.534; Freilij H., 1983, Journal of Clinical Microbiology, V18, P327; LAFUENTE C, 1984, T ROY SOC TROP MED H, V78, P278, DOI 10.1016/0035-9203(84)90299-2; MINTERGOEDBLOED E, 1978, T ROY SOC TROP MED H, V72, P217, DOI 10.1016/0035-9203(78)90196-7; Mjihdi A, 2002, AM J PATHOL, V161, P673, DOI 10.1016/S0002-9440(10)64223-X; Truyens C, 1999, INFECT IMMUN, V67, P5579; WOO PTK, 1969, CAN J ZOOLOG, V47, P921, DOI 10.1139/z69-150; WORTH ROBERT M., 1964, AMER J HYG, V80, P70	9	28	31	0	0	SOCIEDADE BRASILEIRA MEDICINA TROPICAL	BRASILIA	UNIV BRASILIA, NUCLEO MEDICINA TROPICAL E NUTRICAO, CAIXA POSTAL 4356, BRASILIA, DF 70919-970, BRAZIL	0037-8682			REV SOC BRAS MED TRO	Rev. Soc. Bras. Med. Trop.		2005	38			2			58	61						4	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	993TW	WOS:000233979000013	16482816	DOAJ Gold			2019-03-26	
J	Rodriguez, P; Truyens, C; Alonso-Vega, C; Flores, A; Cordova, M; Suarez, E; Torrico, F; Carlier, Y				Rodriguez, P; Truyens, C; Alonso-Vega, C; Flores, A; Cordova, M; Suarez, E; Torrico, F; Carlier, Y			Dosification of IgM and IgA anti-Trypanosoma cruzi antibodies in the blood of the newborn babies of mothers with Chagas-positive serology	REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL			Spanish	Article; Proceedings Paper	International Colloquium on Congenital Trypanosoma Cruzi Infection - From Mechanisms of Transmission to a Strategy for Diagnosis and Control	NOV 06-08, 2002	COCHABAMBA, BOLIVIA			chagas congenital; immunodiagnostic; antibodies IgM and IgA	DISEASE	This study compares the levels of specific antibodies IgM and IgA for Chagas in samples of blood from newborns. Three groups of cord blood samples have been analysed: a group of 42 samples from newborns, displaying positive parasitemia, of seropositive mothers (M+B+), 68 samples from newborns with negative parasitemia whose mothers were seropositive (M+B-) and 2 group of 45 control newborns coming from mothers with negative serology for Chagas. From the 42 M+B+ samples with congenital Chagas disease, 81 and 82.9% displayed detectable levels of IgM and IgA antibodies, respectively. In the M+B- group, 70.6 and 33.8% presented antibodies of IgM and IgA classes, respectively, whereas in the control group M-B-, we detected 61061 and 11.1 % of IgM and IgA antibodies, respectively. The calculated sensitivity of detection of congenital cases using IgM or IgA antibodies was of 82.9% and 80.9% respectively, whereas the specificity of detection was of 29.4% for IgM antibodies and of 66.1 % for IgA antibodies.	Univ Mayor San Simon, Fac Med, CUMETROP, LABIMED, Cochabamba, Bolivia; Univ Libre Bruxelles, Fac Med, Parasitol Lab, Brussels, Belgium	Rodriguez, P (reprint author), Univ Mayor San Simon, Fac Med, CUMETROP, LABIMED, Ave Aniceto Arce 371,Casilla 3023, Cochabamba, Bolivia.	patriciarohe@hotmail.com					Freilij H., 1983, Journal of Clinical Microbiology, V18, P327; LORCA M, 1995, AM J TROP MED HYG, V52, P512, DOI 10.4269/ajtmh.1995.52.512; SCHMUNIS GA, 1991, TRANSFUSION, V31, P547, DOI 10.1046/j.1537-2995.1991.31691306255.x; Torrico F, 2004, AM J TROP MED HYG, V70, P201, DOI 10.4269/ajtmh.2004.70.201; Umezawa ES, 1996, J CLIN LAB ANAL, V10, P407, DOI 10.1002/(SICI)1098-2825(1996)10:6<407::AID-JCLA16>3.3.CO;2-9	5	5	6	2	2	SOC BRASILEIRA MEDICINA TROPICAL	BRASILIA	UNIV BRASILIA, NUCLEO MEDICINA TROPICAL E NUTRICAO, CAIXA POSTAL 4356, BRASILIA, DF 70919-970, BRAZIL	0037-8682			REV SOC BRAS MED TRO	Rev. Soc. Bras. Med. Trop.		2005	38			2			62	64						3	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	993TW	WOS:000233979000014	16482817	DOAJ Gold			2019-03-26	
J	Virreira, M; Torrico, F; Truyens, C; Alonso-Vega, C; Solano, M; Carlier, Y; Svoboda, M				Virreira, M; Torrico, F; Truyens, C; Alonso-Vega, C; Solano, M; Carlier, Y; Svoboda, M			Comparison of PCR methods for the screening of congenital infection by Trypanosoma cruzi	REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL			Spanish	Article; Proceedings Paper	International Colloquium on Congenital Trypanosoma Cruzi Infection - From Mechanisms of Transmission to a Strategy for Diagnosis and Control	NOV 06-08, 2002	COCHABAMBA, BOLIVIA			PCR; congenital Chagas' disease; Trypanosoma cruzi	POLYMERASE-CHAIN-REACTION; CHRONIC CHAGAS-DISEASE; REACTION AMPLIFICATION; SENSITIVE DETECTION; BLOOD-SAMPLES; DNA-SEQUENCE; DIAGNOSIS; IDENTIFICATION; CLASSIFICATION; LINEAGES	PCR is a potentially interesting diagnostic tool to detect congenital I cruzi infection. We have compared the sensitivity and capacity of a battery of I cruzi PCR primers to detect the complete spectrum of known I cruzi lineages, in order to improve and simplify the detection of infection in neonatal blood We found that the primers Tcz1/Tcz2, targeting the 195 hp satellite repeat, detected all the parasitic lineages with the same sensitivity For all other tested primers (nDNA primers: BP1/BP2, O1/O2, Pon1/ Pon2 and Tca1/Tca2; kDNA primers. S35'/S36', 121/122), either, the intensity of amplicons varied according to T. cruzi lineages, or the assess were less sensitive. In order to better assess such PCR protocol, we assayed 311 samples of neonatal blood previously tested with parasitological methods. Reliability of our PCR test was demonstrated since all the 18 blood samples from newborns with congenital T. cruzi infection were positive, whereas the remaining samples (30 from control newborns of uninfected mothers and 262 out of 263 from babies, parasitologically negative, born from infected mothers) were negative. As our PCR method is simple, reliable, robust and cheap, it appears suitable for the detection of T cruzi infection in neonatal blood.	Free Univ Brussels, Fac Med, Chim Biol Lab, B-1070 Brussels, Belgium; Free Univ Brussels, Fac Med, Parasitol Lab, B-1070 Brussels, Belgium; Univ Mayor San Simon, Fac Med, LABIMED, CUMETROP, Cochabamba, Bolivia	Svoboda, M (reprint author), Free Univ Brussels, Fac Med, Chim Biol Lab, 808 Route Lennik, B-1070 Brussels, Belgium.	msvobod@ulb.ac.be					AVILA HA, 1991, MOL BIOCHEM PARASIT, V48, P211, DOI 10.1016/0166-6851(91)90116-N; Braga M. Socorro, 2000, Revista do Instituto de Medicina Tropical de Sao Paulo, V42, P157, DOI 10.1590/S0036-46652000000300009; BRENIERE SF, 1992, AM J TROP MED HYG, V46, P335, DOI 10.4269/ajtmh.1992.46.335; Brisse S, 2000, MOL BIOCHEM PARASIT, V111, P95, DOI 10.1016/S0166-6851(00)00302-9; Brisse S, 2000, INT J PARASITOL, V30, P35, DOI 10.1016/S0020-7519(99)00168-X; BRITTO C, 1993, MEM I OSWALDO CRUZ, V88, P171, DOI 10.1590/S0074-02761993000100030; DIAZ C, 1992, AM J TROP MED HYG, V46, P616, DOI 10.4269/ajtmh.1992.46.616; Kirchhoff LV, 1996, J CLIN MICROBIOL, V34, P1171; MOSER DR, 1989, J CLIN MICROBIOL, V27, P1477; REQUENA JM, 1992, MOL BIOCHEM PARASIT, V51, P271, DOI 10.1016/0166-6851(92)90077-W; Silber AM, 1997, EXP PARASITOL, V85, P225, DOI 10.1006/expr.1996.4141; STURM NR, 1989, MOL BIOCHEM PARASIT, V33, P205, DOI 10.1016/0166-6851(89)90082-0; VEAS F, 1991, CELL MOL BIOL, V37, P73; WINCKER P, 1994, AM J TROP MED HYG, V51, P771, DOI 10.4269/ajtmh.1994.51.771	14	6	7	0	3	SOC BRASILEIRA MEDICINA TROPICAL	BRASILIA	UNIV BRASILIA, NUCLEO MEDICINA TROPICAL E NUTRICAO, CAIXA POSTAL 4356, BRASILIA, DF 70919-970, BRAZIL	0037-8682			REV SOC BRAS MED TRO	Rev. Soc. Bras. Med. Trop.		2005	38			2			65	67						3	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	993TW	WOS:000233979000015	16482818	DOAJ Gold			2019-03-26	
J	Truyens, C; Mjihdi, K; Lambot, MA; Rivera, MT; Noel, JC; Carlier, Y				Truyens, C; Mjihdi, K; Lambot, MA; Rivera, MT; Noel, JC; Carlier, Y			Effects of acute and chronic infection by Trypanosoma cruzi in gestation in mice	REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL			Spanish	Article; Proceedings Paper	International Colloquium on Congenital Trypanosoma Cruzi Infection - From Mechanisms of Transmission to a Strategy for Diagnosis and Control	NOV 06-08, 2002	COCHABAMBA, BOLIVIA			Trypanosoma cruzi; acute phase; chronic phase; gestation; fetal development; mouse	IFN-GAMMA; TNF-ALPHA; PREGNANCY; ANTIBODIES; ANTI-IL-6; CACHEXIA; FAILURE; CELLS	Pathogens may impair reproduction in association or not with congenital infections. We have investigated the effect of acute infection with Trypanosoma cruzi, the protozoan agent of Chagas disease, on reproduction of female mice. In the acute, parasitemic, phase of the infection, female mice were totally unable to reproduce. Most of them (80%) were infertiles and did not develop any gestation. In the few gravid infected mice, implantation numbers were as in uninfected control mice. However, their fetuses presented a weight meanly reduced by 40% as compared to those of uninfected females, and all of them died during the gestation or whithin 48h after birth. Such massive mortality did not result from congenital infection, which did not occur The infertility and the fetal mortality occuring early in gestation (resorptions) were significantly correlated with a high maternal parasitemia, whereas later fetal mortality was associated with the presence of intracellular parasites in the utero-placental unit. The decidua was particularly receptive to T. cruzi multiplication, since this tissue harboured 125 fold more amastigotes than the maternal heart or other placental tissues. In addition, placentas of dead fetuses presented histopathological lesions (inflammatory infiltrates, fibrine deposits and ischemic necrosis). Such harmfull effects of acute infection were not observed when female mice were in the chronic phase of the infection, since these reproduce normally. Their fetuses only suffered from moderate and reversible growth retardation. These results indicate that, following the maternal parasite burden, I cruzi infection may induce very deleterious effects on gestation.	Free Univ Brussels, Fac Med, Parasitol Lab, B-1070 Brussels, Belgium; Free Univ Brussels, Hop Erasme, Anat Pathol Lab, B-1070 Brussels, Belgium	Truyens, C (reprint author), Free Univ Brussels, Fac Med, Parasitol Lab, 808 Route Lennik, B-1070 Brussels, Belgium.	ctruyens@med.ulb.ac.be					Argiles Josep M., 1997, Cytokine and Growth Factor Reviews, V8, P181, DOI 10.1016/S1359-6101(97)00012-9; Bittencourt A.L., 2000, TRYPANOSOMA CRUZI DO, P16; BITTENCOURT AL, 1992, REV I MED TROP, V34, P403, DOI 10.1590/S0036-46651992000500006; Boulouis HJ, 2001, INFECT IMMUN, V69, P5313, DOI 10.1128/IAI.69.9.5313-5317.2001; CARLIER Y, 1987, AM J TROP MED HYG, V37, P534, DOI 10.4269/ajtmh.1987.37.534; Clark DA, 1999, AM J REPROD IMMUNOL, V42, P37; Clark DA, 1999, AM J REPROD IMMUNOL, V41, P5; de Castilho E A, 1976, Rev Inst Med Trop Sao Paulo, V18, P258; Hall BS, 2000, INFECT IMMUN, V68, P2077, DOI 10.1128/IAI.68.4.2077-2081.2000; HERNANDEZMATHESON IM, 1983, T ROY SOC TROP MED H, V77, P405, DOI 10.1016/0035-9203(83)90174-8; Krishnan L, 1996, J IMMUNOL, V156, P653; OLIVEIRA FAUSTO da CUNHA, 1966, REV INST MED TROP SAO PAULO, V8, P184; Raghupathy R, 1997, IMMUNOL TODAY, V18, P478, DOI 10.1016/S0167-5699(97)01127-4; RIVERA MT, 1995, INFECT IMMUN, V63, P591; SCHENONE H, 1985, Boletin Chileno de Parasitologia, V40, P24; STAHL W, 1994, PARASITOL RES, V80, P22, DOI 10.1007/BF00932619; TERUEL J R, 1970, Revista do Instituto de Medicina Tropical de Sao Paulo, V12, P239; TORRICO F, 1991, J IMMUNOL, V146, P3626; Truyens C, 1999, INFECT IMMUN, V67, P5579; TRUYENS C, 1994, INFECT IMMUN, V62, P692; Truyens C, 1995, PARASITE IMMUNOL, V17, P561, DOI 10.1111/j.1365-3024.1995.tb00999.x	21	5	5	0	1	SOCIEDADE BRASILEIRA MEDICINA TROPICAL	BRASILIA	UNIV BRASILIA, NUCLEO MEDICINA TROPICAL E NUTRICAO, CAIXA POSTAL 4356, BRASILIA, DF 70919-970, BRAZIL	0037-8682			REV SOC BRAS MED TRO	Rev. Soc. Bras. Med. Trop.		2005	38			2			68	72						5	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	993TW	WOS:000233979000016	16482819	DOAJ Gold			2019-03-26	
J	Torrico, F; Castro, M; Solano, M; Rodriguez, P; Torrico, MC; Truyens, C; Carlier, Y				Torrico, F; Castro, M; Solano, M; Rodriguez, P; Torrico, MC; Truyens, C; Carlier, Y			Effects of maternal infection by Trypanosoma cruzi in the development of pregnancy and of the newborn	REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL			Spanish	Article; Proceedings Paper	International Colloquium on Congenital Trypanosoma Cruzi Infection - From Mechanisms of Transmission to a Strategy for Diagnosis and Control	NOV 06-08, 2002	COCHABAMBA, BOLIVIA			Chagas disease; pregnancy; maternal infection; new born	CHAGAS-DISEASE; CONGENITAL TRANSMISSION; MORBIDITY	In the endemic regions of Bolivia the infection of the feminine population in fertile age by T. cruzi is frequent (20 to 50 % of the women in fertile age) and the rate of fetal maternal transmission is of approximately 5 %. A great percentage of infected women do not transmit the infection to the fetus. The intention of the present study carried out at the Maternal-Infantile Hospital German Urquidi of Cochabamba (Bolivia) is to contribute to the knowledge regarding the pregnancy and birth of a newborn of Chagas infected women who do not transmit the infection to the fetus. 2124 mothers and 2,155 newborns were studied. The prevalence of infection by T. cruzi among these pregnant women is of 26.3 %. Two groups of mothers were studied: 554 that presented infection by T cruzi (group M+B-) and 1520 not infected (group control M-B-). Both groups of mothers are comparable in their anthropometric and obstetrical antecedents. The mothers (M+B+) are in average older than those not infected (p < 0.05), which will probably have an influence on the number of gestations and abortion antecedents, which were of p < 0.05 and p = 0.01 respectively. Among the different anthropometric and biological parameters studied in newborns of groups M+B- and M-B-, no statistically significant differences between both groups were found. It can be inferred that the chronic maternal infection by T. cruzi seems to have no clinical influence, neither on the course of the pregnancy, nor during birth, if a group of T. cruzi infected mothers is compared to a non infected group.	Univ Mayor San Simon, Fac Med, Ctr Univ Med Trop, CUMETROP,LABIMED, Cochabamba, Bolivia; Univ Libre Bruxelles, Fac Med, Parasitol Lab, Brussels, Belgium	Torrico, F (reprint author), Univ Mayor San Simon, Fac Med, Ctr Univ Med Trop, CUMETROP,LABIMED, Avenida Aniceto Arce 371,Casilla 2213, Cochabamba, Bolivia.	foxtorrico@yahoo.com					Atala C, 1985, Bol Chil Parasitol, V40, P85; BITTENCOURT A L, 1972, Revista do Instituto de Medicina Tropical de Sao Paulo, V14, P131; BITTENCOURT AL, 1985, ANN SOC BELG MED TR, V65, P103; BITTENCOURT AL, 1992, REV I MED TROP, V34, P403, DOI 10.1590/S0036-46651992000500006; Blanco SB, 1999, MEDICINA-BUENOS AIRE, V59, P138; BRABIN L, 1992, MEM I OSWALDO CRUZ, V87, P73, DOI 10.1590/S0074-02761992000100012; Castillo S, 1984, Bol Chil Parasitol, V39, P28; de Castilho E A, 1976, Rev Inst Med Trop Sao Paulo, V18, P258; De Souza N C Nogueira, 2004, Clin Exp Obstet Gynecol, V31, P217; GILSON GJ, 1995, OBSTET GYNECOL, V86, P646, DOI 10.1016/0029-7844(95)00089-A; Hermann E, 2004, J INFECT DIS, V189, P1274, DOI 10.1086/382511; HERNANDEZMATHESON IM, 1983, T ROY SOC TROP MED H, V77, P405, DOI 10.1016/0035-9203(83)90174-8; Lopes E R, 1977, Rev Inst Med Trop Sao Paulo, V19, P165; Nisida Isabelle Vera Vichr, 1999, Revista do Instituto de Medicina Tropical de Sao Paulo, V41, P305, DOI 10.1590/S0036-46651999000500007; Platero F, 1983, Bol Chil Parasitol, V38, P76; Rassi Anis, 2004, Rev. Soc. Bras. Med. Trop., V37, P485, DOI 10.1590/S0037-86822004000600011; Torrico F, 2004, AM J TROP MED HYG, V70, P201, DOI 10.4269/ajtmh.2004.70.201; Vekemans J, 2000, INFECT IMMUN, V68, P5430, DOI 10.1128/IAI.68.9.5430-5434.2000; Weinborn M E, 1983, Bol Chil Parasitol, V38, P73	19	5	7	2	3	SOC BRASILEIRA MEDICINA TROPICAL	BRASILIA	UNIV BRASILIA, NUCLEO MEDICINA TROPICAL E NUTRICAO, CAIXA POSTAL 4356, BRASILIA, DF 70919-970, BRAZIL	0037-8682			REV SOC BRAS MED TRO	Rev. Soc. Bras. Med. Trop.		2005	38			2			73	76						4	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	993TW	WOS:000233979000017	16482820	DOAJ Gold			2019-03-26	
J	Svoboda, M; Virreira, M; Torrico, F; Truyens, C; Alonso-Vega, C; Solano, M; Carlier, Y				Svoboda, M; Virreira, M; Torrico, F; Truyens, C; Alonso-Vega, C; Solano, M; Carlier, Y			Detection of the molecular heterogeneity of Trypanosoma cruzi	REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL			Spanish	Article; Proceedings Paper	International Colloquium on Congenital Trypanosoma Cruzi Infection - From Mechanisms of Transmission to a Strategy for Diagnosis and Control	NOV 06-08, 2002	COCHABAMBA, BOLIVIA			congenital Chagas' disease; Trypanosma cruzi; typing; lineage	POLYMERASE-CHAIN-REACTION; MULTILOCUS ENZYME ELECTROPHORESIS; AMPLIFIED POLYMORPHIC DNA; RIBOSOMAL-RNA SEQUENCES; MINI-EXON GENES; CHAGAS-DISEASE; SENSITIVE DETECTION; BIOCHEMICAL-CHARACTERIZATION; PHYLOGENETIC LINEAGES; ISOENZYME PATTERNS	Congenital transmission of T. cruzi in Cochabamba affects 6% of newborns from infected mothers. Only limited information is available on the type of transmitted parasites. However, it is well established that T. cruzi isolated from various vectors as well from host animals are highly heterogeneous. In our presentation we analyse aspects of molecular heterogeneity of T. cruzi and we review methods used for the molecular typing of T. cruzi lineages. Experimentally, we performed the PCR amplification of "Sequence-characterised region Markers" for typing T. cruzi isolated from umbilical blood of newborns in Cochabamba. We compared these results with those we obtained from general infected population. All 16 analysed, congenitally infected samples were of lineage IId. Our data also indicated that this lineage was found in about 80% of samples originated from general infected population in Cochabamba.	Free Univ Brussels, Fac Med, Chim Biol Lab, B-1070 Brussels, Belgium; Univ Libre Bruxelles, Fac Med, Parasitol Lab, Brussels, Belgium; Univ Mayor San Simon, Fac Med, LABIMED, CUMETROP, Cochabamba, Bolivia	Svoboda, M (reprint author), Free Univ Brussels, Fac Med, Chim Biol Lab, 808 Route Lennik, B-1070 Brussels, Belgium.	msvobod@ulb.ac.be					Barnabe C, 2000, PARASITOLOGY, V120, P513, DOI 10.1017/S0031182099005661; Barnabe C, 2001, ACTA TROP, V78, P127, DOI 10.1016/S0001-706X(00)00183-2; Bastrenta B, 1999, MEM I OSWALDO CRUZ, V94, P323, DOI 10.1590/S0074-02761999000300008; BOGLIOLO AR, 1987, T ROY SOC TROP MED H, V81, P222, DOI 10.1016/0035-9203(87)90222-7; BOSSENO MF, 1995, MEDICINA-BUENOS AIRE, V55, P277; Bosseno MF, 2000, MEM I OSWALDO CRUZ, V95, P473, DOI 10.1590/S0074-02762000000400005; BRENER Z, 1973, ANNU REV MICROBIOL, V27, P347, DOI 10.1146/annurev.mi.27.100173.002023; Breniere SF, 2002, MEM I OSWALDO CRUZ, V97, P289, DOI 10.1590/S0074-02762002000300002; BRENIERE SF, 1992, AM J TROP MED HYG, V46, P335, DOI 10.4269/ajtmh.1992.46.335; BRENIERE SF, 1985, TROP GEOGR MED, V37, P231; Brisse S, 2001, INT J PARASITOL, V31, P1218, DOI 10.1016/S0020-7519(01)00238-7; Brisse S, 2000, INT J PARASITOL, V30, P35, DOI 10.1016/S0020-7519(99)00168-X; CARNEIRO M, 1990, ACTA TROP, V47, P35, DOI 10.1016/0001-706X(90)90005-K; CARRENO H, 1987, EXP PARASITOL, V64, P252, DOI 10.1016/0014-4894(87)90150-0; CLARK CG, 1994, MOL BIOCHEM PARASIT, V66, P175; de Castro AM, 1999, MEM I OSWALDO CRUZ, V94, P655, DOI 10.1590/S0074-02761999000500017; EBERT F, 1982, TROPENMED PARASITOL, V33, P63; EBERT F, 1982, TROPENMED PARASITOL, V33, P140; EBERT F, 1985, TROP MED PARASITOL, V36, P85; Espinoza AG, 1996, J CLIN MICROBIOL, V34, P485; Fernandes O, 1998, MOL BIOCHEM PARASIT, V95, P129, DOI 10.1016/S0166-6851(98)00073-5; Fernandes O, 1998, AM J TROP MED HYG, V58, P807, DOI 10.4269/ajtmh.1998.58.807; Fernandes O, 1999, PARASITOLOGY, V118, P161, DOI 10.1017/S0031182098003709; GARCIA ES, 1986, ANN TROP MED PARASIT, V80, P361, DOI 10.1080/00034983.1986.11812030; HENRIKSSON J, 1993, EXP PARASITOL, V77, P334, DOI 10.1006/expr.1993.1091; Kawashita SY, 2001, MOL BIOL EVOL, V18, P2250, DOI 10.1093/oxfordjournals.molbev.a003771; KREUTZER RD, 1981, AM J TROP MED HYG, V30, P308, DOI 10.4269/ajtmh.1981.30.308; Lorenzi HA, 2003, GENE, V310, P91, DOI 10.1016/S0378-1119(03)00502-X; MACEDO AM, 1992, MOL BIOCHEM PARASIT, V55, P147, DOI 10.1016/0166-6851(92)90135-7; MILES MA, 1978, NATURE, V272, P819, DOI 10.1038/272819a0; Montamat EE, 1999, J EUKARYOT MICROBIOL, V46, P155, DOI 10.1111/j.1550-7408.1999.tb04599.x; MOREL C, 1980, P NATL ACAD SCI-BIOL, V77, P6810, DOI 10.1073/pnas.77.11.6810; MURTHY VK, 1992, MOL CELL PROBE, V6, P237, DOI 10.1016/0890-8508(92)90022-P; Robello C, 2000, GENE, V246, P331, DOI 10.1016/S0378-1119(00)00074-3; ROJAS MV, 1995, IMMUNOLOGIA; ROMANHA AJ, 1979, COMP BIOCHEM PHYS B, V62, P139, DOI 10.1016/0305-0491(79)90299-2; Santos SS, 2002, ANN TROP MED PARASIT, V96, P755, DOI 10.1179/000349802125002301; Solari A, 2001, EXP PARASITOL, V97, P226, DOI 10.1006/expr.2001.4607; SOUTO RP, 1993, MOL BIOCHEM PARASIT, V62, P45, DOI 10.1016/0166-6851(93)90176-X; STEINDEL M, 1993, MOL BIOCHEM PARASIT, V60, P71, DOI 10.1016/0166-6851(93)90030-2; Stolf BS, 2003, MOL BIOCHEM PARASIT, V126, P73, DOI 10.1016/S0166-6851(02)00270-0; STURM NR, 1989, MOL BIOCHEM PARASIT, V33, P205, DOI 10.1016/0166-6851(89)90082-0; Telleria J, 2004, MOL BIOCHEM PARASIT, V137, P133, DOI 10.1016/j.molbiopara.2004.05.006; TIBAYRENC M, 1983, T ROY SOC TROP MED H, V77, P76, DOI 10.1016/0035-9203(83)90021-4; Tibayrenc M, 1998, INT J PARASITOL, V28, P85, DOI 10.1016/S0020-7519(97)00180-X; TIBAYRENC M, 1993, P NATL ACAD SCI USA, V90, P1335, DOI 10.1073/pnas.90.4.1335; TIBAYRENC M, 1986, P NATL ACAD SCI USA, V83, P115, DOI 10.1073/pnas.83.1.115; TIBAYRENC M, 1988, EVOLUTION, V42, P277, DOI 10.1111/j.1558-5646.1988.tb04132.x; Tibayrenc M, 1988, Mem Inst Oswaldo Cruz, V83 Suppl 1, P249; Torres JP, 2004, PARASITOLOGY, V128, P161, DOI 10.1017/S0031182003004475; Vago AR, 1996, AM J PATHOL, V149, P2153; Vazquez M, 1999, GENE, V239, P207, DOI 10.1016/S0378-1119(99)00387-X; VEAS F, 1990, ACTA TROP, V48, P79, DOI 10.1016/0001-706X(90)90067-A; VEAS F, 1991, CELL MOL BIOL, V37, P73; Virreira M, 2003, AM J TROP MED HYG, V68, P574, DOI 10.4269/ajtmh.2003.68.574; Zingales B, 1999, MEM I OSWALDO CRUZ, V94, P159, DOI 10.1590/S0074-02761999000700020	56	1	1	0	1	SOCIEDADE BRASILEIRA MEDICINA TROPICAL	BRASILIA	UNIV BRASILIA, NUCLEO MEDICINA TROPICAL E NUTRICAO, CAIXA POSTAL 4356, BRASILIA, DF 70919-970, BRAZIL	0037-8682			REV SOC BRAS MED TRO	Rev. Soc. Bras. Med. Trop.		2005	38			2			77	83						7	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	993TW	WOS:000233979000018	16482821	DOAJ Gold			2019-03-26	
J	Fernandez-Aguilar, S; Lambot, MA; Torrico, F; Alonso-Vega, C; Cordoba, M; Suarez, E; Noel, JC; Carlier, Y				Fernandez-Aguilar, S; Lambot, MA; Torrico, F; Alonso-Vega, C; Cordoba, M; Suarez, E; Noel, JC; Carlier, Y			Placentary lesions in human infection by Trypanosoma cruzi	REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL			Spanish	Article; Proceedings Paper	International Colloquium on Congenital Trypanosoma Cruzi Infection - From Mechanisms of Transmission to a Strategy for Diagnosis and Control	NOV 06-08, 2002	COCHABAMBA, BOLIVIA			Trypanosoma cruzi; congenital Chagas' disease; materno-fetal transmission; placental pathology	CONGENITAL CHAGAS-DISEASE	This histopathological study analyzes placentas of babies congenitally infected with T. cruzi (M+B+), or babies not infected but born from infected- (M+B-), or non infected-mothers (M-B-). Placentas M+B+ showed lesions of chorionitis, chorioamnionitis and cord edema with lymphocyte infiltration, whereas such lesions were infiltrated only with polymorphonuclear cells in M+B- and M-B- placentas. Parasites were found in M+B+ placentas, in fibroblasts and macrophages of chorion, membranes, chorionic plate, mainly in the area of membrane insertion, as well as in cells of Wharton jelly and myocytes of umbilical cord vessels. These results suggest that the materno-fetal transmission of parasites occurs mainly through the marginal sinus, spreading into the chorionic plate infecting fibroblasts and macrophages so far as to found a fetal vessel, inducing a fetal infection by hematogenous route.	Free Univ Brussels, Fac Med, Parasitol Lab, B-1070 Brussels, Belgium; Free Univ Brussels, Hop Erasme, Anat Pathol Lab, B-1070 Brussels, Belgium; Univ Mayor San Simon, Fac Med, LABIMED, CUMETROP, Cochabamba, Bolivia	Carlier, Y (reprint author), Free Univ Brussels, Fac Med, Parasitol Lab, 808 Route Lennik, B-1070 Brussels, Belgium.	ycarlier@ulb.ac.be					AZOGUE E, 1985, T ROY SOC TROP MED H, V79, P176, DOI 10.1016/0035-9203(85)90328-1; BITTENCOURT AL, 1976, AM J DIS CHILD, V130, P97, DOI 10.1001/archpedi.1976.02120020099020; Moya P R, 1979, Rev Fac Cien Med Univ Nac Cordoba, V37, P21	3	17	18	0	0	SOC BRASILEIRA MEDICINA TROPICAL	BRASILIA	UNIV BRASILIA, NUCLEO MEDICINA TROPICAL E NUTRICAO, CAIXA POSTAL 4356, BRASILIA, DF 70919-970, BRAZIL	0037-8682			REV SOC BRAS MED TRO	Rev. Soc. Bras. Med. Trop.		2005	38			2			84	86						3	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	993TW	WOS:000233979000019	16482822	DOAJ Gold			2019-03-26	
J	Hermann, E; Truyens, C; Alonso-Vega, C; Even, J; Rodriguez, P; Berthe, A; Gonzalez-Merino, E; Torrico, F; Carlier, Y				Hermann, E; Truyens, C; Alonso-Vega, C; Even, J; Rodriguez, P; Berthe, A; Gonzalez-Merino, E; Torrico, F; Carlier, Y			Human foetuses are capable of generating an T CD8 immuno response similar to that of adults	REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL			Spanish	Article; Proceedings Paper	International Colloquium on Congenital Trypanosoma Cruzi Infection - From Mechanisms of Transmission to a Strategy for Diagnosis and Control	NOV 06-08, 2002	COCHABAMBA, BOLIVIA			umbilical cord; CD8 T cells; cytocines; repertoire TCR	TRYPANOSOMA-CRUZI INFECTION; CHAGAS-DISEASE; T-CELLS; HIV; NK	Fetal/neonatal immune responses are generally considered to be immature and weaker than in adults. We have studied the cord blood T-cells of newborns congenitally-infected with Trypanosoma cruzi, the protozoan agent of Chagas' disease. Our data demonstrate a predominant activation of CD8 T-cells expressing activation markers and armed to mediate effector functions. Indeed, we have detected parasite-specific CD8 T-cells secreting interferon-gamma. Such response is enhanced in the presence of rIL-15. These findings point out that the fetal immune system is more competent than previously appreciated, since fetuses exposed to live pathogens are able to develop an adult-like immune CD8 T-cell response.	Free Univ Brussels, Fac Med, Parasitol Lab, B-1070 Brussels, Belgium; Free Univ Brussels, Hop Erasme, Dept Med Genet, B-1070 Brussels, Belgium; Inst Pasteur, Dept Immunol, INSERM, U277, F-75724 Paris, France; Univ Mayor San Simon, Fac Med, CUMETROP, LABIMED, Cochabamba, Bolivia	Carlier, Y (reprint author), Free Univ Brussels, Fac Med, Parasitol Lab, 808 Route Lennik, B-1070 Brussels, Belgium.	ycarlier@ulb.ac.be	Hermann, Emmanuel/C-6376-2008	Hermann, Emmanuel/0000-0003-0971-4918			Andrieu M, 2000, EUR J IMMUNOL, V30, P3256, DOI 10.1002/1521-4141(200011)30:11<3256::AID-IMMU3256>3.0.CO;2-H; BASSO B, 1984, MEDICINA-BUENOS AIRE, V44, P41; BRENIERE SF, 1985, TROP GEOGR MED, V37, P231; Callan MFC, 1996, NAT MED, V2, P906, DOI 10.1038/nm0896-906; DosReis GA, 1997, PARASITOL TODAY, V13, P335, DOI 10.1016/S0169-4758(97)01073-9; FEILIJ H, 1983, J CLIN MICROBIOL, V18, P327; HANNET I, 1992, IMMUNOL TODAY, V13, P215, DOI 10.1016/0167-5699(92)90157-3; HANNET I, 1992, IMMUNOL TODAY, V13, P218; King CL, 2002, J IMMUNOL, V168, P356, DOI 10.4049/jimmunol.168.1.356; Krampera M, 2000, HAEMATOLOGICA, V85, P675; Marrack P, 2000, NAT IMMUNOL, V1, P107, DOI 10.1038/77778; PANTALEO G, 1994, NATURE, V370, P463, DOI 10.1038/370463a0; Plaeger S, 1999, J INFECT DIS, V179, P1388, DOI 10.1086/314746; Siegrist CA, 2001, VACCINE, V19, P3331, DOI 10.1016/S0264-410X(01)00028-7; Umemura M, 2001, J IMMUNOL, V167, P946, DOI 10.4049/jimmunol.167.2.946; Vekemans J, 2000, INFECT IMMUN, V68, P5430, DOI 10.1128/IAI.68.9.5430-5434.2000; Wizel B, 1997, J IMMUNOL, V159, P6120	17	0	0	0	1	SOC BRASILEIRA MEDICINA TROPICAL	BRASILIA	UNIV BRASILIA, NUCLEO MEDICINA TROPICAL E NUTRICAO, CAIXA POSTAL 4356, BRASILIA, DF 70919-970, BRAZIL	0037-8682			REV SOC BRAS MED TRO	Rev. Soc. Bras. Med. Trop.		2005	38			2			92	95						4	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	993TW	WOS:000233979000021		DOAJ Gold			2019-03-26	
J	Truyens, C; Hermann, E; Alonso-Vega, C; Rodriguez, P; Vekemans, J; Torrico, F; Carlier, Y				Truyens, C; Hermann, E; Alonso-Vega, C; Rodriguez, P; Vekemans, J; Torrico, F; Carlier, Y			Immunoresponse in non-infected neonatals born of mothers infected by Trypanosoma cruzi	REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL			Spanish	Article; Proceedings Paper	International Colloquium on Congenital Trypanosoma Cruzi Infection - From Mechanisms of Transmission to a Strategy for Diagnosis and Control	NOV 06-08, 2002	COCHABAMBA, BOLIVIA			Trypanosoma cruzi; immuner response; neonate	CHAGAS-DISEASE; PARASITE; CELLS	We have investigated if maternal T. cruzi infection could induce in utero innate and/or adaptive immune responses in uninfected neonates by measuring specific IgM and IgA antibodies in cord blood plasma, and by performing phenotypic and functional studies of umbilical cord blood cells of their newborns (M+B- group). We detected T. cruzi-specific IgM and IgA antibodies in M+B- cord blood, indicating they had mounted in utero a strong B call response, although they are not infected On the other hand, circulating T cells of such uninfected neonates displayed a low level of activation, as seen by a slightly increased expression of the activation markers CD45RO on CD4+ T cells and HLA-DR on CD8+ T cells, although the proportion of CD4+ and CD8+ T cells was unmodified as compared to newborns from uninfected mothers (MB- group). This activation did not give rise to a proliferative response upon stimulation by T cruzi antigens in vitro. However, M+B- cells produced low levels of lymphokines (IFN-gamma and IL-13) upon mitogenic stimulation, which was not the case of M-B- newborn cells. Beside this, M+B- blood cells produced higher levels of inflammatory cytokines (IL-1b, IL-6, TNF-alpha) than M-B- cells when stimulated with the T cruzi lysate or LPS, suggesting the over-activation of the innate response in M+B- newborns. Monocytes participated in such inflammatory response since M+B- purified cord blood monocytes produced higher levels of TNF- when incubated with LPS or a T cruzi lysate than M-B- cells. Altogether, these results show that, even in the absence of congenital infection, maternal T. cruzi infection triggers in utero both adaptive and innate immune responses in their babies. This indicates that parasite circulating antigens have been transferred from mothers to their fetuses.	Free Univ Brussels, Fac Med, Parasitol Lab, B-1070 Brussels, Belgium; Univ Mayor San Simon, Fac Med, LABIMED, CUMETROP, Cochabamba, Bolivia	Truyens, C (reprint author), Free Univ Brussels, Fac Med, Parasitol Lab, 808 Route Lennik, B-1070 Brussels, Belgium.	ctruyens@med.ulb.ac.be	Hermann, Emmanuel/C-6376-2008	Hermann, Emmanuel/0000-0003-0971-4918			Almeida IC, 2000, EMBO J, V19, P1476, DOI 10.1093/emboj/19.7.1476; Carlier Yves, 2003, Rev. Soc. Bras. Med. Trop., V36, P767, DOI 10.1590/S0037-86822003000600024; BASSO B, 1984, MEDICINA-BUENOS AIRE, V44, P41; BRENIERE SF, 1985, TROP GEOGR MED, V37, P231; Campos MA, 2001, J IMMUNOL, V167, P416, DOI 10.4049/jimmunol.167.1.416; ELBOUHDIDI A, 1994, PARASITE IMMUNOL, V16, P69; Hermann E, 2004, J INFECT DIS, V189, P1274, DOI 10.1086/382511; Hermann E, 2002, BLOOD, V100, P2153; Hinds LBD, 1999, INFECT IMMUN, V67, P6177; Saavedra E, 1999, J EXP MED, V190, P1825, DOI 10.1084/jem.190.12.1825; Torrico F, 2004, AM J TROP MED HYG, V70, P201, DOI 10.4269/ajtmh.2004.70.201; Vekemans J, 2000, INFECT IMMUN, V68, P5430, DOI 10.1128/IAI.68.9.5430-5434.2000	12	19	21	1	1	SOC BRASILEIRA MEDICINA TROPICAL	BRASILIA	UNIV BRASILIA, NUCLEO MEDICINA TROPICAL E NUTRICAO, CAIXA POSTAL 4356, BRASILIA, DF 70919-970, BRAZIL	0037-8682			REV SOC BRAS MED TRO	Rev. Soc. Bras. Med. Trop.		2005	38			2			96	100						5	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	993TW	WOS:000233979000022	16482825	DOAJ Gold			2019-03-26	
J	Alonso-Vega, C; Hermann, E; Truyens, C; Rodriguez, P; Torrico, MC; Torrico, F; Carlier, Y				Alonso-Vega, C; Hermann, E; Truyens, C; Rodriguez, P; Torrico, MC; Torrico, F; Carlier, Y			Immunological status of mothers infected by T-cruzi	REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL			Spanish	Article; Proceedings Paper	International Colloquium on Congenital Trypanosoma Cruzi Infection - From Mechanisms of Transmission to a Strategy for Diagnosis and Control	NOV 06-08, 2002	COCHABAMBA, BOLIVIA			congenital Chagas' disease; Tripanosoma cruzi; pregnancy; immunology	CHAGAS-DISEASE; PREGNANCY	The mechanisms of congenital transmission of Chagas disease remain largely unknown. To better understand the role of maternal immunology during pregnancy in congenital Chagas transmission, we studied the cytokine production and the parasitic load in three groups of mothers: infected mothers who transmitted the disease to their babies (M+B+), infected mothers who did not transmit the disease to their babies (M+B-) and not infected mothers as a control group (M-B-). M+B+ mothers produced less IFN gamma and more IL-10 than the M+B- mothers, and they are not able to produce IL-2, M+B+ mothers showed a higher parasitic load. These results, indicated that the congenital Chagas transmission is associated with an immunological imbalance and a high parasitic load in the M+B+ mothers.	Univ Mayor San Simon, Fac Med, Ctr Univ Med Trop, Cochabamba, Bolivia; Univ Libre Bruxelles, Fac Med, Parasitol Lab, Brussels, Belgium	Alonso-Vega, C (reprint author), Univ Mayor San Simon, Fac Med, Ctr Univ Med Trop, Avenida Aniceto Arce 371,Casilla 3023, Cochabamba, Bolivia.	cristina@med.umss.edu.bo	Hermann, Emmanuel/C-6376-2008	Hermann, Emmanuel/0000-0003-0971-4918			BASSO B, 1984, MEDICINA-BUENOS AIRE, V44, P41; BRENIERE SF, 1985, TROP GEOGR MED, V37, P231; FEILIJ H, 1983, J CLIN MICROBIOL, V18, P327; PAUL WE, 1999, FUNDAMENTAL IMMUNOLO, V4, P1; PEARCE EJ, 1999, FUNDAMENTAL IMMUNOLO, V4, P1271; Raghupathy R, 2001, SEMIN IMMUNOL, V13, P219, DOI 10.1006/smim.2001.0316; Vekemans J, 2000, INFECT IMMUN, V68, P5430, DOI 10.1128/IAI.68.9.5430-5434.2000; WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D	8	7	7	2	3	SOC BRASILEIRA MEDICINA TROPICAL	BRASILIA	UNIV BRASILIA, NUCLEO MEDICINA TROPICAL E NUTRICAO, CAIXA POSTAL 4356, BRASILIA, DF 70919-970, BRAZIL	0037-8682			REV SOC BRAS MED TRO	Rev. Soc. Bras. Med. Trop.		2005	38			2			101	104						4	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	993TW	WOS:000233979000023	16482826	DOAJ Gold			2019-03-26	
J	Carlier, Y				Carlier, Y			Factors and mechanisms involved in the transmission and the development of congenital infection by Trypanosoma cruzi	REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL			Spanish	Article; Proceedings Paper	International Colloquium on Congenital Trypanosoma Cruzi Infection - From Mechanisms of Transmission to a Strategy for Diagnosis and Control	NOV 06-08, 2002	COCHABAMBA, BOLIVIA			Trypanosoma cruzi; congenital Chagas' disease; materno-fetal transmission; maternal immune response; fetal immune response		This paper synthesizes the results obtained from multidisciplinary studies of Bolivian cases of congenital infection with T. cruzi. Congenital infection and congenital Chagas disease do not result from transmission of a particular strain of parasite, but from an equilibrium between complex phenomena, such as a weak maternal type 1 adaptative immune response associated with high maternal parasitemia, an invasion of placental chorion and umbilical cord by parasites, in front of a fetal T cruzi-specific immune response characterized by an activation of cytotoxic CD8 T cells producing IFN-gamma and able to limit parasite multiplication and morbi-mortality of congenital Chagas disease.	Free Univ Brussels, Fac Med, Parasitol Lab, B-1070 Brussels, Belgium	Carlier, Y (reprint author), Free Univ Brussels, Fac Med, Parasitol Lab, 808 Route Lennik, B-1070 Brussels, Belgium.	ycarlier@ulb.ac.be					Carlier Yves, 2003, Rev. Soc. Bras. Med. Trop., V36, P767, DOI 10.1590/S0037-86822003000600024; Hermann E, 2004, J INFECT DIS, V189, P1274, DOI 10.1086/382511; Hermann E, 2002, BLOOD, V100, P2153; Vekemans J, 2000, INFECT IMMUN, V68, P5430, DOI 10.1128/IAI.68.9.5430-5434.2000	4	16	17	2	2	SOCIEDADE BRASILEIRA MEDICINA TROPICAL	BRASILIA	UNIV BRASILIA, NUCLEO MEDICINA TROPICAL E NUTRICAO, CAIXA POSTAL 4356, BRASILIA, DF 70919-970, BRAZIL	0037-8682			REV SOC BRAS MED TRO	Rev. Soc. Bras. Med. Trop.		2005	38			2			105	107						3	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	993TW	WOS:000233979000024	16482827	DOAJ Gold			2019-03-26	
J	Billot, C; Torrico, F; Carlier, Y				Billot, C; Torrico, F; Carlier, Y			Study of the cost/benefit of a control programme for congenital Chagas disease in Bolivia	REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL			Spanish	Article; Proceedings Paper	International Colloquium on Congenital Trypanosoma Cruzi Infection - From Mechanisms of Transmission to a Strategy for Diagnosis and Control	NOV 06-08, 2002	COCHABAMBA, BOLIVIA			cost-profit; congenital Chagas' disease; direct and indirect costs		Cost effectiveness analysis of Chagas' vertical transmission control program in Bolivia: Today, Bolivia is the most concerned country in America by Chagas disease: Trypanosoma cruzi infection affects 20% of whole population, around 1 800 000 inhabitants, and mother-to-child transmission is around 5%, from 1.6 to 9.8%. Direct and indirect costs derived from disease complications and death, from birth to adulthood, add up around US$ 21 millions per year for 2,718 infected new-borns. This cost falls on individual, family and society, when the nation is struggling in a depressed economy. on the other side, an effective control program could detect and treat all cases with an investment of US$ 123 per infected new-born, or US$ 1.2 per new-born in Bolivia. Indirect benefits, apart of suffering relieve and improving of life quality, are related with Chagas vector control program, increasing the demand thanks to increasing risk awareness and also induced demand testing all pregnant women in endemic areas. So the conclusion is that such investment is profitable.	Univ Mayor San Simon, Fac Med, Ctr Univ Med Trop, IBISMED, Cochabamba, Bolivia; Univ Libre Bruxelles, Fac Med, Parasitol Lab, Brussels, Belgium	Billot, C (reprint author), Univ Mayor San Simon, Fac Med, Ctr Univ Med Trop, IBISMED, Avendia Aniceto Arce 371,Casilla 3023, Cochabamba, Bolivia.	claire.billot@med.umss.edu.bo					Basombrio MA, 1998, T ROY SOC TROP MED H, V92, P137, DOI 10.1016/S0035-9203(98)90720-9; EVEQUOZ MC, ENFOQUE GLOBALIZADO; Miyoshi C, 1994, Nihon Koshu Eisei Zasshi, V41, P1027; OLIVEIRA AM, 1989, MEM I OSWALDO CRUZ, V84, P409, DOI 10.1590/S0074-02761989000800074; TORRICO F, 2002, ENFERMEDAD CHAGAS CO; *UN, 1996, DEM YB; VALENCIA A, 1990, INVESTIGACION EPIDEM, P1; 1993, WORLD BANK ANN REPOR, P216	8	13	15	0	4	SOCIEDADE BRASILEIRA MEDICINA TROPICAL	BRASILIA	UNIV BRASILIA, NUCLEO MEDICINA TROPICAL E NUTRICAO, CAIXA POSTAL 4356, BRASILIA, DF 70919-970, BRAZIL	0037-8682			REV SOC BRAS MED TRO	Rev. Soc. Bras. Med. Trop.		2005	38			2			108	113						6	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	993TW	WOS:000233979000025	16482828	DOAJ Gold			2019-03-26	
J	Carlier, Y; Torrico, F				Carlier, Y; Torrico, F			Congenital infection by Trypanosoma cruzi: from the transmission mechanisms to the strategies for diagnostic and control	REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL			Spanish	Article; Proceedings Paper	International Colloquium on Congenital Trypanosoma Cruzi Infection - From Mechanisms of Transmission to a Strategy for Diagnosis and Control	NOV 06-08, 2002	COCHABAMBA, BOLIVIA						Free Univ Brussels, Fac Med, Parasitol Lab, B-1070 Brussels, Belgium; Univ Mayor San Simon, Fac Med, LABIMED, CUMETROP, Cochabamba, Bolivia	Carlier, Y (reprint author), Free Univ Brussels, Fac Med, Parasitol Lab, 808 Route Lennik, B-1070 Brussels, Belgium.	ycarlier@ulb.ac.be						0	2	2	0	0	SOCIEDADE BRASILEIRA MEDICINA TROPICAL	BRASILIA	UNIV BRASILIA, NUCLEO MEDICINA TROPICAL E NUTRICAO, CAIXA POSTAL 4356, BRASILIA, DF 70919-970, BRAZIL	0037-8682			REV SOC BRAS MED TRO	Rev. Soc. Bras. Med. Trop.		2005	38			2			114	118						5	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	993TW	WOS:000233979000026		DOAJ Gold			2019-03-26	
J	De Doncker, S; Hutse, V; Abdellati, S; Rijal, S; Karki, BMS; Decuypere, S; Jacquet, D; Le Ray, D; Boelaert, M; Koirala, S; Dujardin, JC				De Doncker, S; Hutse, V; Abdellati, S; Rijal, S; Karki, BMS; Decuypere, S; Jacquet, D; Le Ray, D; Boelaert, M; Koirala, S; Dujardin, JC			A new PCR-ELISA for diagnosis of visceral leishmaniasis in blood of HIV-negative subjects	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						visceral leishmaniasis; diagnosis; PCR-ELISA; Nepal	DIRECT AGGLUTINATION-TEST; KALA-AZAR PATIENTS; LINKED-IMMUNOSORBENT-ASSAY; POLYMERASE CHAIN-REACTION; PERIPHERAL-BLOOD; INFANTUM; GENES	The PCR-ELISA represents a promising advance for diagnosis of visceral. leishmaniasis (VL) in blood samples. However, the method has been validated mostly with HIV-positive patients who are known to have high levels of parasitaemia. We developed a new PCR-ELISA assay for specific detection of Leishmania in patients' blood and validated it in Nepalese subjects with clinically suspected VL, almost all of whom were HIV-negative. For blood samples, PCR-ELISA was more sensitive (83.9%) than conventional PCR (73.2%), and demonstrated 100% and 87.2% specificity when using healthy controls who had never travelled to a VL-endemic area and controls from a VL-endemic area as references, respectively. We have demonstrated the ability of PCR-ELISA to detect parasites in blood of HIV-negative patients. The method could be used for epidemiological as well as clinical purposes, as it reduces the need for traumatic bone marrow sampling and risky spleen aspiration. (C) 2004 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.	Prins Leopold Inst Trop Geneeskunde, Mol Parasitol Lab, B-2000 Antwerp, Belgium; Prins Leopold Inst Trop Geneeskunde, Dept Microbiol, B-2000 Antwerp, Belgium; BP Koirala Inst Hlth Sci, Ghopa, Dharan, Nepal	Dujardin, JC (reprint author), Prins Leopold Inst Trop Geneeskunde, Mol Parasitol Lab, Natl Str 155, B-2000 Antwerp, Belgium.	jcdujard@itg.be	Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776; Decuypere, Saskia/0000-0001-5036-4601			Adhya S, 1995, T ROY SOC TROP MED H, V89, P622, DOI 10.1016/0035-9203(95)90416-6; Bern C, 2000, AM J TROP MED HYG, V63, P153, DOI 10.4269/ajtmh.2000.63.153; Boelaert M, 1999, AM J TROP MED HYG, V60, P129, DOI 10.4269/ajtmh.1999.60.129; Costa JM, 1996, J CLIN MICROBIOL, V34, P1831; DEBEENHOUWER H, 1995, TUBERCLE LUNG DIS, V76, P425, DOI 10.1016/0962-8479(95)90009-8; Desjeux P, 1996, CLIN DERMATOL, V14, P417, DOI 10.1016/0738-081X(96)00057-0; Desjeux P, 2001, T ROY SOC TROP MED H, V95, P239, DOI 10.1016/S0035-9203(01)90223-8; DYE C, 1993, EPIDEMIOL INFECT, V103, P647; Hommel M, 1997, ANN TROP MED PARASIT, V91, P795, DOI 10.1080/00034983.1997.11813205; LANDGRAF A, 1991, ANAL BIOCHEM, V198, P86, DOI 10.1016/0003-2697(91)90510-Z; le Fichoux Y, 1999, J CLIN MICROBIOL, V37, P1953; Martin-Sanchez J, 2002, ANN TROP MED PARASIT, V96, P669, DOI 10.1179/000349802125001906; Martin-Sanchez J, 2001, PARASITOLOGY, V122, P607, DOI 10.1017/S0031182001007909; MARTINEZ P, 1993, AIDS, V7, P227, DOI 10.1097/00002030-199302000-00011; ORLE KA, 1998, METHODS MOL MED SEXU, V20, P67; Osman OF, 1997, J CLIN MICROBIOL, V35, P2454; Saran R, 1997, ACTA TROP, V68, P357, DOI 10.1016/S0001-706X(97)00104-6; SMYTH AJ, 1992, PARASITOLOGY, V105, P183, DOI 10.1017/S0031182000074096; Tintaya KWQ, 2004, J INFECT DIS, V189, P1035, DOI 10.1086/382049; VANEYS GJJM, 1992, MOL BIOCHEM PARASIT, V51, P133; World Health Organization (WHO), 1990, WHO TECHN REP SER, V793	21	20	20	0	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0035-9203	1878-3503		T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	JAN	2005	99	1					25	31		10.1016/j.trstmh.2004.01.015				7	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	877ZO	WOS:000225615000006	15550258				2019-03-26	
J	D'Alessandro, U; Talisuna, A; Boelaert, M				D'Alessandro, U; Talisuna, A; Boelaert, M			Should artemisinin-based combination treatment be used in the home-based management of malaria?	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Editorial Material						falciparum malaria; self-treatment; artemisinin combination drugs; Africa	MOTHERS; KENYA		Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium	D'Alessandro, U (reprint author), Inst Trop Med Prince Leopold, Natl Str 155, B-2000 Antwerp, Belgium.	udalessandro@itg.be; mboelaert@itg.be	D'Alessandro, Umberto/D-3457-2015; Boelaert, Marleen/E-2698-2012	D'Alessandro, Umberto/0000-0001-6341-5009; Boelaert, Marleen/0000-0001-8051-6776			Amexo M, 2004, LANCET, V364, P1896, DOI 10.1016/S0140-6736(04)17446-1; D'Alessandro U, 1997, T ROY SOC TROP MED H, V91, P638, DOI 10.1016/S0035-9203(97)90502-2; Duong S, 2004, LANCET, V364, P1754, DOI 10.1016/S0140-6736(04)17391-1; Kidane G, 2000, LANCET, V356, P550, DOI 10.1016/S0140-6736(00)02580-0; KIWAWULO C, 2004, GOVT GETS NEW DRUG; MWENESI H, 1995, SOC SCI MED, V40, P1271, DOI 10.1016/0277-9536(94)00250-W; SNOW RW, 1992, T ROY SOC TROP MED H, V86, P237, DOI 10.1016/0035-9203(92)90290-S; Talisuna AO, 2004, CLIN MICROBIOL REV, V17, P235, DOI 10.1128/CMR.17.1.235-254.2004	8	44	44	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	JAN	2005	10	1					1	2		10.1111/j.1365-3156.2004.01375.x				2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	896IQ	WOS:000226928200001	15655007				2019-03-26	
J	Sanchez, L; Perez, D; Perez, T; Sosa, T; Cruz, G; Kouri, G; Boelaert, M; Van der Stuyft, P				Sanchez, L; Perez, D; Perez, T; Sosa, T; Cruz, G; Kouri, G; Boelaert, M; Van der Stuyft, P			Intersectoral coordination in Aedes aegypti control. A pilot project in Havana City, Cuba	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						Aedes aegypti control; dengue prevention and control; intersectoral coordination; social mobilization; Cuba	INTEGRATED CONTROL; CONTROL PROGRAM; EL-PROGRESO; DENGUE; INFESTATION; PREVENTION; KNOWLEDGE; HONDURAS; HEALTH	BACKGROUND The 55th World Health Assembly declared dengue prevention and control a priority and urged Member States to develop sustainable intersectoral strategies to this end. To provide evidence for the reorientation of the dengue prevention policy in Cuba, we launched an intervention study to document the effectiveness of a local-level interscctoral approach. METHODS We used a quasi-experimental design. Social scientists introduced participatory methods to facilitate dialogue in the biweekly meetings of the intersectoral Health Council of the intervention area. This council subsequently developed an intersectoral plan for dengue prevention, of which the core objective was to design and implement activities for communication and social mobilization. In the control area, routine dengue control activities continued without additional input. Knowledge, attitudes and perceptions of dengue, and entomological indices were compared inside and between the areas before and after the 1-year intervention period. RESULTS In the intervention area the Health Council elaborated an intersectoral plan for dengue prevention focused on source reduction. The Aedes aegypti control methods consisted in eliminating useless containers in the houses and surroundings, covering tanks, and cleaning public and inhabited areas. It was implemented through communication and social mobilization. The Health Council in the control area occasionally discussed dengue issues but did not develop a coordinated action plan. Good knowledge about breeding sites and disease symptoms increased significantly (by 49.7% and 17.1% respectively) in the intervention area as well as the proportion of respondents eliminating containers in and around their houses (by 44%). No changes were observed in the control area. The House Index in the intervention area was 3.72% at baseline and decreased to 0.61% after 1 year. In the control area it remained stable throughout the study period (1.31% and 1.65% respectively). CONCLUSION The introduction of a participatory approach by social scientists promotes changes in intersectoral management. This facilitates social mobilization which, in its turn, leads to significant changes in knowledge, attitudes and dengue-related practices in the population and eventually to more effective control of Ae. aegypti.	Trop Med Inst Pedro Kouri, Dept Informat & Biostat, Havana, Cuba; Policlin 26 Julio, Div Epidemiol, Havana, Cuba; Hyg & Epidemiol Ctr, Div Epidemiol, Havana, Cuba; Inst Trop Med, Dept Publ Hlth, Epidemiol & Dis Control Unit, B-2000 Antwerp, Belgium	Sanchez, L (reprint author), Trop Med Inst Pedro Kouri, Dept Informat & Biostat, Autopista Novia Mediodia Km 6,La Lise AP 601,Mari, Havana, Cuba.	lsanchez@ipk.sld.cu; dennis@ipk.sld.cu; tami@ipk.sld.cu; cervera@infomed.sld.cu; cruzora@inforned.sld.cu; gkouri@ipk.sid.cu; mboelaert@itg.be; pvds@itg.be	Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776			Acosta OS, 1999, REV CUBANA HIGIENE E, V37, P6; BOS R, 1988, PARASITOL TODAY, V4, P295, DOI 10.1016/0169-4758(88)90029-4; Chiaravalloti Neto F, 1998, Cad Saude Publica, V14 Suppl 2, P101; de la Cruz A M, 1999, Rev Cubana Med Trop, V51, P135; Fernandez EA, 1998, ACTA TROP, V70, P171, DOI 10.1016/S0001-706X(98)00033-3; GORROCHOTEGUIESCAL, 1998, J MED ENTOMOL, V35, P699; GUBLER DJ, 1994, AM J TROP MED HYG, V50, P50, DOI 10.4269/ajtmh.1994.50.50; Gubler DJ, 1996, ACTA TROP, V61, P169, DOI 10.1016/0001-706X(95)00103-L; Guzman M G, 1999, Int J Infect Dis, V3, P130, DOI 10.1016/S1201-9712(99)90033-4; Guzman MG, 2002, LANCET INFECT DIS, V2, P33, DOI 10.1016/S1473-3099(01)00171-2; HALSTEAD SB, 1994, YI XUE KE XUE ZA Z S, V10, pS2; IATRIDIS DS, 1990, SOC WORK, V35, P29; KADT E, 1989, SOC SCI MED, V29, P503; Kay BH, 2002, AM J TROP MED HYG, V66, P40, DOI 10.4269/ajtmh.2002.66.40; KAY BH, 1994, YI XUE KE XUE ZA Z S, V10, pS56; Kilonzo B. S., 1994, Central African Journal of Medicine, V40, P186; KITTAYAPONG P, 1993, AM J TROP MED HYG, V49, P158, DOI 10.4269/ajtmh.1993.49.158; Kouri G, 1986, Bull Pan Am Health Organ, V20, P24; Kroeger A, 1995, TROP MED PARASITOL, V46, P241; LEONTSINI E, 1993, T ROY SOC TROP MED H, V87, P267, DOI 10.1016/0035-9203(93)90120-F; LLOYD LS, 1992, AM J TROP MED HYG, V46, P635, DOI 10.4269/ajtmh.1992.46.635; MARQUETTI MC, 1995, REV CUBANA MED TROPI, V47, P88; MARTINEZ R, 2001, B EPIDEMIOLOGICO, V22, P4; *PAHO, 1994, SCI PUBLICATION, V548, P29; SAHAN TSA, 1988, ASIA PACIFIC J PUBLI, V2, P163; Sanchez L, 2004, REV PANAM SALUD PUBL, V15, P19, DOI 10.1590/S1020-49892004000100004; Santos A. H. dos, 1999, Revista de Patologia Tropical, V28, P233; Schaefer M, 1981, Public Health Pap, V74, P1; SCHAEFER M, 1982, WHO CHRON, V36, P37; Swaddiwudhipong Witaya, 1992, Southeast Asian Journal of Tropical Medicine and Public Health, V23, P200; TERAZON O, 1999, REV CUBANA MED GEN I, V15, P386; Tsai Roussos S., 2000, ANNU REV PUBL HEALTH, V21, P369; Wang CH, 2000, J AM MOSQUITO CONTR, V16, P93; Winch PJ, 2002, AM J TROP MED HYG, V67, P363, DOI 10.4269/ajtmh.2002.67.363; *WORLD HLTH ASS, 2002, A5519 WORLD HLTH ASS	35	48	56	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	JAN	2005	10	1					82	91		10.1111/j.1365-3156.2004.01347.x				10	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	896IQ	WOS:000226928200011	15655017	Bronze			2019-03-26	
J	Tchuente, LAT; Shaw, DJ; Polla, L; Cioli, D; Vercruysse, J				Tchuente, LAT; Shaw, DJ; Polla, L; Cioli, D; Vercruysse, J			Efficacy of praziquantel against Schistosoma haematobium infection in children	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							MANSONI INFECTIONS; NORTHERN SENEGAL; CHEMOTHERAPY	A study was performed to determine the efficacy of praziquantel (PZQ) against Schistosoma haematobium. Children (n = 592) infected with S. haematobium received either a single treatment with PZQ (40 mg/kg) or two or three treatments with PZQ at three-week intervals after the initial treatment and efficacy was monitored for nine weeks. Cure rates at three-weeks post-treatment were low (< 50%), suggesting either that worms are killed very slowly or, more likely, that eggs continue to be released from tissues after worm death. Interestingly, a single dose of PZQ showed high efficacy (cure rate > 83% and egg reduction rate > 98%) when assessed from six weeks post-treatment onward. There were no significant differences in cure rates or intensity of infection between the three cohorts at any point in the study, despite the different treatment regimens. Since children were in contact with transmission sites during the study period, the results suggest good efficacy of PZQ against all stages of S. haematobium, including the immature worms.	Univ Yaounde, Fac Sci, Lab Gen Biol, Yaounde, Cameroon; Ctr Schistosomiasis & Parasitol, Yaounde, Cameroon; Univ Edinburgh, Easter Bush Vet Ctr, Ctr Trop Vet Med, Roslin, Midlothian, Scotland; Dist Hosp, Loum, Cameroon; Inst Cell Biol, Monterotondo, Rome, Italy; Ghent Univ, Fac Med Vet, Dept Virol Parasitol & Immunol, Merelbeke, Belgium	Tchuente, LAT (reprint author), Univ Yaounde, Fac Sci, Lab Gen Biol, Yaounde, Cameroon.	tchuemtchuente@schisto.com; Darren.Shaw@ed.ac.uk; laurentpolla@yahoo.fr; dcioli@ibc.cnr.it; jozef.vercruysse@UGent.be					Giboda M, 1992, J Hyg Epidemiol Microbiol Immunol, V36, P346; GONNERT R, 1977, Z PARASITENKD, V52, P129, DOI 10.1007/BF00389899; Gryseels B, 2001, TROP MED INT HEALTH, V6, P864, DOI 10.1046/j.1365-3156.2001.00811.x; GRYSEELS B, 1994, TROP GEOGR MED, V46, P209; Guirguis FR, 2003, ARZNEIMITTELFORSCH, V53, P57; Hagan P, 2004, TRENDS PARASITOL, V20, P92, DOI 10.1016/j.pt.2003.11.010; HERWALDT BL, 1995, CLIN INFECT DIS, V20, P309, DOI 10.1093/clinids/20.2.309; Katz N, 1989, Rev Soc Bras Med Trop, V22, P183; LOKER ES, 1983, PARASITOLOGY, V87, P343, DOI 10.1017/S0031182000052689; MCMAHON JE, 1979, BRIT MED J, V2, P1396, DOI 10.1136/bmj.2.6202.1396; Picquet M, 1998, T ROY SOC TROP MED H, V92, P90, DOI 10.1016/S0035-9203(98)90971-3; SABAH AA, 1986, EXP PARASITOL, V61, P294, DOI 10.1016/0014-4894(86)90184-0; Stelma FF, 1997, J INFECT DIS, V176, P304, DOI 10.1086/517273; Tchuente LAT, 1997, T ROY SOC TROP MED H, V91, P664, DOI 10.1016/S0035-9203(97)90513-7; Tchuente LAT, 2001, T ROY SOC TROP MED H, V95, P65, DOI 10.1016/S0035-9203(01)90335-9; *WHO, 1993, CONTR SCH 2 REP WHO; *WHO, 2002, 912 WHO	17	46	48	0	4	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	DEC	2004	71	6					778	782		10.4269/ajtmh.2004.71.778				5	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	884ZN	WOS:000226125300016	15642971				2019-03-26	
J	Harries, AD; Gomani, P; Teck, R; Ascurra, O; de Teck, OA; Bakali, E; Zachariah, R; Libamba, E; Mwansambo, A; Salaniponi, F; Mpazanje, R				Harries, AD; Gomani, P; Teck, R; Ascurra, O; de Teck, OA; Bakali, E; Zachariah, R; Libamba, E; Mwansambo, A; Salaniponi, F; Mpazanje, R			Monitoring the response to antiretroviral therapy in resource-poor settings: the Malawi model	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						HIV; AIDS; antiretroviral therapy; monitoring; Malawi		With assistance from the Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM), Malawi is scaling-up the delivery of antiretroviral (ARV) therapy to HIV-positive eligible patients. The country has developed National ARV Treatment Guidelines, which emphasize a structured and standardized approach for all aspects of ARV delivery, including monitoring and evaluation. Using the successful DOTS model adapted by National TB Control Programmes throughout the world, Malawi has developed a system of quarterly ARV cohort and cumulative ARV quarterly analyses. Thyolo district, in the southern region of Malawi, has been using this system since April 2003. This paper describes the standardized ARV treatment regimens and the treatment outcomes used in Thyolo, to assess the impact of treatment, the registration and monitoring systems and how the cohort analyses are carried out. Data are presented for case registration and treatment outcome for the first quarterly cohort (April to June) and the combined cohorts (April to June and July to September). Such quarterly analyses may be useful for districts and Ministries of Health in assessing ARV delivery, although the burden of work involved in calculating the numbers may become large once ARV delivery systems have been established for several years. (C) 2004 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.	Natl TB Control Programme, Minist Hlth & Populat, Lilongwe, Malawi; Medicins Sans Frontieres Brussels, Operat Ctr, Brussels, Belgium; Minist Hlth & Populat, Clin Serv, HIV AIDS Unit, Lilongwe, Malawi; Natl AIDS Commiss, Lilongwe, Malawi	Harries, AD (reprint author), British High Commiss, POB 30042, Lilongwe, Malawi.	adharries@malawi.net					CHIMZIZI R, 2003, REPORT COUNTRY WIDE; Enarson D.A., 2000, MANAGEMENT TUBERCULO; *MIN HLTH MAL, 2003, TREATM AIDS GUID US; *MIN HLTH POP MAL, 2002, MAN NAT TUB CONTR PR; *NAT AIDS COMM, 2003, NAT EST HIV AIDS MAL; WHO, 2003, COMM DIS; World Health Organisation, 2003, WHOCDSTB2003313; World Health Organization, 2004, SCAL ANT THER RES LT; Zachariah R, 2001, INT J TUBERC LUNG D, V5, P843	9	46	49	0	3	ROYAL SOC TROPICAL MEDICINE	LONDON	MANSON HOUSE 26 PORTLAND PLACE, LONDON W1N 1EY, ENGLAND	0035-9203			T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	DEC	2004	98	12					695	701		10.1016/j.trstmh.2004.05.002				7	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	868FX	WOS:000224900600002	15485699	Green Published			2019-03-26	
J	Dondorp, AM; Newton, PN; Mayxay, M; Van Damme, W; Smithuis, FM; Yeung, S; Petit, A; Lynam, AJ; Johnson, A; Hien, TT; McGready, R; Farrar, JJ; Looareesuwan, S; Day, NPJ; Green, MD; White, NJ				Dondorp, AM; Newton, PN; Mayxay, M; Van Damme, W; Smithuis, FM; Yeung, S; Petit, A; Lynam, AJ; Johnson, A; Hien, TT; McGready, R; Farrar, JJ; Looareesuwan, S; Day, NPJ; Green, MD; White, NJ			Fake antimalarials in Southeast Asia are a major impediment to malaria control: multinational cross-sectional survey on the prevalence of fake antimalarials	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						counterfeit drugs; fake antimalarials; Southeast Asia; malaria	ARTESUNATE; DRUGS	Objective To assess the prevalence of counterfeit antimalarial drugs in Southeast (SE) Asia. Design Cross-sectional survey. Setting Pharmacies and shops selling antimalarial drugs in Myanmar (Burma), Lao PDR, Vietnam, Cambodia and Thailand. Main Outcome Measures Proportion of artemisinin derivatives or mefloquine containing drugs of substandard quality. Results Of the 188 tablet packs purchased which were labelled as 'artesunate' 53% did not contain any artesunate. All counterfeit artesunate tablets were labelled as manufactured by 'Guilin Pharma', and refinements of the fake blisterpacks made them often hard to distinguish from their genuine counterparts. No other artemisinin derivatives were found to be counterfeited. Of the 44 mefloquine samples, 9% contained <10% of the expected amount of active ingredient. Conclusions An alarmingly high proportion of antimalarial drugs bought in pharmacies and shops in mainland SE Asia are counterfeit, and the problem has increased significantly compared with our previous survey in 1999-2000. This is a serious threat to public health in the region.	Mahidol Univ, Fac Trop Med, Bangkok 10400, Thailand; Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Ctr Trop Med, Oxford OX3 9DU, England; Mahosot Hosp, Wellcome Trust Mahosot Hosp Oxford Trop Med Res C, Viangchan, Laos; Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium; Med Sans Frontieres, Yangon, Myanmar; Thailand Program, Wildlife Conservat Soc, Bangkok 10210, Thailand; Lao PDR Program, Wildlife Conservat Soc, Viangchan, Laos; Shoklo Malaria Res Unit, St Louis, MO 63110 USA; Hosp Ctr Trop Dis, Ho Chi Minh City, Vietnam; Hosp Trop Dis, Oxford Univ Clin Res Unit, Ho Chi Minh City, Vietnam; Ctr Dis Control & Prevent, Atlanta, GA 30333 USA	White, NJ (reprint author), Mahidol Univ, Fac Trop Med, 420-6 Rajvithi Rd, Bangkok 10400, Thailand.	nickw@tropmedres.ac	Van Damme, Wim/F-7404-2011; White, Nicholas/I-4629-2012; /A-3290-2014	/0000-0003-1621-3257; Lynam, Antony/0000-0002-8395-7902			Frankish H, 2003, LANCET, V362, P1730, DOI 10.1016/S0140-6736(03)14891-X; Green MD, 2000, J PHARMACEUT BIOMED, V24, P65, DOI 10.1016/S0731-7085(00)00360-5; Green MD, 2001, TROP MED INT HEALTH, V6, P980, DOI 10.1046/j.1365-3156.2001.00793.x; Newton P, 2001, LANCET, V357, P1948, DOI 10.1016/S0140-6736(00)05085-6; Newton PN, 2003, LANCET, V362, P169, DOI 10.1016/S0140-6736(03)13872-X; Newton PN, 2002, BRIT MED J, V324, P800, DOI 10.1136/bmj.324.7341.800; ROZENDAAL J, 2000, B MEKONG MALARIA FOR, V7, P62; White NJ, 1999, PARASSITOLOGIA, VOL 41, NOS 1-3, SEPTEMBER 1999, P301; 2003, MIAMI HERALD    0305; 2001, NEW LIGHT MYANMAR; 1913, NY TIMES        0213; 2003, NIGERIA NAFDAC INTER	12	151	152	0	19	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	DEC	2004	9	12					1241	1246		10.1111/j.1365-3156.2004.01342.x				6	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	878HQ	WOS:000225637800002	15598255				2019-03-26	
J	Debacker, M; Aguiar, J; Steunou, C; Zinsou, C; Meyers, WM; Scott, JT; Dramaix, M; Portaels, F				Debacker, M; Aguiar, J; Steunou, C; Zinsou, C; Meyers, WM; Scott, JT; Dramaix, M; Portaels, F			Mycobacterium ulcerans disease: role of age and gender in incidence and morbidity	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						Mycobacterium ulcerans; Buruli ulcer; Benin; age; gender; osteomyelitis	BURULI ULCER; SOUTHERN BENIN; GHANA	During the 5-year period, 1997-2001, 1700 patients with a clinical diagnosis of Mycobacterium ulcerans disease [Buruli ulcer (BU)] were treated at the Centre Sanitaire et Nutritionnel Gbemoten, Zagnanado, Benin. The patients lived in the four regions of southern Benin: Atlantique, Mono, Oueme and Zou, with the largest number coming from the Zou Region where the centre is located. The median age of BU patients was 15 years (q1 = 7, q3 = 30). Lower limbs are involved 3.2 times more frequently than upper limbs in older patients and younger patients have the highest prevalence of multiple lesions. The latter are frequently associated with bone lesions. Specific detection rates for age and gender showed a distribution with maximum peaks in the 10-14 years group and among adults between 75 and 79 years. Over 59 years, males are more at risk of developing M. ulcerans disease than females. Children under 15 years represent the largest part of the BU disease burden and of the general population. The highest detection rates (per 100 000 population) were in the 75-79-year-old patients. The most likely explanation of this was reactivation of disease from a latent infection of M. ulcerans. Educational programmes should target especially these two groups of population at risk.	Inst Trop Med, B-2000 Antwerp, Belgium; Ctr Sanitaire & Nutr Gbemoten, Zagnanado, Benin; Armed Forces Inst Pathol, Washington, DC 20306 USA; Ecole Sante Publ, B-1070 Brussels, Belgium	Portaels, F (reprint author), Inst Trop Med, Nationalestr 155, B-2000 Antwerp, Belgium.	mdebacker@itg.be; gbemontin@ifrance.bj; wmekmeyers@erols.com; janet.scott@worc.ox.ac.uk; miwilmet@ulb.ac.be; portaels@itg.be					AGUIAR J, 1997, B SEANCES ACAD ROYAL, V43, P325; Amofah G, 2002, EMERG INFECT DIS, V8, P167, DOI 10.3201/eid0802.010119; Asiedu K, 1998, AM J TROP MED HYG, V59, P1015, DOI 10.4269/ajtmh.1998.59.1015; ASIEDU K, 2000, BURULI ULCER MYCOBAC, P9; Aujoulat I, 2003, TROP MED INT HEALTH, V8, P750, DOI 10.1046/j.1365-3156.2003.01089.x; BARKER DJP, 1972, T ROY SOC TROP MED H, V66, P867, DOI 10.1016/0035-9203(72)90121-6; *BEN DEM HLTH SURV, 1996, REP BEN ENQ DEM SANT, P318; BUNTINE J, 2001, BURULI UCER MANAGEME, P3; Debacker M, 2004, EMERG INFECT DIS, V10, P1391, DOI 10.3201/eid1008.030886; Lagarrigue V, 2000, Med Trop (Mars), V60, P262; MEYERS WM, 1974, AM J TROP MED HYG, V23, P919, DOI 10.4269/ajtmh.1974.23.919; *MIN PLAN RESTR EC, 1994, 2 REC GEN POP HAB; Portaels F., 2003, Bulletin des Seances, Academie Royale des Sciences d'Outre- Mer, V49, P161; PORTAELS F, 2001, BURULI ULCER DIAGNOS, P27; Pszolla N, 2003, CLIN INFECT DIS, V37, pE78, DOI 10.1086/377170; Scott JT, 2004, EMERG INFECT DIS, V10, P551, DOI 10.3201/eid1003.020514; SMITH JH, 1970, AM J TROP MED HYG, V19, P657, DOI 10.4269/ajtmh.1970.19.657; Stienstra Y, 2002, AM J TROP MED HYG, V67, P207, DOI 10.4269/ajtmh.2002.67.207; Uganda Buruli Group, 1971, T R SOC TROP MED HYG, V65, P763	19	58	58	3	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	DEC	2004	9	12					1297	1304		10.1111/j.1365-3156.2004.01339.x				8	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	878HQ	WOS:000225637800008	15598261	Bronze			2019-03-26	
J	el-Safi, SH; Hamid, N; Omer, A; Abdel-Haleem, A; Hammad, A; Kareem, HG; Boelaert, M				el-Safi, SH; Hamid, N; Omer, A; Abdel-Haleem, A; Hammad, A; Kareem, HG; Boelaert, M			Infection rates with Leishmania donovani and Mycobacterium tuberculosis in a village in eastern Sudan	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						visceral leishmaniasis; epidemiology; leishmanin skin test; tuberculin; survey; Sudan	AZAR DERMAL LEISHMANIASIS; VISCERAL LEISHMANIASIS; KALA-AZAR; SKIN-TEST; MEDITERRANEAN LEISHMANIASIS; MASKING TUBERCULOSIS; CANINE LEISHMANIASIS; BARINGO DISTRICT; HUMAN-POPULATION; EPIDEMIOLOGY	Background Leishmania-tuberculosis co-infection is not uncommon in clinical practice in East Africa, but little is known about the epidemiology of this problem at population level. A cross-sectional household survey was carried out in an active visceral leishmaniasis (VL) focus in Eastern Sudan in February 2002. Methods All inhabitants of Marbata village in Atbara River Area, Gedarif State, who gave informed consent, underwent both a leishmanin skin test (LST) and a tuberculin test for infection with L. donovani and Mycobacterium tuberculosis. All subjects were clinically screened for VL and tuberculosis (TB). Results About 66% (252 of 382) were LST-positive, 26% (100 of 382) were tuberculin-positive and 20% (77 of 382) were positive for both tests. By the age of 15, more than 60% of inhabitants were LST-positive, but <20% were tuberculin-positive. By the age of 30, these percentages increased to 100 and 50%. No association was found at the individual level between leishmanial and tuberculous infection after controlling for age. Conclusions In this community study, we found no association between the risk of infection with L. donovani and M. tuberculosis. However, the progression to active VL disease might be different in M. tuberculosis-infected than in non-infected persons and vice versa. Prospective studies are needed to document the prognosis of TB/VL co-infection.	Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium; Univ Khartoum, Fac Med, Khartoum, Sudan; Fed Minist Hlth, Natl Malaria Schistosomiasis & Leishmaniasis Prog, Directorate Gen Prevent & Social Med, Natl Leishmaniasis Programme, Khartoum, Sudan; Univ Khartoum, Fac Med Lab Sci, Khartoum, Sudan	Boelaert, M (reprint author), Inst Trop Med, Dept Publ Hlth, Nationalestr 155, B-2000 Antwerp, Belgium.	syda_h@hotmail.com; nuhahamid@hotmail.com; mboelaert@itg.be	Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776			ALI A, 1993, ANN TROP MED PARASIT, V87, P163, DOI 10.1080/00034983.1993.11812750; BETTINI S, 1977, T ROY SOC TROP MED H, V71, P73, DOI 10.1016/0035-9203(77)90212-7; BRYCESON ADM, 1985, T ROY SOC TROP MED H, V79, P700, DOI 10.1016/0035-9203(85)90197-X; Cantwell MF, 1996, TUBERCLE LUNG DIS, V77, P220, DOI 10.1016/S0962-8479(96)90004-0; CHAUDHURI A, 1989, LANCET, V2, P1396; DECOCK KM, 1995, LANCET, V346, P675, DOI 10.1016/S0140-6736(95)92284-9; Desjeux P, 1996, CLIN DERMATOL, V14, P417, DOI 10.1016/0738-081X(96)00057-0; El-Safi SH, 2002, MICROBES INFECT, V4, P1439, DOI 10.1016/S1286-4579(02)00026-6; El-Sony AI, 2003, INT J TUBERC LUNG D, V7, P445; ELHASSAN AM, 1992, T ROY SOC TROP MED H, V86, P245, DOI 10.1016/0035-9203(92)90294-M; ELHASSAN AM, 1995, TROP GEOGR MED, V47, P151; ELSAFI S, 1995, SUDAN MED J, V33, P113; ELSONY AL, 2002, INT J TUBERC LUNG D, V4, P657; GRAMICCIA M, 1990, T ROY SOC TROP MED H, V84, P371, DOI 10.1016/0035-9203(90)90322-6; HO M, 1983, CLIN EXP IMMUNOL, V51, P207; HOOGSTRA.H, 1969, AM J TROP MED HYG, V18, P1091, DOI 10.4269/ajtmh.1969.18.1091; Khalil EAG, 1998, ANN TROP MED PARASIT, V92, P151, DOI 10.1080/00034983.1998.11813274; LEEUWENBURG J, 1983, E AFR MED J, V60, P81; LUCAS SB, 1993, AIDS, V7, P1569, DOI 10.1097/00002030-199312000-00005; MARTY P, 1992, T ROY SOC TROP MED H, V86, P249, DOI 10.1016/0035-9203(92)90295-N; McCallion H, 1995, Nurs Manag (Harrow), V1, P20; Migliori G B, 1992, G Ital Chemioter, V39, P5; MONTALBAN C, 1990, LANCET, V335, P299, DOI 10.1016/0140-6736(90)90127-Q; NANDY A, 1987, ANN TROP MED PARASIT, V81, P693, DOI 10.1080/00034983.1987.11812172; NARAIN JP, 1992, TUBERCLE LUNG DIS, V73, P311, DOI 10.1016/0962-8479(92)90033-G; OMER EE, 1979, J TROP MED HYG, V82, P75; PAMPIGLIONE S, 1975, T ROY SOC TROP MED H, V69, P60, DOI 10.1016/0035-9203(75)90012-7; RAB MA, 1994, T ROY SOC TROP MED H, V88, P541, DOI 10.1016/0035-9203(94)90153-8; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; RIEDER HL, 1995, TUBERCLE LUNG DIS, V76, P114, DOI 10.1016/0962-8479(95)90552-9; SATI MOHAMMED HAMAD, 1942, ANN TROP MED AND PARASITOL, V36, P1; SCHAEFER KU, 1994, AM J TROP MED HYG, V50, P78, DOI 10.4269/ajtmh.1994.50.78; Seaman J, 1996, INT J EPIDEMIOL, V25, P862, DOI 10.1093/ije/25.4.862; SHIDDO SA, 1995, T ROY SOC TROP MED H, V89, P21, DOI 10.1016/0035-9203(95)90640-1; SOKAL JE, 1975, NEW ENGL J MED, V293, P501, DOI 10.1056/NEJM197509042931013; TREMONTI L, 1970, AM J TROP MED HYG, V19, P49, DOI 10.4269/ajtmh.1970.19.49; *WHO, 1958, TUB SURV LOW INC COU; ZIJLSTRA EE, 1993, T ROY SOC TROP MED H, V87, P425, DOI 10.1016/0035-9203(93)90024-K; ZIJLSTRA EE, 1994, AM J TROP MED HYG, V51, P826, DOI 10.4269/ajtmh.1994.51.826; Zijlstra EE, 2001, T ROY SOC TROP MED H, V95, pS27, DOI 10.1016/S0035-9203(01)90218-4	40	10	10	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	DEC	2004	9	12					1305	1311		10.1111/j.1365-3156.2004.01337.x				7	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	878HQ	WOS:000225637800009	15598262	Bronze			2019-03-26	
J	Schoonbaert, D				Schoonbaert, D			Citation patterns in tropical medicine journals	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						tropical medicine; biomedical literature; journals; bibliometrics; citation analysis; Journal Citation Reports		Selections of most important journals in the field of tropical medicine have previously been identified with the help of resources such as bibliographical and citation databases. This article uses ISI's Journal Citation Reports (JSR) for 2002 to analyse the citation characteristics of the Tropical Medicine category. According to these data, this small but diverse group of 12 journals bestows some 40% more citations than it receives. Its six typical core journals tend to cite one another heavily, but they also refer a lot to multidisciplinary science and general medicine journals, and to infectious diseases and parasitology journals. Looking at the sources from which JCR's tropical medicine journals derive their citations, it is clear that in this reverse direction, the specialty's literature is still more concentrated. Apart from the typical core, this JCR category also contains a number of journals with more idiosyncratic citing patterns, focused on specialties such as paediatrics, a single disease (leprosy) and a representative of Latin American and Francophone biomedical science each. Implications of concentrated citedness and language biases are discussed briefly. This paper features a selection of bibliometric parameters relating to the tropical medicine journals and lists of the 80 journals most citing and cited by them.	Inst Trop Med, B-2000 Antwerp, Belgium	Schoonbaert, D (reprint author), Inst Trop Med, Natl Str 155, B-2000 Antwerp, Belgium.	bib@itg.be					APTED FIC, 1977, USE MED LIT, P192; Bradford SC., 1948, DOCUMENTATION; BRENNEN PW, 1978, B MED LIBR ASSOC, V66, P24; DIAZ IG, 1980, REV CUBANA MED TROPI, V32, P101; Gibbs W. W., 1995, SCI AM, V273, P76; Horton R, 2003, LANCET, V361, P712, DOI 10.1016/S0140-6736(03)12665-7; *ISI, 2003, J CIT REP 2002 SCI E; Maisonneuve H, 2003, LANCET, V361, P1387, DOI 10.1016/S0140-6736(03)13056-5; MERTON RK, 1968, SCIENCE, V159, P56, DOI 10.1126/science.159.3810.56; Obuaya CC, 2003, LANCET, V361, P1387, DOI 10.1016/S0140-6736(03)13054-1; ROELANTS G, 1987, ANN SOC BELG MED TR, V67, P315; Schoonbaert D, 1996, TROP MED INT HEALTH, V1, P739	12	16	16	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	NOV	2004	9	11					1142	1150		10.1111/j.1365-3156.2004.01327.x				9	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	872DR	WOS:000225188100002	15548309	Bronze			2019-03-26	
J	Musango, L; Dujardin, B; Dramaix, M; Criel, B				Musango, L; Dujardin, B; Dramaix, M; Criel, B			Profiles of members and non-members of the mutual health insurance systems in Rwanda - The case of the Kabutare health district	TROPICAL MEDICINE & INTERNATIONAL HEALTH			French	Article								The establishment of mutual health insurance systems is one of the priorities of the Rwandan government. Pilot studies have been conducted in three districts of the country. Nonetheless, after 4 years of implementation ( 1999 - 2003), the population coverage by these insurance systems remains relatively low. A cross-sectional study of 1042 households in the Kabutare health district allowed for a comparison of socio-economic and demographic variables, and the medical, surgical, gynaecological, and obstetrical history of health insurance scheme members and non-members. The results of the study demonstrate that the distribution of members and non-members is similar in terms of sex, marital status, professional status and medical history. However, larger households ( more than five members) and those having a relatively higher income ( more than US$ 230 per annum) are more likely to be insured than other households. Members of the mutual health insurance use more the health services than nonmembers, spend less on health care and increasingly maintain membership. The study emphasizes the relevance to further promote mutual health insurance, but also points to the need for mechanisms to ensure financial access for the poor rural population.	Minist Sante, Kigali, Butare, Rwanda; Free Univ Brussels, Ecole Sante Publ, Dept Polit & Syst Sante, B-1070 Brussels, Belgium; Inst Trop Med, Dept Sante Publ, B-2000 Antwerp, Belgium	Musango, L (reprint author), Minist Sante, BP 274, Kigali, Butare, Rwanda.	musangol@yahoo.fr; bruno.dujardin@ulb.ac.be; michele.dramaix@ulb.ac.be; bcriel@itg.be					ATIM C, 2000, CONTRIBUTION MUTUELL; CARRIN G, 2002, REV INT SECURITE SOC, V55, P73; CRIEL B, 2002, EXPERIENCE ORG MUTUE, P121; CRIEL B, 1998, STUDIES HLTH SERVICE, V9, P31; Fonteneau B, 2000, EMERGENCE PRATIQUES; HUTTON G, 2003, ANAL SITUATION MOYEN; Meessen B, 2002, REV INT SECURITE SOC, V55, P91; *MIN FIN EC PLANN, 2002, RWAND DEV IND POV RE; *MIN SANT, 1998, DEF CAS GUID SURV EP; Musango L., 2004, Cahiers d'Etudes et de Recherches Francophones/Sante, V14, P101; Musango L., 2004, Cahiers d'Etudes et de Recherches Francophones/Sante, V14, P93; *OFF NAT POP, 2001, ENQ DEM SANT 2000	12	9	10	0	3	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	NOV	2004	9	11					1222	1227		10.1111/j.1365-3156.2004.01318.x				6	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	872DR	WOS:000225188100013	15548320				2019-03-26	
J	Criel, B; Atim, C; Basaza, R; Blaise, P; Waelkens, MP				Criel, B; Atim, C; Basaza, R; Blaise, P; Waelkens, MP			Editorial: Community health insurance (CHI) in sub-Saharan Africa: researching the context	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Editorial Material						Community health insurance; sub-Saharan Africa; access to health care; context; research	HOSPITAL-CARE; BWAMANDA; SCHEME; COUNTRIES; VOLUNTARY; LESSONS; GUINEA; ZAIRE		Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium; Partners Hlth Res, Dakar, Senegal; Minist Hlth, Kampala, Uganda	Criel, B (reprint author), Inst Trop Med, Dept Publ Hlth, Natl Str 155, B-2000 Antwerp, Belgium.	bcriel@itg.be; cbatim@dircon.co.uk; grbasaza@hotmail.com; mpwaelkens@itg.be					Atim C, 1999, SOC SCI MED, V48, P881, DOI 10.1016/S0277-9536(98)00390-6; Barnighausen T, 2002, SOC SCI MED, V54, P1559, DOI 10.1016/S0277-9536(01)00137-X; Chee G., 2002, ASSESSMENT COMMUNITY; Criel B, 1997, TROP MED INT HEALTH, V2, P654, DOI 10.1046/j.1365-3156.1997.d01-349.x; Criel B, 2003, SOC SCI MED, V57, P1205, DOI 10.1016/S0277-9536(02)00495-1; Criel B, 1999, SOC SCI MED, V48, P897, DOI 10.1016/S0277-9536(98)00391-8; Criel B, 1998, TROP MED INT HEALTH, V3, P640; CRIEL B, 2002, PROJET PRIMA GUINEE, P255; Dror D., 1999, MICROINSURANCE EXTEN; Haddad S, 1998, SOC SCI MED, V47, P381, DOI 10.1016/S0277-9536(98)00075-6; JAFFRE Y, 2003, MED INHOSPITALIERE D, P461; MOENS F, 1990, SOC SCI MED, V30, P1319, DOI 10.1016/0277-9536(90)90312-G; Pawson R, 1997, REALISTIC EVALUATION, P235; *UN THEM GROUP HL, 2003, CHIN HLTH SIT ASS, P101; van den Heever A., 1997, PRIVATE HLTH PROVIDE; Waelkens M.-P., 2004, MUTUELLES SANTE AFRI	16	16	16	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2004	9	10					1041	1043		10.1111/j.1365-3156.2004.01315.x				3	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	862BK	WOS:000224464400001	15482395				2019-03-26	
J	Erhart, A; Thang, ND; Bien, TH; Tung, NM; Hung, NQ; Hung, LX; Tuy, TQ; Speybroeck, N; Cong, LD; Coosemans, M; D'Alessandro, U				Erhart, A; Thang, ND; Bien, TH; Tung, NM; Hung, NQ; Hung, LX; Tuy, TQ; Speybroeck, N; Cong, LD; Coosemans, M; D'Alessandro, U			Malaria epidemiology in a rural area of the Mekong Delta: a prospective community-based study	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						malaria; Plasmodium falciparum; P. vivax; transmission; private health care providers; over-treatment; Mekong Delta	CHI-MINH CITY; CLINICAL ALGORITHM; TUBERCULOSIS; DIAGNOSIS; CHILDREN; TRANSMISSION; PRIVATE; VIETNAM; PRACTITIONERS; INDIA	Over the past 10 years, the Mekong Delta region in Vietnam has experienced fast socio-economic development with subsequent changes in malaria vectors ecology. We conducted a 2-year prospective community-based study in a coastal rural area in the southern Mekong Delta to re-assess the malaria epidemiological situation and the dynamics of transmission. The incidence rate of clinical malaria, established on 558 individuals followed for 23 months by active case detection and biannual cross-sectional surveys, was 2.6/100 person-years. Over the 2-year study period, the parasite rate and malaria seroprevalence (Plasmodium falciparum and P. vivax) decreased significantly from 2.4% to almost 0%. Passive case detection (PCD) of clinical cases and serological follow-up of newborns carried out in a larger population confirmed the low and decreasing trend of malaria transmission. The majority of fever cases were seen in the private sector and most were unnecessarily treated with antimalarials. Training and involvement of the private sector in detection of malaria cases would greatly improve the quality of health care and health information system.	Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium; NIMPE, Hanoi, Vietnam; PMS, Bac Lieu, Vietnam; IMPE, Ho Chi Minh City, Vietnam	Erhart, A (reprint author), Inst Trop Med Prince Leopold, Natl Str 155, B-2000 Antwerp, Belgium.	aerhart@itg.be; thangnimpevn@fpt.vn; vmcpimpehcm@saigonnet.vn; lxhung@netnam.vn; nimpe@netnam.org.vn; nspeybroeck@itg.be; mcoos@itg.be; udalessandro@itg.be	D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009			Aljunid S, 1995, HEALTH POLICY PLANN, V10, P333, DOI 10.1093/heapol/10.4.333; AM NT, 1993, CAHIERS SANTE, V3, P323; *AUSTR GOVT, 2002, CAS STUD MEK DELT MI; Bojang KA, 2000, TROP MED INT HEALTH, V5, P231, DOI 10.1046/j.1365-3156.2000.00538.x; Chandramohan D, 2001, TROP MED INT HEALTH, V6, P505, DOI 10.1046/j.1365-3156.2001.00739.x; COOSEMANS M, 1992, MEM I OSWALDO CRUZ, V87, P385, DOI 10.1590/S0074-02761992000700065; DEMEDTS P, 1985, ANN SOC BELG MED TR, V65, P89; Erhart A, 2004, AM J TROP MED HYG, V70, P110, DOI 10.4269/ajtmh.2004.70.110; ERHART A, 1999, RETROSPECTIVE STUDY; GERTLER P, 1998, HOUSEHOLD WELFARE VI, P61; GOMES M, 1994, B WORLD HEALTH ORGAN, V72, P383; *JIRCAS JAP, 1997, COLL RES METH IMPR F; Lonnroth K, 2001, SOC SCI MED, V52, P935, DOI 10.1016/S0277-9536(00)00195-7; Lonnroth K, 2001, HEALTH POLICY PLANN, V16, P47, DOI 10.1093/heapol/16.1.47; Luxemburger C, 1998, T ROY SOC TROP MED H, V92, P45, DOI 10.1016/S0035-9203(98)90950-6; MCNAMEE P, 2003, MEASURES SUSTAINABLE; *MIN AGR RUR DEV, 2001, WAT RES MAN AGR DEV; *NAT I MAL, 2002, ANN REP NAT MAL CONT; *NAT I MAL, 2003, ANN REP NAT MAL CONT; OLIVAR M, 1991, T ROY SOC TROP MED H, V85, P729, DOI 10.1016/0035-9203(91)90432-X; Phan V. T., 1998, EPIDEMIOLOGICAL CHAR; Redd SC, 1996, LANCET, V347, P223, DOI 10.1016/S0140-6736(96)90404-3; Singla N, 1998, INT J TUBERC LUNG D, V2, P384; Trung HD, 2004, TROP MED INT HEALTH, V9, P230, DOI 10.1046/j.1365-3156.2003.01179.x; UPLEKAR MW, 1993, TUBERCLE LUNG DIS, V74, P332, DOI 10.1016/0962-8479(93)90108-A; Uplekar MW, 1996, INDIAN J TUBERC, V43, P19; White N, 1999, PHILOS T R SOC B, V354, P739, DOI 10.1098/rstb.1999.0426; *WHO, 1982, WKLY EPIDEMIOL REC, V57, P361; *WHO, 1980, MAN BAS TECHN HLTH L, P379; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	30	11	11	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2004	9	10					1081	1090		10.1111/j.1365-3156.2004.01310.x				10	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	862BK	WOS:000224464400006	15482400	Bronze			2019-03-26	
J	Rwagacondo, CE; Karema, C; Mugisha, V; Erhart, A; Dujardin, JC; Overmeir, CV; Ringwald, P; D'Alessandro, U				Rwagacondo, CE; Karema, C; Mugisha, V; Erhart, A; Dujardin, JC; Overmeir, CV; Ringwald, P; D'Alessandro, U			Is amodiaquine failing in Rwanda? Efficacy of amodiaquine alone and combined with artesunate in children with uncomplicated malaria	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						amodiaquine; artesunate; uncomplicated malaria; Rwanda	PLASMODIUM-FALCIPARUM MALARIA; SULFADOXINE-PYRIMETHAMINE; POLICY; TRIAL; COMBINATION; AFRICA; CHLOROQUINE; RESISTANCE	We investigated the safety and efficacy of amodiaquine alone (AQ) and combined with artesunate (AQ + AS) in 308 Rwandan children 6-59 months old with uncomplicated Plasmodium falciparum malaria attending three sentinel sites. The two treatment regimes were well tolerated and no serious adverse events were recorded. After excluding new infections, children treated with AQ + AS had fewer clinical failures at day 28 after treatment than those treated with AQ alone: OR = 0.20 [95% CI: 0.06-0.57 (P = 0.001)]. Total (parasitological and clinical) failure was also significantly less frequent in the AQ + AS group: OR = 0.34 [95% CI: 0.17-0.67 (P = 0.001)]. When adjusting for study site, the hazard ratio for treatment failure was 0.37 [95% CI: 0.20-0.68 (P = 0.001)]. Combining AQ with AS increases the efficacy of the treatment but the apparent increase of AQ resistance observed in just a 1-year period is worrying and casts doubts on the suitability of implementing AQ + AS as first-line treatment in Rwanda. Alternative treatments should be identified and tested.	Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium; Natl Malaria Control Program, Kigali, Rwanda; WHO, Roll Back Malaria, CH-1211 Geneva 27, Switzerland	Rwagacondo, CE (reprint author), Inst Trop Med Prince Leopold, Natl Str 155, B-2000 Antwerp, Belgium.	crwagacondo@hotmail.com; corine_k@hotmail.com; vnmugisha@hotmail.com; aerhart@itg.be; jcdujard@itg.be; cvoverm@itg.be; ringwaldp@who.int; udalessandro@itg.be	D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009			Adjuik M, 2002, LANCET, V359, P1365, DOI 10.1016/S0140-6736(02)08348-4; BLOLAND PB, 1993, J INFECT DIS, V167, P932, DOI 10.1093/infdis/167.4.932; Bloland PB, 2003, AM J TROP MED HYG, V68, P125, DOI 10.4269/ajtmh.2003.68.125; Brasseur P, 1999, T ROY SOC TROP MED H, V93, P645, DOI 10.1016/S0035-9203(99)90083-4; Checchi F, 2002, T ROY SOC TROP MED H, V96, P670, DOI 10.1016/S0035-9203(02)90348-2; Dorsey G, 2002, LANCET, V360, P2031, DOI 10.1016/S0140-6736(02)12021-6; GIL VS, IN PRESS T ROYAL SOC; Hastings IM, 2000, PARASITOL TODAY, V16, P340, DOI 10.1016/S0169-4758(00)01707-5; Irion A, 1998, TROP MED INT HEALTH, V3, P490, DOI 10.1046/j.1365-3156.1998.00253.x; *MIN SANT, 1999, RAPP ANN 1998; Nosten F, 2000, LANCET, V356, P297, DOI 10.1016/S0140-6736(00)02505-8; Ringwald P, 2000, TROP MED INT HEALTH, V5, P620, DOI 10.1046/j.1365-3156.2000.00614.x; Rwagacondo CE, 2003, AM J TROP MED HYG, V68, P743, DOI 10.4269/ajtmh.2003.68.743; Schellenberg D, 2002, AM J TROP MED HYG, V67, P17, DOI 10.4269/ajtmh.2002.67.17; Shretta R, 2000, TROP MED INT HEALTH, V5, P755, DOI 10.1046/j.1365-3156.2000.00643.x; TRAPE JF, 2001, AM J TROP MED HYG, V64, pS12; von Seidlein L, 2000, LANCET, V355, P352, DOI 10.1016/S0140-6736(99)10237-X; White N J, 1998, Med Trop (Mars), V58, P54; *WHO, 2003, WHOHTMRBM200350; Wongsrichanalai C, 2000, LANCET, V355, P2245, DOI 10.1016/S0140-6736(00)02416-8	20	39	39	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2004	9	10					1091	1098		10.1111/j.1365-3156.2004.01316.x				8	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	862BK	WOS:000224464400007	15482401	Bronze			2019-03-26	
J	Jena, AB; Mohanty, KC; Devadasan, N				Jena, AB; Mohanty, KC; Devadasan, N			An outbreak of leptospirosis in Orissa, India: the importance of surveillance	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						surveillance; leptospirosis; outbreak		OBJECTIVE To demonstrate the importance of surveillance systems in detecting emerging diseases and highlighting the strengths and weaknesses of an existing one. METHODS The Orissa multi-disease surveillance system (OMDSS) was introduced in November 1999. Reporting units from the periphery send data to the district on a weekly basis. These reports are analysed regularly. A district task force (DTF) was available to intervene in the event of an outbreak. The OMDSS detected an increasing number of cases with fever and jaundice in June 2002. The DTF investigated this outbreak using clinical, epidemiological and laboratory tools to identify its cause. RESULTS This outbreak, in a remote corner of India, was detected within 4 days by an existing surveillance system. Action was initiated within 24 h, but it took approximately two more weeks for the causative agent to be diagnosed. A total of 143 people were suspected to have leptospirosis between 23 June 2002 and 31 July 2002. The attack rate was 5.95% and the case fatality ratio (CFR) was 7.69%, both lower than outbreaks reported elsewhere in India. While males were infected more often than females, the CFR was higher among females and among the 6-15 year age groups. Exposure to infected water in a canal was the probable cause of the outbreak. IgM antibodies were positive in 33 of the patients and six patients tested positive for PCR and culture. Leptospirosis interrogans serovar canicola, Leptospirosis interrogans serovar pomona and Leptospirosis interrogans serovar hebdomadis were isolated. CONCLUSIONS Leptospirosis is a new disease in this region of India. This outbreak was detected and diagnosed because of the surveillance system. The prompt response helped in containing the outbreak early enough. However, the morbidity and mortality could have been further mitigated if the delays in transmitting information had been minimized. An adequate laboratory support would have also helped considerably. We conclude stressing the importance of surveillance as a public health tool.	Dist Hlth Off, Baripada, Orissa, India; ITG, Antwerp, Belgium	Devadasan, N (reprint author), Inst Trop Med, 155 Natl Str, B-2000 Antwerp, Belgium.	abanijena@yahoo.com; devadasan@itg.be					*AM PUBL HLTH ASS, 2000, CONTR COMM DIS MAN, P293; Ciceroni L, 2000, EUR J EPIDEMIOL, V16, P79, DOI 10.1023/A:1007658607963; Clerke A M, 2002, J Postgrad Med, V48, P117; *DEP HLTH FAM WELF, 2001, LEPT MAH STAT, P1; GERRITSEN MA, 1995, J MED MICROBIOL, V42, P336, DOI 10.1099/00222615-42-5-336; KAKKILAYA BS, 2000, INVESTIGATION LEPTOS, P1; Karande Sunil, 2002, Indian Journal of Pediatrics, V69, P855, DOI 10.1007/BF02723705; Ko AI, 1999, LANCET, V354, P820, DOI 10.1016/S0140-6736(99)80012-9; Kuriakose M, 1997, EUR J EPIDEMIOL, V13, P691, DOI 10.1023/A:1007300729615; Morgan J, 2002, CLIN INFECT DIS, V34, P1593, DOI 10.1086/340615; Murhekar MV, 1998, INDIAN J MED RES, V107, P218; *NAT SLEEP FDN, 2002, EX SUMM 2002 SLEEP A, P1; RATNAM S, 1993, J TROP MED HYG, V96, P41; SEHGAL SC, 1995, INDIAN J MED RES, V102, P9; Sehgal SC, 2002, NATL MED J INDIA, V15, P22; Sehgal SC, 2000, NATL MED J INDIA, V13, P228; *WEEKL EP REP, 2000, WER, V75, P217; WHO, 2003, WHO TECH REP SER, V916, P1	18	29	31	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	SEP	2004	9	9					1016	1021		10.1111/j.1365-3156.2004.01293.x				6	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	855OH	WOS:000223983100012	15361116	Bronze			2019-03-26	
J	Van Geertruyden, JP; Thomas, F; Erhart, A; D'Alessandro, U				Van Geertruyden, JP; Thomas, F; Erhart, A; D'Alessandro, U			The contribution of malaria in pregnancy to perinatal mortality	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							LOW-BIRTH-WEIGHT; PLACENTAL MALARIA; INFANT-MORTALITY; RURAL MALAWI; RISK-FACTORS; AREA; INFECTION; AFRICA; ANEMIA; MORBIDITY	The link between malaria and perinatal mortality was explored by systematically reviewing 117 studies published between 1948 and 2002. The mean perinatal mortality rate was higher in malaria endemic countries (61.1/1,000, 95% confidence interval [CI] = 52.1-70.1) than in non-endemic countries (25.8/1,000, 95% CI = 21.1-30.6). Similarly, the fetal mortality rate was higher in endemic countries (40.1/1,000, 95% CI = 32.1-48.0) than in non-endemic countries (20.0/1,000, 95% CI = 13.2-26.8) countries. Considering that perinatal mortality is an important indicator of obstetric care quality and socioeconomic development, further analysis was restricted to countries with a human development index between 500 and 800. In this category, the perinatal mortality rate was also significantly higher in endemic countries (50.5/1,000, 95% CI = 35.5-65.5) than in non-endemic countries (30.0/1,000, 95% CI = 25.7-34.3). In some publications, the occurrence of placental malaria and stillbirth was available. Placental malaria was significantly associated with a higher risk for stillbirth, regardless of parity (odds ratio = 2.19, 95% CI = 1.49-3.22, P < 0.001). Despite the limitations involved in this kind of review, all information found indicates that in endemic countries, malaria is an important determinant of perinatal mortality. Preventive measures such as intermittent preventive treatment or insecticide-treated bed nets could substantially reduce perinatal mortality and fetal wastage.	Inst Trop Med Prince Leopold, Dept Parasitol, B-2000 Antwerp, Belgium	D'Alessandro, U (reprint author), Inst Trop Med Prince Leopold, Dept Parasitol, Nationalestr 155, B-2000 Antwerp, Belgium.	udalessandro@itg.be	Van geertruyden, Jean-Pierre/K-6425-2014; D'Alessandro, Umberto/D-3457-2015	Van geertruyden, Jean-Pierre/0000-0001-5006-6364; D'Alessandro, Umberto/0000-0001-6341-5009			Amoa Apeawusu B., 1998, Papua New Guinea Medical Journal, V41, P126; ANAGNOS D, 1986, Z PARASITENKD, V72, P57, DOI 10.1007/BF00927734; ARCHIBALD H. MUNRO, 1956, BULL WORLD HEALTH ORGAN, V15, P842; BARROS FC, 1987, B WORLD HEALTH ORGAN, V65, P95; Blacklock DB, 1925, ANN TROP MED PARASIT, V19, P327; BRABIN BJ, 1983, B WORLD HEALTH ORGAN, V61, P1005; BRUCECHWATT LJ, 1952, ANN TROP MED PARASIT, V46, P173, DOI 10.1080/00034983.1952.11685522; BRUCECHWATT LJ, 1983, BRIT MED J, V286, P63; Carles G., 1998, Journal de Gynecologie Obstetrique et Biologie de la Reproduction, V27, P798; Cohn LD, 2003, PSYCHOL METHODS, V8, P243, DOI 10.1037/1082-989X.8.3.243; CONNOR DSH, 1958, BRIT MED J, V2, P877; DAlessandro U, 1996, T ROY SOC TROP MED H, V90, P487, DOI 10.1016/S0035-9203(96)90289-8; Das L. K., 2000, Indian Journal of Malariology, V37, P11; GARNER P, 2003, COCHRANE DB SYST REV, V1, P169; Geelhoed DW, 2001, INT J GYNECOL OBSTET, V74, P133, DOI 10.1016/S0020-7292(01)00419-2; GREENWOOD AM, 1994, T ROY SOC TROP MED H, V88, P311, DOI 10.1016/0035-9203(94)90094-9; GREENWOOD AM, 1987, B WORLD HEALTH ORGAN, V65, P635; Guildea ZES, 2001, ARCH DIS CHILD, V84, P307, DOI 10.1136/adc.84.4.307; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Hodges M, 1998, West Afr J Med, V17, P95; Jamieson DJ, 2000, JAMA-J AM MED ASSOC, V283, P397, DOI 10.1001/jama.283.3.397; JELLIFFE EF, 1968, B WORLD HEALTH ORGAN, V38, P69; Kalenga M K, 1992, Rev Fr Gynecol Obstet, V87, P26; Kasumba IN, 2000, ANN TROP MED PARASIT, V94, P7, DOI 10.1080/00034980057563; KRAMER MS, 1987, B WORLD HEALTH ORGAN, V65, P663; Kulmala T, 2000, PAEDIATR PERINAT EP, V14, P219, DOI 10.1046/j.1365-3016.2000.00270.x; Lamikanra O T, 1993, West Afr J Med, V12, P213; Lefait J. F., 1999, Medecine d'Afrique Noire, V46, P93; Luxemburger C, 2001, AM J EPIDEMIOL, V154, P459, DOI 10.1093/aje/154.5.459; Matteelli A, 1996, ANN TROP MED PARASIT, V90, P125, DOI 10.1080/00034983.1996.11813036; MCCORMICK MC, 1985, NEW ENGL J MED, V312, P82, DOI 10.1056/NEJM198501103120204; McDermott J, 1996, B WORLD HEALTH ORGAN, V74, P165; McGready R, 2001, CLIN INFECT DIS, V33, P2009, DOI 10.1086/324349; MCGREGOR IA, 1983, T ROY SOC TROP MED H, V77, P232, DOI 10.1016/0035-9203(83)90081-0; MCLAREN DS, 1962, E AFR MED J, V39, P182; MENENDEZ C, 1994, T ROY SOC TROP MED H, V88, P590, DOI 10.1016/0035-9203(94)90176-7; Menon R, 1972, Med J Malaya, V27, P115; Mola G, 1999, AUST NZ J OBSTET GYN, V39, P31, DOI 10.1111/j.1479-828X.1999.tb03439.x; Murphy SC, 2001, AM J TROP MED HYG, V64, P57, DOI 10.4269/ajtmh.2001.64.57; NAIDU J, 2001, J OBSTET GYNAECOL, V21, P443; Ndyomugyenyi R, 2001, T ROY SOC TROP MED H, V95, P463, DOI 10.1016/S0035-9203(01)90003-3; Newman RD, 2003, J INFECT DIS, V187, P1765, DOI 10.1086/374878; Newman RD, 2003, TROP MED INT HEALTH, V8, P488, DOI 10.1046/j.1365-3156.2003.01066.x; Nosten F, 1999, CLIN INFECT DIS, V28, P808, DOI 10.1086/515183; NOSTEN F, 1991, T ROY SOC TROP MED H, V85, P424, DOI 10.1016/0035-9203(91)90205-D; Nosten F, 1999, LANCET, V354, P546, DOI 10.1016/S0140-6736(98)09247-2; NYIRJESY P, 1993, CLIN INFECT DIS, V16, P127, DOI 10.1093/clinids/16.1.127; Okoko BJ, 2002, J HEALTH POPUL NUTR, V20, P4; Osman NB, 1995, J TROP PEDIATRICS, V41, P258, DOI 10.1093/tropej/41.5.258; PAKSOY N, 1986, T ROY SOC TROP MED H, V80, P174, DOI 10.1016/0035-9203(86)90237-3; Peel E., 1948, Annales de la Societe Belge de Medecine Tropicale, V28, P413; PHILIPPE E, 1984, Journal de Gynecologie Obstetrique et biologie de la Reproduction, V13, P515; Reinhardt M. C., 1978, Helvetica Paediatrica Acta, V33, P65; RICHARDUS JH, 2003, BJOG, V11, P97; SACHS J, 2003, EC ANAL INDICATE BUR; Schwetz J, 1934, T ROY SOC TROP MED H, V28, P167; Shulman CE, 2003, T ROY SOC TROP MED H, V97, P30, DOI 10.1016/S0035-9203(03)90012-5; Singh N, 2001, ANN TROP MED PARASIT, V95, P19, DOI 10.1080/00034980020035889; Snow RW, 1999, B WORLD HEALTH ORGAN, V77, P624; SPITZ A J, 1959, Bull World Health Organ, V21, P242; Steketee RW, 1996, AM J TROP MED HYG, V55, P17, DOI 10.4269/ajtmh.1996.55.17; Steketee RW, 2001, AM J TROP MED HYG, V64, P28, DOI 10.4269/ajtmh.2001.64.28; Sule-Odu A O, 2002, J Obstet Gynaecol, V22, P25, DOI 10.1080/01443610120101664; TABUTIN D, 1980, MORTALITY SOC SUBSAH, P35; TAHA TE, 1993, AM J EPIDEMIOL, V138, P563, DOI 10.1093/oxfordjournals.aje.a116896; *UNDP, 2003, RAPP MOND DEV HUM 20; VANHUNG L, 1951, REV PAL MED TROP, V83, P75; VOORHOEVE AM, 1979, TROP GEOGR MED, V31, P607; WALRAVEN GEL, 1994, TROP GEOGR MED, V46, P11; Weiner R, 2003, B WORLD HEALTH ORGAN, V81, P561; *WHO, 1996, WHOFRHMSM9671996; WOODRUFF AW, 1983, LANCET, V2, P262	72	92	96	0	1	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637	1476-1645		AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	AUG	2004	71	2		S			35	40		10.4269/ajtmh.2004.71.35				6	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	850LM	WOS:000223612900007	15331817	Green Published			2019-03-26	
J	Ballou, WR; Arevalo-Herrera, M; Carucci, D; Richie, TL; Corradin, G; Diggs, C; Druilhe, P; Giersing, BK; Saul, A; Heppner, DG; Kester, KE; Lanar, DE; Lyon, J; Hill, AVS; Pan, WQ; Cohen, JD				Ballou, WR; Arevalo-Herrera, M; Carucci, D; Richie, TL; Corradin, G; Diggs, C; Druilhe, P; Giersing, BK; Saul, A; Heppner, DG; Kester, KE; Lanar, DE; Lyon, J; Hill, AVS; Pan, WQ; Cohen, JD			Update on the clinical development of candidate malaria vaccines	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article; Proceedings Paper	3rd Multilateral Initiative on Malaria Pan-African Malaria Conference	NOV 17-22, 2002	ARUSHA, TANZANIA	Ctr Dis Control & Prevent, US Agcy Int Dev, JHPIEGO Corp			PLASMODIUM-FALCIPARUM MALARIA; CIRCUMSPOROZOITE PROTEIN VACCINE; APICAL MEMBRANE ANTIGEN-1; HUMORAL IMMUNE-RESPONSES; CYTOTOXIC T-LYMPHOCYTES; VIRUS ANKARA; DNA VACCINE; IN-VITRO; IMMUNOGENICITY; EFFICACY	The recent availability of significantly increased levels of funding for unmet medical needs in the developing world, made available by newly created public-private-partnerships, has proven to be a powerful driver for stimulating clinical development of candidate vaccines for malaria. This new way forward promises to greatly increase the likelihood of bringing a safe and effective vaccine to licensure. The investigators bring together important published and unpublished information that illuminates the status of malaria vaccine development. They focus their comments on those candidate vaccines that are currently in or expected to enter clinical trials in the next 12 months.	GlaxoSmithKline Biol, Clin Res & Dev, Emerging Dis, Rixensart, Belgium; GlaxoSmithKline Biol, Res & Dev, Rixensart, Belgium; Malaria Vaccine & Drug Testing Ctr, Cali, Colombia; USN, Med Res Ctr, Malaria Program, Silver Spring, MD USA; Univ Lausanne, Lausanne, Switzerland; US Agcy Int Dev, Malaria Vaccine Dev Program, Washington, DC USA; Inst Pasteur, Paris, France; NIAID, Malaria Vaccine Dev Unit, NIH, Bethesda, MD 20892 USA; Walter Reed Army Inst Res, Dept Immunol, Silver Spring, MD USA; Walter Reed Army Inst Res, Dept Clin Trials, Silver Spring, MD USA; Univ Oxford, Ctr Clin Vaccinol & Trop Med, Oxford, England; Second Mil Med Univ, Shanghai, Peoples R China	Ballou, WR (reprint author), GlaxoSmithKline Biol, Clin Res & Dev, Emerging Dis, 89 Rue Inst, Rixensart, Belgium.	Ripley.Ballou@gskbio.com	Lanar, David/B-3560-2011; HILL, Adrian/C-1306-2008; Kester, Kent/A-2114-2011; Saul, Allan/I-6968-2013; Richie, Thomas/A-8028-2011	Kester, Kent/0000-0002-5056-0802; Saul, Allan/0000-0003-0665-4091; Arevalo, Myriam/0000-0002-3434-9425			Anders RF, 1998, VACCINE, V16, P240, DOI 10.1016/S0264-410X(97)88331-4; Angov E, 2003, MOL BIOCHEM PARASIT, V128, P195, DOI 10.1016/S0166-6851(03)00077-X; Arevalo-Herrera M, 2002, PARASITE IMMUNOL, V24, P161, DOI 10.1046/j.1365-3024.2002.00449.x; BALLOU WR, 1987, LANCET, V1, P1277; Birkett A, 2002, INFECT IMMUN, V70, P6860, DOI 10.1128/IAI.70.12.6860-6870.2002; Bojang KA, 2001, LANCET, V358, P1927, DOI 10.1016/S0140-6736(01)06957-4; Chang SP, 1996, INFECT IMMUN, V64, P253; Daubersies P, 2000, NAT MED, V6, P1258; Doherty JF, 1999, AM J TROP MED HYG, V61, P865, DOI 10.4269/ajtmh.1999.61.865; Garcon Nathalie, 2003, Expert Rev Vaccines, V2, P231, DOI 10.1586/14760584.2.2.231; Garraud O, 1999, SCAND J IMMUNOL, V49, P431, DOI 10.1046/j.1365-3083.1999.00511.x; Genton B, 2002, J INFECT DIS, V185, P820, DOI 10.1086/339342; Good MF, 2001, NAT REV IMMUNOL, V1, P117, DOI 10.1038/35100540; GORDON DM, 1995, J INFECT DIS, V171, P1576, DOI 10.1093/infdis/171.6.1576; Gozar MMG, 2001, EXP PARASITOL, V97, P61, DOI 10.1006/expr.2000.4580; Hodder AN, 2001, INFECT IMMUN, V69, P3286, DOI 10.1128/IAI.69.5.3286-3294.2001; Hoffman SL, 2002, J INFECT DIS, V185, P1155, DOI 10.1086/339409; Holder A. A., 1999, Parassitologia (Rome), V41, P409; Kennedy MC, 2002, INFECT IMMUN, V70, P6948, DOI 10.1128/IAI.70.12.6948-6960.2002; Kester KE, 2001, J INFECT DIS, V183, P640, DOI 10.1086/318534; Lalvani A, 1999, J INFECT DIS, V180, P1656, DOI 10.1086/315074; Le TP, 2000, VACCINE, V18, P1893, DOI 10.1016/S0264-410X(99)00407-7; Lopez JA, 2001, EUR J IMMUNOL, V31, P1989, DOI 10.1002/1521-4141(200107)31:7<1989::AID-IMMU1989>3.3.CO;2-D; McConkey SJ, 2003, NAT MED, V9, P729, DOI 10.1038/nm881; Milich DR, 2001, VACCINE, V20, P771, DOI 10.1016/S0264-410X(01)00400-5; Moorthy VS, 2003, J INFECT DIS, V188, P1239, DOI 10.1086/378515; Nevill CG, 1996, TROP MED INT HEALTH, V1, P139; NUSSENZWEIG RS, 1967, NATURE, V216, P160, DOI 10.1038/216160a0; Oeuvray C, 2000, INFECT IMMUN, V68, P2617, DOI 10.1128/IAI.68.5.2617-2620.2000; OEUVRAY C, 1994, BLOOD, V84, P1594; Pan WQ, 1999, NUCLEIC ACIDS RES, V27, P1094, DOI 10.1093/nar/27.4.1094; Schneider J, 1998, NAT MED, V4, P397, DOI 10.1038/nm0498-397; Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202; Stoute JA, 1998, J INFECT DIS, V178, P1139, DOI 10.1086/515657; Wang RB, 1998, INFECT IMMUN, V66, P4193; Wang RB, 1998, SCIENCE, V282, P476, DOI 10.1126/science.282.5388.476	36	95	96	0	3	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	AUG	2004	71	2		S			239	247						9	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	850LM	WOS:000223612900033	15331843				2019-03-26	
J	Robays, J; Kadima, AE; Lutumba, P; Bilenge, CMM; Mesu, VKBK; De Deken, R; Makabuza, J; Deguerry, M; Van der Stuyft, P; Boelaert, M				Robays, J; Kadima, AE; Lutumba, P; Bilenge, CMM; Mesu, VKBK; De Deken, R; Makabuza, J; Deguerry, M; Van der Stuyft, P; Boelaert, M			Human African trypanosomiasis amongst urban residents in Kinshasa: a case-control study	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						human African trypanosomiasis; urban; case-control study; risk factors; Democratic Republic of Congo	SLEEPING SICKNESS; COTE-DIVOIRE; RISK; ACQUISITION	BACKGROUND Increasing numbers of human African trypanosomiasis (HAT) cases have been reported in urban residents of Kinshasa, Democratic Republic Congo since 1996. We set up a case-control study to identify risk factors for the disease. METHODS All residents of the urban part of Kinshasa with parasitologically confirmed HAT and presenting for treatment to the city's specialized HAT clinics between 1 August, 2002 and 28 February, 2003 were included as cases. We defined the urban part as the area with contiguous habitation and a population density >5000 inhabitants per square kilometre. A digital map of the area was drawn based on a satellite image. For each case, two serologically negative controls were selected, matched on age, sex and neighbourhood. Logistic regression models were fitted to control for confounding. RESULTS The following risk factors were independently associated with HAT: travel, commerce and cultivating fields in Bandundu, and commerce and cultivating fields in the rural part of Kinshasa. No association with activities in the city itself was found. DISCUSSION In 2002, the emergence of HAT in urban residents of Kinshasa appears mainly linked to disease transmission in Bandundu and rural Kinshasa. We recommend to intensify control of these foci, to target HAT screening in urban residents to people with contact with these foci, to increase awareness of HAT amongst health workers in the urban health structures and to strengthen disease surveillance.	Inst Trop Med, Epidemiol Unit, B-2000 Antwerp, Belgium; Programme Natl Lutte THA, Kinshasa, Zaire; Med Sans Frontieres, B-1090 Brussels, Belgium; Inst Trop Med, Dept Vet Sci, B-2000 Antwerp, Belgium	Robays, J (reprint author), Inst Trop Med, Epidemiol Unit, Natl Str 155, B-2000 Antwerp, Belgium.	jrobays@itg.be; kadima_ebeja@hotmail.com; lutumba@everyday.com; rdeken@itg.be; murielle.deguerry@msf.be; pvds@itg.be; mboelaert@itg.be	Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776			[Anonymous], 1998, WHO TECHN REP SER, V881; Bilengue C M, 2001, Med Trop (Mars), V61, P445; BURKE J, 1992, MED HYGIENE AFRIQUE, P1399; DUPONT WD, 1988, BIOMETRICS, V44, P1157, DOI 10.2307/2531743; EBEJA AK, 2003, TROP MED INT HEALTH, V8, P945; Fevre EM, 2001, LANCET, V358, P625, DOI 10.1016/S0140-6736(01)05778-6; Fournet F, 2000, ANN TROP MED PARASIT, V94, P113, DOI 10.1080/00034980057455; Gouteux J.P., 1987, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V40, P59; Gouteux J.P., 1986, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V39, P355; Grebaut P, 2001, Med Trop (Mars), V61, P377; LAVEISSIERE C, 1994, T ROY SOC TROP MED H, V88, P645, DOI 10.1016/0035-9203(94)90207-0; MAGNUS E, 1978, ANN SOC BELG MED TR, V58, P169; Meda A H, 1993, Med Trop (Mars), V53, P83; MULUMBA PM, 1993, PANORAMA MED, V4, P169; Noireau F., 1987, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V40, P67; OKIA M, 1994, ANN SOC BELG MED TR, V74, P105; Van Nieuwenhove S, 2001, TROP MED INT HEALTH, V6, P335, DOI 10.1046/j.1365-3156.2001.00731.x; VANHOOF L, 1933, ANN SOC BELG MED TR, V13, P496; VANNIEUWENHOVE S, 1991, SEM MOD APPL OPT PRI, P131; WATSENGA TN, 1998, CONGO MED, V2, P453; Welburn SC, 2001, TRENDS PARASITOL, V17, P19, DOI 10.1016/S1471-4922(00)01839-0; WYATT GB, 1985, ANN TROP MED PARASIT, V79, P385, DOI 10.1080/00034983.1985.11811936	22	18	18	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	AUG	2004	9	8					869	875		10.1111/j.1365-3156.2004.01266.x				7	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	845ED	WOS:000223217900005	15303991				2019-03-26	
J	Danso-Appiah, A; De Vlas, SJ; Bosompem, KM; Habbema, JDF				Danso-Appiah, A; De Vlas, SJ; Bosompem, KM; Habbema, JDF			Determinants of health-seeking behaviour for schistosomiasis-related symptoms in the context of integrating schistosomiasis control within the regular health services in Ghana	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						schistosomiasis; health-seeking behaviour; health services; integration; Ghana	COMMUNITY-BASED CHEMOTHERAPY; GENITAL SCHISTOSOMIASIS; URINARY SCHISTOSOMIASIS; PERIPORTAL FIBROSIS; MANSONI INFECTION; CONTROL PROJECT; SELF-TREATMENT; WESTERN KENYA; CARE PROGRAM; VOLTA LAKE	Morbidity control of schistosomiasis through integration within existing health care delivery systems is considered a potentially sustainable and cost-effective approach. We conducted a questionnaire-based field study in a Ghanaian village endemic for both urinary and intestinal schistosomiasis to determine whether infected individuals self-reported to health centres or clinics and to identify factors that influenced their decision to seek health care. A total of 317 subjects were interviewed about having signs and symptoms suggestive of schistosomiasis: blood in urine, painful urination, blood in stool/bloody diarrhoea, abdominal pain, diarrhoea, swollen abdomen and fatigue within 1 month of the day of the interview. Fever (for malaria) was included as a disease of high debility for comparison. Around 70% with blood in urine or painful urination did not seek health care, whilst diarrhoea, blood in stool, abdominal pain and fever usually led to action (mainly self-medication, with allopathic drugs being used four to five times more often than herbal treatment). On average 20% of schistosomiasis-related signs and symptoms were reported to health facilities either as the first option or second and third alternative by some of those that self-medicated. A few of those who visited a clinic or health centre as first option still self-medicated afterwards. Children under 10 years and adults were more likely to seek health care than teenagers. Also, females were more likely to visit a health facility than males of the same age groups. Socio-economic status and duration of symptoms did not appear to affect health-seeking behaviour. 'Do not have the money' (43%) and 'Not serious enough' (41%) were the commonest reasons for not visiting a clinic, reported more frequently by lower and higher socio-economic classes, respectively, for both urinary or intestinal schistosomiasis. The regular health service shows some potential in passive control of schistosomiasis as some, but far too few, people visit a health facility as first or second option.	Univ Med Ctr Rotterdam, Erasmus MC, Dept Publ Hlth, NL-3000 DR Rotterdam, Netherlands; Univ Ghana, NMIMR, Legon, Accra, Ghana; Inst Trop Med, B-2000 Antwerp, Belgium	De Vlas, SJ (reprint author), Univ Med Ctr Rotterdam, Erasmus MC, Dept Publ Hlth, POB 1738, NL-3000 DR Rotterdam, Netherlands.	s.devlas@erasmusmc.nl					ABOSEDE OA, 1984, SOC SCI MED, V19, P699, DOI 10.1016/0277-9536(84)90242-9; AGYEPONG IA, 1992, SOC SCI MED, V35, P131, DOI 10.1016/0277-9536(92)90160-R; Ahmed SM, 2000, SOC SCI MED, V51, P361, DOI 10.1016/S0277-9536(99)00461-X; AMANKWA JA, 1994, TROP MED PARASITOL, V45, P319; [Anonymous], 1985, WHO TECHN REP SER, V728; [Anonymous], 1993, WHO TECHN REP SER, V830; Aryeetey ME, 1999, E AFR MED J, V76, P324; Aryeetey ME, 2000, PARASITOL INT, V49, P155, DOI 10.1016/S1383-5769(00)00044-1; Asenso-Okyere WK, 1998, HEALTH POLICY PLANN, V13, P181, DOI 10.1093/heapol/13.2.181; AsensoOkyere WK, 1997, SOC SCI MED, V45, P659, DOI 10.1016/S0277-9536(96)00383-8; Azene G, 1999, ACTA TROP, V73, P183; Barakat R, 1995, TROP GEOGR MED, V47, P266; Biritwum R B, 1994, West Afr J Med, V13, P124; CHU KY, 1978, B WORLD HEALTH ORGAN, V56, P313; Curtale F, 1999, J TROP PEDIATRICS, V45, P14, DOI 10.1093/tropej/45.1.14; DOEHRINGSCHWERDTFEGER E, 1992, AM J TROP MED HYG, V46, P409, DOI 10.4269/ajtmh.1992.46.409; ELKATSHA S, 1995, J TROP MED HYG, V98, P136; ELMALATAWY A, 1992, B WORLD HEALTH ORGAN, V70, P47; ENGELS D, 1994, ACTA TROP, V58, P127, DOI 10.1016/0001-706X(94)90052-3; Gazzinelli A, 1998, Cad Saude Publica, V14, P841, DOI 10.1590/S0102-311X1998000400026; Geissler PW, 2000, SOC SCI MED, V50, P1771, DOI 10.1016/S0277-9536(99)00428-1; GRYSEELS B, 1991, AM J TROP MED HYG, V45, P509, DOI 10.4269/ajtmh.1991.45.509; Haider Sohail, 1995, JPMA (Journal of the Pakistan Medical Association), V45, P297; Hewlett BS, 1997, TROP MED INT HEALTH, V2, pA25; Jaramillo E, 1998, TROP MED INT HEALTH, V3, P138, DOI 10.1046/j.1365-3156.1998.00202.x; Keller SD, 1997, HEALTH SERV RES, V32, P367; KLOOS H, 1987, SOC SCI MED, V25, P1003, DOI 10.1016/0277-9536(87)90005-0; KLOOS H, 1995, SOC SCI MED, V40, P1497, DOI 10.1016/0277-9536(94)00310-P; KUMAR V, 1994, INT J ANTIMICROB AG, V4, P313, DOI 10.1016/0924-8579(94)90032-9; Lavoipierre G J, 1973, Rev Infirm, V23, P51; Leutscher P, 2000, LANCET, V355, P117, DOI 10.1016/S0140-6736(99)04856-4; Mock C, 1999, INT J EPIDEMIOL, V28, P750, DOI 10.1093/ije/28.4.750; MOHAMEDALI Q, 1991, AM J TROP MED HYG, V44, P444, DOI 10.4269/ajtmh.1991.44.444; Needham DM, 2001, TROP MED INT HEALTH, V6, P256, DOI 10.1046/j.1365-3156.2001.00709.x; Nokes C, 1999, AM J TROP MED HYG, V60, P556, DOI 10.4269/ajtmh.1999.60.556; Oberlander L, 2000, B WORLD HEALTH ORGAN, V78, P1352; ODEI M A, 1983, Bulletin de l'Institut Fondamental d'Afrique Noire Serie A Sciences Naturelles, V45, P195; Paperna I, 1970, Z Tropenmed Parasitol, V21, P411; Poggensee G, 2001, ACTA TROP, V79, P193, DOI 10.1016/S0001-706X(01)00086-9; RAMBAJAN I, 1994, TROP GEOGR MED, V46, P331; RUEBUSH TK, 1995, B WORLD HEALTH ORGAN, V73, P229; SCHULPEN TWJ, 1980, TROP GEOGR MED, V32, P340; SCOTT D, 1982, B WORLD HEALTH ORGAN, V60, P89; SLOOTWEG R, 1995, TROP GEOGR MED, V47, P6; Sodemann M, 1997, B WORLD HEALTH ORGAN, V75, P205; Soucat A, 1997, INT J HEALTH PLAN M, V12, pS137, DOI 10.1002/(SICI)1099-1751(199706)12:1+<S137::AID-HPM469>3.3.CO;2-7; TANNER M, 1986, TROP MED PARASITOL, V37, P220; TANNER M, 1986, TROP MED PARASITOL, V37, P164; Thorson A, 2000, LANCET, V356, P1823, DOI 10.1016/S0140-6736(00)03241-4; van der Werf MJ, 2003, T ROY SOC TROP MED H, V97, P146, DOI 10.1016/S0035-9203(03)90102-7; Wagatsuma Y, 1999, J INFECT DIS, V179, P1515, DOI 10.1086/314786; WEN ST, 1984, ANN TROP MED PARASIT, V78, P129, DOI 10.1080/00034983.1984.11811786; Wyss K, 1996, E AFR MED J, V73, P357	53	30	30	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	JUL	2004	9	7					784	794		10.1111/j.1365-3156.2004.01267.x				11	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	834QR	WOS:000222426100005	15228488				2019-03-26	
J	Pletschette, M; Nair, S				Pletschette, M; Nair, S			Editorial: Tuberculosis research: an end to neglect and negligence	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Editorial Material						EC; tuberculosis; research policy; control strategies			Commiss European Communities, SDME, DG Res, B-1049 Brussels, Belgium; INSERM, F-75014 Paris, France	Pletschette, M (reprint author), Commiss European Communities, SDME, DG Res, 200 Rue Loi, B-1049 Brussels, Belgium.	michel.pletschette@cec.eu.int; nair@necker.fr						0	1	2	0	0	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	JUL	2004	9	7					817	817		10.1111/j.1365-3156.2004.01271.x				1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	834QR	WOS:000222426100009	15228492				2019-03-26	
J	Garros, C; Koekemoer, LL; Coetzee, M; Coosemans, M; Manguin, S				Garros, C; Koekemoer, LL; Coetzee, M; Coosemans, M; Manguin, S			A single multiplex assay to identify major malaria vectors within the African Anopheles funestus and the Oriental An. minimus groups	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							POLYMERASE-CHAIN-REACTION; INTERNAL TRANSCRIBED SPACER; STRAND CONFORMATION POLYMORPHISM; RIBOSOMAL DNA; GAMBIAE COMPLEX; SPECIES COMPLEX; SEQUENCE VARIATION; CULICIDAE GROUP; ITS2 SEQUENCES; DIPTERA	The African Anopheles funestus and the Oriental An. minimus groups are closely related and composed of major malaria vectors in Africa and Southeast Asia, respectively. None of the species of either the An. funestus or the An. minimus group can be identified with absolute certainty using the adult morphology. Polymorphisms present on the internal transcribed spacer 2 (ITS2) of ribosomal DNA allowed the development of 10 primers that combined with an universal forward primer lead to a simple and sensitive multiplex allele-specific polymerase chain reaction (AS-PCR). Moreover, the possible additional amplification of the entire ITS2 allows one to detect other anopheline species in sympatry with members of both groups not included in this assay and serves as a control band. This universal PCR method permits the discrimination of 10 species within the subgenus Cellia, among which figure three major malaria vectors, and constitutes a very efficient and powerful tool to improve our knowledge on these species distribution and biology. Not only restricted to anophelines, this AS-PCR could also be developed and applied to other insect groups.	Ctr Biol & Management Populat, Inst Dev Res, Montpellier, France; Natl Inst Communicable Dis, Vector Control Reference Unit, Johannesburg, South Africa; Natl Hlth Lab Serv, Dept Clin Microbiol & Infect Dis, Sch Pathol, Johannesburg, South Africa; Univ Witwatersrand, Johannesburg, South Africa; Inst Trop Med Prince Leopold, Dept Parasitol, B-2000 Antwerp, Belgium	Garros, C (reprint author), Ctr Biol & Management Populat, Campus Int Baillarguet,CS 30016, F-34988 Montferrier Sur Lez, France.	garros@mpl.ird.fr; manguin@mpl.ird.fr	Manguin, Sylvie/G-1787-2015; Garros, Claire/C-2715-2011	Manguin, Sylvie/0000-0002-5925-7164; Coetzee, Maureen/0000-0003-2019-866X			Beebe NW, 1999, INSECT MOL BIOL, V8, P381, DOI 10.1046/j.1365-2583.1999.83127.x; Beebe NW, 2001, INSECT MOL BIOL, V10, P407, DOI 10.1046/j.0962-1075.2001.00278.x; Collins FH, 1996, INSECT MOL BIOL, V5, P1, DOI 10.1111/j.1365-2583.1996.tb00034.x; Cornel AJ, 1996, J MED ENTOMOL, V33, P109, DOI 10.1093/jmedent/33.1.109; Fettene M, 2003, J MED ENTOMOL, V40, P112, DOI 10.1603/0022-2585-40.1.112; Fritz GN, 1998, DNA SEQUENCE, V8, P215, DOI 10.3109/10425179809008454; GILLIES MT, 1968, PUBLICATION S AFRICA, V54; GILLIES MT, 1987, PUBLICATION S AFRICA, V55; GREEN CA, 1982, J HERED, V73, P2; Hackett BJ, 2000, INSECT MOL BIOL, V9, P369, DOI 10.1046/j.1365-2583.2000.00198.x; Hall T.A., 1999, NUCL ACIDS S SER, V41, P95, DOI DOI 10.1021/BK-1999-0734.CH008; HARBACH RE, 1994, B ENTOMOL RES, V84, P331, DOI 10.1017/S0007485300032454; Harbach RE, 1997, MED VET ENTOMOL, V11, P329, DOI 10.1111/j.1365-2915.1997.tb00418.x; HARRISON B A, 1980, Contributions of the American Entomological Institute, V17, P1; *IMPE, 1987, KEYS AN VIETN AD PUP; Kengne P, 2001, INSECT MOL BIOL, V10, P427, DOI 10.1046/j.0962-1075.2001.00281.x; Koekemoer LL, 1999, J MED ENTOMOL, V36, P125, DOI 10.1093/jmedent/36.2.125; Koekemoer LL, 1998, INSECT MOL BIOL, V7, P273, DOI 10.1046/j.1365-2583.1998.00072.x; Koekemoer LL, 2002, AM J TROP MED HYG, V66, P804, DOI 10.4269/ajtmh.2002.66.804; Koekemoer LL, 2002, AFR ENTOMOL, V10, P235; Linton YM, 2002, INSECT MOL BIOL, V11, P379, DOI 10.1046/j.1365-2583.2002.00338.x; Linton YM, 2001, SYST ENTOMOL, V26, P357, DOI 10.1046/j.1365-3113.2001.00153.x; Manguin S, 2001, Med Trop (Mars), V61, P463; Manonmani A, 2001, ACTA TROP, V78, P3, DOI 10.1016/S0001-706X(00)00154-6; MCLAIN DK, 1989, HEREDITY, V62, P233, DOI 10.1038/hdy.1989.33; PAPE T, 1992, Mosquito Systematics, V24, P1; Paskewitz S.M., 1993, Insect Molecular Biology, V2, P247; PORTER CH, 1991, AM J TROP MED HYG, V45, P271, DOI 10.4269/ajtmh.1991.45.271; SCOTT JA, 1993, AM J TROP MED HYG, V49, P520, DOI 10.4269/ajtmh.1993.49.520; Sharpe RG, 1999, MED VET ENTOMOL, V13, P265, DOI 10.1046/j.1365-2915.1999.00178.x; Van Bortel W, 2000, INSECT MOL BIOL, V9, P335, DOI 10.1046/j.1365-2583.2000.00192.x; Walton C, 1999, MED VET ENTOMOL, V13, P24, DOI 10.1046/j.1365-2915.1999.00142.x; Wilkes TJ, 1996, MED VET ENTOMOL, V10, P108, DOI 10.1111/j.1365-2915.1996.tb00092.x	33	60	60	0	4	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637	1476-1645		AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	JUN	2004	70	6					583	590		10.4269/ajtmh.2004.70.583				8	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	831IK	WOS:000222187900001	15210996				2019-03-26	
J	Caceres, AG; Villaseca, P; Dujardin, JC; Banuls, AL; Inga, R; Lopez, M; Arana, M; Le Ray, D; Arevalo, J				Caceres, AG; Villaseca, P; Dujardin, JC; Banuls, AL; Inga, R; Lopez, M; Arana, M; Le Ray, D; Arevalo, J			Epidemiology of Andean cutaneous leishmaniasis: Incrimination of Lutzomyia ayacuchensis (Diptera : Psychodidae) as a vector of Leishmania in geographically isolated, upland valleys of Peru	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							SAND FLIES DIPTERA; VIANNIA PERUVIANA; INFECTION; ECUADOR; BRAZILIENSIS; POPULATIONS; PERUENSIS; MEXICANA; FOCUS	The southernmost limit of the distribution of endemic Andean cutaneous leishmaniasis (CL), commonly known as Uta, is localized in the western Andean valleys of Ayacucho, Peru. This area is completely isolated from other regions endemic for this disease. Identification of the insect vector for Andean CL was carried out by combining entomologic and parasitologic approaches. Two Lutzomyia species were captured: Lutzomyia ayacuchensis and Lu. noguchii. The former species was considered responsible for transmission of Leishmania because 1) there was a coincidence in space and time between the presence of this insect and the distribution of Andean CL, 2) it was shown to be highly anthropophilic, 3) Leishmania parasites of the subgenus Viannia were detected by a specific polymerase chain reaction assay, 4) promastigotes isolated from this insect were shown by multilocus enzyme electrophoresis and molecular karyotyping to belong to the same deme of Leishmania (Viannia) peruviana as the one circulating in humans living in the study area, and 5) the complete cycle of L. (V.) peruviana was observed in experimental infections of Lit. ayacuchensis. Parasite and vector homogeneity found in Ayacucho contrasted with the heterogeneity reported for other areas endemic for Andean CL. The potential influence of ecologic determinants on this geographically isolated area is discussed.	Inst Nacl Salud, Lima, Peru; Univ Peruana Cayetano Heredia, Dept Fisiol, Lima, Peru; Univ Peruana Cayetano Heredia, Inst Med Trop Alexander Von Humboldt, Lima, Peru; Inst Trop Geneeskunde, Mol Parasitol Lab, Antwerp, Belgium; CNRS, Genet Malad Infect, Unite Mixte Rech, Inst Rech Dev, Montpellier, France	Caceres, AG (reprint author), Inst Nacl Salud, Calle Capac Yupanqui 1400,Jesus Maria, Lima, Peru.	acaceres3l@hotmail.com		Caceres Lazaro, Abraham German/0000-0002-0507-7002; Banuls, Anne-Laure/0000-0002-2106-8667; Arevalo, Jorge/0000-0003-3837-2849			Abderrazak S., 1993, METHOD MOL BIOL, V21, P361; ALEXANDER JB, 1992, MEM I OSWALDO CRUZ, V87, P123, DOI 10.1590/S0074-02761992000100019; Arevalo Jorge, 1993, P456; Banuls AL, 2000, J EUKARYOT MICROBIOL, V47, P197, DOI 10.1111/j.1550-7408.2000.tb00039.x; BARRETT TG, 1995, J ACCID EMERG MED, V12, P154; BARROS TDP, 1895, CRON MED, V12, P234; BARROS TDP, 1895, CRON MED, V12, P172; BARROS TDP, 1895, CRON MED, V12, P250; Caceres A., 1990, Revista Peruana de Entomologia, V32, P29; CACERES A, 1988, Revista Brasileira de Entomologia, V32, P55; Caceres A. G., 1993, REV PERU ENTOMOL, V34, P53; Caceres Abraham G., 1995, Revista da Sociedade Brasileira de Medicina Tropical, V28, P215; CACERES GA, 1996, REV PERU ENTOMOL, V38, P23; DAVIES CR, 1995, EPIDEMIOL INFECT, V114, P297, DOI 10.1017/S0950268800057964; Davies CR, 1997, AM J TROP MED HYG, V56, P85, DOI 10.4269/ajtmh.1997.56.85; DUJARDIN JC, 1993, ANN TROP MED PARASIT, V87, P335, DOI 10.1080/00034983.1993.11812777; DUJARDIN JC, 1995, PARASITOLOGY, V110, P21, DOI 10.1017/S0031182000081002; GALATI EAB, 1992, REV BRAS ENTOMOL, V36, P446; GOMEZ EAL, 1991, ANN TROP MED PARASIT, V85, P407, DOI 10.1080/00034983.1991.11812584; GOMEZ EAL, 1992, KYOWA REPORT SERIES, V3, P49; HASHIGUCHI Y, 1991, AM J TROP MED HYG, V44, P205; Herrer A., 1982, Revista do Instituto de Medicina Tropical de Sao Paulo, V24, P168; Herrer A, 1982, Rev Inst Med Trop Sao Paulo, V24, P162; HERRER A, 1962, SCI REPORTS I SUPERI, V2, P131; Herrer A., 1951, REV MED EXP LIMA, V8, P119; Herrer A., 1951, REV MED EXP, V8, P45; LAINSON R, 1979, BIOL KINETOPLASTIDA, V2, P2; Lamas G., 1982, P336; LUMBRERAS H, 1985, LEISHMANIASIS, V1, P291; PEREZ JE, 1991, T ROY SOC TROP MED H, V85, P60, DOI 10.1016/0035-9203(91)90158-U; PEREZ JE, 1994, T ROY SOC TROP MED H, V88, P161, DOI 10.1016/0035-9203(94)90276-3; PESCE H, 1943, PERU AM J HYG, V37, P255; TAKAOKA H, 1990, J MED ENTOMOL, V27, P701, DOI 10.1093/jmedent/27.4.701; VILLASECA P, 1993, AM J TROP MED HYG, V49, P260, DOI 10.4269/ajtmh.1993.49.260; WALTON BC, 1977, J PARASITOL, V63, P1118, DOI 10.2307/3279862; *WHO EXP COMM, 1990, WHO TECH REP SER, V793; YOUNG DG, 1987, J MED ENTOMOL, V24, P587, DOI 10.1093/jmedent/24.5.587	37	24	25	0	2	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	JUN	2004	70	6					607	612		10.4269/ajtmh.2004.70.607				6	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	831IK	WOS:000222187900005	15211000				2019-03-26	
J	Buttiens, H; Marchal, B; De Brouwere, V				Buttiens, H; Marchal, B; De Brouwere, V			Editorial: Skilled attendance at childbirth: let us go beyond the rhetorics	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Editorial Material						childbirth; skilled birth attendants; maternal mortality; developing countries	MATERNAL MORTALITY		Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium	Buttiens, H (reprint author), Inst Trop Med, Dept Publ Hlth, Natl Str 155, B-2000 Antwerp, Belgium.	hbuttiens@itg.be; bmarchal@itg.be; vdbrouw@itg.be					AbouZahr C, 2001, B WORLD HEALTH ORGAN, V79, P561; ABOUZAHR C, 2001, SAFE MOTHERHOOD STRA, P387; AbouZahr C., 2003, MATERNAL MORTALITY 2; Andaleeb SS, 2001, SOC SCI MED, V52, P1359, DOI 10.1016/S0277-9536(00)00235-5; Bergstrom S, 2001, SAFE MOTHERHOOD STRA, P77; d'Oliveira AFPL, 2002, LANCET, V359, P1681, DOI 10.1016/S0140-6736(02)08592-6; De Brouwere V, 1998, TROP MED INT HEALTH, V3, P771, DOI 10.1046/j.1365-3156.1998.00310.x; HALL MH, 1980, LANCET, V2, P78; HOGBERG U, 1986, INT J GYNECOL OBSTET, V24, P251, DOI 10.1016/0020-7292(86)90081-0; Jaffre Y., 2003, MED INHOSPITALIERE D; Jewkes R, 1998, SOC SCI MED, V47, P1781, DOI 10.1016/S0277-9536(98)00240-8; Loudon Irvine, 1992, DEATH CHILDBIRTH INT; Pathmanathan I., 2003, INVESTING MATERNAL H; ROONEY C, 1992, WHOMSM924 DIV FAM HL; Starrs A., 1998, SAFE MOTHERHOOD ACTI; VANLERBERGHE W, 2001, SAFE MOTHERHOOD STRA, P7	16	14	14	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	JUN	2004	9	6					653	654		10.1111/j.1365-3156.2004.01256.x				2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	832XH	WOS:000222300500001	15189454	Bronze			2019-03-26	
J	Rijal, S; Boelaert, M; Regmi, S; Karki, BMS; Jacquet, D; Singh, R; Chance, ML; Chappuis, F; Hommel, M; Desjeux, P; Van der Stuyft, P; Le Ray, D; Koirala, S				Rijal, S; Boelaert, M; Regmi, S; Karki, BMS; Jacquet, D; Singh, R; Chance, ML; Chappuis, F; Hommel, M; Desjeux, P; Van der Stuyft, P; Le Ray, D; Koirala, S			Evaluation of a urinary antigen-based latex agglutination test in the diagnosis of kala-azar in eastern Nepal	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						visceral leishmaniasis; sensitivity and specificity; diagnostic accuracy; urine antigen detection test; Nepal	INDIAN VISCERAL LEISHMANIASIS; DIPSTICK TEST; STRIP-TEST; FIELD; RK39	BACKGROUND We evaluated the diagnostic accuracy as well as the reproducibility of the urine latex agglutination test 'KAtex' in the diagnosis of kala-azar in patients recruited at a tertiary care centre in Dharan, Nepal, between November 2000 and January 2002. METHODS All patients presenting with fever of 2 weeks or more and splenomegaly were consecutively enrolled. Bone marrow and - if negative - spleen aspirates were examined for Leishmania donovani. Serum and urine samples were taken in duplicate for the Direct Agglutination Test (DAT) and KAtex. The reference laboratory determined sensitivity and specificity of KAtex. Reproducibility between both laboratories was assessed. RESULTS KAtex was performed on urine from 155 parasitologically confirmed kala-azar and 77 non-kala-azar cases (parasitology and DAT-negative). KAtex showed a sensitivity of 47.7% (74/155, 95% CI: 39.7-55.9) and a specificity of 98.7% (76/77, 95% CI: 93.0-100.0). Reproducibility of KAtex showed a kappa of 0.684 (P < 0.001, n = 232). CONCLUSION KAtex evaluation showed high specificity, low sensitivity and moderate reproducibility. A urine test for kala-azar could become a real breakthrough in kala-azar management if its reproducibility and sensitivity could be further improved.	BP Koirala Inst Hlth Sci, Dharan, Nepal; Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium; Univ Liverpool Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England; Univ Hosp Geneva, CH-1211 Geneva 14, Switzerland; WHO, CH-1211 Geneva 27, Switzerland	Rijal, S (reprint author), BP Koirala Inst Hlth Sci, Dharan, Nepal.	sumanrijal2@yahoo.com; boelaert@itg.be; sudhirregmi@yahoo.com; bmskarki@hotmail.com; djacquet@proto.itg.be; rupasingh@hotmail.com; mchance@liv.ca.uk; francois.chappuis@hcuge.ch; mhommel@liv.ac.uk; desjeuxp@who.int; pvds@itg.be; dleray@itg.be; shekharkoirala@hotmail.com	Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776			Attar ZJ, 2001, ACTA TROP, V78, P11, DOI 10.1016/S0001-706X(00)00155-8; Badaro R, 1996, J INFECT DIS, V173, P758, DOI 10.1093/infdis/173.3.758; Bern C, 2000, AM J TROP MED HYG, V63, P153, DOI 10.4269/ajtmh.2000.63.153; Boelaert M, 2004, AM J TROP MED HYG, V70, P72, DOI 10.4269/ajtmh.2004.70.72; Boelaert M, 1999, AM J TROP MED HYG, V60, P129, DOI 10.4269/ajtmh.1999.60.129; Chappuis F, 2003, TROP MED INT HEALTH, V8, P277, DOI 10.1046/j.1365-3156.2003.01026.x; ELHARITH A, 1988, J CLIN MICROBIOL, V26, P1321; ELHARITH AE, 1986, T ROY SOC TROP MED H, V80, P583; *HGMN, 2001, ANN REP, P119; Sarkari B, 2002, ACTA TROP, V82, P339, DOI 10.1016/S0001-706X(02)00043-8; Sarker C B, 2003, Mymensingh Med J, V12, P93; Sundar S, 1998, LANCET, V351, P563, DOI 10.1016/S0140-6736(97)04350-X; Sundar S, 2002, ANN TROP MED PARASIT, V96, P19, DOI 10.1179/000349802125000466; *WHO, 1990, WHO TECHN REP SER, V793, P154; *WHO EXP COMM, 1984, WHO TECH REP SER, V701, P99; ZIJLSTRA EE, 1992, T ROY SOC TROP MED H, V86, P505, DOI 10.1016/0035-9203(92)90086-R; Zijlstra EE, 2001, TROP MED INT HEALTH, V6, P108, DOI 10.1046/j.1365-3156.2001.00680.x; Zijlstra EE, 1998, CLIN DIAGN LAB IMMUN, V5, P717	18	45	45	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	JUN	2004	9	6					724	729		10.1111/j.1365-3156.2004.01251.x				6	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	832XH	WOS:000222300500011	15189464	Bronze			2019-03-26	
J	Coetzee, D; Hilderbrand, K; Goemaere, E; Matthys, F; Boelaert, M				Coetzee, D; Hilderbrand, K; Goemaere, E; Matthys, F; Boelaert, M			Integrating tuberculosis and HIV care in the primary care setting in South Africa	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						HIV; tuberculosis; integration; health policy; disease control; South Africa	HUMAN-IMMUNODEFICIENCY-VIRUS	BACKGROUND In many countries including South Africa, the increasing human immunodeficiency virus (HIV) and tuberculosis (TB) epidemics have impacted significantly on already weakened public health services. This paper reviews the scope, process and performance of the HIV and TB services in a primary care setting where antiretroviral therapy is provided, in Khayelitsha, South Africa, in order to assess whether there is a need for some form of integration. METHODS The scope and process of both services were assessed through observations of the service and individual and group interviews with key persons. The performance was assessed by examining the 2001-2002 reports from the health information system and clinical data. RESULTS The TB service is programme oriented to the attainment of an 85% cure rate amongst smear-positive patients while the HIV service has a more holistic approach to the patient with HIV. The TB service is part of a well-established programme that is highly standardized. The HIV service is in the pilot phase. There is a heavy load at both services and there is large degree of cross-referral between the two services. There are lessons that can be learnt from each service. There is an overlap of activities, duplication of services and under-utilization of staff. There are missed opportunities for TB and HIV prevention, diagnosis and management. CONCLUSIONS The study suggests that there may be benefits to integrating HIV and TB services. Constraints to this process are discussed.	Univ Cape Town, Dept Publ Hlth & Family Med, Infect Dis Res Unit, ZA-7925 Observatory, South Africa; Inst Trop Med Prince Leopold, Dept Publ Hlth, B-2000 Antwerp, Belgium; Med San Frontieres S Africa, ZA-8050 Cape Town, South Africa	Coetzee, D (reprint author), Univ Cape Town, Dept Publ Hlth & Family Med, Infect Dis Res Unit, Anzio Rd, ZA-7925 Observatory, South Africa.	dcoetzee@cormack.uct.ac.za; khild@mweb.co.za; goemaere@mweb.co.za; fmatthys@itg.be; boelaert@itg.be	Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776			Anderson SR, 2001, ANAL INTERACTION TB; AYLES H, 2003, LESS LEARNT WORKSH D; Cantwell MF, 1996, TUBERCLE LUNG DIS, V77, P220, DOI 10.1016/S0962-8479(96)90004-0; Connolly C, 1999, AIDS, V13, P1543, DOI 10.1097/00002030-199908200-00015; Godfrey-Faussett P, 2002, B WORLD HEALTH ORGAN, V80, P939; MAHER D, 2002, STRATEGIC FRAMEWORK; RIEDER HL, 1989, EPIDEMIOL REV, V11, P79, DOI 10.1093/oxfordjournals.epirev.a036046; von Reyn CF, 1999, AIDS, V13, P2193; *WHO, 2003, GUID IMPL COLL TB HI	9	72	73	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	JUN	2004	9	6					A11	A15		10.1111/j.1365-3156.2004.01259.x				5	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	832XH	WOS:000222300500016	15189469				2019-03-26	
J	Criel, B; Kegels, G; Van der Stuyft, P				Criel, B; Kegels, G; Van der Stuyft, P			Editorial: A framework for analysing the relationship between disease control programmes and basic health care	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Editorial Material						disease control; basic health care; vertical programmes; integration		In this paper, we present a framework for analysing the complex relationship between disease control programmes and basic health care systems. Many of the ideas and concepts presented in this paper were developed by the staff of the Public Health Department of the Antwerp Institute of Tropical Medicine (ITM) over the last 20 years. They are thus the product of the reflection of an entire team.	Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium	Criel, B (reprint author), Inst Trop Med, Dept Publ Hlth, Natl Str 155, B-2000 Antwerp, Belgium.	bcriel@itg.be; gkegels@itg.be; pvds@itg.be					Cairncross S, 1997, LANCET, V349, P20; CRIEL B, 1992, EDITORIAL ANN DOS BE, V72, P1; Criel BD, 1997, STUDIES HLTH SERVICE, V3; DEBROUWERE V, 1989, ANN SOC BELG MED TR, V69, P221; GISH O, 1992, INT J HEALTH SERV, V22, P179, DOI 10.2190/DUKB-DPGP-5W81-YKCW; KEGELS G, 1995, THESIS U ANTWERP; LORETTI A, 1989, LEPROSY REV, V60, P306; MILLS A, 1983, SOC SCI MED, V17, P1971, DOI 10.1016/0277-9536(83)90137-5	8	7	7	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	JUN	2004	9	6					A1	A4		10.1111/j.1365-3156.2004.01257.x				4	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	832XH	WOS:000222300500014	15189467				2019-03-26	
J	Kegels, G				Kegels, G			Epilogue	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article									Inst Trop Med Prince Leopold, Dept Publ Hlth, B-2000 Antwerp, Belgium	Kegels, G (reprint author), Inst Trop Med Prince Leopold, Dept Publ Hlth, Natl Str 155, B-2000 Antwerp, Belgium.	gkegels@itg.be						0	0	0	0	0	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	JUN	2004	9	6					A27	A28		10.1111/j.1365-3156.2004.01262.x				2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	832XH	WOS:000222300500019					2019-03-26	
J	Mahendradhata, Y; Moerman, F				Mahendradhata, Y; Moerman, F			Integration and disease control: Notes from The Prince Leopold Institute of Tropical Medicine colloquium 2002	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						integration; disease control; health service		The discussion on the desirability or not to integrate disease control activities with general health services is a longstanding one. The recent creations of global health initiatives for poverty-related disease control have refuelled the debate. The Prince Leopold Institute of Tropical Medicine (ITM) convened a colloquium in Antwerp to clarify concepts involved in integrated disease control and contribute to the creation of a common scientific language and a better understanding of the issues at stake. We present an overview of highlights from the colloquium sessions. Some of the contributions reported here are presented in more detail elsewhere in this special issue.	Inst Trop Med Prince Leopold, Dept Publ Hlth, Epidemiol Unit, B-2000 Antwerp, Belgium; Inst Trop Med Prince Leopold, Dept Parasitol, B-2000 Antwerp, Belgium	Mahendradhata, Y (reprint author), Inst Trop Med Prince Leopold, Dept Publ Hlth, Epidemiol Unit, Natl Str 155, B-2000 Antwerp, Belgium.	ymahendradhata@itg.be; fmoerman@itg.be		Mahendradhata, Yodi/0000-0002-4522-1785				0	3	3	0	0	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	JUN	2004	9	6					A5	A10		10.1111/j.1365-3156.2004.01258.x				6	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	832XH	WOS:000222300500015	15189468				2019-03-26	
J	Van Balen, H				Van Balen, H			Disease control in primary health care: a historical perspective	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						disease control; primary health care; health policy; systems approach; health district; users participation	DEVELOPING-COUNTRIES; KASONGO	The effectiveness of disease control by mobile teams decreased when countries became independent. Early case-finding and continuity of care require permanently accessible health care facilities where rationalization by professionals and participation of the users are well balanced. The Primary Health Care concept, a plea for this equilibrium, has been discredited by different types of misapplication. Correctly functioning and accessible first line health services, completed by a referral level, are a precondition for effective participation of the users. Where 'ideal health districts' cannot be realized, a form of steady exchanges between generalists and the specialists of the referral level has lead to diverse 'functional districts'.	Inst Trop Med, Antwerp, Belgium	Van Balen, H (reprint author), Inst Trop Med, Antwerp, Belgium.	harrie.vanbalen@belgacom.net					Balen H. van, 1990, Implementing primary health care: experiences since Alma-Ata., P21; BANERJI D, 1963, B WORLD HEALTH ORGAN, V29, P665; BERMAN PA, 1987, SOC SCI MED, V25, P443, DOI 10.1016/0277-9536(87)90168-7; Grodos D, 2002, TROP MED INT HEALTH, V7, P977, DOI 10.1046/j.1365-3156.2002.00925.x; GRODOS D, 2000, STUDIES HLTH SERVICE, V15; *KAS PROJ TEAM, 1981, ANN SOC BELGE MED S, V61, P5; KEGELS G, 1995, THESIS U INSTELLINGE; MAHLER H, 1981, ROLE HOSP PRIMARY HL; Newell K, 1975, HLTH PEOPLE; PAGANINI JM, 1990, PUBLICACION CIENTIFI, V519; PANGU KA, 1988, THESIS U LIBRE BRUXE; RAZUM O, 2002, TROP MED INT HEALTH, V7, P1047; SENGHOR D, 1984, FAMILLE DEV, V28, P34; Unger JP, 1995, ANN SOC BELG MED TR, V75, P7; UNGER JP, 1989, HLTH POLICY PLANNING, V4, P148; UNGER JP, 2000, SANTE CONJUGUEE, V20, P131; VANBALEN H, 1994, TROP DOCT, V24, P13, DOI 10.1177/004947559402400106; VANBALEN H, 1981, LANCET, V1, P764; VANBALEN H, 1999, INT SOCIAL SCI J; VANLERBERGHE W, 1990, SHSCC902 WHO; WALSH JA, 1980, SOC SCI MED-MED ECON, V14, P145, DOI 10.1016/0160-7995(80)90034-9; WHO and UNICEF, 1978, INT C PRIM HLTH CAR; World Health Organization, 1987, INT M STRENGTH HLTH	23	5	5	0	0	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	JUN	2004	9	6					A22	A26		10.1111/j.1365-3156.2004.01261.x				5	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	832XH	WOS:000222300500018	15189471	Bronze			2019-03-26	
J	Walsh, DS; Pichyangkul, S; Gettayacamin, M; Tongtawe, P; Siegrist, CA; Hansukjariya, P; Kester, KE; Holland, CA; Voss, G; Cohen, J; Stewart, AV; Miller, RS; Ballou, WR; Heppner, DG				Walsh, DS; Pichyangkul, S; Gettayacamin, M; Tongtawe, P; Siegrist, CA; Hansukjariya, P; Kester, KE; Holland, CA; Voss, G; Cohen, J; Stewart, AV; Miller, RS; Ballou, WR; Heppner, DG			Safety and immunogenicity of RTS,S+TRAP malaria vaccine, formulated in the AS02A adjuvant system, in infant rhesus monkeys	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							PLASMODIUM-FALCIPARUM MALARIA; CIRCUMSPOROZOITE PROTEIN VACCINE; COMBINATION VACCINES; IMMUNE-RESPONSES; EFFICACY; THROMBOSPONDIN; TRANSMISSION; IMMUNIZATION; RTS,S/SBAS2; SPOROZOITES	Malaria vaccine RTS,S combined with thrombospondin-related anonymous protein (TRAP) and formulated with AS02A (RTS,S+TRAP/AS02A) is safe and immunogenic in adult humans and rhesus monkeys (Macaca mulatta). Here, RTS,S+TRAP/AS02A was administered on a 0-, 1-, and 3-month schedule to three cohorts of infant monkeys, along with adult comparators. Cohort I evaluated 1/5, 1/2, and full adult doses, with the first dose administration at one month of age; cohort 2 monkeys received full adult doses, with the first dose administration at one versus three months of age; and, cohort 3 compared infants gestated in mothers with or without previous RTS,S/AS02A immunization. Immunization site reactogenicity was mild. Some infants, including the phosphate-buffered saline only recipient, developed transient iron-deficiency anemia, which is considered a result of repeated phlebotomies. All RTS,S+TRAP/AS02A regimens induced vigorous antibody responses that persisted through 12 weeks after the last vaccine dose. Modest lymphoproliferative and ELISPOT (interferon-gamma and interleukin-5) responses, particularly to TRAP, approximated adult comparators. RTS,S+TRAP/AS02A was safe and well tolerated. Vigorous antibody production and modest, selective cell-mediated immune responses suggest that RTS,S+TRAP/AS02A may be immunogenic in human infants.	Armed Forces Res Inst Med Sci, USA, Med Component, Dept Vet Med, Bangkok 10400, Thailand; Univ Geneva, Sch Med, Dept Pathol & Pediat, World Hlth Org Collaborating Ctr Vaccinol & Neona, CH-1211 Geneva, Switzerland; Walter Reed Army Inst Res, Dept Immunol, Silver Spring, MD USA; GlaxoSmithKline Biol, Rixensart, Belgium; Armed Forces Res Inst Med Sci, USA, Med Component, Dept Immunol & Med, Bangkok 10400, Thailand	Walsh, DS (reprint author), Eisenhower Army Med Ctr, Serv Dermatol, Ft Gordon, GA 30905 USA.	douglas.walsh@se.amedd.army.mil	Kester, Kent/A-2114-2011; Holland, Carolyn/B-7880-2011	Kester, Kent/0000-0002-5056-0802; 			Ariey F, 2003, TRENDS PARASITOL, V19, P158, DOI 10.1016/S1471-4922(03)00054-0; Ballou WR, 2002, CHEM IMMUNOL, V80, P253; Bojang KA, 2001, LANCET, V358, P1927, DOI 10.1016/S0140-6736(01)06957-4; Doherty JF, 1999, AM J TROP MED HYG, V61, P865, DOI 10.4269/ajtmh.1999.61.865; Eden AN, 1997, ARCH PEDIAT ADOL MED, V151, P986, DOI 10.1001/archpedi.1997.02170470020003; Elliman D, 2003, BMJ-BRIT MED J, V326, P995, DOI 10.1136/bmj.326.7397.995; FERNIE S, 1994, J TOXICOL ENV HEALTH, V42, P53, DOI 10.1080/15287399409531863; Guerin PJ, 2002, LANCET INFECT DIS, V2, P564, DOI 10.1016/S1473-3099(02)00372-9; Hay SI, 2003, LANCET, V361, P1705, DOI 10.1016/S0140-6736(03)13366-1; Kester KE, 2001, J INFECT DIS, V183, P640, DOI 10.1086/318534; Kohli-Kumar M, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.3.e56; Korenromp EL, 2003, LANCET INFECT DIS, V3, P349, DOI 10.1016/S1473-3099(03)00657-1; Kovarik J, 2001, ARCH IMMUNOL THER EX, V49, P209; Kurtzhals JAL, 2003, LANCET, V361, P1393, DOI 10.1016/S0140-6736(03)13068-1; Lalvani A, 1999, J INFECT DIS, V180, P1656, DOI 10.1086/315074; Marcy SM, 2003, AM J MANAG CARE, V9, P314; McVernon J, 2003, LANCET, V361, P1521, DOI 10.1016/S0140-6736(03)13171-6; Olliaro P, 2001, TROP MED INT HEALTH, V6, P922, DOI 10.1046/j.1365-3156.2001.00752.x; Ota MOC, 2004, VACCINE, V22, P511, DOI 10.1016/j.vaccine.2003.07.020; ROBSON KJH, 1995, EMBO J, V14, P3883, DOI 10.1002/j.1460-2075.1995.tb00060.x; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; ROGERS WO, 1992, P NATL ACAD SCI USA, V89, P9176, DOI 10.1073/pnas.89.19.9176; Siegrist C A, 2000, Int Rev Immunol, V19, P195, DOI 10.3109/08830180009088505; Siegrist CA, 2001, VACCINE, V19, P3331, DOI 10.1016/S0264-410X(01)00028-7; Snow RW, 2002, ADV PARASIT, V52, P235, DOI 10.1016/S0065-308X(02)52013-3; Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202; Stoute JA, 1998, J INFECT DIS, V178, P1139, DOI 10.1086/515657; Sultan AA, 1997, CELL, V90, P511, DOI 10.1016/S0092-8674(00)80511-5	28	12	12	0	3	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	MAY	2004	70	5					499	509		10.4269/ajtmh.2004.70.499				11	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	822OO	WOS:000221549700006	15155981	Green Published			2019-03-26	
J	Noeske, J; Kuaban, C; Rondini, S; Sorlin, P; Ciaffi, L; Mbuagbaw, J; Portaels, F; Pluschke, G				Noeske, J; Kuaban, C; Rondini, S; Sorlin, P; Ciaffi, L; Mbuagbaw, J; Portaels, F; Pluschke, G			Buruli ulcer disease in Cameroon rediscovered	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							MYCOBACTERIUM-ULCERANS; COTE-DIVOIRE; SKIN ULCER; INFECTION	To assess the magnitude of the Buruli ulcer (BU) problem in Cameroon, we conducted a cross-sectional survey in the Nyong River basin and identified on clinical grounds a total of 436 cases of active or inactive BU (202 and 234, respectively). Swab specimens were taken from 162 active cases with ulcerative lesions and in 135 of these (83.3%) the clinical diagnosis was confirmed by the IS2404 polymerase chain reaction. Most lesions (93%) were located on the extremities, with lower limbs being twice as commonly involved as upper limbs. The age of patients with active BU ranged from 2 to 90 years with a median age of 14.5 years. Vaccination with bacilli Calmette-Guerin appeared to protect children against more severe forms of BU with multiple lesions. We conclude that in Cameroon BU is endemic, at least in the study area, and that a comprehensive control program for BU in Cameroon is urgently needed.	Aide Lepreux Emmaus Suisse, Yaounde, Cameroon; Univ Yaounde 1, Yaounde, Cameroon; Swiss Trop Inst, CH-4002 Basel, Switzerland; Ctr Pasteur Cameroun, Yaounde, Cameroon; Med Sans Frontieres Switzerland, Yaounde, Cameroon; Inst Trop Med, Mycobacteriol Unit, B-2000 Antwerp, Belgium	Noeske, J (reprint author), Kolveniersstr 6,Bus 7, B-2000 Antwerp, Belgium.	Gerd.Pluschke@unibas.ch	Rondini, Simona/N-1780-2013	Rondini, Simona/0000-0002-7993-9656			AGUIAR J, 1997, B SEANCES ACAD ROYAL, V43, P325; Amofah G, 2002, EMERG INFECT DIS, V8, P167, DOI 10.3201/eid0802.010119; BOISVERT H, 1977, B SOC PATHOL EXOT, V70, P125; BURCHARD GD, 1986, TROP MED PARASITOL, V37, P1; CLANCEY JK, 1961, LANCET, V2, P951; DARIE H, 1993, B SOC PATHOL EXOT, V86, P272; Debacker M, 2003, CLIN INFECT DIS, V36, pE67, DOI 10.1086/367660; Kang MJ, 2001, SCI TECHNOL WELD JOI, V6, P94, DOI 10.1179/136217101101538596; Lagarrigue V, 2000, Med Trop (Mars), V60, P262; MACCALLUM P, 1948, J PATHOL BACTERIOL, V60, P93, DOI 10.1002/path.1700600111; MARSTON BJ, 1995, AM J TROP MED HYG, V52, P219, DOI 10.4269/ajtmh.1995.52.219; MEYERS WM, 1974, AM J TROP MED HYG, V23, P919, DOI 10.4269/ajtmh.1974.23.919; Portaels F, 1999, LANCET, V353, P986, DOI 10.1016/S0140-6736(98)05177-0; Portaels F, 2002, CLIN DIAGN LAB IMMUN, V9, P1389, DOI 10.1128/CDLI.9.6.1389-1391.2002; RAVISSE P, 1977, B SOC PATHOL EXOT, V70, P109; RAVISSE P, 1975, MED TROP, V35, P471; Ross BC, 1997, J CLIN MICROBIOL, V35, P1696; SMITH PG, 1977, T R SOC TROP MED HYG, V70, P449; *UG BUR GROUP, 1969, LANCET, V1, P111; VANDERWERF TS, 1990, LANCET, V336, P1440, DOI 10.1016/0140-6736(90)93133-A; *WHO, 2001, WHOCDSCPEGBUI20014; *WHO, 2001, WHOCDSCPEGBU120013	22	49	49	0	1	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637	1476-1645		AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	MAY	2004	70	5					520	526		10.4269/ajtmh.2004.70.520				7	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	822OO	WOS:000221549700009	15155984				2019-03-26	
J	Robays, J; Bilengue, MMC; Van der Stuyft, P; Boelaert, M				Robays, J; Bilengue, MMC; Van der Stuyft, P; Boelaert, M			The effectiveness of active population screening and treatment for sleeping sickness control in the Democratic Republic of Congo	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						human African trypanosomiasis; effectiveness; Democratic Republic of Congo; card agglutination test for trypanosomes; population screening	HUMAN AFRICAN TRYPANOSOMIASIS; BRUCEI-GAMBIENSE; DIAGNOSIS; MELARSOPROL; FAILURE; UGANDA; MODEL; WEST	BACKGROUND The human African trypanosomiasis (HAT) control programme of the Democratic Republic of Congo (DRC) uses mass screening with the card agglutination test for trypanosomes (CATT). We looked at the contribution of CATT and improved parasitological confirmation to the effectiveness of screening and treatment. METHOD The effectiveness of the screening and treatment process is measured by the percentage of HAT cases that is effectively cured after a single round of screening. The process is analysed in five steps: (i) the attendance at the screening, (ii) the sensitivity of the screening procedure, (iii) the sensitivity of the parasitological confirmation, (iv) the proportion of the confirmed cases that effectively receive treatment and (v) the cure rate of the treatment. We used a simplified model that multiplies proportions of infected persons that go through each step. We estimated these parameters using a combination of routine data collected by the national control programme over the period January 1997 to December 1998 and published data. For varying attendance rates we compared the effectiveness of screening strategies based on GATT or on CATT combined with improved parasitological confirmation by mini anion exchange column technique (mAECT) with the previously used strategy based on palpation of neck glands and microscopy alone. RESULTS The model shows that overall effectiveness of the active case detection and treatment strategy is <50% under most scenarios. Attendance rates averaged 74% but showed considerable regional variability and are a major problem in some areas of DRC. The CATT and replacing traditional parasitology by mAECT increases the sensitivity of the screening but a substantial part of the gains are lost at other stages of the screening process. CONCLUSION Improvements of the HAT screening process such as introduction of CATT or mAECT only make sense if other parameters and attendance rate in particular are optimized at the same time.	Inst Trop Med, Epidemiol Unit, B-2000 Antwerp, Belgium; Programme Natl Lutte Contre THA, Kinshasa, Zaire	Robays, J (reprint author), Inst Trop Med, Epidemiol Unit, Natl Str 155, B-2000 Antwerp, Belgium.	jrobays@itg.be; bctrdc@ic.cd; pvds@itg.be; boelaert@itg.be	Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776			Artzrouni M, 1996, TROP MED INT HEALTH, V1, P753; BAILEY JW, 1992, T ROY SOC TROP MED H, V86, P630, DOI 10.1016/0035-9203(92)90160-E; BAILEY JW, 1994, TROP DOCT, V24, P54, DOI 10.1177/004947559402400204; BRUNEEL H, 1994, ANN SOC BELG MED TR, V74, P203; BURRI C, 2003, MANSONS TROPICAL DIS, P1303; Buve A, 2001, TROP MED INT HEALTH, V6, P971, DOI 10.1046/j.1365-3156.2001.00809.x; Dallabetta GA, 1996, CONTROL SEXUALLY TRA; de Muynck A, 1991, RAPPORT FINAL SEMINA, P131; DEMUYNCK A, 1991, RAPPORT FINAL SEMINA, P131; Ekwanzala M, 1996, LANCET, V348, P1427, DOI 10.1016/S0140-6736(96)06088-6; Ginoux P Y, 1984, Med Trop (Mars), V44, P149; JONCHERE H, 1951, B SOC PATHOL EXOT, V46, P386; Jusot JF, 1995, ANN SOC BELG MED TR, V75, P257; Legros D, 1999, T ROY SOC TROP MED H, V93, P439, DOI 10.1016/S0035-9203(99)90151-7; MAGNUS E, 1998, SLEEPING SICKNESS RE; MIEZAN TW, 1994, B SOC PATHOL EXOT, V87, P101; PAQUET C, 1995, B SOC PATHOL EXOT, V88, P38; PEPIN J, 1989, LANCET, V1, P1246, DOI 10.1016/S0140-6736(89)92340-4; PEPIN J, 1994, ADV PARASIT, V33, P1, DOI 10.1016/S0065-308X(08)60410-8; PIOT MA, 1967, WHO TECHNICAL INFORM; SIMARRO PP, 1991, B WORLD HEALTH ORGAN, V69, P451; SIMARRO PP, 1998, SLEEPING SICKNESS RE; Stanghellini A, 2001, TROP MED INT HEALTH, V6, P330, DOI 10.1046/j.1365-3156.2001.00724.x; Trouiller P, 2002, LANCET, V359, P2188, DOI 10.1016/S0140-6736(02)09096-7; Truc P, 2002, B WORLD HEALTH ORGAN, V80, P882; World Health Organization, 1998, WHO TECH REP SER, P1	26	65	65	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	MAY	2004	9	5					542	550		10.1111/j.1365-3156.2004.01240.x				9	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	822FV	WOS:000221525100002	15117297				2019-03-26	
J	Vuylsteke, B; Traore, M; Mah-Bi, G; Konan, Y; Ghys, P; Diarra, J; Laga, M				Vuylsteke, B; Traore, M; Mah-Bi, G; Konan, Y; Ghys, P; Diarra, J; Laga, M			Quality of sexually transmitted infections services for female sex workers in Abidjan, Cote d'Ivoire	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						sexually transmitted infections; female sex workers; quality of care; Africa	STD SERVICES; HEALTH-CARE; INTERVENTION; MANAGEMENT; DISEASES	OBJECTIVES To assess the quality of sexually transmitted infections (STI) care in health care facilities in Abidjan attended by female sex workers. METHODS A cross-sectional study was conducted in June 2000 in the 29 health care facilities and 10 pharmacies, which were reported as points of first encounter for STI care by female sex workers in a previous study on health seeking behaviour. Evaluation components included: (1) checklists of equipment and STI drugs in the facilities; (2) interviews with health care providers and pharmacists; (3) direct observation of the provider/client interaction; (4) exit interviews with women attending with STI or genital problems. RESULTS Private health care facilities were more expensive, had fewer clients, and had less equipment and medical staff than public facilities, with the exception of the special female sex worker clinic. A total of 60 health care providers and 29 pharmacists were interviewed. There was no difference in their scoring on syndromic approach case studies, with the exception of the nurse assistants, who scored less. Overall scores for correct treatment were lowest for the pharmacists. We observed 513 provider-client interactions, of which 161 related to STIs or genital problems in women. Questions about recent sexual contacts were asked in only 20% and preventive messages were given in only 9% of the cases with STI/genital problems. Of 161 clients interviewed, 44% complained about a long waiting time, and 39% thought the health care provider had adequately explained the problem to them. CONCLUSIONS The opportunity for improvement of STI case management in health care facilities in Abidjan where female sex workers go for STI care is enormous. Public and private health care facilities should be made more accessible for sex workers, and their services should be upgraded to better respond to the sexual health needs of high risk women.	Inst Trop Med, B-2000 Antwerp, Belgium; Projet RETRO CI, Abidjan, Cote Ivoire; Inst Natl Sante Publ, Abidjan, Cote Ivoire; Ctr Dis Control & Prevent, Atlanta, GA USA	Vuylsteke, B (reprint author), 01 BP 1712, Abidjan, Cote Ivoire.	vuylstekeb@gapcdcci.org; mamiadjoua@hotmail.com; asapsu@afnet.net; gtzsida@africaonline.co.ci; ghysp@unaids.org; wahooas@fasonet.bf; mlaga@itg.be					Bitera Raphael, 2002, Sante, V12, P233; Brugha R, 1998, HEALTH POLICY PLANN, V13, P107, DOI 10.1093/heapol/13.2.107; BRUNETJAILLET J, 1997, 10 INT C AIDS STD AF; Garcia PJ, 1998, SEX TRANSM INFECT, V74, pS153; Ghys PD, 2002, AIDS, V16, P251, DOI 10.1097/00002030-200201250-00015; LAGA M, 1994, LANCET, V344, P246, DOI 10.1016/S0140-6736(94)93005-8; Nyamuryekung'e K, 1997, E AFR MED J, V74, P343; Saidel TJ, 1998, AIDS, V12, pS57; Somse P, 2000, SEX TRANSM DIS, V27, P458, DOI 10.1097/00007435-200009000-00007; Steen R, 1998, SEX TRANSM INFECT, V74, pS159; Steen R, 2000, SEX TRANSM DIS, V27, P1, DOI 10.1097/00007435-200001000-00001; UNAIDS/World Health Organization, 1999, SEX TRANSM DIS POL P; Vuylsteke B, 2001, SEX TRANSM INFECT, V77, P351, DOI 10.1136/sti.77.5.351	13	13	13	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	MAY	2004	9	5					638	643		10.1111/j.1365-3156.2004.01235.x				6	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	822FV	WOS:000221525100015	15117310	Bronze			2019-03-26	
J	Chatterjee, S; Mbaye, A; Alfidja, AT; Weyler, J; Scott, JD; Van Damme, P; Van De Vijver, K; Deelder, A; Van Marck, EAE				Chatterjee, S; Mbaye, A; Alfidja, AT; Weyler, J; Scott, JD; Van Damme, P; Van De Vijver, K; Deelder, A; Van Marck, EAE			Circulating levels of the neuropeptide hormone somatostatin may determine hepatic fibrosis in Schistosoma mansoni infections	ACTA TROPICA			English	Article						neuropeptide; somatostatin; periportal fibrosis; schistosomiasis; morbidity	IMMUNOREGULATORY CIRCUIT; STELLATE CELLS; T-LYMPHOCYTES; GRANULOMAS; IMMUNITY; EPIDEMIOLOGY; EXPRESSION; SECRETION	The neuropeptide hormone somatostatin reduces fibrosis and Schistosoma-caused clinical morbidity in the rodent model. In our study we aimed to delineate an association between fibrosis and the inability to generate critical levels of endogenous somatostatin in S. mansoni infected subjects. In June 2001, 85 subjects from the district dispensary at Richard Toll in the Medical Region of Saint-Louis, Senegal, were selected. Fifty-seven subjects were infected with S. mansoni of whom 32 were suffering from severe morbidity (SM). Twenty-eight subjects showed an inactive disease status with no evident infection at the actual time of study. All subjects were classified according to age, sex, occupation, height, weight, and parasite eggs per gram. All 85 participated in a water contact and morbidity questionnaire, underwent a clinical examination and donated 5 ml of peripheral blood for detecting plasma levels of somatostatin. Ultrasonography detected fibrosis grade in all the subjects. To address whether inherent somatostatin levels determined clinically evident disease severity (epg, hepatomegaly, splenomegaly, hematemesis, ascites), the mean somatostatin values of the inactive disease status group and severe morbidity group were compared. Low somatostatin levels were depicted in subjects with severe morbidity symptoms associated with schistosomiasis as compared to exposed but inactive disease status subjects residing in the same region. Logistic regression analysis indicated that with decreasing somatostatin values the probability of severe morbidity increased with age being a confounding factor. To address whether inherent somatostatin levels determined fibrosis and if this association was significant, plasma somatostatin levels of non-fibrotics (ultrasonographic grading A), and fibrotics (ultrasonographic grading B-E) were compared. In all age groups as well as in adults alone, mean somatostatin levels were higher in the non-fibrotic group as compared to the fibrotics group, the difference being significant. The group B comprised of borderline fibrotic cases, therefore a separate analysis was done between groups A (non-fibrotics) and groups C, D (confirmed fibrotics). Mean somatostatin values were higher in the non-fibrotic group as compared to the fibrotics group, the difference being borderline significant. In schistosomiasis patients, circulating levels of somatostatin by binding to hepatic stellate cells (HSC) may modulate fibrosis. This phenomenon is regulated by age whereas gender and prior treatment have no effect on this association. Host specific somatostatin levels may create a 'preset environment' status that can determine progression to severe fibrosis. (C) 2004 Elsevier B.V. All rights reserved.	Univ Instelling Antwerp, Dept Med, Pathol Unit, B-2610 Wilrijk, Belgium; ESPOIR, Reg Med St Louis, St Louis, Senegal; CHU Fann, Serv Radiol Gen, Dakar, Senegal; Epidemiol & Social Hlth Unit, Antwerp, Belgium; Inst Trop Med, Antwerp, Belgium; Leiden Univ, Med Ctr, Leiden, Netherlands	Chatterjee, S (reprint author), Univ Instelling Antwerp, Dept Med, Pathol Unit, Univ Pl 1, B-2610 Wilrijk, Belgium.	shyama@uia.ua.ac.be	Weyler, Joost/O-8594-2016	Weyler, Joost/0000-0001-7271-5492			Avgerinos A, 1997, LANCET, V350, P1495, DOI 10.1016/S0140-6736(97)05099-X; BISSETTE G, 1992, LIFE SCI, V51, P1389, DOI 10.1016/0024-3205(92)90534-V; BLOOM SR, 1987, BRIT MED J, V295, P288, DOI 10.1136/bmj.295.6593.288; BLUM AM, 1992, J IMMUNOL, V149, P3621; BRADLEY DJ, 1972, T ROY SOC TROP MED H, V66, P697, DOI 10.1016/0035-9203(72)90083-1; BRAZEAU P, 1973, SCIENCE, V179, P77, DOI 10.1126/science.179.4068.77; BUTTERWORTH AE, 1987, PARASITOL TODAY, V3, P11, DOI 10.1016/0169-4758(87)90091-3; BUTTERWORTH AE, 1987, PARASITOLOGY, V94, P281, DOI 10.1017/S0031182000053956; Chatterjee S, 2003, TROP MED INT HEALTH, V8, P33, DOI 10.1046/j.1365-3156.2003.00989.x; Chatterjee S, 2001, TROP MED INT HEALTH, V6, P1008, DOI 10.1046/j.1365-3156.2001.00744.x; Chatterjee S, 2002, TRENDS PARASITOL, V18, P295, DOI 10.1016/S1471-4922(02)02294-8; Chatterjee S, 2001, TROP MED INT HEALTH, V6, P578, DOI 10.1046/j.1365-3156.2001.00758.x; CHATTERJEE S, 2001, ACTA GASTROENTEROLOG, V64, pA5; Chen M. G., 1988, Tropical Diseases Bulletin, V85, pR1; Elliott DE, 1996, METABOLISM, V45, P88, DOI 10.1016/S0026-0495(96)90093-1; ELLIOTT DE, 1994, J IMMUNOL, V153, P1180; Elliott DE, 1999, EUR J IMMUNOL, V29, P2454, DOI 10.1002/(SICI)1521-4141(199908)29:08<2454::AID-IMMU2454>3.0.CO;2-H; HAGAN P, 1992, PARASITOL TODAY, V8, P12, DOI 10.1016/0169-4758(92)90303-J; JACOBS W, 1998, THESIS U ANTWERP BEL; Mansy SS, 1998, ARZNEIMITTEL-FORSCH, V48, P855; Reynaert H, 2001, J HEPATOL, V34, P6; Reynaert H, 1999, HEPATOLOGY, V30, p236A; SCARPIGNATO C, 1999, DIGESTION S3, V60, pS1; SCHUSDZIARRA V, 1996, PROGR BASIC CLIN PHA, V10, P35; STELMA FF, 1993, AM J TROP MED HYG, V49, P701, DOI 10.4269/ajtmh.1993.49.701; STELMA FF, 1997, THESIS U LEIDEN NETH; WARREN KS, 1973, J INFECT DIS, V127, P595, DOI 10.1093/infdis/127.5.595; Weinstock JV, 1998, ANN NY ACAD SCI, V840, P532, DOI 10.1111/j.1749-6632.1998.tb09592.x; Weinstock JV, 2000, EUR J ENDOCRINOL, V143, pS15, DOI 10.1530/eje.0.143S015; WEINSTOCK JV, 1990, CELL IMMUNOL, V131, P381, DOI 10.1016/0008-8749(90)90262-P; *WHO, 1993, WHO TECHN REP SER, V830, P1; *WHO, 2000, TDRSTRSCH001 WHO, P1; WYLER DJ, 1992, MEM I OSWALDO CRUZ, V87, P117, DOI 10.1590/S0074-02761992000800017; WYLER DJ, 1992, PARASITOL TODAY, V8, P277, DOI 10.1016/0169-4758(92)90145-R	34	10	13	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0001-706X	1873-6254		ACTA TROP	Acta Trop.	APR	2004	90	2					191	203		10.1016/j.actatropica.2003.12.002				13	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	805JC	WOS:000220361600008	15177146				2019-03-26	
J	Garros, C; Koekemoer, LL; Kamau, L; Awolola, TS; Van Bortel, W; Coetzee, M; Coosemans, M; Manguin, S				Garros, C; Koekemoer, LL; Kamau, L; Awolola, TS; Van Bortel, W; Coetzee, M; Coosemans, M; Manguin, S			Restriction fragment length polymorphism method for the identification of major African and Asian malaria vectors within the Anopheles funestus and An. minimus groups	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							INTERNAL TRANSCRIBED SPACER; CHAIN-REACTION ASSAY; SPECIES COMPLEX; CULICIDAE GROUP; SOUTHEAST-ASIA; DIPTERA; MEMBERS; HETEROGENEITY; THAILAND; MARKERS	The African Anopheles funestus and the Asian An. minimus groups are closely related and are probably considered distinct only because of their geographic separation. This study aimed at improving two identification methods based on polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) already developed for either group. Each PCR-RFLP, either on the internal transcribed spacer 2 (ITS2) for the An. minimus group, and domain 3 (D3) for the An. funestus group, was applied to the other group for the standardization of one identification method applicable on both continents. The ITS2 fragment digested by Bsi ZI showed the highest diagnostic power. This assay allowed the discrimination of at least 13 Anopheles species within the subgenus Cellia from two continents (Africa and Asia), among which are five major malaria vectors. Moreover, digestion of the D, with Msp I showed intragenomic variations within An. funestus populations. Two types of D3 copies (M and W) occurred in specimens from southern Africa. The populations from West-Central Africa presented only type W and East-Malagasy populations exhibited type M. Since An. funestus shows a great capacity of adaptation, these molecular variations, along with behavioral and ecologic ones, reinforce the hypothesis of a species complex that will need to be further investigated.	Kenya Govt Med Res Ctr, Ctr Biotechnol Res & Dev, Nairobi, Kenya; Prince Leopold Inst Trop Med, Dept Parasitol, B-2000 Antwerp, Belgium; Ctr Biol & Management Populat, Inst Res Dev, Montpellier, France; Natl Inst Communicable Dis, Vector Control Reference Unit, Johannesburg, South Africa; Univ Witwatersrand, Natl Hlth Lab Serv, Sch Pathol, Dept Clin Microbiol Infect Dis, Johannesburg, South Africa	Garros, C (reprint author), Ctr Biol & Management Populat, Campus Baillarguet,CS 30016, F-34988 Montferrier sur Lez, France.	garros@mpl.ird.fr; manguin@mpl.ird.fr	Garros, Claire/C-2715-2011; Manguin, Sylvie/G-1787-2015	Manguin, Sylvie/0000-0002-5925-7164; Coetzee, Maureen/0000-0003-2019-866X; Van Bortel, Wim/0000-0002-6644-518X			Baimai V, 1996, J AM MOSQUITO CONTR, V12, P97; Boccolini D, 1998, PARASSITOLOGIA, V40, P14; Chen B, 2002, MED VET ENTOMOL, V16, P253, DOI 10.1046/j.1365-2915.2002.00373.x; Collins FH, 1996, INSECT MOL BIOL, V5, P1, DOI 10.1111/j.1365-2583.1996.tb00034.x; Foley DH, 1996, AM J TROP MED HYG, V54, P46, DOI 10.4269/ajtmh.1996.54.46; GILLES MT, 1987, PUBLICATION S AFR I, V55; GILLES MT, 1968, PUBLICATION S AFR I, V54; GREEN CA, 1990, MED VET ENTOMOL, V4, P25, DOI 10.1111/j.1365-2915.1990.tb00256.x; Hall T.A., 1999, NUCL ACIDS S SER, V41, P95, DOI DOI 10.1021/BK-1999-0734.CH008; HARBACH RE, 1994, B ENTOMOL RES, V84, P331, DOI 10.1017/S0007485300032454; HARRISON B A, 1980, Contributions of the American Entomological Institute, V17, P1; *IMPE, 1987, KEYS AN VIETN AD PUP; Kengne P, 2001, INSECT MOL BIOL, V10, P427, DOI 10.1046/j.0962-1075.2001.00281.x; Koekemoer LL, 1999, J MED ENTOMOL, V36, P125, DOI 10.1093/jmedent/36.2.125; Koekemoer LL, 1998, INSECT MOL BIOL, V7, P273, DOI 10.1046/j.1365-2583.1998.00072.x; Koekemoer LL, 2002, AM J TROP MED HYG, V66, P804, DOI 10.4269/ajtmh.2002.66.804; Koekemoer LL, 2002, AFR ENTOMOL, V10, P235; Linton YM, 2001, SYST ENTOMOL, V26, P357, DOI 10.1046/j.1365-3113.2001.00153.x; Lochouarn L, 1998, T ROY SOC TROP MED H, V92, P607, DOI 10.1016/S0035-9203(98)90782-9; Manguin S, 2001, Med Trop (Mars), V61, P463; Manonmani A, 2001, ACTA TROP, V78, P3, DOI 10.1016/S0001-706X(00)00154-6; Mouchet J, 1998, J AM MOSQUITO CONTR, V14, P121; Onyabe DY, 1999, INSECT MOL BIOL, V8, P435, DOI 10.1046/j.1365-2583.1999.00134.x; SINKINS SP, 2000, MOL ECOL, V9, P489; Tang JM, 1996, MOL BIOL EVOL, V13, P244, DOI 10.1093/oxfordjournals.molbev.a025561; Van Bortel W, 2000, INSECT MOL BIOL, V9, P335, DOI 10.1046/j.1365-2583.2000.00192.x	26	51	54	0	3	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637	1476-1645		AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	MAR	2004	70	3					260	265		10.4269/ajtmh.2004.70.260				6	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	802YM	WOS:000220198800006	15031514				2019-03-26	
J	Muhlberger, N; Jelinek, T; Gascon, J; Probst, M; Zoller, T; Schunk, M; Beran, J; Gjorup, I; Behrens, RH; Clerinx, J; Bjorkman, A; McWhinney, P; Matteelli, A; Lopez-Velez, R; Bisoffi, Z; Hellgren, U; Puente, S; Schmid, ML; Myrvang, B; Holthoff-Stich, ML; Laferl, H; Hatz, C; Kollaritsch, H; Kapaun, A; Knobloch, J; Iversen, J; Kotlowski, A; Malvy, DJM; Kern, P; Fry, G; Siikamaki, H; Schulze, MH; Soula, G; Paul, M; Prat, JGI; Lehmann, V; Bouchaud, O; da Cunha, S; Atouguia, J; Boecken, G				Muhlberger, N; Jelinek, T; Gascon, J; Probst, M; Zoller, T; Schunk, M; Beran, J; Gjorup, I; Behrens, RH; Clerinx, J; Bjorkman, A; McWhinney, P; Matteelli, A; Lopez-Velez, R; Bisoffi, Z; Hellgren, U; Puente, S; Schmid, ML; Myrvang, B; Holthoff-Stich, ML; Laferl, H; Hatz, C; Kollaritsch, H; Kapaun, A; Knobloch, J; Iversen, J; Kotlowski, A; Malvy, DJM; Kern, P; Fry, G; Siikamaki, H; Schulze, MH; Soula, G; Paul, M; Prat, JGI; Lehmann, V; Bouchaud, O; da Cunha, S; Atouguia, J; Boecken, G			Epidemiology and clinical features of vivax malaria imported to Europe: Sentinel surveillance data from TropNetEurop	MALARIA JOURNAL			English	Article							PLACEBO-CONTROLLED TRIAL; PLASMODIUM-VIVAX; DRUG-RESISTANCE; PRIMAQUINE; CHEMOPROPHYLAXIS; PROPHYLAXIS; EFFICACY; FALCIPARUM; TRAVELERS; REGIMENS	Background: Plasmodium vivax is the second most common species among malaria patients diagnosed in Europe, but epidemiological and clinical data on imported P. vivax malaria are limited. The TropNetEurop surveillance network has monitored the importation of vivax malaria into Europe since 1999. Objectives: To present epidemiological and clinical data on imported P. vivax malaria collected at European level. Material and methods: Data of primary cases of P. vivax malaria reported between January 1999 and September 2003 were analysed, focusing on disease frequency, patient characteristics, place of infection, course of disease, treatment and differences between network-member countries. Results: Within the surveillance period 4,801 cases of imported malaria were reported. 618 (12.9%) were attributed to P. vivax. European travellers and immigrants were the largest patient groups, but their proportion varied among the reporting countries. The main regions of infection in descending order were the Indian subcontinent, Indonesia, South America and Western and Eastern Africa, as a group accounting for more than 60% of the cases. Regular use of malaria chemoprophylaxis was reported by 118 patients. With 86 (inter-quartile range 41-158) versus 31 days (inter-quartile range 4-133) the median symptom onset was significantly delayed in patients with chemoprophylaxis (p < 0.0001). Common complaints were fever, headache, fatigue, and musculo-skeletal symptoms. All patients survived and severe clinical complications were rare. Hospitalization was provided for 60% and primaquine treatment administered to 83.8% of the patients, but frequencies varied strongly among reporting countries. Conclusions: TropNetEurop data can contribute to the harmonization of European treatment policies.	Humboldt Univ, Inst Trop Med, Berlin, Germany; Hosp Clin Barcelona, IDIBAPS, Seccio Med Trop, Barcelona, Spain; Humboldt Univ, Charite, Dept Med Infect Dis, Berlin, Germany; Univ Munich, Dept Trop Med & Infect Dis, D-80539 Munich, Germany; Univ Hosp Hradec Kralove, Dept Infect Dis, Hradec Kralove, Czech Republic; Univ Copenhagen, Rigshosp, Dept Infect Dis, DK-1168 Copenhagen, Denmark; Hosp Trop Dis, London NW1 0PE, England; Prins Leopold Inst Trop Geneeskunde, Clin Serv, Antwerp, Belgium; Karolinska Inst, Dept Med, Infect Dis Unit, Stockholm, Sweden; Bradford Royal Infirm, Bradford BD9 6RJ, W Yorkshire, England; Univ Brescia, Clin Malattie Infett & Trop, I-25121 Brescia, Italy; Hosp Ramon & Cajal, Infect Dis Microbiol Dept, Trop Med & Clin Parasitol Unit, E-28034 Madrid, Spain; Osped S Cuore, Ctr Malattie Trop, Negrar Verona, Italy; Huddinge Univ Hosp, Karolinska Inst, Div Infect Dis, Stockholm, Sweden; Hosp Carlos III, Inst Salud Carlos III, Secc Med Trop, Serv Enfermedades Infecciosas, Madrid, Spain; Newcastle Gen Hosp, Dept Infect & Trop Med, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; Ullevaal Univ Hosp, Dept Infect Dis, Oslo, Norway; Missionsarztliche Klin, Wurzburg, Germany; Kaiser Franz Josef Spital Stadt Wien, Vienna, Austria; Swiss Trop Inst, CH-4002 Basel, Switzerland; Univ Vienna, Inst Pathophysiol, Abt Spezif Prophylaxe & Trop Med, A-1010 Vienna, Austria; Heidelberg Univ, Inst Trop Hyg & Offentliches Gesundheitswesen, D-6900 Heidelberg, Germany; Univ Klinikum Tubingen, Inst Trop Med, Tubingen, Germany; Univ Copenhagen, Hvidovre Hosp, Dept Infect Dis, DK-2650 Hvidovre, Denmark; Med Univ Gdansk, Interfacultary Inst Maritime & Trop Med, Dept Trop Med & Epidemiol, Gdynia, Poland; CHU, Hop St Andre, Bordeaux, France; Univ Ulm, Sekt Infektiol & Klin Immunol, D-89069 Ulm, Germany; Trop Med Bur, Dublin, Ireland; Univ Helsinki, Cent Hosp, Dept Med, Div Infect Dis, Helsinki, Finland; Stadt Kliniken St Georg, Klin Innere Med 2, Leipzig, Germany; Hop Nord CHU, Dept Infect & Trop Dis, Marseille, France; Poznan Univ Med Sci, Dept Clin Trop & Parasit Dis, Poznan, Poland; Inst Catala Salut, Unitat Malalties Trop Importades & Vacunac Int, Barcelona, Spain; Haukeland Hosp, Ctr Trop Med & Imported Infect Dis, N-5021 Bergen, Norway; Hop Avicenne, Consultat Med Trop, F-93009 Bobigny, France; Univ Hosp, Dept Doencas Infecciosas, Consulta Med Viajante, Coimbra, Portugal; Univ Nova Lisboa, Inst Higiena & Med Trop, P-1200 Lisbon, Portugal; German Navy Inst Maritime Med, Ctr Appl Trop Med & Infect Dis Epidemiol, Kronshagen, Germany	Muhlberger, N (reprint author), Humboldt Univ, Inst Trop Med, Berlin, Germany.	muehlberger@bbges.de; Jelinek@bbges.de; JGASCON@clinic.ub.es; meike.probst@charite.de; thomas.zoller@charite.de; schunk@lrz.uni-muenchen.de; jiri.beran@vakcinace.cz; ida.gjorup@dadlnet.dk; Ron.Behrens@lshtm.ac.uk; jclerinx@poliklin.itg.be; anders.bjorkman@ks.se; pmcw@doctors.org.uk; amatteelli@bsnet.it; rlopezvelez@hrc.insalud.es; zeno.bisoffi@sacrocuore.it; urban.hellgren@medhs.ki.se; spuente@hciii.insalud.es; Matthias.Schmid@nuth.northy.nhs.uk; Bjorn.Myrvang@ulleval.no; ml.ho-stich@missioklinik.de; herman.laferl@KFJ.magwien.gv.at; hatz@keep.touch.ch; herwig.kollaritsch@univie.ac.at; annette_kapaun@med.uni-heidelberg.de; juergen.knobloch@med.uni-tuebingen.de; johan.iversen@inet.uni2.dk; akotl@immt.gdynia.pl; denis.malvy@chu-bordeaux.fr; peter.kern@medizin.uni-ulm.de; tropical@iol.ie; heli.siikamaki@fimnet.fi; mhschulze@yahoo.com; Jean.Delmont@mail.ap-hm.fr; mpaul@eucalyptus.am.poznan.pl; jordigp.pbcn@ics.scs.es; vidar.lehmann@helse-bergen.no; olivier.bouchaud@bch.ap-hop-paris.fr; saraiva@huc.min-saude.pt; jma@ihmt.unl.pt; tropmed.marine@t-online.de	Bisoffi, Zeno/B-6438-2013; Matteelli, Alberto/M-8784-2015; Atouguia, Jorge/J-2877-2012; Schmid, Matthias/B-7750-2008; Gascon, Joaquim/M-3598-2015	Matteelli, Alberto/0000-0001-5109-9248; Gascon, Joaquim/0000-0002-5045-1585			ARNOLD J, 1955, J LAB CLIN MED, V46, P391; Baird JK, 2003, TRENDS PARASITOL, V19, P115, DOI 10.1016/S1471-4922(03)0005-9; Baird JK, 2001, CLIN INFECT DIS, V33, P1990, DOI 10.1086/324085; BRADLEY DJ, 1998, EUROSURVEILLANCE, V3, P40; *CATMAT LAB DIS CO, 2000, CAN COMMUN DIS RE S2, V26, P1; da Silva Rita do Socorro Uchoa, 2003, Rev Soc Bras Med Trop, V36, P235; Danis M, 2002, Med Trop (Mars), V62, P214; Filler Scott, 2003, MMWR Surveill Summ, V52, P1; FRYAUFF DJ, 1995, LANCET, V346, P1190, DOI 10.1016/S0140-6736(95)92898-7; Gogtay NJ, 1999, ANN TROP MED PARASIT, V93, P809, DOI 10.1080/00034989957790; JELINEK T, 1995, AM J TROP MED HYG, V52, P322, DOI 10.4269/ajtmh.1995.52.322; JUCKETT G, 2000, AM FAM PHYSICIAN, V61, P2535; Kain KC, 1998, CLIN INFECT DIS, V27, P142, DOI 10.1086/514616; Kain KC, 2001, CLIN INFECT DIS, V33, P226, DOI 10.1086/321817; Karunaweera ND, 2003, TRENDS PARASITOL, V19, P188, DOI 10.1016/S1471-4922(03)00036-9; Legros F, 1998, EUROSURVEILLANCE, V3, P45; LEGROS F, 1998, EUROSURVEILLANCE, V3, P37; Mendis K, 2001, AM J TROP MED HYG, V64, P97, DOI 10.4269/ajtmh.2001.64.97; Miller LH, 2002, NATURE, V415, P673, DOI 10.1038/415673a; MILLER LH, 1976, NEW ENGL J MED, V295, P302, DOI 10.1056/NEJM197608052950602; Nicolas X, 2001, PRESSE MED, V30, P767; Paul MA, 2003, AVIAT SPACE ENVIR MD, V74, P738; Pukrittayakamee S, 2000, ANTIMICROB AGENTS CH, V44, P1680, DOI 10.1128/AAC.44.6.1680-1685.2000; Ridley RG, 2002, P NATL ACAD SCI USA, V99, P13362, DOI 10.1073/pnas.232483699; *RKI, 2002, EPIDEMIOLS B, P285; Romi R, 2001, Euro Surveill, V6, P143; Schwartz E, 2003, NEW ENGL J MED, V349, P1510, DOI 10.1056/NEJMoa021592; Shanks GD, 2001, CLIN INFECT DIS, V33, P381, DOI 10.1086/321866; Soto J, 1998, ANN INTERN MED, V129, P241, DOI 10.7326/0003-4819-129-3-199808010-00013; Strauss R, 2003, Euro Surveill, V8, P91; Weatherall David J, 2002, Hematology Am Soc Hematol Educ Program, P35; *WHO, 2001, US ANT DRUGS REP INF, P144; Yadav RS, 2002, J PARASITOL, V88, P1042, DOI 10.2307/3285559; 2002, EURO SURVEILL WEEKL, V6, P17; 2000, EUROSURVEILL WEEKL, V4, P38	35	58	61	0	9	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1475-2875			MALARIA J	Malar. J.	MAR	2004	3								5	10.1186/1475-2875-3-5				7	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	820RO	WOS:000221407200004	15003128	DOAJ Gold, Green Published			2019-03-26	
J	Erhart, A; Thang, ND; Hung, NQ; Toi, LV; Hung, LX; Tuy, TQ; Cong, LD; Speybroeck, N; Coosemans, M; D'Alessandro, U				Erhart, A; Thang, ND; Hung, NQ; Toi, LV; Hung, LX; Tuy, TQ; Cong, LD; Speybroeck, N; Coosemans, M; D'Alessandro, U			Forest malaria in Vietnam: A challenge for control	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							UNTREATED BEDNETS; GAMBIAN CHILDREN; MORBIDITY; MORTALITY; INFECTION	Forest malaria is a complex but common phenomenon occurring in southeast Asia. We studied its epidemiology through a prospective community-based study in central Vietnam. A total of 585 individuals were followed for two years by active case detection and biannual cross-sectional surveys. The prevalence of antibodies to Plasmodium falciparum was constantly about 20% across surveys and the incidence rate of clinical episodes of P. falciparum malaria was 0.11/person-year. Multivariate analysis showed that regular forest activity was the main risk factor for clinical malaria and malaria infections. Untreated bed nets had a significant protective effect (60%), except for people regularly sleeping in the forest. The population-attributable fraction for regular forest activity was estimated to be 53%. Our results confirm the major role played by forest activity on the malaria burden in this area and provide the basis for targeting control activities to forest workers. New interventions based on insecticide-treated materials need to be urgently evaluated.	Inst Trop Med Prince Leopold, Epidemiol Unit, Dept Parasitol, B-2000 Antwerp, Belgium; Natl Inst Malariol Parasitol & Entomol, Hanoi, Vietnam; Inst Malariol Parasitol & Entomol, Ho Chi Minh City, Vietnam; Prov Malaria Stn, Phan Thiet, Binh Thuan Prov, Vietnam	Erhart, A (reprint author), Inst Trop Med Prince Leopold, Epidemiol Unit, Dept Parasitol, Natl Str 155, B-2000 Antwerp, Belgium.	aerhart@itg.be; nimpe@netnam.org.vn; vmcpimpehcm@saigonnet.vn	D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009			ALONSO PL, 1991, LANCET, V337, P1499, DOI 10.1016/0140-6736(91)93194-E; Armrattana A., 1993, Transactions of the Royal Society of Tropical Medicine and Hygiene, V87, P340; BUTRAPORN P, 1986, Southeast Asian Journal of Tropical Medicine and Public Health, V17, P386; Clarke SE, 2001, T ROY SOC TROP MED H, V95, P457, DOI 10.1016/S0035-9203(01)90001-X; CONG LD, 1999, RESULTS MALARIA CONT; COOSEMANS M, 2001, IDENTIFICATION CHARA; DALESSANDRO U, 1995, LANCET, V345, P479, DOI 10.1016/S0140-6736(95)90582-0; DEMEDTS P, 1985, ANN SOC BELG MED TR, V65, P89; GENTON B, 1994, ANN TROP MED PARASIT, V88, P263, DOI 10.1080/00034983.1994.11812866; Hung LQ, 2002, B WORLD HEALTH ORGAN, V80, P660; Kondrashin A. V., 1991, Forest malaria in southeast Asia: proceedings of an informal consultative meeting WHO/MRC, 18-22 February 1991., P1; Lansang MAD, 1997, ACTA TROP, V63, P257, DOI 10.1016/S0001-706X(96)00625-0; Luxemburger C, 1996, T ROY SOC TROP MED H, V90, P105, DOI 10.1016/S0035-9203(96)90102-9; Manguin S, 2002, MED VET ENTOMOL, V16, P46, DOI 10.1046/j.0269-283x.2002.00344.x; Nevill CG, 1996, TROP MED INT HEALTH, V1, P139; Phan V. T., 1998, EPIDEMIOLOGICAL CHAR; PHAN VT, 1998, EPIDEMIOLOGIE PULUDI; Rahman W. A., 1998, Southeast Asian Journal of Tropical Medicine and Public Health, V29, P537; SCHUFTAN C, 2000, STORY SHARED SUCCESS; Singhasivanon Pratap, 1999, Southeast Asian Journal of Tropical Medicine and Public Health, V30, P399; SMITH T, 1994, STAT MED, V13, P2345, DOI 10.1002/sim.4780132206; Somboon Pradya, 1998, Southeast Asian Journal of Tropical Medicine and Public Health, V29, P3; TUY TC, 1998, MALARIA SITUATION VI; Van Bortel W, 2001, AM J TROP MED HYG, V65, P729, DOI 10.4269/ajtmh.2001.65.729; Verle P., 1998, Research and Reviews in Parasitology, V58, P169; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; 1991, P INF CONS M WHO MRC	27	64	65	0	2	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637	1476-1645		AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	FEB	2004	70	2					110	118		10.4269/ajtmh.2004.70.110				9	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	773BZ	WOS:000188879000003	14993619				2019-03-26	
J	Torrico, F; Alonso-vega, C; Suarez, E; Rodriguez, P; Torrico, MC; Dramaix, M; Truyens, C; Carlier, Y				Torrico, F; Alonso-vega, C; Suarez, E; Rodriguez, P; Torrico, MC; Dramaix, M; Truyens, C; Carlier, Y			Maternal Trypanosoma cruzi infection, pregnancy outcome, morbidity, and mortality of congenitally infected and non-infected newborns in Bolivia	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article; Proceedings Paper	International Colloquium on Congenital Trypanosoma Cruzi Infection - From Mechanisms of Transmission to a Strategy for Diagnosis and Control	NOV 06-08, 2002	COCHABAMBA, BOLIVIA				POLYMERASE-CHAIN-REACTION; CHAGAS-DISEASE; TRANSMISSION; ARGENTINA; INFANTS	This work compares the results of two epidemiologic and clinical surveys on the consequences of maternal chronic Trypanosoma cruzi infection. They were conducted in 1992-1994 and 1999-2001 in the same maternity clinic in Bolivia, a country highly endemic for infection with this parasite. In both surveys, the materno-fetal transmission of parasites occurred in 5-6% of the infected mothers. Maternal chronic T. cruzi infection had no effect on pregnancy outcome and health of newborns when there was no materno-fetal transmission of parasites. Comparisons between the older and the more recent surveys highlighted significant reductions in frequencies of symptomatic cases (from 54% to 45%), Apgar scores <7, and low birth weights and prematurity (from 32-50% to 6-16%) among congenitally infected babies. Neonatal mortality related to congenital Chagas disease also decreased from 13% to 2% in the interval between both studies. These results suggest that the decrease in poverty that has occurred in Bolivia between both surveys might have contributed to reduce the morbidity and mortality, but not the transmission rate of T cruzi congenital infection, which remains a serious public health problem in this country.	Free Univ Brussels, Fac Med, Parasitol Lab, B-1070 Brussels, Belgium; Univ Mayor San Simon, Fac Med, Ctr Univ Med Trop, Cochabamba, Bolivia; Free Univ Brussels, Ecole Sante Publ, Lab Stat Med, B-1070 Brussels, Belgium	Carlier, Y (reprint author), Free Univ Brussels, Fac Med, Parasitol Lab, 808 Route Lennik CP 616, B-1070 Brussels, Belgium.	ycarlier@ulb.ac.be					Altman DG, 1991, PRACTICAL STAT MED R; ARCAVI M, 1993, MEDICINA-BUENOS AIRE, V53, P217; AZOGUE E, 1993, SOC SCI MED, V37, P503, DOI 10.1016/0277-9536(93)90285-C; Azogue E, 1991, Rev Soc Bras Med Trop, V24, P105; AZOGUE E, 1985, T ROY SOC TROP MED H, V79, P176, DOI 10.1016/0035-9203(85)90328-1; BALLARD JL, 1991, J PEDIATR-US, V119, P417, DOI 10.1016/S0022-3476(05)82056-6; Basombrio MA, 1999, MEDICINA-BUENOS AIRE, V59, P143; BASSO B, 1984, MEDICINA-BUENOS AIRE, V44, P41; BITENCOURT AL, 2000, TRYPANOSOMA CRUZI DO, P16; BITTENCOURT AL, 1992, REV I MED TROP, V34, P403, DOI 10.1590/S0036-46651992000500006; BITTENCOURT AL, 1976, AM J DIS CHILD, V130, P97, DOI 10.1001/archpedi.1976.02120020099020; Bittencourt AL, 1988, PARASITIC INFECT PRE, P62; Blanco SB, 2000, TROP MED INT HEALTH, V5, P293, DOI 10.1046/j.1365-3156.2000.00548.x; BRENIERE SF, 1985, TROP GEOGR MED, V37, P231; CARLIER Y, 2002, ENCY MED CHIRURGICAL; de Castilho E A, 1976, Rev Inst Med Trop Sao Paulo, V18, P258; Freilij H., 1983, Journal of Clinical Microbiology, V18, P327; FREILIJ H, 1995, CLIN INFECT DIS, V21, P551, DOI 10.1093/clinids/21.3.551; FREILIJ H, 1995, PEDIATR INFECT DIS J, V14, P161; GEISSLER RG, 1992, AIDS RES HUM RETROV, V8, P521, DOI 10.1089/aid.1992.8.521; Gelbard A, 1999, POPUL BULL, V54, P3; Hermann E, 2002, BLOOD, V100, P2153; HERNANDEZMATHESON IM, 1983, T ROY SOC TROP MED H, V77, P405, DOI 10.1016/0035-9203(83)90174-8; HOFF R, 1978, T ROY SOC TROP MED H, V72, P247, DOI 10.1016/0035-9203(78)90203-1; KLEIN J, 2001, INFECT DIS FETUS NEW, P1; KLIEGMAN RM, 2002, NELSON ESSENTIALS PE, P179; Lorca H. Myriam, 2002, Revista de Patologia Tropical, V31, P86; Moya P., 1997, CLIN TERAPEUTICA DOE, P383; Moya P R, 1979, Rev Fac Cien Med Univ Nac Cordoba, V37, P21; OLIVEIRA FAUSTO da CUNHA, 1966, REV INST MED TROP SAO PAULO, V8, P184; RUBIO M, 1968, Boletin Chileno de Parasitologia, V23, P113; Russomando G, 1998, AM J TROP MED HYG, V59, P487, DOI 10.4269/ajtmh.1998.59.487; SCHENONE H, 1985, Boletin Chileno de Parasitologia, V40, P24; Schenone H, 1991, Bol Chil Parasitol, V46, P19; Schenone Hugo, 2001, Revista do Instituto de Medicina Tropical de Sao Paulo, V43, P231, DOI 10.1590/S0036-46652001000400011; SCHMUNIS GA, 1977, MEDICINA-BUENOS AIRE, V37, P47; SCHMUNIS GA, 2000, TRYPANOSOMA CRUZI DO, P1; STREIGER M, 1995, MEDICINA-BUENOS AIRE, V55, P125; TERUEL J R, 1970, Revista do Instituto de Medicina Tropical de Sao Paulo, V12, P239; Virreira M, 2003, AM J TROP MED HYG, V68, P574, DOI 10.4269/ajtmh.2003.68.574; Voller A., 1982, Immunoparasitology: principles and methods in malaria and schistosomiasis research., P99	41	144	156	0	13	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637	1476-1645		AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	FEB	2004	70	2					201	209		10.4269/ajtmh.2004.70.201				9	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	773BZ	WOS:000188879000018	14993634				2019-03-26	
J	Talisuna, AO; Nalunkuma-Kazibwe, A; Bakyaita, N; Langi, P; Mutabingwa, TK; Watkins, WW; Van Marck, E; D'Alessandro, U; Egwang, TG				Talisuna, AO; Nalunkuma-Kazibwe, A; Bakyaita, N; Langi, P; Mutabingwa, TK; Watkins, WW; Van Marck, E; D'Alessandro, U; Egwang, TG			Efficacy of sulphadoxine-pyrimethamine alone or combined with amodiaquine or chloroquine for the treatment of uncomplicated falciparum malaria in Ugandan children	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						in vivo efficacy; sulphadoxine-pyrimethamine; chloroquine; amodiaquine; combination therapy; falciparum malaria; Uganda	ANTIMALARIAL-DRUG-RESISTANCE; PLASMODIUM-FALCIPARUM; RANDOMIZED TRIAL; ARTESUNATE; COMBINATION; SULFADOXINE/PYRIMETHAMINE; MUTATION; KAMPALA; PFCRT	The rapid development of falciparum resistance to sulphadoxine-pyrimethamine (SP) in East and Central Africa has raised concerns as to the efficacy of combining it with another drug. In 2002, we assessed the efficacy of SP alone and combined with amodiaquine (AQ/SP) or chloroquine (CQ/SP) in Ugandan children with uncomplicated falciparum malaria. At day 14, adequate clinical response was 100% (84/84) for AQ/SP, 93% (92/101) for CQ/SP and 91% (73/80) for SP. At day 28, parasitological failure (RI-RIII) occurred in 16% (13/80) of children treated with AQ/SP, in 48% (48/100) of those treated with CQ/SP and in 61% (48/79) of those treated with SP alone. Compared with the AQ/SP arm, the odds for parasitological failure at day 28 were five times higher (95% CI, 2-10) in the CQ/SP group and sevenfold higher (95% CI, 3-17) in that of SP alone. CQ/SP does not offer any significant added benefit over SP alone while AQ/SP is an efficacious low-cost combination. These findings have important policy implications for Uganda and other resource-constrained African countries faced with the problematic choice of a new first-line antimalarial treatment in a context of high CQ resistance.	Minist Hlth Uganda, Kampala, Uganda; Med Biotech Labs, Dept Parasitol, Kampala, Uganda; Natl Inst Med Res, Amani, Tanzania; London Sch Hyg & Trop Med, Gates Malaria Partnership, London WC1, England; Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool L69 3BX, Merseyside, England; Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium; Univ Instelling Antwerp, Fac Med, B-2610 Wilrijk, Belgium	Talisuna, AO (reprint author), Minist Hlth Uganda, POB 7272, Kampala, Uganda.	atalisuna@kla1.afsat.com; tkmuta@tanga.net; bwatkins@btinternet.com; eric.van.marck@uza.be; udalessandro@itg.be; egwang@imul.com	D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009			Adjuik M, 2002, LANCET, V359, P1365, DOI 10.1016/S0140-6736(02)08348-4; Dorsey G, 2002, LANCET, V360, P2031, DOI 10.1016/S0140-6736(02)12021-6; Gasasira AF, 2003, AM J TROP MED HYG, V68, P127, DOI 10.4269/ajtmh.2003.68.127; Hastings IM, 2000, PARASITOL TODAY, V16, P340, DOI 10.1016/S0169-4758(00)01707-5; Kamya MR, 2002, TROP MED INT HEALTH, V7, P1031, DOI 10.1046/j.1365-3156.2002.00974.x; Kyosiimire-Lugemwa J, 2002, T ROY SOC TROP MED H, V96, P91, DOI 10.1016/S0035-9203(02)90252-X; Legros D, 2002, T ROY SOC TROP MED H, V96, P199, DOI 10.1016/S0035-9203(02)90304-4; McIntosh HM, 1998, ANN TROP MED PARASIT, V92, P265, DOI 10.1080/00034983.1998.11813289; Mutabingwa T, 2001, LANCET, V358, P1218, DOI 10.1016/S0140-6736(01)06344-9; Nosten F, 2000, LANCET, V356, P297, DOI 10.1016/S0140-6736(00)02505-8; Nzila AM, 2000, J INFECT DIS, V181, P2023, DOI 10.1086/315520; Plowe CV, 1997, J INFECT DIS, V176, P1590, DOI 10.1086/514159; Ranford-Cartwright LC, 1997, T ROY SOC TROP MED H, V91, P719, DOI 10.1016/S0035-9203(97)90539-3; Rwagacondo CE, 2003, AM J TROP MED HYG, V68, P743, DOI 10.4269/ajtmh.2003.68.743; Staedke SG, 2001, LANCET, V358, P368, DOI 10.1016/S0140-6736(01)05557-X; Talisuna AO, 2002, T ROY SOC TROP MED H, V96, P310, DOI 10.1016/S0035-9203(02)90108-2; Talisuna AO, 2002, T ROY SOC TROP MED H, V96, P551, DOI 10.1016/S0035-9203(02)90439-6; TALISUNA OA, 2004, IN PRESS T ROYAL SOC; Watkins WM, 1997, PARASITOL TODAY, V13, P459, DOI 10.1016/S0169-4758(97)01124-1; White N, 1999, PHILOS T R SOC B, V354, P739, DOI 10.1098/rstb.1999.0426; White N. J., 1999, Parassitologia (Rome), V41, P301; *WHO, 1965, WHO TECHN REP SER, V296; *WHO CTD, 1996, WHOMAL961077; World Health Organization, 2001, WHOCDSCSREPH20027	24	27	29	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	FEB	2004	9	2					222	229		10.1046/j.1365-3156.2003.01187.x				8	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	770JZ	WOS:000188720600006	15040559	Bronze			2019-03-26	
J	Trung, HD; Van Bortel, W; Sochantha, T; Keokenchanh, K; Quang, NT; Cong, LD; Coosemans, M				Trung, HD; Van Bortel, W; Sochantha, T; Keokenchanh, K; Quang, NT; Cong, LD; Coosemans, M			Malaria transmission and major malaria vectors in different geographical areas of Southeast Asia	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						Anopheles dirus; Anopheles minimus; Anopheles sundaicus; malaria; transmission; Southeast Asia	LINKED-IMMUNOSORBENT-ASSAY; ANOPHELES-MINIMUS; PLASMODIUM-VIVAX; LAO PDR; THAILAND; IDENTIFICATION; MOSQUITOS; PREVALENCE; VILLAGE; COMPLEX	During the last decade, major progress in malaria control has been achieved in Vietnam, Laos and Cambodia. However, malaria is still a potentially fatal disease in some hilly-forested areas and continues to be endemic in a few coastal foci. To estimate the risk that stems from the major vectors after a decade of intensive malaria control, an entomological study based on human landing collections was conducted between April 1998 and November 2000 in six study villages (four in Vietnam, one in Cambodia and one in Laos) located in different physio-geographical areas. Five villages were selected in places where new cases of malaria still occurred. In the sixth village, in the northern hilly area of Vietnam, no case of malaria was detected during the past 3 years. In three study villages of the hilly forested areas of Cambodia and central Vietnam, Anopheles dirus A still played an important role in malaria transmission and maintain perennial transmission inside the villages despite its low density. Anopheles minimus A was found in all study villages except in the southern coastal village of Vietnam. Its role in malaria transmission, however, varied between localities and surveys. In one study village of central Vietnam it was almost absent (one specimen collected over 480 man nights), and in another village sporozoite positive specimens (2.8%) were only observed during the first two surveys whereas this species disappeared from the collections from November 1998 onwards (six surveys: 360 man nights). In the northern study site An. minimus A and C were found in all collections, but no local malaria transmission occurred. However, the constant presence of these two species associated with a high longevity (parous rate up around 80% and 65%, respectively), suggests that transmission can occur at almost any time if parasite reservoirs are reintroduced in the area. The proper management of malaria cases and population movement is, therefore, important to prevent outbreaks and the reintroduction of malaria in northern Vietnam. In the study site of the Mekong delta, An. sundaicus occurred at high densities (up to 190 bites/man/night). The recent changes in land use from rice cultivation to shrimp farming probably explains the increase of this brackish water breeding species during the study period. However, none of the 11 002 specimens was positive for Plasmodium circumsporozoite protein (CSP). The relative low survival rate as estimated by the parous rate (around 47 %) may reflect its low vectorial status that could explain the very low malaria incidence (1.9 case/100 persons/year) in this study site. A calculated sporozoite rate of maximum 1/300 000 is enough to explain this low malaria incidence. Despite the successes in malaria control, the vector An. dirus A continues to play an important role in malaria transmission, whereas An. minimus A showed temporal and spatial variation in its role as vector. The role of An. sundaicus as vector could not be confirmed because of the low incidence in the coastal study village. Other Anopheles species may be locally involved, but in the five study villages where malaria is still present they probably do not contribute significantly to malaria transmission. The study also points towards the fact that in Southeast Asia it will become increasingly difficult to incriminate Anopheles species in malaria transmission while the risk for malaria transmission still persist.	Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium; Natl Inst Malariol Parasitol & Entomol, Hanoi, Vietnam; Natl Ctr Malaria Control Parasitol & Entomol, Phnom Penh, Cambodia; Ctr Malariol Parasitol & Entomol, Viangchan, Laos	Van Bortel, W (reprint author), Inst Trop Med Prince Leopold, Natl Str 155, B-2000 Antwerp, Belgium.	entomology@fpt.vn; wvbortel@itg.be; sochanthat@cnm.gov.kh; cmpe@laotel.com; kpmalaria@hn.vnn.vn; ldcong@hn.vnn.vn; mcoosemans@itg.be		Van Bortel, Wim/0000-0002-6644-518X			Anno Sumiko, 2000, Kobe Journal of Medical Sciences, V46, P231; BURKOT TR, 1984, AM J TROP MED HYG, V33, P783, DOI 10.4269/ajtmh.1984.33.783; COOSEMANS M, 1992, MEM I OSWALDO CRUZ, V87, P385, DOI 10.1590/S0074-02761992000700065; DAVIDSON G, 1954, NATURE, V174, P792, DOI 10.1038/174792a0; DETINOVA TS, 1962, WHO MONOGRAPH SERIES, V47; ERHART A, 2003, IN PRESS AM J TROPIC; GINGRICH JB, 1990, J MED ENTOMOL, V27, P1016, DOI 10.1093/jmedent/27.6.1016; HARBACH RE, 1987, J AM MOSQUITO CONTR, V3, P296; HARRISON B A, 1980, Contributions of the American Entomological Institute, V17, P1; HINH TD, 1997, ANN SCI WORKS, V1, P299; Hung LQ, 2002, B WORLD HEALTH ORGAN, V80, P660; *IMPE, 1987, KEYS AN VIETN AD PUP; ISMAIL IAH, 1978, ACTA TROP, V35, P69; Kobayashi J, 2000, TROP MED INT HEALTH, V5, P17, DOI 10.1046/j.1365-3156.2000.00516.x; KRAFSUR ES, 1977, J MED ENTOMOL, V14, P180, DOI 10.1093/jmedent/14.2.180; Manguin S, 2002, MED VET ENTOMOL, V16, P46, DOI 10.1046/j.0269-283x.2002.00344.x; MEEK SR, 1995, ANN TROP MED PARASIT, V89, P135, DOI 10.1080/00034983.1995.11812944; Molineaux L., 1988, P913; Overgaard HJ, 2002, ENVIRON ENTOMOL, V31, P134, DOI 10.1603/0046-225X-31.1.134; PARAJULI MB, 1981, T ROY SOC TROP MED H, V75, P603; PHAN VT, 1998, EPIDEMIOLOGIE PALUDI; Rattanarithikul R, 1996, AM J TROP MED HYG, V54, P114, DOI 10.4269/ajtmh.1996.54.114; Rattanarithikul R, 1996, J AM MOSQUITO CONTR, V12, P52; ROSENBERG R, 1990, T ROY SOC TROP MED H, V84, P22; SCANLON JOHN E., 1965, J MED ENTOMOL, V2, P61; Singhasivanon Pratap, 1999, Southeast Asian Journal of Tropical Medicine and Public Health, V30, P399; Van Bortel W, 1999, TROP MED INT HEALTH, V4, P257; Van Bortel W, 2000, INSECT MOL BIOL, V9, P335, DOI 10.1046/j.1365-2583.2000.00192.x; Van Bortel W, 2001, AM J TROP MED HYG, V65, P729, DOI 10.4269/ajtmh.2001.65.729; Verle P., 1998, Research and Reviews in Parasitology, V58, P169; Vythilingam I, 2003, TROP MED INT HEALTH, V8, P525, DOI 10.1046/j.1365-3156.2003.01052.x; WIRTZ RA, 1992, J MED ENTOMOL, V29, P854, DOI 10.1093/jmedent/29.5.854; WIRTZ RA, 1985, AM J TROP MED HYG, V34, P1048, DOI 10.4269/ajtmh.1985.34.1048	33	110	117	4	25	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	FEB	2004	9	2					230	237		10.1046/j.1365-3156.2003.01179.x				8	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	770JZ	WOS:000188720600007	15040560	Bronze			2019-03-26	
J	Van Damme, W; Van Leemput, L; Por, I; Hardeman, W; Meessen, B				Van Damme, W; Van Leemput, L; Por, I; Hardeman, W; Meessen, B			Out-of-pocket health expenditure and debt in poor households: evidence from Cambodia	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						catastrophic health expenditure; out-of-pocket expenditure; dengue; Cambodia; private providers; poverty; health system	CARE EXPENDITURES; ILLNESS; POVERTY; STRATEGIES; COSTS; RISK	OBJECTIVES To document how out-of-pocket health expenditure can lead to debt in a poor rural area in Cambodia. METHODS After a dengue epidemic, 72 households with a dengue patient were interviewed to document health-seeking behaviour, out-of-pocket expenditure, and how they financed such expenditure. One year later, a follow-up visit investigated how the 26 households with an initial debt had coped with it. RESULTS The amount of out-of-pocket health expenditure depended mostly on where households sought care. Those who had used exclusively private providers paid on average US$103; those who combined private and public providers paid US$32, and those who used only the public hospital US$8. The households used a combination of savings, selling consumables, selling assets and borrowing money to finance this expenditure. One year later, most families with initial debts had been unable to settle these debts, and continued to pay high interest rates (range between 2.5 and 15% per month). Several households had to sell their land. CONCLUSIONS In Cambodia, even relatively modest out-of-pocket health expenditure frequently causes indebtedness and can lead to poverty. A credible and accessible public health system is needed to prevent catastrophic health expenditure, and to allow for other strategies, such as safety nets for the poor, to be fully effective.	Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium; Med Sans Frontieres, Phnom Penh, Cambodia	Van Damme, W (reprint author), Inst Trop Med, Dept Publ Hlth, Natl Str 155, B-2000 Antwerp, Belgium.	wvdamme@itg.be; lydialuc@hotmail.com; irpor@yahoo.com; wim_hardeman@hotmail.com; bmeessen@itg.be	Van Damme, Wim/F-7404-2011	Meessen, Bruno/0000-0002-0359-8621			Berki S E, 1986, Health Aff (Millwood), V5, P138, DOI 10.1377/hlthaff.5.4.138; BIRNBAUM H, 1979, Q REV ECON BUS, V19, P17; COLLINS W, 2000, MED PRACTITIONERS TR, P1; *COMM MACR HLTH, 2001, MACR HLTH INV HLTH E, P1; Dercon S, 2002, WORLD BANK RES OBSER, V17, P141, DOI 10.1093/wbro/17.2.141; Gertler P, 2002, AM ECON REV, V92, P51, DOI 10.1257/000282802760015603; Gilson L, 1997, HEALTH POLICY PLANN, V12, P273; Kawabata K, 2002, B WORLD HEALTH ORGAN, V80, P612; Meessen B, 2003, TROP MED INT HEALTH, V8, P581, DOI 10.1046/j.1365-3156.2003.01081.x; MEESSEN B, 2002, NEW DEAL CAMBODIA 2, P1; Morduch J, 1999, WORLD BANK RES OBSER, V14, P187, DOI 10.1093/wbro/14.2.187; Pradhan M, 2002, HEALTH ECON, V11, P431, DOI 10.1002/hec.689; Ranson MK, 2002, B WORLD HEALTH ORGAN, V80, P613; Russell S, 1996, HEALTH POLICY PLANN, V11, P219, DOI 10.1093/heapol/11.3.219; Sauerborn R, 1996, SOC SCI MED, V43, P291, DOI 10.1016/0277-9536(95)00375-4; Sauerborn R, 1996, SOC SCI MED, V43, P281, DOI 10.1016/0277-9536(95)00374-6; SCHWARTZ M, 1978, SOC SCI MED-MED ECON, V12, P13; SEN A, 1990, HUNGER HIST FOOD SHO, P374; Sen AK, 1981, POVERTY FAMINES ESSA; Sen Amartya, 1989, HUNGER PUBLIC ACTION; Uplekar M, 2001, LANCET, V358, P912, DOI 10.1016/S0140-6736(01)06076-7; Uplekar MW, 2000, SOC SCI MED, V51, P897, DOI 10.1016/S0277-9536(00)00069-1; Van Damme W, 2003, LANCET, V362, P996, DOI 10.1016/S0140-6736(03)14375-9; VANDAMME W, 2001, SOTNIKUM NEW DEAL 1, P1; VANLEEMPUT L, 2002, DENGUE EPIDEMIC THMA, P1; Wagstaff A, 2002, HEALTH ECON, V11, P103, DOI 10.1002/hec.685; Wagstaff A, 2002, B WORLD HEALTH ORGAN, V80, P97; Whitehead M, 2001, LANCET, V358, P833, DOI 10.1016/S0140-6736(01)05975-X; WILKES A, 1998, COPING COST SEVERE I, V58, P1; World Health Organization, 2001, WORLD HLTH REP 2000; WYSZEWIANSKI L, 1986, HEALTH SERV RES, V21, P617; Xu K, 2003, LANCET, V362, P111, DOI 10.1016/S0140-6736(03)13861-5; XU K, 2003, CATASTROPHIC HLTH EX, V362, P997	33	119	120	2	32	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	FEB	2004	9	2					273	280						8	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	770JZ	WOS:000188720600013	15040566	Bronze			2019-03-26	
J	Van Damme, W; Van Lerberghe, W				Van Damme, W; Van Lerberghe, W			Strengthening health services to control epidemics: empirical evidence from Guinea on its cost-effectiveness	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						epidemics; cost-effectiveness; health services; cholera; measles; meningococcal meningitis	ECONOMIC-EVALUATION; MEASLES; MENINGITIS; CARE; INTERVENTIONS; VACCINATION; PROGRAM	OBJECTIVE To assess the cost-effectiveness of control measures implemented against epidemics in Guinea, West Africa. METHODS We collected all routine data available on incidence, mortality, control measures implemented and their cost during epidemics of cholera, measles and meningococcal meningitis in 1993-95. Then we estimated for one prefecture the effectiveness and cost-effectiveness of epidemic control measures for three scenarios: (i) 'natural' situation, (ii) 'routine' health services and (iii) 'intervention'. Where uncertainty was considerable, we used sensitivity analysis and estimated ranges. FINDINGS Routine health services reduced potential deaths by 51% (67%, 37% and 60% for cholera, measles and meningitis, respectively), and additional interventions further decreased potential deaths by 28% (28%, 27% and 30% for cholera, measles and meningitis, respectively). The marginal cost-effectiveness of epidemic control measures in routine health services was US$29 per death averted. The marginal cost-effectiveness of additional interventions was US$93 per death averted. CONCLUSION Even with the data weaknesses that characterize situations of epidemics it is possible to show that strengthening health services to control epidemics as was performed in Guinea was highly cost-effective. Moreover, sensitivity analysis over a range of assumptions confirms that (i) well-functioning health services averted the major part of avoidable deaths, (ii) combining existing health services with additional interventions minimizes the health impact of epidemics and (iii) case management should be a cornerstone of control of epidemics of cholera, measles and meningococcal meningitis.	Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium	Van Damme, W (reprint author), Inst Trop Med, Dept Publ Hlth, 155 Natl Str, B-2000 Antwerp, Belgium.	wvdamme@itg.be; isa@itg.be	Van Damme, Wim/F-7404-2011	Van Lerberghe, Wim/0000-0001-9966-6563			AABY P, 1995, SOC SCI MED, V41, P673, DOI 10.1016/0277-9536(95)00038-9; Anderson R. M., 1992, INFECT DIS HUMANS DY, P13; ASSAAD F, 1983, REV INFECT DIS, V5, P452; Banatvala N, 2000, BMJ-BRIT MED J, V321, P101, DOI 10.1136/bmj.321.7253.101; BEGG N, 1995, MENINGOCOCCAL DIS, P285; BENNETT K, 1990, TROPICAL GEOGRAPHICA, P205; BLACK FL, 1982, YALE J BIOL MED, V55, P351; Bres P, 1986, PUBLIC HLTH ACTION E; BRIGGS A, 1994, HEALTH ECON, V3, P95, DOI 10.1002/hec.4730030206; Campbell M, 1997, J Health Serv Res Policy, V2, P253; *COMM MACR HLTH, 2001, MACR HLTH INV HLTH E, P1; Damme W. van, 1999, Journal of Refugee Studies, V12, P36, DOI 10.1093/jrs/12.1.36; FOSTER SO, 1993, DIS CONTROL PRIORITI, P161; GREENWOOD BM, 1984, REV INFECT DIS, V6, P374; HALSEY NA, 1985, NEW ENGL J MED, V313, P544, DOI 10.1056/NEJM198508293130904; HANQUET G, 1997, REFUGEE HLTH APPROAC, P154; Hutubessy RCW, 2001, HEALTH ECON, V10, P473, DOI 10.1002/hec.614; Hutubessy RCW, 2001, ACTA TROP, V78, P191, DOI 10.1016/S0001-706X(00)00176-5; Johannesson M, 1998, HEALTH ECON, V7, P1, DOI 10.1002/(SICI)1099-1050(199802)7:1<1::AID-HEC327>3.0.CO;2-U; KENYA PR, 1990, E AFR MED J, V67, P856; Lambo E, 2003, East Afr Med J, V80, pS1; Luthi JC, 1997, B WORLD HEALTH ORGAN, V75, P427; Mills A, 1985, World Health Stat Q, V38, P402; MOORE PS, 1990, B WORLD HEALTH ORGAN, V68, P587; Murray CJL, 2000, HEALTH ECON, V9, P235, DOI 10.1002/(SICI)1099-1050(200004)9:3<235::AID-HEC502>3.0.CO;2-O; Porignon D, 1998, TROP MED INT HEALTH, V3, P559, DOI 10.1046/j.1365-3156.1998.00263.x; Sondorp E, 2001, TROP MED INT HEALTH, V6, P965, DOI 10.1046/j.1365-3156.2001.00821.x; Soucat A, 1997, INT J HEALTH PLAN M, V12, pS81, DOI 10.1002/(SICI)1099-1751(199706)12:1+<S81::AID-HPM467>3.3.CO;2-X; Van Damme W, 1998, LANCET, V351, P1609, DOI 10.1016/S0140-6736(97)10348-8; Van Damme W, 2000, TROP MED INT HEALTH, V5, P511; VANDAMME W, 1995, LANCET, V346, P360; VANDAMME W, 1998, MED ASSISTANCE SELF, P1990; Varaine F, 1997, T ROY SOC TROP MED H, V91, P3, DOI 10.1016/S0035-9203(97)90371-0; Veeken H, 1998, B WORLD HEALTH ORGAN, V76, P135; *WORLD BANK, 1993, BETT HLTH AFR, P1; World Bank, 1993, WORLD DEV REP 1993 I	36	6	6	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	FEB	2004	9	2					281	291		10.1046/j.1365-3156.2003.01189.x				11	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	770JZ	WOS:000188720600014	15040567	Bronze			2019-03-26	
J	Boelaert, M; Rijal, S; Regmi, S; Singh, R; Karki, B; Jacquet, D; Chappuis, F; Campino, L; Desjeux, P; Le Ray, D; Koirala, S; Van Der Stuyft, P				Boelaert, M; Rijal, S; Regmi, S; Singh, R; Karki, B; Jacquet, D; Chappuis, F; Campino, L; Desjeux, P; Le Ray, D; Koirala, S; Van Der Stuyft, P			A comparative study of the effectiveness of diagnostic tests for visceral leishmaniasis	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							DIRECT AGGLUTINATION-TEST; KALA-AZAR; MODELS; SUDAN	We compared the validity of pancytopenia, the formol-gel test (FGT), the indirect fluorescence antibody test (IFAT), the direct agglutination test (DAT), and the rK39 dipstick test as diagnostic criteria for visceral leishmaniasis (VL) in Nepal. Between September 2000 and January 2002, 310 clinical suspects had a bone marrow aspirate, and if negative, a spleen aspirate smear examined for Leishmania donovani. Sensitivity and specificity of all tests were determined compared with parasitology and by latent class analysis (LCA). Compared with parasitology, the sensitivities of the other tests were as follows: pancytopenia = 16.3% (95% confidence interval [CI] = 11.3-22.5%), FGT = 39.9% (95% CI = 32.7-47.4%), IFAT = 28.4% (95% CI = 22.0-35.5%), DAT = 95.1% (95% CI = 90.8-97.7%), and the rK39 dipstick test = 87.4% (95% CI = 81.7-91.9%). Sensitivity estimates obtained by LCA were similar, but specificity estimates were substantially higher (DAT = 93.7% versus 77.8%; rK39 dipstick test 93.1% versus 77.0%). The DAT or the rK39 dipstick test can replace parasitology as the basis of a decision to treat VL in Nepalese peripheral health services.	Inst Trop Med Prince Leopold, Dept Publ Hlth, B-2000 Antwerp, Belgium; Inst Trop Med Prince Leopold, Dept Parasitol, B-2000 Antwerp, Belgium; BP Koirala Inst Hlth Sci, Dept Med, Dharan, Nepal; BP Koirala Inst Hlth Sci, Dept Pediat, Dharan, Nepal; BP Koirala Inst Hlth Sci, Dept Microbiol, Dharan, Nepal; Univ Hosp Geneva, Dept Community Med, Geneva, Switzerland; Inst Higiene & Med Trop, Unidade Leishmanioses, Lisbon, Portugal; WHO, CH-1211 Geneva, Switzerland	Boelaert, M (reprint author), Inst Trop Med Prince Leopold, Dept Publ Hlth, Nationalestr 155, B-2000 Antwerp, Belgium.	boelaert@itg.be; sumanrijal2@yahoo.com; sudhirregmi@yahoo.com; rupasingh@hotmail.com; hmskarki@hotmail.com; djacquet@proto.itg.be; francois.chappuis@hcuge.ch; campino@ihmt.unl.pt; desjeuxp@who.int; dleray@proto.itg.be; shekharkoirala@hotmail.com; pvds@itg.be	Campino, Lenea/I-6375-2012; Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776; Campino, Lenea/0000-0003-4512-9660			Agresti A., 1990, CATEGORICAL DATA ANA; Boelaert M, 1999, AM J TROP MED HYG, V60, P129, DOI 10.4269/ajtmh.1999.60.129; Campino L, 1997, ANN TROP MED PARASIT, V91, P433, DOI 10.1080/00034983.1997.11813159; Chappuis F, 2003, TROP MED INT HEALTH, V8, P277, DOI 10.1046/j.1365-3156.2003.01026.x; CHOWDHURY MAJ, 1992, TROP DOCT, V22, P185, DOI 10.1177/004947559202200432; DUNCAN S, 1987, MED MED, V369, P10; ELHARITH AE, 1986, T ROY SOC TROP MED H, V80, P583; Goetghebeur E, 2000, STAT METHODS MED RES, V9, P231, DOI 10.1191/096228000701555127; GOODMAN LA, 1974, AM J SOCIOL, V79, P1179, DOI 10.1086/225676; Guerin PJ, 2002, LANCET INFECT DIS, V2, P494, DOI 10.1016/S1473-3099(02)00347-X; Hadgu A, 1998, J R STAT SOC C-APPL, V47, P603, DOI 10.1111/1467-9876.00131; HAGENAARS JA, 1988, SOCIOL METHOD RES, V16, P379, DOI 10.1177/0049124188016003002; HEINEN T, 1996, LATENT CLASS DISCRET; LANOTTE G, 1975, FOYER LEISHMANIOSE V; LERAY D, 1975, ANN SOC BELG MED TR, V55, P132; STAQUET M, 1981, J CHRON DIS, V34, P599, DOI 10.1016/0021-9681(81)90059-X; Sundar S, 1998, LANCET, V351, P563, DOI 10.1016/S0140-6736(97)04350-X; Sundar S, 2002, CLIN INFECT DIS, V35, P581, DOI 10.1086/342057; Trouiller P, 2002, LANCET, V359, P2188, DOI 10.1016/S0140-6736(02)09096-7; ZIJLSTRA EE, 1992, T ROY SOC TROP MED H, V86, P505, DOI 10.1016/0035-9203(92)90086-R; Zijlstra EE, 2001, TROP MED INT HEALTH, V6, P108, DOI 10.1046/j.1365-3156.2001.00680.x; ZIJLSTRA EE, 1991, T ROY SOC TROP MED H, V85, P474, DOI 10.1016/0035-9203(91)90224-M	22	87	89	0	10	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637	1476-1645		AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	JAN	2004	70	1					72	77		10.4269/ajtmh.2004.70.72				6	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	768AT	WOS:000188506600012	14971701				2019-03-26	
S	Gutierrez, C; Corbera, JA; Doreste, F; Buscher, P		Bokma, BH; Blouin, EF; Bechara, GH		Gutierrez, C; Corbera, JA; Doreste, F; Buscher, P			Use of the miniature anion exchange centrifugation technique to isolate Trypanosoma evansi from goats	IMPACT OF ECOLOGICAL CHANGES ON TROPICAL ANIMAL HEALTH AND DISEASE CONTROL	ANNALS OF THE NEW YORK ACADEMY OF SCIENCES		English	Article; Proceedings Paper	7th Biennial Conference of the Society-for-Tropical-Veterinary-Medicine	JUN 22-27, 2003	Iguacu Falls, BRAZIL	USDA, Agr Res Serv, Anim & Plant Hlth Inspect Serv, Cooperat State Res, Educ & Extens Serv, CNPq, CAPES, Fda Amparo & Pesquisa Estado Sao Paulo, Valee Sa, Merial		Trypanosoma evansi; goat; experimental; miniature anion exchange centrifugation technique (mAECT)	PARASITEMIAS	DEAE (anion exchanger diethylaminoethyl)-cellulose and mini Anion Exchange Centrifugation Technique (mAECT) allow salivarian trypanosomes to be separated from the blood of affected animals. The purpose of this study was to assess the mAECT in goats infected with T evansi. Five adult Canary goats were inoculated intravenously with at least 1 X 105 T. evansi isolated from a dromedary camel in the Canary Islands. The goats were monitored for specific antibodies and parasite detection. The inoculated goats became infected and the parasitemia remained very low but was persistent. For mAECT columns, the DEAE gel was equilibrated with phosphate-buffered saline glucose. T evansi was detected by its mobility with a microscope at low magnification (10 X 10). The mAECT proved to be more sensitive than blood smear and buffy coat but less sensitive than mouse inoculation. We conclude that in cases of very low parasitemia in goats, mAECT can be used when other parasite-detection tests have failed.	Univ Las Palmas, Fac Vet, Las Palmas Gran Canaria 35416, Spain; Inst Trop Med, Dept Parasitol, B-2000 Antwerp, Belgium	Gutierrez, C (reprint author), Univ Las Palmas, Fac Vet, Las Palmas Gran Canaria 35416, Spain.	cgutierrez@dpat.ulpgc.es	Buscher, Philippe/B-9956-2012; Corbera, Juan Alberto/K-2289-2014; Gutierrez, Carlos/E-2989-2012	Buscher, Philippe/0000-0002-1926-7472; Corbera, Juan Alberto/0000-0001-7812-2065; Gutierrez, Carlos/0000-0003-0764-7408			Holland WG, 2001, VET PARASITOL, V97, P23, DOI 10.1016/S0304-4017(01)00381-8; Kalu A. U., 1986, Bulletin of Animal Health and Production in Africa, V34, P294; LAMHAM SM, 1968, NATURE, V218, P1273; LANHAM SM, 1970, EXP PARASITOL, V28, P521, DOI 10.1016/0014-4894(70)90120-7; LUMSDEN WHR, 1979, T ROY SOC TROP MED H, V73, P312, DOI 10.1016/0035-9203(79)90092-0; *OFF INT EP, 2000, MAN STAND DIAGN TEST; SACHS R, 1984, T ROY SOC TROP MED H, V78, P694, DOI 10.1016/0035-9203(84)90244-X; SEAMAN CVF, 1963, ARCH BIOCHEM BIOPHYS, V100, P493	8	10	11	0	3	NEW YORK ACAD SCIENCES	NEW YORK	2 EAST 63RD ST, NEW YORK, NY 10021 USA	0077-8923		1-57331-504-4	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2004	1026						149	151		10.1196/annals.1307.020				3	Public, Environmental & Occupational Health; Infectious Diseases; Multidisciplinary Sciences; Tropical Medicine; Veterinary Sciences	Public, Environmental & Occupational Health; Infectious Diseases; Science & Technology - Other Topics; Tropical Medicine; Veterinary Sciences	BBO56	WOS:000226725500020	15604483				2019-03-26	
S	Gutierrez, C; Corbera, JA; Morales, M; Buscher, P		Bokma, BH; Blouin, EF; Bechara, GH		Gutierrez, C; Corbera, JA; Morales, M; Buscher, P			Performance of serological tests for Trypanosoma evansi in experimentally inoculated goats	IMPACT OF ECOLOGICAL CHANGES ON TROPICAL ANIMAL HEALTH AND DISEASE CONTROL	ANNALS OF THE NEW YORK ACADEMY OF SCIENCES		English	Article; Proceedings Paper	7th Biennial Conference of the Society-for-Tropical-Veterinary-Medicine	JUN 22-27, 2003	Iguacu Falls, BRAZIL	USDA, Agr Res Serv, Anim & Plant Hlth Inspect Serv, Cooperat State Res, Educ & Extens Serv, CNPq, CAPES, Fda Amparo & Pesquisa Estado Sao Paulo, Valee Sa, Merial		Trypanosoma evansi; goat; serology; experimental	CANARY-ISLANDS; SEROPREVALENCE	Natural Trypanosoma evansi infection in the Canary Islands has only been diagnosed in the camel population, but dissemination of the disease in other hosts has not been excluded. The objective of this work was to assess the performance of serological antibody tests in experimentally inoculated goats. Five Canarian goats were inoculated intravenously with at least 1 X 105 T evansi. The animals were kept for 8 months and checked monthly for the presence of the parasite and specific antibodies. The serological tests investigated were the direct card agglutination test CATT/T evansi and the indirect card agglutination test LATEX/T evansi. All animals became positive in the CATT/T evansi 1 month post-infection and remained positive with a minimum end-titer of 1/4. Similar results were obtained with the LATEX/T evansi, although at lower end-titers (1/2). We conclude that CATT/T evansi is adequate for assessing infection of Canarian goats by T evansi.	Univ Las Palmas, Fac Vet, Las Palmas Gran Canaria 35416, Spain; Inst Trop Med, Dept Parasitol, Antwerp, Belgium	Gutierrez, C (reprint author), Univ Las Palmas, Fac Vet, Las Palmas Gran Canaria 35416, Spain.	cgutierrez@dpat.ulpgc.es	Corbera, Juan Alberto/K-2289-2014; Buscher, Philippe/B-9956-2012; Gutierrez, Carlos/E-2989-2012	Corbera, Juan Alberto/0000-0001-7812-2065; Buscher, Philippe/0000-0002-1926-7472; Gutierrez, Carlos/0000-0003-0764-7408			Gutierrez C, 2000, VET PARASITOL, V90, P155, DOI 10.1016/S0304-4017(00)00225-9; HORNBY HE, 1952, ANIMAL TRYPANOSOMIAS; JACQUET P, 1993, REV ELEV MED VET PAY, V446, P574; Molina JM, 2000, PREV VET MED, V47, P53, DOI 10.1016/S0167-5877(00)00157-4; NGERANWA JJN, 1993, RES VET SCI, V54, P283, DOI 10.1016/0034-5288(93)90124-X; Rottcher D., 1987, Revue Scientifique et Technique, Office International des Epizooties, V6, P463	6	7	7	0	2	NEW YORK ACAD SCIENCES	NEW YORK	2 EAST 63RD ST, NEW YORK, NY 10021 USA	0077-8923		1-57331-504-4	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2004	1026						152	153		10.1196/annals.1307.021				2	Public, Environmental & Occupational Health; Infectious Diseases; Multidisciplinary Sciences; Tropical Medicine; Veterinary Sciences	Public, Environmental & Occupational Health; Infectious Diseases; Science & Technology - Other Topics; Tropical Medicine; Veterinary Sciences	BBO56	WOS:000226725500021	15604484				2019-03-26	
J	Glynn, JR; Carael, M; Buve, A; Anagonou, S; Zekeng, L; Kahindo, M; Musonda, R				Glynn, JR; Carael, M; Buve, A; Anagonou, S; Zekeng, L; Kahindo, M; Musonda, R		Study Grp Heterogeneity HIV Epide	Does increased general schooling protect against HIV infection? A study in four African cities	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						HIV; schooling; education; risk factors; herpes simplex-2; sexual behaviour; Africa	SUB-SAHARAN AFRICA; SEXUALLY-TRANSMITTED DISEASE; SIMPLEX-VIRUS TYPE-2; RURAL TANZANIA; RISK-FACTORS; EAST-AFRICA; PREVALENCE; EPIDEMIC; BEHAVIOR; TRENDS	BACKGROUND The association between educational attainment and risk of HIV infection varies between populations and over time. Earlier studies in sub-Saharan Africa have found that those with more education are at increased risk of HIV infection. METHODS We investigated the associations between general schooling and both HIV and herpes simplex-2 (HSV-2) infection using data from the multicentre study on factors determining the differential spread of HIV in four African cities. Cross-sectional general population studies were conducted in 1997-1998 in Cotonou (Benin), Yaounde (Cameroon), Kisumu (Kenya), and Ndola (Zambia), including about 2000 adults in each city. RESULTS There was no association between schooling and HIV infection in men or women in Kisumu or Ndola. Women in Yaounde and men in Cotonou, with more schooling, were less likely to be HIV positive. These associations persisted after adjusting for sociodemographic factors. Similar trends in men in Yaounde and women in Cotonou were not statistically significant. Increased schooling was associated with significantly decreased risk of HSV-2 infection in women in Kisumu and Ndola and men in Cotonou. In all the cities those with more education tended to report less risky sexual behaviour. CONCLUSIONS There was no evidence of an increased risk of HIV infection associated with education as seen in earlier studies. In each city there was some evidence of lower HIV or HSV-2 infection rates and less risky sexual behaviour associated with increased education levels. The most educated may be responding more readily to health education programmes. The challenge is to extend this to the rest of the population.	Univ London London Sch Hyg & Trop Med, Infect Dis Epidemiol Unit, London WC1E 7HT, England; UNAIDS, CH-1211 Geneva 27, Switzerland; Inst Trop Med, B-2000 Antwerp, Belgium; SIDA, Programme Lutte Contre, Cotonou 04378, Benin; Minist Publ Hlth, Yaounde, Cameroon; Natl AIDS, STD Control Programme, Nairobi, Kenya; Trop Dis Res Ctr, Ndola, Zambia	Glynn, JR (reprint author), Univ London London Sch Hyg & Trop Med, Infect Dis Epidemiol Unit, Keppel St, London WC1E 7HT, England.	judith.glynn@lshtm.ac.uk; caraelm@unaids.org; abuve@itg.be; Leopold.zekeng@camnet.com; mkahindo@fhi.or.ke; tdrc@zmanet.zm					Abebe Y, 2003, AIDS, V17, P1835, DOI 10.1097/01.aids.0000072651.21517.lf; Auvert B, 2001, AIDS, V15, pS15, DOI 10.1097/00002030-200108004-00003; Buve A, 2001, AIDS, V15, pS117, DOI 10.1097/00002030-200108004-00013; Buve A, 2001, AIDS, V15, pS5, DOI 10.1097/00002030-200108004-00002; Crampin AC, 2003, AIDS, V17, P1817, DOI 10.1097/01.aids.0000076278.54156.7e; Fontanet AL, 2000, ANN TROP MED PARASIT, V94, P145, DOI 10.1080/00034980057482; Fylkesnes K, 1997, AIDS, V11, P339, DOI 10.1097/00002030-199703110-00012; Fylkesnes K, 2001, AIDS, V15, P907, DOI 10.1097/00002030-200105040-00011; Glynn JR, 2001, AIDS, V15, P2025, DOI 10.1097/00002030-200110190-00016; Gregson S, 2001, INT J STD AIDS, V12, P189, DOI 10.1258/0956462011917009; GREGSON S, 2001, J INT DEV, V13, P467, DOI DOI 10.1002/JID.798; GROSSKURTH H, 1995, AIDS, V9, P927, DOI 10.1097/00002030-199508000-00015; Hargreaves JR, 2002, TROP MED INT HEALTH, V7, P489, DOI 10.1046/j.1365-3156.2002.00889.x; Kelly R, 1999, AIDS, V13, P399, DOI 10.1097/00002030-199902250-00013; Kilian AHD, 1999, AIDS, V13, P391, DOI 10.1097/00002030-199902250-00012; Kirunga C T, 1997, Health Transit Rev, V7 Suppl, P175; KREISS JK, 1986, NEW ENGL J MED, V314, P414, DOI 10.1056/NEJM198602133140704; Kwesigabo G, 1998, J ACQ IMMUN DEF SYND, V17, P262, DOI 10.1097/00042560-199803010-00012; Lagarde E, 2001, AIDS, V15, P1399, DOI 10.1097/00002030-200107270-00009; McFarland W, 1999, J INFECT DIS, V180, P1459, DOI 10.1086/315076; Obasi A, 1999, J INFECT DIS, V179, P16, DOI 10.1086/314555; Over M., 1993, DIS CONTROL PRIORITI, P455; Quigley M, 1997, AIDS, V11, P237, DOI 10.1097/00002030-199702000-00015; RODIER GR, 1993, AM J TROP MED HYG, V48, P682, DOI 10.4269/ajtmh.1993.48.682; Smith J, 1999, INT J STD AIDS, V10, P452, DOI 10.1258/0956462991914456; Taha TE, 1998, AIDS, V12, P197, DOI 10.1097/00002030-199802000-00010; UNAIDS, 1998, LOOK DEEP HIV EP QUE; WEISS HA, 2001, AIDS S4, V15; WILKINS A, 1991, AIDS, V5, P1127, DOI 10.1097/00002030-199109000-00012	29	53	53	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	JAN	2004	9	1					4	14		10.1046/j.1365-3156.2003.01168.x				11	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	775WL	WOS:000189083600002	14728602	Bronze			2019-03-26	
J	van der Werf, MJ; de Vlas, SJ; Landoure, A; Bosompem, KM; Habbema, JDF				van der Werf, MJ; de Vlas, SJ; Landoure, A; Bosompem, KM; Habbema, JDF			Measuring schistosomiasis case management of the health services in Ghana and Mali	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						schistosomiasis; disease control; primary health care; integration; passive case detection; Ghana; Mali	URINARY SCHISTOSOMIASIS; STANDARDIZED PATIENTS; PRACTICING PHYSICIANS; GENERAL-PRACTITIONERS; SIMULATED PATIENTS; IRRIGATION SCHEME; VOLTA LAKE; AREA; INFECTION; DIARRHEA	The World Health Organization recommends passive case detection by regular health services as a minimum strategy for schistosomiasis morbidity control. To evaluate preparedness of the health systems in Ghana and Mali, we presented four clinical scenarios, two with blood in urine (main early symptom of Schistosoma haematobium) and two with (bloody) diarrhoea (main early symptom of S. mansoni), to health workers. We requested the health personnel for an initial diagnosis and case management strategy without providing information about our primary interest in schistosomiasis. The information was used to determine the chance that a person reporting with symptoms that might have been caused by schistosomiasis would receive praziquantel. All selected health workers participated. Their initial diagnosis was frequently S. haematobium for both scenarios with blood in urine. For the two scenarios with (bloody) diarrhoea, only few mentioned S. mansoni. At health centre level, case management in Mali mainly consisted of direct prescription of medication, whereas in Ghana health workers often referred to a hospital or requested a diagnostic test. The ultimate probability of prescribing praziquantel was relatively high for the scenarios with blood in urine, 60% in Ghana and 75% in Mali, but very low for both scenarios with (bloody) diarrhoea (<20%). Of those health care facilities that would prescribe praziquantel, 60% (Ghana) and 80% (Mali) had it in stock. In conclusion, the clinical scenario study showed that patients reporting with blood in urine will be treated with praziquantel at approximately half of the health care facilities, whereas of those presenting with (bloody) diarrhoea only few would receive treatment with praziquantel. Considering these facts, it is questionable if passive case detection is a sufficient basis for effective schistosomiasis morbidity control, especially for S. mansoni infection.	Erasmus MC Univ, Med Ctr Rotterdam, Dept Publ Hlth, NL-3000 DR Rotterdam, Netherlands; Inst Natl Rech Sante Publ, Bamako, Mali; Univ Ghana, Noguchi Mem Inst Med Res, Legon, Accra, Ghana; Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium	van der Werf, MJ (reprint author), Erasmus MC Univ, Med Ctr Rotterdam, Dept Publ Hlth, POB 1738, NL-3000 DR Rotterdam, Netherlands.	vanderwerfm@kncvtbc.nl; s.devlas@erasmusmc.nl; inrsp@spider.toolnet.org; kbosompem@noguchi.mimcom.net; j.d.f.habbema@erasmusmc.nl					AMANKWA JA, 1994, TROP MED PARASITOL, V45, P319; Beria JU, 1998, SOC SCI MED, V47, P341, DOI 10.1016/S0277-9536(98)00078-1; Beullens J, 1997, FAM PRACT, V14, P58, DOI 10.1093/fampra/14.1.58; Biritwum R B, 1994, West Afr J Med, V13, P124; Bosompem KM, 1996, HYBRIDOMA, V15, P443, DOI 10.1089/hyb.1996.15.443; BOWMAN MA, 1992, ARCH INTERN MED, V152, P1823, DOI 10.1001/archinte.152.9.1823; BRINKMANN UK, 1988, TROP MED PARASITOL, V39, P157; CUTTS F, 1988, J TROP MED HYG, V91, P61; DABO A, 1995, B SOC PATHOL EXOT, V88, P29; DECLERCQ D, 1994, T ROY SOC TROP MED H, V88, P653, DOI 10.1016/0035-9203(94)90212-7; Engels D, 2002, ACTA TROP, V82, P139, DOI 10.1016/S0001-706X(02)00045-1; Font F, 2001, TROP MED INT HEALTH, V6, P423, DOI 10.1046/j.1365-3156.2001.00727.x; GARNER P, 1989, BRIT MED J, V299, P277, DOI 10.1136/bmj.299.6694.277; GRYSEELS B, 1992, TROP GEOGR MED, V44, P189; Guyatt H, 1995, AM J TROP MED HYG, V53, P660, DOI 10.4269/ajtmh.1995.53.660; KARDORFF R, 1994, AM J TROP MED HYG, V51, P190, DOI 10.4269/ajtmh.1994.51.190; KLUMPP RK, 1987, J TROP MED HYG, V90, P265; KOPELOW ML, 1992, ACAD MED, V67, pS19, DOI 10.1097/00001888-199210000-00026; Landoure A, 2003, ANN TROP MED PARASIT, V97, P723, DOI 10.1179/000349803225001544; Lengeler C, 2002, B WORLD HEALTH ORGAN, V80, P235; LYONS GRL, 1974, B WORLD HEALTH ORGAN, V51, P621; MANSON-BAHR P. E. C., 1987, MANSONS TROPICAL DIS; MILHOLLAND AV, 1973, NEW ENGL J MED, V288, P1272, DOI 10.1056/NEJM197306142882405; MOTT KE, 1985, AM J TROP MED HYG, V34, P1119, DOI 10.4269/ajtmh.1985.34.1119; Nizami SQ, 1996, SOC SCI MED, V42, P1133, DOI 10.1016/0277-9536(95)00386-X; NIZAMI SQ, 1995, J DIARRHOEAL DIS RES, V13, P29; OforiAdjei D, 1996, SOC SCI MED, V42, P1169, DOI 10.1016/0277-9536(95)00389-4; OFORIADJEI D, 1986, ANN TROP MED PARASIT, V80, P365, DOI 10.1080/00034983.1986.11812031; PAPERNA I., 1969, Ghana Medical Journal, V8, P35; PAPERNA I, 1968, Ghana Medical Journal, V7, P210; RETHANS JJE, 1987, BRIT MED J, V294, P809, DOI 10.1136/bmj.294.6575.809; RUSSELL NK, 1991, ACAD MED, V66, pS37, DOI 10.1097/00001888-199109000-00034; SCOTT D, 1982, B WORLD HEALTH ORGAN, V60, P89; TAMNLYN RM, 1992, ACAD MED, V67, pS22; Traore M, 1998, TROP MED INT HEALTH, V3, P214; TRAORE M, 1989, TROP MED PARASITOL, V40, P228; Traore M, 1996, World Health Forum, V17, P184; van der Linden Marcel, 2003, THESIS ERASMUS U ROT, P201; van der Werf MJ, 2003, T ROY SOC TROP MED H, V97, P146, DOI 10.1016/S0035-9203(03)90102-7; van der Werf MJ, 2002, TROP MED INT HEALTH, V7, P70, DOI 10.1046/j.1365-3156.2002.00823.x; VANDERWERF MJ, SOCIAL SCI MED, V42, P1133; VANDERWERF MJ, 2003, ACTA TROP, V56, P125; Voeten HACM, 2001, SEX TRANSM DIS, V28, P633, DOI 10.1097/00007435-200111000-00005; Wagatsuma Y, 1999, J INFECT DIS, V179, P1515, DOI 10.1086/314786; WEN ST, 1984, ANN TROP MED PARASIT, V78, P129, DOI 10.1080/00034983.1984.11811786; WERLER C, 1989, TROP MED PARASITOL, V40, P234; *WHO, 1985, TECHN REP SER WHO, V728; *WHO, 1998, REP WHO INF CONS SCH; *WHO, 2002, TECHN REP SER WHO, V912; WHO and UNICEF (United Nations Children's Fund), 1978, INT C PRIM HLTH CAR; WOODWARD CA, 1985, MED CARE, V23, P1019, DOI 10.1097/00005650-198508000-00009; Zijlmans C W, 1989, Ned Tijdschr Geneeskd, V133, P2552	52	10	11	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	JAN	2004	9	1					149	157						9	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	775WL	WOS:000189083600019	14728619				2019-03-26	
J	Gil, VS; Ferreira, MCR; d'Alva, FSM; d'Abreu, JA; Will, IM; Gomes, ML; Mugittu, K; Castelli, F; Taylor, WR; Olliaro, P; D'Alessandro, U				Gil, V. S.; Ferreira, M. C. R.; d'Alva, F. S. M.; d'Abreu, J. A.; Will, I. M.; Gomes, M. L.; Mugittu, K.; Castelli, F.; Taylor, W. R.; Olliaro, P.; D'Alessandro, U.			Efficacy of artesunate plus chloroquine for uncomplicated malaria in children in Sao Tome and Principe: a double-blind, randomized, controlled trial (vol 97, pg 703, 2003)	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Correction									Ctr Nacl Endemias, Sao Tome, Sao Tome & Prin; Dist Sanitario Lobata, Minist Hlth, Sao Tome, Sao Tome & Prin; Ifakara Hlth Res & Dev Ctr, Ifakara, Tanzania; Swiss Trop Inst, CH-4002 Basel, Switzerland; Univ Brescia, Inst Infect & Trop Dis, I-25121 Brescia, Italy; WHO, TDR, UNDP, World Bank,Special Program Res & TDR, CH-1211 Geneva, Switzerland; Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium	Gil, VS (reprint author), Ctr Nacl Endemias, Sao Tome, Sao Tome & Prin.		D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009			Gil VS, 2003, T ROY SOC TROP MED H, V97, P703, DOI 10.1016/S0035-9203(03)80107-4	1	0	0	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0035-9203			T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	NOV-DEC	2003	97	6					I	II						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	V43WB	WOS:000202964100002					2019-03-26	
J	Marlet, MVL; Wuillaume, F; Jacquet, D; Quispe, KW; Dujardin, JC; Boelaert, M				Marlet, M. V. L.; Wuillaume, F.; Jacquet, D.; Quispe, K. W.; Dujardin, J. C.; Boelaert, M.			A neglected disease of humans: a new focus of visceral leishmaniasis in Bakool, Somalia	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						visceral leishmaniasis; Leishmania donovani; epidemiology; outbreak; Somalia		Visceral leishmaniasis (VL) was observed in children in Bakool region, Somalia, an area where VL has not been reported before. We describe the extent of the problem in this war- and famine-stricken area. A retrospective analysis was done of all cases admitted to a VL treatment centre between July 2000 and August 2001. Patients with longstanding fever, splenomegaly and a positive direct agglutination test ( DAT; titre > 1: 3200) were treated as suspected VL cases. A rapid epidemiological and entomological assessment was performed in the area. Species identification was attempted from blood samples by polymerase chain reaction-restriction fragment length polymorphism analysis of cysteine proteinase B genes. In 1 year, 230 serologically-positive cases were diagnosed as VL, and response to therapy was good in 91.6% of the 225 treated with sodium stibogluconate. Parasitological confirmation was attempted and obtained in 2 cases. Parasites were found to be most similar to Sudanese and Ethiopian reference strains of the Leishmania donovani complex. In a serological survey of 161 healthy displaced persons, 15% were positive by the leishmanin skin test and 3 (2%) were positive by the DAT. The sandfly captures showed Phlebotomus martini and P. vansomerenae. VL seems to be a longstanding and serious health problem in Bakool region. Food insecurity might have contributed to the emergence and detection of VL in this area.	Med Frontieres, B-1090 Brussels, Belgium; Inst Trop Med, B-2000 Antwerp, Belgium	Boelaert, M (reprint author), Inst Trop Med, Epidemiol Unit, Nationalestraat 155, B-2000 Antwerp, Belgium.	boelaert@itg.be	Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776			BARUFFA G, 1965, T ROY SOC TROP MED H, V59, P705, DOI 10.1016/0035-9203(65)90103-3; Boelaert M, 1999, AM J TROP MED HYG, V60, P129, DOI 10.4269/ajtmh.1999.60.129; Boussery G, 2001, EMERG INFECT DIS, V7, P603; El-Hassan AM, 2001, T R SOC TROP MED S1, V95, P1; GebreMichael T, 1996, MED VET ENTOMOL, V10, P53, DOI 10.1111/j.1365-2915.1996.tb00082.x; Moise R, 1955, ANN MED NAVALE TROPI, V68, P481; Pratlong F, 2001, PARASITOLOGY, V122, P599, DOI 10.1017/S0031182001007867; RIOUX JA, 1990, ANN PARASIT HUM COMP, V65, P111, DOI 10.1051/parasite/1990653111; SHIDDO SA, 1995, T ROY SOC TROP MED H, V89, P361, DOI 10.1016/0035-9203(95)90008-X; *WHO, 1984, 701 WHO; *WHO, 1996, WHOLEISH9640; Woolhead A, 1995, ANN TROP MED PARASIT, V89, P687, DOI 10.1080/00034983.1995.11813003	12	20	20	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0035-9203			T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	NOV-DEC	2003	97	6					667	671		10.1016/S0035-9203(03)80099-8				5	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	V43WB	WOS:000202964100056	16117959				2019-03-26	
J	Zoli, AP; Shey-Njila, O; Nforninwe, DN; Speybroeek, N; Ito, A; Sato, MO; Dorny, P; Brandt, J; Geerts, S				Zoli, Andre P.; Shey-Njila, Oliver; Nforninwe, Denis Nsame; Speybroeek, Niko; Ito, Akira; Sato, Marcello O.; Dorny, Pierre; Brandt, Jef; Geerts, Stanny			Neurocysticercosis and epilepsy in Cameroon	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						cysticercosis; Taenia solium; epilepsy; enzyme-linked immunosorbent assay; Cameroon		During January 2002 the frequency of Taenia solium cysticercosis was studied in a series of 504 epileptic patients from 3 rural localities in the West and North-West provinces of Cameroon using an enzyme-linked immunosorbent assay for both circulating antigen (Ag-ELISA) and antibody (Ab-ELISA) detection. Taenia solium antigens were detected in the sera of 1.2% of the patients whereas specific antibodies against the parasite were present in 44.6% of the patients. Significantly less seropositive results in Ab-ELISA were recorded in Batibo than in Bandjoun and Bamendjou, whereas a borderline significant difference was recorded with increasing age. Furthermore, 56.2% of patients with late-onset epilepsy showed antibodies against cysticercosis. Taenia solium cysticercosis appears to be an important cause of epilepsy in Cameroon.	[Speybroeek, Niko; Dorny, Pierre; Geerts, Stanny] Inst Trop Med, B-2000 Antwerp, Belgium; [Zoli, Andre P.; Shey-Njila, Oliver] Univ Dschang, Dschang, Cameroon; [Nforninwe, Denis Nsame] Batibo District Hosp, Batibo, Cameroon; [Ito, Akira; Sato, Marcello O.] Asahikawa Med Coll, Dept Parasitol, Asahikawa, Hokkaido, Japan	Geerts, S (reprint author), Inst Trop Med, Natlstr 155, B-2000 Antwerp, Belgium.	sgeerts@itg.be	Sato, Marcello/F-7674-2014; ito, akira/E-9377-2014	Sato, Marcello/0000-0002-9204-0602; ito, akira/0000-0002-5070-9187; Geerts, Stanny/0000-0001-9885-8846			ADAMOLEKUM B, 1994, EPILEPSIA, V35, P89; ADRIANTSIMAHAVA.A, 1997, TROP MED INT HEALTH, V8, P741; BRANDT JRA, 1992, INT J PARASITOL, V22, P471, DOI 10.1016/0020-7519(92)90148-E; Carpio A, 1998, EPILEPSIA, V39, P1025, DOI 10.1111/j.1528-1157.1998.tb01287.x; Cruz ME, 1999, INT J EPIDEMIOL, V28, P799, DOI 10.1093/ije/28.4.799; deBittencourt PRM, 1996, EPILEPSIA, V37, P1121, DOI 10.1111/j.1528-1157.1996.tb01035.x; DELBRUTTO OH, 1992, NEUROLOGY, V42, P389; DUMAS M, 1990, B SOC PATHOL EXOT, V83, P263; Erhart A, 2002, T ROY SOC TROP MED H, V96, P270, DOI 10.1016/S0035-9203(02)90095-7; Garcia HH, 2001, AM J TROP MED HYG, V65, P31, DOI 10.4269/ajtmh.2001.65.31; GARCIA HH, 1993, LANCET, V341, P197, DOI 10.1016/0140-6736(93)90064-N; Garcia-Noval J, 2001, ANN TROP MED PARASIT, V95, P167, DOI 10.1080/00034980120050260; GarciaNoval J, 1996, AM J TROP MED HYG, V55, P282, DOI 10.4269/ajtmh.1996.55.282; *ILAE, 1993, EPILEPSIA, V34, P592; Ito A, 1998, AM J TROP MED HYG, V59, P291, DOI 10.4269/ajtmh.1998.59.291; Ito Akira, 1999, Parasitology International, V48, P95, DOI 10.1016/S1383-5769(99)00005-7; LARAAGUILERA R, 1992, AM J TROP MED HYG, V46, P85, DOI 10.4269/ajtmh.1992.46.85; Nash TE, 2001, CLIN INFECT DIS, V33, P1649, DOI 10.1086/323670; Nguekam A, 2003, VET PARASITOL, V111, P323, DOI 10.1016/S0304-4017(02)00391-6; Nguekam JP, 2003, TROP MED INT HEALTH, V8, P144, DOI 10.1046/j.1365-3156.2003.01000.x; Obregon-Henao A, 2001, MOL BIOCHEM PARASIT, V114, P209, DOI 10.1016/S0166-6851(01)00256-0; Ohsaki Y, 1999, INTERNAL MED, V38, P67, DOI 10.2169/internalmedicine.38.67; Palacio LG, 1998, EPILEPSIA, V39, P1334, DOI 10.1111/j.1528-1157.1998.tb01333.x; Pouedet MSR, 2002, VET PARASITOL, V106, P45, DOI 10.1016/S0304-4017(02)00035-3; Preux PM, 2000, EPILEPSIA, V41, P432, DOI 10.1111/j.1528-1157.2000.tb00185.x; Restrepo BI, 2000, INT J PARASITOL, V30, P689, DOI 10.1016/S0020-7519(00)00057-6; Sako Y, 2000, J CLIN MICROBIOL, V38, P4439; SARTI E, 1992, AM J TROP MED HYG, V46, P677, DOI 10.4269/ajtmh.1992.46.677; SARTI E, 1994, T ROY SOC TROP MED H, V88, P49, DOI 10.1016/0035-9203(94)90493-6; SENANAYAKE N, 1993, B WORLD HEALTH ORGAN, V71, P247; Sokal RR, 1981, BIOMETRY PRINCIPLES; SOTELO J, 1985, ARCH INTERN MED, V145, P442, DOI 10.1001/archinte.145.3.442; VANAS AD, 1991, S AFR MED J, V80, P327; Vondou L, 2002, PARASITE, V9, P271, DOI 10.1051/parasite/2002093271; *WHO, 2000, BRING EP OUT SHAD AF; WILSON M, 1991, J INFECT DIS, V164, P1007, DOI 10.1093/infdis/164.5.1007	36	21	21	0	6	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0035-9203	1878-3503		T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	NOV-DEC	2003	97	6					683	686		10.1016/S0035-9203(03)80103-7				4	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	V43WB	WOS:000202964100060	16117963				2019-03-26	
J	Gil, VS; Ferreira, MCR; d'Alva, FSM; d'Abreu, JA; Will, IM; Gomes, ML; Castelli, F; Taylor, WR; Olliaro, P; D'Alessandro, U				Gil, V. S.; Ferreira, M. C. R.; d'Alva, F. S. M.; d'Abreu, J. A.; Will, I. M.; Gomes, M. L.; Castelli, F.; Taylor, W. R.; Olliaro, P.; D'Alessandro, U.			Efficacy of artesunate plus chloroquine for uncomplicated malaria in children in Sao Tome and Principe: a double-blind, randomized, controlled trial	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						malaria; Plasmodium falciparum; combination therapy; artesunate; chloroquine; Sao Tome and Principe		We conducted a double-blind, randomized, placebo-controlled trial in Sao Tome and Principe to investigate the safety, tolerability and efficacy of chloroquine (CQ) combined with artesunate (AS) over CQ monotherapy. Four hundred children, aged 6-59 months, with acute uncomplicated Plasmodium falciparum malaria were randomized to receive a standard dose of CQ (25 mg/kg bodyweight) over 3 d or CQ + AS (4 mg/kg bodyweight) daily for 3 d. Children were followed- up for 28 d. The combined treatment was well tolerated and there were no serious drug-related adverse events. By day 2 parasite clearance was significantly faster for children treated with CQ + AS compared with CQ alone (29/194 [14.9%] vs. 168/190 [88.4%] still parasitaemic, P < 0.0001). Day 14 parasitological failure rates were 153/191 (80.1%) for CQ alone compared with 32/ 193 (16.6%) in the CQ + AS group (odds ratio [OR] = 20.2, 95% CI 11.7- 35.4, P < 0.001). Corresponding clinical failure rates were 128/191 (67.0%) and 12/193 (6.2%) (OR = 30.6, 95% CI 15.3- 62.7, P < 0.001). By day 28 the parasitological failure rates (new infections excluded) were 155/ 191 (81.1%) in the CQ group and 63/194 (32.4%) in the CQ + AS group (OR: 8.9, 95% CI 5.4-14.7, P < 0.001). Symptoms resolved faster in children who received AS. They were also less likely to be gametocytaemic after treatment. The combination treatment was well tolerated and considerably improved treatment efficacy. However, the current levels of CQ resistance preclude its use in Sao Tome where CQ should be abandoned as first-line drug. However, CQ + AS may be an option in areas where CQ resistance is lower.	Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium; Minist Hlth, Ctr Nacl Endemias, Sao Tome, Sao Tome & Prin; Minist Hlth, Distrito Sanitaria Lobata, Sao Tome, Sao Tome & Prin; Univ Brescia, Inst Infect & Trop Dis, I-25121 Brescia, Italy; WHO, TDR, UNDP, Special Programme Res & Training Trop Med, Geneva, Switzerland	D'Alessandro, U (reprint author), Inst Trop Med Prince Leopold, Natlstr 155, B-2000 Antwerp, Belgium.	udalessandro@itg.be	D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009			Adjuik M, 2002, LANCET, V359, P1365, DOI 10.1016/S0140-6736(02)08348-4; Baptista JL, 1997, TROP MED INT HEALTH, V2, P582, DOI 10.1046/j.1365-3156.1997.d01-325.x; BLOLAND PB, 1993, J INFECT DIS, V167, P932, DOI 10.1093/infdis/167.4.932; COULIBALY SO, 2000, MOVING TARGETS PARAS, P39; Djimde A, 2001, NEW ENGL J MED, V344, P257, DOI 10.1056/NEJM200101253440403; FARNERT A, 2002, 3 MIM PAN AFR MAL C, P106; Greenwood B, 2002, TROP MED INT HEALTH, V7, P1012, DOI 10.1046/j.1365-3156.2002.00980.x; Irion A, 1998, TROP MED INT HEALTH, V3, P490, DOI 10.1046/j.1365-3156.1998.00253.x; Loureiro LF, 1996, ANN TROP MED PARASIT, V90, P223, DOI 10.1080/00034983.1996.11813048; MARTET G, 1991, B SOC PATHOL EXOT, V84, P273; NOSTEN F, 1994, J INFECT DIS, V170, P971, DOI 10.1093/infdis/170.4.971; Trape JF, 2001, AM J TROP MED HYG, V64, P12, DOI 10.4269/ajtmh.2001.64.12; von Seidlein L, 2000, LANCET, V355, P352, DOI 10.1016/S0140-6736(99)10237-X; *WHO, 1993, WHOMAL961077; *WHO, 1993, IMPL GLOB MAL CONTR; WHO, 2001, US ANT DRUGS; World Health Organization (WHO), 2000, T ROYAL SOC TROPICAL, V94	17	5	6	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0035-9203			T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	NOV-DEC	2003	97	6					703	706		10.1016/S0035-9203(03)80107-4				4	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	V43WB	WOS:000202964100064	16117967				2019-03-26	
J	Tchuem Tchuente, LA; Behnke, JM; Gilbert, FS; Southgate, VR; Vercruysse, J				Tchuem Tchuente, LA; Behnke, JM; Gilbert, FS; Southgate, VR; Vercruysse, J			Polyparasitism with Schistosoma haematobium and soil-transmitted helminth infections among school children in Loum, Cameroon	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						schistosomiasis; Schistosoma haematobium; soil-transmitted helminthiasis; epidemiology; Cameroon	GEOHELMINTH INFECTIONS; ASCARIS-LUMBRICOIDES; HOOKWORM INFECTIONS; TRICHURIS-TRICHIURA; RURAL COMMUNITIES; POLY-PARASITISM; SCHOOLCHILDREN; EPIDEMIOLOGY; ASSOCIATIONS; MANSONI	Prevalence and abundance of Schistosoma haematobium and soil-transmitted helminths (STH) were assessed among a total of 1600 pupils (urine, n = 1190; faecal samples, n = 1454) attending five schools in Loum, Littoral Province, Cameroon, with the specific aim of assessing the extent of polyparasitism and the extent to which infections were focused in particular subsets of the study group. Prevalence of S. haematobium was 62.8% with an abundance (arithmetic mean of egg counts) of 54 eggs/10 ml urine. For the STH these were 47.7% and 619 eggs per gram of faeces (EPG) for Trichuris trichiura, 65.5% and 3636 EPG for Ascaris lumbricoides, and 1.4% and <0.1 EPG for hookworms. Most children (90.3%) were infected with at least one of these four species, the largest proportion (34.3%) carrying two species; 27.4% carried three and 1.1% carried concurrently all four species of parasites. The average number of species harboured increased with age, as did the prevalences of S. haematobium and T. trichiura but not that of A. lumbricoides. All STH showed marked differences in prevalence between the five schools but only T. trichiura varied significantly between sexes. Mean abundance of infection varied significantly between age classes, among schools and between the sexes, with females showing heavier mean EPGs for A. lumbricoides and T. trichiura and males higher mean eggs/10 ml urine for S. haematobium infections. A highly significant association was detected between A. lumbricoides and T. trichiura, that was not context-dependent. This was confirmed in quantitative analyses after controlling for differences in abundance between schools, sexes and age classes. A weaker context-dependent association (prevalence data) was detected between S. haematobium and A. lumbricoides (sex- and age-dependent) but quantitative associations between these two species, as well as between S. haematobium and T. trichiura, were not convincing.	Univ Nottingham, Sch Biol, Nottingham NG7 2RD, England; Univ Yaounde, Fac Sci, Lab Gen Biol, Yaounde, Cameroon; Nat Hist Museum, Dept Zool, London SW7 5BD, England; Univ Ghent, Fac Vet Med, Dept Virol Parasitol & Immunol, B-9820 Merelbeke, Belgium	Behnke, JM (reprint author), Univ Nottingham, Sch Biol, Univ Pk, Nottingham NG7 2RD, England.	tchuemtchuente@camnet.cm; jerzy.behnke@nottingham.ac.uk; v.southgate@nhm.ac.uk; jozef.vercruyss@UGent.be	Gilbert, Francis/K-3817-2013	Gilbert, Francis/0000-0002-2727-4103			Abel L, 1997, CURR OPIN IMMUNOL, V9, P509, DOI 10.1016/S0952-7915(97)80103-3; ASHFORD RW, 1992, ANN TROP MED PARASIT, V86, P671, DOI 10.1080/00034983.1992.11812724; BOOTH M, 1992, PARASITOLOGY, V105, P151, DOI 10.1017/S0031182000073807; Booth M, 1998, PARASITOLOGY, V116, P85, DOI 10.1017/S003118209700190X; Booth M, 1995, PARASITOLOGY, V111, P645, DOI 10.1017/S0031182000077131; Booth M, 1998, T ROY SOC TROP MED H, V92, P491, DOI 10.1016/S0035-9203(98)90886-0; Brooker S, 1999, T ROY SOC TROP MED H, V93, P125, DOI 10.1016/S0035-9203(99)90281-X; Brooker S, 2000, B WORLD HEALTH ORGAN, V78, P1456; Brooker S, 2000, E AFR MED J, V77, P157; BUCK AA, 1978, TROPENMED PARASITOL, V29, P61; Chunge RN, 1995, J TROP MED HYG, V98, P440; Crawley M, 1993, GLIM ECOLOGISTS; DASH KM, 1988, AUST VET J, V65, P66, DOI 10.1111/j.1751-0813.1988.tb07359.x; Drake LJ, 2001, PARASITOLOGY, V122, pS73, DOI 10.1017/S0031182000017662; Drake LJ, 2000, SEMIN PEDIAT INFECT, V11, P245, DOI DOI 10.1053/SPID.2000.9638; ELLIOTT JM, 1977, SOME METHODS STAT AN; Flores A, 2001, T ROY SOC TROP MED H, V95, P272, DOI 10.1016/S0035-9203(01)90232-9; FULFORD AJC, 1994, PARASITOL TODAY, V10, P446, DOI 10.1016/0169-4758(94)90181-3; Howard SC, 2002, ACTA TROP, V83, P141, DOI 10.1016/S0001-706X(02)00093-1; Howard SC, 2001, PARASITOLOGY, V122, P233, DOI 10.1017/S0031182001007272; JANOVY J, 1995, ECOL MODEL, V77, P189, DOI 10.1016/0304-3800(93)E0087-J; Keiser J, 2002, ACTA TROP, V84, P31, DOI 10.1016/S0001-706X(02)00135-3; KEUSCH GT, 1982, REV INFECT DIS, V4, P880; KEYMER A, 1990, HOOKWORM DISEASE : CURRENT STATUS AND NEW DIRECTIONS, P177; KVALSVIG JD, 1988, PARASITOL TODAY, V4, P206, DOI 10.1016/0169-4758(88)90158-5; Lwambo NJS, 1999, T ROY SOC TROP MED H, V93, P497, DOI 10.1016/S0035-9203(99)90349-8; MARGOLIS L, 1982, J PARASITOL, V68, P131, DOI 10.2307/3281335; Needham C, 1998, TROP MED INT HEALTH, V3, P904, DOI 10.1046/j.1365-3156.1998.00324.x; POULIN R, 1993, INT J PARASITOL, V23, P937, DOI 10.1016/0020-7519(93)90060-C; RAMDATH DD, 1995, PARASITOLOGY, V110, P347, DOI 10.1017/S0031182000080938; RATARD RC, 1991, T ROY SOC TROP MED H, V85, P84, DOI 10.1016/0035-9203(91)90170-4; RATARD RC, 1990, AM J TROP MED HYG, V42, P561, DOI 10.4269/ajtmh.1990.42.561; Rohlf F. J., 1995, STAT TABLES; Sokal RR, 1981, BIOMETRY; Tchuente LAT, 1997, T ROY SOC TROP MED H, V91, P664, DOI 10.1016/S0035-9203(97)90513-7; TINGLEY GA, 1988, T ROY SOC TROP MED H, V82, P448, DOI 10.1016/0035-9203(88)90159-9; Williams-Blangero S, 1999, AM J TROP MED HYG, V60, P921, DOI 10.4269/ajtmh.1999.60.921; Williams-Blangero S, 2002, P NATL ACAD SCI USA, V99, P5533, DOI 10.1073/pnas.082115999; Wilson K, 1997, PARASITOL TODAY, V13, P33, DOI 10.1016/S0169-4758(96)40009-6	39	53	55	0	5	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	NOV	2003	8	11					975	986		10.1046/j.1360-2276.2003.01120.x				12	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	736NZ	WOS:000186178000003	14629763	Bronze			2019-03-26	
J	Rapuoda, B; Ali, A; Bakyaita, N; Mutabingwa, TK; Mwita, A; Rwagacondo, C; Mugisha, V; Staedke, S; Snow, RW; Watkins, WM; D'Alessandro, U				Rapuoda, B; Ali, A; Bakyaita, N; Mutabingwa, TK; Mwita, A; Rwagacondo, C; Mugisha, V; Staedke, S; Snow, RW; Watkins, WM; D'Alessandro, U		E African Network Monitoring Antim	The efficacy of antimalarial monotherapies, sulphadoxine-pyrimethamine and amodiaquine in East Africa: implications for sub-regional policy	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						East African Network for Monitoring Antimalarial Treatment; antimalarial drugs; sulphadoxine-pyrimethamine; amodiaquine; drug resistance; drug policy	PLASMODIUM-FALCIPARUM INFECTIONS; ELIMINATION HALF-LIFE; MALARIA; RESISTANCE; KENYA; EVOLUTION	Between 1998 and 2001, Kenya, Uganda, Tanzania, Zanzibar, Rwanda and Burundi changed antimalarial drug policy, in the face of widespread chloroquine resistance. The new first-line treatment is either sulphadoxine-pyrimethamine (SP) monotherapy, or a combination of SP with either chloroquine or amodiaquine. Two national malaria control programmes, Burundi and Zanzibar, have decided upon amodiaquine-artesunate as their first-line treatment, although SP will continue to fill this role until the new policy can be implemented. Given the broad uniformity of parasite chemoresistance in the six countries, The East African Network for Monitoring Antimalarial Treatment (EANMAT) has focused attention on, and worked towards, a sub-regional antimalarial drug policy, where the evidence base would be the entire portfolio of network in vivo test results. Currently, there are several different antimalarial drug policies within the EANMAT area: the intention is to eventually replace this plethora of policies with a single, sub-regional policy based upon combination therapy. Currently, successful malaria treatment depends primarily upon the efficacy of SP, and of amodiaquine, which is either a component of first-line treatment, or the second line drug. This report addresses the results of WHO in vivo tests on these two monotherapies within the network. Results are analysed to assess the evidence for change in parasite susceptibility over time; the range of susceptibility to each drug within countries, and the implications of test results on policy.	Minist Hlth, Div Malaria Control, Nairobi, Kenya; Natl Malaria Control Programme, Zanzibar, Tanzania; Natl Malaria Control Programme, Kampala, Uganda; Tanzania & Gates Malaria Partnership, LSHTM, Natl Inst Med Res, London, England; Natl Malaria Control Programme, Dar Es Salaam, Tanzania; Programme Natl Lutte Contre Palidisme, Kigali, Rwanda; Minist Hlth, Directorate Epidemiol & Publ Hyg, Kigali, Rwanda; Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, San Francisco, CA USA; KEMRI Wellcome Trust Res Programme, Nairobi, Kenya; Univ Oxford, Oxford OX1 2JD, England; Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool L69 3BX, Merseyside, England; Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium	Watkins, WM (reprint author), Minist Hlth, Div Malaria Control, Nairobi, Kenya.		D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009			ALNWICK D, 2001, AFRICA HLTH S, P18; [Anonymous], 2001, WHOCDSRBM200135; [Anonymous], 2001, WHOCDSRBM200133; BRANDLINGBENNETT AD, 1988, T ROY SOC TROP MED H, V82, P833, DOI 10.1016/0035-9203(88)90009-0; Clarke D, 1996, T ROY SOC TROP MED H, V90, P302, DOI 10.1016/S0035-9203(96)90262-X; *E AFR NETW MON AN, 2002, EANMAT NEWSLETTER, V5, P4; *E AFR NETW MON AN, 1999, EANMAT NEWSLETTER, V2, P1; Hastings IM, 2003, TRENDS PARASITOL, V19, P70, DOI 10.1016/S1471-4922(02)00017-X; Hastings IM, 2002, PHILOS T ROY SOC B, V357, P505, DOI 10.1098/rstb.2001.1036; Hay SI, 2002, TRENDS PARASITOL, V18, P530, DOI 10.1016/S1471-4922(02)02374-7; Junghanss T, 2001, TROP MED INT HEALTH, V6, P1, DOI 10.1046/j.1365-3156.2001.00679.x; Mutabingwa T, 2001, LANCET, V358, P1218, DOI 10.1016/S0140-6736(01)06344-9; O'Neill PM, 1998, PHARMACOL THERAPEUT, V77, P29, DOI 10.1016/S0163-7258(97)00084-3; Shretta R, 2000, TROP MED INT HEALTH, V5, P755, DOI 10.1046/j.1365-3156.2000.00643.x; Talisuna AO, 2002, T ROY SOC TROP MED H, V96, P310, DOI 10.1016/S0035-9203(02)90108-2; WATKINS WM, 1984, LANCET, V1, P357; WATKINS WM, 1993, T ROY SOC TROP MED H, V87, P75, DOI 10.1016/0035-9203(93)90431-O; Watkins WM, 1997, PARASITOL TODAY, V13, P459, DOI 10.1016/S0169-4758(97)01124-1; White NJ, 1999, LANCET, V353, P1965, DOI 10.1016/S0140-6736(98)07367-X; *WHO, 2002, WHOCDSRBM200239; *WHO, 1996, WHOMAL961077; *WHO SECR RBM PART, 2002, RBM PARTN M 26 28 FE	22	71	71	0	3	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2003	8	10					860	867						8	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	727BD	WOS:000185635400003	14516296				2019-03-26	
J	Ebeja, AK; Lutumba, P; Molisho, D; Kegels, G; Bilenge, CMM; Boelaert, M				Ebeja, AK; Lutumba, P; Molisho, D; Kegels, G; Bilenge, CMM; Boelaert, M			Sleeping sickness in Kinshasa: Retrospective analysis of data collected from 1996 to 2000	TROPICAL MEDICINE & INTERNATIONAL HEALTH			French	Article						human African trypanosomiasis; Kinshasa; urban; Democratic Republic of Congo; epidemiological surveillance; outbreak		In the Democratic Republic of Congo, the re-emergence of sleeping sickness is no longer limited to rural areas. Over the course of the past decade, more and more cases have been reported from urban centres such as Kinshasa, Mbuji-mayi, Matadi and Boma. This paper presents a retrospective analysis on the region of Kinshasa over the period 1996-2000, using epidemiological surveillance, individual case files and available entomological data. There are 22 health districts in total; they were classified as urban when the population exceeded 5000 per square kilometre. The Human African Trypanosomiasis ( HAT) control programme reported 2451 parasitologically confirmed new cases between 1996 and 2000, in the entire region of Kinshasa. Affected people (66%) were aged 15-49 years. Cases occurred in every health district, and 956 (39%) occurred in urban residents. Glossina captures in 1999 established the presence of Trypanosoma spp. Local HAT transmission is plausible but not proven. The high number of urban cases necessitates development of control strategies adapted to cities.	Med Frontieres, Kinshasa, Zaire; Bur Cent Lutte Contre Trypanosomiase, Kinshasa, Zaire; FOMETRO, Kinshasa, Zaire; Inst Trop Med Prince Leopold, Dept Sante Publ, B-2000 Antwerp, Belgium	Boelaert, M (reprint author), Med Frontieres, 1 Av LOUA,Concess Eternit, Kinshasa, Zaire.		Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776			BURKE J, 1992, MED HYGIENE AFRIQUE, P1399; CHALLIER A, 1971, Annales des Societes Belges de Medecine Tropicale de Parasitologie et de Mycologie, V51, P549; CHALLIER A, 1962, 9 REUN COM SCI INT R; Elsen P., 1973, Annales Soc belge Med trop, V53, P137; Fournet F, 2000, ANN TROP MED PARASIT, V94, P113, DOI 10.1080/00034980057455; Kabeya N.M., 1988, Medecine Tropicale, V48, P277; LAVEISSIERE C, 1992, VERS EPIDEMIOLOGIE T, P69; MULUMBA PM, 1993, PANORAMA MED, V4, P169; Noireau F., 1987, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V40, P67; SICE A, 1937, TRYPANOSOMIASE HUMAI, P12; Van Nieuwenhove S, 2001, TROP MED INT HEALTH, V6, P335, DOI 10.1046/j.1365-3156.2001.00731.x; WATSENGA TN, 1998, CONGO MED, V2, P453	12	16	16	0	3	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2003	8	10					949	955		10.1046/j.1365-3156.2003.01116.x				7	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	727BD	WOS:000185635400014	14516307	Bronze			2019-03-26	
J	Verle, P; Kongs, A; De, NV; Thieu, NQ; Depraetere, K; Kim, HT; Dorny, P				Verle, P; Kongs, A; De, NV; Thieu, NQ; Depraetere, K; Kim, HT; Dorny, P			Prevalence of intestinal parasitic infections in northern Vietnam	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						intestinal parasites; Vietnam		We surveyed the prevalence of parasitic infections in the mountainous province of Hoa Binh, north-west Vietnam, involving 526 households of six ethnic groups: Muong, Kinh, Dao, Thai, Tay and Hmong. Eggs or cysts of at least one parasite species were detected in 88% of stool samples (n = 2522). Prevalences of nematodes were high among all ethnic groups: hookworm (52%), Trichuris trichiura (50%) and Ascaris lumbricoides (45%). Ascaris infection appeared to be lower in households owning a latrine, was highest among children and decreased with age. Prevalence of hookworm rose during childhood, remained high until old age, was highest among adult women, but was not linked to anaemia. Eggs of Chlonorchis spp. were found in 126 (5%) individuals ( of the Muong, Kinh or Thai groups only). Chlonorchiasis increased with age and was highest among adult men. Taenia eggs were found in three individuals (0.1%). Giardia lamblia was found in all districts and among all groups and the prevalence of infection was estimated at 3%.	Belgian Tech Corp, Hanoi, Vietnam; Inst Trop Med, Dept Anim Hlth, B-2000 Antwerp, Belgium; Natl Inst Malariol Parasitol & Entomol, Hanoi, Vietnam	Dorny, P (reprint author), Belgian Tech Corp, Hoogstr 147, B-1000 Brussels, Belgium.						DE NV, 2001, J CONTROL MALARIA OT, V3, P87; DE NV, 1995, THESIS HANOI MED COL; DE NV, 1998, J CONTROL MALARIA OT, V2, P29; DE NV, 2003, SE ASIAN J TROPICAL, V34, P1; *GEN STAT OFF, 2001, POP HOUS CENS VIETN; *GOV VIETN, 2002, COMPR POV RED GROWTH; KHUONG LH, 2001, SCI VET TECHNIQUES, V1, P36; Kino Hideto, 1998, Southeast Asian Journal of Tropical Medicine and Public Health, V29, P250; Needham C, 1998, TROP MED INT HEALTH, V3, P904, DOI 10.1046/j.1365-3156.1998.00324.x; THU LT, 1996, SCI VET TECHNIQUES, V1, P74; Verle P., 1998, Research and Reviews in Parasitology, V58, P169; *WHO, 1991, BAS LAB METH MED PAR; Woodliff H J, 1966, Med J Aust, V2, P410	13	38	48	0	11	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2003	8	10					961	964		10.1046/j.1365-3156.2003.01123.x				4	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	727BD	WOS:000185635400016	14516309	Green Published, Bronze			2019-03-26	
J	Rijal, S; Chappuis, F; Singh, R; Boelaert, M; Loutan, L; Koirala, S				Rijal, S; Chappuis, F; Singh, R; Boelaert, M; Loutan, L; Koirala, S			Sodium stibogluconate cardiotoxicity and safety of generics	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						visceral leishmaniasis; chemotherapy; sodium stibogluconate; generic drugs; cardiotoxicity; Nepal	VISCERAL LEISHMANIASIS; ANTIMONY	Between April 9 and May 5 2000, an outbreak of fatal cardiotoxicity occurred in Nepal amongst visceral leishmaniasis patients treated with a recently introduced batch of generic sodium stibogluconate (SSG) from GL Pharmaceuticals, Calcutta, India. Eight (36%) of 23 patients treated with this batch died I and in 5 (23%) death was attributed to the cardiotoxicity of the drug. This contrasts with the low total death rate (3.2%) and death rate due to cardiotoxicity (0.8%) observed among 252 patients treated between August 1999 and December 2001 with generic SSG from Albert David Ltd, Calcutta, India. These data show that every batch of generic SSG should be subject to rigorous quality control prior to use.	Univ Hosp Geneva, Travel & Migrat Med Unit, CH-1211 Geneva 14, Switzerland; BP Koirala Inst Hlth Sci, Dharan, Nepal; Inst Trop Med Prince Leopold, Dept Publ Hlth, B-2000 Antwerp, Belgium	Chappuis, F (reprint author), Univ Hosp Geneva, Travel & Migrat Med Unit, Rue Micheli-Du-Crest 24, CH-1211 Geneva 14, Switzerland.	francois.chappuis@hcuge.ch	Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776			BERMAN JD, 1988, REV INFECT DIS, V10, P560; CHAKRABORTY A, 2000, STATESMAN       0610, P1; CHAKRABORTY A, 2000, STATESMAN       0610, P5; Moore E, 2001, B WORLD HEALTH ORGAN, V79, P388; Ritmeijer K, 2001, T ROY SOC TROP MED H, V95, P668, DOI 10.1016/S0035-9203(01)90110-5; Sundar S, 1998, AM J TROP MED HYG, V59, P139, DOI 10.4269/ajtmh.1998.59.139; Sundar S, 2000, CLIN INFECT DIS, V31, P1104, DOI 10.1086/318121; Veeken H, 2000, TROP MED INT HEALTH, V5, P312, DOI 10.1046/j.1365-3156.2000.00555.x	8	23	25	0	2	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0035-9203	1878-3503		T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	SEP-OCT	2003	97	5					597	598		10.1016/S0035-9203(03)80043-3				2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	844RE	WOS:000223176500030	15307436				2019-03-26	
J	Leunen, K; Hall, DR; Odendaal, HJ; Grove, D				Leunen, K; Hall, DR; Odendaal, HJ; Grove, D			The profile and complications of women with placental abruption and intrauterine death	JOURNAL OF TROPICAL PEDIATRICS			English	Article							HYPERTENSIVE DISORDERS; CIGARETTE-SMOKING; EARLY-ONSET; EXPECTANT MANAGEMENT; SEVERE PREECLAMPSIA; RISK-FACTORS; PREGNANCY; METAANALYSIS	The aim of this study was to evaluate the profile and outcome of patients with placental abruption and intrauterine death. It was a retrospective study over 2 years from 1 January 1999 to 31 December 2000. All women (n=96) presenting with placental abruption and intrauterine death at a tertiary referral center were identified from the records of weekly perinatal mortality meetings. Data were reviewed by a single researcher. Hypertensive disorders were diagnosed in 75 per cent (n=72) women, most often at admission once intrauterine death had already occurred. Thirty-nine per cent had a previous history of hypertensive disease during pregnancy, placental abruption, intrauterine death, or preterm delivery. Twenty-two per cent of patients (n=21) were unbooked. Major maternal complications occurred in 53 per cent of women. There were no maternal deaths. In conclusion, previous obstetric history and hypertensive disorders are important factors in women with placental abruption causing intrauterine death. Severe complications are common but careful management in a tertiary center can reduce their impact.	Katholieke Univ Leuven, Dept Obstet & Gynecol, B-3000 Louvain, Belgium; Tygerberg Hosp, Dept Obstet & Gynecol, Tygerberg, Western Cape, South Africa; Univ Stellenbosch, MRC, Perinatal Mortal Res Unit, ZA-7505 Tygerberg, Western Cape, South Africa	Leunen, K (reprint author), Katholieke Univ Leuven, Dept Obstet & Gynecol, Herestr 49, B-3000 Louvain, Belgium.						ABDELLA TN, 1984, OBSTET GYNECOL, V63, P365; Ananth CV, 1997, BRIT J OBSTET GYNAEC, V104, P572, DOI 10.1111/j.1471-0528.1997.tb11535.x; Ananth CV, 1999, OBSTET GYNECOL, V93, P622, DOI 10.1016/S0029-7844(98)00408-6; Ananth CV, 1996, OBSTET GYNECOL, V88, P309, DOI 10.1016/0029-7844(96)00088-9; Ananth CV, 1996, AM J EPIDEMIOL, V144, P881; BRINK AL, 1987, S AFR MED J, V72, P250; DAVEY DA, 1988, AM J OBSTET GYNECOL, V158, P892, DOI 10.1016/0002-9378(88)90090-7; *DEP HLTH, 1999, SAV MOTH REP CONF EN; Hall DR, 2000, BRIT J OBSTET GYNAEC, V107, P1258, DOI 10.1111/j.1471-0528.2000.tb11617.x; Hall DR, 2000, BRIT J OBSTET GYNAEC, V107, P1252, DOI 10.1111/j.1471-0528.2000.tb11616.x; Hall DR, 2001, INT J GYNECOL OBSTET, V74, P143, DOI 10.1016/S0020-7292(01)00421-0; Kramer MS, 1997, OBSTET GYNECOL, V89, P221, DOI 10.1016/S0029-7844(96)00478-4; ODENDAAL ES, 1998, 17 C PRIOR PER CAR S; Odendaal H J, 2000, J Obstet Gynaecol, V20, P358; Rasmussen S, 1999, PAEDIATR PERINAT EP, V13, P9; Sibai BM, 1998, NEW ENGL J MED, V339, P667, DOI 10.1056/NEJM199809033391004	16	17	17	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0142-6338			J TROP PEDIATRICS	J. Trop. Pediatr.	AUG	2003	49	4					231	234		10.1093/tropej/49.4.231				4	Pediatrics; Tropical Medicine	Pediatrics; Tropical Medicine	705FB	WOS:000184384100008	12929885	Bronze			2019-03-26	
J	Claeys, P; De Vuyst, H; Gonzalez, C; Garcia, A; Bello, RE; Temmerman, M				Claeys, P; De Vuyst, H; Gonzalez, C; Garcia, A; Bello, RE; Temmerman, M			Performance of the acetic acid test when used in field conditions as a screening test for cervical cancer	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						cervical cancer; screening; visual inspection; cytology; developing countries	DIRECT VISUAL INSPECTION; VISUALIZATION; NICARAGUA; NEOPLASIA; COUNTRIES	OBJECTIVES To assess if visual inspection with acetic acid (VIA) is a useful alternative screening test for cervical cancer, when used in a resource-poor setting with an existing cytology-based screening programme. METHODS Women living in Rivas district (Nicaragua), who attended the programme, were concurrently screened with VIA and Papanicolau (PAP) smear. Screening was performed by health providers who had received training in VIA and a refresher course in cytology. Women testing positive for either of the results were referred for colposcopy and biopsy when indicated. The performance of VIA was compared with PAP smear, calculating the relative true and false positive rate (RELTPR and RELFPR) and for a high threshold on biopsy (cervical intraepithelial neoplasia grade 2 or a higher grade). We determined the trade-off between both tests by calculating the ratio of extra false positives detected through extra true positives (EFP:ETP ratio). RESULTS A total of 1076 patients were screened. Nearly 33% had a positive screening test. On biopsy, 7.6% had a low-grade intraepithelial lesion, 4.5% a high-grade intraepithelial lesion (HSIL) and 0.5% invasive cancer. The RELTPR (VIA to PAP) was 1.96, the RELFPR 5.02 and the EFP:ETP ratio 8.04. VIA detected twice as much HSIL and invasive cancers as the PAP smear. Yet, for every extra diagnosis, eight extra false positives had to be examined at the referral level. CONCLUSIONS The VIA spectacularly increases the number of HSIL and invasive cancers detected. The high FPR is a concern for the organization of the referral level. There is a need to establish uniform criteria on test positivity and to further improve the performance in field conditions.	State Univ Ghent Hosp, Int Ctr Reprod Hlth, B-9000 Ghent, Belgium; Univ Nacl Autonoma Nicaragua, Dept Microbiol, Managua, Nicaragua; Serv Med Comunales, San Juan Del Sur, Nicaragua	Temmerman, M (reprint author), State Univ Ghent Hosp, Int Ctr Reprod Hlth, De Pintelaan 185,P3, B-9000 Ghent, Belgium.						Belinson JL, 2001, OBSTET GYNECOL, V98, P441, DOI 10.1016/S0029-7844(01)01454-5; Chock C, 1997, J CLIN EPIDEMIOL, V50, P1211, DOI 10.1016/S0895-4356(97)00122-4; Claeys P, 2002, SEX TRANSM INFECT, V78, P204, DOI 10.1136/sti.78.3.204; Claeys P, 2002, TROP MED INT HEALTH, V7, P935, DOI 10.1046/j.1365-3156.2002.00953.x; Denny L, 2002, CANCER, V94, P1699, DOI 10.1002/cncr.10381; Eluf-Neto J, 2001, SEMIN ONCOL, V28, P188, DOI 10.1053/sonc.2001.21966; Gaffikin L, 1999, LANCET, V353, P869; Kitchener HC, 1999, LANCET, V353, P856, DOI 10.1016/S0140-6736(98)00417-6; Kurman RJ, 1994, BETHESDA SYSTEM REPO; Mandelblatt JS, 2002, JNCI-J NATL CANCER I, V94, P1469, DOI 10.1093/jnci/94.19.1469; Megevand E, 1996, OBSTET GYNECOL, V88, P383, DOI 10.1016/0029-7844(96)00189-5; PARKIN DM, 1991, CANC SCREENING, P184; Sankaranarayanan R, 2001, B WORLD HEALTH ORGAN, V79, P954; Sankaranarayanan R, 1999, INT J CANCER, V80, P161, DOI 10.1002/(SICI)1097-0215(19990105)80:1<161::AID-IJC28>3.3.CO;2-#; SCHATZKIN A, 1987, AM J EPIDEMIOL, V125, P672, DOI 10.1093/oxfordjournals.aje.a114580; Sherris J, 2001, WESTERN J MED, V175, P231, DOI 10.1136/ewjm.175.4.231; Solomon D, 2002, JAMA-J AM MED ASSOC, V287, P2114, DOI 10.1001/jama.287.16.2114; Wright TC, 2002, ACTA CYTOL, V46, P793, DOI 10.1159/000327049	18	9	9	0	1	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	AUG	2003	8	8					704	709		10.1046/j.1365-3156.2003.01082.x				6	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	703FE	WOS:000184268700005	12869091				2019-03-26	
J	Sow, S; de Vlas, SJ; Mbaye, A; Polman, K; Gryseels, B				Sow, S; de Vlas, SJ; Mbaye, A; Polman, K; Gryseels, B			Low awareness of intestinal schistosomiasis in northern Senegal after 7 years of health education as part of intense control and research activities	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						intestinal schistosomiasis; northern Senegal; health education; control programme; questionnaire survey	RECENTLY EXPOSED COMMUNITY; PRIMARY-SCHOOL STUDENTS; MANSONI INFECTION; MACHAKOS DISTRICT; RIVER BASIN; CURE RATES; BEHAVIOR; PRAZIQUANTEL; KNOWLEDGE; PATTERNS	We evaluated the awareness of and knowledge about intestinal schistosomiasis in a highly infected rural community of northern Senegal where a variety of health information and education activities had taken place for 7 years as a component of different research and control programmes. As the infection had been introduced only recently, an initial 'zero' knowledge can be assumed. Most of the health education activities had been performed with adapted messages through local health and community workers. By a questionnaire, 566 individuals were asked simple questions on symptoms, mode of transmission, the sources of information and health-seeking behaviour. About 86% of the respondents stated that they knew what schistosomiasis was, and 92% that in case of illness they would seek treatment at the health centre. However, only half of the people accurately quoted symptoms associated with intestinal schistosomiasis: diarrhoea, abdominal pain and bloody stools. The majority of respondents realized that the disease was somehow linked with water and (lack of) hygiene, but only 44% of respondents reported water contact as the source of infection. Ultimately, only 30% of the respondents gave adequate answers about both symptoms and mode of transmission. We conclude that even intense and long-lasting education efforts for a specific and straightforward problem as schistosomiasis are not enough to have profound impact on the knowledge of rural traditional communities.	Erasmus Univ, Med Ctr Rotterdam, Dept Publ Hlth, Erasmus MC, NL-3000 DR Rotterdam, Netherlands; Inst Trop Med, Helminthol Unit, B-2000 Antwerp, Belgium; Projet ESPOIR, Reg Med St Louis, St Louis, Senegal	de Vlas, SJ (reprint author), Erasmus Univ, Med Ctr Rotterdam, Dept Publ Hlth, Erasmus MC, POB 1738, NL-3000 DR Rotterdam, Netherlands.						ANDRADE Z A, 1985, Memorias do Instituto Oswaldo Cruz, V80, P363; Burchard GD, 1998, TROP MED INT HEALTH, V3, P234, DOI 10.1046/j.1365-3156.1998.00217.x; BUTTERWORTH AE, 1991, PARASITOLOGY, V103, P339, DOI 10.1017/S0031182000059850; GRYSEELS B, 1994, TROPICAL GEOGRAPHICA, V46, P115; Guisse F, 1997, AM J TROP MED HYG, V56, P511, DOI 10.4269/ajtmh.1997.56.511; Kardorff R, 1996, AM J TROP MED HYG, V54, P586; KLOOS H, 1986, TROP MED PARASITOL, V37, P171; KLOOS H, 1995, SOC SCI MED, V40, P1497, DOI 10.1016/0277-9536(94)00310-P; MEHANNA S, 1997, TROP MED INT HEALTH, V2, pA49; NDAMBA J, 1989, SOC SCI MED, V28, P1249, DOI 10.1016/0277-9536(89)90343-2; POLDERMAN AM, 1989, TROP MED PARASITOL, V40, P177; SCHALL V T, 1987, Memorias do Instituto Oswaldo Cruz, V82, P285; Schall VT, 1998, MEM I OSWALDO CRUZ, V93, P51, DOI 10.1590/S0074-02761998000700007; SCHALL VT, 1987, REV SAUDE PUBL, V21, P387, DOI 10.1590/S0034-89101987000500005; Sow S, 2002, ANN TROP MED PARASIT, V96, P575, DOI 10.1179/000349802125001636; Stelma FF, 1997, J INFECT DIS, V176, P304, DOI 10.1086/517273; STELMA FF, 1994, AM J TROP MED HYG, V50, P575, DOI 10.4269/ajtmh.1994.50.575; STELMA FF, 1993, AM J TROP MED HYG, V49, P701, DOI 10.4269/ajtmh.1993.49.701; TALLA I, 1992, T ROY SOC TROP MED H, V86, P182, DOI 10.1016/0035-9203(92)90562-Q; TALLA I, 1990, ANN SOC BELG MED TR, V70, P173; TAYLOR P, 1987, SOC SCI MED, V24, P607, DOI 10.1016/0277-9536(87)90065-7; THOMAS AK, 1997, ACTA TROP, V68, P647; Uchoa E, 2000, SOC SCI MED, V51, P1529, DOI 10.1016/S0277-9536(00)00052-6; Useh MF, 1999, ANN TROP MED PARASIT, V93, P711, DOI 10.1080/00034989957961; van der Werf MJ, 2002, TROP MED INT HEALTH, V7, P70, DOI 10.1046/j.1365-3156.2002.00823.x; Van Lieshout L, 1999, AM J TROP MED HYG, V61, P760, DOI 10.4269/ajtmh.1999.61.760; vanDam GJ, 1996, J INFECT DIS, V173, P1232, DOI 10.1093/infdis/173.5.1232; Yazdanpanah Y, 1997, AM J TROP MED HYG, V57, P245, DOI 10.4269/ajtmh.1997.57.245; Yuan LP, 2000, TROP MED INT HEALTH, V5, P538, DOI 10.1046/j.1365-3156.2000.00602.x	29	21	22	0	3	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	AUG	2003	8	8					744	749		10.1046/j.1365-3156.2003.01080.x				6	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	703FE	WOS:000184268700011	12869097				2019-03-26	
J	Aujoulat, I; Johnson, C; Zinsou, C; Guedenon, A; Portaels, F				Aujoulat, I; Johnson, C; Zinsou, C; Guedenon, A; Portaels, F			Psychosocial aspects of health seeking behaviours of patients with Buruli ulcer in southern Benin	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						Buruli ulcer; Benin; prevention; health education; beliefs; perceptions; psychosocial aspects	MYCOBACTERIUM-ULCERANS	We investigated cultural beliefs and psychosocial factors associated with Buruli ulcer in southern Benin in order to elaborate and deliver appropriate health education messages. We conducted a qualitative study among 130 adults and 30 children in Zou province, a highly endemic region. Focus group interviews of inhabitants, patients and their assistants, health care professionals and traditional healers took place in Dasso, Ouinhi, Sagon and Zagnanado. Drawing sessions followed by individual interviews were organized among school children in Dasso and Sagon. We found that although Buruli ulcer is well known and recognized - even at a very early stage of the disease - and perceived as threatening, most people are reluctant to seek treatment at the health care centre. They are unclear about the origin of the disease (environmental factors or sorcery) and treatment is considered devastating, expensive and ineffective in some cases.	Univ Catholique Louvain, Sch Publ Hlth, Fac Med, Hlth & Patient Educ Unit RESO, B-1200 Brussels, Belgium; Natl Buruli Ulcer Programme, Cotonou, Benin; Inst Trop Med, Dept Microbiol, Mycobacteriol Unit, B-2000 Antwerp, Belgium; Ctr Sanit & Nutr Gbemonten, Zagnanado, Benin	Aujoulat, I (reprint author), Univ Catholique Louvain, Sch Publ Hlth, Fac Med, Hlth & Patient Educ Unit RESO, B-1200 Brussels, Belgium.						AGUIAR J, 1997, B SEANCES ACAD ROYAL, V43, P325; AMOFAH G, 2000, BURULI ULCER MYCOBAC, P49; Asiedu K, 1998, AM J TROP MED HYG, V59, P1015, DOI 10.4269/ajtmh.1998.59.1015; AUJOULAT I, 1996, DEV SANTE, V125, P22; AUJOULAT I, 1999, ENQUETE PERCEPTIONS; BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037//0033-295X.84.2.191; CONNER M, 1995, PREDICTING HLTH BEHA, P197; FASSIN D, 1992, POWVOIR MALADIES AFR, P129; FOLCHLYON E, 1981, STUD FAMILY PLANN, V12, P443, DOI 10.2307/1965656; HAYMAN J, 2000, BURULI ULCER MYCOBAC, P9; Hochbaum GM, 1958, PUBLIC PARTICIPATION; JOHNSON C, 1997, THESIS NATL U BENIN; Lagarrigue V, 2000, Med Trop (Mars), V60, P262; MACCALLUM P, 1948, J PATHOL BACTERIOL, V60, P93, DOI 10.1002/path.1700600111; Malterud K, 2001, LANCET, V358, P483, DOI 10.1016/S0140-6736(01)05627-6; MEYERS WM, 1974, AM J TROP MED HYG, V23, P919, DOI 10.4269/ajtmh.1974.23.919; POPE C, 1995, BRIT MED J, V311, P42, DOI 10.1136/bmj.311.6996.42; Portaels F, 2001, REV SCI TECH OIE, V20, P252, DOI 10.20506/rst.20.1.1270; ROSENSTOCK IM, 1960, AM J PUBLIC HEALTH N, V50, P295, DOI 10.2105/AJPH.50.3_Pt_1.295; SARGENT CF, 1982, CULTURAL CONTEXT THE, P19; VALADE B, 1985, ENCY UNIVERSALIS COR, V16, P1185; WALLSTON BS, 1976, J CONSULT CLIN PSYCH, V44, P580, DOI 10.1037//0022-006X.44.4.580; *WHO, 2001, 199 WHO	23	58	58	0	2	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	AUG	2003	8	8					750	759		10.1046/j.1365-3156.2003.01089.x				10	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	703FE	WOS:000184268700012	12869098	Bronze			2019-03-26	
J	Mutapi, F; Gryseels, B; Roddam, A				Mutapi, F; Gryseels, B; Roddam, A			On the calculation of intestinal schistosome infection intensity	ACTA TROPICA			English	Article						schistosomiasis; infection intensity; geometric mean; arithmetic mean; age-infection relationship	IMMUNITY; MANSONI; EPIDEMIOLOGY; HAEMATOBIUM; AGGREGATION; HETEROGENEITIES; SIMULATION; RESPONSES; PATTERNS	The effects of using different methods to calculate individual infection intensities on the age-infection distribution of Schistosoma mansoni field data are demonstrated. Methods are tested on a maximum of three stool samples per person collected on three consecutive days; the methods considered for the calculation of individual infection intensities are the geometric mean (GM), arithmetic mean (AM) and pseudo geometric mean (GM of stool samples instead of replicates). In addition, the effects of calculating the infection intensity for each age group using either AMs or GMs are compared. Differences occur in the shape of the age-infection profiles obtained by using either the arithmetic or geometric group mean. When using the AM, peak infection intensity occurs in a younger age group compared to using the GM, and all three methods of calculating individual infection intensity give the first peak of infection in the same age group. However, differences occur in the position of the second peak which occurs earlier with the two GMs than with the AM. Bootstrapping procedures show that the individual AM, gives a different age group for the first peak of infection at least 25% of the time when compared to either of the GMs, and 3 NO of the time for the second peak, while the two GMs give the same peak age groups around 90-92% of the time for both peaks. When using the GM, to calculate infection intensity for each age group, there are no differences between the three methods used to calculate individual infection intensity. This is confirmed by bootstrapping procedures. The results are discussed in relation to the distribution of parasites and levels of parasite aggregation. The implications of the results for field studies are also discussed. (C) 2003 Elsevier Science B.V. All rights reserved.	Univ London Birkbeck Coll, London WC1E 7HX, England; Inst Trop Med, B-2000 Antwerp, Belgium; Dept Zool, Wellcome Trust Ctr Epidemiol Infect Dis, Oxford OX1 3PS, England	Mutapi, F (reprint author), Univ Edinburgh, Inst Cell Anim & Populat Biol, Ashworth Labs, Kings Bldg,W Mains Rd, Edinburgh EH9 3JT, Midlothian, Scotland.			Mutapi, Francisca/0000-0002-2537-3466			Anderson RM, 1992, INFECT DIS HUMANS DY; BUTTERWORTH AE, 1985, T ROY SOC TROP MED H, V79, P393, DOI 10.1016/0035-9203(85)90391-8; Chan MS, 2000, PARASITOLOGY, V120, P161, DOI 10.1017/S003118209900534X; CHANDIWANA SK, 1991, PARASITOLOGY, V103, P363, DOI 10.1017/S0031182000059874; DEVLAS S, 1996, THESIS; Engels D, 1997, TROP MED INT HEALTH, V2, P265, DOI 10.1046/j.1365-3156.1997.d01-264.x; ENGELS D, 1997, AM J TROP MED HYG, V57, P572; ENGELS D, 1996, AM J TROP MED HYG, V54, P3119; FULFORD ACJ, 1994, PARASITOL TODAY, V11, P446; FULFORD AJC, 1992, PARASITOLOGY, V105, P219, DOI 10.1017/S003118200007414X; GREGORY RD, 1993, ACTA TROP, V54, P131, DOI 10.1016/0001-706X(93)90059-K; GRYSEELS B, 1989, T ROY SOC TROP MED H, V83, P219, DOI 10.1016/0035-9203(89)90655-X; GRYSEELS B, 1994, TROP GEOGR MED, V46, P209; Hagan P, 1991, NATURE, V349, P234; Katz N, 1972, Rev Inst Med Trop Sao Paulo, V14, P397; Mutapi F, 1997, PARASITE IMMUNOL, V19, P255, DOI 10.1046/j.1365-3024.1997.d01-206.x; Ross AGP, 1998, ACTA TROP, V70, P205, DOI 10.1016/S0001-706X(98)00022-9; Shaw DJ, 1998, PARASITOLOGY, V117, P597, DOI 10.1017/S0031182098003448; STELMA FF, 1997, THESIS U LEIDEN; Woolhouse MEJ, 1997, P NATL ACAD SCI USA, V94, P338, DOI 10.1073/pnas.94.1.338; WOOLHOUSE MEJ, 1991, NATURE, V351, P757, DOI 10.1038/351757a0; Zar JH, 1999, BIOSTATISTICAL ANAL	22	6	6	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0001-706X			ACTA TROP	Acta Trop.	JUL	2003	87	2					225	233		10.1016/S0001-706X(03)00115-3				9	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	699FL	WOS:000184046000004	12826298				2019-03-26	
J	van der Werf, MJ; Borsboom, GJJM; de Vlas, SJ				van der Werf, MJ; Borsboom, GJJM; de Vlas, SJ			No effect of recall period length on prevalence of self-reported haernaturia in Schistosoma haematobium-endemic areas	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						schistosomiasis; Schistosoma haematobium; haematuria; prevalence; recall period length; Africa	QUESTIONNAIRES	Assessing prevalence of haematuria by interview is commonly used as a rapid method to identify communities for mass treatment of Schistosoma haematobium infection. We analysed, using 21 published studies, to what extent the prevalence estimates of haematuria were affected by the length of the recall period for which respondents were requested to report symptoms. There was a strong positive association between prevalence of haematuria and infection, but no effect of recall period length. This suggests that the choice of recall period is of minor importance in control programmes or studies based on reported haematuria.	Univ Rotterdam, Erasmus MC, Ctr Med, Dept Publ Hlth, NL-3000 DR Rotterdam, Netherlands; Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium	van der Werf, MJ (reprint author), Univ Rotterdam, Erasmus MC, Ctr Med, Dept Publ Hlth, POB 1738, NL-3000 DR Rotterdam, Netherlands.	vanderwerfm@kncvtbc.nl					Adom H., 1992, Medecine d'Afrique Noire, V39, P550; COUGHLIN SS, 1990, J CLIN EPIDEMIOL, V43, P87, DOI 10.1016/0895-4356(90)90060-3; Guyatt H, 1999, TROP MED INT HEALTH, V4, P751, DOI 10.1046/j.1365-3156.1999.00483.x; Lengeler C, 2002, B WORLD HEALTH ORGAN, V80, P235; LENGELER C, 1991, INT J EPIDEMIOL, V20, P796, DOI 10.1093/ije/20.3.796; WARREN KS, 1979, AM J TROP MED HYG, V28, P964; *WHO, 2002, TECHN REP SER, V912	7	4	5	0	0	ROYAL SOC TROPICAL MEDICINE	LONDON	MANSON HOUSE 26 PORTLAND PLACE, LONDON W1N 1EY, ENGLAND	0035-9203			T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	JUL-AUG	2003	97	4					373	374		10.1016/S0035-9203(03)90057-5				2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	839AC	WOS:000222754700002	15259459				2019-03-26	
J	Mugisho, E; Dramaix, M; Porignon, D; Mouafo, JB; Vanbellinghen, AM; Hennart, P; Meuris, S				Mugisho, E; Dramaix, M; Porignon, D; Mouafo, JB; Vanbellinghen, AM; Hennart, P; Meuris, S			Ineffectiveness of chloroquine antenatal prophylaxis in East of Democratic Republic of Congo (RDC)	TROPICAL DOCTOR			English	Article							PLASMODIUM-FALCIPARUM; SENSITIVITY; ZAIRE		Free Univ Brussels, Dept Epidemiol & Prevent Med, Sch Publ Hlth, Fac Med, 808 Route Lennik,CP 595, B-1070 Brussels, Belgium; Free Univ Brussels, Fac Med, Lab Expt Hormonol, B-1070 Brussels, Belgium; Free Univ Brussels, Fac Med, CEMUBAC, B-1070 Brussels, Belgium; Hlth Dist Rutshuru, N Kivu, DEM REP CONGO	Hennart, P (reprint author), Free Univ Brussels, Dept Epidemiol & Prevent Med, Sch Publ Hlth, Fac Med, 808 Route Lennik,CP 595, B-1070 Brussels, Belgium.	philippe.hennart@ulb.ac.be					COOSEMANS MH, 1985, ANN SOC BELG MED TR, V65, P115; GARNER P, 1994, B WORLD HEALTH ORGAN, V72, P89; MEURIS S, 1993, AM J TROP MED HYG, V48, P603, DOI 10.4269/ajtmh.1993.48.603; WERY M, 1986, ANN SOC BELG MED TR, V66, P309; Wolday D, 1995, T ROY SOC TROP MED H, V89, P654, DOI 10.1016/0035-9203(95)90431-X	5	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0049-4755	1758-1133		TROP DOCT	Trop. Dr.	JUL	2003	33	3					177	+		10.1177/004947550303300323				2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	701QX	WOS:000184180300022	12870613				2019-03-26	
J	Meessen, B; Zhenzhong, Z; Van Damme, W; Devadasan, N; Criel, B; Bloom, G				Meessen, B; Zhenzhong, Z; Van Damme, W; Devadasan, N; Criel, B; Bloom, G			Iatrogenic poverty	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Editorial Material						poverty; iatrogenesis; catastrophic health care expenditure; health insurance; social assistance; Asia; transition	HEALTH-INSURANCE SCHEME; CARE; ACCESS		Inst Trop Med, B-2000 Antwerp, Belgium; Peking Univ, Med Sci Ctr, Chinese Hlth Econ Inst, Beijing 100083, Peoples R China; Univ Sussex, Inst Dev Studies, Brighton BN1 9RE, E Sussex, England	Meessen, B (reprint author), Inst Trop Med, Natl Str 155, B-2000 Antwerp, Belgium.		Van Damme, Wim/F-7404-2011	Bloom, Gerald/0000-0002-7047-2412; Meessen, Bruno/0000-0002-0359-8621			Bennett S, 1998, 16 ARA WHO; BLOOM G, 2000, HLTH POVERTY SUBSAHA; Carrin G, 2002, INT SOCIAL SECURITY, V55, P57; CHAMBERS R, 1983, RURAL DEV PUTTING LA; Criel B, 1997, TROP MED INT HEALTH, V2, P654, DOI 10.1046/j.1365-3156.1997.d01-349.x; De Swaan A, 1988, CARE STATE HLTH CARE; Devereux S., 2002, SOCIAL PROTECTION PO; Ensor T, 1996, INT J HEALTH PLAN M, V11, P69; Gertler P, 2002, AM ECON REV, V92, P51, DOI 10.1257/000282802760015603; Kassie A., 2000, CREDIT LANDLESSNESS; Kawabata K, 2002, B WORLD HEALTH ORGAN, V80, P612; Meessen B, 2002, REV INT SECURITE SOC, V55, P91; MEESSEN B, 2003, FINANCER SANTE PAYS; Meessen B, 2002, NEW DEAL CAMBODIA 2; Milimo J T, 2002, POOR ZAMBIA SPEAK WH; Norton A., 2001, SOCIAL PROTECTION CO; Ranson MK, 2002, B WORLD HEALTH ORGAN, V80, P613; Sen AK, 1981, POVERTY FAMINES ESSA; Stierle F, 1999, INT J HEALTH PLAN M, V14, P81, DOI 10.1002/(SICI)1099-1751(199904/06)14:2<81::AID-HPM543>3.0.CO;2-P; VANLEEMPUT L, 2002, DENGUE EPIDEMIC THMA; Wagstaff A, 2002, B WORLD HEALTH ORGAN, V80, P97; Wilkes A, 1997, 58 IDS; WILLIS CY, 1995, HLTH POLICY PLANNING, V10, P214; Wright P, 2003, LANCET, V361, P185, DOI 10.1016/S0140-6736(03)12233-7; ZHANG Z, 2002, CHINA HLTH EC, V11, P32; ZHAO K, 2002, CHINA HLTH EC, V3, P29	26	48	48	0	5	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	JUL	2003	8	7					581	584		10.1046/j.1365-3156.2003.01081.x				4	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	701TJ	WOS:000184184800001	12828538	Bronze			2019-03-26	
J	Lejon, V; Kwete, J; Buscher, P				Lejon, V; Kwete, J; Buscher, P			Towards saliva-based screening for sleeping sickness?	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						diagnosis; sleeping sickness; Trypanosoma brucei gambiense; saliva; ELISA; CATT/T. b. gambiense; LATEX/T. b. gambiense	AGGLUTINATION-TEST; ANTIBODIES; SERUM; FLUID	A pilot study was carried out on the detection of trypanosome-specific antibodies in saliva for diagnosis of sleeping sickness. All twenty-three saliva samples of parasitologically confirmed Trypanosoma brucei gambiense patients tested positive in an indirect enzyme-linked immunosorbent assay, whereas all 14 saliva samples of a negative control group remained negative. Trypanosome-specific antibody levels in patient saliva correlated with antibody levels in serum, but were about 250-fold lower. Eight of 23 undiluted saliva samples of sleeping sickness patients tested positive in CATT/T. b. gambiense and two of 23 in LATEX/T. b. gambiense. All fourteen saliva samples of the negative control group were also positive in CATT/T. b. gambiense, as were four of 14 in LATEX/T. b. gambiense. CATT and LATEX were thus inappropriate for antibody detection in saliva. These results indicate that trypanosome-specific antibody detection in saliva is possible. This could lead to the development of a simple, non-invasive, reliable saliva field test for diagnosis of sleeping sickness.	Inst Trop Med, Dept Parasitol, Natl Str 155, B-2000 Antwerp, Belgium; Programme Natl Lutte Trypanosomiase Humaine Afric, Kinshasa, DEM REP CONGO	Lejon, V (reprint author), Inst Trop Med, Dept Parasitol, Natl Str 155, B-2000 Antwerp, Belgium.	vlejon@itg.be; jeankwete@yahoo.fr; pbuscher@itg.be	Buscher, Philippe/B-9956-2012	Buscher, Philippe/0000-0002-1926-7472			Buscher P, 1999, ACTA TROP, V73, P11, DOI 10.1016/S0001-706X(99)00009-1; Buscher P, 1995, 22 M INT SCI COUNC T, P46; Ettiegne-Traore V, 1998, INT J STD AIDS, V9, P173, DOI 10.1258/0956462981921819; MAGNUS E, 1978, ANN SOC BELG MED TR, V58, P169; MASUM MA, 1994, T ROY SOC TROP MED H, V88, P660, DOI 10.1016/0035-9203(94)90216-X; Mitoma M, 2001, J BIOL CHEM, V276, P18060, DOI 10.1074/jbc.M101459200; Nokes DJ, 2001, B WORLD HEALTH ORGAN, V79, P588; PARRY JV, 1987, LANCET, V2, P72, DOI 10.1016/S0140-6736(87)92737-1; RUNDEGREN J, 1987, INFECT IMMUN, V55, P288; Santos MMAG, 2000, T ROY SOC TROP MED H, V94, P289	10	9	9	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	JUL	2003	8	7					585	588		10.1046/j.1365-3156.2003.01077.x				4	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	701TJ	WOS:000184184800002	12828539	Bronze			2019-03-26	
J	Jamonneau, V; Solano, P; Garcia, A; Lejon, V; Dje, N; Miezan, TW; N'Guessan, P; Cuny, G; Buscher, P				Jamonneau, V; Solano, P; Garcia, A; Lejon, V; Dje, N; Miezan, TW; N'Guessan, P; Cuny, G; Buscher, P			Stage determination and therapeutic decision in human African trypanosomiasis: value of polymerase chain reaction and immunoglobulin M quantification on the cerebrospinal fluid of sleeping sickness patients in Cote d'lvoire	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						human African trypanosomiasis; diagnosis; polymerase chain reaction; immunoglobulin M; cerebrospinal fluid; Cote d'Ivoire	BRUCEI-GAMBIENSE; FOLLOW-UP; DIVOIRE; PENTAMIDINE; DNA; CENTRIFUGATION; AMPLIFICATION; CONGOLENSE; DIAGNOSIS; INFECTION	In human African trypanosomiasis (HAT), two disease stages are defined: the first, or haemo-lymphatic stage, and the second, or meningo-encephalitic stage. Stage determination forms the basis of therapeutic decision and is of prime importance, as the drug used to cure second-stage patients has considerable side-effects. However, the tests currently used for stage determination have low sensitivity or specificity. Two new tests for stage determination in the cerebrospinal fluid (CSF) were evaluated on 73 patients diagnosed with HAT in Cote d'Ivoire. The polymerase chain reaction (PCR) detecting trypanosome DNA (PCR/CSF) is an indirect test for trypanosome detection whereas the latex agglutination test detecting immunoglobulin M (LATEX/IgM) is an indicator for neuro-inflammation. Both tests were compared with classically used tests, double centrifugation and white blood cell count of the CSF. PCR/CSF appeared to be the most sensitive test (96%), and may be of use to improve stage determination. However, its value for therapeutic decision appears limited, as patients whose CSF was positive with PCR were successfully treated with pentamidine. This result confirms those of previous works that showed that some patients with trypanosomes in the CSF could be treated successfully with pentamidine. LATEX/IgM, which depending on the cut-off, showed lower sensitivity of 76% and 88%, but higher specificity of 83% and 71% for LATEX/IgM 16 and LATEX/IgM 8 respectively, appears more appropriate for therapeutic decision making.	Inst Rech Dev, Inst Pierre Richet, Bouake, Cote Ivoire; Inst Rech Dev, UR 010, Dakar, Senegal; Inst Trop Med, Dept Parasitol, B-2000 Antwerp, Belgium; Projet Rech Clin Trypanosomiase, Daloa, Cote Ivoire; Programme Sante Anim, Lab Rech & Coordinat Trypanosomoses, F-34398 Montpellier 5, France	Solano, P (reprint author), Inst Rech Dev, Inst Pierre Richet, UR 035,01 BP 1500, Bouake, Cote Ivoire.	solano@ird.ci; Andie.Garcia@ird.sn; ngorannorbert@yahoo.fe; Pbuscher@itg.be	Buscher, Philippe/B-9956-2012; Garcia, Andre/S-2959-2016; Solano, Philippe/B-2328-2010; Jamonneau, Vincent/K-1124-2016	Buscher, Philippe/0000-0002-1926-7472; Garcia, Andre/0000-0002-1808-472X; 			Bisser S, 1997, B SOC PATHOL EXOT, V90, P321; Blum J, 2001, TROP MED INT HEALTH, V6, P390, DOI 10.1046/j.1365-3156.2001.00710.x; Bouteille B, 1998, B SOC PATHOL EXOT, V91, P127; BRONNER U, 1991, T ROY SOC TROP MED H, V85, P608, DOI 10.1016/0035-9203(91)90364-5; CATTAND P, 1988, B WORLD HEALTH ORGAN, V66, P83; Doua F, 1996, AM J TROP MED HYG, V55, P586, DOI 10.4269/ajtmh.1996.55.586; Garcia A, 2000, TROP MED INT HEALTH, V5, P786, DOI 10.1046/j.1365-3156.2000.00623.x; Jamonneau V, 2000, ANN TROP MED PARASIT, V94, P831, DOI 10.1080/00034980020028004; Kabiri M, 1999, TROP MED INT HEALTH, V4, P658, DOI 10.1046/j.1365-3156.1999.00465.x; Kyambadde JW, 2000, B WORLD HEALTH ORGAN, V78, P119; Lejon V, 1998, B WORLD HEALTH ORGAN, V76, P553; Lejon V, 2001, Med Trop (Mars), V61, P355; Lejon V, 2002, TROP MED INT HEALTH, V7, P685, DOI 10.1046/j.1365-3156.2002.00917.x; MATTERN P, 1968, B WORLD HEALTH ORGAN, V38, P1; Miezan TW, 2000, T ROY SOC TROP MED H, V94, P293, DOI 10.1016/S0035-9203(00)90327-4; MIEZAN TW, 1994, T ROY SOC TROP MED H, V88, P332, DOI 10.1016/0035-9203(94)90105-8; MOSER DR, 1989, PARASITOLOGY, V99, P57, DOI 10.1017/S0031182000061023; Penchenier L, 1996, PARASITE, V3, P387, DOI 10.1051/parasite/1996034387; PENTREATH VW, 1992, ANN TROP MED PARASIT, V86, P29, DOI 10.1080/00034983.1992.11812627; PEPIN J, 1994, ADV PARASIT, V33, P1, DOI 10.1016/S0065-308X(08)60410-8; Solano P, 2002, ACTA TROP, V82, P349, DOI 10.1016/S0001-706X(02)00029-3; Truc P, 1998, T ROY SOC TROP MED H, V92, P537, DOI 10.1016/S0035-9203(98)90904-X; Truc P, 1999, B WORLD HEALTH ORGAN, V77, P745; WALSH PS, 1991, BIOTECHNIQUES, V10, P506; *WHO, 1986, TECHN REP SER WHO, V739; *WHO, 1998, TECHN REP SER WHO, V881	26	29	30	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	JUL	2003	8	7					589	594		10.1046/j.1365-3156.2003.01079.x				6	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	701TJ	WOS:000184184800003	12828540	Bronze			2019-03-26	
J	Phiri, IK; Ngowi, H; Afonso, S; Matenga, E; Boa, M; Mukaratirwa, S; Githigia, S; Saimo, M; Sikasunge, C; Maingi, N; Lubega, GW; Kassuku, A; Michael, L; Siziya, S; Krecek, RC; Noormahomed, E; Vilhena, M; Dorny, P; Willingham, AL				Phiri, IK; Ngowi, H; Afonso, S; Matenga, E; Boa, M; Mukaratirwa, S; Githigia, S; Saimo, M; Sikasunge, C; Maingi, N; Lubega, GW; Kassuku, A; Michael, L; Siziya, S; Krecek, RC; Noormahomed, E; Vilhena, M; Dorny, P; Willingham, AL			The emergence of Taenia solium cysticercosis in Eastern and Southern Africa as a serious agricultural problem and public health risk	ACTA TROPICA			English	Article; Proceedings Paper	International Workshop on Taenia Solium Cysticercosis/Taeniosis with Special Focus on Eastern and Southern Africa	AUG 19-22, 2002	ARUSHA, TANZANIA	Cysticercosis Working Grp Eastern & SO Africa		pig; Taenia solium; porcine cysticercosis; prevalence; enzyme-linked immunosorbent assay; Kenya; Uganda; Tanzania; Mozambique; Zambia; Zimbabwe; South Africa	2 RURAL-AREAS; PREVALENCE; NEUROCYSTICERCOSIS; PIGS; EPIDEMIOLOGY; EPILEPTICS; TOMOGRAPHY; DIAGNOSIS; VILLAGE; HUMANS	Pig production has increased significantly in the Eastern and Southern Africa (ESA) region during the past decade, especially in rural, resource-poor, smallholder communities. Concurrent with the increase in smallholder pig keeping and pork consumption, there have been increasing reports of porcine cysticercosis in the ESA region. This article reviews the findings concerning the presence and impact of porcine cysticercosis in seven of the ESA countries. Most of the reported findings are based on surveys utilising lingual palpation and post-mortem examination, however, some also used serological assays. In Tanzania, community-based studies on porcine cysticercosis indicate a prevalence of 17.4% in the northern highlands district of Mbulu and a prevalence range of 5.1-16.9% in the southern highlands. in Kenya recent surveys in the southwestern part of the country where smallholder pig keeping is popular indicate that 10-14% of pigs are positive for cysticercosis by lingual examination. Uganda has the most pigs in Eastern Africa, most of which are kept under smallholder conditions. Preliminary surveys in 1998 and 1999 at slaughterhouses in Kampala indicated a prevalence of porcine cysticercosis between 0.12 and 1.2%, however, a rural survey in northern Uganda in 1999 indicated 34-45% of pigs slaughtered in selected villages were infected. Additionally, a new survey of 297 pigs slaughtered in Kampala in 2002 indicated that pigs from the central region of the country were negative for cysticercosis while 33.7% of the pigs coming from the rural Lira district in the north were positive. Interestingly, 8 piglet foetuses removed from an infected slaughtered sow coming from Lira district were all found to harbour cysts of T solium providing evidence of congenital transmission of porcine cysticercosis. In Mozambique, abattoir records indicate that porcine cysticercosis is present in all provinces of the country. A serological survey on pigs in rural Tete Province found 15% of pigs positive. In Zimbabwe, a retrospective study in official abattoirs around the country from 1994 to 2001 reported a mean prevalence of 0.34% which is in contrast to a post-mortem survey in 1999, which showed that the prevalence of porcine cysticercosis in rural west Zimbabwe where smallholder pig keeping is popular was 28.6%. In Zambia, abattoir records reported porcine cysticercosis in six of the nine provinces. Routine meat inspection of 1316 pigs at a slaughter slab in Lusaka showed that 20.6% of the pigs had cysticercosis whereas serological testing of 874 pigs at the same abattoir indicated that 56.6% were found to have circulating antigens of Taenia solium. Field surveys based on lingual palpation in Southern and Eastern Provinces of Zambia revealed prevalences of 8.2-28.4 and 5.2%, respectively. South Africa has the largest number of pigs in Southern Africa and cysticercosis has been recognised as a problem in the country for many decades. There is strong evidence supporting the high prevalence of neurocysticercosis infecting humans from resource-poor areas of the country where pigs are being raised under smallholder conditions. In spite of this community-based surveys on porcine cysticercosis have never been conducted in South Africa and the last slaughterhouse survey was conducted nearly 40 years ago. The prevalences of porcine cysticercosis found in these ESA countries rank among the highest in the world and the disease is emerging as an important constraint for the nutritional and economic well being of resource-poor smallholder farming communities. The current findings suggest the widespread presence of human tapeworm carriers and thus a high risk of human cysticercosis in both rural areas and urban centres in the ESA region. More research is required in the region to assess the extent and public health and economic impact of T. solium infection in order to determine whether and what prevention and control efforts are needed. (C) 2003 Elsevier Science B.V. All rights reserved.	Univ Zambia, Sch Vet Med, Dept Clin Studies, Lusaka 32379, Zambia; Royal Vet & Agr Univ, Dept Vet Microbiol, Danish Ctr Expt Parasitol,WHO,FAO, Collaborating Ctr Parasit Zoonoses, DK-1870 Frederiksberg, Denmark; Inst Trop Med Prince Leopold, Dept Anim Hlth, B-2000 Antwerp, Belgium; Univ Evora, Evora, Portugal; Univ Eduardo Mondlane, Fac Med, Maputo, Mozambique; Univ Pretoria, Fac Nat & Agr Sci, Dept Zool & Entomol, ZA-0002 Pretoria, South Africa; Univ Zambia, Sch Med, Lusaka, Zambia; Onderstepoort Vet Inst, Div Parasitol, Onderstepoort, South Africa; Makerere Univ, Fac Vet Med, Kampala, Uganda; Univ Nairobi, Fac Vet Med, Dept Vet Pathol Microbiol & Parasitol, Nairobi, Kenya; Univ Zimbabwe, Fac Vet Sci, Harare, Zimbabwe; Sokoine Univ Agr, Fac Vet Med, Dept Vet Microbiol & Parasitol, Morogoro, Tanzania	Phiri, IK (reprint author), Univ Zambia, Sch Vet Med, Dept Clin Studies, POB 32379, Lusaka 32379, Zambia.		Mukaratirwa, Samson/E-9752-2010	Mukaratirwa, Samson/0000-0001-6843-1497			AFONSO SMS, 2001, P WORKSH HUM HELM IN, P32; ANYANZO T, 1999, PREVALENCE CYSTICERC; Birbeck GL, 2000, EPILEPSIA, V41, P277, DOI 10.1111/j.1528-1157.2000.tb00156.x; BOA ME, 1995, J HELMINTHOL, V69, P113, DOI 10.1017/S0022149X00013997; BOA ME, 2001, P 18 INT C WORLD ASS, pA10; CAMPBELL GD, 1987, S AFR MED J, V72, P885; DIAZ F, 1992, AM J EPIDEMIOL, V135, P875, DOI 10.1093/oxfordjournals.aje.a116383; *FAO UN, 2002, FAOSTAT STAT DAT FAO; GITHIGIA SM, 2002, P 11 ANN M ENRECA LI; Heinz H J, 1965, S Afr J Med Sci, V30, P19; Joubert J J, 1997, Southeast Asian J Trop Med Public Health, V28 Suppl 1, P7; Kisakye J, 2002, UGANDA J AGR SCI, V7, P23; MASON P, 1992, CENT AFR J MED, V38, P149; MATENGA E, 2002, P 11 ANN M ENRECA LI; NAIDOO DV, 1987, S AFR MED J, V72, P837; Ndhlovu C. E., 1997, Central African Journal of Medicine, V43, P207; Newell E, 1997, T ROY SOC TROP MED H, V91, P389, DOI 10.1016/S0035-9203(97)90251-0; Ngowi H.A., 1999, THESIS SOKOINE U AGR; Nsengwa G.R.M., 1995, TANZANIA VET J, V15, P9; PAMMENTER MD, 1987, T ROY SOC TROP MED H, V81, P242, DOI 10.1016/0035-9203(87)90228-8; Phiri IK, 2002, VET PARASITOL, V108, P31, DOI 10.1016/S0304-4017(02)00165-6; PHIRI IK, 2001, P 18 INT C WORLD ASS, pA9; Rachman I, 1970, Cent Afr J Med, V16, P201; ROBINSON JTR, 1978, THESIS; Sacks L V, 1990, Trop Gastroenterol, V11, P30; SANTOS M, 1999, ACTA PARASITOLOGICA, V5; SARTI E, 1992, AM J TROP MED HYG, V46, P677, DOI 10.4269/ajtmh.1992.46.677; Sciutto E, 2000, MICROBES INFECT, V2, P1875, DOI 10.1016/S1286-4579(00)01336-8; SHASHA W, 1991, ANN TROP MED PARASIT, V85, P349, DOI 10.1080/00034983.1991.11812573; Thomson A J, 1984, Ann Trop Paediatr, V4, P67; VANAS AD, 1991, S AFR MED J, V80, P327; Vilhena M, 1999, AM J TROP MED HYG, V61, P59, DOI 10.4269/ajtmh.1999.61.59; Vilhena M., 1994, REV MED MOCAMBIQUE, V5, P6; VILJOEN NOEL FRANCOIS, 1937, ONDERSTEPOORT JOUR VET SCI AND ANIMAL INDUST, V9, P337; White AC, 2000, ANNU REV MED, V51, P187, DOI 10.1146/annurev.med.51.1.187; 1995, PAHO WHO INFORMAL CO, P20	36	113	117	2	22	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0001-706X			ACTA TROP	Acta Trop.	JUN	2003	87	1					13	23		10.1016/S0001-706X(03)00051-2				11	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	690XX	WOS:000183576700004	12781374	Green Published			2019-03-26	
J	Zoli, A; Shey-Njila, O; Assana, E; Nguekam, JP; Dorny, P; Brandt, J; Geerts, S				Zoli, A; Shey-Njila, O; Assana, E; Nguekam, JP; Dorny, P; Brandt, J; Geerts, S			Regional status, epidemiology and impact of Taenia solium cysticercosis in Western and Central Africa	ACTA TROPICA			English	Article; Proceedings Paper	International Workshop on Taenia Solium Cysticercosis/Taeniosis with Special Focus on Eastern and Southern Africa	AUG 19-22, 2002	ARUSHA, TANZANIA	Cysticercosis Working Grp Eastern & SO Africa		Taenia solium; cysticercosis; man; pigs; Africa; economic burden; review	PREVALENCE; CAMEROON; PIGS; DISEASES; NIGERIA; BENIN; TOGO	In West Africa, Taenia solium cysticercosis in both pigs and man has been reported in Benin, Burkina-Faso, Ghana, Ivory Coast, Senegal and Togo, and although official data are lacking, T solium is anticipated to be present in most of the pig-raising regions of other West African countries as well. In some regions of Nigeria, the prevalence of porcine cysticercosis and human taeniosis is quite high (20.5 and 8.6%, respectively). Surprisingly, however, no cases of human cysticercosis have been reported, although epilepsy is very common. Large epidemiological surveys have only been carried out in Togo and Benin, where the prevalence of human cysticercosis was 2.4 and 1.3%, respectively. In Central Africa, porcine and human cysticercosis are (hyper)-endemic in Rwanda, Burundi, the Democratic Republic of Congo and Cameroon. The parasite also has been reported in pigs in Chad and Angola. Cysticercosis has been shown to be one of the major causes of epilepsy in Cameroon with figures as high as 44.6%. Cameroon is one of the few countries where the taeniosis-cysticercosis complex has been examined more in detail. In the Western province of Cameroon large scale surveys have shown that active cysticercosis is present in 0.4-3% of the local population and in 11% of the village pigs. However, the prevalence of adult T solium was only 0.1%, which underscores the frequency of the T. solium paradox. Based on the available information, a very conservative economic estimate indicates that the annual losses due to porcine cysticercosis in 10 West and Central African countries amount to about 25 million Euro. The financial losses due to human cysticercosis are very difficult to estimate, but are certainly exceeded by the social impact of the disease, especially because of the particular perception of epilepsy in many African communities. It is concluded that the true prevalence of T. solium cysticercosis in pigs and humans in Central and West Africa remains underestimated because of unreliable slaughterhouse data and the lack of awareness and diagnostic facilities in the public health sector. (C) 2003 Elsevier Science B.V. All rights reserved.	Inst Trop Med, Dept Anim Hlth, B-2000 Antwerp, Belgium; Univ Dschang, Fac Agr & Agr Sci, Dschang, Cameroon	Geerts, S (reprint author), Inst Trop Med, Dept Anim Hlth, Natl Str 155, B-2000 Antwerp, Belgium.	sgeerts@itg.be		Geerts, Stanny/0000-0001-9885-8846			Acevedo-Hernandez A., 1982, Cysticercosis: present state of knowledge and perspectives. (Proc. Internat. workshop on cysticercosis, San Miguel de Allende, Guanajuato, Mexico, Nov. 16-18, 1981)., P63; Assana E., 2001, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V54, P123; Avode DG, 1996, B SOC PATHOL EXOT, V89, P45; AVODE DG, 1998, B SOC PATHOL EXOT, V87, P186; Awa D. N., 1999, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V52, P93; BOWESMAN C, 1952, ANN TROP MED PARASIT, V46, P101, DOI 10.1080/00034983.1952.11685511; BRANDT J, 1997, HLTH CENTRAL AFRICA, V1, P530; CHARTIER C, 1990, ANN SOC BELG MED TR, V70, P213; Collomb H, 1964, B MEMOIRE FACULTE MI, V12, P148; Coulibaly ND, 2000, ACTA TROP, V76, P53, DOI 10.1016/S0001-706X(00)00090-5; DADA BJO, 1980, J HELMINTHOL, V54, P293, DOI 10.1017/S0022149X00006799; DJOU C, 2000, THESIS U DSCHANG CAM; DUMAS M, 1990, B SOC PATHOL EXOT, V83, P263; DUMAS M, 1989, Acta Leidensia, V57, P191; FAIN A, 1997, HLTH CENTRAL AFRICA, V1, P485; *FAO, 1999, Q B STAT, V12; GEERTS S, 1995, PARASITOL TODAY, V11, P389, DOI 10.1016/0169-4758(95)80009-3; Geerts S, 2002, NATO SCI SER I LIFE, V341, P13; GEERTS S, 1993, MEDED ZITT KON ACAD, V38, P245; GRABER M, 1970, REV ELVE MED VET PAY, V23, P263; GRUNITZKY E, 1995, ANN MED INTERNE, V146, P419; Gyorkos T. W., 1996, Cahiers d'Etudes et de Recherches Francophones/Sante, V6, P377; Heroin P, 1972, REV MED COTE IVOIRE, V8, P26; Houinato D, 1998, T ROY SOC TROP MED H, V92, P621, DOI 10.1016/S0035-9203(98)90785-4; Kama K. L., 1998, 9 INT C ASS I TROP V, P62; Mishra G. S., 1978, REV ELEV MED VET PAY, V31, P63; NELSON GS, 1965, T ROY SOC TROP MED H, V59, P509; Newell E, 1997, T ROY SOC TROP MED H, V91, P389, DOI 10.1016/S0035-9203(97)90251-0; Nguekam JP, 2003, TROP MED INT HEALTH, V8, P144, DOI 10.1046/j.1365-3156.2003.01000.x; NGUEKAM JP, 1998, THESIS U MED TROPICA, P42; ODAMTTEN S. E., 1967, Ghana med., V6, P97; ONAH DN, 1995, ANN TROP MED PARASIT, V89, P399, DOI 10.1080/00034983.1995.11812968; PANDEY VS, 1976, ANN SOC BELG MED TR, V56, P46; Permin A, 1999, VET PARASITOL, V87, P63, DOI 10.1016/S0304-4017(99)00159-4; Pouedet MSR, 2002, VET PARASITOL, V106, P45, DOI 10.1016/S0304-4017(02)00035-3; Preux PM, 2000, EPILEPSIA, V41, P432, DOI 10.1111/j.1528-1157.2000.tb00185.x; PREUX PM, 1996, NEUROL INFECT EPIDEM, V1, P63; PROCTOR EM, 1965, ANN TROP MED PARASIT, V60, P146; ROBERTS T, 1994, PARASITOL TODAY, V10, P419, DOI 10.1016/0169-4758(94)90171-6; SARTI E, 1992, AM J TROP MED HYG, V46, P677, DOI 10.4269/ajtmh.1992.46.677; SHEYNJILA O, IN PRESS J HELMINTHO; THIENPONT D, 1959, Ann Soc Belg Med Trop (1920), V39, P507; TSANG VCW, 1995, PARASITOL TODAY, V11, P124, DOI 10.1016/0169-4758(95)80175-8; Vanderick F X, 1972, Ann Soc Belg Med Trop, V52, P153; Vondou L, 2002, PARASITE, V9, P271, DOI 10.1051/parasite/2002093271; ZOLI A, 1998, P 9 INT C A I T I V, P571; ZOLI PA, 1992, CAMEROON B ANIMAL PR, V1, P42; ZOLI PA, 1987, HELMINTH ZOONOSES, P85	48	77	78	0	16	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0001-706X			ACTA TROP	Acta Trop.	JUN	2003	87	1					35	42		10.1016/S0001-706X(03)00053-6				8	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	690XX	WOS:000183576700006	12781376				2019-03-26	
J	Dorny, P; Brandt, J; Zoli, A; Geerts, S				Dorny, P; Brandt, J; Zoli, A; Geerts, S			Immunodiagnostic tools for human and porcine cysticercosis	ACTA TROPICA			English	Article; Proceedings Paper	International Workshop on Taenia Solium Cysticercosis/Taeniosis with Special Focus on Eastern and Southern Africa	AUG 19-22, 2002	ARUSHA, TANZANIA	Cysticercosis Working Grp Eastern & SO Africa		Taenia solium; cysticercosis; immunodiagnosis; man; pigs; review	TAENIA-SOLIUM CYSTICERCOSIS; LINKED IMMUNOELECTROTRANSFER BLOT; DETECTING CIRCULATING ANTIGEN; CEREBROSPINAL-FLUID; HUMAN NEUROCYSTICERCOSIS; SAGINATA CYSTICERCOSIS; GLYCOPROTEIN ANTIGENS; ELISA; DIAGNOSIS; PIGS	The development of improved immunodiagnostic tools has contributed to our knowledge on the importance of taeniosis/cysticercosis by enabling sero-epidermological surveys and community-based studies to be carried out. Immunodiagnostic techniques include detection methods for specific antibodies and for circulating parasite antigen in serum or cerebrospinal fluid. The antigens used in immunoblot and enzyme-linked immunosorbent assay (ELISA) for antibody detection have evolved from crude extracts to highly purified specific fractions and recombinant antigens of the glycoprotein family, increasing both the sensitivity and the specificity of the tests. The application of ELISA for the detection of circulating parasite antigens may present some diagnostic advantages since it demonstrates not only exposure but also active infections. Until now only a few of the current techniques have been standardised and fully validated, making comparisons between studies difficult. The lack of a gold standard is a serious drawback. In surveys on cysticercosis, antibody detection systems have been useful in identifying the risk factors associated with transmission of Taenia solium; a high seroprevalence in a community indicates a "hot spot" where preventive and control measures should be applied. In contrast, the potential use of immunodiagnostic tools to identify cases of neurocysticercosis (NCC) in man is subject to debate. The correlation between a positive serology and neurological symptoms and/or lesions indicative for NCC on neuro-imaging techniques is poor to fair in most studies. This may be explained by the unpredictable clinical outcome of the infection and the variable immunological response of the human host to infection. A major problem is that in many developing countries, neuro-imaging methods are inaccessible and/or too expensive for the rural population at risk. Under these conditions, serology may provide the only tool for diagnosis of the infection. (C) 2003 Elsevier Science B.V. All rights reserved.	Inst Trop Med, Dept Anim Hlth, B-2000 Antwerp, Belgium; Univ Dschang, Fac Agr & Agr Sci, Dschang, Cameroon; Univ Ghent, Fac Vet Med, Dept Parasitol, B-9820 Ghent, Belgium	Dorny, P (reprint author), Inst Trop Med, Dept Anim Hlth, Natl Str 155, B-2000 Antwerp, Belgium.	pdorny@itg.be		Geerts, Stanny/0000-0001-9885-8846			Bern C, 1999, CLIN INFECT DIS, V29, P1203, DOI 10.1086/313470; BRANDT JRA, 1992, INT J PARASITOL, V22, P471, DOI 10.1016/0020-7519(92)90148-E; CAMACHO SPD, 1991, AM J TROP MED HYG, V45, P522, DOI 10.4269/ajtmh.1991.45.522; Carpio A, 1998, EPILEPSIA, V39, P1025, DOI 10.1111/j.1528-1157.1998.tb01287.x; CHANG KH, 1988, AM J NEURORADIOL, V9, P125; CHOROMANSKI L, 1990, J PARASITOL, V76, P69, DOI 10.2307/3282629; Chung JY, 1999, J INFECT DIS, V180, P1307, DOI 10.1086/315020; CORREA D, 1989, T ROY SOC TROP MED H, V83, P814, DOI 10.1016/0035-9203(89)90340-4; DelBrutto OH, 1996, J NEUROL SCI, V142, P1, DOI 10.1016/0022-510X(96)00130-X; Erhart A, 2002, T ROY SOC TROP MED H, V96, P270, DOI 10.1016/S0035-9203(02)90095-7; Ferreira Andreia P., 1997, Revista do Instituto de Medicina Tropical de Sao Paulo, V39, P29; Fleury A, 2001, TROP MED INT HEALTH, V6, P688, DOI 10.1046/j.1365-3156.2001.00767.x; Flisser A, 2002, NATO SCI SER I LIFE, V341, P3; GARCIA E, 1991, J NEUROL, V238, P379, DOI 10.1007/BF00319856; Garcia HH, 2000, T ROY SOC TROP MED H, V94, P673, DOI 10.1016/S0035-9203(00)90228-1; Garcia HH, 2001, AM J TROP MED HYG, V65, P31, DOI 10.4269/ajtmh.2001.65.31; Garcia HH, 1998, T ROY SOC TROP MED H, V92, P411, DOI 10.1016/S0035-9203(98)91069-0; Garcia HH, 1997, J INFECT DIS, V175, P486, DOI 10.1093/infdis/175.2.486; Garcia HH, 2000, INFECT DIS CLIN N AM, V14, P97, DOI 10.1016/S0891-5520(05)70220-8; GarciaNoval J, 1996, AM J TROP MED HYG, V55, P282, DOI 10.4269/ajtmh.1996.55.282; Gonzalez AE, 1999, VET PARASITOL, V86, P113, DOI 10.1016/S0304-4017(99)00106-5; Goodman Karyn, 1997, Journal of the Neurological Sciences, V150, pS326, DOI 10.1016/S0022-510X(97)86494-5; GOTTSTEIN B, 1986, AM J TROP MED HYG, V35, P308, DOI 10.4269/ajtmh.1986.35.308; HARRISON LJS, 1989, PARASITE IMMUNOL, V11, P351, DOI 10.1111/j.1365-3024.1989.tb00673.x; Ito A, 2002, NATO SCI SER I LIFE, V341, P25; Ito A, 1998, AM J TROP MED HYG, V59, P291, DOI 10.4269/ajtmh.1998.59.291; MILLER B, 1984, NEUROLOGY, V34, P695, DOI 10.1212/WNL.34.5.695; Nguekam A, 2003, VET PARASITOL, V111, P323, DOI 10.1016/S0304-4017(02)00391-6; Ohsaki Y, 1999, INTERNAL MED, V38, P67, DOI 10.2169/internalmedicine.38.67; Pardini AX, 2002, CLIN DIAGN LAB IMMUN, V9, P190, DOI 10.1128/CDLI.9.1.190-193.2002; PARKHOUSE RME, 1987, PARASITE IMMUNOL, V9, P263, DOI 10.1111/j.1365-3024.1987.tb00505.x; Phiri IK, 2003, ACTA TROP, V87, P13, DOI [10.1016/S0001-706X(03)00051-2, 10.1016/S0001-706X(03)00202-X]; Pouedet MSR, 2002, VET PARASITOL, V106, P45, DOI 10.1016/S0304-4017(02)00035-3; Rajshekhar V, 2003, ACTA TROP, V87, P53, DOI 10.1016/S0001-706X(03)00055-X; RAMOSKURI M, 1992, ARCH NEUROL-CHICAGO, V49, P633, DOI 10.1001/archneur.1992.00530300069012; ROCHA Sérgio M., 2002, Rev. Inst. Med. trop. S. Paulo, V44, P57, DOI 10.1590/S0036-46652002000100011; ROSAS N, 1986, ARCH NEUROL-CHICAGO, V43, P353, DOI 10.1001/archneur.1986.00520040039016; Sako Y, 2000, J CLIN MICROBIOL, V38, P4439; SARTI E, 1992, AM J TROP MED HYG, V46, P677, DOI 10.4269/ajtmh.1992.46.677; Sarti E, 2000, T ROY SOC TROP MED H, V94, P85, DOI 10.1016/S0035-9203(00)90451-6; Sato MO, 2003, VET PARASITOL, V111, P309, DOI 10.1016/S0304-4017(02)00383-7; SCHANTZ P M, 1989, Acta Leidensia, V57, P153; Schantz P.M., 1998, EMERG INFECT DIS, V2, P213; SCHANTZ PM, 1996, TAENIASIS CYSTICERCO, P277; Sciutto E, 1998, VET PARASITOL, V79, P299, DOI 10.1016/S0304-4017(98)00180-0; Subahar R, 2001, T ROY SOC TROP MED H, V95, P388, DOI 10.1016/S0035-9203(01)90190-7; TSANG VCW, 1991, VET IMMUNOL IMMUNOP, V29, P69, DOI 10.1016/0165-2427(91)90053-F; TSANG VCW, 1989, J INFECT DIS, V159, P50, DOI 10.1093/infdis/159.1.50; Vazquez-Flores S, 2001, SALUD PUBLICA MEXICO, V43, P574, DOI 10.1590/S0036-36342001000600009; WANG CY, 1992, HYBRIDOMA, V11, P825; White AC, 2002, CLIN INFECT DIS, V34, P1627; WILSON M, 1991, J INFECT DIS, V164, P1007, DOI 10.1093/infdis/164.5.1007; World Health Organization, 2002, WHO TECH REP SER, P1; ZINI D, 1990, J NEUROL NEUROSUR PS, V53, P656, DOI 10.1136/jnnp.53.8.656	54	73	78	0	9	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0001-706X	1873-6254		ACTA TROP	Acta Trop.	JUN	2003	87	1					79	86		10.1016/S0001-706X(03)00058-5				8	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	690XX	WOS:000183576700011	12781381				2019-03-26	
J	Ito, A; Yamasaki, H; Nakao, M; Sako, Y; Okamoto, M; Sato, MO; Nakaya, K; Margono, SS; Ikejima, T; Kassuku, AA; Afonso, SMS; Ortiz, WB; Plancarte, A; Zoli, A; Geerts, S; Craig, PS				Ito, A; Yamasaki, H; Nakao, M; Sako, Y; Okamoto, M; Sato, MO; Nakaya, K; Margono, SS; Ikejima, T; Kassuku, AA; Afonso, SMS; Ortiz, WB; Plancarte, A; Zoli, A; Geerts, S; Craig, PS			Multiple genotypes of Taenia solium - ramifications for diagnosis, treatment and control	ACTA TROPICA			English	Article; Proceedings Paper	International Workshop on Taenia Solium Cysticercosis/Taeniosis with Special Focus on Eastern and Southern Africa	AUG 19-22, 2002	ARUSHA, TANZANIA	Cysticercosis Working Grp Eastern & SO Africa		Taenia solium; cestode zoonosis; cysticercosis; taeniosis; mitochondrial DNA; DNA polymorphism	PHYLOGENETIC HYPOTHESIS; DIFFERENTIAL-DIAGNOSIS; HUMAN CYSTICERCOSIS; MITOCHONDRIAL-DNA; RIBOSOMAL DNA; TAIWAN TAENIA; NEUROCYSTICERCOSIS; SEQUENCE; CESTODE; CYCLOPHYLLIDEA	Mitochondrial DNA sequences of Taenia solium have fully been analyzed. Analysis of the full length of cytochrome c oxidase subunit 1 (1620 bp) and cytochrome b (1068 bp) genes of T solium, isolated from Asia (China, Thailand, Indonesia and India), from Latin America (Mexico, Ecuador, Bolivia, Peru and Brazil) and from Africa (Tanzania, Mozambique and Cameroon), has revealed that the two phylogenies obtained were similar to each other regardless of the genes examined. The isolates from Asia formed a single cluster, whereas those from Latin America combined with those from Africa to form an additional cluster. It was estimated that these two genotypes emerged approximately 4-8 x 10(5) years ago. These results together with recent study of the ancient of human taeniid cestodes emerged several MYA in Africa, historical data on swine domestication, distribution of pigs and colonization patterns suggest that T solium was introduced recently into Latin America and Africa from different regions of Europe during the colonial age, which started 500 years ago, and that T solium of another origin independently spread in Asian countries, perhaps from China. Why did not T solium of European origin invade or spread into Asia during the colonial age? Analysis of T. solium distribution must include other Taenia species, especially T saginata and T asiatica, which can not be differentiated from each other morphologically. BESS T-base analysis for differentiation of all human Taenia species including the two genotypes of T. solium, and T saginata and T asiatica has also been characterized. BESS T-base analysis differentiates African isolates from Latin American isolates as well but more samples should be analyzed for obtaining conclusive evidence for the latter. Serological analysis of cyst fluid of T solium cysticerci obtained in China and Indonesia and from Mozambique and Ecuador indicates geographical differences in their banding patterns. These differences are discussed in the light of possible differences in pathology of T solium worldwide. As it has been speculated that the ancient T. solium emerged several million years ago in Africa, it is necessary to analyze more isolates from Africa. Such working hypothesis may be evaluated combined with symptomatology and serology when we get additional DNA data from such areas, since there are some varieties of manifestation of neurocysticercosis with or without subcutaneous cysticercosis and of antigens of cyst fluid of T solium from Asia and from Africa and/or America. Transfer of techniques of molecular identification and sero- and immuno-diagnoses between researchers and technicians from endemic countries using their own materials should be promoted with the aim of better international cooperation for the control of cysticercosis. (C) 2003 Elsevier Science B.V. All rights reserved.	Asahikawa Med Coll, Dept Parasitol, Asahikawa, Hokkaido 0788510, Japan; Univ Salford, Sch Environm & Life Sci, Biosci Res Inst, Manchester, England; Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium; Univ Dschang, Dschang, Cameroon; Univ Nacl Autonoma Mexico, Fac Med, Dept Microbiol & Parasitol, Mexico City 04510, DF, Mexico; Univ Cent Ecuador, Ctr Int Zoonosis, Quito, Ecuador; Eduardo Mondlane Univ, Fac Vet, Para Clin Dept, Maputo, Mozambique; Sokoine Univ Agr, Dept Vet Microbiol & Parasitol, Morogoro, Tanzania; Shenyang Pharmaceut Univ, China Japan Inst Med & Pharmaceut Sci, Shenyang, Peoples R China; Univ Indonesia, Fac Med, Dept Parasitol, Jakarta, Indonesia; Asahikawa Med Coll, Anim Lab Med Res, Asahikawa, Hokkaido 078, Japan; Tottori Univ, Sch Vet Med, Dept Lab Anim Sci, Tottori 680, Japan	Ito, A (reprint author), Asahikawa Med Coll, Dept Parasitol, Asahikawa, Hokkaido 0788510, Japan.	akiraito@asahikawa-med.ac.jp	ito, akira/E-9377-2014; Sato, Marcello/F-7674-2014	ito, akira/0000-0002-5070-9187; Sato, Marcello/0000-0002-9204-0602; Geerts, Stanny/0000-0001-9885-8846			BAER JEAN G., 1940, JOUR PARASITOL, V26, P127, DOI 10.2307/3272379; BOA ME, 1995, J HELMINTHOL, V69, P113, DOI 10.1017/S0022149X00013997; BOWLES J, 1994, AM J TROP MED HYG, V50, P33; Bradley DG, 1996, P NATL ACAD SCI USA, V93, P5131, DOI 10.1073/pnas.93.10.5131; CAMERON T, 1956, PARASITES PARASITISM, P1; CLUTTONBROCK J, 1987, BRIT MUSEUM NATURAL, P1; Craig PS, 1996, ADV PARASIT, V38, P169, DOI 10.1016/S0065-308X(08)60035-4; CRUZ I, 1994, AM J TROP MED HYG, V51, P405, DOI 10.4269/ajtmh.1994.51.405; DUMAS M, 1990, B SOC PATHOL EXOT, V83, P263; Eom Keeseon S., 1993, Korean Journal of Parasitology, V31, P1; Eom Keeseon S., 2001, Korean Journal of Parasitology, V39, P267; Eom KS, 2002, J PARASITOL, V88, P758, DOI 10.1645/0022-3395(2002)088[0758:IOTAIC]2.0.CO;2; Epstein H, 1984, EVOLUTION DOMESTICAT, P145; Fan P.C., 1988, CHINESE J PARASITOLO, V1, P56; FAN P-C, 1990, Yonsei Reports on Tropical Medicine, V21, P39; FAN PC, 1988, PARASITOL TODAY, V4, P86, DOI 10.1016/0169-4758(88)90204-9; FAN PC, 1990, J HELMINTHOL, V64, P223, DOI 10.1017/S0022149X00012207; Fan PC, 1995, J HELMINTHOL, V69, P299, DOI 10.1017/S0022149X00014863; FENG Y, 1979, CHINESE MED J-PEKING, V92, P770; GASSER RB, 1995, ACTA TROP, V59, P31, DOI 10.1016/0001-706X(94)00085-F; Gasser RB, 1999, ELECTROPHORESIS, V20, P2834, DOI 10.1002/(SICI)1522-2683(19991001)20:14<2834::AID-ELPS2834>3.0.CO;2-F; Geerts S, 2002, NATO SCI SER I LIFE, V341, P13; Gonzalez LM, 2000, J CLIN MICROBIOL, V38, P737; Hancock K, 2001, INT J PARASITOL, V31, P1601, DOI 10.1016/S0020-7519(01)00295-8; Hoberg EP, 2001, P ROY SOC B-BIOL SCI, V268, P781, DOI 10.1098/rspb.2000.1579; Hoberg EP, 2000, J PARASITOL, V86, P89, DOI 10.1645/0022-3395(2000)086[0089:APHFSO]2.0.CO;2; Ito A, 2001, Southeast Asian J Trop Med Public Health, V32 Suppl 2, P85; Ito A, 2002, NATO SCI SER I LIFE, V341, P25; Ito A, 1997, PARASITOLOGY, V114, P85, DOI 10.1017/S0031182096008074; Ito Akira, 2002, P47, DOI 10.1079/9780851996288.0047; JAEGER JJ, 1986, CR ACAD SCI II, V302, P917; Le TH, 2002, TRENDS PARASITOL, V18, P206, DOI 10.1016/S1471-4922(02)02252-3; Nakao M, 2002, MITOCHONDRION, V1, P497, DOI 10.1016/S1567-7249(02)00040-5; Nakao M, 2002, PARASITOLOGY, V124, P657, DOI 10.1017/S0031182002001725; Nakao M, 2000, MOL BIOCHEM PARASIT, V111, P415, DOI 10.1016/S0166-6851(00)00334-0; Nguekam JP, 2003, TROP MED INT HEALTH, V8, P144, DOI 10.1046/j.1365-3156.2003.01000.x; Okamoto M, 2001, Southeast Asian J Trop Med Public Health, V32 Suppl 2, P90; Overbosch D, 2002, NATO SCI SER I LIFE, V341, P33; Pearson M, 2002, NATO SCI SER I LIFE, V341, P205; Schantz P M, 1993, Bull Pan Am Health Organ, V27, P397; Schantz P.M., 1998, EMERG INFECT DIS, V2, P213; SCHANTZ PM, 1992, NEW ENGL J MED, V327, P692, DOI 10.1056/NEJM199209033271004; Simanjuntak GM, 1997, PARASITOL TODAY, V13, P321, DOI 10.1016/S0169-4758(97)01104-6; Singh SN, 2002, EUR T ELECTR POWER, V12, P127, DOI 10.1002/etep.4450120207; Vilhena M, 1999, AM J TROP MED HYG, V61, P59, DOI 10.4269/ajtmh.1999.61.59; White AC, 1997, CLIN INFECT DIS, V24, P101, DOI 10.1093/clinids/24.2.101; Wouters G., 1987, Helminth zoonoses., P76; Yamasaki H, 2002, J CLIN MICROBIOL, V40, P3818, DOI [10.1128/JCM.40.10.3818-3821.2002, 10.1128/JCM.40.10.3818-3821-2002]; YAMASAKI H, 2002, P ICOPA, V10, P189; ZARLENGA DS, 1991, EXP PARASITOL, V72, P174, DOI 10.1016/0014-4894(91)90135-J	50	45	48	1	14	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0001-706X	1873-6254		ACTA TROP	Acta Trop.	JUN	2003	87	1					95	101		10.1016/S0001-706X(03)00024-X				7	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	690XX	WOS:000183576700013	12781383				2019-03-26	
J	Rwagacondo, CE; Niyitegeka, F; Sarushi, J; Karema, C; Mugisha, V; Dujardin, JC; Van Overmeir, C; van den Ende, J; D'Alessandro, U				Rwagacondo, CE; Niyitegeka, F; Sarushi, J; Karema, C; Mugisha, V; Dujardin, JC; Van Overmeir, C; van den Ende, J; D'Alessandro, U			Efficacy of amodiaquine alone and combined with sulfadoxine-pyrimethamine and of sulfadoxine pyrimethamine combined with artesunate	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							ANTIMALARIAL-DRUG-RESISTANCE; PLASMODIUM-FALCIPARUM MALARIA; COMBINATION CHEMOTHERAPY; UNCOMPLICATED MALARIA; GAMBIAN CHILDREN; TRIAL; CHLOROQUINE; POLICY; THERAPY; AFRICA	The safety and the efficacy of amodiaquine (AQ) alone, AQ plus sulfadoxine-pyrimethamine (SP) (AQ plus SP), and artesunate (ART) plus SP (ART plus SP), three possible alternatives to chloroquine (CQ), were investigated in 379 Rwandan children 6-59 months old with uncomplicated Plasmodium falciparum malaria who visited one urban/peri-urban health center and two rural health centers. The three treatment regimens were well tolerated and no serious adverse effects were observed. Children treated with AQ plus SP had less clinical failures than those treated with ART plus SP (odds ratio [OR]=0.25, 95% confidence interval [CI]=0.06-0.81, P=0.01) or AQ alone (OR=0.33, 95% CI=0.07-1.10, P=0.08). Even after new infections were excluded, AQ plus SP was still significantly more efficacious than ART plus SP (P=0.05). At day 14, the mean packed cell volume was significantly higher in the AQ plus SP group compared with the ART plus SP group (P=0.02) and with the AQ alone group (P=0.01). In Rwanda, AQ plus SP has been chosen to replace CQ as a first-line treatment. However, this is considered an interim measure and new combinations, possibly co-formulated, should be identified and tested.	Natl Malaria Control Program, Kigali, Rwanda; Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium	Rwagacondo, CE (reprint author), Natl Malaria Control Program, Kigali, Rwanda.		D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009			Adjuik M, 2002, LANCET, V359, P1365, DOI 10.1016/S0140-6736(02)08348-4; BLOLAND PB, 1993, J INFECT DIS, V167, P932, DOI 10.1093/infdis/167.4.932; Doherty JF, 1999, T ROY SOC TROP MED H, V93, P543, DOI 10.1016/S0035-9203(99)90376-0; Greenwood B, 2002, TROP MED INT HEALTH, V7, P1012, DOI 10.1046/j.1365-3156.2002.00980.x; Hastings IM, 2000, PARASITOL TODAY, V16, P340, DOI 10.1016/S0169-4758(00)01707-5; Irion A, 1998, TROP MED INT HEALTH, V3, P490, DOI 10.1046/j.1365-3156.1998.00253.x; Magesa SM, 2002, ACTA TROP, V84, P83, DOI 10.1016/S0001-706X(02)00179-1; MCINTOSH HM, 2002, COCHRANE LIB; *MIN SANT, 1999, RAPP ANN 1998 MIN SA; Nosten F, 2000, LANCET, V356, P297, DOI 10.1016/S0140-6736(00)02505-8; OLLIARO P, 2002, COCHRANE LIB; Shretta R, 2000, TROP MED INT HEALTH, V5, P755, DOI 10.1046/j.1365-3156.2000.00643.x; Staedke SG, 2001, LANCET, V358, P368, DOI 10.1016/S0140-6736(01)05557-X; Trape JF, 2001, AM J TROP MED HYG, V64, P12, DOI 10.4269/ajtmh.2001.64.12; von Seidlein L, 2000, LANCET, V355, P352, DOI 10.1016/S0140-6736(99)10237-X; White N, 1999, PHILOS T R SOC B, V354, P739, DOI 10.1098/rstb.1999.0426; White N J, 1998, Med Trop (Mars), V58, P54; White NJ, 1996, PARASITOL TODAY, V12, P399, DOI 10.1016/0169-4758(96)10055-7; White NJ, 1998, DRUG RESIST UPDATE, V1, P3, DOI 10.1016/S1368-7646(98)80208-2; *WHO, 1993, IMPL GLOB MAL CONTR; *WHO, 1996, WHOMAL961077; Wongsrichanalai C, 2000, LANCET, V355, P2245, DOI 10.1016/S0140-6736(00)02416-8; World Health Organization, 1990, T R SOC TROP MED S2, V84, P1, DOI DOI 10.1016/0035-9203(90)90363-J	23	54	55	0	0	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	JUN	2003	68	6					743	747		10.4269/ajtmh.2003.68.743				5	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	699UZ	WOS:000184075500024	12887037				2019-03-26	
J	Couvreur, B; Bollen, A; Le Ray, D; Dujardin, JC				Couvreur, B; Bollen, A; Le Ray, D; Dujardin, JC			Reverse transcription-polymerase chain reaction construction of plasmid-based, full-length cDNA libraries from Leishmania infantum for in vitro expression screening	MEMORIAS DO INSTITUTO OSWALDO CRUZ			English	Article						kinetoplastid; cDNA libraries; spliced leader	BRUGIA-MALAYI; PARASITE; CLONING; UPDATE; RNA	We describe a streamlined reverse transcription-polymerase chain reaction methodology for constructing full-length cDNA libraries of trypanosomatids on the basis of conserved sequences located at the 5' and 3' ends of trans-spliced mRNAs. The amplified cDNA corresponded to full-length messengers and was amenable to in vitro expression. Fractionated libraries could be rapidly constructed in a plasmid vector by the TA cloning method (Invitrogen). We believe this is useful when there are concerns over the use of restriction enzymes and phage technology as well as in cases where expression of proteins in their native conformation is desired.	Free Univ Brussels, IBMM, Lab Appl Genet, Gosselies, Belgium; Inst Trop Med Prince Leopold, Dept Parasitol, Lab Protozool, B-2000 Antwerp, Belgium	Couvreur, B (reprint author), Vet & Agrochem Res Ctr, Groeselenberg 99, B-1180 Brussels, Belgium.						AJIOKA JW, 1995, METHODS MOL GENETICS, V6, P30; BARRY MA, 1995, NATURE, V377, P632, DOI 10.1038/377632a0; Blaxter ML, 1996, MOL BIOCHEM PARASIT, V77, P77, DOI 10.1016/0166-6851(96)02571-6; BONEN L, 1993, FASEB J, V7, P40; Devaney E, 1996, PARASITOL TODAY, V12, P418, DOI 10.1016/0169-4758(96)10065-X; ELSAYED NMA, 1995, MOL BIOCHEM PARASIT, V73, P75, DOI 10.1016/0166-6851(95)00098-L; Fernandez C, 2002, MOL BIOCHEM PARASIT, V122, P171, DOI 10.1016/S0166-6851(02)00098-1; Gregory WF, 1997, MOL BIOCHEM PARASIT, V87, P85, DOI 10.1016/S0166-6851(97)00050-9; HAMES BD, 1990, GEL ELECTROPHORESIS; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Levick MP, 1996, MOL BIOCHEM PARASIT, V76, P345, DOI 10.1016/0166-6851(95)02569-3; Magnuson VL, 1996, BIOTECHNIQUES, V21, P700, DOI 10.2144/96214rr03; NILSEN TW, 1995, MOL BIOCHEM PARASIT, V73, P1, DOI 10.1016/0166-6851(94)00107-X; OFVERSTEDT LG, 1984, BIOCHIM BIOPHYS ACTA, V782, P120, DOI 10.1016/0167-4781(84)90014-9; RICCA GA, 1981, J BIOL CHEM, V256, P362; Sambrook J., 1989, MOL CLONING LAB MANU	16	0	1	0	0	FUNDACO OSWALDO CRUZ	RIO DE JANEIRO, RJ	AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL	0074-0276			MEM I OSWALDO CRUZ	Mem. Inst. Oswaldo Cruz	JUN	2003	98	4					477	480		10.1590/S0074-02762003000400008				4	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	698HN	WOS:000183993100008	12937757	DOAJ Gold			2019-03-26	
J	Lafort, Y; Sawadogo, Y; Delvaux, T; Vuylsteke, B; Laga, M				Lafort, Y; Sawadogo, Y; Delvaux, T; Vuylsteke, B; Laga, M			Should family planning clinics provide clinical services for sexually transmitted infections? A case study from Cote d'Ivoire	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						family planning; sexually transmitted infections; integration; Cote d'Ivoire; case management; human immunodeficiency virus prevention	BACTERIAL VAGINOSIS; CASE-MANAGEMENT; RISK-FACTORS; HEALTH; DISEASES; WOMEN; HIV; TRANSMISSION; INTEGRATION; PREVENTION	OBJECTIVES To evaluate the quality and usefulness of integrated sexually transmitted infection (STI) care at non-governmental family planning (FP) clinics in Cote d'Ivoire. METHODS Evaluation components included: (1) a survey measuring the prevalence of STI and the predictive value of the Ivorian vaginal discharge treatment algorithm, (2) client exit interviews, (3) direct observations of client-provider contacts, (4) the monitoring of the clinics' workload and available equipment and supplies and (5) interviews of programme managers and FP providers. RESULTS Among 368 FP clients surveyed, the prevalence of Neisseria gonorrhoeae, Chlamydia trachomatis, Trichomonas vaginalis, B. vaginosis and Candida albicans were respectively 1.6, 5.7, 7.1, 44.8 and 5.2%. The positive predictive value of the national algorithm for the detection of cervicitis was only 6.3%, and was 17.9% among a subgroup of young, single women. Of 200 clients interviewed, 96% were satisfied with the services and 95% would return to the FP clinic if they had genital problems. In 215 observed client-provider contacts, 88% of 94 STI cases were correctly managed. Programme managers and providers reported no substantial work overload as a result of the integration of STI services. CONCLUSIONS The prevalence of cervical infections is relatively low in this population and the Ivorian algorithm that treats all women with vaginal discharge performs poorly. Over-treatment of cervicitis can be reduced by modifying the algorithm, although improved diagnostic tools are urgently needed to detect cervicitis in this population. Continued STI case management at the FP clinics is nevertheless justified because there exists an easily identifiable group of higher risk women who need STI care; and because of the demand by a large proportion of clients, the high prevalence of vaginal pathogens, and the limited costs to the FP programme.	Inst Trop Med, STD HIV Res & Intervent Unit, B-2000 Antwerp, Belgium; Family Hlth Int, Abidjan, Cote Ivoire	Lafort, Y (reprint author), POB 2498, Mbabane, Swaziland.						Behets FMT, 1998, SEX TRANSM INFECT, V74, pS123; Cotch MF, 1997, SEX TRANSM DIS, V24, P353, DOI 10.1097/00007435-199707000-00008; Dallabetta GA, 1998, SEX TRANSM INFECT, V74, pS1; DALY CC, 1994, GENITOURIN MED, V70, P155; Dehne KL, 2000, B WORLD HEALTH ORGAN, V78, P628; Fleming DT, 1999, SEX TRANSM INFECT, V75, P3, DOI 10.1136/sti.75.1.3; Franco LM, 1997, B WORLD HEALTH ORGAN, V75, P523; Iskandar MB, 2000, INT J STD AIDS, V11, P180, DOI 10.1258/0956462001915499; KAPIGA SH, 1998, SEX TRANSM INFECT S1, V74, P132; Kisubi W, 1997, AFRICAN RESPONSE CHA; Koumans EH, 2001, SEX TRANSM DIS, V28, P292, DOI 10.1097/00007435-200105000-00011; LAGA M, 1993, AIDS, V7, P95, DOI 10.1097/00002030-199301000-00015; Mayhew SH, 2000, STUD FAMILY PLANN, V31, P151, DOI 10.1111/j.1728-4465.2000.00151.x; Morris M, 2001, BRIT J OBSTET GYNAEC, V108, P439; NUGENT RP, 1991, J CLIN MICROBIOL, V29, P297; *PROGR NATL LUTT S, 1997, PRIS CHARG MST CONT; Saidel TJ, 1998, AIDS, V12, pS57; Shelton JD, 1999, INT FAM PLAN PERSPEC, V25, P147, DOI 10.2307/2991964; Sloan NL, 2000, STUD FAMILY PLANN, V31, P55, DOI 10.1111/j.1728-4465.2000.00055.x; Taha TE, 1998, AIDS, V12, P1699, DOI 10.1097/00002030-199813000-00019; TEMMERMAN M, 1994, CURR OPIN INFECT DIS, V7, P20, DOI 10.1097/00001432-199402000-00004; Tyndall MW, 1999, SEX TRANSM DIS, V26, P476, DOI 10.1097/00007435-199909000-00010; *UNFPA, 1994, INT C POP DEV CAIR E; *USAID, 1998, INT FAM PLANN MCH HI; VUYLSTEKE B, 1993, CLIN INFECT DIS, V17, P82, DOI 10.1093/clinids/17.1.82; Welsh M, 1997, E AFR MED J, V74, P764	26	4	4	0	2	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	JUN	2003	8	6					552	560		10.1046/j.1365-3156.2003.01065.x				9	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	686YQ	WOS:000183348900009	12791061	Bronze			2019-03-26	
J	van der Werf, MJ; de Vlas, SJ; Brooker, S; Looman, CWN; Nagelkerke, NJD; Habbema, JDF; Engels, D				van der Werf, MJ; de Vlas, SJ; Brooker, S; Looman, CWN; Nagelkerke, NJD; Habbema, JDF; Engels, D			Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa	ACTA TROPICA			English	Article; Proceedings Paper	Meeting of the Joint WHO Expert Committees on the prevention and Control of Schistosomiasis and Soil-Transmitted Helminthiasis	APR, 2002	GENEVA, SWITZERLAND	WHO		Schistosoma mansoni; Schistosoma haematobium; schistosomiasis; morbidity; pathology	URINARY-TRACT MORBIDITY; HAEMATOBIUM INFECTION; BLADDER-CANCER; COMMUNITY PREVALENCE; HELMINTH INFECTION; EGG COUNTS; MANSONI; SCHOOLCHILDREN; QUESTIONNAIRES; EGYPT	Health policy making in developing countries requires estimates of the (global) burden of disease. At present, most of the available data on schistosomiasis is limited to numbers of individuals harbouring the infection. We explored the relationship between the presence of schistosome infection and clinical morbidity, in order to estimate numbers of individuals with disease-specific morbidity for Schistosoma haematobium and Schistosoma mansoni infection in sub-Saharan Africa. We searched the literature for cross-sectional data from field studies reporting both schistosome infection and morbidity. This was used to derive a functional relationship between morbidity and infection. After standardisation for diagnostic method, the number of individuals with specific types of clinical morbidity or pathology was predicted. As only aggregated prevalences of infection were available for countries or areas, we adjusted for heterogeneity in infection levels within communities in those countries. In total, 70 million individuals out of 682 million (2000 estimate) in sub-Saharan Africa were estimated to experience haematuria in the last 2 weeks associated with S. haematobium infection, and 32 million dysuria. Ultrasound detected serious consequences of S. haematobium, major bladder wall pathology and major hydronephrosis, were predicted at 18 and 10 million, respectively. Infection with S. mansoni was estimated to cause diarrhoea in 0.78 million individuals, blood in stool in 4.4 million and hepatomegaly in 8.5 million. As the associations between prevalence of S. mansoni infection and prevalence of diarrhoea and blood in stool were not very clear, the resulting estimates may be underestimations. Using the very limited data available, we estimated the mortality rates due to non-functioning kidney (from S. haematobium) and haematemesis (from S. mansoni) at 150 000 and 130 000 per year. Given the overall high number of cases with schistosomiasis-related disease and associated death, we conclude that schistosomiasis remains an important public health problem in sub-Saharan Africa. (C) 2003 Elsevier Science B.V. All rights reserved.	Erasmus Univ, Med Ctr, Dept Publ Hlth, NL-3000 DR Rotterdam, Netherlands; Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium; Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Infect Dis Epidemiol, London W2 1PG, England; WHO, Parasit Dis & Vector Control, Communicable Dis Control, CH-1211 Geneva 27, Switzerland	van der Werf, MJ (reprint author), Erasmus Univ, Med Ctr, Dept Publ Hlth, POB 1738, NL-3000 DR Rotterdam, Netherlands.						Abdel-Wahab MF, 2000, AM J TROP MED HYG, V62, P55, DOI 10.4269/ajtmh.2000.62.55; ABDELSALAM E, 1977, AM J TROP MED HYG, V26, P463, DOI 10.4269/ajtmh.1977.26.463; ABDELWAHAB MF, 1992, T ROY SOC TROP MED H, V86, P406, DOI 10.1016/0035-9203(92)90241-4; Barakat R, 1995, TROP GEOGR MED, V47, P259; Bedwani R, 1998, BRIT J CANCER, V77, P1186, DOI 10.1038/bjc.1998.197; Booth M, 1998, PARASITOLOGY, V116, P85, DOI 10.1017/S003118209700190X; Booth M, 1998, T ROY SOC TROP MED H, V92, P484, DOI 10.1016/S0035-9203(98)90884-7; Brooker S, 2002, TRENDS PARASITOL, V18, P70, DOI 10.1016/S1471-4922(01)02223-1; Brooker S, 2000, PARASITOL TODAY, V16, P303, DOI 10.1016/S0169-4758(00)01687-2; Brooker S, 2000, B WORLD HEALTH ORGAN, V78, P1456; Chan MS, 1996, AM J TROP MED HYG, V55, P52, DOI 10.4269/ajtmh.1996.55.52; CHAN MS, 1994, PARASITOLOGY, V109, P373, DOI 10.1017/S0031182000078410; Chen M. G., 1989, Tropical Diseases Bulletin, V86, pR1; Chen M. G., 1988, Tropical Diseases Bulletin, V85, pR1; Chitsulo L, 2000, ACTA TROP, V77, P41, DOI 10.1016/S0001-706X(00)00122-4; Crompton DWT, 1999, J PARASITOL, V85, P397, DOI 10.2307/3285768; deSilva NR, 1997, TROP MED INT HEALTH, V2, P519; DEVLAS SJ, 1992, PARASITOLOGY, V104, P451, DOI 10.1017/S003118200006371X; DEVLAS SJ, 1992, PARASITOL TODAY, V8, P274, DOI 10.1016/0169-4758(92)90144-Q; Doumenge J., 1987, ATLAS REPARTITION MO, P400; EFRON B, 1993, INTRO BOOTSTRAP, P412; Ekanem E. E., 1994, Central African Journal of Medicine, V40, P38; FORSYTH D. M., 1964, LANCET, P169; Forsyth D M, 1970, Lancet, V2, P472; FORSYTH DM, 1966, B WORLD HEALTH ORGAN, V34, P715; FORSYTH DM, 1969, B WORLD HEALTH ORGAN, V40, P771; Gabr NS, 2000, AM J TROP MED HYG, V62, P65, DOI 10.4269/ajtmh.2000.62.2_suppl.10813502; GRYSEELS B, 1991, PARASITOL TODAY, V7, P244, DOI 10.1016/0169-4758(91)90238-J; GRYSEELS B, 1989, TROP MED PARASITOL, V40, P134; GRYSEELS B, 1992, TROP GEOGR MED, V44, P189; GRYSEELS B, 1988, ANN TROP MED PARASIT, V82, P581, DOI 10.1080/00034983.1988.11812294; Guyatt H, 1999, TROP MED INT HEALTH, V4, P751, DOI 10.1046/j.1365-3156.1999.00483.x; Guyatt HL, 1999, PARASITOLOGY, V118, P257, DOI 10.1017/S0031182098003862; GUYATT HL, 1991, T ROY SOC TROP MED H, V85, P778, DOI 10.1016/0035-9203(91)90453-6; Hammam HM, 2000, AM J TROP MED HYG, V62, P73, DOI 10.4269/ajtmh.2000.62.2_suppl.10813503; Hammam HM, 2000, AM J TROP MED HYG, V62, P80, DOI 10.4269/ajtmh.2000.62.80; IAROTSKI LS, 1981, B WORLD HEALTH ORGAN, V59, P115; JORDAN P, 1993, HUMAN SCHISTOSOMIASI, P442; Kheir MM, 1999, AM J TROP MED HYG, V60, P307, DOI 10.4269/ajtmh.1999.60.307; KIIRE CF, 1989, BRIT MED J, V298, P1363, DOI 10.1136/bmj.298.6684.1363; KING CH, 1988, AM J TROP MED HYG, V39, P361, DOI 10.4269/ajtmh.1988.39.361; KITINYA JN, 1986, T ROY SOC TROP MED H, V80, P935, DOI 10.1016/0035-9203(86)90264-6; KVALSVIG JD, 1986, J TROP MED HYG, V89, P85; KVALSVIG JD, 1988, PARASITOL TODAY, V4, P206, DOI 10.1016/0169-4758(88)90158-5; LENGELER C, 1991, INT J EPIDEMIOL, V20, P796, DOI 10.1093/ije/20.3.796; Lengeler C, 2000, ACTA TROP, V74, P77, DOI 10.1016/S0001-706X(99)00046-7; LUCAS SB, 1982, E AFR MED J, V59, P345; MASABA SC, 1983, J TROP MED HYG, V86, P65; Medley GF, 1996, AM J TROP MED HYG, V55, P149, DOI 10.4269/ajtmh.1996.55.149; Mostafa MH, 1999, CLIN MICROBIOL REV, V12, P97, DOI 10.1128/CMR.12.1.97; MUNGOMBA LM, 1995, ANN TROP MED PARASIT, V89, P439, DOI 10.1080/00034983.1995.11812973; MURRAY CJ, 1996, GLOBAL BURDEN DIS CO, P990; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; NOKES C, 1994, PARASITOL TODAY, V10, P14, DOI 10.1016/0169-4758(94)90348-4; Richter J, 1998, TROP MED INT HEALTH, V3, P728, DOI 10.1046/j.1365-3156.1998.00285.x; Savioli L, 1997, PARASITOL TODAY, V13, P444, DOI 10.1016/S0169-4758(97)01141-1; STEPHENSON LS, 1985, AM J TROP MED HYG, V34, P322, DOI 10.4269/ajtmh.1985.34.322; THOMAS JE, 1990, T ROY SOC TROP MED H, V84, P551, DOI 10.1016/0035-9203(90)90036-E; Traquinho GA, 1998, T ROY SOC TROP MED H, V92, P279, DOI 10.1016/S0035-9203(98)91011-2; Utzinger J, 2000, B WORLD HEALTH ORGAN, V78, P389; Utzinger J, 2001, PARASITOLOGY, V122, P537, DOI 10.1017/S0031182001007752; van der Werf MJ, 2002, ACTA TROP, V82, P127, DOI 10.1016/S0001-706X(02)00007-4; VANDERWERF MJ, UNPUB DIAGNOSIS EARL; WARREN KS, 1979, AM J TROP MED HYG, V28, P864, DOI 10.4269/ajtmh.1979.28.864; World Health Organization, 1993, TECHN REP SER WHO, P86	65	523	530	2	29	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0001-706X			ACTA TROP	Acta Trop.	MAY	2003	86	2-3					125	139		10.1016/S0001-706X(03)00029-9				15	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	685EQ	WOS:000183248200002	12745133				2019-03-26	
J	Virreira, M; Torrico, F; Truyens, C; Alonso-Vega, C; Solano, M; Carlier, Y; Svoboda, M				Virreira, M; Torrico, F; Truyens, C; Alonso-Vega, C; Solano, M; Carlier, Y; Svoboda, M			Comparison of polymerase chain reaction methods for reliable and easy detection of congenital Trypanosoma cruzi infection	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							CHRONIC CHAGASIC PATIENTS; KINETOPLAST MINICIRCLE DNA; HUMAN BLOOD-SAMPLES; REACTION AMPLIFICATION; SENSITIVE DETECTION; MAMMALIAN HOSTS; DIAGNOSIS; DISEASE; PCR; IDENTIFICATION	The polymerase chain reaction (PCR) is a potentially interesting diagnostic tool for detecting congenital Trypanosoma cruzi infection at birth. We have compared the sensitivity and capacity of a group of T. cruzi PCR primers in detecting the complete spectrum of known T cruzi lineages, and to improve and simplify the detection of infection in neonatal blood. We found that the two primers, Tcz1/Tcz2 and Diaz1/Diaz2, which target the 195-basepair satellite repeat, detected all parasitic lineages with the same sensitivity. However, the intensity of the amplicon was somewhat higher with Tcz1/Tcz2. For other tested primers (nuclear DNA primers BP1/BP2, O1/O2, Pon1/Pon2, and Tca1/Tca2 and kinetoplast DNA primers S35'/S36' and 121/122), either the intensity of amplicons varied according to T. cruzi lineages or the PCR assay was less sensitive. The use of the Tcz1/Tcz2 primers, which target a tandem repetitive sequence, requires a careful determination of the appropriate amount of Taq polymerase to avoid the formation of smears and multiple amplicon bands. The Tcz1/Tcz2 primers resulted in an intense 200-basepair amplicon with DNA extracted from blood equivalent to 0.02 parasites per assay when used with a simple DNA extraction method and of a low amount of Taq polymerase from a standard PCR kit. To better assess such PCR protocol, we assayed 311 samples of neonatal blood previously tested by parasitologic methods. The reliability of our PCR test was demonstrated, since all the 18 blood samples from newborns with congenital T. cruzi infection were positive, whereas the remaining samples (30 from control newborns of uninfected mothers and 262 of 263 from babies born to infected mothers) were negative. Since our PCR method is simple, reliable, robust, and inexpensive, it appears suitable for the detection of T. cruzi infection in neonatal blood, even in laboratories that are not equipped for performing the PCR.	Free Univ Brussels, Fac Med, Chim Biol Lab, B-1070 Brussels, Belgium; Free Univ Brussels, Fac Med, Parasitol Lab, Brussels, Belgium; Univ Mayor San Simon, Ctr Univ Med Trop, Lab Med, Fac Med, Cochabamba, Bolivia	Virreira, M (reprint author), Free Univ Brussels, Fac Med, Chim Biol Lab, 808 Route Lennik, B-1070 Brussels, Belgium.						Aguero F, 2000, GENOME RES, V10, P1996, DOI 10.1101/gr.GR-1463R; Antas PRZ, 1999, AM J TROP MED HYG, V61, P308, DOI 10.4269/ajtmh.1999.61.308; AVILA HA, 1991, MOL BIOCHEM PARASIT, V48, P211, DOI 10.1016/0166-6851(91)90116-N; BASSO B, 1984, MEDICINA-BUENOS AIRE, V44, P41; Bastrenta B, 1999, MEM I OSWALDO CRUZ, V94, P323, DOI 10.1590/S0074-02761999000300008; Bittencourt A.L., 2000, TRYPANOSOMA CRUZI DO, P16; BRENIERE SF, 1992, AM J TROP MED HYG, V46, P335, DOI 10.4269/ajtmh.1992.46.335; BRENIERE SF, 1985, TROP GEOGR MED, V37, P231; Brisse S, 2000, INT J PARASITOL, V30, P35, DOI 10.1016/S0020-7519(99)00168-X; BRITTO C, 1995, PARASITOLOGY, V110, P241, DOI 10.1017/S0031182000080823; Britto C, 1995, EXP PARASITOL, V81, P462, DOI 10.1006/expr.1995.1139; BRITTO C, 1993, MEM I OSWALDO CRUZ, V88, P171, DOI 10.1590/S0074-02761993000100030; Carlier Y., 2002, ENCY MED CHIR MALADI, P8; Carriazo CS, 1998, DIAGN MICR INFEC DIS, V30, P183, DOI 10.1016/S0732-8893(97)00238-1; CENTURIONLARA A, 1994, J INFECT DIS, V170, P1334, DOI 10.1093/infdis/170.5.1334; DIAZ C, 1992, AM J TROP MED HYG, V46, P616, DOI 10.4269/ajtmh.1992.46.616; Dorn PL, 1997, MEM I OSWALDO CRUZ, V92, P253, DOI 10.1590/S0074-02761997000200020; Freilij H., 1983, Journal of Clinical Microbiology, V18, P327; Gomes ML, 1999, AM J TROP MED HYG, V60, P205, DOI 10.4269/ajtmh.1999.60.205; Kirchhoff LV, 1996, J CLIN MICROBIOL, V34, P1171; Marcon GEB, 2002, DIAGN MICR INFEC DIS, V43, P39, DOI 10.1016/S0732-8893(02)00366-8; MOSER DR, 1989, J CLIN MICROBIOL, V27, P1477; REQUENA JM, 1992, MOL BIOCHEM PARASIT, V51, P271, DOI 10.1016/0166-6851(92)90077-W; Ribeiro-Dos-Santos G, 1999, ANN TROP MED PARASIT, V93, P689, DOI 10.1080/00034989957934; Russomando G, 1998, AM J TROP MED HYG, V59, P487, DOI 10.4269/ajtmh.1998.59.487; RUSSOMANDO G, 1992, J CLIN MICROBIOL, V30, P2864; Silber AM, 1997, EXP PARASITOL, V85, P225, DOI 10.1006/expr.1996.4141; STURM NR, 1989, MOL BIOCHEM PARASIT, V33, P205, DOI 10.1016/0166-6851(89)90082-0; Vallejo GA, 1999, ACTA TROP, V72, P203, DOI 10.1016/S0001-706X(98)00085-0; VEAS F, 1991, CELL MOL BIOL, V37, P73; WINCKER P, 1994, AM J TROP MED HYG, V51, P771, DOI 10.4269/ajtmh.1994.51.771	31	111	115	0	3	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	MAY	2003	68	5					574	582		10.4269/ajtmh.2003.68.574				9	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	681QX	WOS:000183047800018	12812349	Bronze			2019-03-26	
J	Talisuna, AO; Langi, P; Mutabingwa, TK; Watkins, W; Van Marck, E; Egwang, TG; D'Alessandro, U				Talisuna, AO; Langi, P; Mutabingwa, TK; Watkins, W; Van Marck, E; Egwang, TG; D'Alessandro, U			Population-based validation of dihydrofolate reductase gene mutations for the prediction of sulfadoxine-pyrimethamine resistance in Uganda	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						malaria; Plasmodium falciparum; chemotherapy; drug resistance; sulfadoxine-pyrimethamine; dhfr gene mutations; Uganda	PLASMODIUM-FALCIPARUM MALARIA; POINT MUTATIONS; IN-VITRO; DIHYDROPTEROATE SYNTHETASE; CHLORPROGUANIL-DAPSONE; CYCLOGUANIL; SYNTHASE; MUTANTS; AFRICA	Mutations in the dihydrofolate reductase gene (dhfr) of Plasmodium falciparum have been proposed as molecular markers for the surveillance of sulfadoxine-pyrimethamine (SP)-resistant malaria, but such proposals have not been validated. At 7 Ugandan sites in 1999, we determined the population-based prevalence of infections with mutations and the mutant allele frequency of dhfr codons 108, 51, and 59 using a random sample of infected individuals aged 1-45 years. Sulfadoxine-pyrimethamine treatment failure was independently estimated by in vivo tests in 327 children aged 6-59 months with clinical malaria. The prevalence of infections with the single point mutations and the dhfr codons 108 and 51 mutant allele frequency were not correlated to SP treatment failure. However, the dhfr codon 59 mutant allele frequency was positively correlated to SP treatment failure (r = 0.72, P = 0.06). The ratio of the infections with the mutant to wild genotype (M/W) and that of the mutant to wild allele (MA/WA) had the same values. Both dhfr codon 59 M/W and MA/WA ratio were significantly and positively correlated to SP treatment failure (r = 0.73, P = 0.05). Moreover, the prevalence of infections with only 2 mutations (Asn-108 plus Ile-51) was significantly and inversely correlated to the prevalence of infections with 3 mutations (Asn-108 plus Ile-51 plus Arg-59) (r = 0.92, P = 0.004), suggesting the stepwise accumulation of the dhfr mutations is Asn-108 Ile-51 Arg-59 and further supporting the idea of using the dhfr codon 59 M/W ratio as a molecular index for the prediction of SP treatment failure. At the population level, the dhfr codon 59 M/W ratio is a simple and stable index for the estimation of SP treatment failure.	Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium; Minist Hlth, Kampala, Uganda; Natl Inst Med Res, Amani Tanga, Tanzania; London Sch Hyg & Trop Med, Gates Malaria Partnership, London WC1, England; KEMRI Wellcome Trust Collaborat Programme, Nairobi, Kenya; Univ Antwerp, B-2020 Antwerp, Belgium; Med Biotech Labs, Kampala, Uganda	Talisuna, AO (reprint author), Inst Trop Med Prince Leopold, Nationalestr 155, B-2000 Antwerp, Belgium.	atalisuna@itg.be	D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009			BASCO LK, 1995, MOL BIOCHEM PARASIT, V69, P135, DOI 10.1016/0166-6851(94)00207-4; dePecoulas PE, 1996, T ROY SOC TROP MED H, V90, P181, DOI 10.1016/S0035-9203(96)90130-3; Doumbo OK, 2000, J INFECT DIS, V182, P993, DOI 10.1086/315787; Kublin JG, 2002, J INFECT DIS, V185, P380, DOI 10.1086/338566; Mutabingwa T, 2001, LANCET, V358, P1218, DOI 10.1016/S0140-6736(01)06344-9; Nzila-Mounda A, 1998, ANTIMICROB AGENTS CH, V42, P164, DOI 10.1128/AAC.42.1.164; PETERSON DS, 1990, P NATL ACAD SCI USA, V87, P3018, DOI 10.1073/pnas.87.8.3018; PLOWE CV, 1995, AM J TROP MED HYG, V52, P565, DOI 10.4269/ajtmh.1995.52.565; Plowe CV, 1997, J INFECT DIS, V176, P1590, DOI 10.1086/514159; Reeder JC, 1996, AM J TROP MED HYG, V55, P209, DOI 10.4269/ajtmh.1996.55.209; Sibley CH, 2001, TRENDS PARASITOL, V17, P582, DOI 10.1016/S1471-4922(01)02085-2; Sirawaraporn W, 1997, P NATL ACAD SCI USA, V94, P1124, DOI 10.1073/pnas.94.4.1124; Talisuna AO, 2002, T ROY SOC TROP MED H, V96, P310, DOI 10.1016/S0035-9203(02)90108-2; Wang P, 1997, MOL BIOCHEM PARASIT, V89, P161, DOI 10.1016/S0166-6851(97)00114-X; Watkins WM, 1997, PARASITOL TODAY, V13, P459, DOI 10.1016/S0169-4758(97)01124-1; *WHO, 1996, WHOMAL961077	16	13	13	0	1	ROYAL SOC TROPICAL MEDICINE	LONDON	MANSON HOUSE 26 PORTLAND PLACE, LONDON W1N 1EY, ENGLAND	0035-9203			T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	MAY-JUN	2003	97	3					338	342		10.1016/S0035-9203(03)90163-5				5	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	834AM	WOS:000222383800018	15228255				2019-03-26	
J	Remoue, F; Diallo, TO; Angeli, V; Herve, M; de Clercq, D; Schacht, AM; Charrier, N; Capron, M; Vercruysse, J; Ly, A; Capron, A; Riveau, G				Remoue, F; Diallo, TO; Angeli, V; Herve, M; de Clercq, D; Schacht, AM; Charrier, N; Capron, M; Vercruysse, J; Ly, A; Capron, A; Riveau, G			Malaria co-infection in children influences antibody response to schistosome antigens and inflammatory markers associated with morbidity	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						schistosomiasis; malaria; Schistosoma haematobium; Plasmodium falciparum; Senegal	PLASMODIUM-FALCIPARUM MALARIA; MANSONI; DISEASE; INTERLEUKIN-10; ICAM-1; GAMMA; TNF	The epidemiological coexistence of schistosomiasis and malaria is frequently observed in developing countries. Co-infection with malaria in children could influence the development of acquired immunity associated with the resistance or the pathology of schistosomiasis. In the present study, performed during May to June 1996 in Senegal, the humoral immune response to Schistosoma haematobium 28 kDa glutathione S-transferase (Sh28GST) vaccinal antigen and to soluble egg antigens (SEA) has been evaluated in individuals infected by S. haematobium. Specific immunoglobulin G3 (IgG3) and IgE responses were significantly higher in co-infected children with Plasmodium falciparum compared with children infected with S. haematobium only. In addition, circulating levels of interferon-gamma (IFN-gamma), interleukin-10 (IL-10), and soluble tumor necrosis factor receptor II (sTNF-RII), 3 parameters associated with schistosomiasis morbidity, were significantly increased in co-infected children. Taken together, this study indicated that malaria co-infection can both influence the acquired specific immune response to schistosome antigens and unbalance the regulation of inflammatory factors closely involved in schistosomiasis pathology.	Inst Pasteur, INSERM, U547, F-59019 Lille, France; Reg Med St Louis, Programme ESPOIR, St Louis, Senegal; State Univ Ghent, Parasitol Lab, B-9820 Merelbeke, Belgium	Remoue, F (reprint author), Ctr IRD, Inst Rech Dev, UR24, 911 Av Agropolis,BP 64501, F-34394 Montpellier 5, France.	franck.remoue@mpl.ird.fr					AURIAULT C, 1990, J CLIN MICROBIOL, V28, P1918; Capron A, 2001, INT ARCH ALLERGY IMM, V124, P9, DOI 10.1159/000053656; Day NPJ, 1999, J INFECT DIS, V180, P1288, DOI 10.1086/315016; Dickensheets HL, 1997, BLOOD, V90, P4162; Esterre P, 1998, PARASITE IMMUNOL, V20, P369; Fallon PG, 2000, IMMUNOL TODAY, V21, P29, DOI 10.1016/S0167-5699(99)01551-0; Montenegro SML, 1999, J INFECT DIS, V179, P1502, DOI 10.1086/314748; Mutapi F, 2000, PARASITE IMMUNOL, V22, P207, DOI 10.1046/j.1365-3024.2000.00288.x; Mwatha JK, 1998, J IMMUNOL, V160, P1992; Ouma John H., 2001, Trends in Parasitology, V17, P117, DOI 10.1016/S1471-4922(00)01877-8; Perlmann P, 1997, INFECT IMMUN, V65, P116; PEYRON F, 1994, CLIN EXP IMMUNOL, V95, P300; Remoue F, 2001, CLIN EXP IMMUNOL, V124, P62, DOI 10.1046/j.1365-2249.2001.01495.x; Remoue F, 2000, J INFECT DIS, V181, P1855, DOI 10.1086/315454; Sow S, 2002, ANN TROP MED PARASIT, V96, P575, DOI 10.1179/000349802125001636; WENISCH C, 1994, CLIN IMMUNOL IMMUNOP, V71, P344, DOI 10.1006/clin.1994.1096	16	27	27	0	5	ROYAL SOC TROPICAL MEDICINE	LONDON	MANSON HOUSE 26 PORTLAND PLACE, LONDON W1N 1EY, ENGLAND	0035-9203			T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	MAY-JUN	2003	97	3					361	364		10.1016/S0035-9203(03)90170-2				4	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	834AM	WOS:000222383800023	15228260				2019-03-26	
J	Colebunders, R; Kolsteren, P; Ryder, R				Colebunders, R; Kolsteren, P; Ryder, R			Editorial: Giving antiretrovirals in the peripartum period to prevent mother-to-child HIV transmission in low-income countries: only a short-term stopgap measure	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Editorial Material						HIV; AIDS; mother-to-child transmission; ART; HAART; low-income countries	VERTICAL TRANSMISSION; RECEIVING NEVIRAPINE; UGANDAN WOMEN; SOUTH-AFRICA; LESSONS; AIDS		Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium; N Carolina Ctr Publ Hlth Preparedenss, Chapel Hill, NC 27599 USA; Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium	Colebunders, R (reprint author), Inst Trop Med, Dept Clin Sci, Natl Str 155, B-2000 Antwerp, Belgium.						Beckerman KP, 2002, LANCET, V359, P1168, DOI 10.1016/S0140-6736(02)08248-X; Cartoux M, 1998, AIDS, V12, P2489, DOI 10.1097/00002030-199818000-00019; *COL U MAILM SCH P, 2002, UNPR COLL PRIV FDN S; Coutsoudis A, 2001, AIDS, V15, P379, DOI 10.1097/00002030-200102160-00011; Dabis F, 2002, LANCET, V359, P2097, DOI 10.1016/S0140-6736(02)08909-2; *E GLAZ PED AIDS F, 2002, CALL ACT PROJ FDN TA; Eshleman SH, 2001, AIDS, V15, P1951, DOI 10.1097/00002030-200110190-00006; Gaillard P, 2002, AIDS, V16, P937, DOI 10.1097/00002030-200204120-00019; Jackson JB, 2000, AIDS, V14, pF111, DOI 10.1097/00002030-200007280-00001; Kanshana S, 2002, AIDS, V16, P953, DOI 10.1097/00002030-200205030-00001; Kumar S, 2001, LANCET, V357, P616, DOI 10.1016/S0140-6736(05)71411-2; Msellati P, 2001, B WORLD HEALTH ORGAN, V79, P641; MSELLATI P, 1995, J ACQ IMMUN DEF SYND, V8, P506; Musoke P, 1999, AIDS, V13, P479, DOI 10.1097/00002030-199903110-00006; Nduati R, 2000, JAMA-J AM MED ASSOC, V283, P1167, DOI 10.1001/jama.283.9.1167; Rollins NC, 2002, LANCET, V360, P389, DOI 10.1016/S0140-6736(02)09599-5; Saba J, 2002, LANCET, V359, P1178; *UNICEF, 2002, MOTH TO CHILD TRANSM; *WHO, 2001, EFF BREASTF MORT HIV; World Health Organization, 2002, SCAL ANT THER RES LT	20	4	4	0	2	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	MAY	2003	8	5					375	377		10.1046/j.1365-3156.2003.01041.x				3	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	674UA	WOS:000182653300001	12753629				2019-03-26	
J	Moerman, F; Colebunders, B; D'Alessandro, U				Moerman, F; Colebunders, B; D'Alessandro, U			Untitled	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Letter							THROMBOCYTOPENIA; CHILDREN		Inst Trop Med, B-2000 Antwerp, Belgium	Moerman, F (reprint author), Inst Trop Med, Natl Str 155, B-2000 Antwerp, Belgium.		D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009; Newton, Charles/0000-0002-6999-5507			Gerardin P, 2002, AM J TROP MED HYG, V66, P686, DOI 10.4269/ajtmh.2002.66.686; Gillis S, 1998, BAILLIERE CLIN HAEM, V11, P361, DOI 10.1016/S0950-3536(98)80054-1; HOERNLE EH, 1995, AM J HEALTH-SYST PH, V52, P961; Monpoux F, 1999, J PEDIAT HEMATOL ONC, V21, P441, DOI 10.1097/00043426-199909000-00020; Roux W, 2001, J TROP PEDIATRICS, V47, P208, DOI 10.1093/tropej/47.4.208; Scaradavou A, 2002, BLOOD REV, V16, P73, DOI 10.1054/bire.2001.0188	6	4	4	0	0	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	APR	2003	68	4					379	379		10.4269/ajtmh.2003.68.4.0680379				1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	670RX	WOS:000182423600001	12875280				2019-03-26	
J	van der Werf, MJ; Bosompem, KM; de Vlas, SJ				van der Werf, MJ; Bosompem, KM; de Vlas, SJ			Schistosomiasis control in Ghana: case management and means for diagnosis and treatment within the health system	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article; Proceedings Paper	Meeting of the Royal-Society-of-Tropical-Medicine-and-Hygiene	DEC 12, 2002	LONDON, ENGLAND	Royal Soc Trop Med & Hyg		schistosomiasis; Schistosoma mansoni; Schistosoma haematobium; control; primary health care; integration; cost analysis; Ghana	PRACTICING PHYSICIANS; VOLTA REGION; HAEMATOBIUM; INFECTION; LAKE	An essential component of integrated schistosomiasis control as promoted by WHO is adequate clinical care for patients presenting at health care facilities. We evaluated the functioning of the Ghanaian health system for diagnosis and treatment of schistosomiasis by interviewing health workers from 70 health care facilities in 4 geographical areas in April and May 2000. Results from presentation of 4 hypothetical cases and a subsequent interview demonstrated that patients presenting with symptoms related to schistosomiasis have a small chance of receiving adequate treatment: often health workers do not recognize the symptoms, especially those of Schistosoma mansoni; patients are frequently referred for a diagnostic test or treatment with a large risk of non-compliance; and praziquantel was not available in 78% of the health care facilities with reported schistosomiasis in their coverage area. The overall cost of treatment is considerable: E2.13 for S. haematobium and E1.81 for S. mansoni patients, with drug costs contributing approximately 40% of the total cost. To better meet WHO recommendations for passive case detection as part of integrated schistosomiasis control, the Ghanaian health system needs to emphasize training of health workers in schistosomiasis case recognition and case management and increase the availability of praziquantel. Experience from other West African countries indicate that this is feasible.	Univ Med Ctr Rotterdam, Erasmus MC, Dept Publ Hlth, NL-3000 DR Rotterdam, Netherlands; Univ Ghana, Noguchi Mem Inst Med Res, Legon, Accra, Ghana; Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium	van der Werf, MJ (reprint author), Univ Med Ctr Rotterdam, Erasmus MC, Dept Publ Hlth, POB 1738, NL-3000 DR Rotterdam, Netherlands.	vanderwerfm@kncvtbc.nl					AMANKWA JA, 1994, TROP MED PARASITOL, V45, P319; Biritwum R B, 1994, West Afr J Med, V13, P124; EDINGTON G M, 1957, West Afr Med J, V6, P45; Engels D, 2002, ACTA TROP, V82, P139, DOI 10.1016/S0001-706X(02)00045-1; KLUMPP RK, 1987, J TROP MED HYG, V90, P265; KOPELOW ML, 1992, ACAD MED, V67, pS19, DOI 10.1097/00001888-199210000-00026; McCullough F. S., 1957, West African Medical Journal NS, V6, P87; McCULLOUGH F. S., 1965, Ghana Medical Journal, V4, P83; Nyonator F, 1999, HEALTH POLICY PLANN, V14, P329, DOI 10.1093/heapol/14.4.329; ONORI E, 1963, ANN TROP MED PARASIT, V57, P59, DOI 10.1080/00034983.1963.11686162; RUSSELL NK, 1991, ACAD MED, V66, pS37, DOI 10.1097/00001888-199109000-00034; SCOTT D, 1982, B WORLD HEALTH ORGAN, V60, P89; van der Werf MJ, 2002, TROP MED INT HEALTH, V7, P70, DOI 10.1046/j.1365-3156.2002.00823.x; WEN ST, 1984, ANN TROP MED PARASIT, V78, P129, DOI 10.1080/00034983.1984.11811786; *WHO, 1993, TECHN REP SER WHO, V830; WHO and UNICEF (United Nations Children's Fund), 1978, INT C PRIM HLTH CAR; Zijlmans C W, 1989, Ned Tijdschr Geneeskd, V133, P2552	17	14	14	0	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0035-9203	1878-3503		T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	MAR-APR	2003	97	2					146	152		10.1016/S0035-9203(03)90102-7				7	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	734AZ	WOS:000186034200005	14584366				2019-03-26	
J	Chappuis, F; Rijal, S; Singh, R; Acharya, P; Karki, BMS; Das, ML; Bovier, PA; Desjeux, P; Le Ray, D; Koirala, S; Loutan, L				Chappuis, F; Rijal, S; Singh, R; Acharya, P; Karki, BMS; Das, ML; Bovier, PA; Desjeux, P; Le Ray, D; Koirala, S; Loutan, L			Prospective evaluation and comparison of the direct agglutination test and an rK39-antigen-based dipstick test for the diagnosis of suspected kala-azar in Nepal	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						visceral leishmaniasis; kala-azar; diagnosis; direct agglutination test; k39 antigen; dipstick; Nepal	LINKED-IMMUNOSORBENT-ASSAY; FREEZE-DRIED ANTIGEN; VISCERAL LEISHMANIASIS; SUDAN; FIELD; INDIA; RK39; DAT	The diagnosis of visceral leishmaniasis (kala-azar) remains difficult in rural endemic areas and practical and reliable tests are badly needed. Two serological tests, the Direct Agglutination Test (DAT) and an rK39-antigen-based dipstick test, were compared to parasitological diagnosis in a group of 184 patients presenting at a tertiary care centre in south-eastern Nepal with a history of fever greater than or equal to14 days and splenomegaly; 139 patients had a parasitologically proven kala-azar and 45 patients had a negative parasitological work-up. The rK39 dipstick showed a sensitivity of 97% and a specificity of 71%. The DAT was up to 99% sensitive with a low cut-off titre (1:400) but its specificity did not exceed 82% even with a high cut-off titre (1:51 200). Both tests could be used for screening suspect patients in endemic areas. However, their use as confirmatory tests should be restricted to situations where the proportion of kala-azar among clinical suspect patients is high. The rK39 dipstick is cheaper and easier to use than the DAT and could be used widely provided that both its performance and production remain stable.	Univ Hosp Geneva, Dept Community Med, Travel & Migrat Med Unit, CH-1211 Geneva 14, Switzerland; BP Koirala Inst Hlth Sci, Dept Med, Dharan, Nepal; Univ Hosp Geneva, Dept Community Med & Qual Care, CH-1211 Geneva, Switzerland; WHO, Communicable Dis Surveillance & Response, CH-1211 Geneva 27, Switzerland; BP Koirala Inst Hlth Sci, Dept Microbiol, Dharan, Nepal; Inst Trop Med Prince Leopold, Dept Parasitol, Protozool Unit, B-2000 Antwerp, Belgium; BP Koirala Inst Hlth Sci, Dept Med, Dharan, Nepal; BP Koirala Inst Hlth Sci, Dept Pediat, Dharan, Nepal	Chappuis, F (reprint author), Univ Hosp Geneva, Dept Community Med, Travel & Migrat Med Unit, CH-1211 Geneva 14, Switzerland.			Das, Murari/0000-0001-6816-2389			ALLAIN DS, 1975, AM J TROP MED HYG, V24, P232, DOI 10.4269/ajtmh.1975.24.232; Badaro R, 1996, J INFECT DIS, V173, P758, DOI 10.1093/infdis/173.3.758; Bern C, 2000, AM J TROP MED HYG, V63, P153, DOI 10.4269/ajtmh.2000.63.153; Boelaert M, 1999, TROP MED INT HEALTH, V4, P395, DOI 10.1046/j.1365-3156.1999.00421.x; Boelaert M, 1999, AM J TROP MED HYG, V60, P129, DOI 10.4269/ajtmh.1999.60.129; Boelaert M, 1999, TROP MED INT HEALTH, V4, P31, DOI 10.1046/j.1365-3156.1999.00348.x; Boelaert M, 1999, B WORLD HEALTH ORGAN, V77, P667; Desjeux P, 1996, CLIN DERMATOL, V14, P417, DOI 10.1016/0738-081X(96)00057-0; ELHARITH A, 1988, J CLIN MICROBIOL, V26, P1321; ELHARITH A, 1987, T R SOC TROP MED HYG, V81, P603; ELHARITH AE, 1986, T ROY SOC TROP MED H, V80, P583; ELSAFI SH, 1989, T ROY SOC TROP MED H, V83, P334, DOI 10.1016/0035-9203(89)90493-8; HAILU A, 1990, T ROY SOC TROP MED H, V84, P673, DOI 10.1016/0035-9203(90)90141-Z; HO EA, 1948, T ROY SOC TROP MED H, V41, P629, DOI 10.1016/S0035-9203(48)90458-1; Joshi A. B., 1999, Southeast Asian Journal of Tropical Medicine and Public Health, V30, P583; KAGER PA, 1983, TROP GEOGR MED, V35, P111; Medrano FJ, 1998, AM J TROP MED HYG, V59, P155, DOI 10.4269/ajtmh.1998.59.155; MEREDITH SEO, 1995, J CLIN MICROBIOL, V33, P1742; Oskam L, 1999, T ROY SOC TROP MED H, V93, P275, DOI 10.1016/S0035-9203(99)90021-4; ROSENBERG SA, 1995, CANCER J SCI AM, V1, P89; SACKETT DL, 1991, CLIN EPIDEMIOLOGY BA, P57; SCHAEFER KU, 1995, T ROY SOC TROP MED H, V89, P471, DOI 10.1016/0035-9203(95)90070-5; Singh S, 1995, J PARASITOL, V81, P1000, DOI 10.2307/3284056; SINGLA N, 1993, T ROY SOC TROP MED H, V87, P276, DOI 10.1016/0035-9203(93)90125-A; SINHA R, 1994, J TROP MED HYG, V97, P333; Sundar S, 1998, LANCET, V351, P563, DOI 10.1016/S0140-6736(97)04350-X; Sundar S, 2000, CLIN INFECT DIS, V31, P1104, DOI 10.1086/318121; World Health Organization (WHO), 1984, TECHN REP SER WHO; ZIJLSTRA EE, 1992, T ROY SOC TROP MED H, V86, P505, DOI 10.1016/0035-9203(92)90086-R; Zijlstra EE, 2001, TROP MED INT HEALTH, V6, P108, DOI 10.1046/j.1365-3156.2001.00680.x; Zijlstra EE, 1998, CLIN DIAGN LAB IMMUN, V5, P717; Zijlstra EE, 1997, T ROY SOC TROP MED H, V91, P671, DOI 10.1016/S0035-9203(97)90518-6; ZIJLSTRA EE, 1991, T ROY SOC TROP MED H, V85, P474, DOI 10.1016/0035-9203(91)90224-M	33	45	48	0	0	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	MAR	2003	8	3					277	285		10.1046/j.1365-3156.2003.01026.x				9	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	654GH	WOS:000181485500015	12631320				2019-03-26	
J	Scott, JT; Diakhate, M; Vereecken, K; Fall, A; Diop, M; Ly, A; De Clercq, D; de Vlas, SJ; Berkvens, D; Kestens, L; Gryseels, B				Scott, JT; Diakhate, M; Vereecken, K; Fall, A; Diop, M; Ly, A; De Clercq, D; de Vlas, SJ; Berkvens, D; Kestens, L; Gryseels, B			Human water contacts patterns in Schistosoma mansoni epidemic foci in northern Senegal change according to age, sex and place of residence, but are not related to intensity of infection	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						Schistosoma mansoni; human; Senegal; water contact	RECENTLY EXPOSED COMMUNITY; HAEMATOBIUM; RESISTANCE; REINFECTION; IMMUNITY; BEHAVIOR; CHEMOTHERAPY; IMMUNOLOGY; RESPONSES; CHILDREN	In an epidemic focus in northern Senegal, adults had lower intensities of infection than adolescents, a phenomenon that could not be attributed to immunity acquired over the previous 10-15 years of exposure to the parasite because all age groups had had the same number of years' experience of the worm. This article considers whether this pattern could have been because of higher levels of exposure to the parasite in younger age groups. Personal contact with infected water was recorded using a questionnaire in Schistosoma mansoni foci not more than 3 years old and in another, 10-year-old focus. Many aspects of contact (e.g. frequency, duration or time of day of contact) may contribute to the number of encounters with infective cercariae (true exposure), so various assumptions regarding the relationship between water contact and true exposure were tested. resulting in a range of exposure indices. People reported a mean of 4.4 separate contacts, and spent a median of 57 min per day in water. Patterns of water contact differed depending on the exposure index used, e.g. considering duration, males spent a longer time in water than females (P < 0.001). But using frequency, females had more contacts with water than males in most villages (P < 0.001). Generally, exposure levels dropped as people become aged (P <,0.001) and residents of the older focus were more exposed than residents of other foci (P < 0.002). Intensity of (re)infection was not related to exposure either alone or in models incorporating age, sex and/or village irrespective of the index used. There is therefore evidence that age, sex and place of residence determine exposure but none to suggest that exposure had an influence on the relationship between these factors and intensity of infection. We propose therefore that in this population other factors have principal importance in determining intensity of infection.	Inst Trop Med, B-2000 Antwerp, Belgium; Reg Med, Programme ESPOIR, St Louis, Senegal; State Univ Ghent, B-9000 Ghent, Belgium; Erasmus Univ, Dept Publ Hlth, Rotterdam, Netherlands	Scott, JT (reprint author), Inst Trop Med, Natl Str 155, B-2000 Antwerp, Belgium.		Scott, Janet/K-4364-2012				BUTTERWORTH AE, 1992, IMMUNOL INVEST, V21, P391, DOI 10.3109/08820139209069381; BUTTERWORTH AE, 1988, PHILOS T ROYAL SOC T, V81, P29; CHANDIWANA SK, 1991, PARASITOLOGY, V103, P363, DOI 10.1017/S0031182000059874; DEMEURE CE, 1993, J INFECT DIS, V168, P1000, DOI 10.1093/infdis/168.4.1000; ERNOULD JC, 1996, EPIDEMIOLOGIE SCHIST; ETARD JF, 1995, AM J TROP MED HYG, V52, P549, DOI 10.4269/ajtmh.1995.52.549; Fulford AJC, 1996, PARASITOLOGY, V113, P223, DOI 10.1017/S0031182000082007; Gazzinelli A, 2001, TROP MED INT HEALTH, V6, P126, DOI 10.1046/j.1365-3156.2001.00684.x; GRYSEELS B, 1994, PARASITOL TODAY, V10, P380, DOI 10.1016/0169-4758(94)90226-7; GRYSEELS B, 1994, TROP GEOGR MED, V46, P209; HAGAN P, 1985, PARASITE IMMUNOL, V7, P625, DOI 10.1111/j.1365-3024.1985.tb00106.x; Hagan P, 1998, PARASITOL TODAY, V14, P407, DOI 10.1016/S0169-4758(98)01325-8; HAGAN P, 1992, PARASITOL TODAY, V8, P12, DOI 10.1016/0169-4758(92)90303-J; Kabatereine NB, 1999, PARASITOLOGY, V118, P101, DOI 10.1017/S0031182098003576; Katz N, 1972, Rev Inst Med Trop Sao Paulo, V14, P397; KLOETZEL K, 1967, AM J TROP MED HYG, V16, P167, DOI 10.4269/ajtmh.1967.16.167; Kloos H, 1998, MEM I OSWALDO CRUZ, V93, P37, DOI 10.1590/S0074-02761998000700006; Kloos H, 1997, SOC SCI MED, V44, P949, DOI 10.1016/S0277-9536(96)00218-3; KLOOS H, 1983, SOC SCI MED, V17, P545, DOI 10.1016/0277-9536(83)90297-6; Lindsey J. K., 1997, APPL GEN LINEAR MODE, P256; Lund CC, 1944, SURG GYNECOL OBSTET, V79, P352; MOSTELLER RD, 1987, NEW ENGL J MED, V317, P1098; PRENTICE MA, 1999, PARASITOLOGY, V78, P169; SAMA MT, 1994, ANN TROP MED PARASIT, V88, P629, DOI 10.1080/00034983.1994.11812914; Scott JT, 2001, PARASITE IMMUNOL, V23, P519, DOI 10.1046/j.1365-3024.2001.00409.x; *STAT CORP, 2001, STAT VERS 7; STELMA F, 1997, THESIS; STELMA FF, 1993, AM J TROP MED HYG, V49, P701, DOI 10.4269/ajtmh.1993.49.701; Tchuente LAT, 1999, PARASITOLOGY, V118, P595, DOI 10.1017/S0031182099004345; vanDam GJ, 1996, J INFECT DIS, V173, P1232, DOI 10.1093/infdis/173.5.1232; WILKINS HA, 1987, T ROY SOC TROP MED H, V81, P29, DOI 10.1016/0035-9203(87)90273-2; WOOLHOUSE MEJ, 1991, NATURE, V351, P757, DOI 10.1038/351757a0; Woolhouse MEJ, 2000, PARASITOLOGY, V120, P37, DOI 10.1017/S0031182099005156	33	33	33	0	5	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	FEB	2003	8	2					100	108		10.1046/j.1365-3156.2003.00993.x				9	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	651WR	WOS:000181345600002	12581433	Bronze			2019-03-26	
J	Nguekam, JP; Zoli, AP; Zogo, PO; Kamga, ACT; Speybroeck, N; Dorny, P; Brandt, J; Losson, B; Geerts, S				Nguekam, JP; Zoli, AP; Zogo, PO; Kamga, ACT; Speybroeck, N; Dorny, P; Brandt, J; Losson, B; Geerts, S			A seroepidemiological study of human cysticercosis in West Cameroon	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						Taenia solium; cysticercosis; antigen-enzyme-linked immunosorbent assay; neurocysticercosis; computed tomography-scan; Cameroon	TAENIA-SOLIUM CYSTICERCOSIS; SAGINATA CYSTICERCOSIS; NEUROCYSTICERCOSIS; SEROPREVALENCE; DIAGNOSIS; ANTIGENS; EPILEPSY; VILLAGE; ELISA	We studied the occurrence of human cysticercosis in 4993 individuals from three rural communities of Menoua Division, West Province of Cameroon. Circulating antigens of Taenia solium metacestodes were detected in 0.4%, 1.0% and 3.0% of the serum samples taken in Bafou, Bamendou and Fonakekeu, respectively, and examined using a monoclonal antibody-based enzyme-linked immunosorbent assay. This test detects only carriers of living cysticerci and gives thus a good idea of the presence of Active cysticercosis. The percentage of persons infected with cysticercosis increased with age. Twenty-two of the 34 seropositives underwent computed tomography (CT) of the brain. Thirteen of them were CT-scan positive, which shows that neurocysticercosis was present in 59.1% of the tested seropositive persons. No living cysticerci were detected among 20 seronegative people. About 20.6% of the seropositives had a history of or current taeniasis against only 1.9% of the seronegatives. Based on these figures and on the data on porcine cysticercosis (prevalence: 11%) and human taeniasis (prevalence: 0.13%) collected in the same region, we conclude that T. solium cysticercosis is an endemic, but overlooked public health problem in West Cameroon.	Inst Trop Med, B-2000 Antwerp, Belgium; Univ Dschang, Dschang, Cameroon; Cent Hosp Yaounde, Dept Radiol, Yaounde, Cameroon; Dist Hosp Dschang, Dschang, Cameroon; Univ Liege, Fac Med Vet, Sart Tilman Par Liege, Belgium	Geerts, S (reprint author), Inst Trop Med, Natl Str 155, B-2000 Antwerp, Belgium.	sgeerts@itg.be		Geerts, Stanny/0000-0001-9885-8846			Agresti A, 1998, AM STAT, V52, P119, DOI 10.2307/2685469; BRANDT JRA, 1992, INT J PARASITOL, V22, P471, DOI 10.1016/0020-7519(92)90148-E; Carpio A, 1998, EPILEPSIA, V39, P1025, DOI 10.1111/j.1528-1157.1998.tb01287.x; CRUZ I, 1994, AM J TROP MED HYG, V51, P405, DOI 10.4269/ajtmh.1994.51.405; Dorny P, 2000, VET PARASITOL, V88, P43, DOI 10.1016/S0304-4017(99)00196-X; DUMAS M, 1990, B SOC PATHOL EXOT, V83, P263; DUMAS M, 1989, Acta Leidensia, V57, P191; Erhart A, 2002, T ROY SOC TROP MED H, V96, P270, DOI 10.1016/S0035-9203(02)90095-7; Garcia HH, 2000, T ROY SOC TROP MED H, V94, P673, DOI 10.1016/S0035-9203(00)90228-1; Garcia HH, 2001, AM J TROP MED HYG, V65, P31, DOI 10.4269/ajtmh.2001.65.31; GARCIA HH, 1993, LANCET, V341, P197, DOI 10.1016/0140-6736(93)90064-N; Geerts S, 2002, NATO SCI SER I LIFE, V341, P13; Houinato D, 1998, T ROY SOC TROP MED H, V92, P621, DOI 10.1016/S0035-9203(98)90785-4; Ito A, 1998, AM J TROP MED HYG, V59, P291, DOI 10.4269/ajtmh.1998.59.291; Marty P, 1986, Med Trop (Mars), V46, P181; Marty P, 1985, Med Trop (Mars), V45, P83; Pouedet MSR, 2002, VET PARASITOL, V106, P45, DOI 10.1016/S0304-4017(02)00035-3; PREUX PM, 1996, NEUROL INFECT EPIDEM, V1, P63; SARTI E, 1992, AM J TROP MED HYG, V46, P677, DOI 10.4269/ajtmh.1992.46.677; Schantz P.M., 1998, EMERG INFECT DIS, V2, P213; Sokal RR, 1981, BIOMETRY PRINCIPLES; *STAT, 2001, STAT STAT SOFTW REL; TSANG VCW, 1995, PARASITOL TODAY, V11, P124, DOI 10.1016/0169-4758(95)80175-8; TSANG VCW, 1989, J INFECT DIS, V159, P50, DOI 10.1093/infdis/159.1.50; Vondou L, 2002, PARASITE, V9, P271, DOI 10.1051/parasite/2002093271; White AC, 2000, ANNU REV MED, V51, P187, DOI 10.1146/annurev.med.51.1.187; Zoli A., 1987, Helminth zoonoses., P85; ZOLI A, 1998, ANIMAL HLTH PRODUCTI, P571	28	33	35	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	FEB	2003	8	2					144	149		10.1046/j.1365-3156.2003.01000.x				6	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	651WR	WOS:000181345600009	12581440				2019-03-26	
J	Penchenier, L; Grebaut, P; Njokou, F; Eyenga, VE; Buscher, P				Penchenier, L; Grebaut, P; Njokou, F; Eyenga, VE; Buscher, P			Evaluation of LATEX/T.b.gambiense for mass screening of Trypanosoma brucei gambiense sleeping sickness in Central Africa	ACTA TROPICA			English	Article						human African trypanosomiasis; Central Africa; screening; diagnosis; CATT; LATEX; Trypanosoma brucei gambiense	CARD-AGGLUTINATION-TEST; DIAGNOSIS; CATT; SERODIAGNOSIS; CONGO	We compared the Card Agglutination Test for Trypanosomiasis (CATT), which consists of lyophilized bloodstream form trypomastigotes of Trypanosoma brucei gambiense (Tb.g.) variable antigen type LiTat 1.3, with LATEX/Tb,g., which consists of a lyophilized suspension of latex particles coated with variable surface glycoproteins of Tb.g. variable antigen types LiTat 1.3, 1.5 and 1.6. This study was carried out during two mass screening surveys in 1998 in Campo, a sleeping sickness focus in Cameroon, with a low prevalence (0.3%) and in 1999 in Batangafo which belongs to the Central African focus of Ouham which has a higher prevalence (3%). In Campo, we compared the CATT performed on whole blood with the LATEX/Tb.g. on diluted blood. In Batangafo, both tests were performed on diluted blood. In all circumstances, the specificity of the LATEX/Tb.g. was higher than of CATT. The use of LATEX/Tb.g. on diluted blood instead of CATT results in an important decrease of workload and as a consequence, of costs related to parasitological examinations, In the case of Campo the workload was up to 12 times less than when using CATT 1.3 on whole blood and the cost divided by 3. In Batangafo the workload was decreased by nearly 20% with the LATEX/ Tb.g. Finally, it should be noted that in Batangafo, one of the parasitologically confirmed sleeping sickness patients was negative in CATT and positive in LATEX/Tb.g. and that the reading of the test result in LATEX/Tb.g. is easier than in CATT. (C) 2002 Elsevier Science B.V. All rights reserved.	OCEAC, Yaounde, Cameroon; Univ Yaounde 1, Yaounde, Cameroon; Minist Publ Hlth & Populat, Yaounde, Cameroon; Inst Trop Med, B-2000 Antwerp, Belgium	Penchenier, L (reprint author), ORSTOM, Inst Rech Dev, 911 Ave Agropolis, F-34000 Montpellier 01, France.		Buscher, Philippe/B-9956-2012	Buscher, Philippe/0000-0002-1926-7472			AERTS D, 1992, T ROY SOC TROP MED H, V86, P394, DOI 10.1016/0035-9203(92)90234-4; BAFORT JM, 1986, S AFR MED J, V69, P541; BAILEY JW, 1992, T ROY SOC TROP MED H, V86, P630, DOI 10.1016/0035-9203(92)90160-E; Buscher P, 1999, ACTA TROP, V73, P11, DOI 10.1016/S0001-706X(99)00009-1; DUKES P, 1992, ACTA TROP, V51, P123, DOI 10.1016/0001-706X(92)90054-2; Jamonneau V, 2000, ACTA TROP, V76, P175, DOI 10.1016/S0001-706X(00)00095-4; LANHAM SM, 1970, EXP PARASITOL, V28, P521, DOI 10.1016/0014-4894(70)90120-7; MAGNUS E, 1978, ANN SOC BELG MED TR, V58, P169; NOIREAU F, 1988, T ROY SOC TROP MED H, V82, P237, DOI 10.1016/0035-9203(88)90430-0; PENCHENIER L, 1991, ANN SOC BELG MED TR, V71, P221; Penchenier L, 1999, B SOC PATHOL EXOT, V92, P185; Penchenier L, 2000, T ROY SOC TROP MED H, V94, P392, DOI 10.1016/S0035-9203(00)90116-0; PENCHENIER L, 1998, B LIAIS DOC OCEAC, V31, P8; Simarro PP, 1999, B OCEAC, V32, P28; ZILLMANN U, 1986, TROP MED PARASITOL, V37, P390	15	18	18	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0001-706X			ACTA TROP	Acta Trop.	JAN	2003	85	1					31	37	PII S0001-706X(02)00232-2	10.1016/S0001-706X(02)00232-2				7	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	637KB	WOS:000180509300003	12505181				2019-03-26	
J	Alloueche, A; Milligan, P; Conway, DJ; Pinder, M; Bojang, K; Doherty, T; Tornieporth, N; Cohen, J; Greenwood, BM				Alloueche, A; Milligan, P; Conway, DJ; Pinder, M; Bojang, K; Doherty, T; Tornieporth, N; Cohen, J; Greenwood, BM			Protective efficacy of the RTS,S/AS02 Plasmodium falciparum malaria vaccine is not strain specific	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							CIRCUMSPOROZOITE PROTEIN VACCINE; IMMUNE-RESPONSES; TRIAL; IMMUNIZATION; CHILDREN	RTS,S/AS02 is a recombinant protein malaria vaccine that contains a large portion of the C-terminal of the circumsporozoite protein (CSP) sequence of the NF54 isolate of Plasmodium falciparum fused to the hepatitis B virus surface antigen. It has been shown to induce significant protection to challenge infection with a homologous parasite strain in American volunteers. In a recently completed trial in semi-immune Gambian adults, vaccine efficacy against natural infection was 34% (95% confidence interval = 8-53%, P = 0.014) during the malaria season following vaccination. Breakthrough P. falciparum parasites sampled from vaccinated subjects and from controls were genotyped at two polymorphic regions of the csp gene encoding T cell epitopes (csp-th2r and csp-th3r) to determine if the vaccine conferred a strain-specific effect. The overall distribution of csp allelic variants was similar in infections occurring in vaccine and control groups. Also, the mean number of genotypes per infection in the RTS,S/AS02 group was not reduced compared with the controls.	London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England; MRC Labs, Fajara, Gambia; GlaxoSmithKline Biol, B-1330 Rixensart, Belgium	Alloueche, A (reprint author), London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.	ali.allouechc@lshtm.ac.uk	Milligan, Paul/D-8985-2017	Milligan, Paul/0000-0003-3430-3395; Conway, David/0000-0002-8711-3037			Alloueche A, 2000, MOL BIOCHEM PARASIT, V106, P273, DOI 10.1016/S0166-6851(99)00221-2; Beck HP, 1997, J INFECT DIS, V175, P921, DOI 10.1086/513991; Bojang KA, 2001, LANCET, V358, P1927, DOI 10.1016/S0140-6736(01)06957-4; CUZICK J, 1985, STAT MED, V4, P87, DOI 10.1002/sim.4780040112; CUZICK J, 1985, BIOMETRICS, V41, P609, DOI 10.2307/2531281; GRAVES P, 2001, COCHRANE LIB, V1; GUIGUEMDE TR, 1990, B SOC PATHOL EXOT, V83, P217; Haywood M, 1999, T ROY SOC TROP MED H, V93, pS65, DOI 10.1016/S0035-9203(99)90330-9; HERRINGTON D, 1991, AM J TROP MED HYG, V45, P539, DOI 10.4269/ajtmh.1991.45.539; Kester KE, 2001, J INFECT DIS, V183, P640, DOI 10.1086/318534; Lalvani A, 1999, J INFECT DIS, V180, P1656, DOI 10.1086/315074; NARDIN EH, 1993, ANNU REV IMMUNOL, V11, P687, DOI 10.1146/annurev.iy.11.040193.003351; REBERLISKE R, 1995, TROP GEOGR MED, V47, P61; Sherwood JA, 1996, VACCINE, V14, P817, DOI 10.1016/0264-410X(95)00221-L; Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202; Stoute JA, 1998, J INFECT DIS, V178, P1139, DOI 10.1086/515657; VIRIYAKOSOL S, 1995, B WORLD HEALTH ORGAN, V73, P85; ZAVALA F, 1983, J EXP MED, V157, P1947, DOI 10.1084/jem.157.6.1947	18	59	60	0	0	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637	1476-1645		AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	JAN	2003	68	1					97	101		10.4269/ajtmh.2003.68.97				5	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	632YV	WOS:000180253200018	12556156	Green Published			2019-03-26	
J	Victoir, K; De Doncker, S; Cabrera, L; Alvarez, E; Arevalo, J; Llanos-Cuentas, A; Le Ray, D; Dujardin, JC				Victoir, K; De Doncker, S; Cabrera, L; Alvarez, E; Arevalo, J; Llanos-Cuentas, A; Le Ray, D; Dujardin, JC			Direct identification of Leishmania species in biopsies from patients with American tegumentary leishmaniasis	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article; Proceedings Paper	Meeting of the Royal-Society-of-Tropical-Medicine-and-Hygiene	MAY   17, 2001	LONDON, ENGLAND	Royal Soc Trop Med & Hygiene		leishmaniasis; Leishmania (Viannia) braziliensis; Leishmania (Viannia) peruviana; Leishmania (Viannia) guyanensis; diagnosis; polymerase chain reaction; Peru	POLYMERASE-CHAIN-REACTION; CUTANEOUS LEISHMANIASIS; VIANNIA BRAZILIENSIS; PERUVIAN ANDES; DIAGNOSIS; HYBRIDS; COMPLEX; DNA	Accurate identification of Leishmania species is important for monitoring clinical outcome, adequately targeting treatment, and evaluation of epidemiological risk in tegumentary leishmaniasis. This is especially the case in regions where several species coexist and for travel medicine where the geographical source of infection is not always obvious. Species identification presently depends on parasite isolation, which is not very sensitive and not necessarily representative of parasites actually present in human tissues. We evaluated a polymerase chain reaction (PCR) assay combining amplification of the gp63 genes and restriction fragment length polymorphism (RFLP) analysis (gp63 PCR-RFLP) for direct Leishmania species-identification in tissues collected from Peruvian patients in 1999. By comparison with a kinetoplast DNA-based PCR, our PCR assay showed a detection sensitivity of 85%. Three species were encountered among patient samples, Leishmania (Viannia) braziliensis, L. (V.) peruviana and L. (V.) guyanensis, and their frequency and geographical distribution corresponded to earlier epidemiological studies of leishmaniasis in Peru. However, unexpected results raised questions about (i) the contribution of human migration to the emergence of new foci of given species, (ii) the pathogenicity of some species, and (iii) the frequency of mixed or hybrid infections.	Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium; Inst Med Trop Alexander Humboldt, Grp Studies Leishmaniasis, Lima 100, Peru	Dujardin, JC (reprint author), Inst Trop Med Prince Leopold, Nationalestr 155, B-2000 Antwerp, Belgium.			Arevalo, Jorge/0000-0003-3837-2849			BANULS AL, 1998, THESIS U MONTPELLIER; Berman JD, 1997, CLIN INFECT DIS, V24, P684, DOI 10.1093/clind/24.4.684; CUNY G, 1991, ANAL BIOCHEM, V193, P45, DOI 10.1016/0003-2697(91)90041-Q; CUPOLILLO E, 1995, MOL BIOCHEM PARASIT, V73, P145, DOI 10.1016/0166-6851(95)00108-D; Davies CR, 1997, CLIN INFECT DIS, V25, P302, DOI 10.1086/514535; DEBRUIJN MHL, 1992, ACTA TROP, V52, P45, DOI 10.1016/0001-706X(92)90006-J; Desjeux P, 2001, T ROY SOC TROP MED H, V95, P239, DOI 10.1016/S0035-9203(01)90223-8; DUJARDIN JC, 1995, ACTA TROP, V59, P293, DOI 10.1016/0001-706X(95)00094-U; Guerbouj S, 2001, PARASITOLOGY, V122, P25, DOI 10.1017/S0031182000007125; *I GEOGR NAC PER, 1989, ATL PER; LLANOSCUENTAS EA, 1991, THESIS U PERUANA CAY; LOPEZ M, 1993, AM J TROP MED HYG, V49, P348, DOI 10.4269/ajtmh.1993.49.348; Lucas CM, 1998, AM J TROP MED HYG, V59, P312, DOI 10.4269/ajtmh.1998.59.312; *PAHO, 1999, HLTH AM, V2; Pirmez C, 1999, J CLIN MICROBIOL, V37, P1819; Sambrook J., 1989, MOL CLONING LAB MANU; SANTRICH C, 1990, AM J TROP MED HYG, V42, P51, DOI 10.4269/ajtmh.1990.42.51; Schubach A, 1998, J INFECT DIS, V178, P911, DOI 10.1086/515355; Singh B, 1997, INT J PARASITOL, V27, P1135, DOI 10.1016/S0020-7519(97)00111-2; TIBAYRENC M, 1990, P NATL ACAD SCI USA, V87, P2414, DOI 10.1073/pnas.87.7.2414; TOBIE EJ, 1950, J PARASITOL, V34, P53; Torrico MC, 1999, ACTA TROP, V72, P99, DOI 10.1016/S0001-706X(98)00076-X; VANEYS GJJM, 1992, MOL BIOCHEM PARASIT, V51, P133; Victoir K, 1998, PARASITOLOGY, V117, P1; VICTOIR K, 1995, PARASITOLOGY, V111, P265, DOI 10.1017/S0031182000081828; VILLASECA P, 1993, AM J TROP MED HYG, V49, P260, DOI 10.4269/ajtmh.1993.49.260; World Health Organization (WHO), 1990, WHO TECHN REP SER, V793	27	31	33	1	3	ROYAL SOC TROPICAL MEDICINE	LONDON	MANSON HOUSE 26 PORTLAND PLACE, LONDON W1N 1EY, ENGLAND	0035-9203			T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	JAN-FEB	2003	97	1					80	87		10.1016/S0035-9203(03)90031-9				8	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	702NY	WOS:000184231000021	12886810				2019-03-26	
J	Chatterjee, S; Mbaye, A; Van Marck, E				Chatterjee, S; Mbaye, A; Van Marck, E			Lower levels of the circulating neuropeptide somatostatin in Schistosoma mansoni infected patients may have pathological significance	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						somatostatin; Schistosoma mansoni; enzyme immuno-assay method; morbidity		In recent years, cases of severe morbidity (fibrosis, haematemesis, hepatosplenomegaly, ascites) caused to Schistosoma mansoni infections are on the rise in Northern Senegal. The neuropeptide somatostatin is reported to decrease portal pressure, control variceal bleeding and fibrosis, and reduce Schistosoma -caused clinical morbidity in the rodent model. The aim of this study was to delineate the role of somatostatin in S. mansoni -caused pathogenesis, by studying host levels of somatostatin in the peripheral blood of uninfected and S. mansoni -infected individuals. Subjects from the district dispensary at Richard Toll, in the Medical Region of Saint-Louis, Senegal, infected with S. mansoni and suffering from severe morbidity were selected. A separate group consisted of individuals resident in the same region but uninfected at the time of the study. Significantly lower somatostatin levels were detected in severe morbidity patients, compared with the exposed but uninfected subjects. In patients with schistosomiasis physiological levels of somatostatin may determine disposition of particular individuals towards severe morbidity, as opposed to others. Host pathology can thus be alleviated by the therapeutic ability of somatostatin to treat bleeding oesophageal varices, reduce portal pressure and prevent progression to severe fibrosis.	Univ Antwerp, Dept Med, Pathol Unit, Wilrijk, Belgium; Reg Med St Louis, St Louis, Senegal	Chatterjee, S (reprint author), Univ Antwerp, Dept Med, Pathol Unit, Wilrijk, Belgium.				NIDDK NIH HHS [DK34987]		Avgerinos A, 1997, LANCET, V350, P1495, DOI 10.1016/S0140-6736(97)05099-X; Chatterjee S, 2001, TROP MED INT HEALTH, V6, P1008, DOI 10.1046/j.1365-3156.2001.00744.x; Chatterjee S, 2001, TROP MED INT HEALTH, V6, P578, DOI 10.1046/j.1365-3156.2001.00758.x; CHTTERJEE S, 2002, TRENDS PARASITOL, V18, P295; Mansy SS, 1998, ARZNEIMITTEL-FORSCH, V48, P855; Reynaert H, 2001, J HEPATOL, V34, P6; Roca CA, 1999, BIOL PSYCHIAT, V46, P551, DOI 10.1016/S0006-3223(99)00006-2; SCARPIGNATO C, 1999, DIGESTION, P1; Weinstock JV, 2000, EUR J ENDOCRINOL, V143, pS15, DOI 10.1530/eje.0.143S015; WEINSTOCK JV, 1990, CELL IMMUNOL, V131, P381, DOI 10.1016/0008-8749(90)90262-P	10	3	3	0	0	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	JAN	2003	8	1					33	36		10.1046/j.1365-3156.2003.00989.x				4	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	636UR	WOS:000180476100008	12535248	Bronze			2019-03-26	
J	Vercammen, F; Fernandez-Perez, FJ; del Amo, C; Alunda, JM				Vercammen, F; Fernandez-Perez, FJ; del Amo, C; Alunda, JM			Follow-up of Leishmania infantum naturally infected dogs treated with allopurinol: immunofluorescence antibody test, ELISA and Western blot	ACTA TROPICA			English	Article						Leishmania infantum; dog; allopurinol; follow-up; serology	CANINE LEISHMANIASIS; IGG2 ANTIBODY; RESPONSES; DIAGNOSIS	Fourteen dogs naturally infected with Leishmania infantum and treated with allopurinol were monitored clinically and serologically with immunofluorescent antibody test (IFAT, amastigotes and promastigotes), enzyme linked-immunosorbent-assay (ELISA, IgG1 and IgG2) and Western blotting (WB). In all dogs therapy lead to clinical improvement together with decreasing specific antibodies in IFAT, ELISA and WB, demonstrating the usefulness of serology for follow-up. Although IgG1 and IgG2 varied considerably between individual animals, IgG2 of all dogs was predominantly in both ELISA and WB. This suggests the value of monitoring the IgG2 response (especially against 29 and 67 kDa antigens) in the follow-up of treated dogs. (C) 2002 Elsevier Science B.V. All rights reserved.	Inst Trop Med, Vet Dept, B-2000 Antwerp, Belgium; Univ Complutense, Fac Vet, Dept Anim Pathol 1, E-28040 Madrid, Spain	Vercammen, F (reprint author), Inst Trop Med, Vet Dept, Nationalestr 155, B-2000 Antwerp, Belgium.						ABRANCHES P, 1991, PARASITE IMMUNOL, V13, P537, DOI 10.1111/j.1365-3024.1991.tb00550.x; ALVAR J, 1994, ANN TROP MED PARASIT, V88, P371, DOI 10.1080/00034983.1994.11812879; Alvar J, 1997, CLIN MICROBIOL REV, V10, P298, DOI 10.1128/CMR.10.2.298; Bourdoiseau G, 1997, VET IMMUNOL IMMUNOP, V59, P21, DOI 10.1016/S0165-2427(97)00072-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999; CUQUERELLA M, 1991, VET PARASITOL, V38, P131, DOI 10.1016/0304-4017(91)90123-D; DEPLAZES P, 1995, PARASITE IMMUNOL, V17, P451, DOI 10.1111/j.1365-3024.1995.tb00914.x; Fernandez-Perez FJ, 1999, AM J TROP MED HYG, V61, P652, DOI 10.4269/ajtmh.1999.61.652; Fernandez-Perez FJ, 1999, J VET DIAGN INVEST, V11, P170, DOI 10.1177/104063879901100211; FERRER L, 1995, VET REC, V136, P514, DOI 10.1136/vr.136.20.514; Mendez S, 1996, INT J PARASITOL, V26, P619, DOI 10.1016/0020-7519(96)00037-9; Morillas F, 1996, PARASITOL RES, V82, P569, DOI 10.1007/s004360050164; Solano-Gallego L, 2001, VET PARASITOL, V96, P265, DOI 10.1016/S0304-4017(00)00446-5; Vercammen F, 1996, VET REC, V139, P264, DOI 10.1136/vr.139.11.264-a; ZUCKERMAN A, 1977, PARASITIC PROTOZOA, V1, P57	15	27	28	1	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0001-706X			ACTA TROP	Acta Trop.	DEC	2002	84	3					175	181	PII S0001-706X(02)00178-X	10.1016/S0001-706X(02)00178-X				7	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	622ZB	WOS:000179677200002	12443795				2019-03-26	
J	Heyman, P; Van Mele, R; De Jaegere, F; Klingstrom, J; Vandenvelde, C; Lundkvist, A; Rozenfeld, F; Zizi, M				Heyman, P; Van Mele, R; De Jaegere, F; Klingstrom, J; Vandenvelde, C; Lundkvist, A; Rozenfeld, F; Zizi, M			Distribution of hantavirus foci in Belgium	ACTA TROPICA			English	Article						hantavirus; Puumala virus; Clethrionomys glareolus; Apodemus sylvaticus; Microtus arvalis	HEMORRHAGIC-FEVER; RENAL SYNDROME; DOBRAVA-HANTAVIRUS; NEPHROPATHIA EPIDEMICA; GENETIC IDENTIFICATION; INFECTION; PUUMALA; VIRUS; POPULATIONS; SLOVENIA	During 1999 and 2000, we performed rodent captures on 15 sites all over Belgium to evaluate the presence of hantaviruses in local rodent populations. Viral antibody and RNA detection was performed by ELISA/focus reduction neutralisation test and RT-PCR, respectively. We found hantavirus-positive rodents on 13 out of 15 trapping sites and 3 rodent species were found positive for hantavirus infection. Apart from Puumala virus that was carried by Clethrionomys glareolus, 2 additional rodent species, Microtus arvalis and Apodemus sylvaticus, were found antibody-and/or RNA-positive. (C) 2002 Elsevier Science B.V. All rights reserved.	Queen Astrid Mil Hosp MSBT, Res Lab Vector Borne Dis, B-1120 Brussels, Belgium; Free Univ Brussels, Dept Mammal Behav Studies, Brussels, Belgium; Swedish Inst Infect Dis Control, Stockholm, Sweden; Karolinska Inst, Tumor Biol Ctr, Stockholm, Sweden; Queen Astrid Mil Hosp, Natl Reference Ctr Hantavirus Infect, Brussels, Belgium; Queen Astrid Mil Hosp, Belgian Min Def, Dept Well Being, Brussels, Belgium; Free Univ Brussels, Brussels, Belgium	Heyman, P (reprint author), Queen Astrid Mil Hosp MSBT, Res Lab Vector Borne Dis, Bruynstr 1, B-1120 Brussels, Belgium.						Avsic-Zupanc T, 2000, J GEN VIROL, V81, P1747, DOI 10.1099/0022-1317-81-7-1747; AVSICZUPANC T, 1992, J MED VIROL, V38, P132, DOI 10.1002/jmv.1890380211; BRUMMERKORVENKONTIO M, 1980, J INFECT DIS, V141, P131, DOI 10.1093/infdis/141.2.131; Escutenaire S, 2000, VIRUS RES, V67, P91, DOI 10.1016/S0168-1702(00)00136-2; Heyman P, 1999, EPIDEMIOL INFECT, V122, P447, DOI 10.1017/S0950268899002344; Heyman P, 2001, VIRUS RES, V77, P71, DOI 10.1016/S0168-1702(01)00267-2; HEYMAN P, 2002, EPIDEMIOL INFECT, V128, P99; LEE HW, 1982, J INFECT DIS, V146, P638, DOI 10.1093/infdis/146.5.638; LEE HW, 1978, J INFECT DIS, V137, P289; Lundkvist A, 1997, J MED VIROL, V53, P51; Lundkvist A, 2000, EUR J CLIN MICROBIOL, V19, P802, DOI 10.1007/s100960000372; Nemirov K, 1999, J GEN VIROL, V80, P371, DOI 10.1099/0022-1317-80-2-371; NICHOL ST, 1993, SCIENCE, V262, P914, DOI 10.1126/science.8235615; NIKLASSON B, 1987, J INFECT DIS, V155, P269; PILASKI J, 1994, J INFECT DIS, V170, P1456, DOI 10.1093/infdis/170.6.1456; PLUYSNIN A, 2001, ADV VIRUS RES, V57, P105; Plyusnin A, 1996, J GEN VIROL, V77, P2677, DOI 10.1099/0022-1317-77-11-2677; SCHMALJOHN CS, 1985, SCIENCE, V227, P1041, DOI 10.1126/science.2858126; Schultze D, 2002, EUR J CLIN MICROBIOL, V21, P304, DOI 10.1007/s10096-002-0705-5; Sibold C, 2001, J MED VIROL, V63, P158, DOI 10.1002/1096-9071(20000201)63:2<158::AID-JMV1011>3.3.CO;2-R; Sjolander KB, 2002, EPIDEMIOL INFECT, V128, P99, DOI 10.1017/S095026880100632X; VERHAGEN R, 1987, ACTA VIROL, V31, P43; VERHAGEN R, 1986, ARCH VIROL, V91, P193, DOI 10.1007/BF01314280	23	17	18	1	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0001-706X			ACTA TROP	Acta Trop.	DEC	2002	84	3					183	188	PII S0001-706X(02)00235-8	10.1016/S0001-706X(02)00235-8				6	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	622ZB	WOS:000179677200003	12443796				2019-03-26	
J	Radwanska, M; Chamekh, M; Vanhamme, L; Claes, F; Magez, S; Magnus, E; De Baetselier, P; Buscher, P; Pays, E				Radwanska, M; Chamekh, M; Vanhamme, L; Claes, F; Magez, S; Magnus, E; De Baetselier, P; Buscher, P; Pays, E			The serum resistance-associated gene as a diagnostic tool for the detection of Trypanosoma brucei rhodesiense	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							SURFACE GLYCOPROTEIN GENES; SLEEPING SICKNESS; ANIMAL RESERVOIR; ANTIGEN GENE; GAMBIENSE; STOCKS; EXPRESSION; IDENTIFICATION; UGANDA; CONGO	In the search for new diagnostic methods that would distinguish Trypanosoma brucei rhodesiense from T. b. brucei and T b. gambiense, we have developed two polymerase chain reaction (PCR) primer sets. The first primer set was derived from the serum resistance-associated (SRA) gene of T. b. rhodesiense that confers resistance to lysis by normal human serum (NHS). The specificity of the SRA-based PCR was tested on 97 different trypanosome populations originating from various taxonomic groups, host species, and geographic regions. Only one of 25 T b. rhodesiense samples was negative in this PCR. and none of 72 other samples were positive in this assay. Interestingly, a reference T. brucei strain (TREU927/4) currently used for genome sequencing was negative for the SRA gene; however, this strain was resistant to lysis by NHS. The second primer set was derived from a specific variant surface glycoprotein (VSG) expression site where the SRA gene is expressed (R-ES). This primer set identified the strain as T. b. rhodesiense in 17 of 17 SRA gene-positive strains in which it was tested. These data strongly suggest that expression of the SRA gene is generally involved in resistance to lysis by NHS in T. b. rhodesiense strains.	Groote Schuur Hosp, Dept Immunol, Observ, ZA-7925 Cape Town, South Africa; Free Univ Brussels VIB, Cellular Immunol Lab, B-1640 Rhode St Genese, Belgium; Free Univ Brussels, Mol Parasitol Lab, Inst Biol & Mol Med, B-6041 Gosselies, Belgium; Inst Trop Med, Dept Parasitol, B-2000 Antwerp, Belgium	Radwanska, M (reprint author), Groote Schuur Hosp, Dept Immunol, Observ, Old Main Bldg H47, ZA-7925 Cape Town, South Africa.	mradwans@uctgshl.uct.ac.za	Magez, Stefan/D-9497-2014; Buscher, Philippe/B-9956-2012; Radwanska, Magdalena/Q-4279-2018; De Baetselier, Patrick/D-3866-2014	Magez, Stefan/0000-0003-3760-7968; Buscher, Philippe/0000-0002-1926-7472; Radwanska, Magdalena/0000-0002-0797-6001; 			AERTS D, 1992, T ROY SOC TROP MED H, V86, P394, DOI 10.1016/0035-9203(92)90234-4; Berberof M, 2001, MOL BIOCHEM PARASIT, V113, P127, DOI 10.1016/S0166-6851(01)00208-0; BROMIDGE T, 1993, ACTA TROP, V53, P107, DOI 10.1016/0001-706X(93)90023-5; DEGREEF C, 1994, MOL BIOCHEM PARASIT, V68, P277, DOI 10.1016/0166-6851(94)90172-4; DEGREEF C, 1989, MOL BIOCHEM PARASIT, V36, P169, DOI 10.1016/0166-6851(89)90189-8; DERO B, 1987, MOL BIOCHEM PARASIT, V26, P247, DOI 10.1016/0166-6851(87)90077-6; DUKES P, 1992, ACTA TROP, V51, P123, DOI 10.1016/0001-706X(92)90054-2; Enyaru JCK, 1999, ANN TROP MED PARASIT, V93, P817, DOI 10.1080/00034989957817; Gibson W, 2001, TROP MED INT HEALTH, V6, P401, DOI 10.1046/j.1365-3156.2001.00711.x; GIBSON W C, 1986, Parasitology Today, V2, P255, DOI 10.1016/0169-4758(86)90011-6; GIBSON WC, 1989, PARASITOLOGY, V99, P391, DOI 10.1017/S0031182000059114; Hide G, 1999, CLIN MICROBIOL REV, V12, P112, DOI 10.1128/CMR.12.1.112; HIDE G, 1994, PARASITOLOGY, V109, P95, DOI 10.1017/S0031182000077805; Hoare C. A., 1972, TRYPANOSOMES MAMMALS; Kanmogne GD, 1996, ACTA TROP, V61, P239, DOI 10.1016/0001-706X(96)00006-X; LANHAM SM, 1970, EXP PARASITOL, V28, P521, DOI 10.1016/0014-4894(70)90120-7; MAGNUS E, 1978, ANN SOC BELG MED TR, V58, P169; MEHLITZ D, 1982, TROPENMED PARASITOL, V33, P113; Milner JD, 1999, MOL BIOCHEM PARASIT, V104, P271, DOI 10.1016/S0166-6851(99)00151-6; NOIREAU F, 1989, TROP MED PARASITOL, V40, P9; PAINDAVOINE P, 1986, PARASITOLOGY, V92, P31, DOI 10.1017/S0031182000063435; PAINDAVOINE P, 1989, MOL BIOCHEM PARASIT, V32, P61, DOI 10.1016/0166-6851(89)90130-8; PAYS E, 1994, ANNU REV MICROBIOL, V48, P25, DOI 10.1146/annurev.mi.48.100194.000325; Pays E, 2001, MOL BIOCHEM PARASIT, V114, P1, DOI 10.1016/S0166-6851(01)00242-0; Radwanska M, 2002, AM J TROP MED HYG, V67, P289, DOI 10.4269/ajtmh.2002.67.289; TRUC P, 1991, ACTA TROP, V49, P127, DOI 10.1016/0001-706X(91)90060-W; VANMEIRVENNE N, 1976, ANN SOC BELG MED TR, V56, P55; VANMEIRVENNE N, 1999, PROGR HUMAN AFRICAN, P235; Welburn SC, 2001, LANCET, V358, P2017, DOI 10.1016/S0140-6736(01)07096-9; World Health Organization, 1998, WHO TECH REP SER, P1; Xong HV, 1998, CELL, V95, P839	31	96	101	0	5	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637	1476-1645		AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	DEC	2002	67	6					684	690		10.4269/ajtmh.2002.67.684				7	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	628QJ	WOS:000180007500020	12518862	Bronze			2019-03-26	
J	Boelaert, M; Van Damme, W; Meessen, B; Van der Stuyft, P				Boelaert, M; Van Damme, W; Meessen, B; Van der Stuyft, P			Editorial: The AIDS crisis, cost-effectiveness and academic activism	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Editorial Material						AIDS; HIV; policy-making; cost-effectiveness analysis; sub-Saharan Africa; HAART	DRUGS		Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium; Med Sans Frontieres, Phnom Penh, Cambodia	Boelaert, M (reprint author), Inst Trop Med, Dept Publ Hlth, Natl Str 155, B-2000 Antwerp, Belgium.		Boelaert, Marleen/E-2698-2012; Van Damme, Wim/F-7404-2011	Boelaert, Marleen/0000-0001-8051-6776; Meessen, Bruno/0000-0002-0359-8621			Creese A, 2002, LANCET, V359, P1635, DOI 10.1016/S0140-6736(02)08595-1; Freedberg KA, 2001, NEW ENGL J MED, V344, P824, DOI 10.1056/NEJM200103153441108; Goemaere E, 2002, LANCET, V360, P86, DOI 10.1016/S0140-6736(02)09343-1; Kahn JG, 2000, AIDS, V14, P2609, DOI 10.1097/00002030-200011100-00026; Kumaranayake Lilani, 2002, HLTH POLICY GLOBALIS, P140; Marseille E, 2002, LANCET, V359, P1851, DOI 10.1016/S0140-6736(02)08705-6; Perez-Casas C, 2001, TROP MED INT HEALTH, V6, P960, DOI 10.1046/j.1365-3156.2001.00801.x; Piot P, 2002, LANCET, V360, P86, DOI 10.1016/S0140-6736(02)09342-X; Razum O, 2001, TROP MED INT HEALTH, V6, P421, DOI 10.1046/j.1365-3156.2001.00733.x; Roberts M, 2002, LANCET, V359, P1055, DOI 10.1016/S0140-6736(02)08097-2; Robertson DW, 2002, LANCET, V360, P330, DOI 10.1016/S0140-6736(02)09558-2; 2001, M DECL HLTH CAR ALL	12	4	4	0	1	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	DEC	2002	7	12					1001	1002		10.1046/j.1365-3156.2002.00972.x				2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	620TP	WOS:000179548800001	12460389	Bronze			2019-03-26	
J	Getahun, H; Lambein, F; Van der Stuyft, P				Getahun, H; Lambein, F; Van der Stuyft, P			ABO blood groups, grass pea preparation, and neurolathyrism in Ethiopia	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						neurolathyrism; Lathyrus sativus; ABO blood groups; Ethiopia	LATHYRUS-SATIVUS; DISEASE; EPIDEMIC	An exploratory study was conducted in the rural Estie district of Ethiopia in 1997 to identify the role of ABO blood group, rhesus factor, and type of grass pea (Lathyrus sativus) diet in the susceptibility to neurolathyrism. Five-hundred study subjects (250 cases and 250 controls) were examined and interviewed, and had their ABO and rhesus blood groups determined. The majority (86%) of the cases were males. Blood group O was the most common in the patients and controls followed by groups A, B, and AB. The vast majority of the study subjects were rhesus-positive. The gravy (Shiro) grass pea preparation was consumed by 91.6% of the study population, boiled (Nifiro) by 86%, and roasted (Kollo) by 56.4%. Almost half (48%) of the cases had consumed grass pea for > 4 months compared to 8% of controls (P<0.001). There was a significant association between the risk for neurolathyrism and the consumption of boiled (adjusted odds ratio [AOR] = 98.4) and roasted (AOR = 5562) forms of grass pea. There was no risk of paralysis associated with consumption of the gravy form of grass pea (AOR = 0.40, 95% confidence interval 0.1-2.0). Blood group O remained significantly associated with the disease after adjusting forage, type of grass pea preparation consumed, and duration of consumption (AOR = 2.90).	State Univ Ghent, Fac Med & Hlth Sci, Physiol Chem Lab, B-9000 Ghent, Belgium; S Gonder Hlth Dept, Gondar, Ethiopia; State Univ Ghent, Dept Publ Hlth, B-9000 Ghent, Belgium; Inst Trop Med, Epidemiol Unit, B-2000 Antwerp, Belgium	Lambein, F (reprint author), State Univ Ghent, Fac Med & Hlth Sci, Physiol Chem Lab, Jozef Kluyskensstr 27, B-9000 Ghent, Belgium.						Cooper GS, 1999, ENVIRON HEALTH PERSP, V107, P693, DOI 10.2307/3434329; *CSA, 1998, REP 1994 CENS AMH RE; FEIZI T, 1982, MED BIOL, V60, P7; Getahun H, 2002, TROP MED INT HEALTH, V7, P118, DOI 10.1046/j.1365-3156.2002.00836.x; Getahun H, 1999, LANCET, V354, P306, DOI 10.1016/S0140-6736(99)02532-5; GORODEZKY C, 1986, HUM IMMUNOL, V16, P364, DOI 10.1016/0198-8859(86)90063-7; Haimanot RT, 1993, NUTR RES, V13, P1113; Haque A, 1996, NEUROEPIDEMIOLOGY, V15, P83, DOI 10.1159/000109893; Jain RK, 1998, NEUROCHEM RES, V23, P1191, DOI 10.1023/A:1020782119057; Kauffmann F, 1996, AM J RESP CRIT CARE, V153, P76, DOI 10.1164/ajrccm.153.1.8542166; LaBella V, 1996, NEUROSCIENCE, V70, P1039, DOI 10.1016/0306-4522(95)00401-7; LAMBEIN F, 1994, TOXICON, V32, P461, DOI 10.1016/0041-0101(94)90298-4; Lambein Fernand, 1993, Natural Toxins, V1, P246, DOI 10.1002/nt.2620010408; MENTIS A, 1991, EPIDEMIOL INFECT, V106, P221, DOI 10.1017/S0950268800048366; NUNN PB, 1994, ARCH INT PHYSL BIOCH, V102, pB89; Spencer PS, 1999, DRUG METAB REV, V31, P561, DOI 10.1081/DMR-100101936; SPENCER PS, 1983, NEUROBEH TOXICOL TER, V5, P625; TEKLEHAIMANOT R, 1990, INT J EPIDEMIOL, V19, P664	18	2	2	0	0	ROYAL SOC TROPICAL MEDICINE	LONDON	MANSON HOUSE 26 PORTLAND PLACE, LONDON W1N 1EY, ENGLAND	0035-9203			T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	NOV-DEC	2002	96	6					700	703		10.1016/S0035-9203(02)90355-X				4	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	648RW	WOS:000181165200030	12625154				2019-03-26	
J	Talisuna, OA; D'Alessandro, U				Talisuna, OA; D'Alessandro, U			Malaria transmission, antimalarial-drug use, and resistance - Reply	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Letter									Minist Hlth, Kampala, Uganda; Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium	Talisuna, OA (reprint author), Minist Hlth, POB 7272, Kampala, Uganda.		D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009			Newton P, 2001, LANCET, V357, P1948, DOI 10.1016/S0140-6736(00)05085-6; Ogwal-Okeng JW, 1998, E AFR MED J, V75, P692; Shakoor O, 1997, TROP MED INT HEALTH, V2, P839, DOI 10.1046/j.1365-3156.1997.d01-403.x; TALISUNA, 2002, TRANSACTIONS, V96, P310	4	0	0	0	1	ROYAL SOC TROPICAL MEDICINE	LONDON	MANSON HOUSE 26 PORTLAND PLACE, LONDON W1N 1EY, ENGLAND	0035-9203			T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	NOV-DEC	2002	96	6					704	704		10.1016/S0035-9203(02)90358-5				1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	648RW	WOS:000181165200032					2019-03-26	
J	Tinto, H; Zoungrana, EB; Coulibaly, SO; Ouedraogo, JB; Traore, M; Guiguemde, TR; Van Marck, E; D'Alessandro, U				Tinto, H; Zoungrana, EB; Coulibaly, SO; Ouedraogo, JB; Traore, M; Guiguemde, TR; Van Marck, E; D'Alessandro, U			Chloroquine and sulphadoxine-pyrimethamine efficacy for uncomplicated malaria treatment and haematological recovery in children in Bobo-Dioulasso, Burkina Faso during a 3-year period 1998-2000	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						malaria; chloroquine; sulphadoxine-pyremethamine; resistance; children; Burkina Faso	PLASMODIUM-FALCIPARUM; SULFADOXINE; AFRICA	We determined the parasitological resistance and the clinical failure to chloroquine (CQ) and sulphadoxine-pyrimethamine (SP) by the WHO 14-day in vivo test over three consecutive years in 948 children aged 6-59 months with uncomplicated malaria attending four health centres in the province of Houet, Burkina Faso. Children were alternatively allocated to either CQ or SP. Packed cell volume (PCV) was measured at days 0 and 14. Parasitological resistance (RI, RII and RIII) to CQ was 18% (83 of 455) and to SP <1% (two of 308). Clinical failure with CQ was 12% (53 of 455) with no evidence of increase over time. Only one case of clinical failure was detected among the children treated with SP. The prevalence of anaemia (PCV <25%) was about 40% at day 0 and had decreased substantially by day 14 in both groups. However, in children treated with SP the prevalence of anaemia at day 14 was significantly lower than in those treated with CQ: RR = 3.15 (95% CI: 1.33-7.42, P = 0.008). CQ and SP are still efficacious for the treatment of uncomplicated malaria in children, at least in this area of Burkina Faso. However, the prevalences of CQ resistance reported from other areas of the country are worrying because of its potential spread. Regular surveillance of resistance to commonly used antimalarial drugs should continue.	IRSS, Ctr Muraz, Bobo Dioulasso, Burkina Faso; Inst Rech Sci Sante, Bobo Dioulasso, Burkina Faso; Univ Antwerp, B-2020 Antwerp, Belgium; Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium	Tinto, H (reprint author), IRSS, Ctr Muraz, 01 BP 153, Bobo Dioulasso, Burkina Faso.		D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009			BAKYAITA N, 2000, INT C ANTW 4 6 DEC 2, P50; BAUDON D, 1984, B SOC PATHOL EXOT, V77, P658; BLOLAND PB, 1993, J INFECT DIS, V167, P932, DOI 10.1093/infdis/167.4.932; Del Nero L., 1994, Parassitologia (Rome), V36, P287; Diourte Y, 1999, AM J TROP MED HYG, V60, P475, DOI 10.4269/ajtmh.1999.60.475; DOUMBO SN, 1999, THESIS BAMAKO; GUIGUEMDE TR, 1994, AM J TROP MED HYG, V50, P699, DOI 10.4269/ajtmh.1994.50.699; KEITA M, 1994, MALARIA PALUDISME MA, V1, P32; LEBRAS J, 1986, B EPIDEMIOLOGIQUE HE, V41, P163; *MIN SANT DEP, 1995, STAT SAN NAT ANN 199; OUEDRAOGO JB, 1998, TROP MED INT HEALTH, V5, P381; ROBERT V, 1988, ANN SOC BELG MED TR, V68, P107; von Seidlein L, 2000, LANCET, V355, P352, DOI 10.1016/S0140-6736(99)10237-X; *WHO, 1996, WHOMAL961077; WHO, 1993, GLOB STRAT MAL CONTR	15	22	23	0	1	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	NOV	2002	7	11					925	930		10.1046/j.1365-3156.2002.00952.x				6	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	607QD	WOS:000178801500004	12390597	Bronze			2019-03-26	
J	Claeys, P; Gonzalez, C; Gonzalez, M; Page, H; Bello, RE; Temmerman, M				Claeys, P; Gonzalez, C; Gonzalez, M; Page, H; Bello, RE; Temmerman, M			Determinants of cervical cancer screening in a poor area: results of a population-based survey in Rivas, Nicaragua	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						cervical cancer; determinants; population-based survey	SOUTH-AFRICA; WOMEN; PROGRAMS	OBJECTIVE To obtain baseline information for designing a community-based intervention programme aimed at increasing the cervical cancer screening coverage of women most at risk. METHODS A population-based survey, using proportional stratified two-stage cluster sampling in Rivas, one of the 16 Departments of Nicaragua. The individuals selected were interviewed at home by one of 26 interviewers, using a structured questionnaire. The questionnaire was designed to elicit (1) knowledge, attitudes and practices concerning sexual and reproductive health and behaviour, (2) risk factors for cervical cancer and (3) the use of health and cervical cancer screening services. RESULTS A total of 612 men and 634 women participated in the survey. Of the women who had been sexually active at least 3 years, only 41.1% had undergone screening within that period and were considered adequately screened. Correlates of inadequate screening status included low educational level, exclusive use of public health facilities and lack of knowledge about prevention and symptoms of cervical cancer. Negligence, absence of medical problems, fear, lack of knowledge and economic reasons were the main reasons given for not being screened. Reluctance to be screened in the future was related to lack of knowledge of the disease, inadequate screening status, older age and low educational level. CONCLUSIONS The current screening programme is not effective in reaching the majority of the population. Complementary activities such as education and information, as well as a more pro-active approach to invite women for screening are necessary.	State Univ Ghent, Int Ctr Reprod Hlth, B-9000 Ghent, Belgium; Univ Nacl Autonoma Nicaragua, Dept Microbiol, Managua, Nicaragua; State Univ Ghent, Dept Populat Studies & Social Sci Res Methods, B-9000 Ghent, Belgium; Serv Med Comunales, San Juan Del Sur, Nicaragua	Temmerman, M (reprint author), State Univ Ghent Hosp, Int Ctr Reprod Hlth, Pintelaan 185,P3, B-9000 Ghent, Belgium.						BENDER DE, 1987, SOC SCI MED, V24, P515, DOI 10.1016/0277-9536(87)90341-8; Bird JA, 1998, PREV MED, V27, P821, DOI 10.1006/pmed.1998.0365; Bishop A, 1995, REPROD HEALTH MATTER, V6, P60; Branoff R, 1997, Fam Med, V29, P119; BRINTON LA, 1989, INT J CANCER, V44, P199, DOI 10.1002/ijc.2910440202; Claeys P, 2002, SEX TRANSM INFECT, V78, P204, DOI 10.1136/sti.78.3.204; Eluf-Neto J, 2001, SEMIN ONCOL, V28, P188, DOI 10.1053/sonc.2001.21966; HAKAMA M, 1985, MATURITAS, V7, P3, DOI 10.1016/0378-5122(85)90029-5; HERRERO R, 1990, Boletin de la Oficina Sanitaria Panamericana, V109, P6; Herrero R, 1993, Bull Pan Am Health Organ, V27, P15; Hislop TG, 1996, CAN FAM PHYSICIAN, V42, P1701; Hoffman M, 1997, SOC SCI MED, V45, P149, DOI 10.1016/S0277-9536(96)00328-0; *I NAC EST CENS MI, 1998, ENC NIC DEM SAL; Irwin K L, 1991, Bull Pan Am Health Organ, V25, P16; LAARA E, 1987, LANCET, V1, P1247; Marcus AC, 1998, PREV MED, V27, P13, DOI 10.1006/pmed.1997.0251; MILLER AB, 1992, CERVICAL CANC SCREEN; MONTOYA O, 2001, COMISION EC AM LATIN, V82, P5; Pan American Health Organization, 1998, HLTH AM, V1; Parkin DM, 1999, INT J CANCER, V80, P827, DOI 10.1002/(SICI)1097-0215(19990315)80:6<827::AID-IJC6>3.0.CO;2-P; Wood K, 1997, SOC SCI MED, V45, P283, DOI 10.1016/S0277-9536(96)00344-9; Zelaya E, 1997, J ADOLESCENT HEALTH, V21, P39, DOI 10.1016/S1054-139X(96)00277-7	22	24	27	0	5	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	NOV	2002	7	11					935	941		10.1046/j.1365-3156.2002.00953.x				7	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	607QD	WOS:000178801500006	12390599	Bronze			2019-03-26	
J	Chappuis, F; Pittet, A; Bovier, PA; Adams, K; Godineau, V; Hwang, SY; Magnus, E; Buscher, P				Chappuis, F; Pittet, A; Bovier, PA; Adams, K; Godineau, V; Hwang, SY; Magnus, E; Buscher, P			Field evaluation of the CATT/Trypanosoma brucei gambiense on blood-impregnated filter papers for diagnosis of human African trypanosomiasis in southern Sudan	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						African trypanosomiasis; diagnosis; CATT; filter paper; Sudan	SLEEPING SICKNESS; CATT; SAMPLES; ANGOLA; FOCUS	Most Human African Trypanosomiasis (HAT) control programmes in areas endemic for Trypanosoma brucei gambiense rely on a strategy of active mass screening with the Card Agglutination Test for Trypanosomiasis (CATT)/T. b. gambiense. We evaluated the performance, stability and reproducibility of the CATT/T. b. gambiense on blood-impregnated filter papers (CATT-FP) in Kajo-Keji County, South-Sudan, where some areas are inaccessible to mobile teams. The CATT-FP was performed with a group of 100 people with a positive CATT on whole blood including 17 confirmed HAT patients and the results were compared with the CATT on plasma (CATT-P). The CATT-FP was repeated on impregnated filter papers stored at ambient and refrigerated temperature for 1, 3, 7 and 14 days. Another 82 patients with HAT, including 78 with a positive parasitology, were tested with the CATT-FP and duplicate filter paper samples were sent to a reference laboratory to assess reproducibility. The CATT-FP was positive in 90 of 99 patients with HAT (sensitivity: 91%). It was less sensitive than the CATT-P (mean dilution difference: -2.5). There was no significant loss of sensitivity after storage for up to 14 days both at ambient and cool temperature. Reproducibility of the CATT-FP was found to be excellent (kappa: 0.84). The CATT-FP can therefore be recommended as a screening test for HAT in areas where the use of CATT-P is not possible. Further studies on larger population samples in different endemic foci are still needed before the CATT-FP can be recommended for universal use.	Med Sans Frontieres, CH-1211 Geneva 6, Switzerland; Univ Hosp Geneva, Dept Community Med, Geneva, Switzerland; Univ Hosp Geneva, Qual Care Unit, Geneva, Switzerland; Inst Trop Med Prince Leopold, Dept Parasitol, B-2000 Antwerp, Belgium	Chappuis, F (reprint author), Med Sans Frontieres, Rue Lac 12, CH-1211 Geneva 6, Switzerland.		Buscher, Philippe/B-9956-2012	Buscher, Philippe/0000-0002-1926-7472			[Anonymous], 1998, WHO TECHN REP SER, V881; Boelaert M, 1999, TROP MED INT HEALTH, V4, P395, DOI 10.1046/j.1365-3156.1999.00421.x; Ekwanzala M, 1996, LANCET, V348, P1427, DOI 10.1016/S0140-6736(96)06088-6; MAGNUS E, 1978, ANN SOC BELG MED TR, V58, P169; MIEZAN T, 1991, B WORLD HEALTH ORGAN, V69, P603; Moore A, 2001, TROP MED INT HEALTH, V6, P342, DOI 10.1046/j.1365-3156.2001.00714.x; NOIREAU F, 1991, B WORLD HEALTH ORGAN, V69, P607; Simarro PP, 1999, TROP MED INT HEALTH, V4, P858, DOI 10.1046/j.1365-3156.1999.00494.x; Stanghellini A, 2001, TROP MED INT HEALTH, V6, P330, DOI 10.1046/j.1365-3156.2001.00724.x; STANGHELLINI A, 1999, PROGR HUMAN AFRICAN, P301; Van Nieuwenhove S, 2001, TROP MED INT HEALTH, V6, P335, DOI 10.1046/j.1365-3156.2001.00731.x	11	17	19	0	3	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	NOV	2002	7	11					942	948		10.1046/j.1365-3156.2002.00956.x				7	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	607QD	WOS:000178801500007	12390600	Bronze			2019-03-26	
J	Boelaert, M; Le Ray, D; Van der Stuyft, P				Boelaert, M; Le Ray, D; Van der Stuyft, P			How better drugs could change kala-azar control. Lessons from a cost-effectiveness analysis	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						visceral leishmaniasis; drug treatment; cost-effectiveness analysis	INDIAN VISCERAL LEISHMANIASIS; SODIUM STIBOGLUCONATE; EFFICACY; SUDAN	Conditional on correct diagnosis and treatment, current drug regimens for visceral leishmaniasis (VL) will only prevent about 90% of deaths. Furthermore, the cost of pentavalent antimonials, the long duration of the regimen and its parenteral administration are major obstacles for patients. Poor patient compliance and the use of counterfeit drugs contribute to therapeutic failure, amplification of the reservoir and the appearance of drug resistance. We assessed the impact of potential improvements in chemotherapy on the cost-effectiveness of VL test-treatment strategies. Competing test-treatment strategies were compared in a formal decision analysis - from the viewpoint of the clinician facing a VL suspect -, with avoided VL-mortality and cost as outcomes of interest. Sensitivity analysis was done involving the following parameters: efficacy, toxicity and cost of treatment including patient care. When safer and more efficacious drugs are considered, they only result in a more cost-effective strategy if the total cost of treatment falls below US$ 390 per patient. A serological test-treatment strategy remains the optimal choice, also when better drugs become available.	Inst Trop Med Prince Leopold, Epidemiol Unit, B-2000 Antwerp, Belgium	Boelaert, M (reprint author), Inst Trop Med Prince Leopold, Epidemiol Unit, Natl Str 155, B-2000 Antwerp, Belgium.		Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776			ADDY M, 1992, B WORLD HEALTH ORGAN, V70, P341; Alvar J, 1997, CLIN MICROBIOL REV, V10, P298, DOI 10.1128/CMR.10.2.298; BALLOU WR, 1987, LANCET, V2, P13; Boelaert M, 1999, TROP MED INT HEALTH, V4, P31, DOI 10.1046/j.1365-3156.1999.00348.x; Boelaert M, 1999, B WORLD HEALTH ORGAN, V77, P667; Boelaert M, 2000, T ROY SOC TROP MED H, V94, P465, DOI 10.1016/S0035-9203(00)90055-5; ELHARITH AE, 1986, T ROY SOC TROP MED H, V80, P583; Elnaiem DA, 1999, MED VET ENTOMOL, V13, P310, DOI 10.1046/j.1365-2915.1999.00191.x; Griekspoor A, 1999, HEALTH POLICY PLANN, V14, P70, DOI 10.1093/heapol/14.1.70; HERWALDT BL, 1992, AM J TROP MED HYG, V46, P296, DOI 10.4269/ajtmh.1992.46.296; Jha TK, 1999, NEW ENGL J MED, V341, P1795, DOI 10.1056/NEJM199912093412403; MARSDEN PD, 1986, T ROY SOC TROP MED H, V80, P859, DOI 10.1016/0035-9203(86)90243-9; Sundar S, 1997, J INFECT DIS, V176, P1117, DOI 10.1086/516526; SUNDAR S, 1997, J ASSOC PHYSICIAN I, V45, P640; Thakur CP, 1998, ANN TROP MED PARASIT, V92, P561, DOI 10.1080/00034983.1998.11813313; Veeken H, 2000, TROP MED INT HEALTH, V5, P312, DOI 10.1046/j.1365-3156.2000.00555.x	16	20	21	0	3	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	NOV	2002	7	11					955	959		10.1046/j.1365-3156.2002.00959.x				5	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	607QD	WOS:000178801500009	12390602	Bronze			2019-03-26	
J	Gupta, R; Cegielski, JP; Espinal, MA; Henkens, M; Kim, JY; Lambregts-van Weezenbeek, CSB; Lee, JW; Raviglione, MC; Suarez, PG; Varaine, F				Gupta, R; Cegielski, JP; Espinal, MA; Henkens, M; Kim, JY; Lambregts-van Weezenbeek, CSB; Lee, JW; Raviglione, MC; Suarez, PG; Varaine, F			Increasing transparency in partnerships for health - introducing the Green Light Committee	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						MDR-TB; partnerships; access to drugs; tuberculosis	PUBLIC-PRIVATE PARTNERSHIPS; DRUG-RESISTANT TUBERCULOSIS	Public-private partnerships have become central to efforts to combat infectious diseases. The characteristics of specific partnerships, their governance structures, and their ability to effectively address the issues for which they are developed are being clarified as experience is gained. In an attempt to promote access to and rational use of second-line anti-tuberculosis (TB) drugs for the treatment of multidrug-resistant TB, a unique partnership known as the Green Light Committee (GLC) was established by the World Health Organization. This partnership relies on five categories of actors to achieve its goal: academic institutions, civil society organizations, bilateral donors, governments of resource-limited countries, and a specialized United Nations agency. While the for-profit private sector is involved in terms of supplying concessionally priced drugs it is excluded from decision-making. The effectiveness of the partnership emerges from its review process, flexibility to modify its modus operandi to overcome obstacles, independence from the commercial sector, and its ability to link access, rational use, technical assistance, and policy development. The GLC mechanism may be useful in the development of other partnerships needed in the rational allocation of resources and tools for combating additional infectious diseases.	WHO, CDS, STB, TBS, CH-1211 Geneva, Switzerland; Harvard Univ, Sch Med, Programme Infect Dis & Social Change, Boston, MA USA; Ctr Dis Control & Prevent, Int Act Branch, Atlanta, GA USA; Med Sans Frontieres, Int Off, Brussels, Belgium; Royal Netherlands TB Assoc, The Hague, Netherlands; Minist Salud, Programa Control TB, Lima, Peru; Med Sans Frontieres, Paris, France	Gupta, R (reprint author), WHO, CDS, STB, TBS, 20 Ave Appia, CH-1211 Geneva, Switzerland.			RAVIGLIONE, Mario/0000-0002-9331-2067			BIRMINGHAM K, 2000, NAT MED, V5, P481; Brugha R, 2002, LANCET, V359, P435, DOI 10.1016/S0140-6736(02)07607-9; Brugha R, 2001, BRIT MED J, V323, P152, DOI 10.1136/bmj.323.7305.152; BRUNDTLAND GH, 2001, STOP TB PARTNERS FOR; BRUNDTLAND GH, 2001, AM PUBL HLTH ASS ANN; Buse K, 2000, B WORLD HEALTH ORGAN, V78, P699; Buse K, 2000, B WORLD HEALTH ORGAN, V78, P549; Buse K, 2001, B WORLD HEALTH ORGAN, V79, P748; Cullinan T, 2001, LANCET, V357, P1124, DOI 10.1016/S0140-6736(00)04268-9; DONNELLY J, 2001, BOSTON GLOBE    0625; DONNELLY J, 2001, BOSTON GLOBE    0717; DYE C, 2001, J INFECT DIS, V185, P1197; Farmer P, 2001, LANCET, V358, P404, DOI 10.1016/S0140-6736(01)05550-7; FREEMAN P, 1999, PAN AM HLTH ORG REVO; *GREEN LIGHT COMM, 2002, INT J TUBERCULOSIS, V6, P1; Gupta R, 2001, SCIENCE, V293, P1049, DOI 10.1126/science.1061861; GUPTA R, 1999, PROCUREMENT 2 LINE A; GUPTA R, 2001, P M WORK GROUP DOTS; Gupta Rajesh, 2000, GUIDELINES ESTABLISH; Heaton A, 2002, LONG WAY GO CRITIQUE; LAMBREGTSVANWEE.CS, 2001, INT J TUBERC LUNG D, V4, P995; LAMBREGTSVANWEEZENBEEK CSB, 1995, TUBERCLE LUNG DIS, V76, P455, DOI 10.1016/0962-8479(95)90014-4; Reich MR, 2000, NAT MED, V6, P617, DOI 10.1038/76176; Smith R, 2000, BRIT MED J, V320, P952, DOI 10.1136/bmj.320.7240.952; *SOC INT DEV, 2001, INT SEM GLOB PUBL PR; *WHO, 2001, DOTS PLUS GREEN LIGH; *WHO, 2002, GLOB TUB CONTR SURV; *WHO, 2001, 6 M 20 21 SEPT 2000; *WHO, 2001, INSTR APPL GREEN LIG; Widdus R, 2001, B WORLD HEALTH ORGAN, V79, P713; [World Health Organization International Union Against Tuberculosis and Lung Disease Global Project on Anti-Tuberculosis Drug Resistance Surveillance], 1997, ANT DRUG RES WORLD W	31	86	87	1	10	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	NOV	2002	7	11					970	976		10.1046/j.1365-3156.2002.00960.x				7	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	607QD	WOS:000178801500011	12390604	Bronze			2019-03-26	
J	Grodos, D; Tonglet, R				Grodos, D; Tonglet, R			Managing a coherent and effective health care system in Subsaharan African cities: The health care district put to the test	TROPICAL MEDICINE & INTERNATIONAL HEALTH			French	Article						health policy; health system; health district; health sector reform; urban health; primary health care	DEVELOPING-COUNTRIES; PRIVATE-SECTOR; SERVICES; EXPERIENCE; STRATEGIES; LESSONS; DOCTORS; NEED	BACKGROUND Urban health is a fashionable topic which generates a bulk of research work most often focused on particularities of health problems in urban settings. This focus distracts from the importance of research on how local urban health systems are organized and managed. OBJECTIVE To analyse the conceptual, managerial and technical problems faced by urban health system policy and organization in sub-Saharan Africa, in order to make recommendations. METHODS We report here on a research programme carried out to review the available evidence on health system policy and organization in urban areas, and to learn lessons from a number of case studies. RESULTS First, while the health district approach is usually regarded as a means of implementing primary health care in rural areas, we argue that it is likewise appropriate - theoretically and empirically - for the formulation and implementation of a coherent and effective health system in urban areas. Secondly, we concentrate on a number of contextual features that have to be taken into account in order to strengthen district organization and management in the urban context. Spatial, managerial and technical constraints which do not exist in rural areas, proliferation and fragmentation of uncontrolled health services in the private sector, lack of control over political power of the large national and university hospitals, insufficient governance and leadership of the urban health authorities are pointed out for attention. Having noted and thoroughly analysed these issues is not to suggest therefore that the health district approach has to be rejected but that it has to be modified and adapted in key respects. Thirdly, we outline district health system strengthening in the cities as a policy option less fashionable but more appropriate, including the World Bank agenda for reform, the sector-wide approaches for health development, the health promotion approaches based on the Ottawa Charter, and the poverty reduction approaches focusing on coping strategies of local actors. CONCLUSION Greater achievements could be reached by urban health systems in sub-Saharan Africa if they were organized and structured according to a health district policy. Key elements of such an organizational and managerial strategy should be realistically understood and assessed so as to provide health managers with a suitable tool for the successful development of primary health care in urban settings. Given the identified contextual constraints, implementation of a district health system in an urban context appears to depend mainly on political will and decision. It calls only incidentally for technical solutions. The following are among the most important requirements that have to be taken into account: ensuring appropriate allocation of resources to a legitimate urban health authority responsible for effective co-ordination of the many actors involved in urban health, setting out key developmental guidelines for the big city hospitals and effective communication channels with these institutions, ensuring development regulation and good governance of the private health sector. The role of the state remains crucial in this perspective.	Univ Catholique Louvain, Ecole Sante Publ, Unite Epidemiol EPID 30 34, B-1200 Brussels, Belgium	Grodos, D (reprint author), Univ Catholique Louvain, Ecole Sante Publ, Unite Epidemiol EPID 30 34, Clos Chapelle Champs 30, B-1200 Brussels, Belgium.						ABELSMITH B, 1992, HEALTH POLICY PLANN, V7, P215, DOI 10.1093/heapol/7.3.215; ABELSMITH B, 1992, HEALTH POLICY PLANN, V7, P329, DOI 10.1093/heapol/7.4.329; Akin John S., 1987, FINANCING HLTH SERVI; Atkinson S, 1999, SOC SCI MED, V49, P27, DOI 10.1016/S0277-9536(99)00072-6; Banerji D, 1978, Dev Dialogue, V1, P19; *BANQ MOND, 1994, BETT HLTH AFR EXP LE; *BANQ MOND, 1993, RAPP DEV MOND 1993 I; *BANQ MOND, 1997, STRAT SECT SANT NUTR; Banque Mondiale, 1994, MEILL SANT AFR LEC E; BENNETT S, 1994, HEALTH POLICY PLANN, V9, P1; BENNETT S, 1992, HEALTH POLICY PLANN, V7, P97, DOI 10.1093/heapol/7.2.97; BENNETT S, 1993, INT J HLTH PLANNING, V8, P137; Brugha R, 1998, HEALTH POLICY PLANN, V13, P107, DOI 10.1093/heapol/13.2.107; BRUNETJAILLY J, 1997, INNOVERA SYSTEMES SA; Carrin G, 1998, TROP MED INT HEALTH, V3, P512, DOI 10.1046/j.1365-3156.1998.00261.x; Cassels A, 1998, LANCET, V352, P1777, DOI 10.1016/S0140-6736(98)05350-1; Cassels A, 1997, GUIDE SECTOR WIDE AP; Collins C, 1989, HEALTH POLICY PLANN, V4, P168; Develay A, 1996, SOC SCI MED, V43, P1611, DOI 10.1016/S0277-9536(96)00061-5; FASSIN D., 1992, POUVOIR MALADIE AFRI; Ferrinho P, 1998, HEALTH POLICY PLANN, V13, P332, DOI 10.1093/heapol/13.3.332; FOUREZ G, 2000, REV NOUV, V2, P88; Gilson L, 1997, HEALTH POLICY PLANN, V12, P273; GILSON L, 1988, UNPUB GOVT HLTH CARE; Grodos D, 2000, STUDIES HLTH SERVICE, V14; GRODOS D, 2000, THESIS U CATHOLIQUE; GRUNDY F, 1973, CAHIERS SANTE PUBLIQ, V51; HARPHAM T, 1995, URBAN HLTH DEV COUNT; HARPHAM T, 1988, SHADOW CITY COMMUNIT; Harpham T, 1996, URBAN HLTH RES DEV C; KUTZIN J, 1992, INT J HLTH PLANNING, V7, P51; Leighton C, 1996, WORLD DEV, V24, P1511, DOI 10.1016/0305-750X(96)00058-7; LEIGHTON C, 1995, HEALTH POLICY PLANN, V10, P213, DOI 10.1093/heapol/10.3.213; McMichael AJ, 2000, B WORLD HEALTH ORGAN, V78, P1117; MCPAKE B, 1993, SOC SCI MED, V36, P1397, DOI 10.1016/0277-9536(93)90382-E; MOULOUD N, 1995, ENCY UNIVERSALIS, V15, P529; *OMS FISE, 1978, SER SANT TOUS OMS, V1; *OMS WHO, 1987, WHOHPRHEP951 OMS; Roenen C, 1997, TROP MED INT HEALTH, V2, P127, DOI 10.1046/j.1365-3156.1997.d01-240.x; Rossi-Espagnet A., 1984, 2499M UNICEF WHO; Russell S, 1996, HEALTH POLICY PLANN, V11, P219, DOI 10.1093/heapol/11.3.219; SALEM Gerard, 1998, SANTE VILLE GEOGRAPH; SROME B, 1988, ROLE HOPITAL RENFORC; TABIBZADEH I, 1991, PLEINS FEUX VILLES A; TABIBZADEH I, 1989, SPOTLIGHT CITY IMPRO; VANLERBERGHE W, 1992, ANN SOC BELGE MED S2, V72; WALT G, 1994, HEALTH POLICY PLANN, V9, P353, DOI 10.1093/heapol/9.4.353; *WHO, 1991, WORLD HLTH STAT Q, V44, P185; WILLEMS M, 2001, TRAVAUX UERD, V11; World Health Organization (WHO), 1987, WHOSHSDHS8713; Zwi AB, 2001, BRIT MED J, V323, P463, DOI 10.1136/bmj.323.7311.463	51	6	6	0	4	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	NOV	2002	7	11					977	992		10.1046/j.1365-3156.2002.00925.x				16	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	607QD	WOS:000178801500012	12390605				2019-03-26	
J	Polman, K; Stelma, FF; le Cessie, S; de Vlas, SJ; Ferreira, STMF; Talla, I; Deelder, AM; Gryseels, B				Polman, K; Stelma, FF; le Cessie, S; de Vlas, SJ; Ferreira, STMF; Talla, I; Deelder, AM; Gryseels, B			Evaluation of the patterns of Schistosoma mansoni infection and re-infection in Senegal, from faecal egg counts and serum concentrations of circulating anodic antigen	ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY			English	Article							RECENTLY EXPOSED COMMUNITY; NORTHERN SENEGAL; HAEMATOBIUM INFECTION; CATHODIC ANTIGEN; WORM BURDEN; CURE RATES; PRAZIQUANTEL; CHEMOTHERAPY; FOCUS; RESPONSES	Infection and re-infection patterns were evaluated in a recent Schistosoma mansoni focus in northern Senegal, by determining concentrations of serum circulating anodic antigen (CAA), as a measure of worm burden, and counting eggs in faeces before, 6 or 12 weeks and 1 year after praziquantel treatment in two subsequent cohorts (cohort A and B). No differences in egg counts and CAA concentrations or their relationship were found between the cohorts, which were examined 2 years apart. Within both cohorts, CAA concentrations showed the same, typical, age-related patterns as egg counts, with a peak in children and a strong decline in adults. These trends were apparent both before and 1 year after treatment. The results indicate that an age-related resistance to infection and to re-infection has been firmly established, at a steady level, in the recent S. mansoni focus investigated, with no indication of a gradual development of immunity or anti-fecundity immunity over a period of 2 years. Both shortly and 1 year after treatment, the decrease in egg counts was stronger than that in CAA concentrations, indicating that that there had been a reduction in worm fecundity after treatment. The possibility that praziquantel may induce anti-fecundity immunity has important implications for the use and interpretation of the results of (egg-count-based) re-infection studies designed to follow the development of naturally acquired immunity.	Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium; Leiden Univ, Med Ctr, Dept Parasitol, NL-2300 RC Leiden, Netherlands; Univ Maastricht, Dept Epidemiol, NL-6200 MD Maastricht, Netherlands; Leiden Univ, Med Ctr, Dept Med Stat, NL-2300 RC Leiden, Netherlands; Erasmus Univ, Dept Publ Hlth, NL-3000 DR Rotterdam, Netherlands; Reg Med St Louis, St Louis, Senegal	Polman, K (reprint author), Inst Trop Med Prince Leopold, Natl Str 155, B-2000 Antwerp, Belgium.			le Cessie, Saskia/0000-0003-2154-4923			AGNEW A, 1995, PARASITOLOGY, V111, P67, DOI 10.1017/S0031182000064611; AGNEW AM, 1996, AM J TROP MED HYG, V53, P338; BUTTERWORTH AE, 1994, PARASITOL TODAY, V10, P378, DOI 10.1016/0169-4758(94)90225-9; Capron A, 1998, PARASITOL TODAY, V14, P379, DOI 10.1016/S0169-4758(98)01322-2; Cioli D, 1998, PARASITOL TODAY, V14, P418, DOI 10.1016/S0169-4758(98)01323-4; DEELDER AM, 1989, AM J TROP MED HYG, V40, P268, DOI 10.4269/ajtmh.1989.40.268; DEELDER AM, 1994, TROPICAL GEOGRAPHICA, V46, P235; ERBEKE G, 1997, LINEAR MIXED MODELS; Grogan JL, 1996, J INFECT DIS, V173, P1242, DOI 10.1093/infdis/173.5.1242; GRYSEELS B, 1994, PARASITOL TODAY, V10, P380, DOI 10.1016/0169-4758(94)90226-7; Gryseels B, 2001, TROP MED INT HEALTH, V6, P864, DOI 10.1046/j.1365-3156.2001.00811.x; GRYSEELS B, 1994, TROP GEOGR MED, V46, P209; Guisse F, 1997, AM J TROP MED HYG, V56, P511, DOI 10.4269/ajtmh.1997.56.511; Katz N, 1972, Rev Inst Med Trop Sao Paulo, V14, P397; KREMSNER PG, 1994, CLIN INFECT DIS, V18, P408, DOI 10.1093/clinids/18.3.408; Mutapi F, 1998, PARASITE IMMUNOL, V20, P595; Mutapi F, 1998, J INFECT DIS, V178, P289, DOI 10.1086/517456; Mutapi F, 2001, TRENDS PARASITOL, V17, P518, DOI 10.1016/S1471-4922(01)02118-3; POLDERMAN AM, 1985, ANN SOC BELG MED TR, V65, P243; POLMAN K, 1995, AM J TROP MED HYG, V53, P152, DOI 10.4269/ajtmh.1995.53.152; Polman K, 2001, TROP MED INT HEALTH, V6, P538, DOI 10.1046/j.1365-3156.2001.00742.x; Polman K, 2001, PARASITOLOGY, V122, P161, DOI 10.1017/S0031182001007193; Polman K, 2000, PARASITOLOGY, V121, P601, DOI 10.1017/S0031182000006843; Stelma FF, 1997, J INFECT DIS, V176, P304, DOI 10.1086/517273; STELMA FF, 1995, AM J TROP MED HYG, V53, P167, DOI 10.4269/ajtmh.1995.53.167; STELMA FF, 1993, AM J TROP MED HYG, V49, P701, DOI 10.4269/ajtmh.1993.49.701; Van Lieshout L, 1999, AM J TROP MED HYG, V61, P760, DOI 10.4269/ajtmh.1999.61.760; Van Lieshout L, 1998, T ROY SOC TROP MED H, V92, P115, DOI 10.1016/S0035-9203(98)90980-4; VANLIESHOUT L, 1995, J INFECT DIS, V172, P1336, DOI 10.1093/infdis/172.5.1336; Woolhouse MEJ, 1999, NAT MED, V5, P1225, DOI 10.1038/15169	30	12	12	0	4	MANEY PUBLISHING	LEEDS	HUDSON RD, LEEDS LS9 7DL, ENGLAND	0003-4983			ANN TROP MED PARASIT	Ann. Trop. Med. Parasitol.	OCT	2002	96	7					679	689		10.1179/000349802125001708				11	Public, Environmental & Occupational Health; Parasitology; Tropical Medicine	Public, Environmental & Occupational Health; Parasitology; Tropical Medicine	621FF	WOS:000179577300004	12537629				2019-03-26	
J	Gomez-Marin, JE; Franco, CIL; Guerrero, MI; Rigouts, L; Portaels, F				Gomez-Marin, JE; Franco, CIL; Guerrero, MI; Rigouts, L; Portaels, F			IS6110 fingerprinting of sensitive and resistant strains (1991-1992) of Mycobacterium tuberculosis in Colombia	MEMORIAS DO INSTITUTO OSWALDO CRUZ			English	Article						IS6110; Mycobacterium tuberculosis; Colombia	FRAGMENT-LENGTH-POLYMORPHISM; EPIDEMIOLOGY; TRANSMISSION; RESTRICTION	The standardized method to study the polymorphism of IS6110 was used to characterize 53 isolates of Mycobacterium tuberculosis obtained during 1991-1992 from 14 regions in Colombia. In Valle region cluster rate was 25% (4/16). The mean number of IS6110 band was 10 +/- 3. Similarity between strains was of 60% in 81% of strains and this tended to be correlated with geographic origin. For the first time M. tuberculosis without IS6110 bands in restriction fragment length polymorphism analysis was found in Colombia. Additional studies are necessaries in order to best characterize the situation in relation to human immunodeficiency virus epidemic and recent changes in tuberculosis control program.	Univ Quindio, Fac Med, Ctr Invest Biomed, Armenia, Q, Colombia; Inst Nacl Salud, Subdirecc Invest & Desarrollo, Lab Micobacterias, Bogota, Colombia; Inst Trop Med, Lab Mycobacteriol, B-2000 Antwerp, Belgium	Gomez-Marin, JE (reprint author), Univ Quindio, Fac Med, Ctr Invest Biomed, Armenia, Q, Colombia.	jegomezmarin@hotmail.com	Gomez-Marin, Jorge/L-9793-2013	Gomez-Marin, Jorge/0000-0001-6472-3329			CANNETTI G, 1969, B WORLD HEALTH ORGAN, V41, P21; CRAWFORD JT, 1993, RES MICROBIOL, V144, P111, DOI 10.1016/0923-2508(93)90024-V; Diaz R, 2001, MEM I OSWALDO CRUZ, V96, P437, DOI 10.1590/S0074-02762001000400001; Escalante P., 1998, Tubercle and Lung Disease, V79, P111, DOI 10.1054/tuld.1998.0013; Ferrazoli L, 2000, INT J TUBERC LUNG D, V4, P18; GENEWEIN A, 1993, LANCET, V342, P841, DOI 10.1016/0140-6736(93)92698-S; Gomez Marin J E, 1995, Bull Pan Am Health Organ, V29, P226; Henao G, 1999, INFORME QUINCENAL EP, V4, P85; HERMANS PWM, 1995, J INFECT DIS, V171, P1504, DOI 10.1093/infdis/171.6.1504; Kent PT, 1985, PUBLIC HLTH MYCOBACT; LASLO A, 1995, B OFICINA SANIT PANA, V119, P226; OROZCO LC, 1985, I NACL SALUD SERIE P, V1; PinedaGarcia L, 1997, J CLIN MICROBIOL, V35, P2393; Sola C, 1997, J CLIN MICROBIOL, V35, P843; Suffys PN, 2000, RES MICROBIOL, V151, P343, DOI 10.1016/S0923-2508(00)00157-1; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406; VanSoolingen D, 1996, J BACTERIOL, V178, P78, DOI 10.1128/jb.178.1.78-84.1996; VANSOOLINGEN D, 1991, J CLIN MICROBIOL, V29, P2578; VANSOOLINGEN D, 1993, J CLIN MICROBIOL, V31, P1987; VICTORIA JE, 1999, INFORME QUINCENAL EP, V4, P82; Yang ZH, 2001, INT J TUBERC LUNG D, V5, P313; YANG ZH, 1994, J CLIN MICROBIOL, V32, P3018; YANG ZH, 1995, J CLIN MICROBIOL, V33, P1064; YUEN LKW, 1993, J CLIN MICROBIOL, V31, P1615	24	0	3	0	0	FUNDACO OSWALDO CRUZ	RIO DE JANEIRO, RJ	AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL	0074-0276	1678-8060		MEM I OSWALDO CRUZ	Mem. Inst. Oswaldo Cruz	OCT	2002	97	7					1005	1008		10.1590/S0074-02762002000700013				4	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	614WY	WOS:000179215500013	12471428	DOAJ Gold			2019-03-26	
J	Borchert, M; Muyembe-Tamfum, JJ; Colebunders, R; Libande, M; Sabue, M; Van der Stuyft, P				Borchert, M; Muyembe-Tamfum, JJ; Colebunders, R; Libande, M; Sabue, M; Van der Stuyft, P			A cluster of Marburg virus disease involving an infant	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						Marburg haemorrhagic fever; filoviridae; active surveillance; outbreak control; Democratic Republic of Congo	EBOLA-VIRUS	A noteworthy cluster of six cases of Marburg haemorrhagic fever (MHF) was identified in the Democratic Republic of Congo. One of the cases is the first infant Marburg fever patient ever documented. Three of six cases presented surprisingly mild symptoms. The results of epidemiological and virological investigations are compatible with person-to-person transmission through body fluids and with mother-to-child transmission while nurturing. The findings show that mild cases of MHF have to be expected during an outbreak and point out the difficulty to base patient management decisions on clinical case definitions alone.	Inst Trop Med, Dept Publ Hlth, Epidemiol Unit, Natl Str 155, B-2000 Antwerp, Belgium; Inst Rech Biomed, Kinshasa, DEM REP CONGO; Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium	Borchert, M (reprint author), Inst Trop Med, Dept Publ Hlth, Epidemiol Unit, Natl Str 155, B-2000 Antwerp, Belgium.	mborchert@itg.be					[Anonymous], 2001, Wkly Epidemiol Rec, V76, P41; *CDCP, 2000, DIS INF MARB HAEM FE; Dowell SF, 1996, PEDIATR INFECT DIS J, V15, P189, DOI 10.1097/00006454-199603000-00002; GEAR JSS, 1975, BRIT MED J, V4, P489, DOI 10.1136/bmj.4.5995.489; Johnson ED, 1996, ARCH VIROL, P101; KSIAZEK TG, 1992, J CLIN MICROBIOL, V30, P947; Ksiazek TG, 1999, J INFECT DIS, V179, pS192, DOI 10.1086/514313; MARTINI G A, 1971, P1; SANCHEZ A, 1995, PCR PROTOCOLS DIAGNO, P411; SLENCZKA WG, 1999, MARBURG EBOLA VIRUSE, P49; SMITH DH, 1982, LANCET, V1, P816; STILLE W, 1971, P10; TODOROVITCH K, 1971, P19; *WHO, 1999, WKLY EPIDEMIOL REC, V74, P157; ZELLER H, 2000, MED TROP, V60, pS23	15	25	26	1	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2002	7	10					902	906		10.1046/j.1365-3156.2002.00945.x				5	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	599MN	WOS:000178338900014	12358627				2019-03-26	
J	Radwanska, M; Claes, F; Magez, S; Magnus, E; Perez-Morga, D; Pays, E; Buscher, P				Radwanska, M; Claes, F; Magez, S; Magnus, E; Perez-Morga, D; Pays, E; Buscher, P			Novel primer sequences for polymerase chain reaction-based detection of Trypanosoma brucei gambiense	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							SLEEPING-SICKNESS SUSPECTS; SURFACE GLYCOPROTEIN GENES; NORTH-WESTERN UGANDA; HUMAN-SERUM; AFRICAN TRYPANOSOMIASIS; PCR AMPLIFICATION; ARBITRARY PRIMERS; ANIMAL RESERVOIR; IDENTIFICATION; EXPRESSION	Progress in diagnosis, treatment, and epidemiology of human African trypanosomiasis (sleeping sickness) depends on the existence of specific and sensitive diagnostic tools. Inherent shortcomings of serologic and parasitologic diagnostic methods can be overcome by molecular techniques. Therefore. we have developed a new polymerase chain reaction (PCR) test using primers derived from the recently identified sequence of the Trypanosoma brucei gambiense-specific glycoprotein (TgsGP). The specificity of the TgsGP-PCR was evaluated on DNA extracted from 73 different trypanosome populations belonging to diverse taxonomic groups that were isolated from various host species, and from different geographic origins. The TgsG-PCR was shown to be specific for T. b. gambiense and was suitable for detection of trypanosome DNA in blood samples of patients with confirmed sleeping sickness.	Inst Trop Med, Dept Parasitol, B-2000 Antwerp, Belgium; Free Univ Brussels VIB, Cellular Immunol Lab, B-1640 Rhode St Genese, Belgium; ULB, Free Univ Brussels, IBMM, Mol Parasitol Lab, B-6041 Gosselies, Belgium	Radwanska, M (reprint author), Inst Trop Med, Dept Parasitol, Nationalstr 155, B-2000 Antwerp, Belgium.	mradwans@dbm.ulb.ac.be	Radwanska, Magdalena/Q-4279-2018; Buscher, Philippe/B-9956-2012; Magez, Stefan/D-9497-2014	Radwanska, Magdalena/0000-0002-0797-6001; Buscher, Philippe/0000-0002-1926-7472; Magez, Stefan/0000-0003-3760-7968			AERTS D, 1992, T ROY SOC TROP MED H, V86, P394, DOI 10.1016/0035-9203(92)90234-4; BARROWMAN P R, 1976, Onderstepoort Journal of Veterinary Research, V43, P201; Berberof M, 2001, MOL BIOCHEM PARASIT, V113, P127, DOI 10.1016/S0166-6851(01)00208-0; Biteau N, 2000, MOL BIOCHEM PARASIT, V105, P185, DOI 10.1016/S0166-6851(99)00171-1; BROMIDGE T, 1993, ACTA TROP, V53, P107, DOI 10.1016/0001-706X(93)90023-5; BRUN R, 1987, Z PARASITENKD, V73, P218; CAPBERN A, 1977, EXP PARASITOL, V43, P1, DOI 10.1016/0014-4894(77)90002-9; Desquesnes M, 2001, INT J PARASITOL, V31, P610, DOI 10.1016/S0020-7519(01)00161-8; DUKES P, 1992, ACTA TROP, V51, P123, DOI 10.1016/0001-706X(92)90054-2; Enyaru JCK, 1998, ANN TROP MED PARASIT, V92, P845; Enyaru JCK, 1999, ANN TROP MED PARASIT, V93, P817, DOI 10.1080/00034989957817; Garcia A, 2000, TROP MED INT HEALTH, V5, P786, DOI 10.1046/j.1365-3156.2000.00623.x; Gibson W, 2001, TROP MED INT HEALTH, V6, P401, DOI 10.1046/j.1365-3156.2001.00711.x; GIBSON W C, 1986, Parasitology Today, V2, P255, DOI 10.1016/0169-4758(86)90011-6; GIBSON WC, 1986, MOL BIOCHEM PARASIT, V18, P127, DOI 10.1016/0166-6851(86)90033-2; HAGEBOCK JM, 1993, AM J VET RES, V54, P1201; HAWKING F, 1976, T ROY SOC TROP MED H, V70, P504, DOI 10.1016/0035-9203(76)90138-3; HIDE G, 1990, MOL BIOCHEM PARASIT, V39, P213, DOI 10.1016/0166-6851(90)90060-Y; HIDE G, 1994, PARASITOLOGY, V109, P95, DOI 10.1017/S0031182000077805; Hoare C.A., 1972, P1; HOLLAND WG, 2001, VET PARASITOL, V97, P22; Kabiri M, 1999, TROP MED INT HEALTH, V4, P658, DOI 10.1046/j.1365-3156.1999.00465.x; Kanmogne GD, 1996, ACTA TROP, V61, P239, DOI 10.1016/0001-706X(96)00006-X; Kanmogne GD, 1996, ANN TROP MED PARASIT, V90, P475, DOI 10.1080/00034983.1996.11813072; Keiser J, 2001, TRENDS PARASITOL, V17, P42, DOI 10.1016/S1471-4922(00)01829-8; KINOSHITA T, 1992, ANAL BIOCHEM, V206, P231, DOI 10.1016/0003-2697(92)90358-E; Kyambadde JW, 2000, B WORLD HEALTH ORGAN, V78, P119; LANHAM SM, 1970, EXP PARASITOL, V28, P521, DOI 10.1016/0014-4894(70)90120-7; Lejon V, 2001, AM J TROP MED HYG, V65, P931, DOI 10.4269/ajtmh.2001.65.931; LUN ZR, 1992, ANN TROP MED PARASIT, V86, P333, DOI 10.1080/00034983.1992.11812675; MAGNUS E, 1978, ANN SOC BELG MED TR, V58, P169; MATHIEUDAUDE F, 1994, AM J TROP MED HYG, V50, P13, DOI 10.4269/ajtmh.1994.50.13; Matovu E, 2001, TROP MED INT HEALTH, V6, P407, DOI 10.1046/j.1365-3156.2001.00712.x; MEHLITZ D, 1982, TROPENMED PARASITOL, V33, P113; MOSER DR, 1989, PARASITOLOGY, V99, P57, DOI 10.1017/S0031182000061023; NOIREAU F, 1989, TROP MED PARASITOL, V40, P9; ORTIZ JC, 1994, J PARASITOL, V80, P550, DOI 10.2307/3283190; PAINDAVOINE P, 1986, PARASITOLOGY, V92, P31, DOI 10.1017/S0031182000063435; PAQUET C, 1992, LANCET, V340, P250, DOI 10.1016/0140-6736(92)90524-7; PAYS E, 1994, ANNU REV MICROBIOL, V48, P25, DOI 10.1146/annurev.mi.48.100194.000325; Penchenier L, 2000, T ROY SOC TROP MED H, V94, P392, DOI 10.1016/S0035-9203(00)90116-0; Ramos A, 1996, EXP PARASITOL, V82, P242, DOI 10.1006/expr.1996.0031; SALMON D, 1994, CELL, V78, P75, DOI 10.1016/0092-8674(94)90574-6; Schares G, 1996, TROP MED INT HEALTH, V1, P59, DOI 10.1046/j.1365-3156.1996.d01-11.x; Simarro PP, 1999, TROP MED INT HEALTH, V4, P858, DOI 10.1046/j.1365-3156.1999.00494.x; SLOOF P, 1953, J MOL BIOL, V167, P1; STEVENS JR, 1992, ANN TROP MED PARASIT, V86, P9, DOI 10.1080/00034983.1992.11812626; STEVERDING D, 1994, EUR J CELL BIOL, V64, P78; TIBAYRENC M, 1993, P NATL ACAD SCI USA, V90, P1335, DOI 10.1073/pnas.90.4.1335; TRUE P, 1999, B WORLD HEALTH ORGAN, V77, P745; TRUE P, 1991, ACTA TROP, V49, P127; VANDERPLOEG LHT, 1984, CELL, V39, P213, DOI 10.1016/0092-8674(84)90207-1; VANMEIRVENNE N, 1976, ANN SOC BELG MED TR, V56, P55; VANMEIRVENNE N, 1999, PROGR HUMAN AFRICAN, P235; VANNIEUWENHOVE S, 1999, PROGR HUMAN AFRICAN, P253; Verloo D, 2000, VET PARASITOL, V89, P129, DOI 10.1016/S0304-4017(00)00191-6; Verloo D, 2001, VET PARASITOL, V97, P183, DOI 10.1016/S0304-4017(01)00412-5; WAITUMBI JN, 1993, MOL BIOCHEM PARASIT, V58, P181, DOI 10.1016/0166-6851(93)90105-7; WELSH J, 1990, NUCLEIC ACIDS RES, V18, P7213, DOI 10.1093/nar/18.24.7213; World Health Organization, 1998, WHO TECH REP SER, P1; Xong HV, 1998, CELL, V95, P839	61	85	89	2	9	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637	1476-1645		AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	SEP	2002	67	3					289	295		10.4269/ajtmh.2002.67.289				7	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	604QW	WOS:000178633400013	12408669	Bronze			2019-03-26	
J	Sow, S; de Vlas, SJ; Engels, D; Gryseels, B				Sow, S; de Vlas, SJ; Engels, D; Gryseels, B			Water-related disease patterns before and after the construction of the Diama dam in northern Senegal	ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY			English	Article							RECENTLY EXPOSED COMMUNITY; VECTOR-BORNE DISEASES; RIVER BASIN; SCHISTOSOMA-MANSONI; INTESTINAL SCHISTOSOMIASIS; WEST-AFRICA; EPIDEMIOLOGY; MALARIA; DELTA; TRANSMISSION	The ecological changes caused by projects for the development of water resources are known to affect the epidemiology of water-related diseases. The effects of the construction of the Diama dam (completed in 1986) in the Senegal River on the epidemiology of malaria, urinary and intestinal schistosomiasis, diarrhoea and dysentery were investigated in four districts in northern Senegal. To make allowance for any general trend in reported morbidity (caused by changes in demography or the healthcare system), the numbers of cases of these illnesses reported by the basic healthcare facilities before and after the completion of the dam were compared with those of respiratory disease. Prior to the construction of the dam, malaria was the most encountered water-related disease in the medical records of all districts, followed by diarrhoea, dysentery and urinary schistosomiasis. This order remained the same after the completion of the dam. Despite the optimism of health-assessment reports prepared prior to the construction of the Diama dam, the unexpected appearance and spread of intestinal schistosomiasis as well as an increase in the incidence of urinary schistosomiasis have aggravated public health in the Senegal River basin. It remains to be judged whether the economic benefits of the dam will counterbalance its adverse effects.	Inst Trop Med Prince Leopold, Dept Parasitol, Helminthol Unit, B-2000 Antwerp, Belgium; Reg Med St Louis, Programme ESPOIR, St Louis, Senegal; Erasmus Univ, Dept Publ Hlth, NL-3000 DR Rotterdam, Netherlands; WHO, CH-1211 Geneva, Switzerland	Sow, S (reprint author), Inst Trop Med Prince Leopold, Dept Parasitol, Helminthol Unit, Natl Str 155, B-2000 Antwerp, Belgium.						BENEFICE E, 1993, ECOL FOOD NUTR, V31, P45, DOI 10.1080/03670244.1993.9991349; BEY MK, 1949, J EGYPT MED ASSOC, V32, P820; Bradley D J, 1970, J Trop Med Hyg, V73, P286; CARRARA GC, 1990, MED VET ENTOMOL, V4, P421, DOI 10.1111/j.1365-2915.1990.tb00460.x; CHAINE JP, 1983, TROP GEOGR MED, V35, P249; CROUSSE B, 1991, VALLEE SENEGAL EVALU, P47; DIAW OT, 1991, B SOC PATHOL EXOT, V84, P174; DIOP M, 1994, 453 WASH US AG INT D; DOWNS WC, 1977, SENEGAL RIVER PILOT; ERNOULD JC, 1994, CARTOGRAPHIE ENDEMIE; FARID MA, 1972, ASWAN HIGH DAM PROJE; FAYE O, 1993, ANN SOC BELG MED TR, V73, P21; Faye O, 1995, ANN SOC BELG MED TR, V75, P179; GRYSEELS B, 1994, TROP GEOGR MED, V46, P209; HANDSCHUMACHER P, 1992, SECHERESSE, V4, P219; HUNTER JM, 1982, SOC SCI MED, V16, P1127, DOI 10.1016/0277-9536(82)90115-0; JOBIN RW, 1999, DAMS DIS ECOLOGICAL; KANE F, 1993, AIDS, V7, P1261, DOI 10.1097/00002030-199309000-00017; KOLSKY PJ, 1993, T ROY SOC TROP MED H, V87, P43, DOI 10.1016/0035-9203(93)90537-Z; Molyneux DH, 1997, ANN TROP MED PARASIT, V91, P827, DOI 10.1080/00034983.1997.11813208; MONJOUR L, 1981, ANN SOC BELG MED TR, V61, P453; MOUCHET J, 1990, B SOC PATHOL EXOT, V83, P376; Obeng L.E., 1975, P221; PETRARCA V, 1987, MED VET ENTOMOL, V1, P303, DOI 10.1111/j.1365-2915.1987.tb00359.x; PIQUET M, 1996, T ROYAL SOC TROPIAL, V90, P340; Rogerie F, 1997, Med Trop (Mars), V57, P361; Singh N, 1999, ANN TROP MED PARASIT, V93, P477, DOI 10.1080/00034983.1999.11813447; STELMA FF, 1993, AM J TROP MED HYG, V49, P701, DOI 10.4269/ajtmh.1993.49.701; TALLA I, 1990, ANN SOC BELG MED TR, V70, P173; VERCRUYSSE J, 1994, TROP GEOGR MED, V46, P220; VERCRUYSSE J, 1985, ACTA TROP, V42, P249; VERLE P, 1994, T ROY SOC TROP MED H, V88, P104; WADDY BB, 1975, T ROY SOC TROP MED H, V69, P39, DOI 10.1016/0035-9203(75)90009-7; *WHO, 1990, MAN TREATM DIARRH US; Xu X J, 1999, Southeast Asian J Trop Med Public Health, V30, P549; 1980, ASSESSMENT ENV EFFEC	36	40	40	0	12	MANEY PUBLISHING	LEEDS	HUDSON RD, LEEDS LS9 7DL, ENGLAND	0003-4983			ANN TROP MED PARASIT	Ann. Trop. Med. Parasitol.	SEP	2002	96	6					575	586		10.1179/000349802125001636				12	Public, Environmental & Occupational Health; Parasitology; Tropical Medicine	Public, Environmental & Occupational Health; Parasitology; Tropical Medicine	600JQ	WOS:000178387200005	12396320				2019-03-26	
J	Pattyn, S; Grillone, S				Pattyn, S; Grillone, S			Relapse rates and a 10-year follow-up of a 6-week quadruple drug regimen for multibacillary leprosy	LEPROSY REVIEW			English	Article							MYCOBACTERIUM-TUBERCULOSIS; EXOGENOUS REINFECTION; INFECTION; LEPRAE; MICE	Between 1989 and 1993, 136 multibacillary leprosy patients received a 6-week treatment regimen consisting of daily rifampicin 600 mg, ofloxacin 400 mg, clofazimine 100mg and a weekly dose of 100mg minocycline. A previous analysis after a mean follow-up of 4-7 years revealed a relapse rate of 2%, involving six late (after more than 5 years of follow-up) relapses. During the following years, 12 more relapses appeared during years 8-9 of follow-up. A mean follow-up period of 5 years is insufficient to evaluate treatment regimens in multibacillary leprosy. The present regimen cannot be recommended.	Inst Trop Med, B-2000 Antwerp, Belgium	Pattyn, S (reprint author), Inst Trop Med, Natl Str 155, B-2000 Antwerp, Belgium.						Chaves F, 1999, AIDS, V13, P615, DOI 10.1097/00002030-199904010-00011; GELBER RH, 1987, J INFECT DIS, V156, P236, DOI 10.1093/infdis/156.1.236; LIENHARDT C, 1995, LANCET, V345, P736, DOI 10.1016/S0140-6736(95)90911-7; Pattyn S, 2000, LEPROSY REV, V71, P43; PATTYN SR, 1993, INT J LEPROSY, V61, P76; PATTYN SR, 1987, ANTIMICROB AGENTS CH, V31, P671, DOI 10.1128/AAC.31.4.671; SMALL PM, 1993, NEW ENGL J MED, V328, P1137, DOI 10.1056/NEJM199304223281601; WATERS MFR, 1995, LEPROSY REV, V66, P1; WHOCTDLEP941	9	11	12	0	1	LEPRA	COLCHESTER	FAIRFAX HOUSE, CAUSTON ROAD, COLCHESTER CO1 1PU, ENGLAND	0305-7518			LEPROSY REV	Lepr. Rev.	SEP	2002	73	3					245	247						3	Dermatology; Infectious Diseases; Pathology; Tropical Medicine	Dermatology; Infectious Diseases; Pathology; Tropical Medicine	610ZP	WOS:000178992200006	12449889				2019-03-26	
J	Talisuna, AO; Kyosiimire-Lugemwa, J; Langi, P; Mutabingwa, TK; Watkins, W; Van Marck, E; Egwang, T; D'Alessandro, U				Talisuna, AO; Kyosiimire-Lugemwa, J; Langi, P; Mutabingwa, TK; Watkins, W; Van Marck, E; Egwang, T; D'Alessandro, U			Role of the pfcrt codon 76 mutation as a molecular marker for population-based surveillance of chloroquine (CQ)-resistant Plasmodium falciparum malaria in Ugandan sentinel sites with high CQ resistance	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						malaria; Plasmodium falciparum; gene mutation; genes; pfcrt; drug resistance; chloroquine; Uganda	DIHYDROFOLATE-REDUCTASE; POLYMORPHISMS; PYRIMETHAMINE; PROTEIN; AFRICA; GENE	The mutant genotype at codon 76 of the pfcrt gene (T76) has been proposed as a molecular marker for surveillance of chloroquine (CQ)-resistant Plasmodium falciparum malaria but this proposal has not been validated by population-based surveys. In 1998-99, in 6 Ugandan sentinel sites, the prevalence of P. falciparum infections with the T76 genotype and the level of CQ use were measured by community surveys, and CQ resistance was determined by in-vivo tests on 6-59-month-old children with clinical malaria. The prevalence of T76 was not related to the overall clinical (early and late treatment failure: ETF+LTF; r = 0.14, P = 0.78) or parasitological (RI+RII+RIII; r = 0.17, P = 0.73) CQ resistance. However, the percentage of individuals carrying only infections with the T76 genotype (T76 alone) increased with increasing ETF (r = 0.76, P = 0.07) and type RIII parasitological failure (r = 0.69, P = 0.12). Similarly, the ratio between T76 and K76 (the wild type) prevalences (T76/K76) was strongly and positively correlated with ETF (r = 0.85, P = 0.03) and RIII (r = 0.82, P = 0.04). Moreover, T76 alone (r = 0.90, P = 0.01) as well as T76/K76 (r = 0.90, P = 0.01) significantly increased with increasing community CQ use. T76 alone and T76/K76 can be useful markers to estimate the ETF and RIII prevalence as well as the amount of CQ use in the community.	Minist Hlth, Kampala, Uganda; Med Biotech Labs, Kampala, Uganda; Natl Inst Med Res, Amanitanga, Tanzania; London Sch Hyg & Trop Med, London, England; KEMRI Wellcome Trust Collaborat Programme, Nairobi, Kenya; Univ Antwerp, B-2020 Antwerp, Belgium; Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium	Talisuna, AO (reprint author), Minist Hlth, POB 7272, Kampala, Uganda.	udalessandro@proto.itg.be	D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009			Babiker HA, 2001, J INFECT DIS, V183, P1535, DOI 10.1086/320195; Djimde A, 2001, NEW ENGL J MED, V344, P257, DOI 10.1056/NEJM200101253440403; Djimde A, 2001, LANCET, V358, P890, DOI 10.1016/S0140-6736(01)06040-8; Dorsey G, 2001, J INFECT DIS, V183, P1417, DOI 10.1086/319865; EGGELTE TA, 1992, P 13 INT C TROP MED, V2, P242; Eggelte TA, 1990, INT MONOGRAPH SERIES, V3, P35; Fidock DA, 2000, MOL CELL, V6, P861, DOI 10.1016/S1097-2765(00)00084-8; FOGH S, 1979, T ROY SOC TROP MED H, V73, P228, DOI 10.1016/0035-9203(79)90220-7; FOOTE SJ, 1990, NATURE, V345, P255, DOI 10.1038/345255a0; FOSTER S, 1995, J TROP MED HYG, V98, P29; Hastings IM, 2000, PARASITOL TODAY, V16, P340, DOI 10.1016/S0169-4758(00)01707-5; Kitua AY, 1999, LANCET, V354, P32; Kyosiimire-Lugemwa J, 2002, T ROY SOC TROP MED H, V96, P91, DOI 10.1016/S0035-9203(02)90252-X; LEMESHOW S, 1991, World Health Statistics Quarterly, V44, P115; MANTEL N, 1959, J NATL CANCER I, V22, P719; McCombie SC, 1996, SOC SCI MED, V43, P933, DOI 10.1016/0277-9536(95)00446-7; Metselaar D, 1959, TROPICAL GEOGRAPHICA, V11, P157; PLOWE CV, 1995, AM J TROP MED HYG, V52, P565, DOI 10.4269/ajtmh.1995.52.565; Plowe CV, 1997, J INFECT DIS, V176, P1590, DOI 10.1086/514159; Schwick P, 1998, TROP MED INT HEALTH, V3, P828, DOI 10.1046/j.1365-3156.1998.00307.x; Su XZ, 1997, CELL, V91, P593, DOI 10.1016/S0092-8674(00)80447-X; Takechi M, 2001, TROP MED INT HEALTH, V6, P429, DOI 10.1046/j.1365-3156.2001.00735.x; WERNSDORFER WH, 1991, PARASITOL TODAY, V7, P297, DOI 10.1016/0169-4758(91)90262-M; *WHO, 1996, WHOMAL961077	24	19	20	0	1	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0035-9203	1878-3503		T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	SEP-OCT	2002	96	5					551	556		10.1016/S0035-9203(02)90439-6				6	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	621UQ	WOS:000179609800021	12474488				2019-03-26	
J	Lejon, V; Legros, D; Richer, M; Ruiz, JA; Jamonneau, V; Truc, P; Doua, F; Dje, N; N'Siesi, FX; Bisser, S; Magnus, E; Wouters, I; Konings, J; Vervoort, T; Sultan, F; Buscher, P				Lejon, V; Legros, D; Richer, M; Ruiz, JA; Jamonneau, V; Truc, P; Doua, F; Dje, N; N'Siesi, FX; Bisser, S; Magnus, E; Wouters, I; Konings, J; Vervoort, T; Sultan, F; Buscher, P			IgM quantification in the cerebrospinal fluid of sleeping sickness patients by a latex card agglutination test	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						cerebrospinal fluid; IgM; stage determination; latex microspheres; card agglutination; Trypanosoma brucei gambiense; sleeping sickness; intrathecal IgM synthesis	HUMAN AFRICAN TRYPANOSOMIASIS; GAMBIENSE TRYPANOSOMIASIS; DIAGNOSIS; DISEASES; PATTERNS; STAGE	An increased IgM concentration in cerebrospinal fluid (CSF), occurring as a consequence of massive intrathecal IgM synthesis, is a marker of interest for diagnosis of the meningo-encephalitic stage in human African trypanosomiasis. However, in current practice, IgM in CSF is not determined because of the lack of a simple and robust test that is applicable in African rural regions where the disease prevails. We describe the development of a sensitive semiquantitative card agglutination test, LATEX/IgM, for IgM quantification in CSF. The test is simple and fast and the lyophilized reagent remains stable even at 45 degreesC. CSF end-titres obtained with LATEX/IgM parallel the IgM concentrations determined by nephelometry and enzyme-linked immunosorbent assay. Detection of intrathecal IgM synthesis is the most sensitive marker for CNS involvement in sleeping sickness. At a cut-off value of greater than or equal to 8, the sensitivity and specificity of LATEX/IgM for intrathecal IgM synthesis are 89.4 and 92.7%. As a consequence, patients with LATEX/IgM end-titres greater than or equal to 8 are likely to have intrathecal IgM synthesis, thus central nervous system involvement and therefore should be treated accordingly. Further studies should concentrate on the relationship between the LATEX/IgM end-titres, presence of intrathecal IgM synthesis and occurrence of treatment failures in patients treated with pentamidine.	Inst Trop Med, Dept Parasitol, Natl Str 155, B-2000 Antwerp, Belgium; Univ Antwerp, Dept Biochem, Antwerp, Belgium; EPICENTRE, Paris, France; Int Med Corps, Nairobi, Kenya; Medecins Sans Frontieres Espagne, Haut Mbomou, Cent Afr Republ; Inst Pierre Richet, Bouake, Cote Ivoire; OCEAC, Lab Etude Chimiosensibil Trypanosomes, Yaounde, Cameroon; Projet Rech Clin Trypanosomiase, Daloa, Cote Ivoire; Bur Cent Trypanosomiase, Bwamanda, DEM REP CONGO; Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium; Merck Eurolab, Fontenay Sous Bois, France	Lejon, V (reprint author), Inst Trop Med, Dept Parasitol, Natl Str 155, B-2000 Antwerp, Belgium.	vlejon@itg.be	Buscher, Philippe/B-9956-2012; Jamonneau, Vincent/K-1124-2016	Buscher, Philippe/0000-0002-1926-7472; 			Bisser S, 1997, B SOC PATHOL EXOT, V90, P321; Bisser S, 2002, J NEUROL SCI, V193, P127, DOI 10.1016/S0022-510X(01)00655-4; Doua F, 1996, AM J TROP MED HYG, V55, P586, DOI 10.4269/ajtmh.1996.55.586; Felgenhauer K, 1998, CLIN LAB DIAGNOSTICS, P1308; GREENWOOD BM, 1973, LANCET, V2, P525; ITAZI OK, 1981, INT SCI COUNC TRYP R, P101; Jacobson RH, 1998, REV SCI TECH OIE, V17, P469, DOI 10.20506/rst.17.2.1119; Lejon V, 1998, B WORLD HEALTH ORGAN, V76, P553; Lejon V, 1998, ACTA TROP, V69, P151, DOI 10.1016/S0001-706X(97)00137-X; MAGNUS E, 1978, ANN SOC BELG MED TR, V58, P169; MATTERN P, 1968, B WORLD HEALTH ORGAN, V38, P1; MATTERN P, 1967, SEPT C TECHN OCCGE M, P1053; Pagano M, 2000, PRINCIPLES BIOSTATIS, P285; Reiber H, 1998, MULT SCLER, V4, P99, DOI 10.1177/135245859800400302; Reiber H, 2001, J NEUROL SCI, V184, P101, DOI 10.1016/S0022-510X(00)00501-3; REIBER H, 1987, CLIN CHIM ACTA, V163, P319, DOI 10.1016/0009-8981(87)90250-6; SINDIC CJM, 1994, J NEUROL SCI, V124, P215, DOI 10.1016/0022-510X(94)90329-8; Stanghellini A, 2001, TROP MED INT HEALTH, V6, P330, DOI 10.1046/j.1365-3156.2001.00724.x; VANMEIRVENNE N, 1999, PROGR HUMAN AFRICAN, P235; VANNIEUWENHOVE S, 1999, PROGR HUMAN AFRICAN, P253; WHITTLE HC, 1977, AM J TROP MED HYG, V26, P1129, DOI 10.4269/ajtmh.1977.26.1129; World Health Organization, 1998, WHO TECH REP SER, P1	22	39	40	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	AUG	2002	7	8					685	692		10.1046/j.1365-3156.2002.00917.x				8	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	582ZL	WOS:000177381000007	12167095				2019-03-26	
J	Risha, PG; Shewiyo, D; Msami, A; Masuki, G; Vergote, G; Vervaet, C; Remon, JP				Risha, PG; Shewiyo, D; Msami, A; Masuki, G; Vergote, G; Vervaet, C; Remon, JP			In vitro evaluation of the quality of essential drugs on the Tanzanian market	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						Tanzania; essential drugs; drug quality; dissolution; stability	DISSOLUTION STABILITY; CHLOROQUINE; COUNTRIES; TABLETS	We evaluated the in vitro availability and its stability under simulated tropical conditions of various formulations of four essential drugs marketed in Tanzania. We obtained 22 formulations (containing paracetamol, acetylsalicylic acid, chloroquine or sulphadoxine/pyrimethamine) from wholesale pharmacies in Dar es Salaam and the Medical Stores Department (Tanzania). The drug content, in vitro availability (dissolution) and its stability under simulated tropical conditions were determined using methods specified in the United States Pharmacopoeia (USP) 24 monograph of the respective drugs. All formulations passed the pharmacopoeia requirements for the drug content. However, seven formulations (three acetylsalicylic acid, two sulphadoxine/pyrimethamine and two paracetamol) failed to meet the USP 24 tolerance limits for dissolution. Another five formulations (three paracetamol and two chloroquine) failed to meet the dissolution tolerance limits after being subjected to an accelerated stability test under simulated tropical conditions (75% RH/40 degreesC) for 6 months. The study has demonstrated the presence on the Tanzanian market of essential drug formulations that met potency requirements and yet had unsatisfactory in vitro availability as they were not robust enough to withstand storage under simulated tropical conditions.	State Univ Ghent, Pharmaceut Technol Lab, Fac Pharmaceut Sci, B-9000 Ghent, Belgium; Muhimbili Univ, Dept Pharmaceut, Fac Pharm, Coll Hlth Sci, Dar Es Salaam, Tanzania; Minist Hlth, Dar Es Salaam, Tanzania	Remon, JP (reprint author), State Univ Ghent, Pharmaceut Technol Lab, Fac Pharmaceut Sci, Harelbekestr 72, B-9000 Ghent, Belgium.						ABDI YA, 1995, LANCET, V346, P1161, DOI 10.1016/S0140-6736(95)91834-5; [Anonymous], 1988, WORLD DRUG SIT; Ballereau F, 1997, AM J TROP MED HYG, V57, P31, DOI 10.4269/ajtmh.1997.57.31; GILSON L, 1993, INT J HLTH PLANNING, V8, P37; Grimm W, 1998, DRUG DEV IND PHARM, V24, P313, DOI 10.3109/03639049809085626; HOGERZEIL HV, 1991, LANCET, V338, P754, DOI 10.1016/0140-6736(91)91470-F; KIBWAGE IO, 1992, E AFR MED J, V69, P577; MASSELE AY, 1993, E AFR MED J, V71, P314; MURTHY KS, 1993, J PHARM SCI, V82, P113, DOI 10.1002/jps.2600820202; Nazerali H, 1998, BRIT MED J, V317, P512; Pandit JK, 1997, PHARMAZIE, V52, P538; PETRALANDA I, 1995, LANCET, V345, P1433, DOI 10.1016/S0140-6736(95)92620-8; PUSSARD E, 1986, J CHROMATOGR, V374, P111, DOI 10.1016/S0378-4347(00)83258-2; Saville DJ, 2001, INT J PHARM, V224, P39, DOI 10.1016/S0378-5173(01)00734-7; Shakoor O, 1997, TROP MED INT HEALTH, V2, P839, DOI 10.1046/j.1365-3156.1997.d01-403.x; Taylor RB, 2001, LANCET, V357, P1933, DOI 10.1016/S0140-6736(00)05065-0; *US PHARM CONV INC, 2000, US PHARM 24 NF19	17	37	38	1	2	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	AUG	2002	7	8					701	707		10.1046/j.1365-3156.2002.00937.x				7	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	582ZL	WOS:000177381000009	12167097	Bronze			2019-03-26	
J	Noeske, J; Nguenko, PN				Noeske, J; Nguenko, PN			Impact of resistance to anti-tuberculosis drugs on treatment outcome using World Health Organization standard regimens	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						tuberculosis; Mycobacterium tuberculosis; chemotherapy; drug resistance; treatment outcome; Cameroon	DOTS-PLUS; MDR-TB	We compared treatment outcome in 410 patients with drug-susceptible tuberculosis (DS-TB) and 150 patients with drug-resistant tuberculosis (DR-TB) among 560 adult patients (greater than or equal to15 years old) notified with smear-positive pulmonary tuberculosis between July 1997 and June 1998 in the West Province of Cameroon and treated with World Health Organization (WHO) standard regimens under field conditions. Information on treatment outcome was collected for all smear-positive TB patients having a positive culture with drug susceptibility tests performed for isoniazid, rifampicin, ethambutol and streptomycin. Treatment outcome was recorded as cured, completed treatment, failed, defaulted, died or transferred out. 332 of the 410 patients (81%) with DS-TB were cured, compared to 109/150 (72(.)7%) patients with DR-TB (odds ratio [OR] = 0(.)62, 95% confidence interval [CI] 0(.)40-0(.)99). Seven patients (1(.)7%) failed treatment in the DS-TB group vs. 9 (6(.)0%) in the DR-TB group (OR = 3(.)67, 95% CI 1(.)23-11(.)18). No significant difference was found in rates of death, default or transfer. Sputum smear conversion at the end of the intensive treatment phase was observed in 78-8% of the cases, drug resistance having no effect on the conversion rate. After adjusting for age, sex and resistance, the death rate was higher in patients also infected with human immunodeficiency virus (HIV). In TB cases with multidrug resistance, standard regimens result in unacceptably high failure rates (26(.)1%). For all other drug-resistant forms of TB, rifampicin-based short-course chemotherapy gave satisfactory results. The death toll in the West Province seems due to HIV co-infection rather than to TB alone. To prevent development of drug-resistance, the proportion of defaulters must be decreased and prevention and control strategies endorsed by the WHO and the International Union Against Tuberculosis and Lung Disease must be implemented nation-wide.	Hlth Delegat W Province Cameroon, Bafoussam, Cameroon	Noeske, J (reprint author), Kolveniersstr 6,Bus 7, B-2000 Antwerp, Belgium.						Bastian I, 2000, B WORLD HEALTH ORGAN, V78, P238; Cauthen GM, 1988, WHOTB88154; Coninx R, 1999, LANCET, V353, P969, DOI 10.1016/S0140-6736(98)08341-X; ENARSON DA, 2000, TUBERCULOSIS GUIDE L; Espinal MA, 1999, INT J TUBERC LUNG D, V3, P561; FARMER EP, 2000, TUBERCULOSIS COMPREH, P447; Farmer P, 1999, INT J TUBERC LUNG D, V3, P643; Farmer P, 1998, BRIT MED J, V317, P671, DOI 10.1136/bmj.317.7159.671; Glynn JR, 1998, B WORLD HEALTH ORGAN, V76, P295; HOPEWELL CH, 2000, TUBERCULOSIS COMPREH, P525; KUABAN C, 2000, INT J TUBERC LUNG D, V4, P355; Lienhardt C, 1998, INT J TUBERC LUNG D, V2, P712; Mitchison DA, 2000, INT J TUBERC LUNG D, V4, P796; Rieder HL, 2001, INT J TUBERC LUNG D, V5, P1; Trebucq A, 1998, PUBLIC HLTH SERVICE; *WHO, 1997, WHOTB97229; *WHO, 1997, WHOTB97220; *WHO, 2000, UNAIDS WHO WORK GROU; *WHO, 1999, WHOCDSCPCTB99259	19	14	17	0	1	ROYAL SOC TROPICAL MEDICINE	LONDON	MANSON HOUSE 26 PORTLAND PLACE, LONDON W1N 1EY, ENGLAND	0035-9203			T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	JUL-AUG	2002	96	4					429	433		10.1016/S0035-9203(02)90383-4				5	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	639GR	WOS:000180619700014	12497982				2019-03-26	
J	Lambert, ML; van der Stuyft, P				Lambert, ML; van der Stuyft, P			Editorial: Global health fund or global fund to fight AIDS, tuberculosis, and malaria?	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Editorial Material									Inst Trop Med Prince Leopold, Dept Publ Hlth, Epidemiol Unit, B-2000 Antwerp, Belgium	Lambert, ML (reprint author), Inst Trop Med Prince Leopold, Dept Publ Hlth, Epidemiol Unit, Natl Str 155, B-2000 Antwerp, Belgium.						Brugha R, 2002, LANCET, V359, P435, DOI 10.1016/S0140-6736(02)07607-9; *DAM FDN BANGL, 2000, ANN REP; Raviglione MC, 2002, LANCET, V359, P775, DOI 10.1016/S0140-6736(02)07880-7; *WHO, 2002, GLOB TUB CONTR SURV; *WHO, 2002, MACROECO HLTH INVEST; *WHO UNICEF UNAIDS, 2002, SCAL RESP INF DIS WA; World Health Organization, 2000, WORLD HLTH REP 2000, P2000; 2001, 1 STOP TB PARTN FOR; 2002, GLOBAL FUND FIGHT AI; 2001, C HLTH CAR ALL M DEC	10	10	10	0	1	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	JUL	2002	7	7					557	558		10.1046/j.1365-3156.2002.00913.x				2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	568YP	WOS:000176572800001	12100436	Bronze			2019-03-26	
J	Solano, P; Jamonneau, V; N'Guessan, P; N'Dri, L; Dje, NN; Miezan, TW; Lejon, V; Buscher, P; Garcia, A				Solano, P; Jamonneau, V; N'Guessan, P; N'Dri, L; Dje, NN; Miezan, TW; Lejon, V; Buscher, P; Garcia, A			Comparison of different DNA preparation protocols for PCR diagnosis of Human African Trypanosomosis in Cote d'Ivoire	ACTA TROPICA			English	Article						Human African Trypanosomosis; Ivory Coast; PCR; diagnosis; Trypanosoma brucei gambiense	POLYMERASE-CHAIN-REACTION; SLEEPING-SICKNESS SUSPECTS; BRUCEI-GAMBIENSE; FOLLOW-UP; CATTLE; UGANDA; AMPLIFICATION; CONGOLENSE	During a medical survey the sleeping sickness focus in Bonon, Ivory Coast, PCR with Trypanosoma brucei specific primers (TBR 1-2 from Parasitology 99 (1989) 57) was tested on DNA derived from blood samples. DNA purification using a chelating resin was performed either on whole blood or on the buffy coat prepared in two different ways. The preparation based on whole blood performed better than those using the buffy-coat. Using this first method, the sensitivity was 100% on parasitologically confirmed patients, and the specificity was 92%. However, problems of reproducibility of the technique were pointed out, particularly on samples from serologically positive but apparently aparasitemic individuals. It is suggested that the PCR could help in the diagnosis of Human African Trypanosomosis, but the use of other primers should be investigated. (C) 2002 Elsevier Science B.V. All rights reserved.	IPR, IRD UR 035, Bouake, Cote Ivoire; CIRAD, IRD, Lab Commun Rech Trypanosomoses, Baillarguet, France; PRCT, Daloa, Cote Ivoire; Inst Trop Med, Dept Parasitol, B-2000 Antwerp, Belgium	Solano, P (reprint author), IPR, IRD UR 035, BP 1500, Bouake, Cote Ivoire.		Garcia, Andre/S-2959-2016; Jamonneau, Vincent/K-1124-2016; Buscher, Philippe/B-9956-2012; Solano, Philippe/B-2328-2010	Garcia, Andre/0000-0002-1808-472X; Buscher, Philippe/0000-0002-1926-7472; 			BURCKHARDT J, 1994, PCR METH APPL, V3, P329; Clausen PH, 1998, ANN NY ACAD SCI, V849, P21, DOI 10.1111/j.1749-6632.1998.tb11029.x; DEALMEIDA PJL, 1998, THESIS U LIBRE BRUXE, P302; deAlmeida PJLP, 1997, ACTA TROP, V66, P45, DOI 10.1016/S0001-706X(97)00677-3; DIXON WJ, 1969, BINOMIAL DISTRIBUTIO, P13; DUKES P, 1992, ACTA TROP, V51, P123, DOI 10.1016/0001-706X(92)90054-2; Enyaru JCK, 1998, ANN TROP MED PARASIT, V92, P845; Fleiss JL, 1981, STAT METHODS RATES P; Garcia A, 2000, TROP MED INT HEALTH, V5, P786, DOI 10.1046/j.1365-3156.2000.00623.x; HIGUCHI R, 1989, PCR TECHNOLOGY PRINC, P31; Kabiri M, 1999, TROP MED INT HEALTH, V4, P658, DOI 10.1046/j.1365-3156.1999.00465.x; Katakura K, 1997, PARASITOL RES, V83, P241, DOI 10.1007/s004360050240; Kyambadde JW, 2000, B WORLD HEALTH ORGAN, V78, P119; MAGNUS E, 1978, ANN SOC BELG MED TR, V58, P169; MAJIWA PAO, 1994, PARASITOLOGY, V108, P313, DOI 10.1017/S0031182000076150; Molyneux D. H., 1997, Trypanosomiasis and leishmaniasis: biology and control., P39; MOSER DR, 1989, PARASITOLOGY, V99, P57, DOI 10.1017/S0031182000061023; MURRAY M, 1977, T ROY SOC TROP MED H, V71, P325, DOI 10.1016/0035-9203(77)90110-9; Penchenier L, 2000, T ROY SOC TROP MED H, V94, P392, DOI 10.1016/S0035-9203(00)90116-0; Penchenier L, 1996, PARASITE, V4, P387; Simo G, 1999, B LIAISON DOCUMENTAT, V32, P17; Solano P, 1999, VET PARASITOL, V86, P95, DOI 10.1016/S0304-4017(99)00137-5; Tang YW, 1998, J CLIN MICROBIOL, V36, P2714; TRUC P, 1994, T ROY SOC TROP MED H, V88, P419, DOI 10.1016/0035-9203(94)90410-3; Truc P, 1999, B WORLD HEALTH ORGAN, V77, P745; WALSH PS, 1991, BIOTECHNIQUES, V10, P506; Woo P. T. K., 1970, Acta trop., V27, P384	27	34	34	1	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0001-706X			ACTA TROP	Acta Trop.	JUN	2002	82	3					349	356	PII S0001-706X(02)00029-3	10.1016/S0001-706X(02)00029-3				8	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	561XQ	WOS:000176168700003	12039674				2019-03-26	
J	Rivera, MT; De Souza, AP; Moreno, AHM; Xavier, SS; Gomes, JAS; Rocha, MOC; Correa-Oliveira, R; Neve, J; Vanderpas, J; Araujo-Jorge, TC				Rivera, MT; De Souza, AP; Moreno, AHM; Xavier, SS; Gomes, JAS; Rocha, MOC; Correa-Oliveira, R; Neve, J; Vanderpas, J; Araujo-Jorge, TC			Progressive Chagas' cardiomyopathy is associated with low selenium levels	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							ANTI-TRYPANOSOMA-CRUZI; HUMAN HEALTH; DISEASE; DEFICIENCY; ANTIBODIES; LAMININ; IODINE	Selenium (Se) deficiency is linked with some cardiomyopathies. Its status was determined in 170 patients with chronic Chagas' disease from 2 Brazilian regions (Rio de Janeiro and Belo Horizonte), clinically stratified into groups as follows: indeterminate or asymptomatic (IND); cardiac asymptomatic (CARDa); cardiac symptomatic with moderate to severe heart dysfunction (CARDb); and healthy adults (HA), used for comparison. In most HA, Se levels were normal, excluding an overall Se deficiency. Se was significantly lower in CARDb than in HA, IND, or CARDa patients. This was not associated with a concomitant decrease in activity of glutathione peroxidase. Thyrotropin was normal, excluding iodine deficiency. Se correlated positive and significantly with ventricular ejection fraction (assessed via echocardiography). Asymptomatic children with acute Chagas' disease had normal Se as well as 5 noninfectious cases of cardiomyopathy. Low Se was found in 6 of 10 chagasic patients with digestive megasyndromes. Thus, the decrease in Se in chagasic patients seems to be a biological marker for Trypanosoma cruzi infection and related to the progression of pathology.	Fiocruz MS, Inst Oswaldo Cruz, Dept Ultra Estrutura & Biol Celular, Lab Biol Celular, BR-21045900 Rio De Janeiro, RJ, Brazil; Univ Fed Minas Gerais, Inst Med, Fac, BR-30130100 Belo Horizonte, MG, Brazil; ULB, Inst Pharm, B-1050 Brussels, Belgium; Hop Ambroise Pare, B-7000 Mons, Belgium; Fiocruz MS, Inst Pesquisas Clin Evandro Chagas, BR-21045900 Rio De Janeiro, Brazil; Fiocruz MS, Ctr Pesquisas Rene Rachou, Belo Horizonte, MG, Brazil	Araujo-Jorge, TC (reprint author), Fiocruz MS, Inst Oswaldo Cruz, Dept Ultra Estrutura & Biol Celular, Lab Biol Celular, Av Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.		Gomes, Juliana/M-4083-2017; Hasslocher-Moreno, Alejandro Marcel/F-3414-2011; Rocha, Manoel Otavio/H-4776-2013	Gomes, Juliana/0000-0002-8332-2907; 			Antas PRZ, 1999, AM J TROP MED HYG, V61, P308, DOI 10.4269/ajtmh.1999.61.308; AVILA JL, 1989, J IMMUNOL, V142, P2828; Barceloux DG, 1999, J TOXICOL-CLIN TOXIC, V37, P145, DOI 10.1081/CLT-100102417; BENDICH A, 1990, ANN NY ACAD SCI, V587, P168, DOI 10.1111/j.1749-6632.1990.tb00144.x; BERRY MJ, 1992, ENDOCR REV, V13, P207, DOI 10.1210/er.13.2.207; BITTENCOURT AL, 1998, PARASITIC INFECT PRE, P62; BLUMBERG JB, 1995, AM J CLIN NUTR, V62, P1521, DOI 10.1093/ajcn/62.6.1521S; Chagas C., 1934, Revista de Biologia e Hygiene Sao Paolo, V5, P58; DEANDRADE ALSS, 1995, J TROP PEDIATRICS, V41, P112, DOI 10.1093/tropej/41.2.112; DIAS JCP, 1987, CHAGAS DIS VECTORS; DIPLOCK AT, 1987, AM J CLIN NUTR, V45, P1313, DOI 10.1093/ajcn/45.5.1313; DWORKIN BM, 1994, CHEM-BIOL INTERACT, V91, P181, DOI 10.1016/0009-2797(94)90038-8; GAZZINELLI R, 1988, T ROY SOC TROP MED H, V82, P574, DOI 10.1016/0035-9203(88)90513-5; GAZZINELLI RT, 1988, J CLIN MICROBIOL, V26, P1795; HARRIGE LS, 1996, NUTR HLTH, V10, P285; HIGUCHI ML, 1994, ARQ BRAS CARDIOL, V64, P251; Kocyigit A, 1998, BIOL TRACE ELEM RES, V65, P271, DOI 10.1007/BF02789102; LI G, 1985, HUM PATHOL, V16, P602, DOI 10.1016/S0046-8177(85)80110-6; LOMONACO DA, 1966, ACTA ENDOCRINOL-COP, V53, P162, DOI 10.1530/acta.0.0530162; LOPES ER, 1997, CLIN TERAPEUTICA DOE, P67; Marin-Neto JA, 1998, INT J CARDIOL, V65, P261, DOI 10.1016/S0167-5273(98)00132-6; MILEI J, 1993, MOL CELL BIOCHEM, V129, P161, DOI 10.1007/BF00926364; MILEI J, 1994, CARDIOPATIA CHAGASIC; Moreno-Reyes R, 1998, NEW ENGL J MED, V339, P1112, DOI 10.1056/NEJM199810153391604; Morgan J, 1998, J PARASITOL, V84, P641, DOI 10.2307/3284744; Neve J, 1996, J Cardiovasc Risk, V3, P42; NEVE J, 1995, J TRACE ELEM MED BIO, V51, P1208; Rayman MP, 2000, LANCET, V356, P233, DOI 10.1016/S0140-6736(00)02490-9; ROSSI MA, 1995, CARDIOLOGY, V86, P1, DOI 10.1159/000176822; Schofield CJ, 1999, ADV PARASIT, V42, P1, DOI 10.1016/S0065-308X(08)60147-5; SCRIMSHAW N S, 1975, Progress in Food and Nutrition Science, V1, P393; Solomons NW, 1998, J TRACE ELEM EXP MED, V11, P177; Tamura T, 1996, P NATL ACAD SCI USA, V93, P1006, DOI 10.1073/pnas.93.3.1006; TAN J, 1985, ATLAS ENDEMIC DIS TH; THIELE R, 1995, MED KLIN, V90, P45; Tokarnia CH, 1999, PESQUISA VET BRASIL, V19, P47, DOI 10.1590/S0100-736X1999000200001; VANDERPAS J, 2000, THYROID ENV; VANDERPAS JB, 1990, AM J CLIN NUTR, V52, P1087; *WHO, 1997, CHAG DIS TROP DIS RE; Xu GL, 1997, BIOMED ENVIRON SCI, V10, P316	40	38	38	0	2	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637	1476-1645		AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	JUN	2002	66	6					706	712		10.4269/ajtmh.2002.66.706				7	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	587UB	WOS:000177660700013	12224578	Bronze			2019-03-26	
J	Rojas-Espinosa, O; Wek-Rodriguez, K; Arce-Paredes, P; Aguilar-Torrentera, F; Truyens, C; Carlier, Y				Rojas-Espinosa, O; Wek-Rodriguez, K; Arce-Paredes, P; Aguilar-Torrentera, F; Truyens, C; Carlier, Y			Contrary to BCG, MLM fails to induce the production of TNF alpha and NO by macrophages	INTERNATIONAL JOURNAL OF LEPROSY AND OTHER MYCOBACTERIAL DISEASES			English	Article; Proceedings Paper	16th International Leprosy Congress	AUG 04-09, 2002	SALVADOR, BRAZIL				TUMOR-NECROSIS-FACTOR; MYCOBACTERIUM-BOVIS BCG; NITRIC-OXIDE PRODUCTION; PERITONEAL-MACROPHAGES; ANTIMICROBIAL ACTIVITY; ACTIVATED MACROPHAGES; ALVEOLAR MACROPHAGES; MURINE MACROPHAGES; IFN-GAMMA; IN-VITRO		Natl Polytech Inst, Natl Sch Biol Sci, Dept Immunol, Mexico City, DF, Mexico; Free Univ Brussels, Fac Med, Parasitol Lab, Brussels, Belgium	Rojas-Espinosa, O (reprint author), Esuela Nacl Ciencias Biol, Inst Politecn Nacl, Dept Immunol, Carpio & Plan Ayala, Mexico City 11340, DF, Mexico.						Akaki T, 1997, J LEUKOCYTE BIOL, V62, P795; AKIYAMA T, 1982, INT J LEPROSY, V50, P595; BACH MA, 1983, ANN INST PASTEUR IMM, VD134, P75, DOI 10.1016/S0769-2625(83)80058-0; BRETT SJ, 1984, CELL IMMUNOL, V89, P132, DOI 10.1016/0008-8749(84)90204-1; BROWN CA, 1969, NATURE, V221, P658, DOI 10.1038/221658a0; CHAN J, 1992, J EXP MED, V175, P1111, DOI 10.1084/jem.175.4.1111; DENIS M, 1991, INFECT IMMUN, V59, P705; DENIS M, 1991, INT J IMMUNOPHARMACO, V13, P897, DOI 10.1016/0192-0561(91)90042-6; DENIS M, 1991, INT J IMMUNOPHARMACO, V13, P889, DOI 10.1016/0192-0561(91)90041-5; DRAPER D, 1980, 5 M SCI WORK GROUP I; DRAPER P, 1973, J GEN MICROBIOL, V77, P79, DOI 10.1099/00221287-77-1-79; DRAPER P, 1975, MONONUCLEAR PHAGOCYT, P575; Fazal N, 1996, BIOCHEM MOL BIOL INT, V40, P1033; Frankova D, 1998, EUR J IMMUNOL, V28, P838, DOI 10.1002/(SICI)1521-4141(199803)28:03<838::AID-IMMU838>3.3.CO;2-K; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GREEN SJ, 1994, IMMUNOL LETT, V43, P87, DOI 10.1016/0165-2478(94)00158-8; JEEVAN A, 1988, LYMPHOKINE RES, V7, P129; JIANG XS, 1993, CELL IMMUNOL, V151, P309, DOI 10.1006/cimm.1993.1241; KONETSUNA F, 1980, MICROBIOL IMMUNOL, V24, P1151; Laochumroonvorapong P, 1997, INFECT IMMUN, V65, P4850; Le Page C, 2000, Rev Immunogenet, V2, P374; LIEW FY, 1993, ANN TROP MED PARASIT, V87, P637, DOI 10.1080/00034983.1993.11812822; LIEW FY, 1991, IMMUNOPARASITOL TOD, pA17, DOI 10.1016/S0167-5699(05)80006-4; LINARES E, 2001, FREE RADIC BIOL MED, V11, P1234; MIGLIORINI P, 1991, J IMMUNOL METHODS, V139, P107, DOI 10.1016/0022-1759(91)90357-L; Nozaki Y, 1997, INFECT IMMUN, V65, P3644; Paulnock DM, 2000, J LEUKOCYTE BIOL, V67, P677; Petricevich VL, 2000, MEDIAT INFLAMM, V9, P261, DOI 10.1080/09629350020027564; PRABHAKARAN K, 1976, INT J LEPROSY, V44, P58; RAMASESH N, 1991, INFECT IMMUN, V59, P2864; Reiling N, 2001, J IMMUNOL, V167, P3339, DOI 10.4049/jimmunol.167.6.3339; Rojas-Espinosa O, 1998, INT J LEPROSY, V66, P365; ROJASESPINOSA O, 1991, INT J LEPROSY, V59, P605; ROOS D, 1991, KLIN WOCHENSCHR, V69, P975, DOI 10.1007/BF01645142; Saito S, 1996, J LEUKOCYTE BIOL, V59, P908; SILBAQ F, 1990, INT J LEPROSY, V58, P681; SILVA JS, 1995, INFECT IMMUN, V63, P4862; Skerrett SJ, 1996, INFECT IMMUN, V64, P3236; SPITZNAGEL JK, 1985, REV INFECT DIS, V7, P398; Thoma-Uszynski S, 2001, SCIENCE, V291, P1544, DOI 10.1126/science.291.5508.1544; Underhill DM, 1999, P NATL ACAD SCI USA, V96, P14459, DOI 10.1073/pnas.96.25.14459; VALONE SE, 1988, INFECT IMMUN, V56, P3313	42	5	5	0	0	INT JOURNAL LEPROSY	GREENVILLE	BUSINESS & CIRCULATION OFFICE, 1 ALM WAY, GREENVILLE, SC 29601-9999 USA	0148-916X			INT J LEPROSY	Int. J. Lepr. Other Mycobact. Dis.	JUN	2002	70	2					111	118						8	Microbiology; Pathology; Tropical Medicine	Microbiology; Pathology; Tropical Medicine	587WW	WOS:000177667900003	12211895				2019-03-26	
J	Yuasa, Y				Yuasa, Y			Report of the International Leprosy Association Technical Forum - 25-28 February 2002 - Paris, France	LEPROSY REVIEW			English	Editorial Material									Int Leprosy Assoc, Brussels, Belgium	Yuasa, Y (reprint author), Int Leprosy Assoc, Brussels, Belgium.							0	0	0	0	0	LEPRA	COLCHESTER	FAIRFAX HOUSE, CAUSTON ROAD, COLCHESTER CO1 1PU, ENGLAND	0305-7518			LEPROSY REV	Lepr. Rev.	JUN	2002	73			S			S7	S8						2	Dermatology; Infectious Diseases; Pathology; Tropical Medicine	Dermatology; Infectious Diseases; Pathology; Tropical Medicine	586EN	WOS:000177571800002					2019-03-26	
J	van der Werf, MJ; de Vlas, SJ; Looman, CWN; Nagelkerke, NJD; Habbema, JDF; Engels, D				van der Werf, MJ; de Vlas, SJ; Looman, CWN; Nagelkerke, NJD; Habbema, JDF; Engels, D			Associating community prevalence of Schistosoma mansoni infection with prevalence of signs and symptoms	ACTA TROPICA			English	Article; Proceedings Paper	International Symposium on Schistosomiasis Control in the 21st Century	JUL 04-06, 2001	SHANGHAI, PEOPLES R CHINA			Schistosoma mansoni; schistosomiasis; morbidity; pathology; diarrhoea; blood in stool; abdominal pain; hepatomegaly; splenomegaly; haematemesis; ascitis	MACHAKOS DISTRICT; QUANTITATIVE-ANALYSIS; NORTHERN SENEGAL; GEZIRA-MANAGIL; EGG EXCRETION; MINAS-GERAIS; ENDEMIC AREA; MORBIDITY; EPIDEMIOLOGY; EGYPT	Information on the prevalence of morbidity is needed for re-calculation of the Global Burden of Disease (WHO) due to Schistosoma mansoni. This study presents a statistical association which can be used to predict the prevalence of morbidity from the prevalence of S. mansoni in a community. We collected data from field studies reporting prevalence of infection and prevalence of morbidity. Data on infection prevalence were standardised to a default diagnostic sensitivity (i.e. Kato-Katz technique 41.7 mg). The data were described by an expression related to logistic regression. We determined associations between prevalence of infection and prevalence of early morbidity (diarrhoea, blood in stool and abdominal pain). hepatosplenic morbidity and late morbidity (haematemesis and ascitis). Diarrhoea and blood in stool due to S. mansoni infection mainly occurs in communities with a high prevalence of infection. An influence on hepatosplenic morbidity is already present at low community prevalence of infection. For the aspecific symptom abdominal pain we did not find an association. (C) 2002 Elsevier Science B.V. All rights reserved.	Erasmus Univ, Dept Publ Hlth, NL-3000 DR Rotterdam, Netherlands; Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium; WHO, CH-1211 Geneva 27, Switzerland	van der Werf, MJ (reprint author), Erasmus Univ, Dept Publ Hlth, Box 1738, NL-3000 DR Rotterdam, Netherlands.	vanderwerf@mgz.fgg.eur.nl					Abdel-Wahab MF, 2000, AM J TROP MED HYG, V62, P28, DOI 10.4269/ajtmh.2000.62.28; Abdel-Wahab MF, 2000, AM J TROP MED HYG, V62, P55, DOI 10.4269/ajtmh.2000.62.55; ABDELWAHAB MF, 1990, T ROY SOC TROP MED H, V84, P69, DOI 10.1016/0035-9203(90)90388-U; Barakat R, 2000, AM J TROP MED HYG, V62, P21, DOI 10.4269/ajtmh.2000.62.21; BARRETO ML, 1985, REV I MED TROP, V27, P167, DOI 10.1590/S0036-46651985000400001; Boisier P, 1998, T ROY SOC TROP MED H, V92, P451, DOI 10.1016/S0035-9203(98)91090-2; BOISIER P, 1995, T ROY SOC TROP MED H, V89, P208, DOI 10.1016/0035-9203(95)90498-0; Brooker S, 2000, PARASITOL TODAY, V16, P303, DOI 10.1016/S0169-4758(00)01687-2; BULSARA MK, 1985, T ROY SOC TROP MED H, V79, P535, DOI 10.1016/0035-9203(85)90088-4; Chen M. G., 1988, Tropical Diseases Bulletin, V85, pR1; CORBETT EL, 1992, T ROY SOC TROP MED H, V86, P266, DOI 10.1016/0035-9203(92)90305-V; COSTA MFFDE, 1985, REV I MED TROP, V27, P66; DECLERCQ D, 1985, ANN SOC BELG MED TR, V65, P153; DEVLAS SJ, 1992, PARASITOLOGY, V104, P451, DOI 10.1017/S003118200006371X; DEVLAS SJ, 1996, THESIS ERASMUS U ROT, P201; El-Hawey A. M., 1995, Journal of the Egyptian Society of Parasitology, V25, P649; El-Hawey AM, 2000, AM J TROP MED HYG, V62, P42, DOI 10.4269/ajtmh.2000.62.42; ELTOUM IA, 1993, J TROP MED HYG, V96, P100; FORSYTH DM, 1966, B WORLD HEALTH ORGAN, V34, P715; FRIIS H, 1987, TROP GEOGR MED, V39, P251; FULFORD AJC, 1991, T ROY SOC TROP MED H, V85, P481, DOI 10.1016/0035-9203(91)90229-R; Gabr NS, 2000, AM J TROP MED HYG, V62, P65, DOI 10.4269/ajtmh.2000.62.2_suppl.10813502; Gaye O., 1991, Medecine d'Afrique Noire, V38, P732; Gerspacher-Lara R, 1998, MEM I OSWALDO CRUZ, V93, P245, DOI 10.1590/S0074-02761998000700045; GREMILLION DH, 1978, AM J TROP MED HYG, V27, P924, DOI 10.4269/ajtmh.1978.27.924; GRYSEELS B, 1991, T ROY SOC TROP MED H, V85, P626, DOI 10.1016/0035-9203(91)90371-5; GRYSEELS B, 1987, T ROY SOC TROP MED H, V81, P202, DOI 10.1016/0035-9203(87)90215-X; GRYSEELS B, 1990, T ROY SOC TROP MED H, V84, P542, DOI 10.1016/0035-9203(90)90033-B; GRYSEELS B, 1992, TROP GEOGR MED, V44, P189; GRYSEELS B, 1988, T ROY SOC TROP MED H, V82, P582, DOI 10.1016/0035-9203(88)90519-6; GUIMARAES MDC, 1905, REV INST MED TROP SP, V27, P123; Habib M, 2000, AM J TROP MED HYG, V62, P49, DOI 10.4269/ajtmh.2000.62.49; Hammam HM, 2000, AM J TROP MED HYG, V62, P73, DOI 10.4269/ajtmh.2000.62.2_suppl.10813503; Hammam HM, 2000, AM J TROP MED HYG, V62, P80, DOI 10.4269/ajtmh.2000.62.80; HIATT RA, 1976, AM J TROP MED HYG, V25, P808, DOI 10.4269/ajtmh.1976.25.808; HIATT RA, 1977, AM J TROP MED HYG, V26, P473, DOI 10.4269/ajtmh.1977.26.473; Homeida MMA, 1996, AM J TROP MED HYG, V54, P140, DOI 10.4269/ajtmh.1996.54.140; JOHANSEN MV, 1994, ACTA TROP, V58, P21, DOI 10.1016/0001-706X(94)90118-X; JORDAN P, 1993, HUMAN SCHISTOSOMIASI, P442; KABATEREINE N, 2000, THESIS SCHISTOSOMA M, pCH3; Kardorff R, 1997, TROP MED INT HEALTH, V2, P230, DOI 10.1046/j.1365-3156.1997.d01-269.x; KLOETZEL K, 1987, T ROY SOC TROP MED H, V81, P365, DOI 10.1016/0035-9203(87)90137-4; Kongs A, 1996, TROP MED INT HEALTH, V1, P191; LEHMAN JS, 1976, AM J TROP MED HYG, V25, P285, DOI 10.4269/ajtmh.1976.25.285; Lengeler C, 2000, ACTA TROP, V74, P77, DOI 10.1016/S0001-706X(99)00046-7; Martins MJ, 1998, MEM I OSWALDO CRUZ, V93, P243, DOI 10.1590/S0074-02761998000700044; MUNGOMBA LM, 1995, ANN TROP MED PARASIT, V89, P439, DOI 10.1080/00034983.1995.11812973; Murray C., 1996, GLOBAL BURDEN DIS; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; NDAMBA J, 1991, INT J EPIDEMIOL, V20, P787, DOI 10.1093/ije/20.3.787; Nooman ZM, 2000, AM J TROP MED HYG, V62, P35, DOI 10.4269/ajtmh.2000.62.35; OMER AHS, 1976, J TROP MED HYG, V79, P151; ONGOM VL, 1972, T ROY SOC TROP MED H, V66, P835, DOI 10.1016/0035-9203(72)90118-6; RIPERT C, 1982, B SOC PATHOL EXOT, V75, P55; SIONGOK TKA, 1976, AM J TROP MED HYG, V25, P273, DOI 10.4269/ajtmh.1976.25.273; SMITH DH, 1979, AM J TROP MED HYG, V28, P220, DOI 10.4269/ajtmh.1979.28.220; STELMA FF, 1994, AM J TROP MED HYG, V50, P575, DOI 10.4269/ajtmh.1994.50.575; STELMA FF, 1993, AM J TROP MED HYG, V49, P701, DOI 10.4269/ajtmh.1993.49.701; STRICKLAND GT, 1982, J INFECT DIS, V146, P20, DOI 10.1093/infdis/146.1.20; SUKWA TY, 1986, INT J EPIDEMIOL, V15, P248, DOI 10.1093/ije/15.2.248; Tshikuka JG, 1996, ANN TROP MED PARASIT, V90, P277, DOI 10.1080/00034983.1996.11813053; Utzinger J, 2000, B WORLD HEALTH ORGAN, V78, P389; WISELKA MJ, 1988, E AFR MED J, V65, P102	63	11	11	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0001-706X	1873-6254		ACTA TROP	Acta Trop.	MAY	2002	82	2			SI		127	137	PII S0001-706X(02)00007-4	10.1016/S0001-706X(02)00007-4				11	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	561XP	WOS:000176168600004	12020885				2019-03-26	
J	Erhart, A; Dorny, P; Van De, N; Vien, HV; Thach, DC; Toan, ND; Cong, L; Geerts, S; Speybroeck, N; Berkvens, D; Brandt, J				Erhart, A; Dorny, P; Van De, N; Vien, HV; Thach, DC; Toan, ND; Cong, L; Geerts, S; Speybroeck, N; Berkvens, D; Brandt, J			Taenia solium cysticercosis in a village in northern Viet Nam: seroprevalence study using an ELISA for detecting circulating antigen	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						cysticercosis; Taenia solium; diagnosis; enzyme-linked immunosorbent assay; Viet Nam	SAGINATA CYSTICERCOSIS; NEUROCYSTICERCOSIS; DIAGNOSIS	An enzyme-linked immunosorbent assay (ELISA) for detecting circulating Taenia solium antigen was evaluated in Viet Nam; 12 of 2 10 people gave a positive result, including 5 persons with epilepsy. Cysticercosis was confirmed in 9 persons. Agreement between the ELISA, computerized tomography scanning and biopsy examination was high.	Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium; Natl Inst Malariol Parasitol & Entomol, Hanoi, Vietnam	Dorny, P (reprint author), Inst Trop Med Prince Leopold, Natl Str 155, B-2000 Antwerp, Belgium.			Geerts, Stanny/0000-0001-9885-8846			BRANDT JRA, 1992, INT J PARASITOL, V22, P471, DOI 10.1016/0020-7519(92)90148-E; Correa D, 1999, ANN TROP MED PARASIT, V93, P69; DEJONGE N, 1987, J IMMUNOL METHODS, V99, P195, DOI 10.1016/0022-1759(87)90127-X; Dorny P, 2000, VET PARASITOL, V88, P43, DOI 10.1016/S0304-4017(99)00196-X; Garcia HH, 2000, T ROY SOC TROP MED H, V94, P673, DOI 10.1016/S0035-9203(00)90228-1; Garcia HH, 1998, T ROY SOC TROP MED H, V92, P411, DOI 10.1016/S0035-9203(98)91069-0; Graham P, 1998, J CLIN EPIDEMIOL, V51, P763, DOI 10.1016/S0895-4356(98)00048-1; Sanchez AL, 1999, ANN TROP MED PARASIT, V93, P247, DOI 10.1080/00034983.1999.11813420; Sokal RR, 1981, BIOMETRY, P859	9	50	53	0	6	ROYAL SOC TROPICAL MEDICINE	LONDON	MANSON HOUSE 26 PORTLAND PLACE, LONDON W1N 1EY, ENGLAND	0035-9203			T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	MAY-JUN	2002	96	3					270	272		10.1016/S0035-9203(02)90095-7				3	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	579DV	WOS:000177161900009	12174775				2019-03-26	
J	Talisuna, AO; Langi, P; Bakyaita, N; Egwang, T; Mutabingwa, TK; Watkins, W; Van Marck, E; D'Alessandro, U				Talisuna, AO; Langi, P; Bakyaita, N; Egwang, T; Mutabingwa, TK; Watkins, W; Van Marck, E; D'Alessandro, U			Intensity of malaria transmission, antimalarial-drug use and resistance in Uganda: what is the relationship between these three factors?	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						malaria; Plasmodium falciparum; transmission intensity; drug resistance; drug use; chloroquine; sulfadoxine-pyrimethamine; Uganda	FALCIPARUM DIHYDROFOLATE-REDUCTASE; KENYAN PLASMODIUM-FALCIPARUM; SULFADOXINE-PYRIMETHAMINE; IN-VITRO; CHLOROQUINE; MUTATIONS; CHILDREN; POLICY; AFRICA; POPULATION	We studied (in 1998 and 1999) some factors that may be linked to the spread of chloroquine (CQ) and sulfadoxine-pyrimethamine (SP) resistance in 7 discrete communities in Uganda. Exposure to malaria infection was measured by parasitological surveys in children aged 1-9 years, drug use by community surveys and drug resistance by in-vivo tests on children aged 6-59 months with clinical malaria. CQ use was inversely related to parasite prevalence (r = 0.85, P = 0.01). CQ and SP treatment failure rates varied significantly according to parasite prevalence (P = 0.001 and 0-04 respectively). The highest CQ (42.4%, 43.8%) and SP (12.5%, 14.8%) treatment failure rates were observed in sites characterized by high parasite prevalence. Using areas with medium parasite prevalence as reference, the relative risk (RR) for CQ treatment failure was 3-2 (95% CI 1.6-6-4) in high parasite prevalence sites and 3-1 (95% CI 1.2-7.7) in low parasite prevalence sites. The RR for SP treatment failure was also higher in sites with high parasite prevalence but low in those with low parasite prevalence. According to our findings, drug resistance seems to spread faster in higher transmission areas, regardless of drug pressure. In low transmission areas, drug pressure seems to be the critical factor. A decrease in transmission coupled with rational use of drugs may delay the spread of resistance.	Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium; Minist Hlth, Kampala, Uganda; Med Biotech Labs, Kampala, Uganda; Natl Inst Med Res, Amani Tanga, Tanzania; London Sch Hyg & Trop Med, Gates Malaria Programme, London, England; KEMRI Wellcome Trust Collaborat Programme, Nairobi, Kenya; Univ Antwerp, B-2020 Antwerp, Belgium	Talisuna, AO (reprint author), Minist Hlth, POB 7272, Kampala, Uganda.	atalisuna@kla1.afsat.com; udalessandro@proto.itg.be	D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009			Babiker HA, 1997, PARASITOL TODAY, V13, P262, DOI 10.1016/S0169-4758(97)01075-2; BABIKER HA, 1994, PARASITOLOGY, V109, P413, DOI 10.1017/S0031182000080665; BLOLAND PB, 1993, J INFECT DIS, V167, P932, DOI 10.1093/infdis/167.4.932; Clarke D, 1996, T ROY SOC TROP MED H, V90, P302, DOI 10.1016/S0035-9203(96)90262-X; dePecoulas PE, 1996, T ROY SOC TROP MED H, V90, P181, DOI 10.1016/S0035-9203(96)90130-3; Djimde A, 1998, AM J TROP MED HYG, V59, P376, DOI 10.4269/ajtmh.1998.59.376; Djimde A, 2001, NEW ENGL J MED, V344, P257, DOI 10.1056/NEJM200101253440403; EGGELTE TA, 1992, P 13 INT C TROP MED, V2, P242; Eggelte TA, 1990, INT MONOGRAPH SERIES, V3, P35; Hastings IM, 2000, PARASITOL TODAY, V16, P340, DOI 10.1016/S0169-4758(00)01707-5; KATZ D, 1978, BIOMETRICS, V34, P469, DOI 10.2307/2530610; LEMESHOW S, 1991, World Health Statistics Quarterly, V44, P115; MARKWALDER KA, 1982, T ROY SOC TROP MED H, V76, P281, DOI 10.1016/0035-9203(82)90301-7; Menendez C, 2000, PARASITOL TODAY, V16, P469, DOI 10.1016/S0169-4758(00)01774-9; MORGENSTERN H, 1982, AM J PUBLIC HEALTH, V72, P1336, DOI 10.2105/AJPH.72.12.1336; Nwanyanwu OC, 2000, TROP MED INT HEALTH, V5, P355, DOI 10.1046/j.1365-3156.2000.00554.x; Nzila AM, 2000, J INFECT DIS, V181, P2023, DOI 10.1086/315520; Nzila-Mounda A, 1998, ANTIMICROB AGENTS CH, V42, P164, DOI 10.1128/AAC.42.1.164; PAUL REL, 1995, SCIENCE, V269, P1709, DOI 10.1126/science.7569897; PLOWE CV, 1995, AM J TROP MED HYG, V52, P565, DOI 10.4269/ajtmh.1995.52.565; Plowe CV, 1997, J INFECT DIS, V176, P1590, DOI 10.1086/514159; Schwick P, 1998, TROP MED INT HEALTH, V3, P828, DOI 10.1046/j.1365-3156.1998.00307.x; Shretta R, 2000, TROP MED INT HEALTH, V5, P755, DOI 10.1046/j.1365-3156.2000.00643.x; Snow RW, 1997, LANCET, V349, P1650, DOI 10.1016/S0140-6736(97)02038-2; SPENCER HC, 1983, AM J TROP MED HYG, V32, P922, DOI 10.4269/ajtmh.1983.32.922; *UG GOV WHO, 1963, MAL PREER PROGR; Verhoef H, 1999, AM J TROP MED HYG, V61, P770, DOI 10.4269/ajtmh.1999.61.770; *WHO CTD, 1996, WHOMAL961077; WILSON D B, 1962, East Afr Med J, V39, P593	29	65	66	0	2	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0035-9203	1878-3503		T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	MAY-JUN	2002	96	3					310	317		10.1016/S0035-9203(02)90108-2				8	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	579DV	WOS:000177161900020	12174786				2019-03-26	
J	Lejon, V; Lardon, J; Kenis, G; Pinoges, L; Legros, D; Bisser, S; N'Siesi, X; Bosmans, E; Buscher, P				Lejon, V; Lardon, J; Kenis, G; Pinoges, L; Legros, D; Bisser, S; N'Siesi, X; Bosmans, E; Buscher, P			Interleukin (IL)-6, IL-8 and IL-10 in serum and CSF of Trypanosoma brucei gambiense sleeping sickness patients before and after treatment	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						trypanosomiasis; Trypanosoma brucei gambiense; cytokines; interleukin-6; interleukin-8; interleukin-10; tumour necrosis factor alpha; interferon gamma; serum; cerebrospinal fluid; chemotherapy; DR Congo	HUMAN AFRICAN TRYPANOSOMIASIS; NECROSIS-FACTOR-ALPHA; CEREBROSPINAL-FLUID; MONONUCLEAR-CELLS; NERVOUS-SYSTEM; INFECTION; STAGE	Serum and cerebrospinal fluid (CSF) concentrations of interleukin (IL)-6, IL-8, IL- 10, tumour necrosis factor-a and interferon-y were determined in 46 Trypanosoma brucei gambiense sleeping sickness patients in DR Congo, before and after treatment. According to their CSF cell number before treatment, patients were classified as early-stage (0-5 cells/muL), intermediate-stage (6-20 cells/muL) or late-stage patients (>20 cells/ muL). In serum, slightly higher IL-8 concentrations were found in early-stage patients compared to intermediate- or late-stage patients. These high IL-8 levels dropped after treatment. Higher IL-10 concentrations were detected in serum of patients in intermediate or late stage compared to early-stage patients. In both intermediate- and late-stage groups, serum IL-10 decreased after treatment. In CSF, elevated concentrations of IL-6, IL-8 and especially of IL-10 were observed in late-stage T b. gambiense patients. After treatment, these concentrations dropped to levels similar to those of the other patients. Tumour necrosis factor-a was detected only in a few serum and CSF samples, which were scattered over the different patient groups. Interferon-gamma was detected in serum of 5 patients and remained undetectable in CSF.	Inst Trop Med, Dept Parasitol, Nat Str 155, B-2000 Antwerp, Belgium; Eurogenetics, B-3980 Tessenderlo, Belgium; EPICENTRE, F-75011 Paris, France; CDI Bwamanda, Bur Cent Trypanosomiase, Bwamanda, DEM REP CONGO; Fac Med Limoges, Inst Epidemiol Neurol & Neurol Trop, EA3174, F-87025 Limoges, France	Lejon, V (reprint author), Inst Trop Med, Dept Parasitol, Nat Str 155, B-2000 Antwerp, Belgium.	vlejon@itg.be	Buscher, Philippe/B-9956-2012	Buscher, Philippe/0000-0002-1926-7472			ANTHOONS JAMS, 1989, PARASITOL RES, V75, P251, DOI 10.1007/BF00931808; Bisser S, 1997, B SOC PATHOL EXOT, V90, P321; Bisser S, 2002, J NEUROL SCI, V193, P127, DOI 10.1016/S0022-510X(01)00655-4; HUNTER CA, 1992, LAB INVEST, V67, P635; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Lejon V, 1999, AM J TROP MED HYG, V60, P94, DOI 10.4269/ajtmh.1999.60.94; Lejon V, 1998, ACTA TROP, V69, P151, DOI 10.1016/S0001-706X(97)00137-X; Lindley IJD, 1998, CYTOKINES, P125, DOI 10.1016/B978-012498340-3/50009-9; MacLean L, 1999, T ROY SOC TROP MED H, V93, P169, DOI 10.1016/S0035-9203(99)90296-1; Namangala B, 2000, PARASITE IMMUNOL, V22, P361, DOI 10.1046/j.1365-3024.2000.00314.x; Namangala B, 2000, J INFECT DIS, V181, P1110, DOI 10.1086/315322; OKOMOASSOUMOU MC, 1995, AM J TROP MED HYG, V53, P539, DOI 10.4269/ajtmh.1995.53.539; PENTREATH VW, 1990, T ROY SOC TROP MED H, V84, P795, DOI 10.1016/0035-9203(90)90085-S; Quan N, 1999, J COMP NEUROL, V414, P114, DOI 10.1002/(SICI)1096-9861(19991108)414:1<114::AID-CNE9>3.0.CO;2-G; Reincke Martin, 1994, Neuroimmunomodulation, V1, P14, DOI 10.1159/000095930; Rhind SG, 1997, CLIN IMMUNOL IMMUNOP, V83, P185, DOI 10.1006/clin.1997.4350; SCHULTZBERG M, 1988, J NEUROSCI RES, V21, P56, DOI 10.1002/jnr.490210109; Spanaus KS, 1997, J IMMUNOL, V158, P1956	18	49	49	0	2	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0035-9203	1878-3503		T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	MAY-JUN	2002	96	3					329	333		10.1016/S0035-9203(02)90115-X				5	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	579DV	WOS:000177161900025	12174791				2019-03-26	
J	De Clercq, D; Vercruysse, J; Kongs, A; Verle, P; Dompnier, JP; Faye, PC				De Clercq, D; Vercruysse, J; Kongs, A; Verle, P; Dompnier, JP; Faye, PC			Efficacy of artesunate and praziquantel in Schistosoma haematobium infected schoolchildren	ACTA TROPICA			English	Article						artesunate; praziquantel; treatment; cure and egg count reduction rates; Schistosoma haematobium; Senegal	SENEGAL RIVER BASIN; MANSONI INFECTIONS; DRUG-RESISTANCE; ARTEMETHER; CHEMOTHERAPY	Praziquantel is the current mainstay for morbidity control of schistosomiasis. Artemisinin and its derivatives, widely used for the treatment of malaria, also display antischistosomal properties. The present study is an effort to assess the therapeutic efficacy of artesunate, an artemisinin derivative, in Schistosoma haematobium infections in a human population. The efficacy of artesunate and praziquantel were comparatively studied in primary schoolchildren from two villages, Lampsar (n = 180) and Makhana (n = 108), located along the Lampsar river in the delta of the Senegal River Basin in Northern Senegal (West Africa). In each village, half of the infected children were treated with a single oral dose of 40 mg/kg praziquantel and half with artesunate following the recommended malaria monotherapy regimen. For both drugs, cure and egg count reduction rates were, without apparent explanation, higher in Makhana than in Lampsar. In both villages, high and nearly comparable egg count reduction rates were obtained with both drugs at each follow-up after treatment (5, 12 and 24 weeks) in the heavy infected group of children ( > 50 eggs/10 ml of urine). No major adverse effects were observed. The results demonstrate that artesunate is effective against S. haematobium, but the results obtained with praziquantel were consistently better. (C) 2002 Elsevier Science B.V. All rights reserved.	Univ Ghent, Dept Virol Parasitol & Immunol, Fac Vet Med, B-9820 Merelbeke, Belgium; Reg Med St Louis, Programme ESPOIR, St Louis, Senegal; Belgian Tech Corp, Hanoi, Vietnam	Vercruysse, J (reprint author), Univ Ghent, Dept Virol Parasitol & Immunol, Fac Vet Med, Salisburylaan 133, B-9820 Merelbeke, Belgium.	jozef.vercruysse@rug.ac.be					Araujo N, 1999, REV SOC BRASILEIRA M, V32, P7; Borrmann S, 2001, J INFECT DIS, V184, P1363, DOI 10.1086/324004; CHAINE JP, 1983, TROP GEOGR MED, V35, P249; Cioli D, 2000, CURR OPIN INFECT DIS, V13, P659, DOI 10.1097/00001432-200012000-00014; De Clercq D, 2000, TROP MED INT HEALTH, V5, P744, DOI 10.1046/j.1365-3156.2000.00628.x; De Clercq D, 2000, T ROY SOC TROP MED H, V94, P90, DOI 10.1016/S0035-9203(00)90453-X; FELDMEIER H, 1993, ACTA TROP, V52, P205, DOI 10.1016/0001-706X(93)90009-Z; Geerts S, 2000, CLIN MICROBIOL REV, V13, P207, DOI 10.1128/CMR.13.2.207-222.2000; KONGS A, 1993, THESIS LONDON SCH HY; KUMAR V, 1994, INT J ANTIMICROB AG, V4, P313, DOI 10.1016/0924-8579(94)90032-9; Le W J, 1983, Yao Xue Xue Bao, V18, P619; Li SW, 1996, CHINESE MED J-PEKING, V109, P848; Price RN, 2000, EXPERT OPIN INV DRUG, V9, P1815, DOI 10.1517/13543784.9.8.1815; Shaw DJ, 1999, T ROY SOC TROP MED H, V93, P142, DOI 10.1016/S0035-9203(99)90288-2; SHUHUA X, 1989, ANTIMICROB AGENTS CH, V33, P1557, DOI 10.1128/AAC.33.9.1557; Utzinger J, 2000, LANCET, V355, P1320, DOI 10.1016/S0140-6736(00)02114-0; Utzinger J, 2001, ACTA TROP, V80, P9, DOI 10.1016/S0001-706X(01)00138-3; VERCRUYSSE J, 1985, ACTA TROP, V42, P249; White N, 1999, PHILOS T R SOC B, V354, P739, DOI 10.1098/rstb.1999.0426; Winstanley PA, 2000, PARASITOL TODAY, V16, P146, DOI 10.1016/S0169-4758(99)01622-1; Xiao SH, 2000, INT J PARASITOL, V30, P1001, DOI 10.1016/S0020-7519(00)00091-6; Xiao SH, 2000, PARASITOL TODAY, V16, P122, DOI 10.1016/S0169-4758(99)01601-4; Xiao SH, 2000, PARASITOL INT, V49, P25, DOI 10.1016/S1383-5769(00)00029-5; Xiao Shu-Hua, 1995, Southeast Asian Journal of Tropical Medicine and Public Health, V26, P306; 1992, TDR NEWS, V41, P1	25	49	50	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0001-706X	1873-6254		ACTA TROP	Acta Trop.	APR	2002	82	1					61	66	PII S0001-706X(02)00003-7	10.1016/S0001-706X(02)00003-7				6	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	543XA	WOS:000175126200008	11904104				2019-03-26	
J	Zhu, W; Baggerman, G; Secor, WE; Casares, F; Pryor, SC; Fricchione, GL; Ruiz-Tiben, E; Eberhard, NL; Bimi, L; Stefano, GB				Zhu, W; Baggerman, G; Secor, WE; Casares, F; Pryor, SC; Fricchione, GL; Ruiz-Tiben, E; Eberhard, NL; Bimi, L; Stefano, GB			Dracunculus medinensis and Schistosoma mansoni contain opiate alkaloids	ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY			English	Article							PROOPIOMELANOCORTIN-DERIVED PEPTIDES; MOLLUSK MYTILUS-EDULIS; AFFINITY BINDING; PARASITE; MORPHINE; HOST; GANGLIA; MORPHINE-6-GLUCURONIDE; INVERTEBRATES; IMMUNOCYTES	The results of analysis, by high-performance liquid chromatography coupled with electrochemical detection and by nano-electrospray-ionization, double quadrupole orthogonal-acceleration, time-of-flight mass spectrometry, indicate that adult Dracunculus medinensis and Schistosoma mansoni both contain the opiate alkaloid morphine and that D. medinesis also contains the active metabolite of morphine, morphine 6-glucuronide. From these and previous observations, it would appear that many helminths are probably using opiate alkaloids as potent immuno suppressive and antinociceptive signal molecules, to down-regulate immune surveillance responsiveness and pain signalling in their hosts.	SUNY Coll Old Westbury, Neurosci Res Inst, Old Westbury, NY 11568 USA; Catholic Univ Louvain, Inst Zool, Lab Dev Physiol & Mol Biol, B-3000 Louvain, Belgium; Ctr Dis Control & Prevent, Immunol Branch, Div Parasit Dis, Dept Hlth & Human Serv, Atlanta, GA 30341 USA; Carter Ctr, Atlanta, GA 30307 USA; Univ Ghana, Dept Zool, Legon, Accra, Ghana	Stefano, GB (reprint author), SUNY Coll Old Westbury, Neurosci Res Inst, Old Westbury, NY 11568 USA.	gstefano@sunynri.org		Baggerman, Geert/0000-0002-0661-931X; Stefano, George/0000-0002-8146-0740	NIMH NIH HHS [NIMH COR 47392, NIMH COR 17138]; NIDA NIH HHS [NIDA 09010]		Cadet P, 1999, MOL BRAIN RES, V74, P242, DOI 10.1016/S0169-328X(99)00287-9; CAPRON A, 1989, IMMUNOL REV, V112, P27, DOI 10.1111/j.1600-065X.1989.tb00551.x; CAPRON A, 1987, SCIENCE, V238, P1065, DOI 10.1126/science.3317823; CAPRON AR, 1988, NEWS PHYSIOL SCI, V3, P75; DUVAUX-MIRET O, 1990, New Biologist, V2, P93; DUVAUXMIRET O, 1992, ACTA BIOL HUNG, V43, P281; DUVAUXMIRET O, 1992, ADV NEUROIMMUNOL, V2, P297, DOI 10.1016/S0960-5428(06)80053-7; DUVAUXMIRET O, 1992, P NATL ACAD SCI USA, V89, P778, DOI 10.1073/pnas.89.2.778; Eisenstein TK, 1998, J NEUROIMMUNOL, V83, P36, DOI 10.1016/S0165-5728(97)00219-1; Goumon Y, 2000, J IMMUNOL, V165, P339, DOI 10.4049/jimmunol.165.1.339; KREAM RM, 1980, J BIOL CHEM, V255, P9218; LEUNG MK, 1995, EXP PARASITOL, V81, P208, DOI 10.1006/expr.1995.1110; Liu Y, 1996, BRAIN RES, V722, P125, DOI 10.1016/0006-8993(96)00204-1; Salzet M, 2000, PARASITOL TODAY, V16, P536, DOI 10.1016/S0169-4758(00)01787-7; Salzet M, 1997, J IMMUNOL, V159, P5400; Salzet M, 1997, MOL BRAIN RES, V52, P46, DOI 10.1016/S0169-328X(97)00200-3; Salzet M, 1997, BRAIN RES, V768, P224, DOI 10.1016/S0006-8993(97)00646-X; Schoeler GB, 2001, ANN TROP MED PARASIT, V95, P755, DOI 10.1080/0003498012011118; Stefano GB, 2000, TRENDS NEUROSCI, V23, P436, DOI 10.1016/S0166-2236(00)01611-8; STEFANO GB, 1980, BRAIN RES, V181, P440, DOI 10.1016/0006-8993(80)90626-5; Stefano GB, 1999, INT REV CYTOL, V187, P261, DOI 10.1016/S0074-7696(08)62420-1; Stefano GB, 1998, IMMUNOL TODAY, V19, P265, DOI 10.1016/S0167-5699(98)01268-7; STEFANO GB, 1981, BRAIN RES, V225, P107, DOI 10.1016/0006-8993(81)90321-8; Stefano GB, 1996, COMP BIOCHEM PHYS C, V113, P369, DOI 10.1016/0742-8413(96)02111-1; Stefano GB, 1996, CRIT REV IMMUNOL, V16, P109, DOI 10.1615/CritRevImmunol.v16.i2.10; Stefano GB, 1999, MOL BRAIN RES, V63, P340, DOI 10.1016/S0169-328X(98)00252-6; Zhu W, 2001, EUR J MASS SPECTROM, V7, P25, DOI 10.1255/ejms.384; Zhu W, 2001, MOL BRAIN RES, V88, P155, DOI 10.1016/S0169-328X(01)00048-1; Zhu W, 2001, INT J MOL MED, V7, P419	29	25	25	1	8	MANEY PUBLISHING	LEEDS	STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND	0003-4983	1364-8594		ANN TROP MED PARASIT	Ann. Trop. Med. Parasitol.	APR	2002	96	3					309	316		10.1179/000349802125000808				8	Public, Environmental & Occupational Health; Parasitology; Tropical Medicine	Public, Environmental & Occupational Health; Parasitology; Tropical Medicine	551KH	WOS:000175559900008	12061977				2019-03-26	
J	Bossyns, P; Miye, H; vLerberghe, W				Bossyns, P; Miye, H; vLerberghe, W			Supply-level measures to increase uptake of family planning services in Niger: the effectiveness of improving responsiveness	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						family planning; integration; Niger; performance; quality of care; responsiveness; utilization	MOROCCO; ACCESS; IMPACT	OBJECTIVE To show that low-cost attitudinal, structural and procedural changes aimed at improving responsiveness to patients have the potential to increase uptake of family planning (FP) even among populations considered reluctant to do so by health personnel. METHODS Intervention study with before-after comparison of contraceptive acceptance, couple-years of protection (CYP) and an 'index of contraceptive uptake' (IUC) in rural health centres in Niger. The intervention consists of a package of instructions to actively propose family planning, integrated within curative and under-fives consultations, coupled with measures to increase the health centres' responsiveness to their clients. RESULTS Implementation of the intervention package was followed by marked increases in family planning uptake. CONCLUSION Health services in Niger present an untapped potential for improving family planning through low-cost supply-side measures.	Project Alafia GTZ, Niamey, Niger; Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium	Bossyns, P (reprint author), Project Alafia GTZ, BP 10814, Niamey, Niger.						Attama S, 1999, ENQUETE DEMOGRAPHIQU; BINKA FN, 1995, STUD FAMILY PLANN, V26, P121, DOI 10.2307/2137832; GAGE AJ, 1995, STUD FAMILY PLANN, V26, P264, DOI 10.2307/2138012; JANOWITZ B, 1994, STUD FAMILY PLANN, V25, P362, DOI 10.2307/2137880; Katz KR, 1998, INT FAM PLAN PERSPEC, V24, P104, DOI 10.2307/3038206; Kirk D, 1998, STUD FAMILY PLANN, V29, P1, DOI 10.2307/172178; KOURGUENI AI, 1993, ENQUETE DEMOGRAPHIQU; Magnani RJ, 1999, STUD FAMILY PLANN, V30, P120, DOI 10.1111/j.1728-4465.1999.00120.x; Nazzar A, 1995, STUD FAMILY PLANN, V26, P307, DOI 10.2307/2138097; PUST ER, 1985, TROPICAL DOCTOR, V15, P95; Routh S, 2001, B WORLD HEALTH ORGAN, V79, P142; SHAPIRO D, 1994, STUD FAMILY PLANN, V25, P96, DOI 10.2307/2138087; SIMMONS R, 1994, STUD FAMILY PLANN, V25, P1, DOI 10.2307/2137985; Speizer IS, 2000, STUD FAMILY PLANN, V31, P163, DOI 10.1111/j.1728-4465.2000.00163.x; Stanback J, 1999, LANCET, V354, P566, DOI 10.1016/S0140-6736(99)01578-0; Stanback J, 1997, STUD FAMILY PLANN, V28, P245, DOI 10.2307/2137892; Steele F, 1999, STUD FAMILY PLANN, V30, P28, DOI 10.1111/j.1728-4465.1999.00028.x; VANLERBERGHE W, 1988, SOC SCI MED, V26, P949, DOI 10.1016/0277-9536(88)90415-7; 1994, STUDIES FAMILY PLANN, V25, P129; 1996, PLAN DEV SANITAIRE D	20	5	5	0	2	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	APR	2002	7	4					383	390		10.1046/j.1365-3156.2002.00865.x				8	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	541MX	WOS:000174989300014	11952956	Bronze			2019-03-26	
J	Leboulle, G; Rochez, C; Louahed, J; Rutti, B; Brossard, M; Bollen, A; Godfroid, E				Leboulle, G; Rochez, C; Louahed, J; Rutti, B; Brossard, M; Bollen, A; Godfroid, E			Isolation of Ixodes ricinus salivary gland mRNA encoding factors induced during blood feeding	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							TICK RHIPICEPHALUS-APPENDICULATUS; MESSENGER-RNA EXPRESSION; FACTOR-PATHWAY INHIBITOR; LYMPH-NODE CELLS; IN-VITRO; PLATELET-AGGREGATION; CYTOKINE PRODUCTION; MOLECULAR CHARACTERIZATION; EXTRACTS; CLONING	In tick salivary glands, genes induced during blood feeding result in the expression of new proteins secreted into tick saliva. These proteins are potentially involved in modulation of vertebrate host immune and hemostatic responses. In this study, subtractive and full-length cDNA libraries were constructed by use of mRNA extracted from salivary glands of unfed and 5-day engorged Ixodes ricinus. Sequences from these 2 libraries were compared with European Molecular Biology Laboratory (EMBL)/GenBank databases which led to their classification into 2 major groups. The first group comprises cDNAs that failed to match or showed low homology to genes of known function. The second group includes sequences that showed high homology to genes of known function-for example, anticoagulants, inhibitors of platelet aggregation, and immunomodulatory proteins. Analyses of corresponding proteins suggest that they may be secreted by salivary gland cells. To study the properties of the recombinant proteins, selected cDNAs were expressed in mammalian or bacterial systems.	Free Univ Brussels, Dept Appl Genet, Gosselies, Belgium; Catholic Univ Louvain, Ludwig Inst Canc Res, Brussels, Belgium; Univ Neuchatel, Inst Zool, CH-2007 Neuchatel, Switzerland	Godfroid, E (reprint author), Free Univ Brussels, Dept Appl Genet, Rue Prof Jeener & Brachet 12, Gosselies, Belgium.	godfroid@sga.ulb.ac.be					Aeschlimann A., 1991, Parasite-host associations: coexistence or conflict?., P148; Baugh RJ, 1998, J BIOL CHEM, V273, P4378, DOI 10.1074/jbc.273.8.4378; Bode W, 1996, ADV EXP MED BIOL, V389, P1; Brossard M, 1997, MED VET ENTOMOL, V11, P270, DOI 10.1111/j.1365-2915.1997.tb00406.x; COUGHLIN P, 1993, P NATL ACAD SCI USA, V90, P9417, DOI 10.1073/pnas.90.20.9417; Das S, 2000, AM J TROP MED HYG, V62, P99, DOI 10.4269/ajtmh.2000.62.99; FIVAZ BH, 1989, J PARASITOL, V75, P946, DOI 10.2307/3282875; FROHMAN BH, 1995, PCR PRIMER LAB MANUA, P381; Fuchsberger N, 1995, EXP APPL ACAROL, V19, P671, DOI 10.1007/BF00145255; Ganapamo F, 1996, IMMUNOLOGY, V87, P259, DOI 10.1046/j.1365-2567.1996.450512.x; GANAPAMO F, 1995, IMMUNOLOGY, V85, P120; Ganapamo F, 1996, SCAND J IMMUNOL, V44, P388, DOI 10.1046/j.1365-3083.1996.d01-327.x; GORDON JR, 1991, J PARASITOL, V77, P167, DOI 10.2307/3282577; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; JONES LD, 1992, EXP APPL ACAROL, V13, P241, DOI 10.1007/BF01195081; Kamiguti AS, 1997, BBA-GEN SUBJECTS, V1335, P209, DOI 10.1016/S0304-4165(96)00140-7; KARCZEWSKI J, 1995, BIOCHEM BIOPH RES CO, V208, P532, DOI 10.1006/bbrc.1995.1371; KELLER PM, 1993, J BIOL CHEM, V268, P5450; Kopecky J, 1998, PARASITE IMMUNOL, V20, P169; KUBES M, 1994, IMMUNOLOGY, V82, P113; Kuno K, 1997, J BIOL CHEM, V272, P556; LIMO MK, 1991, EXP PARASITOL, V72, P418, DOI 10.1016/0014-4894(91)90088-E; MBOW ML, 1994, CELL IMMUNOL, V156, P254, DOI 10.1006/cimm.1994.1170; MCGEOCH DJ, 1985, VIRUS RES, V3, P271, DOI 10.1016/0168-1702(85)90051-6; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Nuttall PA, 1998, PARASITOLOGY, V116, pS65, DOI 10.1017/S003118200008495X; OAKS JF, 1991, J PARASITOL, V77, P378, DOI 10.2307/3283124; Petersen LC, 1996, EUR J BIOCHEM, V235, P310, DOI 10.1111/j.1432-1033.1996.0310f.x; RAMACHANDRA RN, 1992, J MED ENTOMOL, V29, P818, DOI 10.1093/jmedent/29.5.818; Randolph SE, 1996, PARASITOL TODAY, V12, P472, DOI 10.1016/S0169-4758(96)10072-7; REMOLDODONNELL E, 1992, P NATL ACAD SCI USA, V89, P5635, DOI 10.1073/pnas.89.12.5635; RIBEIRO JMC, 1987, EXP PARASITOL, V64, P347, DOI 10.1016/0014-4894(87)90046-4; SAUER JR, 1995, ANNU REV ENTOMOL, V40, P245, DOI 10.1146/annurev.en.40.010195.001333; URIOSTE S, 1994, J EXP MED, V180, P1077, DOI 10.1084/jem.180.3.1077; USHIO H, 1993, PARASITE IMMUNOL, V15, P209, DOI 10.1111/j.1365-3024.1993.tb00602.x; Valenzuela JG, 2000, J BIOL CHEM, V275, P18717, DOI 10.1074/jbc.M001486200; WANG H, 1994, PARASITOLOGY, V109, P517, DOI 10.1017/S003118200008077X; WANG H, 1995, PARASITOLOGY, V110, P363; Wang XN, 1996, J BIOL CHEM, V271, P17785, DOI 10.1074/jbc.271.30.17785; Wikel SK, 1996, EXP PARASITOL, V84, P304, DOI 10.1006/expr.1996.0118; Wikel SK, 1996, ANNU REV ENTOMOL, V41, P1, DOI 10.1146/annurev.en.41.010196.000245	41	50	54	0	3	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637	1476-1645		AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	MAR	2002	66	3					225	233		10.4269/ajtmh.2002.66.225				9	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	573GH	WOS:000176820600002	12139212	Bronze, Green Published			2019-03-26	
J	Torrentera, FA; Lambot, MA; Laman, JD; Van Meurs, M; Kiss, R; Noel, JC; Carlier, Y				Torrentera, FA; Lambot, MA; Laman, JD; Van Meurs, M; Kiss, R; Noel, JC; Carlier, Y			Parasitic load and histopathology of cutaneous lesions, lymph node, spleen, and liver from BALB/c and C57BL/6 mice infected with Leishmania mexicana	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							CD4(+) T-CELLS; VISCERAL LEISHMANIASIS; AMAZONENSIS INFECTION; GENE; SUSCEPTIBILITY; PROMASTIGOTES; EPIDEMIOLOGY; PATHOGENESIS; RESPONSES; DISEASE	The course of infection, parasitic loads, and histopathology of cutaneous lesions, draining lymph node, spleen, and liver were compared in BALB/c and C57BL/6 mice over a period of 34 weeks after inoculation in footpad with promastigotes of a Leishmania mexicana reference strain. The results show that the primary footpad lesions first present a 12-week phase that develops similarly in both strains of mice. Thereafter, a cutaneous and visceral dissemination of L. mexicana parasites occurs in BALB/c mice; the latter experience an extensive breakdown of the lymphoid organ microarchitecture, whereas C57BL/6 mice succeed in eliminating the parasite infection from the lymph nodes but not from the primary cutaneous lesion, which does not heal. These results highlight marked differences between responses of key anatomical compartments controlling L. mexicana infection in BALB/c and C578L/6 mice.	Free Univ Brussels, Fac Med, Parasitol Lab, B-1070 Brussels, Belgium; Free Univ Brussels, Erasmus Hosp, Dept Pathol, B-1070 Brussels, Belgium; Erasmus Univ, Dept Immunol, NL-3000 DR Rotterdam, Netherlands; Free Univ Brussels, Fac Med, Lab Histopathol, B-1070 Brussels, Belgium; IPN, Escuela Nacl Ciencias Biol, Dept Immunol, Mexico City 07738, DF, Mexico	Carlier, Y (reprint author), Free Univ Brussels, Fac Med, Parasitol Lab, CP 616,Route Lennik 808, B-1070 Brussels, Belgium.						ALEXANDER J, 1985, CLIN EXP IMMUNOL, V61, P674; ANDRADE ZA, 1984, AM J PATHOL, V114, P137; ANDRADENARVAEZ FJ, 1990, T ROY SOC TROP MED H, V84, P219, DOI 10.1016/0035-9203(90)90262-D; BARRALNETTO M, 1987, ACTA TROP, V44, P5; Barreca GS, 1997, J CLIN MICROBIOL, V35, P1867; Blackwell J. M., 1988, Genetics of resistance to bacterial and parasitic infection., P103; BRADLEY DJ, 1987, LEISHMANIASES BIOL M, V2, P551; CONVIT J, 1993, T ROY SOC TROP MED H, V87, P444, DOI 10.1016/0035-9203(93)90030-T; DAVIES EV, 1988, INFECT IMMUN, V56, P1128; Engwerda CR, 2000, IMMUNOL TODAY, V21, P73, DOI 10.1016/S0167-5699(99)01549-2; GRIMALDI G, 1984, PARASITE IMMUNOL, V6, P397; GRIMALDI G, 1989, AM J TROP MED HYG, V41, P687, DOI 10.4269/ajtmh.1989.41.687; GuevaraMendoza O, 1997, SCAND J IMMUNOL, V46, P35, DOI 10.1046/j.1365-3083.1997.d01-96.x; Herwaldt BL, 1999, LANCET, V354, P1191, DOI 10.1016/S0140-6736(98)10178-2; Jones DE, 2000, J IMMUNOL, V165, P364, DOI 10.4049/jimmunol.165.1.364; Lainson R., 1987, LEISHMANIASES BIOL M, V1, P1; Launois P, 1997, IMMUNITY, V6, P541, DOI 10.1016/S1074-7613(00)80342-8; Locksley RM, 1999, J INFECT DIS, V179, pS305, DOI 10.1086/513843; LONG GW, 1994, AM J TROP MED HYG, V51, P613, DOI 10.4269/ajtmh.1994.51.613; McHugh CP, 1996, AM J TROP MED HYG, V55, P547, DOI 10.4269/ajtmh.1996.55.547; Monroy-Ostria A, 1994, Arch Med Res, V25, P401; Monroy-Ostria A, 2000, ACTA TROP, V75, P155, DOI 10.1016/S0001-706X(99)00055-8; Oliveira SHP, 1998, PARASITE IMMUNOL, V20, P405; PEREZ H, 1978, INFECT IMMUN, V22, P301; PEREZ H, 1979, INT J PARASITOL, V9, P27, DOI 10.1016/0020-7519(79)90062-6; REINER SL, 1995, ANNU REV IMMUNOL, V13, P151, DOI 10.1146/annurev.immunol.13.1.151; ROBERTS M, 1990, J IMMUNOGENET, V17, P89; ROBERTS M, 1989, INFECT IMMUN, V57, P875; SAHA B, 1991, EUR J IMMUNOL, V21, P577, DOI 10.1002/eji.1830210307; Saito S, 1996, PARASITOL RES, V82, P485, DOI 10.1007/s004360050150; Salaiza-Suazo N, 1999, TROP MED INT HEALTH, V4, P801, DOI 10.1046/j.1365-3156.1999.00491.x; Smelt SC, 1997, J IMMUNOL, V158, P3813; Solbach W, 2000, Adv Immunol, V74, P275, DOI 10.1016/S0065-2776(08)60912-8; Soong L, 1997, J IMMUNOL, V158, P5374; Torrentera FA, 2001, INFECT IMMUN, V69, P617, DOI 10.1128/IAI.69.1.617-621.2001; VELASCO O, 1989, AM J TROP MED HYG, V41, P280, DOI 10.4269/ajtmh.1989.41.280	36	25	27	0	2	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	MAR	2002	66	3					273	279		10.4269/ajtmh.2002.66.273				7	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	573GH	WOS:000176820600010	12139220	Bronze			2019-03-26	
J	Sene, M; Southgate, VR; de Clercq, D; Ly, A; Vercruysse, J				Sene, M; Southgate, VR; de Clercq, D; Ly, A; Vercruysse, J			Implication of Bulinus truncatus in the transmission of urinary schistosomiasis in Senegal, West Africa	ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY			English	Article							RIVER BASIN; COMPATIBILITY; HAEMATOBIUM; EPIDEMIOLOGY	Studies on the compatibility between Bulinus truncatus and Schistosoma haematobium from various areas in the Senegal River basin (SRB) were carried out, to investigate the role of B. truncatus in the epidemiology of urinary schistosomiasis in Senegal. The results show that B. truncatus from the Lower Valley is not compatible with S. haematobium from the Middle Valley. Interestingly, the study reveals that B. truncatus from the Upper Valley is compatible with S. haematobium from the same area, and that S. haematobium from the Middle Valley is compatible with B. truncatus from the Lower Valley. Bulinus truncatus naturally infected with S. haematobium have been collected from the Upper Valley of the SRB. These results indicate that B. truncatus is involved in the urinary schistosomiasis in Senegal.	IRD, Lab Paludol, Dakar, Senegal; Reg Med St Louis, Programme ESPOIR, St Louis, Senegal; Museum Nat Hist, Dept Zool, London SW7 5BD, England; Fac Med Vet, Dept Parasitol, B-9820 Merelbeke, Belgium	Sene, M (reprint author), IRD, Lab Paludol, BP 17688 Dakar Liberte, Dakar, Senegal.						Brown D, 1994, FRESHWATER SNAILS AF; BROWN DS, 1986, ZOOL J LINN SOC-LOND, V88, P59, DOI 10.1111/j.1096-3642.1986.tb00877.x; COULIBALY G, 1990, Journal of African Zoology, V104, P201; ERNOULD JC, 1996, THESIS U PARIS 12 FR; LEMASSON JM, 1978, DONNEES EPIDEMIOLOGI; Picquet M, 1996, T ROY SOC TROP MED H, V90, P340, DOI 10.1016/S0035-9203(96)90501-5; Rollinson D, 1997, ANN TROP MED PARASIT, V91, P371, DOI 10.1080/00034983.1997.11813152; SOUTHGATE VR, 1985, J NAT HIST, V19, P1249, DOI 10.1080/00222938500770801; Southgate VR, 2000, ANN TROP MED PARASIT, V94, P157, DOI 10.1080/00034980057491; VERCRUYSSE J, 1985, ACTA TROP, V42, P249; VERLE P, 1994, T ROY SOC TROP MED H, V88, P401, DOI 10.1016/0035-9203(94)90400-6	11	2	2	1	4	MANEY PUBLISHING	LEEDS	HUDSON RD, LEEDS LS9 7DL, ENGLAND	0003-4983			ANN TROP MED PARASIT	Ann. Trop. Med. Parasitol.	MAR	2002	96	2					175	180		10.1179/000349802125000420				6	Public, Environmental & Occupational Health; Parasitology; Tropical Medicine	Public, Environmental & Occupational Health; Parasitology; Tropical Medicine	543TV	WOS:000175118000008	12080978				2019-03-26	
J	Holland, WG; Thanh, NG; My, LN; Magnus, E; Verloo, D; Buscher, P; Goddeeris, B; Vercruysse, J				Holland, WG; Thanh, NG; My, LN; Magnus, E; Verloo, D; Buscher, P; Goddeeris, B; Vercruysse, J			Evaluation of whole fresh blood and dried blood on filter paper discs in serological tests for Trypanosoma evansi in experimentally infected water buffaloes	ACTA TROPICA			English	Article						Trypanosoma evansi; water buffalo; diagnosis-protozoa; serology	CARD-AGGLUTINATION-TEST; BRUCEI-GAMBIENSE; DIAGNOSIS; ANTIBODIES; CATT	In this study we investigated if whole blood could substitute for serum in the direct card agglutination test (CATT/Trypansosoma evansi) and the indirect card agglutination test (LATEX/T. evansi) for the sero-diagnosis of T. evansi in buffaloes. Likewise blood spots on filter paper were compared with sera for use in the indirect enzyme-linked immunosorbent assay/T. evansi (ELISA) and immunotrypanolysis test (T.L./T. evansi). Samples were collected weekly from experimentally T. evansi infected- and non-infected water buffaloes. To estimate test agreement between serum and respectively whole fresh blood and dried blood spots on filterpaper of the tests, kappa values with 95% confidence intervals were calculated, 0.75 +/- 0.11 for the CATT/T. evansi; 0.80 +/- 0.11 for the ELISA/T. evansi; 0.84 +/- 0.11 for the LATEX/T. evansi and 0.93 +/- 0.11 for the T.L./T. evansi. In addition kappa values with 95% confidence intervals were computed to assess agreement between results obtained in the reference T.L./T. evansi test and those obtained in the other assays; 0.70 +/- 0.10 for the CATT-Serum; 0.75 +/- 0.11 for the LATEX-Blood; 0.77 +/- 0.11 for the LATEX-Serum; 0.81 +/- 0.10 for the CATT-Blood; 0.81 +/- 0.11 for the ELISA-Serum and 0.84 +/- 0.11 for the ELISA-Confetti, Based on the high kappa values as calculated, we conclude that serum can be replaced by fresh whole blood for the agglutination assays or blood on filter paper for the ELISA/T. evansi and T.L./T. evansi, (C) 2002 Elsevier Science B.V. All rights reserved.	State Univ Ghent, Fac Vet Med, Parasitol Lab, B-9820 Merelbeke, Belgium; Natl Inst Vet Res, Hanoi, Vietnam; Inst Trop Med, Dept Parasitol, B-2000 Antwerp, Belgium; Katholieke Univ Leuven, Dept Anim Prod, Fac Agr & Appl Biol Sci, B-3001 Heverlee, Belgium	Vercruysse, J (reprint author), State Univ Ghent, Fac Vet Med, Parasitol Lab, Salisburylaan 133, B-9820 Merelbeke, Belgium.		Buscher, Philippe/B-9956-2012; Goddeeris, Bruno/L-2440-2015	Buscher, Philippe/0000-0002-1926-7472; Goddeeris, Bruno/0000-0003-3729-7592			Buscher P, 1999, ACTA TROP, V73, P11, DOI 10.1016/S0001-706X(99)00009-1; Davison HC, 1999, EPIDEMIOL INFECT, V123, P149, DOI 10.1017/S0950268899002575; ESPOSITO F, 1990, ACTA TROP, V47, P1, DOI 10.1016/0001-706X(90)90002-H; HOPKINS JS, 1998, PREV VET MED, V37, P1; Jacobson RH, 1998, REV SCI TECH OIE, V17, P469, DOI 10.20506/rst.17.2.1119; KATENDE JM, 1987, TROP MED PARASITOL, V38, P41; LAVEISSIERE C, 2000, 288 OCEAC BP, V3; LOHR KF, 1986, TROP ANIM HEALTH PRO, V18, P103, DOI 10.1007/BF02359721; Luckins A. G, 1992, WORLD ANIM REV, V71, P15; LUCKINS AG, 1988, PARASITOL TODAY, V4, P137, DOI 10.1016/0169-4758(88)90188-3; MAGNUS E, 1978, ANN SOC BELG MED TR, V58, P169; My L. N., 1998, Journal of Protozoology Research, V8, P171; Nantulya V.M., 1990, Revue Scientifique et Technique Office International des Epizooties, V9, P357; SONGA EB, 1988, ANN SOC BELG MED TR, V68, P233; SONGA EB, 1987, ANN SOC BELG MED TR, V67, P51; Thu L. T., 1998, Journal of Protozoology Research, V8, P177; VanMeirvenne N, 1995, ACTA TROP, V60, P189, DOI 10.1016/0001-706X(95)00127-Z; Verloo D., 1998, Journal of Protozoology Research, V8, P190; Verloo D, 2000, VET PARASITOL, V92, P87, DOI 10.1016/S0304-4017(00)00284-3	19	15	15	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0001-706X			ACTA TROP	Acta Trop.	FEB	2002	81	2					159	165		10.1016/S0001-706X(01)00211-X				7	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	516QL	WOS:000173568200007	11801223				2019-03-26	
J	Kroeger, A; Falkenberg, T; Tomson, G; Sen, K; Diesfeld, HJ; Dujardin, B; Tang, SL; Van der Stuyft, P				Kroeger, A; Falkenberg, T; Tomson, G; Sen, K; Diesfeld, HJ; Dujardin, B; Tang, SL; Van der Stuyft, P			Does Brussels listen? European health systems research in developing countries at the edge of extinction	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Editorial Material						health systems research; EU funding; developing countries; north-south co-operation			Karolinska Inst, Stockholm, Sweden; Univ Cambridge, Cambridge CB2 1TN, England; Univ Heidelberg, D-6900 Heidelberg, Germany; Free Univ Brussels, B-1050 Brussels, Belgium; Shanghai Med Univ, Shanghai, Peoples R China; Inst Trop Med, B-2000 Antwerp, Belgium; Univ Liverpool Liverpool Sch Trop Med, Liverpool, Merseyside, England	Kroeger, A (reprint author), Liverpool Inst Trop Med, Pembroke Pl, Liverpool L3 5QA, Merseyside, England.						Boelaert M, 2001, TROP MED INT HEALTH, V6, P843; DeBruycker M, 1996, TROP MED INT HEALTH, V1, P553; McMichael AJ, 2000, LANCET, V356, P495, DOI 10.1016/S0140-6736(00)02564-2	3	0	0	0	0	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	FEB	2002	7	2					101	103		10.1046/j.1365-3156.2002.00851.x				3	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	522WN	WOS:000173920100001	11841699	Bronze			2019-03-26	
J	Getahun, H; Lambein, F; Vanhoorne, M; Van der Stuyft, P				Getahun, H; Lambein, F; Vanhoorne, M; Van der Stuyft, P			Pattern and associated factors of the neurolathyrism epidemic in Ethiopia	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						neurolathyrism; Ethiopia; epidemic	LATHYRISM; IRON; ACID	OBJECTIVES To describe the neurolathyrism epidemic in Ethiopia and to identify associated household factors. METHODS We interviewed 589 randomly selected heads of household in Debre Sina district of Ethiopia, the area afflicted by the recent neurolathyrism epidemic. Disease information was obtained for 2987 family members. RESULTS Neurolathyrism patients were detected in 56 (9.5%) households (prevalence rate 2.38%). The mean number of affected family members per household was 1.27 (SD 0.65, range 1-3). Most (77.5%) patients developed the disability during the epidemic (1995-1999). The median age at onset of paralysis was 11 years with a range of 41 (range 3-44). Younger people were more affected during the epidemic than during the non-epidemic period (P = 0.01). The presence of a neurolathyrism patient in the family was associated with illiteracy [adjusted OR (95% CI) 2.23 (1.07-5.10)] of the head of household, with owning a grass pea farm [adjusted OR (95% CI) 2.01 (1.04-3.88)] and with the exclusive cooking of grass pea foods using handmade traditional clay pots [adjusted OR (95% CI = 2.06 (1.08-3.90)]. CONCLUSION Males aged 10-14 years were most affected by neurolathyrism. Increased household risk was associated with illiteracy of the head of the household and exclusive cooking of grass pea foods with handmade traditional clay pots.	Univ Ghent, Physiol Chem Lab, Dept Biochem, Fac Med & Hlth Sci, B-9000 Ghent, Belgium; Univ Ghent, Dept Publ Hlth, Fac Med & Hlth Sci, B-9000 Ghent, Belgium; S Gonder Hlth Dept, Debre Tabor, Ethiopia; Inst Trop Med, B-2000 Antwerp, Belgium	Lambein, F (reprint author), Univ Ghent, Physiol Chem Lab, Dept Biochem, Fac Med & Hlth Sci, Jozef Kluyskensstr 27, B-9000 Ghent, Belgium.	fernand.lambein@rug.ac.be					Adish AA, 1999, LANCET, V353, P712, DOI 10.1016/S0140-6736(98)04450-X; Cohn DF, 1978, KOROTH, V7, P147; COHN DF, 1987, ADLER MUSEUM B, V13, P5; COHN DF, 1994, GRASS PEA LATHYRISM, P33; DWIVEDI MP, 1964, INDIAN J MED RES, V52, P81; Gebre-ab T, 1978, Ethiop Med J, V16, P1; Getahun H, 1999, LANCET, V354, P306, DOI 10.1016/S0140-6736(99)02532-5; Getahun H, 1998, ETHIOPIAN MED J, V36, P9; GETAHUN H, 1999, 10 ANN SCI C ETH PUB, P26; GETAHUN H, 2002, IN PRESS SOCIAL SCI, V55; GETAHUN H, 2000, LATHYRUS LATHYRISM N, V1, P7; HAIMANOT RT, 1990, INT J EPIDEMIOL, V19, P664, DOI 10.1093/ije/19.3.664; HAIMANOT RT, 1993, ETHIOPIAN MED J, V31, P15; Haque A, 1996, NEUROEPIDEMIOLOGY, V15, P83, DOI 10.1159/000109893; *HLTH BUR, 1999, LATH EP FIELD REP; Jain RK, 1998, NEUROCHEM RES, V23, P1191, DOI 10.1023/A:1020782119057; Jellinger KA, 1999, DRUG AGING, V14, P115, DOI 10.2165/00002512-199914020-00004; JHA K, 1987, ARCH LATINOAM NUTR, V37, P101; Kessler A, 1947, MON PSYCHIATR NEUROL, V113, P345; Kusama Tadashi, 2000, Research Communications in Pharmacology and Toxicology, V5, P37; Rizzotti G., 1952, B SOC ITALIANA MED I, V33, P493; Spencer PS, 1999, DRUG METAB REV, V31, P561, DOI 10.1081/DMR-100101936; SPENCER PS, 1986, LANCET, V2, P1066, DOI 10.1016/S0140-6736(86)90468-X; STRIEFLER M, 1977, NEUROLOGY, V27, P1176, DOI 10.1212/WNL.27.12.1176; Weber KT, 1998, CARDIOVASC RES, V37, P551	25	21	21	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	FEB	2002	7	2					118	124		10.1046/j.1365-3156.2002.00836.x				7	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	522WN	WOS:000173920100003	11841701				2019-03-26	
J	Magnus, E; Lejon, V; Bayon, D; Buyse, D; Simarro, P; Verloo, D; Vervoort, T; Pansaerts, R; Buscher, P; Van Meirvenne, N				Magnus, E; Lejon, V; Bayon, D; Buyse, D; Simarro, P; Verloo, D; Vervoort, T; Pansaerts, R; Buscher, P; Van Meirvenne, N			Evaluation of an EDTA version of CATT/Trypanosoma brucei gambiense for serological screening of human blood samples	ACTA TROPICA			English	Article						Trypanosoma brucei gambiense; sleeping sickness; human African trypanosomosis; diagnosis; CATT	CARD-AGGLUTINATION-TEST; COMPLEMENT; INHIBITION	CATT/Trypanosoma brucei gambiense, a direct card agglutination test designed for field surveys on human African trypanosomosis, is currently used with freshly collected heparinized blood samples. When testing serum samples, it has been observed earlier that, at lower sample dilutions, a complement-mediated inhibition phenomenon may cause false negative test results. This can be avoided by adding an anticomplementary agent such as di-sodium ethylenediaminetetraacetate dihydrate (EDTA) to the reaction. As the sensitivity of the blood assay might be improved in the same way, this possibility has been examined under both laboratory and field conditions, by adding EDTA to the test buffer or, as an anticoagulant, to the blood samples. The CATT-EDTA versions proved up to 7% more sensitive but also 1-2% less specific than the current test. CATT buffer supplemented with EDTA remained stable for at least 2 years at + 45 degreesC. (C) 2002 Elsevier Science B.V. All rights reserved.	Inst Trop Med Prince Leopold, Dept Parasitol, Natl Str 155, B-2000 Antwerp, Belgium; Med Sans Frontieres France, Kampala, Uganda; Fonds Med Trop, FOMETRO, Kinshasa 1, DEM REP CONGO; Fundacio CIDOB, Bata, Equat Guinea	Magnus, E (reprint author), Inst Trop Med Prince Leopold, Dept Parasitol, Natl Str 155, B-2000 Antwerp, Belgium.	emagnus@itg.be	Buscher, Philippe/B-9956-2012	Buscher, Philippe/0000-0002-1926-7472			BAATRUP G, 1989, DAN MED BULL, V36, P443; CHO HJ, 1972, CAN J MICROBIOL, V18, P449, DOI 10.1139/m72-070; Clopper CJ, 1934, BIOMETRIKA, V26, P404, DOI 10.1093/biomet/26.4.404; MAGNUS E, 1978, ANN SOC BELG MED TR, V58, P169; MALKIN K, 1984, CAN J COMP MED, V48, P208; OSULLIVAN MM, 1988, ANN RHEUM DIS, V47, P675, DOI 10.1136/ard.47.8.675; Pagano M, 2000, PRINCIPLES BIOSTATIS, P342; Pansaerts R, 1998, ACTA TROP, V70, P349, DOI 10.1016/S0001-706X(98)00046-1; SCHIFFERLI JA, 1982, CLIN EXP IMMUNOL, V47, P555; VanMeirvenne N, 1995, ACTA TROP, V60, P189, DOI 10.1016/0001-706X(95)00127-Z; *WHO, 1983, TRYP CONTR MAN, P1	11	11	11	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0001-706X	1873-6254		ACTA TROP	Acta Trop.	JAN	2002	81	1					7	12		10.1016/S0001-706X(01)00184-X				6	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	516QK	WOS:000173568100002	11755427				2019-03-26	
J	De Bont, J; Shaw, DJ; Vercruysse, J				De Bont, J; Shaw, DJ; Vercruysse, J			The relationship between faecal egg counts, worm burden and tissue egg counts in early Schistosoma mattheei infections in cattle	ACTA TROPICA			English	Article						Schistosoma mattheei; faecal egg counts; tissue egg counts; worm burdens; cattle	DENSITY-DEPENDENT FECUNDITY; NATURALLY ACQUIRED-RESISTANCE; COMPARATIVE MEDICINE; MANSONI INFECTIONS; BOVIS; SUDAN; PRAZIQUANTEL; EPIDEMIOLOGY; CALVES	The relationships between schistosome faecal egg counts (EPG), total tissue egg counts (TEC) and adult female worm burdens (FW) recorded at post-mortem examination of 30 Friesian calves from three different field trials were analysed. The calves in study 1 (n = 14) had been exposed to natural Schistosoma mattheei infections for 2 months, those of study 2 (n = 9) for between 4 and 12 months, and those in study 3 (n = 7) for 8 months. No clinical schistosomiasis was observed in any of the groups, and at perfusion, EPG's varied from 5 to 210, TEC's from 28,800 to 2,439,400 and FW's from 11 to 1218. There was as much variation in EPG, TEC and FW between calves with the same duration of exposure as between calves with different duration of exposure. There were very similar significant positive relationships between log transformed FW and log transformed EPG in all three groups (P < 0.007, R-2 > 0.46, slopes 0.957-1.015). There were also significant positive relationships between log transformed FW and log transformed TEC in all three groups (P < 0.034, R-2 > 0.45) and between log transformed TEC and log transformed EPG in all three groups (P < 0.025, R-2 > 0,48). All three studies had a linear relationship between log transformed FW and log transformed EPG with a slope value close to 1 (P > 0.845 for different from one). This indicates that there was no evidence of density dependence in the three studies for the relationship between FW and EPG. In contrast, there was no consistent relationship (in terms of slope) between either log transformed TEC and log transformed FW in the three studies (after correcting for differential duration of exposure), or log transformed TEC and log transformed EPG. For all three sets of comparisons the predictability of one parameter based on another was poor for a single sample. (C) 2002 Elsevier Science B.V. All rights reserved.	Inst Pasteur, INSERM, IPL U547, Ctr Immunol & Biol Parasitaire, F-59019 Lille, France; Univ Edinburgh, Easter Bush Vet Ctr, Ctr Trop Vet Med, Roslin EH25 9RG, Midlothian, Scotland; Univ Ghent, Fac Vet Med, Dept Parasitol, B-9820 Merelbeke, Belgium	De Bont, J (reprint author), Inst Pasteur, INSERM, IPL U547, Ctr Immunol & Biol Parasitaire, 1,Rue Professeur Calmette,BP 245, F-59019 Lille, France.	jean.de-bont@pasteur-lille.fr					BUSHARA HO, 1983, AM J TROP MED HYG, V32, P1375, DOI 10.4269/ajtmh.1983.32.1375; BUSHARA HO, 1980, AM J TROP MED HYG, V29, P442, DOI 10.4269/ajtmh.1980.29.442; BUSHARA HO, 1983, AM J TROP MED HYG, V32, P1370, DOI 10.4269/ajtmh.1983.32.1370; CHEEVER AW, 1968, AM J TROP MED HYG, V17, P38, DOI 10.4269/ajtmh.1968.17.38; CHEEVER AW, 1986, T ROY SOC TROP MED H, V80, P991, DOI 10.1016/0035-9203(86)90284-1; COYNE MJ, 1991, INT J PARASITOL, V21, P877, DOI 10.1016/0020-7519(91)90161-Y; De Bont J, 1998, ADV PARASIT, V41, P285, DOI 10.1016/S0065-308X(08)60426-1; DEBONT J, 1991, PARASITOLOGY, V102, P237, DOI 10.1017/S0031182000062545; DEBONT J, 1995, PARASITOLOGY, V111, P485, DOI 10.1017/S0031182000065999; DEBONT J, 1995, VET PARASITOL, V57, P299, DOI 10.1016/0304-4017(94)00695-9; DeBont J, 1997, PARASITOL TODAY, V13, P255, DOI 10.1016/S0169-4758(97)01057-0; DeBont J, 1996, PARASITOLOGY, V113, P465, DOI 10.1017/S0031182000081531; DeBont J, 1997, PARASITOLOGY, V115, P249, DOI 10.1017/S0031182097001352; Gryseels B, 1996, PARASITOL TODAY, V12, P115, DOI 10.1016/0169-4758(96)80671-5; HIRATA M, 1993, PARASITOL RES, V79, P316, DOI 10.1007/BF00932188; Johansen MV, 1996, VET PARASITOL, V62, P83, DOI 10.1016/0304-4017(95)00849-7; JONES JT, 1989, INT J PARASITOL, V19, P769, DOI 10.1016/0020-7519(89)90065-9; KASSUKU A, 1986, ACTA TROP, V43, P153; Lawrence J. A., 1978, Helminthological Abstracts, V47A, P261; LAWRENCE JA, 1973, RES VET SCI, V14, P400, DOI 10.1016/S0034-5288(18)33900-6; LAWRENCE JA, 1973, RES VET SCI, V14, P402, DOI 10.1016/S0034-5288(18)33901-8; LAWRENCE JA, 1978, J COMP PATHOL, V88, P1, DOI 10.1016/0021-9975(78)90056-7; LAWRENCE JA, 1977, VET PARASITOL, V3, P305, DOI 10.1016/0304-4017(77)90017-6; MAJID AA, 1980, AM J TROP MED HYG, V29, P435, DOI 10.4269/ajtmh.1980.29.435; MASSOUD J, 1972, B WORLD HEALTH ORGAN, V47, P591; MCCULLY R M, 1969, Onderstepoort Journal of Veterinary Research, V36, P129; MEDLEY G, 1985, T ROY SOC TROP MED H, V79, P532, DOI 10.1016/0035-9203(85)90087-2; PITCHFORD RJ, 1982, ONDERSTEPOORT J VET, V49, P233; Polman K, 2001, PARASITOLOGY, V122, P161, DOI 10.1017/S0031182001007193; SAAD AM, 1980, RES VET SCI, V28, P105, DOI 10.1016/S0034-5288(18)32782-6; Sokal RR, 1995, BIOMETRY PRINCIPLES; Van Wyk J A, 1974, Onderstepoort J Vet Res, V41, P39; Van Wyk J.A., 1976, Onderstepoort Journal of Veterinary Research, V43, P43; vanEtten L, 1997, AM J TROP MED HYG, V57, P337, DOI 10.4269/ajtmh.1997.57.337; WERTHEIMER SP, 1987, AM J TROP MED HYG, V37, P79, DOI 10.4269/ajtmh.1987.37.79; Woolhouse MEJ, 1999, NAT MED, V5, P1225, DOI 10.1038/15169	36	5	5	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0001-706X	1873-6254		ACTA TROP	Acta Trop.	JAN	2002	81	1					63	76		10.1016/S0001-706X(01)00198-X				14	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	516QK	WOS:000173568100008	11755433				2019-03-26	
J	Lejon, V; Buscher, P				Lejon, V; Buscher, P			Diagnosis of the disease stage in sleeping sickness: towards a new approach	BULLETIN DE LA SOCIETE DE PATHOLOGIE EXOTIQUE			French	Article						T. b. gambiense; human african trypanosomiasis; stage determination; cerebrospinal fluid; IgM	HUMAN AFRICAN TRYPANOSOMIASIS; CEREBROSPINAL-FLUID; BRUCEI-GAMBIENSE; CENTRIFUGATION; QUANTIFICATION; EFFICACY; PATTERNS; SERUM; IGM	Diagnosis of the neurological disease stage in Trypanosoma brucei (T.b.) gambiense infection is essential to select an optimal chemotherapy. The actual parameters for stage determination, the cerebrospinal fluid (CSF) cell count, total protein concentration and trypanosome detection, are insufficiently specific and sensitive. In order to identify new parameters for stage determination, we studied the neuro-inflammatory immune response in the central nervous system, notably the intrathecal humoral immune response in sleeping sickness patients. The presence of intrathecal IgM synthesis was identified as an excellent marker of central nervous system involvement. However, intrathecal IgM detection cannot be performed under field conditions. As a consequence of the strong intrathecal IgM synthesis, extremely high concentrations of IgM are found in the CSF of sleeping sickness. We therefore developed a latex agglutination field test (LATEX/IgM) indicative for intrathecal IgM synthesis and CNS involvement in sleeping sickness. Based on our observations on the intrathecal immune response and with LATEX/IgM, we propose a new approach for stage determination in sleeping sickness.	Inst Trop Med, Dept Parasitol, B-2000 Antwerp, Belgium	Lejon, V (reprint author), Inst Trop Med, Dept Parasitol, Natl Str 155, B-2000 Antwerp, Belgium.	vlejon@itg.be	Buscher, Philippe/B-9956-2012	Buscher, Philippe/0000-0002-1926-7472			ANDERSSON M, 1994, J NEUROL NEUROSUR PS, V57, P897, DOI 10.1136/jnnp.57.8.897; Bisser S, 2002, J NEUROL SCI, V193, P127, DOI 10.1016/S0022-510X(01)00655-4; Burri C, 2000, LANCET, V355, P1419, DOI 10.1016/S0140-6736(00)02141-3; CATTAND P, 1988, B WORLD HEALTH ORGAN, V66, P83; Doua F, 1996, AM J TROP MED HYG, V55, P586, DOI 10.4269/ajtmh.1996.55.586; KNOBLOCH J, 1984, TROPENMED PARASITOL, V35, P137; LAMBERT PH, 1981, J CLIN INVEST, V67, P77, DOI 10.1172/JCI110035; Lejon V, 1998, B WORLD HEALTH ORGAN, V76, P553; Lejon V, 2002, TROP MED INT HEALTH, V7, P685, DOI 10.1046/j.1365-3156.2002.00917.x; LEJON V, 2002, THESIS U ANVERS BELG, P3; MATTERN P, 1968, B WORLD HEALTH ORGAN, V38, P1; Miezan TW, 2000, T ROY SOC TROP MED H, V94, P293, DOI 10.1016/S0035-9203(00)90327-4; *OMS, 1998, SER RAPP TECHN OMS, V881, P1; Reiber H, 1998, MULT SCLER, V4, P99, DOI 10.1177/135245859800400302; REIBER H, 1991, CLIN CHEM, V37, P1153; Reiber H, 2001, J NEUROL SCI, V184, P101, DOI 10.1016/S0022-510X(00)00501-3; Stanghellini A, 2001, TROP MED INT HEALTH, V6, P330, DOI 10.1046/j.1365-3156.2001.00724.x; TUMANI H, 1995, NEUROLOGY, V45, P1663, DOI 10.1212/WNL.45.9.1663; VANNIEUWENHOVE S, 1999, PROGR HUMAN AFRICAN, P253; WHITTLE HC, 1977, AM J TROP MED HYG, V26, P1129, DOI 10.4269/ajtmh.1977.26.1129	20	2	2	0	0	S P E	PARIS	25 RUE DU DOCTEUR ROUX, 75015 PARIS, FRANCE	0037-9085			B SOC PATHOL EXOT	Bull. Soc. Pathol. Exot.		2003	95	5					338	340						3	Public, Environmental & Occupational Health; Infectious Diseases; Pathology; Tropical Medicine	Public, Environmental & Occupational Health; Infectious Diseases; Pathology; Tropical Medicine	654LC	WOS:000181497500010	12696371				2019-03-26	
J	van der Werf, MJ; Mbaye, A; Sow, S; Gryseels, B; de Vlas, SJ				van der Werf, MJ; Mbaye, A; Sow, S; Gryseels, B; de Vlas, SJ			Evaluation of staff performance and material resources for integrated schistosomiasis control in Northern Senegal	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						schistosomiasis; disease control; primary health care; integration; intervention programme; treatment costs; Senegal	RECENTLY EXPOSED COMMUNITY; RIVER BASIN; MANSONI INFECTION; URINARY SCHISTOSOMIASIS; RICHARD-TOLL; PRAZIQUANTEL; EPIDEMIOLOGY; MORBIDITY; ULTRASOUND; HEALTH	BACKGROUND A project to improve integrated control of schistosomiasis in the primary health care system of Northern Senegal was implemented from February 1995 until September 1999, shortly after a Schistosoma mansoni outbreak. The activities included additional training of doctors and nurses in symptom-based treatment and making praziquantel (PZQ) available for an affordable price. OBJECTIVE To investigate staff performance, and the availability and costs of diagnostic materials and PZQ at the end of this intervention project. METHODS We performed structured interviews with staff from 55 health care facilities in five districts. RESULTS Respondents from 23 health care facilities reported both S. haematobium and S. mansoni in the coverage area, 32 reported only S. haematobium and three only S. mansoni. The average cost to patients for consultation, diagnosis, treatment and transportation to a referral health care facility was approximately 1.60 Euro. Fifty-seven per cent of the health care facilities with reported S. haematobium in the coverage area treated patients presenting with haematuria on symptoms; 56% of the health care facilities with reported S. mansoni in the coverage area treated patients presenting with blood in stool on symptoms. Thirteen per cent performed a diagnostic test for patients presenting with haematuria and 12% for patients presenting with blood in stool. The remainder, approximately one-third of the health care facilities, referred their patients to another facility for a diagnostic test. Implementation of symptom-based treatment in all health care facilities will reduce the total costs by 0.43 Euro (29%) for patients infected with S. haematobium and 0.78 Euro (46%) for patients infected with S. mansoni. Of the 53 health care facilities with schistosomiasis in their area, 37 had PZQ in stock of which 33 (88%) sold PZQ for the recommended retail price of 0.15 Euro per tablet (or 0.60 Euro per course of four tablets) or lower. CONCLUSION Four years after the start of the intervention project, patients presenting with schistosomiasis related symptoms can generally expect proper diagnosis and treatment at all levels of the health care system in Northern Senegal, either at the initial visited health care facility or after referral. However, a further reduction of the total costs of treatment is still possible by a better implementation of symptom-based treatment and further reduction of the costs of PZQ.	Erasmus Univ, Dept Publ Hlth, NL-3000 DR Rotterdam, Netherlands; Inst Trop Med Prince Leopold, Antwerp, Belgium; Programme Espoir, St Louis, Senegal	van der Werf, MJ (reprint author), Erasmus Univ, Dept Publ Hlth, POB 1738, NL-3000 DR Rotterdam, Netherlands.						[Anonymous], 1993, WHO TECHN REP SER, V830; Boisier P, 1998, T ROY SOC TROP MED H, V92, P451, DOI 10.1016/S0035-9203(98)91090-2; Burchard GD, 1998, TROP MED INT HEALTH, V3, P234, DOI 10.1046/j.1365-3156.1998.00217.x; CHAINE JP, 1983, TROP GEOGR MED, V35, P249; Diallo I, 1993, World Health Forum, V14, P349; ERNOULD JC, 1998, AMENAGEMENTS HYDROAR, P263; Frenzel K, 1999, AM J TROP MED HYG, V60, P927, DOI 10.4269/ajtmh.1999.60.927; GRYSEELS B, 1989, TROP MED PARASITOL, V40, P134; Kardorff R, 1996, AM J TROP MED HYG, V54, P586; KONGS A, 1994, ANN SOC BELG MED TR, V74, P301; Kongs A, 1996, TROP MED INT HEALTH, V1, P191; Picquet M, 1996, T ROY SOC TROP MED H, V90, P340, DOI 10.1016/S0035-9203(96)90501-5; Renganathan E, 1998, PARASITOL TODAY, V14, P390, DOI 10.1016/S0169-4758(98)01310-6; Stelma FF, 1997, T ROY SOC TROP MED H, V91, P29, DOI 10.1016/S0035-9203(97)90383-7; STELMA FF, 1994, AM J TROP MED HYG, V50, P575, DOI 10.4269/ajtmh.1994.50.575; STELMA FF, 1993, AM J TROP MED HYG, V49, P701, DOI 10.4269/ajtmh.1993.49.701; TALLA I, 1992, T ROY SOC TROP MED H, V86, P182, DOI 10.1016/0035-9203(92)90562-Q; TALLA I, 1990, ANN SOC BELG MED TR, V70, P173; VERCRUYSSE J, 1985, ACTA TROP, V42, P249; VERLE P, 1994, T ROY SOC TROP MED H, V88, P401, DOI 10.1016/0035-9203(94)90400-6; World Health Organization (WHO), 1978, INT C PRIM HLTH CAR, P6; Yazdanpanah Y, 1997, AM J TROP MED HYG, V57, P245, DOI 10.4269/ajtmh.1997.57.245	22	12	12	0	0	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	JAN	2002	7	1					70	79		10.1046/j.1365-3156.2002.00823.x				10	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	512JY	WOS:000173322300010	11851957	Bronze			2019-03-26	
J	Van Bortel, W; Harbach, RE; Trung, HD; Roelants, P; Backeljau, T; Coosemans, M				Van Bortel, W; Harbach, RE; Trung, HD; Roelants, P; Backeljau, T; Coosemans, M			Confirmation of Anopheles varuna in Vietnam, previously misidentified and mistargeted as the malaria vector Anopheles minimus	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							LINKED-IMMUNOSORBENT-ASSAY; SRI-LANKA; IDENTIFICATION; SPOROZOITES; MOSQUITOS; MEMBERS	Malaria control programs in Southeast Asia are faced with several questions concerning vector behavior and species identification, which need to be answered to consolidate and further improve the results of control practices. The vector system in Southeast Asia is complex because of the number of species potentially involved in malaria transmission. Additionally, the follow-up and evaluation of preventive control measures are hampered by the misidentification of vectors due to overlapping morphological characters of the female mosquitoes. In central Vietnam, control practices are aimed at 2 main species, Anopheles dirus s.l. and Anopheles minimus s.l. These reputed vectors were studied in an area of Binh Thuan Province of south-central Vietnam. Different collection methods were used to capture mosquitoes quarterly during a 1-year period. Mosquitoes were identified in the field and later subjected to detailed morphological examination and polymerase chain reaction-restriction fragment length polymorphism analysis. What was thought to be an unusual morphotype of An. minimus was shown to be Anopheles varuna, and most specimens identified as the former species in the field proved to be the latter species. Very few An. minimus individuals were found during the study period. The population of An. varuna was found to be highly zoophilic, and based on this behavior, it cannot be considered a vector in Vietnam. Because this species was previously being misidentified as An. minimus, a nonvector was mistargeted as a malaria vector in Binh Thuan Province. Anopheles dirus, which was found positive for Plasmodium falciparum circumsporozoite via enzyme-linked immunosorbent assay, is clearly the main vector in this area. Despite the fact that several potential secondary vectors were found during the study, the primary target for vector control in the region should be An. dirus.	Inst Trop Med Prince Leopold, Dept Parasitol, B-2000 Antwerp, Belgium; Nat Hist Museum, Dept Entomol & biomed Sci Theme, London SW7 5BD, England; Natl Inst Malariol Parasitol & Entomol, Hanoi, Vietnam; Inst Royal Sci Nat Belgique, Dept Invertebrates, B-1000 Brussels, Belgium	Van Bortel, W (reprint author), Inst Trop Med Prince Leopold, Dept Parasitol, Natl Str 155, B-2000 Antwerp, Belgium.			Van Bortel, Wim/0000-0002-6644-518X			AMERASINGHE FP, 1991, AM J TROP MED HYG, V45, P226, DOI 10.4269/ajtmh.1991.45.226; Amerasinghe PH, 1999, AM J TROP MED HYG, V60, P421, DOI 10.4269/ajtmh.1999.60.421; BURKOT TR, 1984, AM J TROP MED HYG, V33, P783, DOI 10.4269/ajtmh.1984.33.783; Covell G., 1944, JOUR MALARIA INST INDIA, V5, P399; HARRISON B A, 1980, Contributions of the American Entomological Institute, V17, P1; *IMPE, 1987, KEYS AN VIETN AD PUP; Maheswary N. P., 1993, Southeast Asian Journal of Tropical Medicine and Public Health, V24, P776; Maheswary N. P., 1992, Southeast Asian Journal of Tropical Medicine and Public Health, V23, P798; MEEK SR, 1995, ANN TROP MED PARASIT, V89, P135, DOI 10.1080/00034983.1995.11812944; RAO VV, 1961, A VARUNA IYENGAR 192, P103; REISEN WK, 1971, 712 PACAF 1 MED SERV; Sharpe RG, 2000, SYST ENTOMOL, V25, P263, DOI 10.1046/j.1365-3113.2000.00118.x; SUNDARARAMAN S, 1957, Indian J Malariol, V11, P321; THI PV, 1998, EPIDEMIOLOGIE PALUDI; Van Bortel W, 2000, INSECT MOL BIOL, V9, P335, DOI 10.1046/j.1365-2583.2000.00192.x; Verle P., 1998, Research and Reviews in Parasitology, V58, P169; WIRTZ RA, 1992, J MED ENTOMOL, V29, P854, DOI 10.1093/jmedent/29.5.854; WIRTZ RA, 1985, AM J TROP MED HYG, V34, P1048, DOI 10.4269/ajtmh.1985.34.1048	18	49	51	0	10	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	DEC	2001	65	6					729	732		10.4269/ajtmh.2001.65.729				4	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	508YJ	WOS:000173117100012	11791965	Bronze			2019-03-26	
J	Lejon, V; Legros, D; Rosengren, L; Etchegorry, MG; Buscher, P				Lejon, V; Legros, D; Rosengren, L; Etchegorry, MG; Buscher, P			Biological data and clinical symptoms as predictors of astrogliosis and neurodegeneration in patients with second-stage Trypanosoma brucei gambiense sleeping sickness	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							FIBRILLARY ACIDIC PROTEIN; HUMAN AFRICAN TRYPANOSOMIASIS; CENTRAL-NERVOUS-SYSTEM; CEREBROSPINAL-FLUID; PERFORMANCE STATUS; MULTIPLE-SCLEROSIS; BRAIN; NEUROFILAMENT; CSF; AUTOANTIBODIES	Concentrations of glial fibrillary acidic protein (GFAp) and light subunit neurofilament protein (NFL) in cerebrospinal fluid (CSF) were measured in patients with second-stage Trypanosoma brucei gambiense sleeping sickness. Correlations between GFAp and NFL in CSF as markers for astrogliosis and neurodegeneration, and clinical and biological data were investigated. Abnormal levels of GFAp and NFL were significantly associated with increasing CSF cell number and protein concentration, and with the absence of lymph nodes or the absence of trypanosomes in lymph node aspirate. A significant association was found between abnormal NFL and presence of trypanosomes in CSF, abnormal limb movements, difficulties in gait and coordination, and low Karnofsky index. By multivariate analysis, it was shown that increasing CSF cell number, increasing CSF protein concentration, and the absence of lymph nodes or the absence of trypanosomes in the lymph node aspirate were the best predictors for astrogliosis and neurodegeneration among the variables tested. These results demonstrate the importance of CSF cell count and protein determination in assessment of the severity of central nervous system involvement and reinforces the importance of laboratory diagnosis to assess the stage of the disease. The clinical symptoms studied were less useful in predicting astrogliosis or neurodegeneration.	Inst Trop Med, Dept Parasitol, B-2000 Antwerp, Belgium; Univ Antwerp, Dept Biochem, Wilrijk, Belgium; EPICTR, Paris, France; Univ Gothenburg, Sahlgrens Univ Hosp, Dept Neurol, Inst Clin Neurosci, Gothenburg, Sweden; Med Sans Frontieres, Paris, France	Lejon, V (reprint author), Inst Trop Med, Dept Parasitol, Natl Str 155, B-2000 Antwerp, Belgium.		Buscher, Philippe/B-9956-2012	Buscher, Philippe/0000-0002-1926-7472			AMEVIGBE MDD, 1992, AM J TROP MED HYG, V47, P652, DOI 10.4269/ajtmh.1992.47.652; ANTHOONS JAMS, 1989, PARASITOL RES, V75, P251, DOI 10.1007/BF00931808; APTED FIC, 1970, AFRICAN TRYPANOSOMIA, P661; ASONGANYI T, 1989, ANN SOC BELG MED TR, V69, P213; Ayed Z, 1997, AM J TROP MED HYG, V57, P1; BAILEY JW, 1992, T ROY SOC TROP MED H, V86, P630, DOI 10.1016/0035-9203(92)90160-E; BOA YF, 1988, B SOC PATHOL EXOT, V81, P427; Buguet A, 1996, CR ACAD SCI III-VIE, V319, P201; Buguet A., 1999, PROGR HUMAN AFRICAN, P191; CATTAND P, 1988, B WORLD HEALTH ORGAN, V66, P83; deVries HE, 1996, J NEUROIMMUNOL, V64, P37, DOI 10.1016/0165-5728(95)00148-4; Dotevall L, 1996, INFECTION, V24, P125, DOI 10.1007/BF01713316; DUMAS M, 1979, TRENDS NEUROSCI, V2, P256, DOI 10.1016/0166-2236(79)90100-0; DUMAS M, 1978, HDB CLIN NEUROLOGY I, V35, P67; DUTTON JE, 1906, T EPIDEMIOL SOC LOND, V15, P1; Edan G, 1979, Med Trop (Mars), V39, P499; Giovannoni G, 1998, J NEUROL SCI, V156, P53, DOI 10.1016/S0022-510X(98)00021-5; Girard M, 2000, CLIN EXP IMMUNOL, V119, P516, DOI 10.1046/j.1365-2249.2000.01166.x; GREENWOOD BM, 1980, T ROY SOC TROP MED H, V74, P716, DOI 10.1016/0035-9203(80)90184-4; HUNTER CA, 1992, LAB INVEST, V67, P635; HUTCHINSON TA, 1979, J CHRON DIS, V32, P661, DOI 10.1016/0021-9681(79)90096-1; JANNIN J, 1993, B WORLD HEALTH ORGAN, V71, P215; KARLSSON JE, 1991, J NEUROCHEM, V57, P1437, DOI 10.1111/j.1471-4159.1991.tb08311.x; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Lejon V, 1999, AM J TROP MED HYG, V60, P94, DOI 10.4269/ajtmh.1999.60.94; Lindley IJD, 1998, CYTOKINES, P125, DOI 10.1016/B978-012498340-3/50009-9; Lycke JN, 1998, J NEUROL NEUROSUR PS, V64, P402, DOI 10.1136/jnnp.64.3.402; MOR V, 1984, CANCER, V53, P2002, DOI 10.1002/1097-0142(19840501)53:9<2002::AID-CNCR2820530933>3.0.CO;2-W; NEUJEAN G, 1950, Ann Soc Belg Med Trop (1920), V30, P1125; Ormerod W. E., 1970, AFRICAN TRYPANOSOMIA, P587; PENTREATH VW, 1995, T ROY SOC TROP MED H, V89, P9, DOI 10.1016/0035-9203(95)90637-1; PENTREATH VW, 1999, PROGR HUMAN AFRICAN, P105; PEPIN J, 1991, T ROY SOC TROP MED H, V85, P222, DOI 10.1016/0035-9203(91)90032-T; PHILIP KA, 1994, ANN TROP MED PARASIT, V88, P607, DOI 10.1080/00034983.1994.11812911; POLTERA AA, 1980, CLIN EXP IMMUNOL, V40, P496; Quan N, 1999, J COMP NEUROL, V414, P114, DOI 10.1002/(SICI)1096-9861(19991108)414:1<114::AID-CNE9>3.0.CO;2-G; Richards CD, 1998, CYTOKINES, P87, DOI 10.1016/B978-012498340-3/50007-5; ROSEN EM, 1996, INT J CANCER, V67, P1; ROSENGREN LE, 1994, J NEUROSCI METH, V51, P197, DOI 10.1016/0165-0270(94)90011-6; ROSENGREN LE, 1995, J NEUROL SCI, V133, P61, DOI 10.1016/0022-510X(95)00152-R; SCHAG CC, 1984, J CLIN ONCOL, V2, P187, DOI 10.1200/JCO.1984.2.3.187; SCHLEIFER KW, 1993, J IMMUNOL, V151, P5492; SCHULTZBERG M, 1988, J NEUROSCI RES, V21, P56, DOI 10.1002/jnr.490210109; Tullberg M, 1998, NEUROLOGY, V50, P1122, DOI 10.1212/WNL.50.4.1122; VANBOGAERT L, 1957, ANN SOC BELG MED TR, V37, P380; Woo P. T. K., 1970, Acta trop., V27, P384; World Health Organization, 1998, WHO TECH REP SER, P1	47	7	7	0	0	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	DEC	2001	65	6					931	935		10.4269/ajtmh.2001.65.931				5	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	508YJ	WOS:000173117100048	11792001	Bronze			2019-03-26	
J	Buve, A; Changalucha, J; Mayaud, P; Gavyole, A; Mugeye, K; Todd, J; Clayton, T; Mosha, F; Grosskurth, H; Mabey, D; Laga, M; Van Lerberghe, W; Hayes, RJ				Buve, A; Changalucha, J; Mayaud, P; Gavyole, A; Mugeye, K; Todd, J; Clayton, T; Mosha, F; Grosskurth, H; Mabey, D; Laga, M; Van Lerberghe, W; Hayes, RJ			How many patients with a sexually transmitted infection are cured by health services? A Study from Mwanza region, Tanzania	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						cure rate; primary health care services; sexually transmitted infections; Tanzania	MANAGEMENT; GONORRHEA; TRIAL; MEN	OBJECTIVES To estimate the proportion of symptomatic patients with a bacterial sexually transmitted infection (STI) cured by primary health care services in Mwanza Region, Tanzania, and to compare the cure rate achieved by health centres before and after the introduction of improved STI treatment services. METHODS A model was used that describes the different hurdles patients with an STI take before they can be considered cured by the health services. The values for the input parameters for the model were taken from different studies. Data from an intervention trial as well as from a population-based study on male urethritis were used to estimate the proportion of symptomatic patients with an STI who seek care from a health centre. An observational study in four health centres where improved STI treatment services had been introduced provided estimates of the proportions of patients with an STI correctly diagnosed and treated. Patients who returned to the health centres after 1 week were interviewed about compliance. An estimate of the efficacy of treatments prescribed for STIs in health centres before the introduction of improved STI services was obtained from a study on prescription patterns for genital discharge syndrome (GDS) and genital ulcer disease (GUD). RESULTS It was estimated that in the catchment area of health centres offering improved STI services, 51-72% of patients with STI symptoms sought care from those health centres. About 76-85% of cases were correctly diagnosed, and of these 69-80% received efficacious treatment. Compliance with full treatment was estimated at 84%. The estimated overall cure rate achieved by the health centres offering improved STI services ranged between 23 and 41%. The proportion of symptomatic STI patients who attended a health centre before improved STI services were introduced was estimated at 39%. The estimated efficacy of the treatments prescribed was 28%. The overall cure rate achieved by these health centres was less than 10%. CONCLUSIONS When assessing the performance of STI case detection and management all steps have to be taken into account that are taken by patients with an STI before they can be considered cured by the health services. The intervention to improve STI services in Mwanza Region has resulted in an improvement of the cure rate of STIs achieved by primary health care centres.	Inst Trop Med, STD HIV Res & Intervent Unit, B-2000 Antwerp, Belgium; Natl Inst Med Res, Mwanza, Tanzania; African Med & Res Fdn, Mwanza, Tanzania; London Sch Hyg & Trop Med, London WC1, England; Muncipal Hlth Serv, Mwanza, Tanzania	Buve, A (reprint author), Inst Trop Med, STD HIV Res & Intervent Unit, Natl Str 155, B-2000 Antwerp, Belgium.	abuve@itg.be		Hayes, Richard/0000-0002-1729-9892; Van Lerberghe, Wim/0000-0001-9966-6563			Anderson RM, 1999, SEXUALLY TRANSMITTED, P25; BUVE A, 1993, 8 INT C AIDS AFR MAR; *GLOB PROGR AIDS, 1994, EV NAT AIDS PROGR ME; Grosskurth H, 1996, BRIT MED J, V312, P277; Grosskurth H, 2000, SEX TRANSM INFECT, V76, P426, DOI 10.1136/sti.76.6.426; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; Harrison A, 1998, AIDS, V12, P2329, DOI 10.1097/00002030-199817000-00015; HARRISON WO, 1979, NEW ENGL J MED, V300, P1074, DOI 10.1056/NEJM197905103001903; MAYAUD P, 1992, GENITOURIN MED, V68, P361; Mertens TE, 1998, PUBLIC HEALTH, V112, P123, DOI 10.1016/S0033-3506(98)00596-4; PIOT MA, 1967, WHOTB6753; Piot P, 1999, SEXUALLY TRANSMITTED, P1295; Rao P, 1998, SEX TRANSM INFECT, V74, pS17; Saidel TJ, 1998, AIDS, V12, pS57; VANDERVEEN FH, 1994, INT J STD AIDS, V5, P262, DOI 10.1177/095646249400500407; Watson-Jones D, 2000, SEX TRANSM INFECT, V76, P355, DOI 10.1136/sti.76.5.355; WEST B, 1995, GENITOURIN MED, V71, P9; World Health Organization, 1994, WHOGPATEM941	18	23	23	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	DEC	2001	6	12					971	979		10.1046/j.1365-3156.2001.00809.x				9	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	503MP	WOS:000172802500002	11737832				2019-03-26	
J	Chatterjee, S; De Man, J; Van Marck, E				Chatterjee, S; De Man, J; Van Marck, E			Review: Somatostatin and intestinal schistosomiasis: therapeutic and neuropathological implications in host-parasite interactions	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						receptor; schistosomiasis; somatostatin; therapy	MYENTERIC PLEXUS; GASTROINTESTINAL-TRACT; RECEPTOR FAMILY; COS-7 CELLS; RELEASE; RAT; INHIBITION; INTERNALIZATION; ENDOCYTOSIS; SECRETION	A better insight into the mechanisms regulating the human body can lead to improved knowledge of the patho-physiological processes of many diseases. New therapeutic possibilities can be devised at the level of these regulatory mechanisms. Somatostatin is one of the major regulatory hormones in the central nervous system (CNS) and digestive system. Its wide variety of activities means it is implicated in a broad range of conditions. One symptom common to both the acute and chronic stages of schistosomiasis is intestinal pathology characterized by abdominal pain, diarrhoea that is bloody in more chronic stages, nausea and fever. Some chronic patients develop severe hepatosplenic fibrosis, leading to fatal oesophageal variceal bleeding. In this review we assess the therapeutic potential of somatostatin in the treatment of intestinal pathology associated with schistosomiasis. The activity of somatostatin is mediated via binding to specific cell surface receptors. While we are making progress in studies of the expression and regulation of the different somatostatin receptors, the true role and distribution Of each receptor subtype is far from fully understood. Animal models will help to define the specific role of individual receptors in physiological and pathological conditions. The regulation of receptor expression as well as receptor internalization can give us insight into the effect Of exogenous somatostatin on schistosomiasis-mediated intestinal pathology, as well as its modulation by intrinsically produced somatostatin levels.	Univ Antwerp, Dept Med, Pathol Unit, B-2610 Wilrijk, Belgium; Univ Antwerp, Dept Med, Gastroenterol Unit, B-2610 Wilrijk, Belgium	Chatterjee, S (reprint author), Univ Antwerp, Dept Med, Pathol Unit, Univ Pl 1, B-2610 Wilrijk, Belgium.		De Man, Joris/E-2980-2013				Andersen H B, 1996, HPB Surg, V9, P229, DOI 10.1155/1996/12097; ARNOLD R, 1975, ACTA ENDOCRINOL-COP, V193, pS75; Aube AC, 1996, GUT, V39, P470, DOI 10.1136/gut.39.3.470; Benali N, 2000, DIGESTION, V62, P27, DOI 10.1159/000051852; BLOOM SR, 1987, BRIT MED J, V295, P288, DOI 10.1136/bmj.295.6593.288; BORDI C, 1996, OCTREOTIDE BASIC SCI, P2; Burks Thomas F., 1994, P211; CLEMENTS D, 1986, J HEPATOL, V2, P262, DOI 10.1016/S0168-8278(86)80085-X; COLLINS SM, 1989, AM J PHYSIOL, V257, pG898; DAMICO G, 1995, HEPATOLOGY, V22, P332, DOI 10.1016/0270-9139(95)90388-7; DOMINGO EO, 1969, GASTROENTEROLOGY, V56, P231; Elliott DE, 1999, EUR J IMMUNOL, V29, P2454, DOI 10.1002/(SICI)1521-4141(199908)29:08<2454::AID-IMMU2454>3.0.CO;2-H; FENIUK W, 1993, BRIT J PHARMACOL, V110, P1156, DOI 10.1111/j.1476-5381.1993.tb13935.x; Galligan JJ, 1999, J PHARMACOL EXP THER, V291, P92; GREEN DW, 1989, GASTROENTEROL CLIN N, V18, P695; GRYSEELS B, 1992, TROP GEOGR MED, V44, P189; HADZIJAHIC N, 1993, GASTROENTEROLOGY, V105, P1017, DOI 10.1016/0016-5085(93)90944-8; HANSSEN LE, 1977, SCAND J GASTROENTERO, V12, P391, DOI 10.3109/00365527709181678; HO LT, 1986, CLIN PHYSIOL BIOCH, V4, P257; Holt R., 1996, EUROPEAN HEROES MYTH, P1; KAHN CR, 1975, AM J CLIN PATHOL, V63, P656; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; Kreienkamp HJ, 1998, DNA CELL BIOL, V17, P869, DOI 10.1089/dna.1998.17.869; KRUHLICH L, 1968, ENDOCRINOLOGY, V83, P783; LEFKOWITZ RJ, 1978, RECEPTORS HORMONE AC, V3, P179; Mansy SS, 1998, ARZNEIMITTEL-FORSCH, V48, P855; MARTEAU P, 1989, DIGESTION, V42, P16, DOI 10.1159/000199820; Meyerhof W, 1998, Rev Physiol Biochem Pharmacol, V133, P55; Moreels TG, 2001, AM J PHYSIOL-GASTR L, V280, pG1030; Murthy KS, 1996, J BIOL CHEM, V271, P23458, DOI 10.1074/jbc.271.38.23458; Nouel D, 1997, ENDOCRINOLOGY, V138, P296, DOI 10.1210/en.138.1.296; PANETTA R, 1994, MOL PHARMACOL, V45, P417; Patel YC, 1999, FRONT NEUROENDOCRIN, V20, P157, DOI 10.1006/frne.1999.0183; PATEL YC, 1994, ENDOCRINOLOGY, V135, P2814, DOI 10.1210/en.135.6.2814; PATEL YC, 1995, LIFE SCI, V57, P1249, DOI 10.1016/0024-3205(95)02082-T; PEETERS TL, 1981, CLIN CHEM, V27, P888; POLAK JM, 1986, SCANDINAVIAN J  S119, V21, pS11; PRADAYROL L, 1980, FEBS LETT, V109, P55, DOI 10.1016/0014-5793(80)81310-X; RAFF M, 1976, NATURE, V259, P255; REICHLIN S, 1983, NEW ENGL J MED, V309, P1495, DOI 10.1056/NEJM198312153092406; REICHLIN S, 1983, NEW ENGL J MED, V309, P1556, DOI 10.1056/NEJM198312223092506; Reubi JC, 1999, J CLIN ENDOCR METAB, V84, P2942, DOI 10.1210/jc.84.8.2942; REUBI JC, 1992, YALE J BIOL MED, V65, P493; Reynaert H, 1999, HEPATOLOGY, V30, p236A; Schafer J, 1999, NEUROPEPTIDES, V33, P457, DOI 10.1054/npep.1999.0762; Schneider DA, 2000, J PHARMACOL EXP THER, V294, P363; SCHUSDZIARRA V, 1996, PROGR BASIC CLIN PHA, V10, P35; Stroh T, 2000, ENDOCRINOLOGY, V141, P354, DOI 10.1210/en.141.1.354; TAKEDA T, 1989, AM J PHYSIOL, V257, pG532; TOROCSIK A, 1991, EUR J PHARMACOL, V202, P297, DOI 10.1016/0014-2999(91)90270-Z; VARILEK GW, 1991, J PARASITOL, V77, P472, DOI 10.2307/3283138; Venkova K, 2000, J PHARMACOL EXP THER, V293, P60; WAHREN J, 1976, LANCET, V2, P1213; *WHO, 1993, WHO TECHN REP SER, V830, P1; Wood Jackie D., 1994, P423	55	10	10	0	0	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	DEC	2001	6	12					1008	1015		10.1046/j.1365-3156.2001.00744.x				8	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	503MP	WOS:000172802500008	11737838	Bronze			2019-03-26	
J	Moerman, F; D'Alessandro, U				Moerman, F; D'Alessandro, U			Untitled	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Letter							WEST-AFRICAN CITY; HIV-INFECTION; TRANSFUSION; TRANSMISSION; ANTIBODY; RISK		Inst Trop Med Prince Leopold, Dept Parasitol, B-2000 Antwerp, Belgium	Moerman, F (reprint author), Inst Trop Med Prince Leopold, Dept Parasitol, B-2000 Antwerp, Belgium.		D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009			CRAIGHEAD IB, 1993, TROP DOCT, V23, P59, DOI 10.1177/004947559302300207; LACKRITZ EM, 1992, LANCET, V340, P524, DOI 10.1016/0140-6736(92)91719-O; SAVARIT D, 1992, BRIT MED J, V305, P498, DOI 10.1136/bmj.305.6852.498; SCHUTZ R, 1993, BRIT MED J, V307, P1517, DOI 10.1136/bmj.307.6918.1517; *UNAIDS, 1997, BLOOD SAF AIDS; VANHOOGSTRATEN MJ, 2000, TROP MED INT HEALTH, V5, P352; WARD JW, 1988, NEW ENGL J MED, V318, P473, DOI 10.1056/NEJM198802253180803; *WHO, 1999, FACTS FIG WHO GLOB D	8	0	0	0	0	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	DEC	2001	6	12					1084	1084		10.1046/j.1365-3156.2001.00815.x				1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	503MP	WOS:000172802500016	11737846				2019-03-26	
J	Guerbouj, S; Guizani, I; De Doncker, S; Dujardin, JC; Nuwayri-Salti, N				Guerbouj, S; Guizani, I; De Doncker, S; Dujardin, JC; Nuwayri-Salti, N			Identification of Lebanese dermotropic putative Leishmania archibaldi isolates by gp63 PCR-RFLP	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						Leishmania; characterization; gp63 PCR-RFLP; Leishmania (L.) archibaldi; Lebanon	VISCERAL LEISHMANIASIS; EPIDEMIOLOGY; INFANTUM	Leishmania stocks isolated from cutaneous lesions in Lebanon were characterized by PCR methods. The stocks were typed as putative L. (L.) archibaldi (gp63 PCR-RFLP), belonging to 2 different genotypes (PCR-based schizodeme analysis). This constitutes the first report on the presence of L. (L.) archibaldi in the Middle East.	Inst Pasteur Tunis, Lab Epidemiol & Ecol Parasitaire, Tunis, Tunisia; Inst Trop Med Prince Leopold, Protozool Unit, Antwerp, Belgium; Amer Univ Beirut, Beirut, Lebanon	Nuwayri-Salti, N (reprint author), Inst Pasteur Tunis, Lab Epidemiol & Ecol Parasitaire, Tunis, Tunisia.						ALJEBOORI TI, 1980, T ROY SOC TROP MED H, V74, P169, DOI 10.1016/0035-9203(80)90238-2; ALJEBOORI TI, 1980, T ROY SOC TROP MED H, V74, P178, DOI 10.1016/0035-9203(80)90239-4; Baneth G, 1998, AM J TROP MED HYG, V59, P722, DOI 10.4269/ajtmh.1998.59.722; CASTELLANI A, 1919, MANUAL TROPICAL MED, P369; Dereure J, 1998, B SOC PATHOL EXOT, V91, P300; DEREURE J, 1991, ANN PARASIT HUM COMP, V66, P252, DOI 10.1051/parasite/1991666252; Guerbouj S, 2001, PARASITOLOGY, V122, P25, DOI 10.1017/S0031182000007125; Lainson R., 1987, LEISHMANIASES BIOL M, V1, P1; Mauricio IL, 1999, PARASITOLOGY, V119, P237, DOI 10.1017/S0031182099004710; Mauricio IL, 2001, PARASITOLOGY, V122, P393, DOI 10.1017/S0031182001007466; MORENO G, 1986, TAXONOMIE PHYLOGENES, P105; Nuwayri-Salti N, 2000, T ROY SOC TROP MED H, V94, P164, DOI 10.1016/S0035-9203(00)90259-1; NUWAYRISALTI N, 1994, AM J TROP MED HYG, V51, P98, DOI 10.4269/ajtmh.1994.51.98; Oskam L, 1998, T ROY SOC TROP MED H, V92, P120, DOI 10.1016/S0035-9203(98)90982-8; Ozensoy S, 1998, AM J TROP MED HYG, V59, P363, DOI 10.4269/ajtmh.1998.59.363; Qubain HI, 1997, ACTA TROP, V68, P121, DOI 10.1016/S0001-706X(97)00082-X; RIOUX JA, 1990, ANN PARASIT HUM COMP, V65, P111, DOI 10.1051/parasite/1990653111; SMYTH AJ, 1992, PARASITOLOGY, V105, P183, DOI 10.1017/S0031182000074096; Victoir K, 1998, PARASITOLOGY, V117, P1	19	9	9	0	1	ROYAL SOC TROPICAL MEDICINE	LONDON	MANSON HOUSE 26 PORTLAND PLACE, LONDON W1N 1EY, ENGLAND	0035-9203			T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	NOV-DEC	2001	95	6					687	688		10.1016/S0035-9203(01)90117-8				2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	515VF	WOS:000173516800024	11816446				2019-03-26	
J	Boelaert, M; Matthys, F; Henkens, M; D'Alessandro, U				Boelaert, M; Matthys, F; Henkens, M; D'Alessandro, U			Editorial: European Union's research policy: a moving target?	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Editorial Material									Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium; Med Sans Frontieres, Brussels, Belgium	Boelaert, M (reprint author), Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium.		D'Alessandro, Umberto/D-3457-2015; Boelaert, Marleen/E-2698-2012	D'Alessandro, Umberto/0000-0001-6341-5009; Boelaert, Marleen/0000-0001-8051-6776			BUSQUIN P, 2001, COMMUNICATION   0418; DALESSANDRO U, 2001, COMMUNICATION   0315; Etchegorry MG, 2001, TROP MED INT HEALTH, V6, P957, DOI 10.1046/j.1365-3156.2001.00764.x; *EUR COMM, 2001, RES PROGR NEW FRAM P; Trouiller P, 2001, TROP MED INT HEALTH, V6, P945, DOI 10.1046/j.1365-3156.2001.00803.x; *WORLD HLTH ASS, 1978, DECL ALM AT; 2001, BURUNDI TRY DIFFEREN; 2001, LANCET, V358, P1	8	2	2	0	0	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	NOV	2001	6	11					843	844						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	491GE	WOS:000172100000001					2019-03-26	
J	D'Alessandro, U; Buttiens, H				D'Alessandro, U; Buttiens, H			History and importance of antimalarial drug resistance	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article; Proceedings Paper	Colloquium on Moving Target: Parasites, Resistance and Access to Drugs	DEC 04-06, 2000	INST TROP MED, ANTWERP, BELGIUM		INST TROP MED	Africa; antimalarial resistance; chloroquine; strategies; sulphadoxine-pyremethamine	PLASMODIUM-FALCIPARUM; MALARIA; CHLOROQUINE; AFRICA; COMBINATIONS; EFFICACY; SPREAD	The emergence of Plasmodium falciparum resistance to widely used antimalarial drugs such as chloroquine (CQ) has made malaria control and treatment much more difficult. This is particularly dramatic for Africa, as few affordable alternatives are available. Drug pressure has been identified as one of the key factors for the emergence and spread of resistance. The contribution of the extensive use and misuse of antimalarial drugs to the selection of resistant parasites became particularly evident during the Global Malaria Eradication campaign, launched by World Health Organization (WHO) in 1955. The first reports confirming P. falciparum resistance to CQ came almost simultaneously in the early 1960s from South America and South-East Asia, where direct or indirect (through use of medicated cooking salt) mass drug administration (MDA) had been implemented. Similar approaches were very limited in Africa, where P. falciparum resistance to CQ was first reported from the eastern region in the late 1970s and spread progressively west. Most African countries still rely heavily on CQ as first-line treatment despite various levels of resistance, although some states have changed to sulphadoxine-pyrimethamine (SP) as the first-line drug. Unfortunately, the predicted SP useful therapeutic life might be very short, probably because of its prolonged half-life, causing a higher probability of selecting resistant strains and a consequent fast development of resistance. CQ resistance is not evenly distributed and important differences can be found within and between countries. It seems to have spread more rapidly in East than in West Africa. Considering the high level of CQ use in West Africa, other factors such as intensity of transmission, population immunity or population movements should be considered when explaining the different levels of resistance. Understanding such factors may help us in devising strategies to contain the spread of drug resistance.	Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium	D'Alessandro, U (reprint author), Inst Trop Med Prince Leopold, Natl Str 155, B-2000 Antwerp, Belgium.		D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009			Avery J. S., 1958, T ROY SOC TROP MED H, V52, P547; BAKYAITA N, 2000, MOVING TARGETS PARAS; BAUDON D, 1995, MED TROP, V55, pS37; BLOLAND PB, 1993, J INFECT DIS, V167, P932, DOI 10.1093/infdis/167.4.932; BRUCE-CHWATT L. J., 1956, BULL WORLD HEALTH ORGAN, V15, P852; CAMPBELL CC, 1979, LANCET, V2, P1151; CHARLES LJ, 1962, B WORLD HEALTH ORGAN, V26, P103; CLARKE R, 1996, T ROY SOC TROP MED H, V90, P320; CLYDE DF, 1954, T ROY SOC TROP MED H, V48, P495, DOI 10.1016/0035-9203(54)90085-1; COULIBALY SO, 2000, MOVING TARGETS PARAS; Djimde A, 2001, NEW ENGL J MED, V344, P257, DOI 10.1056/NEJM200101253440403; EYLES DE, 1963, AM J TROP MED HYG, V12, P840, DOI 10.4269/ajtmh.1963.12.840; FOGH S, 1979, T ROY SOC TROP MED H, V73, P228, DOI 10.1016/0035-9203(79)90220-7; GIGLIOLI G, 1967, B WORLD HEALTH ORGAN, V36, P283; HALL SA, 1967, AM J TROP MED HYG, V16, P429, DOI 10.4269/ajtmh.1967.16.429; Hartinuta T, 1962, UNESCO 1 REG S SCI K, P143; Hastings IM, 2000, PARASITOL TODAY, V16, P340, DOI 10.1016/S0169-4758(00)01707-5; MOORE DV, 1961, AM J TROP MED HYG, V10, P5, DOI 10.4269/ajtmh.1961.10.5; Nzila AM, 2000, J INFECT DIS, V181, P2023, DOI 10.1086/315520; PAYNE D, 1988, PARASITOL TODAY, V4, P112, DOI 10.1016/0169-4758(88)90042-7; Thera MA, 2000, TROP MED INT HEALTH, V5, P876, DOI 10.1046/j.1365-3156.2000.00652.x; Watkins WM, 1997, PARASITOL TODAY, V13, P459, DOI 10.1016/S0169-4758(97)01124-1; WERNSDORFER WH, 1991, PHARMACOL THERAPEUT, V50, P95; WERNSDORFER WH, 1991, PARASITOL TODAY, V7, P297, DOI 10.1016/0169-4758(91)90262-M; WERNSDORFER WH, 1994, ACTA TROP, V56, P143, DOI 10.1016/0001-706X(94)90060-4; White N. J., 1999, Parassitologia (Rome), V41, P301; White NJ, 1996, PARASITOL TODAY, V12, P399, DOI 10.1016/0169-4758(96)10055-7; White NJ, 1998, DRUG RESIST UPDATE, V1, P3, DOI 10.1016/S1368-7646(98)80208-2; *WHO, 1984, WHO TECHN REP SER, V711; WHO, 1961, WHO TECHN REP SER, V226; *WHO, 1993, IMPLEMENTATION GLOBA; WHO, 1973, WHO TECHN REP SER, V529	32	54	60	1	5	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	NOV	2001	6	11					845	848		10.1046/j.1365-3156.2001.00819.x				4	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	491GE	WOS:000172100000002	11703837				2019-03-26	
J	Gryseels, B; Mbaye, A; De Vlas, SJ; Stelma, FF; Guisse, F; Van Lieshout, L; Faye, D; Diop, M; Ly, A; Tchuem-Tchuente, LA; Engels, D; Polman, K				Gryseels, B; Mbaye, A; De Vlas, SJ; Stelma, FF; Guisse, F; Van Lieshout, L; Faye, D; Diop, M; Ly, A; Tchuem-Tchuente, LA; Engels, D; Polman, K			Are poor responses to praziquantel for the treatment of Schistosoma mansoni infections in Senegal due to resistance? An overview of the evidence	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article; Proceedings Paper	Colloquium on Moving Target: Parasites, Resistance and Access to Drugs	DEC 04-06, 2000	INST TROP MED, ANTWERP, BELGIUM		INST TROP MED	praziquantel; Schistosoma mansoni; drug resistance; low cure rates; Senegal; field data; modelling; review	RECENTLY EXPOSED COMMUNITY; NORTHERN SENEGAL; RIVER BASIN; INTESTINAL SCHISTOSOMIASIS; DRUG-RESISTANCE; SUGAR ESTATE; EGG COUNTS; CURE RATES; OXAMNIQUINE; EFFICACY	This paper summarizes and concludes in-depth field investigations on suspected resistance of Schistosoma mansoni to praziquantel in northern Senegal. Praziquantel at 40 mg/kg usually cures 70-90% of S. mansoni infections. In an initial trial in an epidemic S. mansoni focus in northern Senegal, only 18% of the cases became parasitological ly negative 12 weeks after treatment, although the reduction in mean egg counts was within normal ranges (86%). Among other hypotheses to explain the observed low cure rate in this focus, the possibility of drug resistance or tolerance had to be considered. Subsequent field trials with a shorter follow-up period (6-8 weeks) yielded cure rates of 31-36%. Increasing the dose to 2 x 30 mg/kg did not significantly improve cure rates, whereas treatment with oxamniquine at 20 mg/kg resulted in a normal cure rate of 79%. The efficacy of praziquantel in this focus could be related to age and pre-treatment intensity but not to other host factors, including immune profiles and water contact patterns. Treatment with praziquantel of individuals from the area residing temporarily in an urban region with no transmission, and re-treatment after 3 weeks of non-cured individuals within the area resulted in normal cure rates (78-88%). The application of an epidemiological model taking into account the relation between egg counts and actual worm numbers indicated that the low cure rates in this Senegalese focus could be explained by assuming a 90% worm reduction after treatment with praziquantel; in average endemic situations, such a drug efficacy would result in normal cure rates. Laboratory studies by others on the presence or absence of praziquantel resistance in Senegalese schistosome strains have so far been inconclusive. We conclude that there is no convincing evidence for praziquantel-resistant S. mansoni in Senegal, and that the low cure rates can be attributed to high initial worm loads and intense transmission in this area.	Inst Trop Med, B-2000 Antwerp, Belgium; Reg Med St Louis, St Louis, Senegal; Erasmus Univ, Dept Publ Hlth, Rotterdam, Netherlands; Leiden Univ, Dept Parasitol, Leiden, Netherlands; WHO, CH-1211 Geneva, Switzerland	Gryseels, B (reprint author), Inst Trop Med, Natl Str 155, B-2000 Antwerp, Belgium.						Bennett JL, 1997, EXP PARASITOL, V87, P260, DOI 10.1006/expr.1997.4229; BRINDLEY PJ, 1987, J IMMUNOL, V139, P215; Cioli D, 2000, CURR OPIN INFECT DIS, V13, P659, DOI 10.1097/00001432-200012000-00014; Cioli D, 1998, PARASITOL TODAY, V14, P418, DOI 10.1016/S0169-4758(98)01323-4; CIOLI D, 1993, PARASITOL TODAY, V9, P162, DOI 10.1016/0169-4758(93)90138-6; Davis A., 1993, Human schistosomiasis., P367; DEVLAS SJ, 1992, PARASITOLOGY, V104, P451, DOI 10.1017/S003118200006371X; DEVLAS SJ, 1992, PARASITOL TODAY, V8, P274, DOI 10.1016/0169-4758(92)90144-Q; DEVLAS SJ, 1993, PARASITOL TODAY, V9, P305; DeVlas SJ, 1997, PARASITOLOGY, V114, P113, DOI 10.1017/S0031182096008207; DEVLAS SJ, 1996, THESIS ERASMUS U ROT; El Khoby T, 1998, PARASITOL TODAY, V14, P92, DOI 10.1016/S0169-4758(97)01206-4; Fallon PG, 1997, EXP PARASITOL, V86, P29, DOI 10.1006/expr.1997.4149; FALLON PG, 1995, AM J TROP MED HYG, V53, P61, DOI 10.4269/ajtmh.1995.53.61; FALLON PG, 1994, AM J TROP MED HYG, V51, P83, DOI 10.4269/ajtmh.1994.51.83; Geerts S, 2000, CLIN MICROBIOL REV, V13, P207, DOI 10.1128/CMR.13.2.207-222.2000; GRYSEELS B, 1994, TROP GEOGR MED, V46, P209; GRYSEELS B, 1987, T ROY SOC TROP MED H, V81, P641, DOI 10.1016/0035-9203(87)90439-1; Guisse F, 1997, AM J TROP MED HYG, V56, P511, DOI 10.4269/ajtmh.1997.56.511; HOMEIDA MMA, 1988, AM J TROP MED HYG, V38, P496, DOI 10.4269/ajtmh.1988.38.496; Ismail M, 1999, AM J TROP MED HYG, V60, P932, DOI 10.4269/ajtmh.1999.60.932; Ismail M, 1996, AM J TROP MED HYG, V55, P214, DOI 10.4269/ajtmh.1996.55.214; KONGS A, 1994, ANN SOC BELG MED TR, V74, P301; KUMAR V, 1994, INT J ANTIMICROB AG, V4, P313, DOI 10.1016/0924-8579(94)90032-9; LAW AM, 1991, SIMULATION MODELLING; Picquet M, 1998, T ROY SOC TROP MED H, V92, P90, DOI 10.1016/S0035-9203(98)90971-3; POLDERMAN AM, 1988, T ROY SOC TROP MED H, V82, P115, DOI 10.1016/0035-9203(88)90282-9; Renganathan E, 1998, PARASITOL TODAY, V14, P390, DOI 10.1016/S0169-4758(98)01310-6; SABAH AA, 1986, EXP PARASITOL, V61, P294, DOI 10.1016/0014-4894(86)90184-0; SIMONSEN PE, 1990, E AFR MED J, V67, P532; Stelma FF, 1997, J INFECT DIS, V176, P304, DOI 10.1086/517273; STELMA FF, 1995, AM J TROP MED HYG, V53, P167, DOI 10.4269/ajtmh.1995.53.167; STELMA FF, 1993, AM J TROP MED HYG, V49, P701, DOI 10.4269/ajtmh.1993.49.701; TADDESE K, 1988, ANN TROP MED PARASIT, V82, P175, DOI 10.1080/00034983.1988.11812225; TALLA I, 1992, T ROY SOC TROP MED H, V86, P182, DOI 10.1016/0035-9203(92)90562-Q; TALLA I, 1990, ANN SOC BELG MED TR, V70, P173; Tchuente LAT, 2001, T ROY SOC TROP MED H, V95, P65, DOI 10.1016/S0035-9203(01)90335-9; Van Lieshout L, 1999, AM J TROP MED HYG, V61, P760, DOI 10.4269/ajtmh.1999.61.760; VERCRUYSSE J, 1994, TROP GEOGR MED, V46, P220; *WHO, 1993, TDR NEWS, V42, P10; *WHO, 1993, WHO TECHN REP SER, V830, P1; *WHO, 1983, WHOSCHISTO8370; *WHO, 1985, WHO TECH REP SER, V728, P1; *WHO, 1992, TDR NEWS, V41, P1; XIAO SH, 1985, J INFECT DIS, V151, P1130, DOI 10.1093/infdis/151.6.1130	45	122	126	0	8	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	NOV	2001	6	11					864	873		10.1046/j.1365-3156.2001.00811.x				10	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	491GE	WOS:000172100000005	11703840				2019-03-26	
J	Geerts, S; Gryseels, B				Geerts, S; Gryseels, B			Anthelmintic resistance in human helminths: a review	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article; Proceedings Paper	Colloquium on Moving Target: Parasites, Resistance and Access to Drugs	DEC 04-06, 2000	INST TROP MED, ANTWERP, BELGIUM		INST TROP MED	anthelmintic resistance; livestock; man; review	HUMAN HOOKWORM INFECTIONS; BETA-TUBULIN GENE; HAEMONCHUS-CONTORTUS; SCHISTOSOMA-MANSONI; BENZIMIDAZOLE-RESISTANCE; IVERMECTIN RESISTANCE; DRUG-RESISTANCE; VETERINARY IMPORTANCE; ONCHOCERCA-VOLVULUS; SOUTHERN REGION	We briefly review reports on drug resistance in human helminths and compare the factors which contribute to the development of anthelmintic resistance in livestock and man, i.e. high treatment frequency, single-drug regimens, targeting and timing of mass treatments and underdosing. Conclusions are drawn from the mistakes in the treatment and control of livestock helminths. The advantages and inconveniences of current methods for the detection of drug resistance in helminths of livestock are discussed and some suggestions are put forward to standardize the tests for the detection of resistance in human helminths. Finally, based on veterinary experience, some recommendations are made to reduce the risks of development of drug resistance in human helminths. The dramatic and rapid spread of resistance to all major classes of veterinary anthelmintics should be a warning against too strong a reliance on drugs in helminth control programmes.	Inst Trop Med, B-2000 Antwerp, Belgium	Geerts, S (reprint author), Inst Trop Med, Natl Str 155, B-2000 Antwerp, Belgium.			Geerts, Stanny/0000-0001-9885-8846			Anderson T. J. C., 1998, ADV PARASIT, V41, P220; BARNES EH, 1995, PARASITOL TODAY, V11, P56, DOI 10.1016/0169-4758(95)80117-0; BAUER VC, 1992, DTSCH TIERARTZL WOCH, V99, P353; BEECH RN, 1994, GENETICS, V138, P103; Blackhall WJ, 1998, MOL BIOCHEM PARASIT, V95, P193, DOI 10.1016/S0166-6851(98)00087-5; Bobadilla JL, 1993, DIS CONTROL PRIORITI, P131; BOUDSOCQ A, 1999, WAAVP 17 INT C COP; Burger H. J., 1994, Anthelmintic resistance in nematodes of farm animals. A seminar organised for the European Commission, held in Brussels, Belgium, from 8 to 9 November, 1993., P63; Chitsulo L, 2000, ACTA TROP, V77, P41, DOI 10.1016/S0001-706X(00)00122-4; CIOLI D, 1992, EXP PARASITOL, V75, P425, DOI 10.1016/0014-4894(92)90255-9; CIOLI D, 1993, PARASITOL TODAY, V9, P162, DOI 10.1016/0169-4758(93)90138-6; COLES GC, 1992, VET PARASITOL, V44, P35, DOI 10.1016/0304-4017(92)90141-U; COLES GC, 1995, PARASITOL TODAY, V11, P183, DOI 10.1016/0169-4758(95)80152-9; CONDER GA, 1995, ADV PARASIT, V35, P1, DOI 10.1016/S0065-308X(08)60069-X; DeClercq D, 1997, AM J TROP MED HYG, V57, P25, DOI 10.4269/ajtmh.1997.57.25; Dobson RJ, 1996, INT J PARASITOL, V26, P993; DORNY P, 1994, VET PARASITOL, V55, P327, DOI 10.1016/0304-4017(94)90073-6; El Khoby T, 1998, PARASITOL TODAY, V14, P92, DOI 10.1016/S0169-4758(97)01206-4; Elard L, 1999, VET PARASITOL, V80, P231, DOI 10.1016/S0304-4017(98)00214-3; Engels D, 1996, AM J TROP MED HYG, V54, P319, DOI 10.4269/ajtmh.1996.54.319; Geerts S, 2000, CLIN MICROBIOL REV, V13, P207, DOI 10.1128/CMR.13.2.207-222.2000; GEERTS S, 1990, VLAAMS DIERGEN TIJDS, V59, P90; GEERTS S, 1987, VET PARASITOL, V23, P77, DOI 10.1016/0304-4017(87)90026-4; Geerts S, 1997, PARASITOL TODAY, V13, P149, DOI 10.1016/S0169-4758(97)01024-7; Grant W, 2000, PARASITOL TODAY, V16, P458, DOI 10.1016/S0169-4758(00)01804-4; Huang YJ, 1999, MOL BIOCHEM PARASIT, V102, P273, DOI 10.1016/S0166-6851(99)00104-8; Ismail M, 1999, AM J TROP MED HYG, V60, P932, DOI 10.4269/ajtmh.1999.60.932; JUNG MK, 1992, CELL MOTIL CYTOSKEL, V22, P170, DOI 10.1002/cm.970220304; Katz N, 1972, Rev Inst Med Trop Sao Paulo, V14, P397; Kerboeuf D, 1999, PARASITOL RES, V85, P118, DOI 10.1007/s004360050519; KOENRAADT H, 1992, PHYTOPATHOLOGY, V82, P1348, DOI 10.1094/Phyto-82-1348; KWA MSG, 1994, MOL BIOCHEM PARASIT, V63, P299, DOI 10.1016/0166-6851(94)90066-3; MALAN F. S., 1997, MANAGING ANTHELMINTI, P51; MARTIN LK, 1968, AM J TROP MED HYG, V17, P382, DOI 10.4269/ajtmh.1968.17.382; MARTIN PJ, 1989, AUST VET J, V66, P236, DOI 10.1111/j.1751-0813.1989.tb13578.x; MARTIN PJ, 1982, AUST VET J, V58, P185, DOI 10.1111/j.1751-0813.1982.tb00649.x; Monteiro AM, 1998, VET REC, V142, P396, DOI 10.1136/vr.142.15.396; Pereira C, 1998, PARASITOLOGY, V117, P63, DOI 10.1017/S003118209800273X; POLDERMAN AM, 1985, ANN SOC BELG MED TR, V65, P243; REINEMEYER CR, 1992, VET PARASITOL, V42, P111, DOI 10.1016/0304-4017(92)90107-K; RENGANATHAN E, 1995, B WORLD HEALTH ORGAN, V73, P183; Reynoldson JA, 1997, ACTA TROP, V68, P301, DOI 10.1016/S0001-706X(97)00106-X; Roos M. H., 1994, Anthelmintic resistance in nematodes of farm animals. A seminar organised for the European Commission, held in Brussels, Belgium, from 8 to 9 November, 1993., P141; ROOS MH, 1995, PARASITOL TODAY, V11, P148, DOI 10.1016/0169-4758(95)80136-7; Sacko M, 1999, T ROY SOC TROP MED H, V93, P195, DOI 10.1016/S0035-9203(99)90306-1; Shakoor O, 1997, TROP MED INT HEALTH, V2, P839, DOI 10.1046/j.1365-3156.1997.d01-403.x; SHOOP WL, 1993, PARASITOL TODAY, V9, P154, DOI 10.1016/0169-4758(93)90136-4; Smith G, 1999, INT J PARASITOL, V29, P77, DOI 10.1016/S0020-7519(98)00186-6; Stelma F, 1995, AM J TROP MED HYG, V63, P167; Tsai MH, 2000, J PARASITOL, V86, P146, DOI 10.1645/0022-3395(2000)086[0146:RAPDRP]2.0.CO;2; Van Wyk JA, 1999, ONDERSTEPOORT J VET, V66, P273; Van Wyk JA, 2001, ONDERSTEPOORT J VET, V68, P55; vanWyk JA, 1997, VET PARASITOL, V72, P157, DOI 10.1016/S0304-4017(97)00022-8; vanWyk JA, 1997, VET PARASITOL, V70, P111, DOI 10.1016/S0304-4017(96)01147-8; Waller P. J., 1985, Resistance in nematodes to anthelmintic drugs, P1; Waller PJ, 1996, VET PARASITOL, V62, P181, DOI 10.1016/0304-4017(95)00909-4; *WHO, 1992, WHO TECHN REP SER, V830; WHO, 1999, REP WHO INF CONS MON; World Health Organization, 1995, WHO TECHN REP SER, V852; Xu M, 1998, MOL BIOCHEM PARASIT, V91, P327, DOI 10.1016/S0166-6851(97)00215-6; Young KE, 1999, VET PARASITOL, V85, P205, DOI 10.1016/S0304-4017(99)00100-4	61	79	81	0	11	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	NOV	2001	6	11					915	921		10.1046/j.1365-3156.2001.00774.x				7	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	491GE	WOS:000172100000011	11703846	Bronze			2019-03-26	
J	Trouiller, P; Torreele, E; Olliaro, P; White, N; Foster, S; Wirth, D; Pecoul, B				Trouiller, P; Torreele, E; Olliaro, P; White, N; Foster, S; Wirth, D; Pecoul, B			Drugs for neglected diseases: a failure of the market and a public health failure?	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article; Proceedings Paper	Colloquium on Moving Target: Parasites, Resistance and Access to Drugs	DEC 04-06, 2000	INST TROP MED, ANTWERP, BELGIUM		INST TROP MED	neglected diseases; medicines; pharmaceutical market; public policy	UNITED-STATES; PATENTS; ACCESS; AIDS	Infectious diseases cause the suffering of hundreds of millions of people, especially in tropical and subtropical areas. Effective, affordable and easy-to-use medicines to fight these diseases are nearly absent. Although science and technology are sufficiently advanced to provide the necessary medicines, very few new drugs are being developed. However, drug discovery is not the major bottleneck. Today's R&D-based pharmaceutical industry is reluctant to invest in the development of drugs to treat the major diseases of the poor, because return on investment cannot be guaranteed. With national and international politics supporting a free market-based world order, financial opportunities rather than global health needs guide the direction of new drug development. Can we accept that the dearth of effective drugs for diseases that mainly affect the poor is simply the sad but inevitable consequence of a global market economy? Or is it a massive public health failure, and a failure to direct economic development for the benefit of society? An urgent reorientation of priorities in drug development and health policy is needed. The pharmaceutical industry must contribute to this effort, but national and international policies need to direct the global economy to address the true health needs of society. This requires political will, a strong commitment to prioritize health considerations over economic interests, and the enforcement of regulations and other mechanisms to stimulate essential drug development. New and creative strategies involving both the public and the private sector are needed to ensure that affordable medicines for today's neglected diseases are developed. Priority action areas include advocating an essential medicines R&D agenda, capacity-building in and technology transfer to developing countries, elaborating an adapted legal and regulatory framework, prioritizing funding for essential drug development and securing availability, accessibility, distribution and rational use of these drugs.	VIB Free Univ Brussels, Dept Immunol Parasitol & Ultrastruct, B-1640 Rhode St Genese, Belgium; CHU Grenoble, F-38043 Grenoble, France; WHO, TDR, CH-1211 Geneva, Switzerland; Mahidol Univ, Fac Trop Med, Bangkok, Thailand; Boston Univ, Sch Publ Hlth, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Med Sans Frontieres, Geneva, Switzerland	Torreele, E (reprint author), VIB Free Univ Brussels, Dept Immunol Parasitol & Ultrastruct, Paardenstr 65, B-1640 Rhode St Genese, Belgium.						ATTARAN A, 1999, INT C DRUGS COMM DIS; Bobrow M, 2001, NATURE, V409, P763, DOI 10.1038/35057480; Boyce N, 2000, NEW SCI, V166, P15; Chirac P, 2000, LANCET, V356, P502, DOI 10.1016/S0140-6736(00)02566-6; DIMASI JA, 1994, CLIN PHARMACOL THER, V55, P609, DOI 10.1038/clpt.1994.78; Donald A, 1999, BRIT MED J, V319, P1298, DOI 10.1136/bmj.319.7220.1298; *FORT 500, 2001, TOP PERF IND; GAMBARDELLA A, 2001, GLOBAL COMPETITIVENE; Global Forum for Health Research, 1999, 10 90 REP HLTH RES 1; GRABOWSKI HG, 1994, J HEALTH ECON, V13, P383, DOI 10.1016/0167-6296(94)90010-8; Haffner ME, 1999, DRUG INF J, V33, P565, DOI 10.1177/009286159903300226; Heller MA, 1998, SCIENCE, V280, P698, DOI 10.1126/science.280.5364.698; *IMS, 1999, IMS HLTH GLOB INS RE; Kettler H. E, 1999, UPDATING COST NEW CH; LOVE J, 1997, MARKETLETTER, V13, P24; OBRIEN P, 1998, MED NEW EC ENV, P77; P Trouiller, 2001, LEGAL REGULATORY ISS; Pecoul B, 1999, JAMA-J AM MED ASSOC, V281, P361, DOI 10.1001/jama.281.4.361; PFLAKER K, 1998, PROGRAMMES PROMOTING; Reich MR, 1998, HEALTH POLICY, V44, P1, DOI 10.1016/S0168-8510(98)00002-5; SACHS J, 1990, EC              0814, P17; Trouiller P, 1999, TROP MED INT HEALTH, V4, P412, DOI 10.1046/j.1365-3156.1999.00420.x; Trouiller P, 1998, Int J Infect Dis, V3, P61, DOI 10.1016/S1201-9712(99)90010-3; Trouiller P., 1996, Cahiers d'Etudes et de Recherches Francophones/Sante, V6, P299; Velasquez G, 1999, WHODAP989; Wehrli A., 1997, DRUG INF J, V31, P895; WHO, 1999, WORLD HLTH REP 1999; Wilson D, 1999, LANCET, V354, P1893, DOI 10.1016/S0140-6736(99)06114-0	28	99	104	0	17	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	NOV	2001	6	11					945	951		10.1046/j.1365-3156.2001.00803.x				7	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	491GE	WOS:000172100000015	11703850				2019-03-26	
J	Kindermans, JM; Matthys, F				Kindermans, JM; Matthys, F			Introductory note: The access to Essential Medicines Campaign	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article; Proceedings Paper	Colloquium on Moving Target: Parasites, Resistance and Access to Drugs	DEC 04-06, 2000	INST TROP MED, ANTWERP, BELGIUM		INST TROP MED	medicines; access; research; development; trade		To ensure access to essential medicines for disadvantaged populations there are at least three conditions to be met: drugs prices must be affordable for poor countries; research and development of drugs for tropical diseases must take place; and there is a need for health exceptions to trade agreements.	MSF Int, B-1040 Brussels, Belgium; MSF, B-1090 Brussels, Belgium	Kindermans, JM (reprint author), MSF Int, 37 Rue Tourelle, B-1040 Brussels, Belgium.						CORREA C, 2000, INTEGRATING PUBLIC H, P65; CORREA C, 2000, REV INT DROIT EC, V1, P23; DUMOULIN J, 2000, REV INT DROIT EC, V1, P45; Pecoul B, 1999, JAMA-J AM MED ASSOC, V281, P361, DOI 10.1001/jama.281.4.361; TROUILLER P, 1999, INT J INFECT DIS, V2, P61; *WHO, 1997, DAP SER, V7; *WORLD TRAD AGR, 1995, TRIPS AGR	7	3	3	0	1	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	NOV	2001	6	11					955	956		10.1046/j.1365-3156.2001.00797.x				2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	491GE	WOS:000172100000017	11703852	Bronze			2019-03-26	
J	Chairulfatah, A; Setiabudi, D; Agoes, R; van Sprundel, M; Colebunders, R				Chairulfatah, A; Setiabudi, D; Agoes, R; van Sprundel, M; Colebunders, R			Hospital based clinical surveillance for dengue haemorrhagic fever in Bandung, Indonesia 1994-1995	ACTA TROPICA			English	Article						dengue; dengue haemorrhagic fever; surveillance; Indonesia		In Indonesia, by law dengue haemorrhagic fever (DHF) cases must be reported within 24 h to the district health authority. The objective of this study was to evaluate the adequacy, accuracy and reporting delay of this reporting system. In four major hospitals of the city of Bandung, medical records of hospitalised DHF cases admitted between April 1994 and March 1995 were reviewed. This list of DHF cases was compared with the fist of reported cases to the Bandung Municipality Health Office. During the study period, 569 DHF cases and 81 dengue shock syndrome (DSS),cases were diagnosed. Only 199 (31%) of the 650 hospitalised cases with suspected DHF/DSS were reported to the Bandung Municipality Health Office. The percentage of fatal cases was significantly lower among all hospitalised cases 11/650 (1.7%) than among reported cases 5/199 (2.5%). In only 443 of the 583 hospitalised cases (76%) in which a dengue serological test was performed, was this test positive. Of the 199 reported DHF/DSS cases 151 (76%) had a positive haemagglutination inhibition test. This study shows that the surveillance system for DHF/DSS in Bandung should be strengthened. DHF/DSS cases should be reported on the basis of a diagnosis made during hospitalisation preferably after a serological confirmation is obtained. (C) 2001 Elsevier Science B.V. All rights reserved.	Padjadjaran State Univ, Sch Med, Dr Hasan Sadikin Gen Hosp, Dept Childhlth, Bandung, Indonesia; Padjadjaran State Univ, Sch Med, Dr Hasan Sadikin Gen Hosp, Dept Parasitol, Bandung, Indonesia; Univ Antwerp, Dept Epidemiol & Community Med, B-2610 Wilrijk, Belgium; Inst Trop Med, B-2000 Antwerp, Belgium	Colebunders, R (reprint author), Inst Trop Med, Kronenburgstr 43-3, B-2000 Antwerp, Belgium.						Centers for Disease Control (CDC), 1988, MMWR-MORBID MORTAL W, V37, P1; Chan Y. C., 1990, Southeast Asian Journal of Tropical Medicine and Public Health, V21, P702; CLARKE DH, 1958, AM J TROP MED HYG, V7, P561, DOI 10.4269/ajtmh.1958.7.561; EVANS AS, 1983, EPIDEMIOLOGY CONTROL, P43; GOH KT, 1983, DENGUE HAEMORRHAGIC, P40; Gubler D J, 1989, Bull Pan Am Health Organ, V23, P397; HAYES EB, 1992, PEDIATR INFECT DIS J, V11, P311, DOI 10.1097/00006454-199204000-00010; LUDOVICE ZO, 1983, P 10 SEAMIC SEM DIS, P116; *WHO, 1994, MOTH BAB PACK IMPL S, P1; World Health Organization, 1997, DENG HAEM FEV DIAGN, P1; World Health Organization, 1986, DENG HAEM FEV DIAGN, P58	11	14	15	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0001-706X			ACTA TROP	Acta Trop.	OCT 22	2001	80	2					111	115		10.1016/S0001-706X(01)00180-2				5	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	485EV	WOS:000171741300004	11600087				2019-03-26	
J	Chabwine, JN; Mubagwa, K				Chabwine, JN; Mubagwa, K			Mental health problems in a population without a previous modern psychiatric care system	TROPICAL DOCTOR			English	Article							DEVELOPING-COUNTRY; DISORDERS; AFRICA	Despite the recognized role of traditional healers in helping patients with mental health problems, there is a need for modern mental healthcare facilities in Africa. When made available, these are used by the local population, but less by those at remote locations. Data from the SOSAME centre indicate the high prevalence of mental diseases, especially in urban population and during the active decades of life. To decrease the burden imposed on mental health institutions by patients consulting for non-mental problems, it is desirable to integrate these institutions with the other components of the healthcare system.	Cathol Univ Bukavu, Fac Med, Bukavu, DEM REP CONGO	Mubagwa, K (reprint author), Katholieke Univ Leuven, Campus Gasthuisberg, B-3000 Leuven, Belgium.	kanigula.mubagwa@med.kuleuven.ac.be					Aghanwa HS, 1998, J PSYCHOSOM RES, V45, P353, DOI 10.1016/S0022-3999(98)00006-3; AWANBOR D, 1982, AM J PSYCHOTHER, V36, P206; AZINGE NO, 1983, TROP DOCT, V13, P98, DOI 10.1177/004947558301300302; Bhagwanjee A, 1998, PSYCHOL MED, V28, P1137, DOI 10.1017/S0033291798006965; Collins PY, 1996, PSYCHIAT QUART, V67, P177, DOI 10.1007/BF02238950; JEGEDE RO, 1985, HOSP COMMUNITY PSYCH, V36, P658; Kerson D, 1988, Int J Soc Psychiatry, V34, P31, DOI 10.1177/002076408803400105; KIGAMWA A, 1991, E AFR MED J, V68, P383; LAMONT AM, 1988, S AFR MED J, V73, P430; MSENGI NP, 1981, S AFR MED J, V59, P47; NCHINDA TC, 1977, INT J EPIDEMIOL, V6, P235, DOI 10.1093/ije/6.3.235; Nordberg E, 1997, E AFR MED J, V74, P629; Wig N N, 1985, Acta Psychiatr Belg, V85, P429	13	0	0	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0049-4755	1758-1133		TROP DOCT	Trop. Dr.	OCT	2001	31	4					206	208		10.1177/004947550103100408				3	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	482FY	WOS:000171566600008	11676053				2019-03-26	
J	Vreysen, MJB; Saleh, KM				Vreysen, MJB; Saleh, KM			Long-term sampling of gamma sterilised male Glossina austeni (Diptera : Glossinidae) with sticky panels on Unguja Island (Zanzibar)	ACTA TROPICA			English	Article						Glossina austeni; sticky panels; trap catch; season; Zanzibar	RESPONSES; TSETSE; BREVIPALPIS; PALLIDIPES; FIELD; TRAP	Daily catches of gamma sterilised male Glossina austeni Newstead with experimental sticky panels were analysed from March 1996 to July 1997. The flies were released weekly by light aircraft over primary and secondary forest ecosystems of Unguja Island, Zanzibar. In the primary forest, the cross-shaped royal blue XT panel (two interlocking panels of each 70 x 60 cm) trapped significantly more flies than the royal blue-white leg panel (panel with a body of 65 x 30 cm and two legs of each 15 x 15 cm) in all months, except in July 1996 and July 1997, In the same habitat, the cross-shaped royal blue-white leg panel (two interlocking leg panels) trapped from 1.7 (not significant) to 3.0 times (highly significant) as many flies as the standard leg panel depending on the season. Significantly more flies were trapped with the cross-shaped XT panel than with the leg panel in the secondary forest compared to the primary forest. Catches of the cross-shaped XT panel on each of a series of days, correlated well with those of the leg panel on the same day, except for panels deployed in the primary forest during the hot-dry and the beginning of the cold-dry season. Catches of the cross-shaped leg panel correlated less well with the catches of the standard leg panel in the primary forest. The data presented indicate that the behavioural responses in time and space of sterile male G. austeni are influenced by the type of trapping device used. (C) 2001 Elsevier Science B.V. All rights reserved.	Int Atom Energy Agcy, Vienna, Austria; Commiss Agr Livestock & Nat Resources, Zanzibar, Tanzania	Vreysen, MJB (reprint author), Kapelstr 61, B-2490 Balen Wezel, Belgium.						BRIGHTWELL R, 1991, MED VET ENTOMOL, V5, P153, DOI 10.1111/j.1365-2915.1991.tb00536.x; Brightwell R, 1997, MED VET ENTOMOL, V11, P297, DOI 10.1111/j.1365-2915.1997.tb00410.x; BURSELL E., 1961, Proceedings of the Royal Entomological Society of London, V36, P9; CHALLIER A, 1973, Cahiers O.R.S.T.O.M. (Office de la Recherche Scientifique et Technique Outre-Mer) Serie Entomologie Medicale et Parasitologie, V11, P251; CHALLIER A, 1980, INSECT SCI APPL, V1, P77, DOI 10.1017/S1742758400000187; CHALLIER A, 1977, Cahiers O.R.S.T.O.M. (Office de la Recherche Scientifique et Technique Outre-Mer) Serie Entomologie Medicale et Parasitologie, V15, P283; Cuisance D, 1973, Rev Elev Med Vet Pays Trop, V26, P169; DRANSFIELD RD, 1982, B ENTOMOL RES, V72, P175, DOI 10.1017/S0007485300010488; DRANSFIELD RD, 1984, INSECT SCI APPL, V5, P363, DOI 10.1017/S1742758400008675; FLINT S, 1985, B ENTOMOL RES, V75, P529, DOI 10.1017/S0007485300014620; HARGROVE JW, 1990, B ENTOMOL RES, V80, P397, DOI 10.1017/S0007485300050653; HARGROVE JW, 1980, B ENTOMOL RES, V70, P571, DOI 10.1017/S0007485300007872; KYORKU CA, 1995, BENEFICIAL AFRICAN, P235; LESKINEN J, 1997, 40 METS FOR PARK SER, P103; MADUBUNYI LC, 1990, INSECT SCI APPL, V11, P309, DOI 10.1017/S1742758400012728; Mohamed-Ahmed MM, 1999, B ENTOMOL RES, V89, P177; MSANGI A, 1999, P 2 FAO IAEA SEM AFR, P119; ROBINSON AS, 1995, 33 M INT SCI COUNC T, P264; SALEH KM, 1997, 24 M INT SCI COUNC T, P438; Sokal R. R., 1995, BIOMETRY; TURNER DA, 1980, INSECT SCI APPL, V1, P9, DOI 10.1017/S1742758400000060; TURNER DA, 1985, 18 M INT SCI COUNC T, P263; VALE GA, 1978, J APPL ECOL, V15, P715, DOI 10.2307/2402770; VANETTEN J, 1981, ENTOMOL EXP APPL, V29, P209; Vreysen Marc J.B., 1999, Insect Science and its Application, V19, P99; Vreysen MJB, 2000, J ECON ENTOMOL, V93, P123, DOI 10.1603/0022-0493-93.1.123; Vreysen MJB, 2000, MED VET ENTOMOL, V14, P283, DOI 10.1046/j.1365-2915.2000.00241.x; Vreysen MJB, 1998, MED VET ENTOMOL, V12, P407, DOI 10.1046/j.1365-2915.1998.00129.x; Vreysen MJB, 1996, B ENTOMOL RES, V86, P289, DOI 10.1017/S0007485300052585; VREYSEN MJB, 1999, P 2 FAO IAEA SEM AFR, P231	30	2	2	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0001-706X			ACTA TROP	Acta Trop.	SEP 1	2001	80	1					29	37		10.1016/S0001-706X(01)00143-7				9	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	467MW	WOS:000170709200004	11495641				2019-03-26	
J	Poggensee, G; Sahebali, S; Van Marck, E; Swai, B; Krantz, I; Feldmeier, H				Poggensee, G; Sahebali, S; Van Marck, E; Swai, B; Krantz, I; Feldmeier, H			Diagnosis of genital cervical schistosomiasis: Comparison of cytological, histopathological and parasitological examination	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							LOWER REPRODUCTIVE-TRACT; HAEMATOBIUM; WOMEN	Granulomatous inflammation of the cervix uteri is a common manifestation of infection with Schistosoma haematobium. In women the cervix is the most common site of infection by S. haematobium. Three methods were used to assess the performance of three different ways of detecting schistosome eggs in cervical tissue: cytological examination of a cervical smear, histological examination of a cervical biopsy, and direct examination of cervical tissue obtained by forceps biopsy (quantitative compressed biopsy technique [QCBT]). Of 228 women studied who lived in an S. haematobium endemic area in Tanzania, 112 (49%) had schistosome eggs detected in the cervix using QCBT Histological examination detected eggs in 40 of 228 (18%). The cytological examination of cervical smears yielded only 6 positive results (3%). The median egg load in the cervical tissue of cases correctly diagnosed by histology was significantly higher than the egg load in the misclassified cases, indicating that the sensitivity of histological sectioning increases with egg density. We conclude that the QCBT is the diagnostic test of choice for schistosomiasis of the genital cervix.	Humboldt Univ, Inst Trop Med, D-14050 Berlin, Germany; Humboldt Univ, Fac Med Charite, D-14050 Berlin, Germany; Univ Antwerp, Dept Pathol, B-2020 Antwerp, Belgium; Tumaini Univ, Kilimanjaro Christian Med Coll, Dept Pathol, Moshi, Tanzania; Skaraborg Inst Res & Dev, Skovde, Sweden; Free Univ Berlin, Fac Med, D-1000 Berlin, Germany	Poggensee, G (reprint author), Humboldt Univ, Inst Trop Med, Spandauer Damm 130, D-14050 Berlin, Germany.	gabriele.poggensee@charite.de					BADRAN A, 1955, AM J TROP MED HYG, V4, P1068, DOI 10.4269/ajtmh.1955.4.1068; BELLINGHAM FR, 1972, NZ J OBSTET GYNAECOL, V12, P267; BERRY A, 1971, ACTA CYTOL, V15, P482; BERRY A, 1976, ACTA CYTOL, V20, P361; BERRY A, 1966, J PATHOL BACTERIOL, V91, P325, DOI 10.1002/path.1700910206; BLAND K G, 1970, Journal of Obstetrics and Gynaecology of the British Commonwealth, V77, P1127; BULLOUGH CHW, 1976, BRIT J OBSTET GYNAEC, V83, P819, DOI 10.1111/j.1471-0528.1976.tb00751.x; CAMAIN ROBERT, 1953, BULL SOC PATH EXOT, V46, P412; Diouf B, 1973, Bull Soc Med Afr Noire Lang Fr, V18, P517; EDINGTON GM, 1975, T ROY SOC TROP MED H, V69, P153, DOI 10.1016/0035-9203(75)90027-9; ELLING D, 1988, ZBL GYNAKOL, V110, P671; FELDMEIER H, 1981, TROPMED PARASITOL, V32, P209; GELFAND M, 1953, T ROY SOC TROP MED H, V47, P218, DOI 10.1016/0035-9203(53)90006-6; HellingGiese G, 1996, ACTA TROP, V62, P257, DOI 10.1016/S0001-706X(96)00027-7; Kjetland EF, 1996, ACTA TROP, V62, P239, DOI 10.1016/S0001-706X(96)00026-5; KOLLER AB, 1975, S AFR MED J, V49, P1228; Leutscher P, 1998, TROP MED INT HEALTH, V3, P327, DOI 10.1046/j.1365-3156.1998.00230.x; MAUNOURY V, 1990, GASTROEN CLIN BIOL, V14, P1032; Poggensee G, 1998, AM J TROP MED HYG, V59, P782, DOI 10.4269/ajtmh.1998.59.782; Poggensee G, 2000, J INFECT DIS, V181, P1210, DOI 10.1086/315345; RENAUD G, 1989, T ROY SOC TROP MED H, V83, P797, DOI 10.1016/0035-9203(89)90333-7; Richter J, 1996, ACTA TROP, V62, P289, DOI 10.1016/S0001-706X(96)00030-7; SCHWARTZ DA, 1984, GYNECOL ONCOL, V19, P365, DOI 10.1016/0090-8258(84)90205-1; SHARMA SD, 1970, ACTA CYTOL, V14, P305; SHENNAN DW, 1971, T ROY SOC TROP MED H, V65, P95, DOI 10.1016/0035-9203(71)90191-X; SWART PJ, 1987, S AFR MED J, V72, P631; WRIGHT ED, 1982, T ROY SOC TROP MED H, V76, P822, DOI 10.1016/0035-9203(82)90118-3; YOUSSEF A F, 1970, Journal of Obstetrics and Gynaecology of the British Commonwealth, V77, P847	28	26	27	0	2	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637	1476-1645		AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	SEP	2001	65	3					233	236		10.4269/ajtmh.2001.65.233				4	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	471MP	WOS:000170933400014	11561710	Bronze			2019-03-26	
J	Varandas, L; Julien, M; Gomes, A; Rodrigues, P; Van Lerberghe, W; Malveiro, F; Aguiar, P; Kolsteren, P; Van der Stuyft, P; Hilderbrand, K; Labadarios, D; Ferrinho, P				Varandas, L; Julien, M; Gomes, A; Rodrigues, P; Van Lerberghe, W; Malveiro, F; Aguiar, P; Kolsteren, P; Van der Stuyft, P; Hilderbrand, K; Labadarios, D; Ferrinho, P			A randomised, double-blind, placebo-controlled clinical trial of vitamin A in severe malaria in hospitalised Mozambican children	ANNALS OF TROPICAL PAEDIATRICS			English	Article							RESPIRATORY-TRACT INFECTIONS; POLYMERASE CHAIN-REACTION; PAPUA-NEW-GUINEA; CEREBRAL MALARIA; PLASMODIUM-FALCIPARUM; AFRICAN CHILDREN; MALAWIAN CHILDREN; INTRAVENOUS QUININE; ALPHA-TOCOPHEROL; RISK-FACTORS	This paper reports a randomised, double-blind, placebo-controlled clinical trial of the effect of routine vitamin A supplementation given on admission to children with severe malaria with regard to survival, recovery during hospitalisation and outcome 6 weeks after discharge. Children aged between 6 and 72 months admitted to the paediatric wards of the Central Hospital of Maputo (CHM), Mozambique with a diagnosis of severe malaria were randomly assigned either to a control group (placebo) or an experimental group (vitamin A) and were followed up 6 weeks after discharge. There were 280 children in the experimental and 290 in the placebo group. Seven (2.5%) and 13 (4.5%) children died in the experimental and the placebo groups, respectively, a relative risk of death of 0.56 (95% CI 0.23-1.38, p=0.201). During the 1st 5 hours of admission, the relative risk of death in the vitamin A-supplemented group was 2.54 (0.50-12.96); after 5 hours of admission it was 0.19 (95% CI 0.04-0.85; P=0.015). In the supplemented group, 4/82 (4.9%) of the children developed neurological sequelae vs 2/78 (2.6%) in the placebo group (RR = 1.90; 95% CI 0.36-10.09; P=0.682). Although the overall reduction in the risk of death observed for all children receiving vitamin A is not statistically significant, it might be clinically important. This finding cannot, however, be accepted as a firm conclusion and requires validation by future trials.	Univ Nova Lisboa, Inst Hyg & Trop Med, Hlth Syst Unit, P-1349008 Lisbon, Portugal; Univ Nova Lisboa, Inst Hyg & Trop Med, Ctr Malaria & Other Trop Dis, Epidemiol & Biostat Unit, P-1349008 Lisbon, Portugal; Univ Nova Lisboa, Garcia de Orta Assoc Dev & Cooperat, P-1349008 Lisbon, Portugal; Eduardo Mondlane Univ, Fac Med, Maputo, Mozambique; Maputo Cent Hosp, Maputo, Mozambique; Minist Hlth, Maputo, Mozambique; Inst Trop Med Prince Leopold, Dept Publ Hlth, B-2000 Antwerp, Belgium; Univ Stellenbosch, Fac Med, Dept Human Nutr, ZA-7505 Tygerberg, South Africa	Varandas, L (reprint author), Univ Nova Lisboa, Inst Hyg & Trop Med, Hlth Syst Unit, Rua Junqueira 96, P-1349008 Lisbon, Portugal.	varan-das@ihmt.unl.pt	Ferrinho, Paulo/J-2835-2012; AGUIAR, PEDRO/B-2662-2013	Ferrinho, Paulo/0000-0002-3722-0803; AGUIAR, PEDRO/0000-0002-0074-7732; Varandas, Luis/0000-0002-8419-6033; Van Lerberghe, Wim/0000-0001-9966-6563			Adelekan DA, 1997, ANN TROP PAEDIATR, V17, P223, DOI 10.1080/02724936.1997.11747890; Bernheimer L. P., 1986, ADV SPECIAL ED, V5, P61; BINKA FN, 1995, AM J CLIN NUTR, V61, P853; BONDI FS, 1992, T ROY SOC TROP MED H, V86, P17, DOI 10.1016/0035-9203(92)90420-H; BREWSTER DR, 1990, LANCET, V336, P1039, DOI 10.1016/0140-6736(90)92498-7; CARME B, 1993, AM J TROP MED HYG, V48, P216, DOI 10.4269/ajtmh.1993.48.216; CATIGNANI GL, 1983, CLIN CHEM, V29, P708; COUTSOUDIS A, 1991, AM J CLIN NUTR, V54, P890; Das BS, 1996, AM J CLIN NUTR, V64, P94; DAVIS TM, 1998, ACTA TROP, V62, P99; Gellert S, 1998, J TROP PEDIATRICS, V44, P109, DOI 10.1093/tropej/44.2.109; GREENBERG AE, 1989, B WORLD HEALTH ORGAN, V67, P189; Hien TT, 1996, NEW ENGL J MED, V335, P76, DOI 10.1056/NEJM199607113350202; HUSSEY GD, 1990, NEW ENGL J MED, V323, P160, DOI 10.1056/NEJM199007193230304; Julien M, 1995, J TROP PEDIATRICS, V41, P366, DOI 10.1093/tropej/41.6.366; Julien MR, 1999, TROP MED INT HEALTH, V4, P794, DOI 10.1046/j.1365-3156.1999.00493.x; JULIEN MR, 1993, IVACG 15 M AR TANZ 8; KJOLHEDE CL, 1995, J PEDIATR-US, V126, P807, DOI 10.1016/S0022-3476(95)70416-7; KRISHNAN S, 1976, J NUTR, V106, P784; Lackritz EM, 1997, AIDS, V11, P1487, DOI 10.1097/00002030-199712000-00013; MAIER J, 1995, EUR C TROP MED HAMB; MARSH K, 1995, NEW ENGL J MED, V332, P1399, DOI 10.1056/NEJM199505253322102; Marsh K, 1998, LANCET, V352, P924, DOI 10.1016/S0140-6736(05)61510-3; MILTON RC, 1987, AM J CLIN NUTR, V46, P827; MOLYNEUX ME, 1989, Q J MED, V71, P441; Nacul LC, 1997, BRIT MED J, V315, P505, DOI 10.1136/bmj.315.7107.505; Nkhoma WAC, 1999, ANN TROP MED PARASIT, V93, P231, DOI 10.1080/00034983.1999.11813418; OJWANO A, 1998, E AFR MED J, V75, P450; POCOCK SJ, 1990, CLIN TRIALS PRACTICA; ROSS DA, 1993, LANCET, V342, P7, DOI 10.1016/0140-6736(93)91879-Q; SANTOS NT, 1974, REV CIENC MED, V17, P162; SCHAPIRA A, 1993, T ROY SOC TROP MED H, V87, P299, DOI 10.1016/0035-9203(93)90136-E; Schellenberg D, 1999, AM J TROP MED HYG, V61, P431, DOI 10.4269/ajtmh.1999.61.431; SCHMUTZHARD E, 1984, T ROY SOC TROP MED H, V78, P351, DOI 10.1016/0035-9203(84)90118-4; Seaton RA, 1998, ANN TROP MED PARASIT, V92, P133, DOI 10.1080/00034983.1998.11813272; Semba RD, 1998, NUTR REV, V56, pS38, DOI 10.1111/j.1753-4887.1998.tb01643.x; Shankar AH, 1999, LANCET, V354, P203, DOI 10.1016/S0140-6736(98)08293-2; SHANKAR AH, 1995, AM J CLIN NUTR, V62, P842; SIMPSON D, 1982, LANCET, V2, P450; Skinner-Adams T, 1999, T ROY SOC TROP MED H, V93, P550, DOI 10.1016/S0035-9203(99)90378-4; SNOUNOU G, 1993, MOL BIOCHEM PARASIT, V61, P315, DOI 10.1016/0166-6851(93)90077-B; SNOUNOU G, 1993, MOL BIOCHEM PARASIT, V58, P283, DOI 10.1016/0166-6851(93)90050-8; Snow RW, 1999, B WORLD HEALTH ORGAN, V77, P624; SOMMER A, 1984, AM J CLIN NUTR, V40, P1090; SOMMER A, 1983, LANCET, V2, P585; Sommer A, 1996, VITAMIN A DEFICIENCY; STOLTZFUS RJ, 1989, J NUTR, V119, P2030; TAYLOR TE, 1993, LANCET, V341, P661, DOI 10.1016/0140-6736(93)90423-E; vanHensbroek MB, 1996, NEW ENGL J MED, V335, P69, DOI 10.1056/NEJM199607113350201; WALKER O, 1992, T ROY SOC TROP MED H, V86, P491, DOI 10.1016/0035-9203(92)90082-N; WALLER D, 1995, CLIN INFECT DIS, V21, P577, DOI 10.1093/clinids/21.3.577; WHO, 1976, WHO TECHN REP SER, P1; World Health Organization, 1990, T R SOC TROP MED S2, V84, P1, DOI DOI 10.1016/0035-9203(90)90363-J; World Health Organization [ WHO], 1995, GLOB PREV VIT A DEF; Zucker JR, 1996, AM J TROP MED HYG, V55, P655, DOI 10.4269/ajtmh.1996.55.655	55	17	17	0	0	MANEY PUBLISHING	LEEDS	STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND	0272-4936	1465-3281		ANN TROP PAEDIATR	Ann. Trop. Paediatr.	SEP	2001	21	3					211	222		10.1080/02724930120077781				12	Pediatrics; Tropical Medicine	Pediatrics; Tropical Medicine	475UA	WOS:000171185200005	11579859				2019-03-26	
J	Lechat, MF				Lechat, MF			Acceptance of WHO/MDT over the last 20 years	INTERNATIONAL JOURNAL OF LEPROSY AND OTHER MYCOBACTERIAL DISEASES			English	Editorial Material									Louisiana State Univ, Gillis W Long Hansens Dis Ctr, Baton Rouge, LA 70894 USA	Lechat, MF (reprint author), 109 Rue Trois Tilleuis, B-1170 Brussels, Belgium.							0	0	0	0	0	INT JOURNAL LEPROSY	GREENVILLE	BUSINESS & CIRCULATION OFFICE, 1 ALM WAY, GREENVILLE, SC 29601-9999 USA	0148-916X			INT J LEPROSY	Int. J. Lepr. Other Mycobact. Dis.	SEP	2001	69	3					241	246						6	Microbiology; Pathology; Tropical Medicine	Microbiology; Pathology; Tropical Medicine	525GK	WOS:000174060400009	11875769				2019-03-26	
J	Carneiro, MAS; Martins, RMB; Teles, SA; Silva, SA; Lopes, CL; Cardoso, DDP; Vanderborght, BOM; Yoshida, CFT				Carneiro, MAS; Martins, RMB; Teles, SA; Silva, SA; Lopes, CL; Cardoso, DDP; Vanderborght, BOM; Yoshida, CFT			Hepatitis C prevalence and risk factors in hemodialysis patients in Central Brazil: a survey by polymerase chain reaction and serological methods	MEMORIAS DO INSTITUTO OSWALDO CRUZ			English	Article						hepatitis C; hemodialysis; prevalence; risk factors; Central Brazil	VIRUS-INFECTION; HCV-RNA; UNITS	An hemodialysis population in Central Brazil was screened by polymerase chain reaction (PCR) and serological methods to assess the prevalence of hepatitis C virus (HCV) infection and to investigate associated risk factors. All hemodialysis patients (n=428) were interviewed in eight dialysis units in Goiania city. Blood samples were collected and serum samples screened for anti-HCV antibodies by an enzyme-linked immunosorbent assay (ELISA). Positive samples were retested,for confirmation with a line immunoassay (LIA). All samples were also tested for HCV RNA by the PCR. An overall prevalence of 46.7% (CI 95%: 42-51.5) was found, ranging from 20.7% (CI 95%: 8.8-38.1) to 90.4% (CI 95%: 79.9-96.4) depending on the dialysis unit. Of the 428 patients, 185 were found to be seropositive by ELISA, and 167 were confirmed positive by LIA, resulting in an anti-HCV prevalence of 39%. A total of 131 patients were HCV RNA-positive. HCV viremia was present in 63.5% of the anti-HCV-positive,patients and in 10.3% of the anti-HCV-negative patients. Univariate analysis of risk factors showed that the number of previous blood transfusions, transfusion of blood before mandatory screening for anti-HCV, length of itme on hemodialysis, and treatment in multiple units were associated with HCV positivity. However, multivariate analysis revealed that blood transfusion before screening for anti-HCV and length of time on hemodialysis were significantly associated with HCV infection in this population. These data suggest that nosocomial transmission may playa role in the spread of HCV in the dialysis units studied. In addition to anti-HCV screening, HCV RNA detection is necessary for the diagnosis of HCV infection in hemodialysis patients.	Univ Fed Goias, Inst Patol Trop & Saude Publ, Virol Lab, BR-74605050 Goiania, Go, Brazil; Univ Fed Rio de Janeiro, Hosp Univ Climentino Fraga Filho, Rio De Janeiro, Brazil; Innogenet NV, Ghent, Belgium; Inst Oswaldo Cruz, Dept Virol, BR-20001 Rio De Janeiro, Brazil	Martins, RMB (reprint author), Univ Fed Goias, Inst Patol Trop & Saude Publ, Virol Lab, Caixa Postal 131, BR-74605050 Goiania, Go, Brazil.		Teles, Sheila/D-8837-2015	Teles, Sheila/0000-0003-4030-6947; TELES, SHEILA/0000-0002-7059-4241			BUKH J, 1993, J INFECT DIS, V168, P1343, DOI 10.1093/infdis/168.6.1343; Caramelo C, 1996, KIDNEY INT, V50, P2027, DOI 10.1038/ki.1996.525; Fabrizi F, 1999, AM J NEPHROL, V19, P383, DOI 10.1159/000013482; Ginabreda MGP, 1997, BRAZ J MED BIOL RES, V30, P339; GOLDBLUM SE, 1980, ANN INTERN MED, V93, P597, DOI 10.7326/0003-4819-93-4-597; GONGORA DVN, 1998, REV SOC BRAS MED TRO, V31, P585; Grethe S, 2000, J MED VIROL, V60, P152, DOI 10.1002/(SICI)1096-9071(200002)60:2<152::AID-JMV8>3.0.CO;2-I; KAROHL C, 1995, J BRAS NEFROL, V17, P40; LAMBALLERIE X, 1996, J MED VIROL, V49, P296; Martins R. M. B., 1994, Revista do Instituto de Medicina Tropical de Sao Paulo, V36, P501, DOI 10.1590/S0036-46651994000600005; MARTINS RMB, 1995, MEM I OSWALDO CRUZ, V90, P11, DOI 10.1590/S0074-02761995000100004; Masuko K, 1994, J Viral Hepat, V1, P65, DOI 10.1111/j.1365-2893.1994.tb00063.x; Naghettini A V, 1997, Rev Soc Bras Med Trop, V30, P113; OLMER M, 1996, CLIN NEPHROL, V47, P263; Pujol FH, 1996, J CLIN MICROBIOL, V34, P1633; SAMPIETRO M, 1995, KIDNEY INT, V47, P911, DOI 10.1038/ki.1995.136; Sandhu J, 1999, AM J EPIDEMIOL, V150, P58; Schneeberger PM, 1998, J CLIN MICROBIOL, V36, P1711; Schroter M, 1997, INTERVIROLOGY, V40, P277, DOI 10.1159/000150558; Scotto V, 1999, EUR J EPIDEMIOL, V15, P217, DOI 10.1023/A:1007552226361; SEELIG R, 1994, ANN MED, V26, P45, DOI 10.3109/07853899409147326; Soetjipto, 1996, J CLIN MICROBIOL, V34, P2875; Umlauft F, 1997, AM J GASTROENTEROL, V92, P73; Vanderborght B. O. M., 1995, Revista do Instituto de Medicina Tropical de Sao Paulo, V37, P75	24	55	65	1	4	FUNDACO OSWALDO CRUZ	RIO DE JANEIRO, RJ	AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL	0074-0276			MEM I OSWALDO CRUZ	Mem. Inst. Oswaldo Cruz	AUG	2001	96	6					765	769		10.1590/S0074-02762001000600003				5	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	461JT	WOS:000170361700003	11562698	DOAJ Gold			2019-03-26	
J	Chatterjee, S; Van Marck, E				Chatterjee, S; Van Marck, E			The role of somatostatin in schistosomiasis: a basis for immunomodulation in host-parasite interactions?	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						schistosomiasis; somatostatin; fibrosis	MANSONI INFECTION; KUPFFER CELLS; OCTREOTIDE; GRANULOMAS; RECEPTORS; SECRETION; FIBROSIS	This review explores the possible modulatory role of the neuropeptide somatostatin in the outcome of Schistosoma-caused morbidity in man. Somatostatin could play an important role in Schistosoma mansoni-man interactions via its influence on intersystem signalling; therapeutically, via its direct effect on Schistosoma-caused morbidity (fibrosis, granuloma size, portal hypertension, variceal bleeding); and via immunomodulation of Schistosoma-induced inflammatory responses in the liver and intestines. In schistosomiasis-endemic regions two interesting patterns of infection emerge. First, the intensity of infection is higher in children than in adults; secondly, at any given time, only a fraction of Schistosoma-infected individuals develop Symmer's pipe-stem fibrosis. These morbidity patterns cannot be explained on the basis of acquired immunity alone. Somatostatin has an inhibitory effect on hormone, immune and physiological body functions like growth hormone secretion, Interferon (IFN) gamma production, collagen I and III formation and hepatic stellate cell activation. Levels of somatostatin secreted endogenously by man upon the onset of Schistosoma infection may be one factor regulating the activity of the above, and thereby fibrosis in the host. The neuropeptide hormone somatostatin may determine pre-disposition to Schistosoma-caused morbidity.	Univ Instelling Antwerp, Dept Med, Pathol Unit, B-2610 Wilrijk, Belgium	Chatterjee, S (reprint author), Univ Instelling Antwerp, Dept Med, Pathol Unit, Univ Plein 1, B-2610 Wilrijk, Belgium.						Avgerinos A, 1997, LANCET, V350, P1495, DOI 10.1016/S0140-6736(97)05099-X; BLOOM SR, 1987, BRIT MED J, V295, P288, DOI 10.1136/bmj.295.6593.288; BLUM AM, 1992, J IMMUNOL, V149, P3621; BRAZEAU P, 1973, SCIENCE, V179, P77, DOI 10.1126/science.179.4068.77; Chao TC, 1999, REGUL PEPTIDES, V79, P117, DOI 10.1016/S0167-0115(98)00150-5; Chao TC, 1997, REGUL PEPTIDES, V69, P143, DOI 10.1016/S0167-0115(97)00008-6; Chen M. G., 1988, Tropical Diseases Bulletin, V85, pR1; Dessein AJ, 1999, AM J HUM GENET, V65, P709, DOI 10.1086/302526; ELLIOTT DE, 1994, J IMMUNOL, V153, P1180; Elliott DE, 1999, EUR J IMMUNOL, V29, P2454, DOI 10.1002/(SICI)1521-4141(199908)29:08<2454::AID-IMMU2454>3.0.CO;2-H; ELLIOTT DE, 1996, METABOLISM S1, V45, pS88; FEVERY J, 1997, RES CLIN FORUMS, V19, P7; GRESSNER AM, 1995, J HEPATOL, V22, P28; JACOBS W, 1998, THESIS U ANTWERP ANT; Kardorff R, 1996, AM J TROP MED HYG, V54, P586; Mansy SS, 1998, ARZNEIMITTEL-FORSCH, V48, P855; REICHLIN S, 1983, NEW ENGL J MED, V309, P1495, DOI 10.1056/NEJM198312153092406; Reynaert H, 1999, HEPATOLOGY, V30, p236A; REYNAERT H, 2000, IN PRESS EFFECT SOMA; SCARPIGNATO C, 1999, DIGESTION S3, V60, pS1; SCHUSDZIARRA V, 1996, PROGR BASIC CLIN PHA, V10, P35; Symmers WSC, 1904, J PATHOL BACTERIOL, V9, P237, DOI 10.1002/path.1700090211; ten Bokum AMC, 2000, EUR CYTOKINE NETW, V11, P161; Weinstock JV, 1998, ANN NY ACAD SCI, V840, P532, DOI 10.1111/j.1749-6632.1998.tb09592.x; Weinstock JV, 2000, EUR J ENDOCRINOL, V143, pS15, DOI 10.1530/eje.0.143S015; WEINSTOCK JV, 1990, CELL IMMUNOL, V131, P381, DOI 10.1016/0008-8749(90)90262-P; WYLER DJ, 1992, MEM I OSWALDO CRUZ, V87, P117, DOI 10.1590/S0074-02761992000800017; WYLER DJ, 1992, PARASITOL TODAY, V8, P277, DOI 10.1016/0169-4758(92)90145-R	28	11	12	0	2	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	AUG	2001	6	8					578	581		10.1046/j.1365-3156.2001.00758.x				4	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	469DC	WOS:000170797600002	11555424	Bronze			2019-03-26	
J	Polman, K; Stelma, FF; De Vlas, SJ; Sow, S; Fathers, L; Le Cessie, S; Talla, I; Deelder, AM; Gryseels, B				Polman, K; Stelma, FF; De Vlas, SJ; Sow, S; Fathers, L; Le Cessie, S; Talla, I; Deelder, AM; Gryseels, B			Dynamics of egg counts and circulating antigen levels in a recent Schistosoma mansoni focus in northern Senegal	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						Schistosoma mansoni; circulating anodic antigen (CAA); faecal egg counts; seasonality; worm longevity; Senegal	RECENTLY EXPOSED COMMUNITY; ANODIC ANTIGEN; INTESTINAL SCHISTOSOMIASIS; WORM BURDEN; RIVER BASIN; EPIDEMIOLOGY; INFECTIONS; SERUM	Serum circulating anodic antigen (CAA) levels were compared with faecal egg counts in four subsequent population samples, randomly selected at 8-month intervals, in a recent Schistosoma mansoni focus in northern Senegal. In all four samples, antigen levels showed the same age-intensity profiles as egg counts, with a strong decline in adults. Also across population samples, a consistent relationship was found between egg counts and antigen levels. Assuming the level of CAA to be a direct reflection of worm burden, these findings support the idea that the observed egg count patterns and levels indeed reflect dynamics of worm burdens, and not of egg excretion or worm fecundity. Remarkably similar levels of both egg counts and CAA were observed in the first and last sample, collected in the same season (August-Septemher), hut 2 years apart. This suggests that a steady state of S. mansoni infection had already been reached shortly after the onset of the epidemic in this focus (3 years). Significantly lower infection levels were found in the intermediate population samples collected in January and April. The differences in infection levels across the four population samples may be because of seasonal transmission patterns. They would indicate a substantial turnover of worm populations, with an estimated average life span of only 7 months, probably less, in this recently emerged, intense S. mansoni focus.	Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium; Univ Maastricht, Dept Epidemiol, Maastricht, Netherlands; Erasmus Univ, Dept Publ Hlth, Rotterdam, Netherlands; Reg Med St Louis, St Louis, Senegal; Leiden Univ, Dept Med Stat, Med Ctr, Leiden, Netherlands; Leiden Univ, Dept Parasitol, Med Ctr, Leiden, Netherlands	Polman, K (reprint author), Inst Trop Med Prince Leopold, Natl St 155, B-2000 Antwerp, Belgium.						AGNEW A, 1995, PARASITOLOGY, V111, P67, DOI 10.1017/S0031182000064611; Anderson RM, 1991, INFECT DIS HUMANS DY; DeBont J, 1996, PARASITOLOGY, V113, P465, DOI 10.1017/S0031182000081531; DEELDER AM, 1989, AM J TROP MED HYG, V40, P268, DOI 10.4269/ajtmh.1989.40.268; DEELDER AM, 1994, TROPICAL GEOGRAPHICA, V46, P235; DEVLAS SJ, 1993, PARASITOL TODAY, V9, P305; FULFORD AJC, 1995, PARASITOLOGY, V110, P307, DOI 10.1017/S0031182000080896; GODDARD MJ, 1980, T ROY SOC TROP MED H, V74, P185, DOI 10.1016/0035-9203(80)90240-0; GRYSEELS B, 1994, TROP GEOGR MED, V46, P209; HALL A, 1982, PARASITOLOGY, V85, P605, DOI 10.1017/S0031182000056389; HIATT RA, 1980, AM J TROP MED HYG, V29, P1228, DOI 10.4269/ajtmh.1980.29.1228; Katz N, 1972, Rev Inst Med Trop Sao Paulo, V14, P397; POLDERMAN AM, 1985, ANN SOC BELG MED TR, V65, P243; POLMAN K, 1995, AM J TROP MED HYG, V53, P152, DOI 10.4269/ajtmh.1995.53.152; Polman K, 2001, PARASITOLOGY, V122, P161, DOI 10.1017/S0031182001007193; SCOTT JA, 1937, AM J HYG, V27, P176; STELMA FF, 1993, AM J TROP MED HYG, V49, P701, DOI 10.4269/ajtmh.1993.49.701; TALLA I, 1992, T ROY SOC TROP MED H, V86, P182, DOI 10.1016/0035-9203(92)90562-Q; TALLA I, 1990, ANN SOC BELG MED TR, V70, P173; TEESDALE CH, 1985, T ROY SOC TROP MED H, V79, P369, DOI 10.1016/0035-9203(85)90384-0; Van Lieshout L, 1998, T ROY SOC TROP MED H, V92, P115, DOI 10.1016/S0035-9203(98)90980-4; VANLIESHOUT L, 1995, J INFECT DIS, V172, P1336, DOI 10.1093/infdis/172.5.1336; VERMUND SH, 1983, AM J TROP MED HYG, V32, P1040, DOI 10.4269/ajtmh.1983.32.1040; WARREN KS, 1974, AM J TROP MED HYG, V23, P902, DOI 10.4269/ajtmh.1974.23.902	24	8	8	0	3	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	JUL	2001	6	7					538	544		10.1046/j.1365-3156.2001.00742.x				7	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	455AR	WOS:000170005800009	11469948	Bronze			2019-03-26	
J	Declereq, E				Declereq, E			Prevalence: a valid indicator for monitoring leprosy - "Elimination"?	INTERNATIONAL JOURNAL OF LEPROSY AND OTHER MYCOBACTERIAL DISEASES			English	Editorial Material										Declereq, E (reprint author), Blvd Leopold II 263, B-1081 Brussels, Belgium.						*BUR NAT LEPR, 1999, PROGR EL LEPR RAPP E; Enarson D.A., 2000, MANAGEMENT TUBERCULO; Lechat M F, 2000, Indian J Lepr, V72, P169; *WHO, 2000, WKLY EPIDEMIOL REC, V75, P226; *WHO, 1998, WEEKLY EPIDEMIOLOGIC, V73, P177; *WHO, 2000, GUID EL LEPR PUBL HL	6	3	4	0	0	INT JOURNAL LEPROSY	GREENVILLE	BUSINESS & CIRCULATION OFFICE, 1 ALM WAY, GREENVILLE, SC 29601-9999 USA	0148-916X			INT J LEPROSY	Int. J. Lepr. Other Mycobact. Dis.	JUN	2001	69	2					111	113						3	Microbiology; Pathology; Tropical Medicine	Microbiology; Pathology; Tropical Medicine	494BB	WOS:000172257400005	11757167				2019-03-26	
J	Chemlal, K; De Ridder, K; Fonteyne, PA; Meyers, WM; Swings, J; Portaels, E				Chemlal, K; De Ridder, K; Fonteyne, PA; Meyers, WM; Swings, J; Portaels, E			The use of IS2404 restriction fragment length polymorphisms suggests the diversity of Mycobacterium ulcerans from different geographical areas	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							INFECTION; DISEASE; IDENTIFICATION; PCR	Buruli ulcer, caused by Mycobacterium ulcerans, has been reported in five continents: Africa, Asia, Australia, and North and South America. In the present study, restriction fragment length polymorphism with the recently described M. ulcerans specific insertion sequence IS2404 as a probe, was applied to Mycobacterium shinshuense, Mycobacterium marinum. and 14 clinical M. ulcerans isolates originating from six geographic areas: Africa (n = 6), Australia (n = 2), Mexico (n = 1), south Asia (n = 2), Asia (n = 1), and South America (n = 2). Using this probe, six subtypes of M. ulcerans, related to the six geographic origins of the isolates were distinguished, confirming that M. ulcerans can be divided into subgroups corresponding to different geographic variants of the same species.	Inst Trop Med, Dept Microbiol, Div Mycobacteriol, B-2000 Antwerp, Belgium; State Univ Ghent, Microbiol Lab, B-9000 Ghent, Belgium; Armed Forces Inst Pathol, Washington, DC 20306 USA	Chemlal, K (reprint author), Inst Trop Med, Dept Microbiol, Div Mycobacteriol, B-2000 Antwerp, Belgium.						CHRISTIE M, 1987, MED J AUSTRALIA, V146, P600; Faber WR, 2000, T ROY SOC TROP MED H, V94, P277, DOI 10.1016/S0035-9203(00)90320-1; Guimaraes-Peres A, 1999, J CLIN MICROBIOL, V37, P206; JACKSON K, 1995, J CLIN MICROBIOL, V33, P2250; JOHNSON PDR, 1995, MED J AUSTRALIA, V162, P221, DOI 10.5694/j.1326-5377.1995.tb126034.x; JOSSE R, 1994, B SOC PATHOL EXOT, V87, P170; MACCALLUM P, 1948, J PATHOL BACTERIOL, V60, P93, DOI 10.1002/path.1700600111; MARSTON BJ, 1995, AM J TROP MED HYG, V52, P219, DOI 10.4269/ajtmh.1995.52.219; Palomino JC, 1998, J CLIN MICROBIOL, V36, P3420; PETTIT JHS, 1966, BRIT J DERMATOL, V78, P187, DOI 10.1111/j.1365-2133.1966.tb12204.x; Portaels F, 1999, LANCET, V353, P986, DOI 10.1016/S0140-6736(98)05177-0; PORTAELS F, 1995, CLIN DERMATOL, V13, P207, DOI 10.1016/0738-081X(95)00004-Y; Portaels F, 1996, J CLIN MICROBIOL, V34, P962; Ross BC, 1997, APPL ENVIRON MICROB, V63, P4135; Stinear T, 1999, J CLIN MICROBIOL, V37, P1018; Stinear T, 2000, J CLIN MICROBIOL, V38, P1482; TSUKAMURA M, 1982, MICROBIOL IMMUNOL, V26, P951, DOI 10.1111/j.1348-0421.1982.tb00241.x; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406	18	31	31	0	0	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	MAY-JUN	2001	64	5-6					270	273		10.4269/ajtmh.2001.64.270				4	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	453NH	WOS:000169921600009	11463115	Bronze			2019-03-26	
J	Tchuente, LAT; Southgate, VR; Webster, BL; De Bont, J; Vercruysse, J				Tchuente, LAT; Southgate, VR; Webster, BL; De Bont, J; Vercruysse, J			Impact of installation of a water pump on schistosomiasis transmission in a focus in Cameroon	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						schistosomiasis; Schistosoma haematobium; Schistosoma intercalatum; prevalence; transmission; Bulinus forskalii; water-supply; Cameroon	INTERCALATUM; HAEMATOBIUM; HYBRID; LOUM		Nat Hist Museum, Dept Zool, London SW7 5BD, England; Univ Yaounde, Fac Sci, Lab Biol Gen, Yaounde, Cameroon; Ctr Schistosomiasis & Parasitol, Yaounde, Cameroon; Inst Pasteur, INSERM, U167, F-59019 Lille, France; State Univ Ghent, Fac Vet Med, Dept Parasitol, B-9820 Merelbeke, Belgium	De Bont, J (reprint author), Nat Hist Museum, Dept Zool, Cromwell Rd, London SW7 5BD, England.			Webster, Bonnie/0000-0003-0930-9314			AKUFONGWE PF, 1995, J HELMINTHOL, V69, P103, DOI 10.1017/S0022149X00013973; RATARD RC, 1991, AM J TROP MED HYG, V45, P332, DOI 10.4269/ajtmh.1991.45.332; SOUTHGATE VR, 1976, Z PARASITENKD, V49, P145, DOI 10.1007/BF00382422; Tchuente LAT, 1997, T ROY SOC TROP MED H, V91, P664, DOI 10.1016/S0035-9203(97)90513-7; 1988, AFRICAN SCHISTOSOME, P4	5	10	10	0	3	ROYAL SOC TROPICAL MEDICINE	LONDON	MANSON HOUSE 26 PORTLAND PLACE, LONDON W1N 1EY, ENGLAND	0035-9203			T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	MAY-JUN	2001	95	3					255	256		10.1016/S0035-9203(01)90228-7				2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	460DG	WOS:000170290100005	11490991				2019-03-26	
J	Picot, N; Le Mener, V; Rotivel, Y; Schonfeld, C; Cetre, JC; Costy, F; Grillet, JP; Lanta, N; Lang, J				Picot, N; Le Mener, V; Rotivel, Y; Schonfeld, C; Cetre, JC; Costy, F; Grillet, JP; Lanta, N; Lang, J			Booster effect of a new chromatographically purified Vero-cell rabies vaccine (CPRV): immunogenicity and safety of a single or double injection	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						rabies; Vero-cell vaccine; chromatogaphically purified vaccine; booster schedules; immune response; safety; Europe	TRIAL		Aventis Pasteur, F-69367 Lyon, France; Ecole Natl Vet Toulouse, F-31076 Toulouse, France; Inst Pasteur, Ctr Natl Reference Rage, F-75724 Paris, France; Inst Trop Med, D-10179 Berlin, Germany; Ecole Natl Vet Toulouse, F-69280 Marcy LEtoile, France; Inst Pasteur Bruxelles, B-1180 Brussels, Belgium; Mutualite Sociale Agricole, F-02008 Laon, France; Ecole Natl Vet Nantes, F-44087 Nantes 3, France	Lang, J (reprint author), Aventis Pasteur, 2 Ave Pont Pasteur, F-69367 Lyon, France.						*ACIP, 1991, MMWR-MORBID MORTAL W, V40, P1; Lang J, 1998, BIOLOGICALS, V26, P299, DOI 10.1006/biol.1998.0156; Sabchareon A, 1999, CLIN INFECT DIS, V29, P141, DOI 10.1086/520143; SMITH JS, 1973, WHO MONOGR SER, V23, P354; WHO, 1996, FIGHT DIS FOST DEV; WHO Expert Committee on Rabies, 1992, WHO TECHN REP SER, V824	6	3	3	0	0	ROYAL SOC TROPICAL MEDICINE	LONDON	MANSON HOUSE 26 PORTLAND PLACE, LONDON W1N 1EY, ENGLAND	0035-9203			T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	MAY-JUN	2001	95	3					342	344		10.1016/S0035-9203(01)90262-7				3	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	460DG	WOS:000170290100027	11491012				2019-03-26	
J	D'Alessandro, U; Boelaert, M				D'Alessandro, U; Boelaert, M			The 5th Amendment of the Declaration of Helsinki: implications for medical research in developing countries	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Editorial Material						Declaration of Helsinki; medical research; research ethics	TRIALS		Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium	D'Alessandro, U (reprint author), Inst Trop Med Prince Leopold, Natl Str 155, B-2000 Antwerp, Belgium.		D'Alessandro, Umberto/D-3457-2015; Boelaert, Marleen/E-2698-2012	D'Alessandro, Umberto/0000-0001-6341-5009; Boelaert, Marleen/0000-0001-8051-6776			Aaby P, 1997, LANCET, V350, P1546, DOI 10.1016/S0140-6736(97)26047-2; BOSELEY S, 2001, GUARDIAN WEEKLY 0125, P11; *CIOMS, 1993, INT ETH GUID BIOM RE; Clarke M, 1998, LANCET, V351, P286; LURIE P, 1997, NEW ENGL J MED, V337, P883; Nuffield Council on Bioethics, 1999, ETH CLIN RES DEV COU; Ramjee G, 2000, AIDS, V14, P2553, DOI 10.1097/00002030-200011100-00018; 1999, P MIM AFR MAL C DURB; 1997, LANCET, V350, P897	9	4	4	0	0	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	APR	2001	6	4					245	247		10.1046/j.1365-3156.2001.00715.x				3	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	436XD	WOS:000168960400001	11348513				2019-03-26	
J	Lolekha, S; Tanthiphabha, W; Sornchai, P; Kosuwan, P; Sutra, S; Warachit, B; Chup-Upprakarn, S; Hutagalung, Y; Weil, J; Bock, HL				Lolekha, S; Tanthiphabha, W; Sornchai, P; Kosuwan, P; Sutra, S; Warachit, B; Chup-Upprakarn, S; Hutagalung, Y; Weil, J; Bock, HL			Effect of climatic factors and population density on varicella zoster virus epidemiology within a tropical country	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							AGE; COMPLICATIONS; SEROEPIDEMIOLOGY; PREVALENCE; INDIA	Blood samples were collected from healthy subjects, aged 9 months-29 years in urban and rural communities from 4 distinct regions in Thailand, to determine the seroprevalence rate of varicella-zoster virus (VZV) antibody and its relationship with demographic, climatic, and socioeconomic factors. The overall seroprevalence rate was 52.8% and increased from 15.5% in the 9-month to 4-year-old group to 75.9% in the 20-29 year-olds. The age adjusted seroprevalence was significantly higher in the cooler than in the warmer regions. In the warmer regions only, the age-specific seroprevalence was significantly higher in the urban population than in the rural population. In Thailand, climate is the main determinant of VZV seroprevalence. The delayed onset of natural immunity is more marked in warmer climate areas. Population density is a secondary determinant; in the warmer areas, the pattern of adolescent and adult susceptibility was greater in rural than in urban areas.	Mahidol Univ, Ramathibodi Hosp, Fac Med, Dept Pediat, Bangkok 10400, Thailand; SmithKline Beecham Biol, B-1330 Rixensart, Belgium; Had Yai Reg Hosp, Pediat Unit, Song Kla 90110, Thailand; Khon Kaen Univ, Fac Med, Dept Pediat, Khon Kaen 40002, Thailand; Chiang Mai Univ, Fac Med, Dept Pediat, Chiang Mai 50002, Thailand; Nakornping Hosp, Pediat Unit, Chiang Mai 50002, Thailand	Lolekha, S (reprint author), Mahidol Univ, Ramathibodi Hosp, Fac Med, Dept Pediat, Rama VI Rd, Bangkok 10400, Thailand.		Khon Kaen University, Faculty of Medicine/A-3133-2009				Barzaga NG, 1994, JAMA SE ASIA, V12, P633; *CENS IND POP, 1994, STAT OUTL IND 1994 1, P39; EGUILUZ GC, 1987, J INFECT DIS, V156, P851, DOI 10.1093/infdis/156.5.851; FLEISHER G, 1981, AM J DIS CHILD, V135, P896, DOI 10.1001/archpedi.1981.02130340008004; GARNETT GP, 1993, EPIDEMIOL INFECT, V110, P361, DOI 10.1017/S0950268800068308; Heath RB, 1990, PRINCIPLES PRACTICE, P43; KOSITANONT U, 1985, Southeast Asian Journal of Tropical Medicine and Public Health, V16, P414; Lee BW, 1998, TROP MED INT HEALTH, V3, P886; MANDAL BK, 1998, J INFECT DIS S1, V178, P52; Meunch R, 1986, J INFECT DIS, V153, P153; Migasena S, 1997, INT J INFECT DIS, V2, P26, DOI [DOI 10.1016/S1201-9712(97)90007-2, 10.1016/S1201-9712(97)90007-2]; *MIN PUBL HLTH, 1995, ANN EP SURV REP, P102; *MIN PUBL HLTH, 1996, ANN EP SURV REP, P85; *MIN PUBL HLTH, 1997, ANN EP SURV REP, P98; OOI P-L, 1992, Southeast Asian Journal of Tropical Medicine and Public Health, V23, P22; PREBLUD SR, 1981, PEDIATRICS, V68, P14; PREBLUD SR, 1986, PEDIATRICS, V78, P728; *PUBL COMM EP DIS, 1996, EPIDEMIOL N B, V22, P61; Singh J, 1997, J TROP PEDIATRICS, V43, P111, DOI 10.1093/tropej/43.2.111; SINHA DP, 1976, INT J EPIDEMIOL, V5, P367, DOI 10.1093/ije/5.4.367; TAYLORWIEDEMAN J, 1989, JPN J MED SCI BIOL, V42, P1; TRLIFAJOVA J, 1989, ACTA VIROL, V33, P183	22	81	86	0	6	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	MAR-APR	2001	64	3-4					131	136		10.4269/ajtmh.2001.64.131				6	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	445UA	WOS:000169475900005	11442207	Bronze			2019-03-26	
J	Declercq, E				Declercq, E			"Guide to Eliminate Leprosy as a Public Health Problem" (First edition, 2000, World Health Organization)	INTERNATIONAL JOURNAL OF LEPROSY AND OTHER MYCOBACTERIAL DISEASES			English	Letter									Damien Fdn, B-1081 Brussels, Belgium	Declercq, E (reprint author), Damien Fdn, Blvd Leopold II 263, B-1081 Brussels, Belgium.							0	1	1	0	0	INT JOURNAL LEPROSY	GREENVILLE	BUSINESS & CIRCULATION OFFICE, 1 ALM WAY, GREENVILLE, SC 29601-9999 USA	0148-916X			INT J LEPROSY	Int. J. Lepr. Other Mycobact. Dis.	MAR	2001	69	1					34	35						2	Microbiology; Pathology; Tropical Medicine	Microbiology; Pathology; Tropical Medicine	455KE	WOS:000170025400005	11480314				2019-03-26	
J	Declercq, E				Declercq, E			Guide to eliminating leprosy as a public health problem	LEPROSY REVIEW			English	Letter									Damien Fdn, B-1081 Brussels, Belgium	Declercq, E (reprint author), Damien Fdn, Blvd Leopold II 263, B-1081 Brussels, Belgium.							0	0	0	0	0	LEPRA	COLCHESTER	FAIRFAX HOUSE, CAUSTON ROAD, COLCHESTER CO1 1PU, ENGLAND	0305-7518			LEPROSY REV	Lepr. Rev.	MAR	2001	72	1					106	107						2	Dermatology; Infectious Diseases; Pathology; Tropical Medicine	Dermatology; Infectious Diseases; Pathology; Tropical Medicine	429GW	WOS:000168508800016	11355513				2019-03-26	
J	Kongs, A; Marks, G; Verle, P; Van der Stuyft, P				Kongs, A; Marks, G; Verle, P; Van der Stuyft, P			The unreliability of the Kato-Katz technique limits its usefulness for evaluating S-mansoni infections	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						Kato-Katz technique; Schistoma mansoni; stool examination; reproducibility	SCHISTOSOMA-MANSONI; RICHARD-TOLL; BURUNDI; SMEAR; SENSITIVITY; DIAGNOSIS; SENEGAL; URINE; EGGS	The Kato-Katz technique, a (semi) quantitative stool examination technique, is generally recommended for diagnosis and evaluation of Schistosoma mansoni infection by schistosome experts. However, egg counts are subject to important variability. In order to quantify the reproducibility of egg counts using the Kato-Katz technique, field data of 1255 observations on 299 subjects infected with Schistosoma mansoni were analysed. Agreement between repeated observations was assessed both categorically (kappa statistic) and continuously (analysis of variance). The day-to-day variation of egg counts was much greater than the variation due to different observers or different slides. The quantitative reproducibility was low: the weighted kappa statistic was 0.39 between specimens of different days, 0.62 between slides of the same specimen and 0.81 between observers of the same slide. Therefore the classification of individual patients into groups based on egg counts, used as a measure of morbidity, must be interpreted with great care, especially in longitudinal studies. Usefulness of the Kato-Katz technique appears limited. Its reproducibility is low. It cannot be recommended as a routine test in a primary health care setting or in a hospital laboratory because safety and detection of other parasites are better assured by other techniques. It can be used in epidemiological studies and evaluation of schistosomiasis control programmes, but here too, other techniques might be preferred.	Inst Trop Med, Dept Publ Hlth, Epidemiol Unit, B-2000 Antwerp, Belgium; Univ Sydney, Sydney, NSW 2006, Australia; Univ New S Wales, Sydney, NSW 2006, Australia; Belgian Tech Cooperat, Hanoi, Vietnam	Van der Stuyft, P (reprint author), Inst Trop Med, Dept Publ Hlth, Epidemiol Unit, Natl Str 155, B-2000 Antwerp, Belgium.						ALTMAN DG, 1983, J ROY STAT SOC D-STA, V32, P307, DOI 10.2307/2987937; ANDRADE Z A, 1985, Memorias do Instituto Oswaldo Cruz, V80, P363; [Anonymous], 1985, WHO TECHN REP SER, V728; [Anonymous], 1993, WHO TECHN REP SER, V830; BARRETO ML, 1990, T ROY SOC TROP MED H, V84, P554, DOI 10.1016/0035-9203(90)90037-F; *BSI, 1987, 5497 BSI 1; Carabin H, 2000, TROP MED INT HEALTH, V5, P192, DOI 10.1046/j.1365-3156.2000.00530.x; CHEESBROUGH M, 1991, TECHNIQUES USED IDEN, V1, P178; Cochran W. G, 1989, STAT METHODS; DEVLAS SJ, 1992, PARASITOLOGY, V104, P451, DOI 10.1017/S003118200006371X; Ebrahim A, 1997, AM J TROP MED HYG, V57, P706, DOI 10.4269/ajtmh.1997.57.706; ENGELS D, 1993, B WORLD HEALTH ORGAN, V71, P207; ENGELS D, 1997, OPERATIONAL DIAGNOSI; FELDMEIER H, 1993, ACTA TROP, V52, P205, DOI 10.1016/0001-706X(93)90009-Z; Fleiss JL, 1981, STAT METHODS RATES P; Kato K., 1954, JAPAN J PARASITOL, V3, P35; Katz N, 1972, Rev Inst Med Trop Sao Paulo, V14, P397; KNIGHT WB, 1976, AM J TROP MED HYG, V25, P818, DOI 10.4269/ajtmh.1976.25.818; Kongs A, 1996, TROP MED INT HEALTH, V1, P191; LAMBERTUCCI JR, 1993, HUMAN SCHISTOSOMIASI; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; NIELD JE, 1989, RESP MED, V83, P111, DOI 10.1016/S0954-6111(89)80224-0; PETERS PA, 1980, AM J TROP MED HYG, V29, P217, DOI 10.4269/ajtmh.1980.29.217; POLDERMAN AM, 1985, ANN SOC BELG MED TR, V65, P243; Scott JA, 1938, AM J HYG, V27, P155, DOI 10.1093/oxfordjournals.aje.a118374; SHIFF CJ, 1994, PARASITOL TODAY, V10, P494, DOI 10.1016/0169-4758(94)90164-3; TALLA I, 1992, T ROY SOC TROP MED H, V86, P182, DOI 10.1016/0035-9203(92)90562-Q; TEESDALE CH, 1985, T ROY SOC TROP MED H, V79, P369, DOI 10.1016/0035-9203(85)90384-0; UNICEF. United Nations International Children's Emergency Fund, 1988, EICEF1988PL40 UNICEF; vanEtten L, 1996, AM J TROP MED HYG, V54, P348, DOI 10.4269/ajtmh.1996.54.348; VANLIESHOUT L, 1991, AM J TROP MED HYG, V44, P323, DOI 10.4269/ajtmh.1991.44.323; WEBBE G, 1993, CONTROL HUMAN SCHIST	32	96	102	0	5	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	MAR	2001	6	3					163	169		10.1046/j.1365-3156.2001.00687.x				7	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	420LP	WOS:000168006700002	11299032	Bronze			2019-03-26	
J	Van den Bossche, P; Rowlands, GJ				Van den Bossche, P; Rowlands, GJ			The relationship between the parasitological prevalence of trypanosomal infections in cattle and herd average packed cell volume	ACTA TROPICA			English	Article; Proceedings Paper	3rd Annual Conference on New and Re-Emerging Infectious Diseases - In Honor of Norman Dion Levine	2001	UNIV ILL, DEPT VET PATHOBIOL, URBANA, ILLINOIS		UNIV ILL, DEPT VET PATHOBIOL	bovine trypanosomosis; prevalence; packed cell volume; disease impact	AFRICAN TRYPANOSOMIASIS; LIVESTOCK PRODUCTIVITY; TSETSE CONTROL; ETHIOPIA	The relationship between prevalence of trypanosomal infections (Trypanosoma congolense) and average packed cell volume (PCV) in herds of communally managed adult Angoni breed cattle was investigated in four districts of eastern Zambia. In all areas, regression analyses showed that the herd average PCV decreased with increasing prevalence of trypanosomal infections. The slope of the equation between average PCV and trypanosome prevalence decreased with increasing prevalence of trypanosomal infections. For the same increase in prevalence of trypanosomal infection, the decrease in herd PCV was higher in the areas with low to medium prevalence. Season of sampling also determined the slope of the regression equation. For the same increase in prevalence of trypanosomal infection. the decrease in herd PCV was higher during the dry compared to the rainy season suggesting that trypanosomosis is less well tolerated during the dry season. Results from the study suggest that the relationship between the prevalence of trypanosomal infections and herd average PCV could be a useful tool in the management of trypanosomosis and planning of its control. Reasons for the spatial and temporal variations in the relationship are discussed. (C) 2001 Elsevier Science B.V. All rights reserved.	Inst Trop Med, Vet Dept, Antwerp, Belgium; Int Livestock Res Inst, Nairobi, Kenya	Van den Bossche, P (reprint author), Inst Trop Med, Vet Dept, Natl Str 155, Antwerp, Belgium.						Bauer B, 1999, TROP ANIM HEALTH PRO, V31, P89, DOI 10.1023/A:1005115707181; BOURN D, 1978, TROP ANIM HEALTH PRO, V10, P191, DOI 10.1007/BF02235340; BOYT WP, 1967, P T RHOD SCI ASS, V52, P16; CANNON RM, 1982, LIVESTOCK DIS SURVEY, P26; CONNOR R.J., 1994, INFECT DIS LIVESTOCK, P166; d'leteren G.D., 1998, REV SCI TECH OIE, V17, P154; DECLERCQ K, 1997, THESIS U GHENT GHENT, P143; DORAN M, 1998, SOCIOECONOMIC SURVEY, P42; DORAN M, 1999, SOCIOECONOMIC SURVEY, P40; Hopkins JS, 1998, PREV VET MED, V37, P91, DOI 10.1016/S0167-5877(98)00101-9; HORNBY H. E., 1941, TRANS ROY SOC TROP MED AND HYG, V35, P165, DOI 10.1016/S0035-9203(41)90050-0; KATUNGUKARWAKISHAYA E, 1995, VET PARASITOL, V59, P207, DOI 10.1016/0304-4017(94)00748-2; MARTIN SW, 1992, PREV VET MED, V14, P33, DOI 10.1016/0167-5877(92)90082-Q; MURRAY M, 1988, ACTA TROP, V45, P389; Murray M., 1977, Immunity to blood parasites of animals and man. (Advances in experimental medicine and biology, Volume 93)., P209; PARIS J, 1982, ACTA TROP, V39, P307; Rowlands GJ, 1999, TROP ANIM HEALTH PRO, V31, P279, DOI 10.1023/A:1005251722797; Rowlands GJ, 1996, PREV VET MED, V28, P17, DOI 10.1016/0167-5877(96)01022-7; SAWADOGO GJ, 1991, BRIT VET J, V147, P538; Trail JC, 1991, ACTA TROP, V48, P37; TRAIL JCM, 1993, VET PARASITOL, V45, P241, DOI 10.1016/0304-4017(93)90079-3; Van den Bossche P, 2000, ACTA TROP, V75, P247, DOI 10.1016/S0001-706X(00)00059-0; WILSON A J, 1976, Tropical Animal Health and Production, V8, P1, DOI 10.1007/BF02383357	23	20	21	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0001-706X			ACTA TROP	Acta Trop.	FEB 23	2001	78	2					163	170		10.1016/S0001-706X(00)00182-0				8	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	411AV	WOS:000167476700009	11230826				2019-03-26	
J	Gonzalez, AH; Regalado, VC; Van den Ende, J				Gonzalez, AH; Regalado, VC; Van den Ende, J			Non-invasive management of Ascaris lumbricoides biliary tract migration: a prospective study in 69 patients from Ecuador	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						Ascaris lumbricoides; biliary migration; duodenoscopy; ultrasound; treatment		Ascariasis is one of the most common helminthic diseases. Its most feared complication is migration into the biliary tree. Some authors recommend immediate duodenoscopy in all cases of biliary migration, with sphincterotomy for the extraction of the parasites, and a surgical extraction in case of intrahepatic ascariasis. We followed prospectively 69 patients with ultrasonographical evidence of migration. Initial treatment consisted of intravenous analgesics and antispasmodics, and albendazol 800 me by mouth. Only patients with persisting symptoms or with high amylasaemia underwent duodenoscopy, with extraction in case of a visible worm. Surgery was limited to cases with persistent or progressive complications. In 97% of our cases the worms disappeared with noninvasive therapy alone, A duodenoscopy was done in 30 (42%) cases; in 10 (14.4%) a worm was found in the ampula of Vater and extracted without sphincterotomy. In none of the 6 cases with A. lumbricoides in the intrahepatic biliary tree did the parasite persist. Only one patient required surgical intervention. Treatment of A. lumbricoides migration to the biliary tract should be principally medical. Duodenoscopy with extraction of a visible worm should be limited to cases with persisting pain and/or hyperamylasaemia. Invasive methods like sphincterotomy and surgery should be restricted to patients who do not respond to conservative treatment.	Prov Hosp Homero Castanier Crespo, Minist Publ Hlth, Azogues, Ecuador; Reg Hosp Vincente Corral Moscoso, Minist Publ Hlth, Dept Gastroenterol, Cuenca, Ecuador; Inst Trop Med, B-2000 Antwerp, Belgium	Regalado, VC (reprint author), Prov Hosp Homero Castanier Crespo, Minist Publ Hlth, Azogues, Ecuador.						CERRI GG, 1983, RADIOLOGY, V146, P753, DOI 10.1148/radiology.146.3.6828691; HAMALOGLU E, 1992, INT SURG, V77, P77; KAMATH PS, 1986, GASTROENTEROLOGY, V91, P730, DOI 10.1016/0016-5085(86)90646-3; Kamiya T, 1993, DIGESTIVE ENDOSCOPY, V5, P179; KHUROO MS, 1990, LANCET, V335, P1503, DOI 10.1016/0140-6736(90)93037-P; KHUROO MS, 1985, GASTROENTEROLOGY, V88, P418, DOI 10.1016/0016-5085(85)90501-3; KHUROO MS, 1987, GASTROENTEROLOGY, V93, P267, DOI 10.1016/0016-5085(87)91013-4; 1989, LANCET, V1, P997	8	12	19	0	0	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	FEB	2001	6	2					146	150		10.1046/j.1365-3156.2001.00657.x				5	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	415RN	WOS:000167736600010	11286203				2019-03-26	
J	Tona, L; Mesia, K; Ngimbi, NP; Chrimwami, B; Okond'Ahoka; Cimanga, K; de Bruyne, T; Apers, S; Hermans, N; Totte, J; Pieters, L; Vlietinck, AJ				Tona, L; Mesia, K; Ngimbi, NP; Chrimwami, B; Okond'Ahoka; Cimanga, K; de Bruyne, T; Apers, S; Hermans, N; Totte, J; Pieters, L; Vlietinck, AJ			In-vivo antimalarial activity of Cassia occidentalis, Morinda morindoides and Phyllanthus niruri	ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY			English	Article							TANZANIAN MEDICINAL-PLANTS; DRUG-RESISTANT MALARIA; ANTIPLASMODIAL ACTIVITY; CYTOTOXIC ACTIVITIES; EXTRACTS; SEEDS; CONSTITUENTS; LIMONOIDS; MELIACEAE; EMPHASIS	The ethanolic, dichloromethane and lyophilized aqueous extracts of Cassia occidentalis root bark, Morinda morindoides leaves and whole plants of Phyllanthus niruri were evaluated for their antimalarial activity in vivo, in 4-day, suppressive assays against Plasmodium berghei ANKA in mice. No toxic effect or mortality was observed in mice treated, orally, with any of the extracts as a single dose, of 500 mg/kg body weight, or as the same dose given twice weekly for 4 weeks (to give a total dose of 4 g/kg). No significant lesions were observed, by eye or during histopathological examinations, in the hearts, lungs, spleens, kidneys, livers, large intestines or brains of any mouse. At doses of 200 mg/kg, all the ethanolic and dichloromethane extracts produced significant chemosuppressions of parasitaemia (of > 60% for C. occidentalis root bark and Ph. niruri whole plant, and of 30% for M. morindoides leaves) when administered orally. The most active ethanolic extract, that of Ph. niruri, reduced parasitaemia by 73%. The dichloromethane extracts of M. morindoides and Ph. niruri produced similar reductions (74% and 72% chemosuppression, respectively), whereas that of C. occidentalis was slightly less active (60% chemosuppression). Each lyophilized aqueous extract was less active than the corresponding ethanolic extract.	Univ Kinshasa, Fac Pharm, Kinshasa XI, Zaire; Univ Kinshasa, Fac Med, Inst Trop Med, Kinshasa XI, Zaire; Univ Kinshasa, Fac Med, Lab Anatomopathol, Kinshasa XI, Zaire; Univ Instelling Antwerp, Dept Pharmaceut Sci, B-2610 Wilrijk, Belgium	Cimanga, K (reprint author), Univ Kinshasa, Fac Pharm, BP 212, Kinshasa XI, Zaire.		De Bruyne, Tess/O-6505-2018; Apers, Sandra/P-6286-2016; Hermans, Nina/A-5244-2017; Pieters, Luc/P-5820-2016	De Bruyne, Tess/0000-0001-8597-2084; Hermans, Nina/0000-0003-3946-7313; Pieters, Luc/0000-0002-8288-4254			Addae-Kyereme J., 1997, Journal of Pharmacy and Pharmacology, V49, P113; AGBEDAHUNSI JM, 1998, PHARM BIOL, V1, P8; Benoit F, 1996, AM J TROP MED HYG, V54, P67, DOI 10.4269/ajtmh.1996.54.67; Bickii J, 2000, J ETHNOPHARMACOL, V69, P27, DOI 10.1016/S0378-8741(99)00117-8; BJORKMAN A, 1990, T ROY SOC TROP MED H, V84, P323, DOI 10.1016/0035-9203(90)90302-U; BRAY DH, 1990, PHYTOTHER RES, V4, P29, DOI 10.1002/ptr.2650040108; Calixto JB, 1998, MED RES REV, V18, P225, DOI 10.1002/(SICI)1098-1128(199807)18:4<225::AID-MED2>3.0.CO;2-X; Calore EE, 1998, ECOTOX ENVIRON SAFE, V39, P27, DOI 10.1006/eesa.1997.1604; CAPASSO F, 1985, J ETHNOPHARMACOL, V13, P111, DOI 10.1016/0378-8741(85)90065-0; Cimanga K., 1999, Pharmacy and Pharmacology Communications, V5, P419; Cimanga K, 1997, PLANTA MED, V63, P220, DOI 10.1055/s-2006-957657; CIMANGA K, 1995, J NAT PRODUCTS, V58, P372, DOI 10.1021/np50117a005; CIMANGA K, 1997, THESIS U ANTWERP BEL; COLVIN BM, 1986, J AM VET MED ASSOC, V189, P423; DHIR H, 1990, PHYTOTHER RES, V4, P172, DOI 10.1002/ptr.2650040503; El Tahir A, 1999, J ETHNOPHARMACOL, V64, P227, DOI 10.1016/S0378-8741(98)00129-9; El-Tahir A, 1999, PHYTOTHER RES, V13, P474; ELTAHIR A, 1999, J ETHNOPHARMACOL, V64, P249; FLORY W, 1992, J VET DIAGN INVEST, V4, P65, DOI 10.1177/104063879200400114; FRANCKE L, 1994, SIGHT SOUND, V4, P35; GESSLER MC, 1994, ACTA TROP, V56, P65, DOI 10.1016/0001-706X(94)90041-8; GESSLER MC, 1995, PHYTOTHER RES, V9, P504, DOI 10.1002/ptr.2650090708; Haraguchi M, 1998, VET RES COMMUN, V22, P265, DOI 10.1023/A:1006051618056; JURG A, 1991, J ETHNOPHARMACOL, V33, P79, DOI 10.1016/0378-8741(91)90165-A; Kambu K., 1990, ELEMENTS PHYTOTHERAP; KERHARAO J, 1974, PHARMACOPEE SENEGALA; KOUMAGLO K, 1992, PLANTA MED, V58, P533, DOI 10.1055/s-2006-961543; MARSHALL SJ, 1994, ANTIMICROB AGENTS CH, V38, P96, DOI 10.1128/AAC.38.1.96; MARTIN BW, 1981, VET HUM TOXICOL, V23, P416; Munoz V, 2000, J ETHNOPHARMACOL, V69, P127, DOI 10.1016/S0378-8741(99)00148-8; NKUNYA MHH, 1991, PLANTA MED, V57, P341, DOI 10.1055/s-2006-960113; Oliver-Bever BEP, 1986, MED PLANTS TROPICAL; Omulokoli E, 1997, J ETHNOPHARMACOL, V56, P133, DOI 10.1016/S0378-8741(97)01521-3; PETERS W, 1992, ANN TROP MED PARASIT, V86, P455, DOI 10.1080/00034983.1992.11812694; PHILIPSON JD, 1993, INT S PHYT SOC EUR L, P3; Prakash A, 1995, PHYTOTHER RES, V9, P594, DOI 10.1002/ptr.2650090813; Rasoanaivo P, 1999, J ETHNOPHARMACOL, V64, P117, DOI 10.1016/S0378-8741(98)00114-7; RATSIMAMANGAURVERG S, 1991, J ETHNOPHARMACOL, V33, P231, DOI 10.1016/0378-8741(91)90082-O; RATSIMAMANGAUVE.S, 1990, PHYTOTHER RES, V4, P1; Sittie AA, 1999, PLANTA MED, V65, P259, DOI 10.1055/s-2006-960473; Tona L, 1999, J ETHNOPHARMACOL, V68, P193, DOI 10.1016/S0378-8741(99)00090-2; TRACY JW, 1996, GOODMAN GILMANS PHAR, P965; WEENEN H, 1990, PLANTA MED, V56, P368, DOI 10.1055/s-2006-960984; WERNSDORFER WH, 1991, PARASITOL TODAY, V7, P297, DOI 10.1016/0169-4758(91)90262-M; WERNSDORFER WH, 1994, ACTA TROP, V56, P143, DOI 10.1016/0001-706X(94)90060-4	45	82	88	0	6	CARFAX PUBLISHING	BASINGSTOKE	RANKINE RD, BASINGSTOKE RG24 8PR, HANTS, ENGLAND	0003-4983			ANN TROP MED PARASIT	Ann. Trop. Med. Parasitol.	JAN	2001	95	1					47	57		10.1080/00034983.2001.11813614				11	Public, Environmental & Occupational Health; Parasitology; Tropical Medicine	Public, Environmental & Occupational Health; Parasitology; Tropical Medicine	406VQ	WOS:000167237200005	11235553				2019-03-26	
J	Southgate, VR; Tchuente, LAT; Sene, M; De Clercq, D; Theron, A; Jourdane, J; Webster, BL; Rollinson, D; Gryseels, B; Vercruysse, J				Southgate, VR; Tchuente, LAT; Sene, M; De Clercq, D; Theron, A; Jourdane, J; Webster, BL; Rollinson, D; Gryseels, B; Vercruysse, J			Studies on the biology of schistosomiasis with emphasis on the Senegal river basin	MEMORIAS DO INSTITUTO OSWALDO CRUZ			English	Article; Proceedings Paper	7th International Symposium on Schistosomiasis	DEC 05-09, 1999	RIO DE JANEIRO, BRAZIL	Oswaldo Cruz Fdn		Schistosoma mansoni; Schistosoma haematobium; Biomphalaria pfeifferi; Senegal river basin	URINARY SCHISTOSOMIASIS; HAEMATOBIUM; COMPATIBILITY; MANSONI; EPIDEMIOLOGY; BULINUS; DELTA	The construction of the Diama dam on the Senegal river, the Manantali dam on the Bafing river, Mali and the ensuing ecological changes have led to a massive outbreak of Schistosoma mansoni in Northern Senegal, associated with high intensity of infections, due to intense transmission, and the creation of new foci of S. haematobium. Data on the vectorial capacity of Biomphalaria pfeifferi from Ndombo, nearRichard Toll, Senegal arepresented with sympatric andallopatric (Cameroon) S. mansoni. Comparisons are made on infectivity, cercarial production, chronobiology of cercarial emergence and longevity of infected snails. Recent data on the intermediate host specificity of different isolates of S. haematobium from the Lower and Middle Valley of the Senegal river basin (SRB) demonstrate the existence of at least two strains of S. haematobium. The role of Bulinus truncatus in the transmission of S. haematobium. in the Lower and Middle Valleys of the SRB is reviewed. Both S. haematobium. and S. mansoni are transmitted in the same foci in some areas of the SRB.	Nat Hist Museum, Dept Zool, Biomed Sci Theme, London SW7 5BD, England; IRD Ex ORSTOM, Dakar, Senegal; Univ Yaounde, Yaounde, Cameroon; Programme Espoir, St Louis, Senegal; Univ Perpignan, Lab Biol Anim, F-66025 Perpignan, France; Inst Trop Med, B-2000 Antwerp, Belgium; Fac Vet Med, Merelbeke, Belgium	Southgate, VR (reprint author), Nat Hist Museum, Dept Zool, Biomed Sci Theme, Cromwell Rd, London SW7 5BD, England.		Theron, Andre/B-2848-2010; Rollinson, David/C-7406-2009	Webster, Bonnie/0000-0003-0930-9314			BELOT J, 1993, J MOLLUS STUD, V59, P7, DOI 10.1093/mollus/59.1.7; CHAINE JP, 1983, TROP GEOGR MED, V35, P249; Cisse F, 1983, Dakar Med, V28, P343; De Clercq D, 1999, TROP MED INT HEALTH, V4, P544; DIAW OT, 1990, B SOC FRANC PARASITO, V2, P4; ERNOULD JC, 1996, THESIS U PARIS 12; Miller M.J., 1982, P279; Picquet M, 1996, T ROY SOC TROP MED H, V90, P340, DOI 10.1016/S0035-9203(96)90501-5; SOUTHGATE VR, 1985, J NAT HIST, V19, P1249, DOI 10.1080/00222938500770801; Southgate VR, 2000, ANN TROP MED PARASIT, V94, P157, DOI 10.1080/00034980057491; Southgate VR, 1997, J HELMINTHOL, V71, P125, DOI 10.1017/S0022149X00015790; Southgate VR, 2000, PARASITOLOGY, V121, P501, DOI 10.1017/S0031182099006708; TALLA I, 1990, ANN SOC BELG MED TR, V70, P173; TALLA I, 1992, T ROY SOC TROP MED H, V86, P132; TCHUENTE LAT, 1999, PARASITOLOGY, V118, P593; VERCRUYSSE J, 1985, ACTA TROP, V42, P249; VERLE P, 1994, T ROY SOC TROP MED H, V88, P401, DOI 10.1016/0035-9203(94)90400-6; Webster BL, 1999, J HELMINTHOL, V73, P351	18	24	26	1	4	FUNDACO OSWALDO CRUZ	RIO DE JANEIRO, RJ	AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL	0074-0276			MEM I OSWALDO CRUZ	Mem. Inst. Oswaldo Cruz		2001	96			S			75	78		10.1590/S0074-02762001000900010				4	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	475ZV	WOS:000171200700010	11586429	DOAJ Gold			2019-03-26	
J	Tchuente, LAT; Southgate, VR; Mbaye, A; Engels, D; Gryseels, B				Tchuente, LAT; Southgate, VR; Mbaye, A; Engels, D; Gryseels, B			The efficacy of praziquantel against Schistosoma mansoni infection in Ndombo, northern Senegal	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						schistosomiasis; Schistosoma mansoni; chemotherapy; praziquantel; Senegal	FOCUS		Inst Trop Med, B-2000 Antwerp, Belgium; Nat Hist Museum, Dept Zool, Biomed Sci Theme, London SW7 5BD, England; Univ Yaounde I, Fac Sci, Lab Biol Gen, Yaounde, Cameroon; Programme Espoir, St Louis, Senegal; WHO, CH-1211 Geneva, Switzerland	Tchuente, LAT (reprint author), Inst Trop Med, Natl Str 155, B-2000 Antwerp, Belgium.						FALLON PG, 1995, AM J TROP MED HYG, V53, P61, DOI 10.4269/ajtmh.1995.53.61; Guisse F, 1997, AM J TROP MED HYG, V56, P511, DOI 10.4269/ajtmh.1997.56.511; Ismail M, 1996, AM J TROP MED HYG, V55, P214, DOI 10.4269/ajtmh.1996.55.214; Picquet M, 1998, T ROY SOC TROP MED H, V92, P90, DOI 10.1016/S0035-9203(98)90971-3; POLDERMAN AM, 1988, T ROY SOC TROP MED H, V82, P115, DOI 10.1016/0035-9203(88)90282-9; Renganathan E, 1998, PARASITOL TODAY, V14, P390, DOI 10.1016/S0169-4758(98)01310-6; SABAH AA, 1985, EXP PARASITOL, V60, P348, DOI 10.1016/0014-4894(85)90041-4; SHAW MK, 1990, PARASITOLOGY, V100, P65, DOI 10.1017/S0031182000060121; Stelma FF, 1997, J INFECT DIS, V176, P304, DOI 10.1086/517273; STELMA FF, 1995, AM J TROP MED HYG, V53, P167, DOI 10.4269/ajtmh.1995.53.167; STELMA FF, 1997, THESIS U LEIDEN NETH	11	24	26	1	3	ROYAL SOC TROPICAL MEDICINE	LONDON	MANSON HOUSE 26 PORTLAND PLACE, LONDON W1N 1EY, ENGLAND	0035-9203			T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	JAN-FEB	2001	95	1					65	66		10.1016/S0035-9203(01)90335-9				2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	412NQ	WOS:000167561600017	11280069				2019-03-26	
J	Van den Bossche, P; Chigoma, D; Shumba, W				Van den Bossche, P; Chigoma, D; Shumba, W			The decline of anti-trypanosomal antibody levels in cattle after treatment with trypanocidal drugs and in the absence of tsetse challenge	ACTA TROPICA			English	Article						trypanosoma; antibody; ELISA; diagnosis	LINKED-IMMUNOSORBENT-ASSAY; AFRICAN TRYPANOSOMIASIS; BOVINE TRYPANOSOMOSIS; DIAGNOSIS; VALIDATION	The decline of anti-trypanosomal antibody levels in cattle after treatment with trypanocidal drugs was investigated using an anti-trypanosomal antibody-detection enzyme-linked immunosorbent assay (ELISA). The decline of anti body levels differed between experimental animals but went through two phases. During the first 5 months after trypanocidal drug treatment, the decline is rapid with a monthly average decline of 10% of the average percentage positivity during the treatment. Between months 6 and 13 after treatment, the monthly average decline was only 3.6% of the average percentage positivity at the moment of treatment. It took a total of 13 months for all the experimental animals to become seronegative. The usefulness of the anti-trypanosomal antibody-detection enzyme-linked immunosorbent assay (ELISA) in the monitoring of tsetse control operations is discussed. (C) 2000 Elsevier Science B.V. All rights reserved.	Reg Tsetse & Trypanosomiasis Control Program, Harare, Zimbabwe; Dept Vet Serv, Harare, Zimbabwe	Van den Bossche, P (reprint author), Inst Trop Med Prince Leopold, Nat Str 155, B-2000 Antwerp, Belgium.	pvdbossche@itg.be					AUTHIE E, 1993, PARASITE IMMUNOL, V15, P101, DOI 10.1111/j.1365-3024.1993.tb00589.x; BOCQUENTIN R, 1990, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V43, P479; DWINGER RH, 1988, LIVESTOCK PRODUCTION, P100; Greiner M, 1997, PREV VET MED, V30, P61, DOI 10.1016/S0167-5877(96)01088-4; Hopkins JS, 1998, PREV VET MED, V37, P91, DOI 10.1016/S0167-5877(98)00101-9; HOPKINS JS, 1997, THESIS U EDINBURGH E; LUCKINS AG, 1977, TROP ANIM HEALTH PRO, V9, P53, DOI 10.1007/BF02297393; MURRAY M, 1977, T ROY SOC TROP MED H, V71, P325, DOI 10.1016/0035-9203(77)90110-9; PARIS J, 1982, ACTA TROP, V39, P307; Sokal RR, 1998, BIOMETRY PRINCIPLES, P887; Van den Bossche P, 1999, ONDERSTEPOORT J VET, V66, P103; Van den Bossche P, 2000, VET PARASITOL, V88, P163, DOI 10.1016/S0304-4017(99)00222-8; Warnes ML, 1999, MED VET ENTOMOL, V13, P177, DOI 10.1046/j.1365-2915.1999.00148.x; WILSON A J, 1971, Tropical Animal Health and Production, V3, P133, DOI 10.1007/BF02360742; Wright P F, 1993, Rev Sci Tech, V12, P435; ZWART D, 1973, Tropical Animal Health and Production, V5, P79, DOI 10.1007/BF02236142	16	9	9	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0001-706X	1873-6254		ACTA TROP	Acta Trop.	DEC 1	2000	77	3					263	270		10.1016/S0001-706X(00)00138-8				8	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	381DF	WOS:000165746500003	11114388				2019-03-26	
J	Varandas, L; Julien, M; Van Lerberghe, W; Goncalves, L; Ferrinho, P				Varandas, L; Julien, M; Van Lerberghe, W; Goncalves, L; Ferrinho, P			Independent indicators of outcome in severe paediatric malaria: maternal education, acidotic breathing and convulsions on admission	ANNALS OF TROPICAL PAEDIATRICS			English	Article							CHILDHOOD CEREBRAL MALARIA; AFRICAN CHILDREN; SEQUELAE; MORTALITY; QUININE	Severe malaria is an important cause of death in hospitalized children in Mozambique, but the risk factors for this remain unclear. The objectives of the study were to define simple clinical criteria to identify on admission the children most at risk of dying. We studied prospectively 559 children admitted with severe malaria to the Department of Paediatrics of the Central Hospital of Maputo, Mozambique between March 1995 and August 1996. The case fatality rate was 3.6%. In a multiple logistic regression model, mothers' education (RR = 9.6, 95% CI 1.2-76.0), acidotic breathing (RR = 4.3, 95% CI 1.3-13.8) and convulsions in the emergency room (RR = 8.1, 95% CI 2.6-25.1) were associated with outcome. Together they predicted 97% of outcomes but only 33.3% of deaths.	Univ Nova Lisboa, Inst Higiene & Med Trop, Ctr Malaria & Outras Doencas Trop, Lisbon, Portugal; Univ Eduardo Mondlane, Hosp Cent Maputo, Maputo, Mozambique; Univ Eduardo Mondlane, Fac Med, Maputo, Mozambique; Inst Trop Med Prince Leopold, Dept Publ Hlth, Antwerp, Belgium; Inst Higiene & Med Trop, Epidemiol & Biostat Unit, Lisbon, Portugal; Assoc Desenvolvimento & Cooperacao Garcia Orta, Hlth Syst Unit, Castelo De Vide, Portugal	Varandas, L (reprint author), Univ Nova Lisboa, Inst Higiene & Med Trop, Unidade Sistemas Saude, Rua Junqueira 96, P-1349G008 Lisbon, Portugal.		Goncalves, Luzia/J-6649-2012; Ferrinho, Paulo/J-2835-2012	Goncalves, Luzia/0000-0002-9710-1945; Ferrinho, Paulo/0000-0002-3722-0803; Varandas, Luis/0000-0002-8419-6033; Van Lerberghe, Wim/0000-0001-9966-6563			BREWSTER DR, 1990, LANCET, V336, P1039, DOI 10.1016/0140-6736(90)92498-7; CARME B, 1993, AM J TROP MED HYG, V48, P216, DOI 10.4269/ajtmh.1993.48.216; Ejov MN, 1999, B WORLD HEALTH ORGAN, V77, P310; GREENWOOD B, 1991, PARASITOL TODAY, V7, P277, DOI 10.1016/0169-4758(91)90096-7; Jaffar S, 1997, AM J TROP MED HYG, V57, P20, DOI 10.4269/ajtmh.1997.57.20; Julien M, 1995, J TROP PEDIATRICS, V41, P366, DOI 10.1093/tropej/41.6.366; MARSH K, 1995, NEW ENGL J MED, V332, P1399, DOI 10.1056/NEJM199505253322102; MOLYNEUX ME, 1989, Q J MED, V71, P441; SCHAPIRA A, 1993, T ROY SOC TROP MED H, V87, P299, DOI 10.1016/0035-9203(93)90136-E; SIMPSON D, 1982, LANCET, V2, P450; SNOW RW, 1994, ACTA TROP, V57, P289, DOI 10.1016/0001-706X(94)90074-4; vanHensbroek MB, 1996, NEW ENGL J MED, V335, P69, DOI 10.1056/NEJM199607113350201; vanHensbroek MB, 1997, J PEDIATR-US, V131, P125, DOI 10.1016/S0022-3476(97)70135-5; VARANDAS L, 1997, ARQ BRASIL PEDIAT S1, V4, pS53; *WHO, 1990, T R SOC TROP MED S2, V84, P1	15	8	8	1	1	CARFAX PUBLISHING	BASINGSTOKE	RANKINE RD, BASINGSTOKE RG24 8PR, HANTS, ENGLAND	0272-4936			ANN TROP PAEDIATR	Ann. Trop. Paediatr.	DEC	2000	20	4					265	271		10.1080/1465328002003852				7	Pediatrics; Tropical Medicine	Pediatrics; Tropical Medicine	385GJ	WOS:000165995000003	11219163				2019-03-26	
J	Smith, C; Noordeen, SK; DeClercq, E; Grosset, JH; Cartel, JL; Colston, MJ; Ji, BH				Smith, C; Noordeen, SK; DeClercq, E; Grosset, JH; Cartel, JL; Colston, MJ; Ji, BH			Chemoprophylaxis against leprosy: expectations and methodology of a trial - Discussion	LEPROSY REVIEW			English	Editorial Material									Univ Aberdeen, Sch Med, Dept Publ Hlth, Aberdeen AB25 2ZD, Scotland; Damien Fdn Belgium, B-1080 Brussels, Belgium; Univ Paris 06, F-75634 Paris 13, France; Inst Pasteur, F-97165 Pointe a Pitre, Guadeloupe, Guadeloupe; Natl Inst Med Res, London NW7 1AA, England	Smith, C (reprint author), Univ Aberdeen, Sch Med, Dept Publ Hlth, Aberdeen AB25 2ZD, Scotland.	sme205@abdn.ac.uk; noordeen@eth.net; etienne.declercq@damien-foundation.be; jgr@biomath.jussieu.fr; carteljl@outremer.com; jcolsto@nimr.mrc.ac.uk; baohong_ji@yahoo.com						0	0	0	0	0	LEPRA	COLCHESTER	28 MIDDLEBOROUGH, COLCHESTER CO1 1TG, ESSEX, ENGLAND	0305-7518	2162-8807		LEPROSY REV	Lepr. Rev.	DEC	2000	71			S			S40	S41						2	Dermatology; Infectious Diseases; Pathology; Tropical Medicine	Dermatology; Infectious Diseases; Pathology; Tropical Medicine	401ZB	WOS:000166958500013					2019-03-26	
J	Vijayakumaran, P; Krishnamurthy, P; Rao, P; Declerq, E				Vijayakumaran, P; Krishnamurthy, P; Rao, P; Declerq, E			Chemoprophylaxis against leprosy: expectations and methodology of a trial	LEPROSY REVIEW			English	Article; Proceedings Paper	Workshop on Leprosy Research at the New Millennium	JUN 26-28, 2000	PARIS, FRANCE	Int Federat Anti Leprosy, Assoc Francaise Raoul Follereau, British Leprosy Relief Assoc, Sasakawa Mem Hlth Fdn				Because of the great efficacy of multidrug therapy (MDT), it had been hoped that the widespread use of MDT would bring about a rapid decrease of the incidence of leprosy. To the present, a decrease of incidence has not been observed, possibly because of the long incubation period of the disease, and because general implementation of MDT is still recent. Other reasons, such as environmental sources of infection or the role of healthy carriers in transmitting Mycobacterium leprae, cannot be excluded. Therefore, one must seek alternative or supplementary strategies, such as chemoprophylaxis. Household contacts of leprosy patients are at greater risk of developing leprosy than is the general population. Therefore, a randomized, controlled trial of chemoprophylaxis, using a single 10 mg/kg dose of rifampicin, or a placebo, is planned in nine projects in India, among the household contacts of newly detected leprosy patients. Based upon assumptions of a protective efficacy of the chemoprophylaxis of 50%, an annual incidence of 2 per 1000 contacts, a desired power of the study of 90%, and a level of significance of 95%, 15,000 household contacts will be allocated randomly by household to each arm of the study, and followed for 5 years. Considered as household contacts will be all persons living in the same household as an index case and sharing the same kitchen. Pregnant women and infants will be excluded. To be certain that transmission of the organisms from the index case cannot occur once the prophylaxis is administered, rifampicin will be administered 2 months after diagnosis of the index case. Diagnosis of leprosy will be clinical, and confirmed independently. Although household contacts usually constitute only a small proportion of the new patients detected in a control programme, their high-risk status makes them particularly appropriate for a study of the potential effect of chemoprophylaxis. Following the trial, one could evaluate the usefulness and feasibility of using the same strategy in other population-groups, based on the number of persons necessary to treat to prevent one case.	Damien Fdn India Trust, Chennai, India; Damien Fdn, Brussels, Belgium	Vijayakumaran, P (reprint author), Damien Fdn India Trust, Chennai, India.						BLANC LJ, 1999, INT J LEPR OTHER MYC, V67, pS30; CARTEL JL, 1989, INT J LEPROSY, V57, P810; CARTEL JL, 1992, INT J LEPROSY, V60, P416; Dharmendra Ali M, 1965, LEPROSY INDIA, V37, P447; DHARMENDRA APM, 1967, LEPROSY INDIA, V39, P100; DOULL JA, 1942, INT J LEPROSY, V10, P107; Noordeen S K, 1976, Lepr India, V48, P635; Noordeen S K, 1977, Lepr India, V49, P504; Noordeen S K, 1980, Lepr India, V52, P97; Noordeen SK, 1969, LEPROSY INDIA, V41, P247; Vijayakumaran P, 1998, INT J LEPROSY, V66, P125; *WHO, 1998, WHO TECHN REP SER, V874; *WHO, 1998, WKLY EPIDEMIOL REC, V73, P308	13	7	8	0	1	LEPRA	COLCHESTER	FAIRFAX HOUSE, CAUSTON ROAD, COLCHESTER CO1 1PU, ENGLAND	0305-7518			LEPROSY REV	Lepr. Rev.	DEC	2000	71			S			S37	S40						4	Dermatology; Infectious Diseases; Pathology; Tropical Medicine	Dermatology; Infectious Diseases; Pathology; Tropical Medicine	401ZB	WOS:000166958500012	11201885				2019-03-26	
J	Thera, MA; D'Alessandro, U; Thiero, M; Ouedraogo, A; Packou, J; Souleymane, OAD; Fane, M; Ade, G; Alvez, F; Doumbo, O				Thera, MA; D'Alessandro, U; Thiero, M; Ouedraogo, A; Packou, J; Souleymane, OAD; Fane, M; Ade, G; Alvez, F; Doumbo, O			Child malaria treatment practices among mothers in the district of Yanfolila, Sikasso region, Mali	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						malaria; chloroquine; home case management	ANTIMALARIAL DRUG-RESISTANCE; KENYA; STRATEGIES; PREVENTION; PROGRAM; FEVER	We studied chili malaria treatment practices among mothers living in the District of Yanfolia in southern Mali. For sampling, we first chose five of 13 health areas with probability proportional to size. Then villages, compounds and mothers with at least one child aged 1-5 years were randomly chosen. We assessed the spleen size of one 1-5 year-old child of each mother, collected a thick blood film and recorded the body temperature of every child whose mother thought he/she was sick. 399 mothers in 26 villages were interviewed with a structured questionnaire divided into two parts. If the child had had soumaya (a term previously associated with uncomplicated malaria) during the past rainy season, we asked about signs and symptoms, health-seeking behaviour (who the mother consulted first) and treatment. If not, information about knowledge of the disease and treatment to be given was collected. 86% of the mothers interviewed stared that their child had been sick and almost half of them had had soumaya. All mothers named at least one sign by which they recognized the disease. Vomiting, fever and dark urine/yellow eyes/jaundice were the three most common signs mentioned. 75.8% managed their child's disease at home and used both traditional and modern treatment. The most common anti-malarial drug was chloroquine, often given at inappropriate dosage. The sensitivity and specificity of the mothers' diagnosis was poor, although this might be explained by the large percentage of children who had already been treated at the time of the interview. The results of our survey call for prompt educational action for the correct treatment of uncomplicated malaria/soumaya, particularly for mothers and possibly for shopkeepers. The high spleen rate (58.1%) among randomly selected children confirms that malaria is a common disease in this area. Improved case-management at home could only be beneficial.	Inst Trop Med Prince Leopold, Dept Parasitol, B-2000 Antwerp, Belgium; Fac Med Pharm & Odontostomatol, Dept Epidemiol Affect Parasitaires, Bamako, Mali; Serv Sociosanit Cercle, Sikasso, Mali; Programme Natl Lutte Paludisme, Libreville, Gabon; Moughataa de Maghama, Gorgol, Mauritania; Programme Natl Lutle Paludisme, Bamako, Mali	D'Alessandro, U (reprint author), Inst Trop Med Prince Leopold, Dept Parasitol, Natl Str 155, B-2000 Antwerp, Belgium.		D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009; Thera, Mahamadou A/0000-0002-2679-035X			BENOWITZ NL, 1994, POISONING DRUG OVERD; Carr A B, 1993, J Prosthodont, V2, P2, DOI 10.1111/j.1532-849X.1993.tb00373.x; D'Alessandro U, 1998, MEM I OSWALDO CRUZ, V93, P627, DOI 10.1590/S0074-02761998000500012; D'Alessandro U, 1997, T ROY SOC TROP MED H, V91, P638, DOI 10.1016/S0035-9203(97)90502-2; DIALLO FB, 1998, THESIS U MONTREAL; DICKO A, 1995, THESIS ECOLE NATL ME; Djimde A, 1998, AM J TROP MED HYG, V59, P376, DOI 10.4269/ajtmh.1998.59.376; *EC NAT MED PHARM, 1980, ET SANT POP RIV AV M; English M, 1996, LANCET, V347, P1736, DOI 10.1016/S0140-6736(96)90809-0; FOSTER SD, 1991, B WORLD HEALTH ORGAN, V69, P349; GILLES HM, 1993, BRUCECHWATTS ESSENTI, P124; LACKRITZ EM, 1992, LANCET, V340, P524, DOI 10.1016/0140-6736(92)91719-O; Lubanga RGN, 1997, ACTA TROP, V68, P53, DOI 10.1016/S0001-706X(97)00071-5; Makemba AM, 1996, TROP MED INT HEALTH, V1, P305; Marsh VM, 1999, TROP MED INT HEALTH, V4, P383, DOI 10.1046/j.1365-3156.1999.00403.x; McCombie SC, 1996, SOC SCI MED, V43, P933, DOI 10.1016/0277-9536(95)00446-7; MWENESI H, 1995, SOC SCI MED, V40, P1271, DOI 10.1016/0277-9536(94)00250-W; Nwanyanwu OC, 1996, T ROY SOC TROP MED H, V90, P66, DOI 10.1016/S0035-9203(96)90482-4; Plowe CV, 1996, AM J TROP MED HYG, V55, P467, DOI 10.4269/ajtmh.1996.55.467; ROGER M, 1992, MALADIES ENFANT REGI; RUEBUSH TK, 1995, B WORLD HEALTH ORGAN, V73, P229; SLUTSKER L, 1994, TROP MED PARASITOL, V45, P61; SNOW RW, 1992, T ROY SOC TROP MED H, V86, P237, DOI 10.1016/0035-9203(92)90290-S; THERA MA, 1998, 2 EUR C TROP MED LIV; WERNSDORFER WH, 1991, PARASITOL TODAY, V7, P297, DOI 10.1016/0169-4758(91)90262-M; White NJ, 1996, PARASITOL TODAY, V12, P399, DOI 10.1016/0169-4758(96)10055-7; WHO, 1993, GLOB STRAT MAL CONTR	27	53	55	0	2	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	DEC	2000	5	12					876	881		10.1046/j.1365-3156.2000.00652.x				6	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	399DW	WOS:000166796900008	11169277	Bronze			2019-03-26	
J	Garcia, A; Jamonneau, V; Magnus, E; Laveissiere, C; Lejon, V; N'Guessan, P; N'Dri, L; Van Meirvenne, N; Buscher, P				Garcia, A; Jamonneau, V; Magnus, E; Laveissiere, C; Lejon, V; N'Guessan, P; N'Dri, L; Van Meirvenne, N; Buscher, P			Follow-up of Card Agglutination Trypanosomiasis Test (CATT) positive but apparently aparasitaemic individuals in Cote d'Ivoire: evidence for a complex and heterogeneous population	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						trypanosomiasis; CATT; individual susceptibility; Trypanosoma brucei gambiense	HUMAN AFRICAN TRYPANOSOMIASIS; BRUCEI-GAMBIENSE; PLASMODIUM-FALCIPARUM; GAMBIAN TRYPANOSOMIASIS; SCHISTOSOMA-MANSONI; SEVERE MALARIA; INFECTIONS; DIAGNOSIS; RESISTANCE; CONGOLENSE	The aetiological diagnosis of human African trypanosomiasis (HAT) is based on the detection of the parasite, but currently available parasitological rests have low sensitivity and are hampered by fluctuating parasitaemia. The identification of seropositive individuals on whom to focus parasitological examination is based on antibody detection by means of the Card Agglutination Trypanosomiasi's Test (CATT/T.b.gambiense). A complicating phenomenon is the occurrence of serologically positive but parasitologically unconfirmed results (isolated CATT positivity). This work presents a two-year longitudinal serological, parasitological and molecular follow-up of CATT-positive individuals including repented examinations of each individual, to study the evolution over time of seropositivity at both the population and the individual levels. At the population level, the rate of seropositivity decreased during the first months of the survey, and afterwards showed remarkable stability At the individual level, the results reveal the extreme heterogeneity of this population, with subjects showing fluctuating results, others with a short transient CATT positivity and subjects that maintain their seropositivity over time. The stability of seropositivity and the pattern of results obtained with both immunological and parasitological examinations support the view that individual factors, such as immune response to infection, might be involved in the isolated CATT positivity phenomenon.	Inst Pierre Richet, ORSTOM, IRD, Bouake 01, Cote Ivoire; Inst Trop Med, Dept Parasitol, B-2000 Antwerp, Belgium; Inst Pierre Richet, OCCGE, Bouake, Cote Ivoire	Garcia, A (reprint author), Inst Pierre Richet, ORSTOM, IRD, BP 1500, Bouake 01, Cote Ivoire.		Jamonneau, Vincent/K-1124-2016; Garcia, Andre/S-2959-2016; Buscher, Philippe/B-9956-2012	Garcia, Andre/0000-0002-1808-472X; Buscher, Philippe/0000-0002-1926-7472			ABEL L, 1988, AM J HUM GENET, V42, P256; ABEL L, 1991, AM J HUM GENET, V48, P959; AERTS D, 1992, T ROY SOC TROP MED H, V86, P394, DOI 10.1016/0035-9203(92)90234-4; ASKONA BA, 1985, CURR TOP MICROBIOL, V117, P120; BAILEY JW, 1992, T ROY SOC TROP MED H, V86, P630, DOI 10.1016/0035-9203(92)90160-E; BECK HP, 1995, AM J TROP MED HYG, V53, P284; DUKES P, 1992, ACTA TROP, V51, P123, DOI 10.1016/0001-706X(92)90054-2; GARCIA A, 1995, AM J TROP MED HYG, V52, P370, DOI 10.4269/ajtmh.1995.52.370; Garcia A, 1999, TROP MED INT HEALTH, V4, P565, DOI 10.1046/j.1365-3156.1999.00442.x; Garcia A, 1998, AM J TROP MED HYG, V58, P480, DOI 10.4269/ajtmh.1998.58.480; Garcia A, 1998, AM J TROP MED HYG, V58, P705, DOI 10.4269/ajtmh.1998.58.705; GYANG FN, 1992, EXP PARASITOL, V74, P470, DOI 10.1016/0014-4894(92)90209-S; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; JOSHUA RA, 1989, VET PARASITOL, V31, P107, DOI 10.1016/0304-4017(89)90025-3; Kanmogne GD, 1996, ANN TROP MED PARASIT, V90, P475, DOI 10.1080/00034983.1996.11813072; Kemp SJ, 1997, NAT GENET, V16, P194, DOI 10.1038/ng0697-194; Khonde N, 1997, T ROY SOC TROP MED H, V91, P521, DOI 10.1016/S0035-9203(97)90008-0; Lejon V, 1998, B WORLD HEALTH ORGAN, V76, P553; LUMSDEN WHR, 1981, T ROY SOC TROP MED H, V75, P242, DOI 10.1016/0035-9203(81)90326-6; MAGNUS E, 1978, ANN SOC BELG MED TR, V58, P169; Marquet S, 1996, NAT GENET, V14, P181, DOI 10.1038/ng1096-181; MASIGA DK, 1994, THESIS U BRISTOL UK; MIGOT F, 1995, AM J TROP MED HYG, V52, P252, DOI 10.4269/ajtmh.1995.52.252; MOSER DR, 1989, PARASITOLOGY, V99, P57, DOI 10.1017/S0031182000061023; NOIREAU F, 1986, ANN SOC BELG MED TR, V66, P63; NOIREAU F, 1988, ANN SOC BELG MED TR, V68, P331; OKOMOASSOUMOU MC, 1995, AM J TROP MED HYG, V53, P539, DOI 10.4269/ajtmh.1995.53.539; OLSSON T, 1993, CELL, V72, P1; Penchenier L, 1996, PARASITE, V4, P387; SILEGHEM M, 1989, IMMUNOLOGY, V68, P137; SIMARRO PP, 1999, TROP MED INT HEALTH, V12, P858; Simo G, 1999, B LIAISON DOCUMENTAT, V32, P17; SMITS HL, 1995, J MICROBIOL METH, V23, P41, DOI 10.1016/0167-7012(95)00032-G; Sternberg JM, 1996, T ROY SOC TROP MED H, V90, P395, DOI 10.1016/S0035-9203(96)90519-2; Truc P, 1998, T ROY SOC TROP MED H, V92, P537, DOI 10.1016/S0035-9203(98)90904-X; TRUC P, 1994, T ROY SOC TROP MED H, V88, P419, DOI 10.1016/0035-9203(94)90410-3; TRUC P, 1992, T ROY SOC TROP MED H, V86, P627, DOI 10.1016/0035-9203(92)90158-9; VANDERPLOEG LHT, 1982, NUCLEIC ACIDS RES, V10, P593, DOI 10.1093/nar/10.2.593; VanMeirvenne N, 1995, ACTA TROP, V60, P189, DOI 10.1016/0001-706X(95)00127-Z; WEISS JB, 1995, CLIN MICROBIOL REV, V8, P113, DOI 10.1128/CMR.8.1.113; World Health Organization, 1998, WHO TECH REP SER, P1	42	55	55	1	3	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	NOV	2000	5	11					786	793		10.1046/j.1365-3156.2000.00623.x				8	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	380CQ	WOS:000165681100006	11123826	Bronze			2019-03-26	
J	Schoonbaert, D				Schoonbaert, D			Tropical medicine, the Internet and current trends in biomedical communication	ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY			English	Review							WORLD-WIDE-WEB; DEVELOPING-COUNTRIES; INGELFINGER RULE; JOURNALS; INFORMATION; PUBLISHERS; EMBARGOES; AUTHORS; ARCHIVE; SERVER	Largely unknown only a decade ago, the Internet has now become totally indispensable to biomedical practice and research, as a means of disseminating and retrieving information. Electronic mail, list servers and newsgroups make rapid, personal, targeted and broadcast communication around the globe possible. Hundreds of millions of World Wide Web pages, organized by hierarchically structured web directories, and dissected by general web indexes, give access to an unprecedented amount of information. More and more scientists find their way to factual and bibliographical databases using the Internet. In addition to outlining some of the more relevant resources for the tropical-medicine and international-health communities, this review pays special attention to recent and future changes in the transfer of formal biomedical information. An interesting issue is the future role and position of the published article-either in electronic editions of traditional, peer-reviewed journals, or in even more revolutionary formats, such as electronic preprint servers-and the implications for authors, reviewers, editors, publishers and, ultimately, the readers.	Inst Trop Med, B-2000 Antwerp, Belgium	Schoonbaert, D (reprint author), Inst Trop Med, Natl Str 155, B-2000 Antwerp, Belgium.						Altman LK, 1996, LANCET, V347, P1382, DOI 10.1016/S0140-6736(96)91016-8; Altman LK, 1996, LANCET, V347, P1459, DOI 10.1016/S0140-6736(96)91689-X; [Anonymous], 1999, J CITATION REPORTS C; Borges Jorge Luis, 1962, LABYRINTHS; Butler D, 1999, NATURE, V402, P115, DOI 10.1038/45901; Butler D, 1999, NATURE, V397, P10, DOI 10.1038/16119; Butler D, 1999, NATURE, V399, P623, DOI 10.1038/21265; Butler D, 2000, NATURE, V404, P117, DOI 10.1038/35004746; Butler D, 1999, NATURE, V397, P195, DOI 10.1038/16544; Carroll L., 1982, COMPLETE ILLUSTRATED; Coppel RL, 1996, PARASITOL TODAY, V12, P85, DOI 10.1016/0169-4758(96)80664-8; Davidoff F, 2000, ANN INTERN MED, V133, P57, DOI 10.7326/0003-4819-133-1-200007040-00011; Deering CM, 1995, ANN TROP MED PARASIT, V89, P579, DOI 10.1080/00034983.1995.11812992; Delamothe T, 1999, BRIT MED J, V318, P888, DOI 10.1136/bmj.318.7188.888; Gibbs W. W., 1995, SCI AM, V273, P76; GINSPARG P, 1996, WINNERS LOSERS GLOBA; Harnad S, 1999, NATURE, V401, P423, DOI 10.1038/46659; Koenig R, 2000, SCIENCE, V287, P563, DOI 10.1126/science.287.5453.563; LaPorte RE, 1996, BRIT MED J, V313, P1609, DOI 10.1136/bmj.313.7072.1609; LaPorte RE, 1997, BRIT MED J, V314, P980, DOI 10.1136/bmj.314.7085.980a; LAPORTE RE, 1995, BRIT MED J, V310, P1387, DOI 10.1136/bmj.310.6991.1387; Lawrence S, 1999, NATURE, V400, P107, DOI 10.1038/21987; Lawrence S, 1998, SCIENCE, V280, P98, DOI 10.1126/science.280.5360.98; McConnell J, 1999, LANCET, V354, P2, DOI 10.1016/S0140-6736(99)00226-3; Milstead J, 1999, ONLINE, V23, P24; MILSTEAD J, 1999, ONLINE, V23, P31; Notess GR, 1998, ONLINE, V22, P73; Notess GR, 1998, DATABASE, V21, P69; PakenhamWalsh N, 1997, BRIT MED J, V314, P90, DOI 10.1136/bmj.314.7074.90; Porteous J., 1997, NATURE, V389, P137; Schoonbaert D, 1998, ELECTRON LIBR, V16, P95, DOI 10.1108/eb045622; SCHOONBAERT D, 1998, ENCY LIBRARY INF S26, V63, P82; Smith R, 1998, BRIT MED J, V316, P1116; Smith R, 1999, BRIT MED J, V319, P272, DOI 10.1136/bmj.319.7205.272; Smith R, 1999, BRIT MED J, V318, P142, DOI 10.1136/bmj.318.7177.142; Tegenbos J, 1997, ONLINE CDROM REV, V21, P139, DOI 10.1108/eb024616; VANDESOMPEL H, 2000, SANT FE CONV OP ARCH; VARMUS H, 1999, PUBMED CENTRAL NIH O; Varmus H, 1999, E BIOMED PROPOSAL EL; Wadman M, 1999, NATURE, V398, P272, DOI 10.1038/18506	40	1	1	0	2	CARFAX PUBLISHING	BASINGSTOKE	RANKINE RD, BASINGSTOKE RG24 8PR, HANTS, ENGLAND	0003-4983			ANN TROP MED PARASIT	Ann. Trop. Med. Parasitol.	OCT	2000	94	7					661	674						14	Public, Environmental & Occupational Health; Parasitology; Tropical Medicine	Public, Environmental & Occupational Health; Parasitology; Tropical Medicine	382AW	WOS:000165797100001	11144808				2019-03-26	
J	Beltman, JJ; Segaar, M; Ory, FG				Beltman, JJ; Segaar, M; Ory, FG			Knowledge of high-school students and adult OPD attenders of family planning methods and sexually transmitted diseases (including HIV) in rural Zimbabwe	TROPICAL DOCTOR			English	Letter							FERTILITY; BEHAVIOR; RISK; AIDS		State Univ Ghent, Ghent, Belgium; Gutu Mission Hosp, Gutu, Zimbabwe; Royal Netherlands Embassy, Harare, Zimbabwe	Ory, FG (reprint author), TNO, Netherlands Org Appl Sci Res Prevent & Hlth, PG, POB 2215, NL-2301 CE Leiden, Netherlands.						BOOHENE E, 1991, STUD FAMILY PLANN, V22, P264, DOI 10.2307/1966482; Campbell B., 1994, Central African Journal of Medicine, V40, P245; DIXONMUELLER R, 1993, STUD FAMILY PLANN, V24, P269, DOI 10.2307/2939221; Gaffikin L, 1998, ADV CONTRACEPT, V14, P27, DOI 10.1023/A:1006519409808; Gregson S, 1998, SOC SCI MED, V46, P321, DOI 10.1016/S0277-9536(97)00165-2; Kasule J, 1997, E AFR MED J, V74, P76; Kirk D, 1998, STUD FAMILY PLANN, V29, P1, DOI 10.2307/172178; Lauby JL, 1998, HEALTH EDUC RES, V13, P343, DOI 10.1093/her/13.3.343; Lee K, 1998, SOC SCI MED, V47, P949, DOI 10.1016/S0277-9536(98)00168-3; *MACR INT INC, 1995, DEM HLTH SURV ZIMB 1; MAHOMED K, 1991, CENT AFR J MED, V37, P316; Mbizvo M. T., 1995, Central African Journal of Medicine, V41, P346; *MIN HLTH FAM WELF, 1998, SURV AIDS; REDDY SP, 1999, THESIS U MAASTRICHT; Schaalma HP, 1996, HEALTH EDUC QUART, V23, P469, DOI 10.1177/109019819602300407; Udjo EO, 1996, J BIOSOC SCI, V28, P25; VERKUYL D, 1996, SOUNDINGS, V52; VOGELS T, 1993, INT J ADOLESC MED HL, V6, P137; WILSON A, 1993, RFE RL RES REPORT, V2, P8; WILSON D J, 1990, AIDS Care, V2, P267, DOI 10.1080/09540129008257739	20	0	0	0	0	ROYAL SOC MEDICINE PRESS LTD	LONDON	1 WIMPOLE STREET, LONDON W1M 8AE, ENGLAND	0049-4755			TROP DOCT	Trop. Dr.	OCT	2000	30	4					247	249		10.1177/004947550003000428				3	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	361KY	WOS:000089723300026	11075669				2019-03-26	
J	Van der Stuyft, P; Unger, JP				Van der Stuyft, P; Unger, JP			Improving the performance of health systems: the World Health Report as go-between for scientific evidence and ideological discourse	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Editorial Material							BURDEN		Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium	Van der Stuyft, P (reprint author), ITG, Dept Publ Hlth, Natl Str 155, B-2000 Antwerp, Belgium.						Cooper RS, 1998, LANCET, V351, P208, DOI 10.1016/S0140-6736(97)06512-4; FEIN R, 1972, MILBANK MEML FUND Q, V50, P157, DOI 10.2307/3349437; Halstead S, 1985, GOOD HLTH LOW COST; Mulligan J, 2000, BRIT MED J, V321, P191, DOI 10.1136/bmj.321.7255.191; Murray CJL, 2000, B WORLD HEALTH ORGAN, V78, P717; Stefanini A, 1999, TROP MED INT HEALTH, V4, P709, DOI 10.1046/j.1365-3156.1999.00502.x; Wiseman V, 1998, HEALTH POLICY, V43, P243, DOI 10.1016/S0168-8510(98)00003-7; World Bank, 1993, WORLD DEV REP INV HL; World Health Organization, 2000, WORLD HLTH REP 2000; World Health Organization [WHO], 1978, WHO HLTH ALL SER, V1	10	3	3	0	2	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2000	5	10					675	677		10.1046/j.1365-3156.2000.00635.x				3	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	365EL	WOS:000089935400001	11044260	Bronze			2019-03-26	
J	Ndour, M; Sow, PS; Coll-Seck, AM; Badiane, S; Ndour, CT; Diakhate, N; Diop, B; Faye, M; Soumare, M; Diouf, G; Colebunders, R				Ndour, M; Sow, PS; Coll-Seck, AM; Badiane, S; Ndour, CT; Diakhate, N; Diop, B; Faye, M; Soumare, M; Diouf, G; Colebunders, R			AIDS caused by HIV1 and HIV2 infection: Are there clinical differences ?<Tau Beta > Results of AIDS surveillance 1986-97 at Fann Hospital in Dakar, Senegal	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						HIV1; HIV2; clinical symptoms; Senegal	IMMUNODEFICIENCY-VIRUS TYPE-2; GUINEA-BISSAU; COTE-DIVOIRE; WEST-AFRICA; IVORY-COAST; ABIDJAN; ADULTS; IMMUNOSUPPRESSION; TUBERCULOSIS; TRANSMISSION	OBJECTIVE To compare the clinical manifestations observed in AIDS patients infected with HIV2 and HIV1 infection. METHODS The medical records of AIDS patients hospitalized between January 1986 and July 1997 at the Department of Infectious Diseases of Fann Hospital, Dakar, were reviewed. RESULTS 599 hospitalizations (76%) were HIV1 seropositive patients, 137 (17%) were HIV2 seropositive patients and 54 (7%) were patients serologically dually reactive to HIV1 and HIV2. There was no significant difference in medium CD4 lymphocyte count between patients with HIV1 and HIV2 infection. Chronic diarrhoea and diarrhoea caused by bacterial infections were more frequently observed in HIV2-infected individuals. Oral candidiasis and chronic fever were more often noted in patients with HIV1 infection. Bacterial and cryptococcal meningitis was only observed among patients with HIV1 infection. CONCLUSIONS Certain clinical differences were observed comparing AIDS patients with HIV1 and those with HIV2 infection. As there is no clear physiopathological explanation for these differences, additional studies with larger numbers of AIDS patients are needed to determine whether these differences are real.	Inst Trop Med, B-2000 Antwerp, Belgium; Fann Hosp, Dept Infect Dis, Dakar, Senegal; WHO, UNAIDS, CH-1211 Geneva, Switzerland	Colebunders, R (reprint author), Inst Trop Med, Natl Str 155, B-2000 Antwerp, Belgium.	bcoleb@itg.be					ABOUYA L, 1995, TUBERCLE LUNG DIS, V76, P436, DOI 10.1016/0962-8479(95)90011-X; CLAVEL F, 1987, NEW ENGL J MED, V316, P1180, DOI 10.1056/NEJM198705073161903; COLEBUNDERS R, 1987, LANCET, V1, P492; COLEBUNDERS RL, 1991, AIDS, V5, pS103; DECOCK KM, 1991, AIDS, V5, P859, DOI 10.1097/00002030-199107000-00010; DECOCK KM, 1990, AIDS, V4, P443, DOI 10.1097/00002030-199005000-00010; DECOCK KM, 1991, AIDS, V5, pS89; GILKS CF, 1993, LANCET, V342, P1037, DOI 10.1016/0140-6736(93)92885-W; GILKS CF, 1990, LANCET, V336, P545, DOI 10.1016/0140-6736(90)92096-Z; GNAORE E, 1993, T ROY SOC TROP MED H, V87, P57, DOI 10.1016/0035-9203(93)90420-U; Grant AD, 1997, AIDS, V11, P1357, DOI 10.1097/00002030-199711000-00010; KANKI PJ, 1994, LANCET, V343, P943, DOI 10.1016/S0140-6736(94)90065-5; KANKI PJ, 1994, AIDS S1, V8, pS85; KOFFI K, 1992, EUR J CLIN MICROBIOL, V11, P271, DOI 10.1007/BF02098100; LEGUENNO BM, 1991, J ACQ IMMUN DEF SYND, V4, P421; LISSE IM, 1990, AIDS, V4, P1263, DOI 10.1097/00002030-199012000-00013; LUCAS SB, 1993, AIDS, V7, P1569, DOI 10.1097/00002030-199312000-00005; MARLINK R, 1994, SCIENCE, V265, P1587, DOI 10.1126/science.7915856; NAUCLER A, 1992, SCAND J INFECT DIS, V24, P725, DOI 10.3109/00365549209062457; NAUCLER A, 1991, AIDS, V5, P301, DOI 10.1097/00002030-199103000-00009; NORRGREN H, 1995, 9 INT C AIDS STD AFR; PEETERS M, 1992, LANCET, V340, P339, DOI 10.1016/0140-6736(92)91407-Y; PEPIN J, 1991, AIDS, V5, P1165, DOI 10.1097/00002030-199110000-00002; *PNLS, 1998, PROGR NAT LUTT CONTR; POULSEN AG, 1993, J ACQ IMMUN DEF SYND, V6, P941; POULSEN AG, 1992, J ACQ IMMUN DEF SYND, V5, P25; RICARD D, 1994, AIDS, V8, P977, DOI 10.1097/00002030-199407000-00016; SOW PS, 1994, ANN SOC BELG MED TR, V74, P253; TAELMAN H, 1990, COMMUNITY ACQUIRED B; TRAVERS K, 1995, SCIENCE, V268, P1612, DOI 10.1126/science.7539936; van der Loeff MFS, 1999, AIDS, V13, pS69; WHITE DJG, 1994, XENOTRANSPLANTATION, V2, P1	32	13	13	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2000	5	10					687	691		10.1046/j.1365-3156.2000.00627.x				5	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	365EL	WOS:000089935400003	11044262				2019-03-26	
J	De Clercq, D; Vercruysse, J; Verle, P; Kongs, A; Diop, M				De Clercq, D; Vercruysse, J; Verle, P; Kongs, A; Diop, M			What is the effect of combining artesunate and praziquantel in the treatment of Schistosoma mansoni infections ?	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						artesunate; praziquantel; combination treatment; S. mansoni; Senegal		A group of 110 individuals with Schistosoma mansoni infection was investigated. Patients were allocated to one of three treatment groups and given artesunate or praziquantel alone or both in combination. Combined artesunate-praziquantel significantly increased the number of individuals cured at 5 weeks post-treatment, but at 12 weeks was only better than artesunate alone and at 24 weeks there was no statistically significant difference between the three groups. Egg count reduction rate was similar to the rate obtained with praziquantel used alone.	Univ Ghent, Fac Vet Med, Dept Parasitol, B-9820 Merelbeke, Belgium; Reg Med St Louis, Programme Espoir, St Louis, Senegal; Belgian Tech Cooperat, Hanoi, Vietnam	De Clercq, D (reprint author), Univ Ghent, Fac Vet Med, Dept Parasitol, Salisburylaan 133, B-9820 Merelbeke, Belgium.						Araujo N, 1999, REV SOC BRASILEIRA M, V32, P7; De Clercq D, 2000, T ROY SOC TROP MED H, V94, P90, DOI 10.1016/S0035-9203(00)90453-X; SHUHUA X, 1989, ANTIMICROB AGENTS CH, V33, P1557, DOI 10.1128/AAC.33.9.1557; Utzinger J, 2000, LANCET, V355, P1320, DOI 10.1016/S0140-6736(00)02114-0; Wu LingJuan, 1998, Chinese Journal of Schistosomiasis Control, V10, P65; Xiao SH, 2000, PARASITOL TODAY, V16, P122, DOI 10.1016/S0169-4758(99)01601-4	6	34	35	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2000	5	10					744	746						3	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	365EL	WOS:000089935400011	11044270	Bronze			2019-03-26	
J	Jamonneau, V; Truc, P; Garcia, A; Magnus, E; Buscher, P				Jamonneau, V; Truc, P; Garcia, A; Magnus, E; Buscher, P			Preliminary evaluation of LATEX/T-b. gambiense and alternative versions of CATT/T-b. gambiense for the serodiagnosis of Human African Trypanosomiasis of a population at risk in Cote d'Ivoire: considerations for mass-screening	ACTA TROPICA			English	Article						human African trypanosomiasis; sleeping sickness; Typanosoma brucei gambiense; diagnosis; CATT; LATEX	BRUCEI-GAMBIENSE; AGGLUTINATION-TEST; DIAGNOSIS; SENSITIVITY; INFECTIONS; ANTIGENS; QBC(R)	A study was conducted to compare classical card agglutination test for trypanosomiasis (CATT)/T. b. gambiense with CATT-EDTA and LATEX/T. b. gambiense as alternative field tests for serodiagnosis of Human African Trypanosomiasis. The tests were performed on freshly collected blood in an endemic and a low prevalence area in Cote d'Ivoire. Diagnostic performance of each test was assessed using Quantitative Buffy Coat as the parasitological reference and immune trypanolysis as the serological reference test. According to the parasitological data, CATT-EDTA on 10 mu l and LATEX/T. b. gambiense on blood diluted 1:4, detecting all confirmed cases with good specificity (respectively 94.6% and 98.1%) yielded better results than the classical CATT did (one false negative and 92.5% specific). However, when immune trypanolysis data and feasibility are taken into account, the classical CATT remains the test of choice for mass screening under the given field conditions. (C) 2000 Elsevier Science B.V. All rights reserved.	Anciennement ORSTOM, Cote Ivoire & Inst Rechembe Dev, OCCGE, Inst Pierre Richet,Lab Genet Parasites & Vecteurs, F-34000 Montpellier 01, France; Anciennement ORSTOM, Inst Rech Dev, Lab Etud Maladies Vecteurs, F-34000 Montpellier, France; Inst Trop Med, Dept Parasitol, B-2000 Antwerp, Belgium	Jamonneau, V (reprint author), Anciennement ORSTOM, Cote Ivoire & Inst Rechembe Dev, OCCGE, Inst Pierre Richet,Lab Genet Parasites & Vecteurs, 01 BP 1500 Bouake,911 Ave Agropolis, F-34000 Montpellier 01, France.		Garcia, Andre/S-2959-2016; Jamonneau, Vincent/K-1124-2016; Buscher, Philippe/B-9956-2012	Garcia, Andre/0000-0002-1808-472X; Buscher, Philippe/0000-0002-1926-7472			[Anonymous], 1998, WHO TECHN REP SER, V881; BAFORT JM, 1986, S AFR MED J, V69, P541; BAILEY JW, 1992, T ROY SOC TROP MED H, V86, P630, DOI 10.1016/0035-9203(92)90160-E; Buscher P, 1999, ACTA TROP, V73, P11, DOI 10.1016/S0001-706X(99)00009-1; BUSCHER P, 1991, ANN SOC BELG MED TR, V71, P267; Diallo PB, 1996, B SOC PATHOL EXOT, V89, P262; DUKES P, 1992, ACTA TROP, V51, P123, DOI 10.1016/0001-706X(92)90054-2; DUKES P, 1984, TROPENMED PARASITOL, V35, P141; GERSTMAN BB, 1998, EPIDEMIOLOGY KEPT SI, P120; LAVEISSIERE C, 1986, Cahiers O.R.S.T.O.M. (Office de la Recherche Scientifique et Technique Outre-Mer) Serie Entomologie Medicale et Parasitologie, V24, P111; Le Ray D, 1975, Ann Soc Belg Med Trop, V55, P129; MAGNUS E, 1978, ANN SOC BELG MED TR, V58, P169; MIEZAN T, 1991, B WORLD HEALTH ORGAN, V69, P603; NOIREAU F, 1986, ANN SOC BELG MED TR, V66, P63; NOIREAU F, 1987, B SOC PATHOL EXOT, V80, P797; Pansaerts R, 1998, ACTA TROP, V70, P349, DOI 10.1016/S0001-706X(98)00046-1; PENCHENIER L, 1991, ANN SOC BELG MED TR, V71, P221; PENCHENIER L, 1998, B LIAIS DOC OCEAC, V31, P8; SEED JR, 1974, J PROTOZOOL, V21, P639, DOI 10.1111/j.1550-7408.1974.tb03718.x; Truc P, 1998, T ROY SOC TROP MED H, V92, P288, DOI 10.1016/S0035-9203(98)91014-8; van Meirvenne N., 1975, Annales Soc belge Med trop, V55, P1; VanMeirvenne N, 1995, ACTA TROP, V60, P189, DOI 10.1016/0001-706X(95)00127-Z; VANMEIRVENNE N, 1977, ANN SOC BELG MED TR, V57, P409; ZILLMANN U, 1986, TROP MED PARASITOL, V37, P390	24	14	14	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0001-706X			ACTA TROP	Acta Trop.	SEP 18	2000	76	2					175	183		10.1016/S0001-706X(00)00095-4				9	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	341ZV	WOS:000088621600011	10936577				2019-03-26	
J	de Clercq, D; Vercruysse, J; Sene, M; Seck, I; Sall, CSM; Ly, A; Southgate, VR				de Clercq, D; Vercruysse, J; Sene, M; Seck, I; Sall, CSM; Ly, A; Southgate, VR			The effects of irrigated agriculture on the transmission of urinary schistosomiasis in the Middle and Upper Valleys of the Senegal River basin	ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY			English	Article							EPIDEMIOLOGY; HAEMATOBIUM; COMPATIBILITY; INFECTIONS; PREVALENCE; VILLAGES; PROGRAM; BULINUS; DELTA	The importance of the increase in irrigated land on the perimeters of the Middle and Upper Valleys of the Senegal River basin, on the prevalence and intensity of urinary schistosomiasis, was investigated. Surveys were conducted, in May-June 1997, to determine the prevalence and intensity of Schistosoma haematobium infection among 1445 children aged 7-14 years: 1011 in 10 villages near Matam, and 434 in four villages near Bakel. Macrohaematuria was present in seven of the study villages (four near Matam and three near Bakel), whereas microhaematuria was present in all the villages, with prevalences of 10%-73%. A second survey, conducted, in June 1999, on 755 children from nine of the study villages near Matam, demonstrated significant increases in the prevalences of both micro- and macro-haematuria in three of the villages, all of which were adjacent to the Senegal River and practising irrigated agriculture. None of the other study villages re-surveyed was irrigating any of its agricultural land. A longitudinal survey was also carried out, between May 1997 and November 1998, on about 10% of the population (2272 subjects) of Nguidjilone, north of Matam; selective treatment with praziquantel (40 mg/kg) was given in May 1997, and mass treatment in May 1998. The data analysed were those relating to the 125 individuals who provided samples at each survey. Very severe infections (> 1000 eggs/10 ml urine) were seen in five subjects in May 1997. One year later (i.e. 1 year after the selective treatment), the prevalence of urinary schistosomiasis had increased in every age-group. Although prevalence had decreased slightly by November 1998 (6 months after the mass treatment), the intensity of the infections seen had increased in every age-group. At the end of the dry season (May-June 1997), Bulinus truncatus infected with schistosome cercariae were recovered from the Senegal River. However, immediately after the next rainy season (November 1997), no snails were found at any collection site on the river.	State Univ Ghent, Fac Vet Med, Dept Parasitol, B-9820 Merelbeke, Belgium; Reg Med St Louis, St Louis, Senegal; IRD Ex ORSTOM Bel Air, Lab Paludol, Dakar, Senegal; Ctr Sante, Matam, Senegal; Hop Bakel, Bakel, Senegal; Nat Hist Museum, Dept Zool, Biomed Sci Theme, London SW7 5BD, England	de Clercq, D (reprint author), State Univ Ghent, Fac Vet Med, Dept Parasitol, Salisburylaan 133, B-9820 Merelbeke, Belgium.						[Anonymous], 1985, WHO TECHN REP SER, V728; AUDIBERT M, 1990, AM J TROP MED HYG, V42, P550, DOI 10.4269/ajtmh.1990.42.550; BRINKMANN UK, 1988, TROP MED PARASITOL, V39, P182; CHAINE JP, 1983, TROP GEOGR MED, V35, P249; De Clercq D, 1999, TROP MED INT HEALTH, V4, P544; DIALLO S, 1991, PREVALENCE MALADIES; Ernould JC, 1999, ANN TROP MED PARASIT, V93, P135; Lwambo NJS, 1997, T ROY SOC TROP MED H, V91, P643, DOI 10.1016/S0035-9203(97)90504-6; Picquet M, 1996, T ROY SOC TROP MED H, V90, P340, DOI 10.1016/S0035-9203(96)90501-5; Rollinson D, 1997, ANN TROP MED PARASIT, V91, P371, DOI 10.1080/00034983.1997.11813152; Savioli L, 1997, PARASITOL TODAY, V13, P444, DOI 10.1016/S0169-4758(97)01141-1; Shaw DJ, 1999, T ROY SOC TROP MED H, V93, P142, DOI 10.1016/S0035-9203(99)90288-2; SOUTHGATE VR, 1985, J NAT HIST, V19, P1249, DOI 10.1080/00222938500770801; Southgate VR, 2000, ANN TROP MED PARASIT, V94, P157, DOI 10.1080/00034980057491; STELMA FF, 1993, AM J TROP MED HYG, V49, P701, DOI 10.4269/ajtmh.1993.49.701; TALLA I, 1992, T ROY SOC TROP MED H, V86, P182, DOI 10.1016/0035-9203(92)90562-Q; VERCRUYSSE J, 1994, TROP GEOGR MED, V46, P220; VERCRUYSSE J, 1985, ACTA TROP, V42, P249; VERLE P, 1994, T ROY SOC TROP MED H, V88, P401, DOI 10.1016/0035-9203(94)90400-6	19	9	9	0	8	CARFAX PUBLISHING	BASINGSTOKE	RANKINE RD, BASINGSTOKE RG24 8PR, HANTS, ENGLAND	0003-4983			ANN TROP MED PARASIT	Ann. Trop. Med. Parasitol.	SEP	2000	94	6					581	590		10.1080/00034983.2000.11813581				10	Public, Environmental & Occupational Health; Parasitology; Tropical Medicine	Public, Environmental & Occupational Health; Parasitology; Tropical Medicine	363BZ	WOS:000089815200006	11064760				2019-03-26	
J	Boelaert, M; Criel, B; Leeuwenburg, J; Van Damme, W; Le Ray, D; Van der Stuyft, P				Boelaert, M; Criel, B; Leeuwenburg, J; Van Damme, W; Le Ray, D; Van der Stuyft, P			Visceral leishmaniasis control: a public health perspective	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Review						visceral leishmaniasis; disease control; epidemiology; transmission; clinical aspects; diagnosis; chemotherapy	DIRECT AGGLUTINATION-TEST; AZAR DERMAL LEISHMANIASIS; POLYMERASE CHAIN-REACTION; PLUS INTERFERON-GAMMA; ENDEMIC KALA-AZAR; SODIUM STIBOGLUCONATE; PENTAVALENT ANTIMONY; EASTERN SUDAN; PARASITOLOGICAL METHODS; COST-EFFECTIVENESS	Visceral leishmaniasis (VL), also known as kala-azar, is a vector-borne disease caused by a protozoan of the Leishmania donovani complex. A phlebotomine sandfly transmits the parasite from person to person or via an animal reservoir. VL is a severe, debilitating disease, characterized by prolonged fever, splenomegaly, hypergammaglobulinaemia and pancytopenia. Patients become gradually ill over a period of a few months, and nearly always die if untreated. Case-fatality ratios are high even in treated patients. Worldwide an estimated 500000 VL cases occur each year. This study reviews clinical, epidemiological and public health aspects of the disease and shows how critical adequate case detection is for the success of VL control. Examination of the issue of VL diagnosis with respect to the global challenges in VL control leads to the observation that a sound diagnostic-therapeutic algorithm for the health services in endemic areas is badly needed. Serological tests could be an alternative to parasitological diagnosis and the direct agglutination test (DAT) was found to fulfil many criteria for a 'field test', including cost effectiveness. Although research needs on vaccine and better drugs continue to be high on the agenda, a VL test-treatment: strategy based on currently available highly sensitive serological tests, such as the DAT, should be introduced in the health services in endemic areas.	Inst Trop Med, Epidemiol Unit, Dept Publ Hlth, B-2000 Antwerp, Belgium; Inst Trop Med, Dept Parasitol, B-2000 Antwerp, Belgium; Reg Publ Hlth Serv, Dordrecht, Netherlands	Boelaert, M (reprint author), Inst Trop Med, Epidemiol Unit, Dept Publ Hlth, Nationalestr 155, B-2000 Antwerp, Belgium.	boelaert@itg.be	Van Damme, Wim/F-7404-2011; Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776			ABDELHAMEED AA, 1989, TROP MED PARASITOL, V40, P470; ABRANCHES P, 1983, ANN PARASIT HUM COMP, V58, P307, DOI 10.1051/parasite/1983584307; ADDY M, 1992, B WORLD HEALTH ORGAN, V70, P341; Adhya S, 1995, T ROY SOC TROP MED H, V89, P622, DOI 10.1016/0035-9203(95)90416-6; ALI A, 1994, ANN TROP MED PARASIT, V88, P289, DOI 10.1080/00034983.1994.11812869; ALLAIN DS, 1975, AM J TROP MED HYG, V24, P232, DOI 10.4269/ajtmh.1975.24.232; ASHFORD RW, 1992, PARASITOL TODAY, V8, P104, DOI 10.1016/0169-4758(92)90249-2; BADARO R, 1986, J INFECT DIS, V154, P1003, DOI 10.1093/infdis/154.6.1003; BADARO R, 1990, NEW ENGL J MED, V322, P16, DOI 10.1056/NEJM199001043220104; BALLOU WR, 1987, LANCET, V2, P13; BERMAN JD, 1988, REV INFECT DIS, V10, P560; Berman JD, 1997, CLIN INFECT DIS, V24, P684, DOI 10.1093/clind/24.4.684; Boelaert M, 1999, AM J TROP MED HYG, V60, P129, DOI 10.4269/ajtmh.1999.60.129; Boelaert M, 1999, TROP MED INT HEALTH, V4, P31, DOI 10.1046/j.1365-3156.1999.00348.x; Boelaert M, 1999, B WORLD HEALTH ORGAN, V77, P667; Boelaert M, 1999, TROP MED INT HEALTH, V4, P789, DOI 10.1046/j.1365-3156.1999.00487.x; BRAMACHARI UN, 1922, INDIAN MED GAZETTE, V57, P125; Bryceson A. D. M., 1996, Manson's tropical diseases., P1213; CAHILL KM, 1964, AM J TROP MED HYG, V13, P794, DOI 10.4269/ajtmh.1964.13.794; CERF BJ, 1987, J INFECT DIS, V156, P1030, DOI 10.1093/infdis/156.6.1030; Chowdhury M. S., 1993, Archives de l'Institut Pasteur de Tunis, V70, P333; CHOWDHURY MS, 1993, PARASITOL RES, V79, P444, DOI 10.1007/BF00931580; CHULAY JD, 1983, AM J TROP MED HYG, V32, P475, DOI 10.4269/ajtmh.1983.32.475; CHULAY JD, 1985, AM J TROP MED HYG, V34, P702, DOI 10.4269/ajtmh.1985.34.702; CORKILL NL, 1948, ANN TROP MED PARASIT, V42, P224, DOI 10.1080/00034983.1948.11685366; DEBEER P, 1991, AM J TROP MED HYG, V44, P283, DOI 10.4269/ajtmh.1991.44.283; DEGORGOLAS M, 1994, NATURE, V372, P734, DOI 10.1038/372734b0; DELALOMA A, 1985, T ROY SOC TROP MED H, V79, P421, DOI 10.1016/0035-9203(85)90400-6; DERAADT P, 1977, ECOLOGIE LEISHMANIOS, P313; Desjeux P, 1996, CLIN DERMATOL, V14, P417, DOI 10.1016/0738-081X(96)00057-0; Desjeux P., 1992, World Health Statistics Quarterly, V45, P267; DYE C, 1992, PARASITOLOGY, V104, pS7, DOI 10.1017/S0031182000075211; DYE C, 1988, T ROY SOC TROP MED H, V82, P843, DOI 10.1016/0035-9203(88)90013-2; ELMASUM MA, 1995, T ROY SOC TROP MED H, V89, P185, DOI 10.1016/0035-9203(95)90487-5; Elnaiem DA, 1999, MED VET ENTOMOL, V13, P310, DOI 10.1046/j.1365-2915.1999.00191.x; Elnaiem DEA, 1998, ACTA TROP, V71, P305, DOI 10.1016/S0001-706X(98)00067-9; ELSAFI SH, 1989, T ROY SOC TROP MED H, V83, P334, DOI 10.1016/0035-9203(89)90493-8; EVANS TG, 1992, J INFECT DIS, V166, P1124, DOI 10.1093/infdis/166.5.1124; FERNANDEZGUERRERO ML, 1987, AM J MED, V83, P1098, DOI 10.1016/0002-9343(87)90948-X; Griekspoor A, 1999, HEALTH POLICY PLANN, V14, P70, DOI 10.1093/heapol/14.1.70; GUAN LR, 1991, ASIAN J TROPICAL MED, V22, P291; HAILU A, 1990, T ROY SOC TROP MED H, V84, P673, DOI 10.1016/0035-9203(90)90141-Z; HARITH AE, 1986, T ROY SOC TROP MED H, V80, P583, DOI 10.1016/0035-9203(86)90149-5; HASHIM FA, 1994, T ROY SOC TROP MED H, V88, P431, DOI 10.1016/0035-9203(94)90417-0; HO M, 1982, T ROY SOC TROP MED H, V76, P741, DOI 10.1016/0035-9203(82)90095-5; HOOGSTRA.H, 1969, AM J TROP MED HYG, V18, P1091, DOI 10.4269/ajtmh.1969.18.1091; Jha TK, 1999, NEW ENGL J MED, V341, P1795, DOI 10.1056/NEJM199912093412403; KAGER PA, 1983, TROP GEOGR MED, V35, P125; KAR K, 1995, CRIT REV MICROBIOL, V21, P123, DOI 10.3109/10408419509113537; KAUL SM, 1994, B WORLD HEALTH ORGAN, V72, P79; Khalil EAG, 1998, ANN TROP MED PARASIT, V92, P151, DOI 10.1080/00034983.1998.11813274; KillickKendrick R, 1997, MED VET ENTOMOL, V11, P105, DOI 10.1111/j.1365-2915.1997.tb00298.x; LACERDA MM, 1994, MEM I OSWALDO CRUZ, V89, P489, DOI 10.1590/S0074-02761994000300036; MAGILL AJ, 1993, NEW ENGL J MED, V328, P1383, DOI 10.1056/NEJM199305133281904; MAGNUS E, 1978, ANN SOC BELG MED TR, V58, P169; MAHMOUD AAF, 1977, J INFECT DIS, V136, P160, DOI 10.1093/infdis/136.1.160; MANSONBAHR PEC, 1955, NATURE, V175, P433, DOI 10.1038/175433b0; MANSONBAHR PEC, 1964, J TROP MED HYG, V67, P79; MARSDEN PD, 1986, T ROY SOC TROP MED H, V80, P859, DOI 10.1016/0035-9203(86)90243-9; MEREDITH SEO, 1995, J CLIN MICROBIOL, V33, P1742; MONTALBAN C, 1990, J INFECTION, V21, P261, DOI 10.1016/0163-4453(90)93933-J; MURRAY CJL, 1996, GLOBAL HLTH STAT, V2; Nandy A, 1998, TROP MED INT HEALTH, V3, P76, DOI 10.1046/j.1365-3156.1998.00176.x; NEVA FA, 1990, NEW ENGL J MED, V322, P55, DOI 10.1056/NEJM199001043220111; NUZUM E, 1995, J INFECT DIS, V171, P751, DOI 10.1093/infdis/171.3.751; NYAKUNDI PM, 1988, T ROY SOC TROP MED H, V82, P564, DOI 10.1016/0035-9203(88)90508-1; Pearson RD, 1996, CLIN INFECT DIS, V22, P1, DOI 10.1093/clinids/22.1.1; PROCES S, 1997, LOUVAIN MED, V116, P123; RAMESH V, 1995, INT J DERMATOL, V34, P85, DOI 10.1111/j.1365-4362.1995.tb03584.x; RAMESH V, 1994, INT J DERMATOL, V33, P153, DOI 10.1111/j.1365-4362.1994.tb04968.x; Sati MH, 1958, SUDAN MED J, V1, P98; Saxena N. B. L., 1996, Journal of Communicable Diseases, V28, P122; SCHAEFER KU, 1995, T ROY SOC TROP MED H, V89, P471, DOI 10.1016/0035-9203(95)90070-5; Seaman J, 1996, INT J EPIDEMIOL, V25, P862, DOI 10.1093/ije/25.4.862; SEAMAN J, 1992, ANN TROP MED PARASIT, V86, P481, DOI 10.1080/00034983.1992.11812697; SIDDIG M, 1988, T ROY SOC TROP MED H, V82, P66, DOI 10.1016/0035-9203(88)90265-9; SINGLA N, 1993, T ROY SOC TROP MED H, V87, P276, DOI 10.1016/0035-9203(93)90125-A; SINHA R, 1994, J TROP MED HYG, V97, P333; SQUIRES KE, 1993, AM J TROP MED HYG, V48, P666, DOI 10.4269/ajtmh.1993.48.666; STEPHENSON R. W., 1940, ANN TROP MED AND PARASITOL, V34, P175; Sundar S, 1998, LANCET, V351, P563, DOI 10.1016/S0140-6736(97)04350-X; Sundar S, 1998, LANCET, V352, P1821, DOI 10.1016/S0140-6736(98)04367-0; Sundar S, 1997, AM J TROP MED HYG, V56, P522, DOI 10.4269/ajtmh.1997.56.522; Sundar S, 1997, J INFECT DIS, V176, P1117, DOI 10.1086/516526; SUNDAR S, 1994, J INFECT DIS, V170, P659, DOI 10.1093/infdis/170.3.659; SYMMERS WS, 1960, LANCET, V1, P127; TESH RB, 1995, AM J TROP MED HYG, V52, P287, DOI 10.4269/ajtmh.1995.52.287; THAKUR CP, 1994, WORLD HEALTH FORUM, V15, P245; *UNDP WORLD BANK W, 1997, TROP DIS RES PROGR 1; VanGompel A, 1997, CURR OPIN INFECT DIS, V10, P469; *WHO, 1997, WKLY EPIDEMIOL REC, V72, P49; *WHO, 1998, WHOLEISH9741; *WHO ODA, 1996, WHOLEISH9640178; WIJEYARATNE PM, 1994, ACTA TROP, V56, P349, DOI 10.1016/0001-706X(94)90106-6; World Health Organization, 1998, WHOCTDLEISH989; World Health Organization (WHO), 1990, WHO TECHN REP SER, V793; ZIJLSTRA EE, 1992, T ROY SOC TROP MED H, V86, P505, DOI 10.1016/0035-9203(92)90086-R; ZIJLSTRA EE, 1995, AM J TROP MED HYG, V52, P299, DOI 10.4269/ajtmh.1995.52.299; ZIJLSTRA EE, 1994, AM J TROP MED HYG, V51, P826, DOI 10.4269/ajtmh.1994.51.826; Zijlstra EE, 1997, T ROY SOC TROP MED H, V91, P671, DOI 10.1016/S0035-9203(97)90518-6; ZIJLSTRA EE, 1991, T ROY SOC TROP MED H, V85, P474, DOI 10.1016/0035-9203(91)90224-M; ZIJLSTRA EE, 1995, THESIS U AMSTERDAM N	102	72	77	0	5	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0035-9203	1878-3503		T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	SEP-OCT	2000	94	5					465	471		10.1016/S0035-9203(00)90055-5				7	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	379YD	WOS:000165670000001	11132368				2019-03-26	
J	Van den Ende, J; van Gompel, A; van den Enden, E; Taelman, H; Vanham, G; Vervoort, T				Van den Ende, J; van Gompel, A; van den Enden, E; Taelman, H; Vanham, G; Vervoort, T			Hyperreactive malaria in expatriates returning from sub-Saharan Africa	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						malaria; hyperreactive malarial splenomegaly; splenomegaly	TROPICAL SPLENOMEGALY SYNDROME; SUPPRESSOR LYMPHOCYTES-T; FALCIPARUM-MALARIA; PARASITEMIA; ANTIBODY	The extreme presentation of hyperreactive malaria is hyperreactive malarial splenomegaly syndrome (HMS). Some patients present with a less pronounced syndrome. To investigate whether the degree of splenomegaly correlates with the degree of immune stimulation, whether prophylaxis or recent treatment play a role, and whether short therapy alone is effective, we examined retrospectively the medical records of expatriates with exposure to P. falciparum who attended our outpatient department from 1986 to 1997, particularly subacute symptoms or signs, strongly elevated malarial antibodies and elevated total serum IgM. We analysed duration of stay, prophlyaxis intake, spleen size, serum IgM levels and response to antimalarial treatment. Serum IgM levels were significantly higher in patients with larger splenomegaly. The use of chloroquine alone as treatment for presumptive or proved malaria attacks was correlated with larger spleen size. Short adequate antimalarial therapy resulted in marked improvement or complete recovery In nine patients the hyperreactive response reappeared after re-exposure, in four of them twice. We conclude that patients with subacute symptoms but without gross splenomegaly may have very high levels of IgM and malarial antibodies, and relapse on re-exposure, suggesting the existence of a variant of the hyperreactive malarial splenomegaly syndrome without gross splenomegaly.	Inst Trop Med, B-2000 Antwerp, Belgium; Univ Antwerp Hosp, Edegem, Belgium	Van den Ende, J (reprint author), Inst Trop Med, Natl Str 155, B-2000 Antwerp, Belgium.	JVDE@itg.be					BETTICHER DC, 1990, J INFECT DIS, V161, P157, DOI 10.1093/infdis/161.1.157; BHATTACHARYA DN, 1983, T ROY SOC TROP MED H, V77, P221, DOI 10.1016/0035-9203(83)90077-9; BISOFFI XZ, 1998, GIORNALE ITALIANO ME, P68; BRABIN L, 1988, THESIS RIJKSUNIVERSI, P37; BRYCESON A, 1983, T ROY SOC TROP MED H, V77, P879, DOI 10.1016/0035-9203(83)90319-X; CHAGNON A, 1989, PRESSE MED, V18, P938; CHARMOT G, 1988, MED MALADIES INFECT, V18, P52, DOI 10.1016/S0399-077X(88)80326-3; CRANE G G, 1986, Parasitology Today, V2, P4, DOI 10.1016/0169-4758(86)90067-0; DECOCK KM, 1987, T ROY SOC TROP MED H, V81, P100, DOI 10.1016/0035-9203(87)90296-3; DECOCK KM, 1986, J TROP MED HYG, V89, P119; FAKUNLE YM, 1981, CLIN HEMATOLOGY, V3; HOFFMAN SL, 1984, NEW ENGL J MED, V310, P337, DOI 10.1056/NEJM198402093100601; Jimmy EO, 1996, T ROY SOC TROP MED H, V90, P37, DOI 10.1016/S0035-9203(96)90472-1; Kager P A, 1989, Ned Tijdschr Geneeskd, V133, P2122; LOUGLIN EA, 1947, JAMA-J AM MED ASSOC, V139, P997; LOWENTHAL MN, 1970, BMJ-BRIT MED J, V3, P262, DOI 10.1136/bmj.3.5717.262; MUNIZ JM, 1992, REV SOC BRASILEIRA M, V25, P257; Orus J, 1996, TROP DOCT, V26, P140, DOI 10.1177/004947559602600324; PIESSENS WF, 1985, J CLIN INVEST, V75, P1821, DOI 10.1172/JCI111895; PUENTE S, 1998, EUR C TRAV MED VEN 2, P163; SANSONETTI PJ, 1986, PRESSE MED, V15, P1264; STUIVER PC, 1974, THESIS U AMSTERDAM A, P110; TORRESROJAS JR, 1981, AM J TROP MED HYG, V30, P1; TOUZE JE, 1989, B SOC PATHOL EXOT, V82, P110; VANDENENDE J, 1994, ANN SOC BELG MED TR, V74, P69; VANGOMPEL A, 1991, ACTA CLIN BELG, V46, P125; VOLLER A, 1982, BRIT MED BULL, V38, P173, DOI 10.1093/oxfordjournals.bmb.a071755	27	17	17	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	SEP	2000	5	9					607	611						5	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	363CV	WOS:000089818000003	11044274				2019-03-26	
J	Crabbe, F; Vuylsteke, B; de Clerck, M; Laga, M				Crabbe, F; Vuylsteke, B; de Clerck, M; Laga, M			Cost-effectiveness of management strategies for acute urethritis in the developing world	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						urethritis; treatment; cost-effectiveness; syndromic approach	SEXUALLY-TRANSMITTED DISEASES; NEISSERIA-GONORRHOEAE; RESISTANCE; CIPROFLOXACIN; INFECTION; TANZANIA; TRIAL	OBJECTIVE To recommend a cost-effective approach for the management of acute male urethritis in the developing world, based on the findings of a theoretical study. METHODS A model was developed to assess the cost-effectiveness of three urethritis management strategies in a theoretical cohort of 1000 men with urethral syndrome. (1) All patients were treated with cefixime and doxycycline for gonococcal urethritis (GU) and nongonococcal urethritis (NGU), respectively, as recommended by WHO. (2) All patients were treated with doxycycline for NGU; treatment with cefixime was based on the result of direct microscopy of a urethral smear (3) All patients were treated with cotrimoxazole or kanamycin for GU and doxycycline for NGU. Cefixime was kept for patients not responding to the first GU treatment. Strategy costs included consultations, laboratory diagnosis (where applicable) and drugs. The outcome was the rate of patients cured of urethritis. Cost-effectiveness was measured in terms of cost per cured urethritis. RESULTS Strategy costs in our model depended largely on drug costs. The first strategy was confirmed as the most effective but also the most expensive approach. Cefixime should cost no more than US$ 1.5 for the strategy to be the most cost-effective. The second strategy saved money and drugs but proved a valuable alternative only when laboratory performance was optimal. The third strategy with cotrimoxazole was the least expensive but a low follow-up visit rate, poor treatment compliance or lower drug efficacy limited effectiveness. Maximizing compliance by replacing cotrimoxazole with single-dose kanamycin had the single greatest impact on the effectiveness of the third strategy. CONCLUSION Our model suggested that a cost-effective approach would be to treat gonorrhoea with a single-dose antibiotic selected from locally available produces that cost no more than US$ 1.5.	Inst Trop Med, STD HIV Res & Intervent Unit, B-2000 Antwerp, Belgium	Laga, M (reprint author), Inst Trop Med, STD HIV Res & Intervent Unit, Natl Str 155, B-2000 Antwerp, Belgium.						Bhalla P, 1998, SEX TRANSM INFECT, V74, P210, DOI 10.1136/sti.74.3.210; Bhuiyan BU, 1999, J CLIN MICROBIOL, V37, P1130; GOODHART ME, 1982, SEX TRANSM DIS, V9, P63, DOI 10.1097/00007435-198204000-00002; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; HOLMES KK, 1999, SEXUALLY TRANSMITTED, P833; HOMEDES N, 1993, HEALTH POLICY PLANN, V8, P291, DOI 10.1093/heapol/8.4.291; JORDAN WC, 1989, SEXUALLY TRANSMITTED, V8, P105; KATZ BP, 1991, SEX TRANSM DIS, V18, P36, DOI 10.1097/00007435-199101000-00008; Klausner JD, 1999, J INFECT DIS, V179, P729, DOI 10.1086/314625; KUVANONT K, 1989, SEX TRANSM DIS, V16, P137, DOI 10.1097/00007435-198907000-00004; LANDIS SJ, 1988, SEX TRANSM DIS, V15, P78, DOI 10.1097/00007435-198804000-00002; LOUIS JP, 1993, ANN SOC BELG MED TR, V73, P267; *MAN SCI HLTH, 1999, INT DRUG PRIC IND GU; MAYAUD P, 1992, GENITOURIN MED, V68, P361; MORAN JS, 1995, CLIN INFECT DIS, V20, pS47, DOI 10.1093/clinids/20.Supplement_1.S47; Moss A, 1997, GENITOURIN MED, V73, P331; Ng PPL, 1998, INT J STD AIDS, V9, P323, DOI 10.1258/0956462981922331; Tapsall JW, 1998, SEX TRANSM DIS, V25, P415, DOI 10.1097/00007435-199809000-00005; *WHO, 1994, MAN SEX TRANSM DIS; *WHO, 1991, TECHN REP SER WHO, V810	20	4	4	0	1	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	SEP	2000	5	9					640	647		10.1046/j.1365-3156.2000.00616.x				8	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	363CV	WOS:000089818000008	11044279	Bronze, Green Published			2019-03-26	
J	Parent, F; Coppieters, Y				Parent, F; Coppieters, Y			Assessment of hospital morbidity, mortality, and cost-effectiveness of a nutritional program for children under 5 years of age in Pala, Chad	JOURNAL OF TROPICAL PEDIATRICS			English	Article							MALNOURISHED CHILDREN; SOUTHWEST TANZANIA; REHABILITATION; MALNUTRITION; INDEXES; TRIAL; WASTE; MONEY; RISK; TIME	This paper analyses the effectiveness of case management at referral level for malnourished sick children in a rural district health system in the south of Chad (Pala district). The methodology followed was based on a cohort study of malnourished children as well as a cost-effective analysis of alternative options for nutritional rehabilitation strategies. Results show that effective case management at hospital level is possible with few resources as long as the nutritional rehabilitation programme is implemented on an integrated basis including early diagnosis of malnutrition for all children admitted to hospital and not to wait for a normal weight-for-height but discharge when the hospital is no longer the best place to avoid further mortality.	Inst Trop Med, B-2000 Antwerp, Belgium; Free Univ Brussels, Sch Publ Hlth, Brussels, Belgium	Parent, F (reprint author), Blvd Lambermont,99B, B-1030 Brussels, Belgium.			Coppieters, Yves/0000-0001-8899-9549			Ashworth A, 1997, HEALTH POLICY PLANN, V12, P115, DOI 10.1093/heapol/12.2.115; BEAU JP, 1987, J TROP PEDIATRICS, V33, P4, DOI 10.1093/tropej/33.1.4; BRANDERHORST E, 1983, THESIS ROYAL TROPICA; BRIEND A, 1986, BRIT MED J, V293, P373, DOI 10.1136/bmj.293.6543.373; BRIEND A, 1987, LANCET, V2, P725; CHAPKO MK, 1994, J TROP PEDIATRICS, V40, P225, DOI 10.1093/tropej/40.4.225; Cook R, 1971, J Trop Pediatr Environ Child Health, V17, P15; DRAMAIX M, 1993, REV EPIDEMIOL SANTE, V41, P131; Dramaix M, 1996, AM J EPIDEMIOL, V143, P1235; KHANUM S, 1994, LANCET, V344, P1728; PELLETIER DL, 1995, B WORLD HEALTH ORGAN, V73, P443; Renaudin P, 1997, Med Trop (Mars), V57, P49; VANROOSMALENWIEBENGA MW, 1986, J TROP PEDIATRICS, V32, P240, DOI 10.1093/tropej/32.5.240; VANROOSMALENWIEBENGA MW, 1987, J TROP PEDIATRICS, V33, P24, DOI 10.1093/tropej/33.1.24; Yoon PW, 1997, AM J CLIN NUTR, V65, P1070	15	0	0	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0142-6338			J TROP PEDIATRICS	J. Trop. Pediatr.	AUG	2000	46	4					252	254		10.1093/tropej/46.4.252				3	Pediatrics; Tropical Medicine	Pediatrics; Tropical Medicine	346QZ	WOS:000088883700019	10996995	Bronze			2019-03-26	
J	Van Damme, W; Van Lerberghe, W				Van Damme, W; Van Lerberghe, W			Epidemics and fear	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Editorial Material						epidemics; infectious diseases; disease control	SUDAN		Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium	Van Damme, W (reprint author), Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium.		Van Damme, Wim/F-7404-2011	Van Lerberghe, Wim/0000-0001-9966-6563			[Anonymous], 1995, CAMBRIDGE INT DICT E; ASCHERIO A, 1992, NEW ENGL J MED, V327, P931, DOI 10.1056/NEJM199209243271306; Braudel Fernand, 1973, MEDITERRANEAN MEDITE; Bres P, 1986, PUBLIC HLTH ACTION E; *BRIT MED ASS, 1987, LIV RISK; *CDC, 1991, JAMA-J AM MED ASSOC, V266, P633; Curtin Philip, 1989, DEATH MIGRATION EURO, P62; Delumeau Jean, 1987, MALHEURS TEMPS HIST; Dutton D. B., 1988, WORSE DIS PITFALLS M, P127; Foege W. H., 1991, TIME PLAGUE HIST SOC, P9; HERWALDT BL, 1993, LANCET, V342, P119, DOI 10.1016/0140-6736(93)91324-F; Jammal A., 1988, DICT EPIDEMIOLOGIE; JOHN TJ, 1994, LANCET, V344, P972, DOI 10.1016/S0140-6736(94)91637-3; KOHLAND DE, 1986, SCIENCE, V234, P921; KRUG E, 1994, MED NEWS MED FRONTIE, V3, P20; LACEY SW, 1995, CLIN INFECT DIS, V20, P1409, DOI 10.1093/clinids/20.5.1409; Last JM, 1983, DICT EPIDEMIOLOGY; Livi-Bacci M, 1992, CONCISE HIST WORLD P; MANUILA A, 1971, DICT FRANCAIS MED BI; McNeill W. H., 1976, PLAGUES PEOPLES; MUYEMBE T, 1995, LANCET, V345, P1448, DOI 10.1016/S0140-6736(95)92640-2; Nelkin D., 1991, TIME PLAGUE HIST SOC, P39; OLSER W, 1896, JAMA-J AM MED ASSOC, V26, P999; ROSENBERG CE, 1991, TIME PLAGUE HIST SOC, P5; Seaman J, 1996, INT J EPIDEMIOL, V25, P862, DOI 10.1093/ije/25.4.862; SURETCANALE J, 1964, AFRIQUE NOIRE ERE CO, P490; VANLERBERGHE W, 1988, POPULATION SOC AFRIQ, P335; Veeken H, 1997, BRIT MED J, V315, P1458, DOI 10.1136/bmj.315.7120.1458; WALSH J. A., 1990, TROPICAL GEOGRAPHICA, P185; Ziegler P., 1969, BLACK DEATH; ZINSSER H, 1935, RATS LICE HIST, P150; 1994, DORLANDS ILLUSTRATED; 1995, LANCET, V346, P1439; 1982, STEDMANS MED DICT; 1988, COLL COUB ESS DICT; 1994, LANCET, V344, P1033	36	12	12	0	0	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	AUG	2000	5	8					511	514						4	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	351KG	WOS:000089155900001	10995091				2019-03-26	
J	Polman, K; Diakhate, MM; Engels, D; Nahimana, S; Van Dam, GJ; Ferreira, STMF; Deelder, AM; Gryseels, B				Polman, K; Diakhate, MM; Engels, D; Nahimana, S; Van Dam, GJ; Ferreira, STMF; Deelder, AM; Gryseels, B			Specificity of circulating antigen detection for schistosomiasis mansoni in Senegal and Burundi	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						Schistosoma mansoni; circulating anodic antigen (CAA); circulating cathodic antigen (CCA); specificity; endemic countries; pretreatment	ANODIC ANTIGEN; CATHODIC ANTIGEN; QUANTITATIVE DIAGNOSIS; LINKED POLYSACCHARIDE; MONOCLONAL-ANTIBODIES; SERUM; INFECTIONS; URINE; EPIDEMIOLOGY; ASSAY	The specificity of schistosome circulating antigen detection was determined in negative individuals from two S. mansoni-endemic countries, Senegal and Burundi, and compared with results from Dutch control individuals. A nearly absolute specificity was achieved for circulating anodic antigen (CAA) detection in serum, irrespective of the target population or sample pretreatment method. Circulating cathodic antigen (CCA) detection in serum and urine resulted in a lower specificity than serum CAA detection. Apparent large differences in specificity of CCA detection between countries were mainly due to pretreatment methods. Apparently, the alkaline; heating pretreatment method is not as effective as trichloroacetic acid (TCA)-pretreatment in removing (certain) interfering components, which may vary between populations. In view of the development of the urine CCA assay into a noninvasive screening test, a slightly lower specificity may still be acceptable. For precise epidemiological analyses the highly specific serum CAA assay remains the method of choice.	Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium; Leiden Univ, Med Ctr, Dept Parasitol, Leiden, Netherlands; Reg Med St Louis, St Louis, Senegal; WHO, CH-1211 Geneva, Switzerland; Minist Sante Publ Burundi, Programme Lutte Malad Transmissibles & Carentiell, Bujumbura, Burundi	Polman, K (reprint author), Inst Trop Med Prince Leopold, Natl Str 155, B-2000 Antwerp, Belgium.						BERGWERFF AA, 1994, J BIOL CHEM, V269, P31510; DEELDER AM, 1994, TROP GEOGR MED, V46, P233; DEELDER AM, 1989, AM J TROP MED HYG, V40, P268, DOI 10.4269/ajtmh.1989.40.268; DEJONGE N, 1990, T ROY SOC TROP MED H, V84, P815, DOI 10.1016/0035-9203(90)90094-U; DEJONGE N, 1988, T ROY SOC TROP MED H, V82, P591, DOI 10.1016/0035-9203(88)90523-8; DEVLAS SJ, 1992, PARASITOL TODAY, V8, P274, DOI 10.1016/0169-4758(92)90144-Q; ElMorshedy H, 1996, AM J TROP MED HYG, V54, P149, DOI 10.4269/ajtmh.1996.54.149; GRYSEELS B, 1991, T ROY SOC TROP MED H, V85, P626, DOI 10.1016/0035-9203(91)90371-5; GRYSEELS B, 1994, TROP GEOGR MED, V46, P209; Hakangard C, 1996, ACTA TROP, V61, P213, DOI 10.1016/0001-706X(95)00146-6; KARZ N, 1972, REV INST MED TROP SP, V14, P397; KRIJGER FW, 1994, ACTA TROP, V56, P55, DOI 10.1016/0001-706X(94)90040-X; POLDERMAN AM, 1985, ANN SOC BELG MED TR, V65, P243; POLDERMAN AM, 1994, ACTA TROP, V58, P221, DOI 10.1016/0001-706X(94)90016-7; Polman K, 1998, AM J TROP MED HYG, V59, P150, DOI 10.4269/ajtmh.1998.59.150; POLMAN K, 1995, AM J TROP MED HYG, V53, P152, DOI 10.4269/ajtmh.1995.53.152; SCHUTTE CHJ, 1994, ANN TROP MED PARASIT, V88, P305, DOI 10.1080/00034983.1994.11812871; Van Lieshout L, 1998, T ROY SOC TROP MED H, V92, P115, DOI 10.1016/S0035-9203(98)90980-4; VANDAM GJ, 1994, EUR J BIOCHEM, V225, P467; vanEtten L, 1997, T ROY SOC TROP MED H, V91, P154, DOI 10.1016/S0035-9203(97)90204-2; VISSER PS, 1972, S AFR MED J, V46, P1344	21	41	42	0	1	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	AUG	2000	5	8					534	537		10.1046/j.1365-3156.2000.00600.x				4	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	351KG	WOS:000089155900004	10995094	Bronze			2019-03-26	
J	Laamrani, H; Khallaayoune, K; Boelee, E; Laghroubi, MM; Madsen, H; Gryseels, B				Laamrani, H; Khallaayoune, K; Boelee, E; Laghroubi, MM; Madsen, H; Gryseels, B			Evaluation of environmental methods to control snails in an irrigation system in Central Morocco	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						schistosomiasis; environment; irrigation; snail control; Bulinus truncatus; siphon boxes; Morocco	SCHISTOSOMA-HAEMATOBIUM; BULINUS-TRUNCATUS; INTERMEDIATE HOST; TRANSMISSION; AREA	The Moroccan Ministry of Public Health has launched a programme to eliminate schistosomiasis. One of the components in this process is the control of Bulinus truncatus, the intermediate host snail of Schistosoma haematobium We evaluated three environmentally safe measures to control B. truncatus in siphon boxes, the main breeding sires for these snails in the Tessaout Amont irrigation system. The first method involved covering the siphon boxes to exclude light and reduce algal growth, the second consisted of increasing the frequency of emptying and cleaning the siphon boxes, and the third method increased water velocity to hinder the establishment of the intermediate hosts. The results showed that covering had a pronounced effect on snail and egg mass density, was accepted by the local community and prevented water contact. Cleaning the siphons three times during the irrigation season led to a reduction in snail density although it was not statistically significant and recolonization was rapid. Increasing water velocity by reducing the dimensions of siphon boxes delayed recolonization, but such a control measure can be applied only in specific situations where it does not pose hydraulic problems. The three interventions were selectively effective against B. truncatus, whereas other snails such as Physa acuta and Lymnaea peregra were hardly affected. Covering, the most promising control measure, could be useful in the Moroccan schistosomiasis eradication programme. However, further investigations are needed to assess its impact on water quality.	Danish Bilharziasis Lab, DK-2920 Charlottenlund, Denmark; Inst Agron & Vet Hassan II, Dept Parasitol, Rabat, Morocco; Leiden Univ, Dept Parasitol, Fac Med, Leiden, Netherlands; Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium	Madsen, H (reprint author), Danish Bilharziasis Lab, Jaegersborg Alle 1D, DK-2920 Charlottenlund, Denmark.						APPLETON C C, 1978, Malacological Review, V11, P1; CHERNIN E, 1967, ANN TROP MED PARASIT, V61, P11, DOI 10.1080/00034983.1967.11686450; DAZO BC, 1966, B WORLD HEALTH ORGAN, V35, P339; ELEMAM MA, 1982, HYDROBIOLOGIA, V88, P265, DOI 10.1007/BF00008506; JOBIN WR, 1970, AM J TROP MED HYG, V19, P1049, DOI 10.4269/ajtmh.1970.19.1049; Jones H.R.R., 1993, THESIS LOUGHBOROUGH; KHALLAAYOUNE K, 1991, ANN RECH VET, V22, P219; Khallaayoune K, 1998, J FRESHWATER ECOL, V13, P129, DOI 10.1080/02705060.1998.9663598; KHALLAAYOUNE K, 1992, J HELMINTHOL, V66, P89, DOI 10.1017/S0022149X00012645; Khallaayoune K, 1998, ACTA TROP, V69, P51, DOI 10.1016/S0001-706X(97)00119-8; Laamrani H., 1998, P185; LAAMRANI H, 1997, B SCANDINAVIAN SOC P, V7, P14; LOREAU M, 1991, ANN TROP MED PARASIT, V85, P443, DOI 10.1080/00034983.1991.11812590; *MIN HLTH, 1995, SERV MAL PAR DIR EP, P29; Ministerio de Educacion Nacional, 1998, SERV MAL PAR DIR EP, P25; Mousa A H, 1972, J Egypt Med Assoc, V55, P255; Ofoezie IE, 1997, B WORLD HEALTH ORGAN, V75, P435; OKEEFFE JH, 1985, J APPL ECOL, V22, P85, DOI 10.2307/2403329; OOMEN JMV, 1990, HLTH IRRIGATION, V1, P151; PEARSON HW, 1987, WATER RES, V21, P1067, DOI 10.1016/0043-1354(87)90028-5; PIKE EG, 1987, ENG SCHISTOSOMIASIS, P25; TOWNS DR, 1981, NEW ZEAL J MAR FRESH, V15, P185, DOI 10.1080/00288330.1981.9515911; Watts S, 1998, SOC SCI MED, V46, P755, DOI 10.1016/S0277-9536(97)00171-8; ZAR JH, 1984, BIOSTAT ANAL, P206	24	6	6	0	3	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	AUG	2000	5	8					545	552		10.1046/j.1365-3156.2000.00606.x				8	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	351KG	WOS:000089155900006	10995096	Bronze			2019-03-26	
J	Manzambi, JK; Tellier, V; Bertrand, F; Albert, A; Reginster, JY; Van Balen, H				Manzambi, JK; Tellier, V; Bertrand, F; Albert, A; Reginster, JY; Van Balen, H			Determinants of health care utilization in an African urban environment: Results of a survey in Kinshasa (Congo)	TROPICAL MEDICINE & INTERNATIONAL HEALTH			French	Article							BURKINA-FASO; SERVICES	This study analyses the choice determinants of the population for health centres through a survey of the behaviour of families in a representative sample of 1000 households in the health districts of Kinshasa, Congo in 1997. For the most recent episode of illness, the respondents turned to seven types of care: the health centre (37%), private dispensaries (26.5%), self-medication through a pharmacy (23.9%), traditional practitioner (21%), traditional self-medication (16.9%), private outpatients' clinic (16.7%) and a reference hospital (10.4%). Past logistics have shown that patients resort to a health centre rather than another type of care structure (P = 0.05) when looking for quality care, reasonable prices and the availability of varied services. On the other hand, concern about the geographical proximity in relation to the family's residence calls for using the private dispensary. When looking for a doctor or the existence of a 'convention', families are more inclined to choose a private officially recognized outpatients' clinic. Those who had been looking for a solution to a special type of illness opted primarily for a traditional practitioner. In conclusion, the results of this study show that if people choose the care offered by health centres, it is because they judge it to be of good quality. The integrated cars offered by the same technician, with a required training, is a major asset in the acceptability of the first line of primary health care in Kinshasa. This study suggests that it would no doubt be beneficial to integrate non-official private care structures into the primary health care system, as far as it is possible for them to achieve a level of quality comparable to that of the health centres. In order that the traditional practitioner might play an important complementary role in the realization of primary health care, even in urban areas, the possibility of promoting sires of communication should be studied. Moreover, considering the weak buying power of the city's inhabitants and the previous existence of tontines out of solidarity, the 'conventions' providing relief of health care costs, under the leadership of the local communities. should be integrated into the organization of the urban health system.	Univ Liege, Serv Sante Publ & Epidemiol, B-4000 Liege, Belgium; Univ Catholique Louvain, Unite Epidemiol, Louvain, Belgium; Univ Liege, Serv Informat Med & Biostat, B-4000 Liege, Belgium; Inst Med Trop Anvers, Dept Sante Publ, Antwerp, Belgium	Manzambi, JK (reprint author), Univ Liege, CHU Sart Tilman, Ecole Sante Publ, Serv Sante Publ & Epidemiol, B23, B-4000 Liege, Belgium.						BATANGU M, 1997, CAHIER PHARMACIEN; BIBEAU G, 1979, MED TRADITIONNELLE Z; BROUILLET P, 1997, ENFANT MILIEU TROPIC, V228, P40; BUSCHKENS WFL, 1980, ILLNESS BEHAV E OROM; *CONS URB ORDR MED, 1995, ANN MED VILL KINSH; Develay A, 1996, SOC SCI MED, V43, P1611, DOI 10.1016/S0277-9536(96)00061-5; FASSIN D, 1991, REV EPIDEMIOL SANTE, V39, P89; GALLAND B, 1997, ENFANT MILIEU TROPIC, V228, P9; GILSON L, 1994, SOC SCI MED, V39, P767, DOI 10.1016/0277-9536(94)90038-8; HADDAD S, 1995, SOC SCI MED, V40, P743, DOI 10.1016/0277-9536(94)00134-F; Hosmer D, 1989, APPL LOGISTIC REGRES; MASAKI MNT, 1997, MED PRIVEE MODERNE Q; *MIN SANT, 1997, PROGR ACT MIN 1997 9; MURPHY M, 1981, SOC SCI MED-MED SOC, V15, P265, DOI 10.1016/0271-7123(81)90010-9; *ORG MOND SANT, 1990, ALM AT 2000 REFL MI; PANGU KA, 2000, THESIS U LIBRE BRUXE; *PROJ SANT TOUS KI, 1997, RAPP ACT 1996; *PROJ SANT TOUS KI, 1987, PRES PROJ; SAUERBORN R, 1989, SOC SCI MED, V29, P1163, DOI 10.1016/0277-9536(89)90359-6; van Luijk J N, 1979, Trop Geogr Med, V31, P33; VANBALEN H, 1997, SEANCES ACAD ROYALE, V43, P153; vanderGeest S, 1997, TROP MED INT HEALTH, V2, P903, DOI 10.1046/j.1365-3156.1997.d01-410.x; VANDERGEEST S, 1987, SOC SCI MED, V25, P293, DOI 10.1016/0277-9536(87)90232-2	23	10	10	0	7	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	AUG	2000	5	8					563	570		10.1046/j.1365-3156.2000.00588.x				8	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	351KG	WOS:000089155900008	10995098				2019-03-26	
J	Dujardin, JC; Henriksson, J; Victoir, K; Brisse, S; Gamboa, D; Arevalo, J; Le Ray, D				Dujardin, JC; Henriksson, J; Victoir, K; Brisse, S; Gamboa, D; Arevalo, J; Le Ray, D			Genomic rearrangements in trypanosomatids: an alternative to the "one gene" evolutionary hypotheses?	MEMORIAS DO INSTITUTO OSWALDO CRUZ			English	Article; Proceedings Paper	Trypanosomatid Evolution Workshop	FEB 17-18, 2000	LONDON SCH HYGIENE & TROP MED, ENGLAND	Univ Exeter, Wellcom Trust, WHO, Special Programme Res & Training Trop Dis, Soc Protozoologists, British Sect	LONDON SCH HYGIENE & TROP MED	Leishmania; Trypanosoma cruzi; chromosome evolution	LEISHMANIA VIANNIA BRAZILIENSIS; CONSERVED LINKAGE GROUPS; SUBGENUS VIANNIA; CLONAL EVOLUTION; PERUVIAN ANDES; CRUZI; CHROMOSOMES; POPULATIONS; KARYOTYPE; DISTANCE	Most molecular. trees of trypanosomatids are based on point mutations within DNA sequences. In contrast there ara very few evolutionary studies considering DNA (re) arrangement as genetic characters. Waiting for the completion of the various parasite genome projects, first information may already be obtained from chromosome size-polymorphism, using the appropriate algorithms for data processing. Three illustrative models are presented here. First, the case of Leishmania (Viannia) braziliensis/L. (V.) peruviana is described. Thanks to a fast evolution rate (due essentially to amplification/deletion of tandemly repeated genes), molecular karyotyping seems particularly appropriate for studying recent evolutionary divergence, including eco-geographical diversification. Secondly, karyotype evolution is consider-ed at the level of whole genus Leishmania. Despite the fast chromosome evolution rate, there is qualitative congruence with MLEE- and RAPD-based evolutionary hypotheses. Significant differences may be observed between major lineages, likely corresponding to major and less frequent rearrangements (fusion/fission, translocation). Thirdly, comparison is made with Trypanosoma cruzi. Again congruence is observed with other hypotheses and major lineages are delineated by significant chromosome rearrangements. The level of karyotype polymorphism within that "species" is similar to the one observed in "genus" Leishmania. The relativity of the species concept among these two groups of parasites is discussed.	Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium; Univ Uppsala, Ctr Biomed, Dept Med Genet, S-75123 Uppsala, Sweden; Univ Utrecht, Acad Hosp Utrecht, Eijkman Winkler Inst, NL-3584 CX Utrecht, Netherlands; Univ Peruana Cayetano Heredia, Dept Ciencias Fisiol, Inst Med Trop Alexander Von Humboldt, Lima, Peru	Dujardin, JC (reprint author), Inst Trop Med Prince Leopold, Protozool 155 Natl Str, B-2000 Antwerp, Belgium.			Gamboa, Dionicia/0000-0002-1420-7729; Arevalo, Jorge/0000-0003-3837-2849			Ashburner M.Drosophila, 1989, DROSOPHILA LAB HDB; ASLUND L, 1994, MOL BIOCHEM PARASIT, V65, P317, DOI 10.1016/0166-6851(94)90082-5; Banuls AL, 1999, INT J PARASITOL, V29, P1137, DOI 10.1016/S0020-7519(99)00083-1; BANULS AL, 2000, IN PRESS J EUKARYOT; Bogliolo AR, 1996, ACTA TROP, V61, P31, DOI 10.1016/0001-706X(95)00138-5; Bourke PF, 1996, MOL BIOCHEM PARASIT, V82, P25, DOI 10.1016/0166-6851(96)02715-6; Bringaud F, 1998, MOL BIOCHEM PARASIT, V94, P249, DOI 10.1016/S0166-6851(98)00080-2; Brisse S, 2000, INT J PARASITOL, V30, P35, DOI 10.1016/S0020-7519(99)00168-X; Britto C, 1998, GENE, V222, P107, DOI 10.1016/S0378-1119(98)00472-7; CACERES AG, UNPUB AM J TROP MED; CAMERON MM, 1993, T R SOC TROP MED HYG, V87, P363; CAMPETELLA O, 1992, MOL BIOCHEM PARASIT, V50, P225, DOI 10.1016/0166-6851(92)90219-A; CANO MI, 1995, MOL BIOCHEM PARASIT, V71, P273, DOI 10.1016/0166-6851(95)00066-A; Chouicha N, 1997, PARASITOLOGY, V115, P343, DOI 10.1017/S0031182097001376; Danchin A, 1997, CURR OPIN GENET DEV, V7, P852, DOI 10.1016/S0959-437X(97)80051-2; Danchin A, 1998, BIOINFORMATICS, V14, P383, DOI 10.1093/bioinformatics/14.5.383; DAVIS RA, 1993, J ENZYM INHIB, V7, P87, DOI 10.3109/14756369309040751; de Lana M, 1998, EXP PARASITOL, V90, P20, DOI 10.1006/expr.1998.4304; DOVER GA, 1982, GENOME EVOLUTION, P343; DUJARDIN JC, 1995, PARASITOLOGY, V110, P21, DOI 10.1017/S0031182000081002; Dujardin JC, 1998, PARASITOLOGY, V117, P547, DOI 10.1017/S0031182098003357; DUJARDIN JC, 1995, THESIS VRIJE U BRUSS; FELSENSTEIN J, 1984, EVOLUTION, V38, P16, DOI 10.1111/j.1558-5646.1984.tb00255.x; GOWER JC, 1984, LEISHMANIA TAXONOMIE, P13; GREGORIUS HR, 1984, BIOMETRICAL J, V26, P13, DOI 10.1002/bimj.4710260103; GUERRA H, 1988, RES CONTROL STRATEGI, P135; HENRIKSSON J, 1990, MOL BIOCHEM PARASIT, V42, P213, DOI 10.1016/0166-6851(90)90164-H; HENRIKSSON J, 1995, MOL BIOCHEM PARASIT, V73, P63, DOI 10.1016/0166-6851(95)00096-J; Inga R, 1998, MOL BIOCHEM PARASIT, V92, P219, DOI 10.1016/S0166-6851(98)00009-7; JEFFREYS AJ, 1982, GENOME EVOLUTION, P157; KATZ M, 1988, BIOMETRICAL J, V30, P571; Kebede A, 1999, INT J PARASITOL, V29, P549, DOI 10.1016/S0020-7519(99)00010-7; Kerr SF, 2000, MEM I OSWALDO CRUZ, V95, P75, DOI 10.1590/S0074-02762000000100011; Lamas G., 1982, P336; Larson A., 1994, Experientia Supplementum (Basel), V69, P371; Laurent JP, 1997, PARASITOLOGY, V114, P213, DOI 10.1017/S0031182096008414; Llanos-Cuentas EA, 1999, T ROY SOC TROP MED H, V93, P15, DOI 10.1016/S0035-9203(99)90163-3; MACINTYRE RJ, 1994, BIOESSAYS, V16, P699; MAINGON R, 1988, EUR J BIOCHEM, V171, P285, DOI 10.1111/j.1432-1033.1988.tb13788.x; Mayr E., 1969, PRINCIPLES SYSTEMATI; Montamat EE, 1996, AM J TROP MED HYG, V55, P625, DOI 10.4269/ajtmh.1996.55.625; Moreno G, 1986, LEISHMANIA TAXONOMIE, P105; Noyes H, 1998, MEM I OSWALDO CRUZ, V93, P657, DOI 10.1590/S0074-02761998000500017; POLET S, 1999, THESIS NAMUR; RAMAMOORTHY R, 1995, J BIOL CHEM, V270, P12133, DOI 10.1074/jbc.270.20.12133; Revollo S, 1998, EXP PARASITOL, V89, P30, DOI 10.1006/expr.1998.4216; Rudenko G, 1996, MOL BIOCHEM PARASIT, V80, P65, DOI 10.1016/0166-6851(96)02669-2; Sneath PHA, 1973, NUMERICAL TAXONOMY; SZOSTAK JW, 1980, NATURE, V284, P426, DOI 10.1038/284426a0; THOMAZSOCCOL V, 1993, ANN PARASIT HUM COMP, V68, P107; TIBAYRENC M, 1990, P NATL ACAD SCI USA, V87, P2414, DOI 10.1073/pnas.87.7.2414; TOMASHOW LS, 1983, CELL, V32, P35; Van der Hammen Thomas, 1982, BIOL DIVERSIFICATION, P60; VICTOIR K, 1995, PARASITOLOGY, V111, P265, DOI 10.1017/S0031182000081828; VILLASECA P, 1993, AM J TROP MED HYG, V49, P260, DOI 10.4269/ajtmh.1993.49.260; WAGNER W, 1990, INFECT IMMUN, V58, P3217; WILSON AC, 1974, P NATL ACAD SCI USA, V71, P3028, DOI 10.1073/pnas.71.8.3028; Wincker P, 1996, NUCLEIC ACIDS RES, V24, P1688, DOI 10.1093/nar/24.9.1688	58	21	22	0	3	FUNDACO OSWALDO CRUZ	RIO DE JANEIRO, RJ	AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL	0074-0276			MEM I OSWALDO CRUZ	Mem. Inst. Oswaldo Cruz	JUL-AUG	2000	95	4					527	534		10.1590/S0074-02762000000400015				8	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	333LU	WOS:000088132200015	10904411	DOAJ Gold			2019-03-26	
J	Lechat, MF				Lechat, MF			Comments on leprosy at age 141	INTERNATIONAL JOURNAL OF LEPROSY AND OTHER MYCOBACTERIAL DISEASES			English	Letter										Lechat, MF (reprint author), 109 Rue Trois Tilleuls, B-1170 Brussels, Belgium.						Agrawal S, 1999, INT J LEPROSY, V67, P471	1	0	0	0	0	INT JOURNAL LEPROSY	GREENVILLE	BUSINESS & CIRCULATION OFFICE, 1 ALM WAY, GREENVILLE, SC 29601-9999 USA	0148-916X			INT J LEPROSY	Int. J. Lepr. Other Mycobact. Dis.	JUN	2000	68	2					177	177						1	Microbiology; Pathology; Tropical Medicine	Microbiology; Pathology; Tropical Medicine	362VH	WOS:000089798600009	11036499				2019-03-26	
J	Mattioli, RC; Pandey, VS; Murray, M; Fitzpatrick, JL				Mattioli, RC; Pandey, VS; Murray, M; Fitzpatrick, JL			Immunogenetic influences on tick resistance in African cattle with particular reference to trypanotolerant N'Dama (Bos taurus) and trypanosusceptible Gobra zebu (Bos indicus) cattle	ACTA TROPICA			English	Review						ticks; tick-borne diseases; host resistance; N'Dama; Gobra zebu	BROWN EAR-TICK; RHIPICEPHALUS-APPENDICULATUS NEUMANN; AMBLYOMMA-HEBRAEUM ACARINA; BOOPHILUS-MICROPLUS; TRYPANOSOMA-CONGOLENSE; COWDRIA-RUMINANTIUM; THEILERIA-PARVA; MILK-PRODUCTION; BORAN CATTLE; GUINEA-PIGS	In sub-Saharan Africa, tick infestation and tick-borne infections together with tsetse-transmitted trypanosomosis arguably constitute the main parasitological disease complex constraining livestock production. Resistance to tick attack and tick-borne micro-organisms (TBMs) varies among different breeds of cattle. The magnitude of losses due to these parasites is related to an extent to the degree of breed resistance. Generally, zebu (Bos indicus) cattle possess a higher resistance to ticks and TBMs than European (Bos taurus) cattle. The host's immune system would appear to be the single most important factor that regulates this resistance. This paper reports on the main effector immune mechanisms governing resistance against ticks and TBMs. The cellular immune response appears mote effective and stable than humoral immunity in modulating resistance to ticks and TBMs. Similarities between the immune mechanisms employed by trypanotolerant N'Dama (B, taurus) cattle, when infected with trypanosomes, and those elicited by tick bites and TBMs seem to exist, particularly at the skin level in the early phases of parasitic invasion. Moreover, then is evidence that in the N'Dama breed, resistance against ticks per se also has a genetic basis. Therefore, the N'Dama appears to be a unique breed in that it exhibits resistance to several parasitic diseases and/or infections, including helminths, when compared to other cattle breeds in West Africa. It is concluded that the multi-parasite resistant traits of the N'Dama breed should be exploited in those areas where trypanosomosis, ticks and tick-borne diseases constrain animal production. This should be of benefit for low-input farming systems where the use of chemicals for prophylaxis and therapy is limited by their relatively high cost. Additionally, the potential contribution of multiple disease resistant N'Dama cattle should be considered in crossbreeding programmes with exotic dairy breeds for increasing milk production in West Africa. (C) 2000 Elsevier Science B.V. All rights reserved.	Int Trypanotolerance Ctr, Banjul, Gambia; Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium; Univ Glasgow, Sch Vet, Glasgow G61 1QH, Lanark, Scotland	Mattioli, RC (reprint author), Int Trypanotolerance Ctr, PMB 14, Banjul, Gambia.	raf.mattioli@commit.gm					ADACHI K, 1993, J VET MED SCI, V55, P189, DOI 10.1292/jvms.55.189; ADAMSON D, 1991, VET PARASITOL, V38, P317, DOI 10.1016/0304-4017(91)90143-J; AKOL GWO, 1982, VET REC, V110, P295, DOI 10.1136/vr.110.13.295; ALI M, 1993, TROP ANIM HEALTH PRO, V25, P215, DOI 10.1007/BF02250871; ALLISON AC, 1981, AM J PATHOL, V102, P114; ASSELBERGS MJ, 1989, LIVESTOCK PRODUCTION, P358; AUTHIE E, 1990, VET PARASITOL, V35, P43, DOI 10.1016/0304-4017(90)90115-R; BARBET AF, 1995, VET PARASITOL, V57, P43, DOI 10.1016/0304-4017(94)03108-9; BARNARD DR, 1990, EXP APPL ACAROL, V9, P259, DOI 10.1007/BF01193432; BARON RW, 1987, PARASITOL TODAY, V3, P77, DOI 10.1016/0169-4758(87)90163-3; Barre N, 1988, Rev Elev Med Vet Pays Trop, V41, P339; Barre N, 1988, Rev Elev Med Vet Pays Trop, V41, P129; BARRIGA OO, 1991, J PARASITOL, V77, P703, DOI 10.2307/3282702; BARRIGA OO, 1994, VET PARASITOL, V55, P29, DOI 10.1016/0304-4017(94)90054-X; BARRIGA OO, 1993, J PARASITOL, V79, P710, DOI 10.2307/3283609; BARRIGA OO, 1991, J PARASITOL, V77, P710, DOI 10.2307/3282703; Bennett G. F., 1968, Proceedings of the Ecological Society of Australia, V3, P150; Binnington K.C., 1980, Advances in Parasitology, V18, P315; Bowman AS, 1997, MED VET ENTOMOL, V11, P277, DOI 10.1111/j.1365-2915.1997.tb00407.x; Brizuela CM, 1996, VET PARASITOL, V63, P95, DOI 10.1016/0304-4017(95)00885-3; Brossard M, 1997, MED VET ENTOMOL, V11, P270, DOI 10.1111/j.1365-2915.1997.tb00406.x; Brossard M., 1976, Acta Tropica, V33, P15; Brown S J, 1985, Parasitol Today, V1, P166, DOI 10.1016/0169-4758(85)90175-9; BROWN SJ, 1984, J IMMUNOL, V133, P3319; CLARKE FC, 1989, MED VET ENTOMOL, V3, P35, DOI 10.1111/j.1365-2915.1989.tb00472.x; CLAXTON J, 1991, VET PARASITOL, V40, P293, DOI 10.1016/0304-4017(91)90109-9; DARJI A, 1992, ANN SOC BELG MED TR, V72, P27; DECASTRO JJ, 1993, PARASITOL TODAY, V9, P13, DOI 10.1016/0169-4758(93)90154-8; deCastro JJ, 1997, VET PARASITOL, V71, P77, DOI 10.1016/S0304-4017(97)00033-2; DECASTRO JJ, 1991, BREEDING FOR DISEASE RESISTANCE IN FARM ANIMALS, P244; DECASTRO JJ, 1987, ACIAR P, V17, P118; Deem SL, 1996, VET PARASITOL, V61, P133, DOI 10.1016/0304-4017(95)00820-9; DOENHOFF MJ, 1991, PARASITOL TODAY, V7, P16, DOI 10.1016/0169-4758(91)90079-4; DOKO SA, 1996, THESIS PRINCE LEOPOL; Dossa SC, 1996, VET PARASITOL, V62, P317, DOI 10.1016/0304-4017(95)00875-6; DUPLESSIS JL, 1985, ONDERSTEPOORT J VET, V52, P55; DWINGER RH, 1986, RES VET SCI, V41, P307, DOI 10.1016/S0034-5288(18)30621-0; EMERY DL, 1981, IMMUNOLOGY, V43, P323; EUGUI EM, 1981, NATURE, V290, P251, DOI 10.1038/290251a0; FIVAZ BH, 1993, TROP ANIM HEALTH PRO, V25, P131, DOI 10.1007/BF02236231; FIVAZ BH, 1991, VET PARASITOL, V38, P299, DOI 10.1016/0304-4017(91)90142-I; FIVAZ BH, 1989, TROP ANIM HEALTH PRO, V21, P129, DOI 10.1007/BF02236193; FIVAZ BH, 1989, J PARASITOL, V75, P946, DOI 10.2307/3282875; FLYNN JN, 1991, IMMUNOLOGY, V74, P310; Food and Agriculture Organisation of the United Nation (FAO), 1984, TICKS TICK BORN DIS, V1; FRANCIS J., 1964, AUSTRALIAN VETERINARY J, V40, P247, DOI 10.1111/j.1751-0813.1964.tb08746.x; GAIDO AB, 1995, ANN TROP MED PARASIT, V89, P309, DOI 10.1080/00034983.1995.11812957; GORDON JR, 1990, IMMUNOL TODAY, V11, P458, DOI 10.1016/0167-5699(90)90176-A; GROOTENHUIS JG, 1985, STUDIES EARLY PATHOG, P85; Gueye A, 1990, Rev Elev Med Vet Pays Trop, V42, P517; Gueye A, 1993, Rev Elev Med Vet Pays Trop, V46, P551; Guglielmone A. A., 1992, Research and Reviews in Parasitology, V52, P77; HELLERHAUPT A, 1983, ANN TROP MED PARASIT, V77, P219, DOI 10.1080/00034983.1983.11811700; HERNANDEZ RM, 1994, MED VET ENTOMOL, V8, P238, DOI 10.1111/j.1365-2915.1994.tb00505.x; HOLMES PH, 1987, PARASITOLOGY, V94, pS29; How S J, 1988, Rev Elev Med Vet Pays Trop, V41, P139; Hursey B. S., 1995, World Animal Review, P67; INOKUMA H, 1993, VET PARASITOL, V47, P107, DOI 10.1016/0304-4017(93)90181-L; Itty P, 1996, AGR ECON, V14, P33, DOI 10.1016/0169-5150(95)01170-6; JONGEJAN F, 1994, REV SCI TECH OIE, V13, P1201, DOI 10.20506/rst.13.4.818; JONGEJAN F, 1989, EXP APPL ACAROL, V7, P181, DOI 10.1007/BF01194059; Jordan A. M., 1986, TRYPANOSOMIASIS CONT, P357; KAISER MN, 1988, PREV VET MED, V6, P199, DOI 10.1016/0167-5877(88)90031-1; KAISER MN, 1982, TROP ANIM HEALTH PRO, V14, P63, DOI 10.1007/BF02282583; KARBE E, 1982, REV ELEV MED VET PAY, V35, P365; KAUFMAN WR, 1989, PARASITOL TODAY, V5, P47; KEMP DH, 1980, PARASITOLOGY, V80, P487, DOI 10.1017/S0031182000000950; Kemp SJ, 1996, VET IMMUNOL IMMUNOP, V54, P239, DOI 10.1016/S0165-2427(96)05692-9; Koney E B, 1994, Rev Elev Med Vet Pays Trop, V47, P163; KONEY EBM, 1994, VET PARASITOL, V55, P245, DOI 10.1016/0304-4017(94)00648-V; Konstantinov O.K., 1990, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V43, P85; KUTTLER K L, 1986, Tropical Animal Health and Production, V18, P91; KUTTLER KL, 1988, TROP ANIM HEALTH PRO, V20, P37, DOI 10.1007/BF02239643; LAWRENCE JA, 1980, VET REC, V107, P82, DOI 10.1136/vr.107.4.82; LEMOS AM, 1985, ANIM PROD, V41, P187, DOI 10.1017/S0003356100027847; LLOYD CM, 1995, VET PARASITOL, V59, P59, DOI 10.1016/0304-4017(95)94781-Z; MAGEZ S, 1993, PARASITE IMMUNOL, V15, P635, DOI 10.1111/j.1365-3024.1993.tb00577.x; MAHAN SM, 1995, VET PARASITOL, V57, P51, DOI 10.1016/0304-4017(94)03109-A; Maillard J C, 1993, Rev Elev Med Vet Pays Trop, V46, P283; Maillard J C, 1993, Rev Elev Med Vet Pays Trop, V46, P291; Mattioli R. C., 1992, Parassitologia (Rome), V34, P109; Mattioli R. C., 1995, Tropicultura, V13, P19; Mattioli R. C., 1994, Parassitologia (Rome), V36, P305; Mattioli R. C., 1996, Parassitologia (Rome), V38, P531; Mattioli RC, 1997, MED VET ENTOMOL, V11, P342, DOI 10.1111/j.1365-2915.1997.tb00420.x; Mattioli RC, 1998, PREV VET MED, V34, P137, DOI 10.1016/S0167-5877(97)00082-2; MATTIOLI RC, 1993, VET PARASITOL, V47, P139, DOI 10.1016/0304-4017(93)90184-O; Mattioli RC, 1999, MED VET ENTOMOL, V13, P33, DOI 10.1046/j.1365-2915.1999.00136.x; Mattioli RC, 1998, ACTA TROP, V71, P57, DOI 10.1016/S0001-706X(98)00051-5; MATTIOLI RC, 1995, TROP ANIM HEALTH PRO, V27, P150, DOI 10.1007/BF02248959; MATTIOLI RC, 1995, TROP ANIM HEALTH PRO, V27, P95, DOI 10.1007/BF02236320; McMillan DE, 1996, WORLD DEV, V24, P569, DOI 10.1016/0305-750X(95)00153-4; MCTIER TL, 1981, J PARASITOL, V67, P813, DOI 10.2307/3280705; MELTZER MI, 1995, TROP ANIM HEALTH PRO, V27, P129, DOI 10.1007/BF02248956; MELTZER MI, 1993, EXP APPL ACAROL, V17, P171, DOI 10.1007/BF00118434; Merlin P, 1986, Rev Elev Med Vet Pays Trop, V39, P403; MILLER DK, 1984, TROP ANIM HEALTH PRO, V16, P71, DOI 10.1007/BF02239848; MORRISON WI, 1981, EXP PARASITOL, V52, P248, DOI 10.1016/0014-4894(81)90080-1; MORROW AN, 1993, REVUE D ELEVAGE ET DE MEDECINE VETERINAIRE DES PAYS TROPICAUX, TOME 46 (NOUVELLE SER), NO. 1-2, 1993, P317; MULLENAX CH, 1986, P ANN M AN RES WORK, P2; MURRAY M, 1985, VET PARASITOL, V18, P167, DOI 10.1016/0304-4017(85)90065-2; MURRAY M, 1981, VET REC, V109, P503; MURRAY M, 1984, J INFECT DIS, V149, P311, DOI 10.1093/infdis/149.3.311; MURRAY M, 1982, ADV PARASIT, V21, P1, DOI 10.1016/S0065-308X(08)60274-2; MURRAY M, 1991, BREEDING FOR DISEASE RESISTANCE IN FARM ANIMALS, P203; MUSOKE AJ, 1984, IMMUNOLOGY, V52, P231; Mwangi DM, 1998, DEV BIOL STAND, V92, P309; Norval R A, 1990, Parassitologia, V32, P155; NORVAL RAI, 1988, VET PARASITOL, V30, P149, DOI 10.1016/0304-4017(88)90162-8; Norval RAI, 1997, MED VET ENTOMOL, V11, P143, DOI 10.1111/j.1365-2915.1997.tb00304.x; Norval RAI, 1997, MED VET ENTOMOL, V11, P148, DOI 10.1111/j.1365-2915.1997.tb00305.x; OKELLY JC, 1976, J PARASITOL, V62, P312, DOI 10.2307/3279295; OPDEBEECK JP, 1994, VET PARASITOL, V54, P205, DOI 10.1016/0304-4017(94)90091-4; ORINDA GO, 1994, VET PARASITOL, V53, P53, DOI 10.1016/0304-4017(94)90016-7; PALING RW, 1991, PARASITE IMMUNOL, V13, P427, DOI 10.1111/j.1365-3024.1991.tb00295.x; PALING RW, 1991, PARASITE IMMUNOL, V13, P413, DOI 10.1111/j.1365-3024.1991.tb00294.x; Pegram R G, 1990, Parassitologia, V32, P165; Pegram RG, 1996, TROP ANIM HEALTH PRO, V28, P99, DOI 10.1007/BF02250733; PEGRAM RG, 1990, MED VET ENTOMOL, V4, P327, DOI 10.1111/j.1365-2915.1990.tb00448.x; PEGRAM RG, 1989, MED VET ENTOMOL, V3, P313, DOI 10.1111/j.1365-2915.1989.tb00234.x; PEGRAM RG, 1995, MED VET ENTOMOL, V9, P337, DOI 10.1111/j.1365-2915.1995.tb00144.x; RECHAV Y, 1989, MED VET ENTOMOL, V3, P333, DOI 10.1111/j.1365-2915.1989.tb00239.x; RECHAV Y, 1991, ONDERSTEPOORT J VET, V58, P181; RECHAV Y, 1991, MED VET ENTOMOL, V5, P29, DOI 10.1111/j.1365-2915.1991.tb00517.x; REGE JEO, 1994, ANIM PROD, V59, P21, DOI 10.1017/S0003356100007467; ROITT I, 1991, ESSENTIAL IMMUNOLOGY, P356; RURANGIRWA FR, 1983, PARASITE IMMUNOL, V5, P267, DOI 10.1111/j.1365-3024.1983.tb00743.x; SCHOLTZ MM, 1991, ONDERSTEPOORT J VET, V58, P71; SCHORDERET S, 1993, MED VET ENTOMOL, V7, P186, DOI 10.1111/j.1365-2915.1993.tb00673.x; SEIFERT GW, 1971, AUST J AGR RES, V22, P159, DOI 10.1071/AR9710159; SEIFERT GW, 1984, DEV ANIMAL VET SCI, V15, P553; SHAW APM, 1987, 671 FAO; SHAW APM, 1987, 672 FAO; SILEGHEM MR, 1993, VET IMMUNOL IMMUNOP, V37, P123, DOI 10.1016/0165-2427(93)90060-H; SMITH RE, 1989, VET REC, V124, P583, DOI 10.1136/vr.124.22.583; SOLARI MA, 1992, MEM I OSWALDO CRUZ, V87, P143, DOI 10.1590/S0074-02761992000700022; STACHURSKI F, 1993, VET PARASITOL, V49, P299, DOI 10.1016/0304-4017(93)90128-A; Stachurski F, 1988, Rev Elev Med Vet Pays Trop, V41, P395; STEWART CG, 1987, ONDERSTEPOORT J VET, V54, P341; SUTHERST RW, 1983, AUST J AGR RES, V34, P317, DOI 10.1071/AR9830317; SUTHERST RW, 1981, HDB PEST MANAGEMENT, P385; TATCHELL RJ, 1992, INSECT SCI APPL, V13, P551, DOI 10.1017/S1742758400016131; TATCHELL RJ, 1988, TROP PEST MANAGE, V34, P165; Totte P, 1993, Rev Elev Med Vet Pays Trop, V46, P189; Totte P, 1996, VET IMMUNOL IMMUNOP, V53, P61, DOI 10.1016/0165-2427(96)05603-6; UILENBERG G, 1990, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V43, P297; *UNDP, 1991, GAM87004 UNDP; VANVLIET AHM, 1992, INT J SYST BACTERIOL, V42, P494, DOI 10.1099/00207713-42-3-494; VERCRUYSSE J, 1982, REV ELEV MED VET PAY, V35, P361; WAGLAND BM, 1980, 56 ANN C AUSTR VET A, P55; WAKELIN D, 1991, BREEDING FOR DISEASE RESISTANCE IN FARM ANIMALS, P54; WALKER AR, 1986, INT J PARASITOL, V16, P399, DOI 10.1016/0020-7519(86)90121-9; WALKER AR, 1990, MED VET ENTOMOL, V4, P321, DOI 10.1111/j.1365-2915.1990.tb00447.x; WALKER AR, 1985, INT J PARASITOL, V15, P81, DOI 10.1016/0020-7519(85)90106-7; WALKER JB, 1987, ONDERSTEPOORT J VET, V54, P353; WHITELAW DD, 1979, RES VET SCI, V26, P102; WIKEL SK, 1986, VET PARASITOL, V20, P149, DOI 10.1016/0304-4017(86)90098-1; WIKEL SK, 1994, INT J PARASITOL, V24, P59, DOI 10.1016/0020-7519(94)90059-0; WIKEL SK, 1977, IMMUNOLOGY, V32, P457; Wikel SK, 1997, PARASITOL TODAY, V13, P383, DOI 10.1016/S0169-4758(97)01126-5; WIKEL SK, 1976, IMMUNOLOGY, V30, P311; WILLADSEN P, 1978, INT J PARASITOL, V8, P89, DOI 10.1016/0020-7519(78)90003-6; WILLADSEN P, 1980, 56 ANN C AUSTR VET A, P60; WILLIAMS DJL, 1991, PARASITE IMMUNOL, V13, P171, DOI 10.1111/j.1365-3024.1991.tb00273.x; WRIGHT IG, 1988, PARASITOL TODAY, V4, P214, DOI 10.1016/0169-4758(88)90161-5; YONOW T, 1995, INT J PARASITOL, V25, P1023, DOI 10.1016/0020-7519(95)00020-3	166	51	56	0	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0001-706X	1873-6254		ACTA TROP	Acta Trop.	MAY 31	2000	75	3					263	277		10.1016/S0001-706X(00)00063-2				15	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	319GZ	WOS:000087334300001	10838210				2019-03-26	
J	Faber, WR; Arias-Bouda, LMP; Zeegelaar, JE; Kolk, AHJ; Fonteyne, PA; Toonstra, J; Portaels, F				Faber, WR; Arias-Bouda, LMP; Zeegelaar, JE; Kolk, AHJ; Fonteyne, PA; Toonstra, J; Portaels, F			First reported case of Mycobacterium ulcerans infection in a patient from China	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						Buruli ulcer; Mycobacterium ulcerans; case report; PCR; diagnosis; treatment; China	16S RIBOSOMAL-RNA; PCR ASSAY; IDENTIFICATION	Buruli ulcers have not been previously described in China, and only once at higher latitudes on the northern hemisphere. A patient who travelled in the Shan Dong Province in the People's Republic of China developed an ulcer which was proven to be a Buruli ulcer. The clinical picture and histopathological findings from biopsy specimens are characteristic for a Buruli ulcer, and also the growth in culture (Coletsos medium) at a restricted temperature of 30 degrees C. A multiplex polymerase chain reaction (PCR) based on the amplification of the gene encoding for 16S ribosomal RNA and a nested PCR based on the Mycobacterium ulcerans specific repeated sequence 2404 were performed. These PCR investigations identified the bacteria as M. ulcerans, subspecies shinshuense. The patient was initially treated with clarithromycin and rifampicin, which was changed to ciprofloxacin and rifabutin when rifampicin resistance of the first isolate was established. There were no signs of reactivation of the disease 6 months after the end of treatment. M. ulcerans infection occurs above 30 degrees latitude on the northern hemisphere in China and is caused by M. ulcerans, subspecies shinshuense. This case appears to be cured by chemotherapy alone, in contrast to the general experience that surgical treatment is indicated. The granulomatous reaction with only fragments of acid-fast bacteria in the biopsy at the end of treatment may indicate the development of an adequate cell-mediated immune response leading to resistance to the infection.	Univ Amsterdam, Acad Med Ctr, Dept Dermatol, NL-1105 AZ Amsterdam, Netherlands; Royal Trop Inst, Dept Biomed Res, NL-1105 AZ Amsterdam, Netherlands; Molendael Hosp, Dept Dermatol, Baarn, Netherlands; Inst Trop Med, Dept Microbiol, B-2000 Antwerp, Belgium	Faber, WR (reprint author), Univ Amsterdam, Acad Med Ctr, Dept Dermatol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.						Aguiar J, 1997, Med Trop (Mars), V57, P83; AGUIAR J, 1997, B SEANCES ACAD ROYAL, V43, P325; Guimaraes-Peres A, 1999, J CLIN MICROBIOL, V37, P206; HAYMAN J, 1993, J CLIN PATHOL, V46, P5, DOI 10.1136/jcp.46.1.5; Horsburgh C. Robert Jr., 1997, P119; Josse R, 1995, Med Trop (Mars), V55, P363; Kox LFF, 1997, J CLIN MICROBIOL, V35, P1492; KOX LFF, 1995, J CLIN MICROBIOL, V33, P3225; LEVY MR, 1992, J COMMUN, V42, P3, DOI 10.1111/j.1460-2466.1992.tb00809.x; Portaels F, 1996, J CLIN MICROBIOL, V34, P962; Portaels F, 1998, ANTIMICROB AGENTS CH, V42, P2070, DOI 10.1128/AAC.42.8.2070; Ross BC, 1997, J CLIN MICROBIOL, V35, P1696; SMITH M, 1996, THESIS J COOK U AUST; TSUKAMURA M, 1982, MICROBIOL IMMUNOL, V26, P951, DOI 10.1111/j.1348-0421.1982.tb00241.x; Tsukamura M, 1989, Kekkaku, V64, P1	15	30	31	0	1	ROYAL SOC TROPICAL MEDICINE	LONDON	MANSON HOUSE 26 PORTLAND PLACE, LONDON W1N 4EY, ENGLAND	0035-9203			T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	MAY-JUN	2000	94	3					277	279		10.1016/S0035-9203(00)90320-1				3	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	332XE	WOS:000088099000014	10974998				2019-03-26	
J	Miezan, TW; Meda, HA; Doua, F; Dje, NN; Lejon, V; Buscher, P				Miezan, TW; Meda, HA; Doua, F; Dje, NN; Lejon, V; Buscher, P			Single centrifugation of cerebrospinal fluid in a sealed Pasteur pipette for simple, rapid and sensitive detection of trypanosomes	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						trypanosomiasis; Trypanosoma brucei gambiense; cerebrospinal fluid; diagnosis; centrifugation; methodology			Inst Trop Med, Dept Parasitol, B-2000 Antwerp, Belgium; Projet Rech Clin Trypanosomiase, Daloa, Cote Ivoire; OCCGE, Inst Pierre Richet, Daloa 01, Cote Ivoire	Buscher, P (reprint author), Inst Trop Med, Dept Parasitol, Natl Str 155, B-2000 Antwerp, Belgium.		Buscher, Philippe/B-9956-2012	Buscher, Philippe/0000-0002-1926-7472			CATTAND P, 1988, B WORLD HEALTH ORGAN, V66, P83; LAVERAN A, 1912, TRYPANOSOMES TRYPANO, P673; LUMSDEN WHR, 1979, T ROY SOC TROP MED H, V73, P312, DOI 10.1016/0035-9203(79)90092-0; *WHO, 1998, WHO TECHN REP, V881	4	46	47	0	2	ROYAL SOC TROPICAL MEDICINE	LONDON	MANSON HOUSE 26 PORTLAND PLACE, LONDON W1N 4EY, ENGLAND	0035-9203			T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	MAY-JUN	2000	94	3					293	293		10.1016/S0035-9203(00)90327-4				1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	332XE	WOS:000088099000018	10975002				2019-03-26	
J	Borchert, M; Boelaert, M; Sleurs, H; Muyembe-Tamfum, JJ; Pirard, P; Colebunders, R; Van der Stuyft, P; van der Groen, G				Borchert, M; Boelaert, M; Sleurs, H; Muyembe-Tamfum, JJ; Pirard, P; Colebunders, R; Van der Stuyft, P; van der Groen, G			Viewpoint: Filovirus haemorrhagic fever outbreaks: much ado about nothing?	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						emerging infectious diseases; filovirus haemorrhagic fever; public health	EBOLA-HEMORRHAGIC-FEVER; OF-THE-CONGO; VIRUS INFECTIONS; MONKEYS; GABON; ANTIBODIES; DISEASE; KIKWIT	The recent outbreak of Marburg haemorrhagic fever in the Democratic Republic of Congo has put the filovirus threat hack on the international health agenda. This paper gives an overview of Marburg and Ebola. outbreaks so far observed and puts them in a public health perspective. Damage on the local level has been devastating at times, but was marginal on the international level despite the considerable media attention these outbreaks received. The potential hazard of outbreaks, however. after export of filovirus from its natural environment into metropolitan areas, is argued to be considerable. Some avenues fur future research and intervention are explored. Beyond the obvious need to find the reservoir and study the natural history, public health strategies for a more timely and efficient response are urgently needed.	Inst Trop Med, Dept Publ Hlth, Epidemiol Unit, B-2000 Antwerp, Belgium; Med Sans Frontieres, Brussels, Belgium; Inst Natl Rech Biomed, Kinshasa, Zaire	Borchert, M (reprint author), Inst Trop Med, Dept Publ Hlth, Epidemiol Unit, Natl Str 155, B-2000 Antwerp, Belgium.		Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776			Amblard J, 1997, LANCET, V349, P181, DOI 10.1016/S0140-6736(05)60984-1; Breman J. G., 1978, EBOLA VIRUS HAEMORRH, P85; *CDCP, 1990, MMWR-MORBID MORTAL W, V39, P296; *CDCP, 1998, INF CONTR VIR HAEM F; DOWELLS F, 1999, J INFECT DIS, V179, pS87; ELTAHIR BM, 1978, EBOLA VIRUS HAEMORRH, P98; EMOND RTD, 1978, EBOLA VIRUS HAEMORRH, P31; Francis D, 1978, EBOLA VIRUS HAEMORRH, P100; Georges AJ, 1999, J INFECT DIS, V179, pS65, DOI 10.1086/514290; GeorgesCourbot MC, 1997, EMERG INFECT DIS, V3, P59, DOI 10.3201/eid0301.970107; Guimard Y, 1999, J INFECT DIS, V179, pS268, DOI 10.1086/514315; Heymann DL, 1999, J INFECT DIS, V179, pS283, DOI 10.1086/514287; HUGGINS J, 1999, J INFECT DIS S, V179, P240; ISACSON M, 1978, EBOLA VIRUS HAEMORRH, P22; Jaax N, 1995, LANCET, V346, P1669, DOI 10.1016/S0140-6736(95)92841-3; Jahrling PB, 1999, J INFECT DIS, V179, pS224, DOI 10.1086/514310; JAHRLING PB, 1990, LANCET, V335, P502, DOI 10.1016/0140-6736(90)90737-P; JOHNSON E, 1995, INT J EXP PATHOL, V76, P227; JOHNSON ED, 1993, T ROY SOC TROP MED H, V87, P536, DOI 10.1016/0035-9203(93)90077-4; Khan AS, 1999, J INFECT DIS, V179, pS76, DOI 10.1086/514306; Ksiazek TG, 1999, J INFECT DIS, V179, pS192, DOI 10.1086/514313; Kudoyarova-Zubavichene NM, 1999, J INFECT DIS, V179, pS218, DOI 10.1086/514294; LEGUENNO B, 1999, MARBURG EBOLA VIRUSE, P77; Lloyd ES, 1999, J INFECT DIS, V179, pS274, DOI 10.1086/514312; Martini G.A., 1971, MARBURG VIRUS DIS; Maruyama T, 1999, J INFECT DIS, V179, pS235, DOI 10.1086/514280; McNeill W. H., 1976, PLAGUES PEOPLES; Monath TP, 1999, J INFECT DIS, V179, pS127, DOI 10.1086/514281; Mupapa K, 1999, J INFECT DIS, V179, pS18, DOI 10.1086/514298; Murphy F, 1978, EBOLA VIRUS HAEMORRH, P53; MUYEMBETAMFUM JJ, 1999, RAPPORT MISSION INVE; MUYEMBETAMFUM JJ, 1999, J INFECT DIS S, V179, P259; Peters C. J., 1993, P159; Peters CJ, 1999, J INFECT DIS, V179, pIX; PETERS CJ, 1999, J INFECT DIS S1, V179, pS1; PIANKOV OV, 1995, VOP VIRUSOL, V3, P113; Piot P, 1978, EBOLA VIRUS HAEMORRH, P17; Preston R, 1995, HOT ZONE; Rollin PE, 1999, J INFECT DIS, V179, pS108, DOI 10.1086/514303; RYAN F, 1998, VIRUS 10 UNDERSTANDI; Sadek RF, 1999, J INFECT DIS, V179, pS24, DOI 10.1086/514311; SLENCZKA WG, 1999, MARBURG EBOLA VIRUSE, P49; Swanepoel R, 1996, EMERG INFECT DIS, V2, P321, DOI 10.3201/eid0204.960407; UNAIDS, 1999, AIDS EP UPD, P1; *WHO, 1997, WKLY EPIDEMIOL REC, V72, P7; *WHO, 1999, WKLY EPIDEMIOL REC, V74, P157; *WHO, 1996, WKLY EPIDEMIOL REC, V71, P125; *WHO, 1999, WEEKL EP REC, V74, P143; ZAKI SR, 1999, J INFECT DIS, V179, P536	49	5	5	0	6	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	MAY	2000	5	5					318	324		10.1046/j.1365-3156.2000.00556.x				7	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	328YH	WOS:000087879000003	10886793	Bronze, Green Published			2019-03-26	
J	Behnke, JM; De Clercq, D; Sacko, M; Gilbert, FS; Ouattara, DB; Vercruysse, J				Behnke, JM; De Clercq, D; Sacko, M; Gilbert, FS; Ouattara, DB; Vercruysse, J			The epidemiology of human hookworm infections in the southern region of Mali	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						Necator americanus; hookworms; familial clustering; predisposition; footwear; eyesight	NECATOR-AMERICANUS INFECTION; INDIAN FISHING COMMUNITY; POPULATION BIOLOGY; ANCYLOSTOMA-CEYLANICUM; ASCARIS-LUMBRICOIDES; PARASITIC INFECTION; PREDISPOSITION; SENSITIVITY; AGGREGATION; IVERMECTIN	Two surveys of hookworm (Necator americanus) infections, conducted three years apart (December 1994 and January 1998) in a village in the Sikasso region of Mall, revealed that overall prevalence of infection was 68.7% and 53%, respectively. In both years there was a highly significant difference between the sexes in the prevalence and abundance of infection, with male subjects carrying heavier infections than females. Both prevalence and abundance of infection increased with age, although in 1998 there was a strong interaction between sex and age, arising from the declining egg counts among 16-20-year-old females and the continuing increase among males, reinforced by the subsequent reduction among the older males (greater than or equal to 61 years) and concomitant increase among females. After controlling for the effects of age, sex and their interaction, a highly significant positive relationship was detected between faecal egg counts of individuals who were examined in both 1994 and 1998 (n = 134), indicating predisposition to infection. This relationship remained significant in each of 4 age classes spanning 7-79 years. The members of some family compounds were shown to carry heavier infections than expected whilst others were less infected, suggesting compound-related clustering of hookworm infections. The use of footwear increased with age but there was no significant relationship between the extent of use of footwear and the abundance of hookworm infection. Eyesight deteriorated with age and impaired vision was particularly prominent among the older sectors of the community, a legacy from the time when onchocerciasis was widely prevalent in the region, Although men with partially damaged eyes carried lower infections than expected for their age, no overall significant relationship was found between quality of Vision and hookworm infections. These results are discussed in relation to hookworm epidemiology in general and in Mali in particular.	Univ Nottingham, Sch Biol Sci, Nottingham NG7 2RD, England; State Univ Ghent, Fac Med Vet, Dept Parasitol, Ghent, Belgium; Inst Natl Rech Sante Publ, Serv Parasitol, Bamako, Mali; Med Chef Adjoint Serv Sociosanit Cercle Bougouni, Bougouni, Mali	Behnke, JM (reprint author), Univ Nottingham, Sch Biol Sci, Univ Pk, Nottingham NG7 2RD, England.		Gilbert, Francis/K-3817-2013				ALEXANDER J, 1988, PARASITOL TODAY, V4, P189, DOI 10.1016/0169-4758(88)90077-4; BEHNKE JM, 1987, PARASITOL TODAY, V3, P200, DOI 10.1016/0169-4758(87)90060-3; BEHNKE JM, 1993, INT J PARASITOL, V23, P945, DOI 10.1016/0020-7519(93)90061-3; BRABIN L, 1992, ADV PARASIT, V31, P1, DOI 10.1016/S0065-308X(08)60020-2; BRADLEY M, 1992, T ROY SOC TROP MED H, V86, P73, DOI 10.1016/0035-9203(92)90448-L; BRADLEY M, 1990, T ROY SOC TROP MED H, V84, P826, DOI 10.1016/0035-9203(90)90096-W; Brooker S, 1999, T ROY SOC TROP MED H, V93, P240, DOI 10.1016/S0035-9203(99)90007-X; BUNDY DAP, 1988, PARASITOL TODAY, V4, P186, DOI 10.1016/0169-4758(88)90076-2; Bundy DAP, 1997, PARASITOL TODAY, V13, P407, DOI 10.1016/S0169-4758(97)90019-3; Bundy DAP, 1990, PARASITISM HOST BEHA; CHAN L, 1994, T ROY SOC TROP MED H, V88, P46, DOI 10.1016/0035-9203(94)90492-8; Chan MS, 1997, PARASITOL TODAY, V13, P438, DOI 10.1016/S0169-4758(97)01144-7; Chongsuvivatwong V, 1996, T ROY SOC TROP MED H, V90, P630, DOI 10.1016/S0035-9203(96)90412-5; Crawley M, 1993, GLIM ECOLOGISTS; DASH KM, 1988, AUST VET J, V65, P66, DOI 10.1111/j.1751-0813.1988.tb07359.x; DeClercq D, 1997, AM J TROP MED HYG, V57, P25, DOI 10.4269/ajtmh.1997.57.25; DeClercq D, 1995, ANN SOC BELG MED TR, V75, P191; *EC NAT MED PHARM, 1980, 77006 MLI UNDP EC NA, V1, pCH5; ELLIOTT JM, 1977, SOME METHODS STAT AN; FORRESTER JE, 1988, T ROY SOC TROP MED H, V82, P282, DOI 10.1016/0035-9203(88)90448-8; HASWELLELKINS MR, 1987, PARASITOLOGY, V95, P323, DOI 10.1017/S0031182000057772; HASWELLELKINS MR, 1988, PARASITOLOGY, V96, P565, DOI 10.1017/S0031182000080197; HIGGINS DA, 1984, ANN TROP MED PARASIT, V78, P637, DOI 10.1080/00034983.1984.11811876; Humphries DL, 1997, T ROY SOC TROP MED H, V91, P518, DOI 10.1016/S0035-9203(97)90007-9; Katz N, 1972, Rev Inst Med Trop Sao Paulo, V14, P397; KILAMA WL, 1990, HOOKWORM DISEASE : CURRENT STATUS AND NEW DIRECTIONS, P17; KILLEWO JZJ, 1991, ACTA TROP, V48, P247, DOI 10.1016/0001-706X(91)90053-M; MARGOLIS L, 1982, J PARASITOL, V68, P131, DOI 10.2307/3281335; Miller T.A., 1979, Advances in Parasitology, V17, P315, DOI 10.1016/S0065-308X(08)60552-7; NAWALINSKI T, 1978, AM J TROP MED HYG, V27, P1152, DOI 10.4269/ajtmh.1978.27.1152; Needham C, 1998, TROP MED INT HEALTH, V3, P904, DOI 10.1046/j.1365-3156.1998.00324.x; Palmer DR, 1995, E AFR MED J, V72, P527; POULIN R, 1993, INT J PARASITOL, V23, P937, DOI 10.1016/0020-7519(93)90060-C; PRITCHARD DI, 1990, PARASITOLOGY, V100, P317, DOI 10.1017/S0031182000061333; RICHARDS JC, 1995, INT J PARASITOL, V25, P1185, DOI 10.1016/0020-7519(95)00036-2; Roberts CW, 1996, PARASITOL TODAY, V12, P382, DOI 10.1016/0169-4758(96)10060-0; Schad G. A., 1983, Human ecology and infectious diseases., P187; SCHAD GA, 1985, SCIENCE, V228, P1537, DOI 10.1126/science.4012307; Schad GA, 1990, HOOKWORM DIS CURRENT; Smillie WG, 1925, J AMER MED ASSOC, V85, P1958, DOI 10.1001/jama.1925.02670250032009; UDONSI JK, 1980, Z PARASITENKD, V63, P251, DOI 10.1007/BF00931987; *WHO, 1963, TECHN REP SER WHO, V225; YE XP, 1994, ANN TROP MED PARASIT, V88, P635, DOI 10.1080/00034983.1994.11812915	43	39	39	0	6	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	MAY	2000	5	5					343	354		10.1046/j.1365-3156.2000.00553.x				12	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	328YH	WOS:000087879000008	10886798				2019-03-26	
J	Kazadi, JM; Losson, B; Kageruka, P				Kazadi, JM; Losson, B; Kageruka, P			The vectorial competence of the non-teneral tsetse flies of Glossina morsitans morsitans (strain Mall) infected by Trypanosoma (Nannomonas) congolense IL 1180.	BULLETIN DE LA SOCIETE DE PATHOLOGIE EXOTIQUE			French	Article						Glossina morsitans morsitans; Trypanosoma congolense; non-teneral fly; vectorial competence; laboratory	MIDGUT INFECTIONS; BRUCEI; SUSCEPTIBILITY; ESTABLISHMENT; CENTRALIS; PALPALIS; DIPTERA; LECTINS; BLOOD; CELLS	Non-teneral tsetse flies of Glossina morsitans morsitans (strain Mall) about 16 days old were-fed, once, on a rat infected by Trypanosoma congolense IL 1180. The global vectorial competence (VC) of these flies was appraised at 0.1035. VC in males was more important than for females. Infection by mesoprocyclic index was greater in female flies than in male ones, whereas for metacyclic index the reverse was true. This work shows that the age limits, but does not impede metacyclogenesis of non-teneral tsetse flies of G. m. morsitans (strain Mall).	Inst Trop Med Prince Leopold, Dept Sante Anim, B-2000 Antwerp, Belgium	Kazadi, JM (reprint author), Inst Trop Med Prince Leopold, Dept Sante Anim, Natl Str 155, B-2000 Antwerp, Belgium.	jmkazadi@hotmail.com					CHEESEMAN MT, 1985, INSECT BIOCHEM, V15, P677, DOI 10.1016/0020-1790(85)90094-0; DESAEDELEER L, 38 IMTA; DIALLO A, 1984, REV ELEV MED VET PAY, V37, P130; DISTELMANS W, 1982, ANN SOC BELG MED TR, V62, P41; Duke H.L., 1935, Transactions of the Royal Society of Tropical Medicine and Hygiene London, V29, P203, DOI 10.1016/S0035-9203(35)90058-X; Elsen Pierre, 1993, Journal of African Zoology, V107, P439; ENDEGE WO, 1989, COMP BIOCHEM PHYS B, V92, P25, DOI 10.1016/0305-0491(89)90308-8; GEIGY R, 1973, Acta Tropica, V30, P12; HARLEY J, 1965, ANN TROP MED PARASIT, V65, P191; HARLEY JMB, 1967, B ENTOMOL RES, V57, P459, DOI 10.1017/S0007485300050203; HARMSEN R, 1973, T ROY SOC TROP MED H, V67, P364, DOI 10.1016/0035-9203(73)90113-2; HERBERT WJ, 1976, EXP PARASITOL, V40, P427, DOI 10.1016/0014-4894(76)90110-7; IMBUGA MO, 1992, PARASITOL RES, V78, P10, DOI 10.1007/BF00936174; JORDAN AM, 1976, VET PARASITOL, V2, P143, DOI 10.1016/0304-4017(76)90059-5; Kazadi J.M.L., 1994, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V47, P89; Kazadi JM, 1998, PARASITE, V5, P159, DOI 10.1051/parasite/1998052159; LERAY D, 1989, ANN SOC BELG MED TR, V69, P165; MAKUMYAVIRI AM, 1984, ANN SOC BELG MED TR, V64, P365; MAUDLIN I, 1987, TROP MED PARASITOL, V38, P167; MAUDLIN I, 1988, TROP MED PARASITOL, V39, P56; MAUDLIN I, 1985, Z PARASITENKD, V71, P683, DOI 10.1007/BF00925601; MAWUENA K, 1984, REV ELEV MED VET PAY, V37, P186; MIHOK S, 1993, PARASITOLOGY, V107, P41, DOI 10.1017/S0031182000079385; MOLOO SK, 1989, ACTA TROP, V46, P223, DOI 10.1016/0001-706X(89)90022-3; MURRAY M, 1977, T ROY SOC TROP MED H, V71, P325, DOI 10.1016/0035-9203(77)90110-9; MWANGELWA MI, 1987, INSECT SCI APPL, V8, P33, DOI 10.1017/S1742758400006913; OTIENO LH, 1983, ACTA TROP, V40, P113; VAN HOOF L., 1937, Ann. Soc. Belge de Med. Trop., V17, P249; VANHOOF LMJJ, 1947, T ROY SOC TROP MED H, V40, P728; WARD RA, 1968, T ROY SOC TROP MED H, V62, P672, DOI 10.1016/0035-9203(68)90118-1; WELBURN SC, 1994, MED VET ENTOMOL, V8, P81, DOI 10.1111/j.1365-2915.1994.tb00391.x; WELBURN SC, 1993, PARASITOLOGY, V107, P141, DOI 10.1017/S003118200006724X; WELBURN SC, 1989, MED VET ENTOMOL, V3, P77, DOI 10.1111/j.1365-2915.1989.tb00477.x; WELBURN SC, 1992, ANN TROP MED PARASIT, V86, P529, DOI 10.1080/00034983.1992.11812703; WIGGLESWORTH V. B., 1929, PARASITOLOGY, V21, P288; WIJERS D. J. B., 1958, ANN TROP MED AND PARASITOL, V52, P385; WILLETT KC, 1966, EXP PARASITOL, V18, P290, DOI 10.1016/0014-4894(66)90028-2	37	4	4	0	1	SPRINGER FRANCE	PARIS	22 RUE DE PALESTRO, PARIS, 75002, FRANCE	0037-9085	1961-9049		B SOC PATHOL EXOT	Bull. Soc. Pathol. Exot.	APR	2000	93	2					125	128						4	Public, Environmental & Occupational Health; Infectious Diseases; Pathology; Tropical Medicine	Public, Environmental & Occupational Health; Infectious Diseases; Pathology; Tropical Medicine	464EZ	WOS:000170521400012	10863619				2019-03-26	
J	Apers, LM				Apers, LM			Maternal mortality: the figures-value and validity	TROPICAL DOCTOR			English	Article							SISTERHOOD METHOD; COUNTRIES; ZAMBIA		State Univ Ghent, MPH Int Ctr Reprod Hlth, Ghent, Belgium	Apers, LM (reprint author), Off PMD, POB 206, Gweru, Zimbabwe.						BOERMA JT, 1987, STUD FAMILY PLANN, V18, P213, DOI 10.2307/1966872; BOERMA JT, 1989, STUD FAMILY PLANN, V20, P245, DOI 10.2307/1966761; CHIPHANGWI JD, 1992, E AFRICA MED J, V69, P657; Cutts FT, 1996, INT J EPIDEMIOL, V25, P349, DOI 10.1093/ije/25.2.349; DAVID P, 1991, INT J EPIDEMIOL, V20, P551, DOI 10.1093/ije/20.2.551; DEGROOF D, 1993, ANN SOC BELG MED TR, V73, P279; Garenne M, 1997, STUD FAMILY PLANN, V28, P54, DOI 10.2307/2137971; GRAHAM W, 1989, STUD FAMILY PLANN, V20, P125, DOI 10.2307/1966567; HERNANDEZ B, 1994, INT J GYNECOL OBSTET, V46, P285, DOI 10.1016/0020-7292(94)90407-3; LeBacq F, 1997, INT J EPIDEMIOL, V26, P357, DOI 10.1093/ije/26.2.357; *LOND SCH HYG TROP, 1997, LESS LEARNT DEC MEAS; OBRIEN J, 1994, NEW ZEAL MED J, V107, P268; OOSTERHUIS JWA, 1993, TROP DOCT, V23, P67, DOI 10.1177/004947559302300210; SHIFERAW T, 1993, ETHIOPIAN MED J, V31, P239; STECKLOV G, 1995, STUD FAMILY PLANN, V26, P33, DOI 10.2307/2138049; VANGINNEKEN J, 1984, MATERNAL CHILD HLTH, P22; Vork FC, 1997, ACTA OBSTET GYN SCAN, V76, P646, DOI 10.3109/00016349709024604; WALRAVEN GEL, 1994, BRIT J OBSTET GYNAEC, V101, P414, DOI 10.1111/j.1471-0528.1994.tb11914.x; *WHO, 1986, WHO CHRON, V40, P175; *WHO, 1996, WHOFRHMSM9611; WIRAWAN DN, 1994, STUD FAMILY PLANN, V25, P304, DOI 10.2307/2138061	21	1	1	0	0	ROYAL SOC MEDICINE PRESS LTD	LONDON	1 WIMPOLE STREET, LONDON W1M 8AE, ENGLAND	0049-4755			TROP DOCT	Trop. Dr.	APR	2000	30	2					88	91		10.1177/004947550003000211				4	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	310VP	WOS:000086850000011	10842554				2019-03-26	
J	Colebunders, R; Watelle, M				Colebunders, R; Watelle, M			Voluntary screening for HIV	TROPICAL DOCTOR			English	Letter									Inst Trop Med, B-2000 Antwerp, Belgium	Colebunders, R (reprint author), Inst Trop Med, Natl Str 155, B-2000 Antwerp, Belgium.						AMOAKU E, 1998, TROP DOCT, V4, P248; COLEBUNDERS R, 1993, LANCET, V342, P601, DOI 10.1016/0140-6736(93)91417-K; Kamb ML, 1998, JAMA-J AM MED ASSOC, V280, P1161, DOI 10.1001/jama.280.13.1161; WHO, 1997, WKLY EPIDEMIOL REC, V72, P81; Wilkinson D, 1997, AIDS, V11, P377, DOI 10.1097/00002030-199703110-00016	5	0	0	0	2	ROYAL SOC MEDICINE PRESS LTD	LONDON	1 WIMPOLE STREET, LONDON W1M 8AE, ENGLAND	0049-4755			TROP DOCT	Trop. Dr.	APR	2000	30	2					124	124		10.1177/004947550003000228				1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	310VP	WOS:000086850000028	10842571				2019-03-26	
J	Clement, J; Van Ranst, M; Leirs, H				Clement, J; Van Ranst, M; Leirs, H			Untitled	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Letter							TICK-BORNE ENCEPHALITIS		Rega Inst, Dept Immunol & Microbiol, Lab Clin & Epidemiol Virol, B-3000 Louvain, Belgium; Katholieke Univ Leuven Hosp, B-3000 Louvain, Belgium; Danish Pest Infestat Lab, DK-2800 Lyngby, Denmark; Univ Antwerp, Dept Biol, Lab Evolutionary Biol, B-2020 Antwerp, Belgium	Clement, J (reprint author), Rega Inst, Dept Immunol & Microbiol, Lab Clin & Epidemiol Virol, Kapucijnenvoer 33, B-3000 Louvain, Belgium.		Leirs, Herwig/B-8197-2008; Van Ranst, Marc/P-7522-2017	Leirs, Herwig/0000-0002-7612-5024; Van Ranst, Marc/0000-0002-1674-4157			CLEMENT J, 1994, NATO ADV SCI INST SE, V260, P89; Clement J., 1992, Acta Leidensia, V60, P15; Craig SC, 1999, AM J TROP MED HYG, V61, P874, DOI 10.4269/ajtmh.1999.61.874; Dobler G, 1997, Wien Med Wochenschr, V147, P463; Holzmann H, 1996, J MED VIROL, V48, P102, DOI 10.1002/(SICI)1096-9071(199601)48:1<102::AID-JMV16>3.3.CO;2-Q; MCNEIL JG, 1985, J INFECT DIS, V152, P650, DOI 10.1093/infdis/152.3.650a	6	3	3	0	0	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	MAR	2000	62	3					325	326		10.4269/ajtmh.2000.62.325				2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	362JM	WOS:000089774900002	11037772				2019-03-26	
J	Southgate, VR; de Clercq, D; Sene, M; Rollinson, D; Ly, A; Vercruysse, J				Southgate, VR; de Clercq, D; Sene, M; Rollinson, D; Ly, A; Vercruysse, J			Observations on the compatibility between Bulinus spp. and Schistosoma haematobium in the Senegal River basin	ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY			English	Article							URINARY SCHISTOSOMIASIS; EPIDEMIOLOGY; MALI	Snail-infection experiments were carried out with a number of different species and populations of Bulinus and isolates of Schistosoma haematobium. The parasites came from six localities in the Senegal River basin (SRB), in the Lower Valley (Mbodiene), Middle Valley (Podor, Diatar and Nguidjilone), and Upper Valley (Aroundou and Gallade). Isolates of S. haematobium from the Middle and Upper Valleys all showed some compatibility with laboratory-bred B. truncatus from Mall, but none of these isolates was compatible with laboratory-bred B. truncatus originating from Senegal. Schistosoma haematobium from Diatar (Middle Valley) was compatible with B. senegalensis, whereas S. haematobium from Mbodiene (Lower Valley), which is naturally transmitted by B. globosus, was incompatible with B. senegalensis and B. truncatus. These data demonstrate that different isolates of S. haematobium from different regions of the SRB exhibit distinct intermediate-host specificities, which in turn will have an effect on the epidemiology of the disease, including the periods of transmission. It is apparent that, in addition to B. senegalensis and B. globosus, B. truncatus, the most widespread bulinid snail in the SRB, may be playing a role in the epidemiology of urinary schistosomiasis. This conclusion has obvious implications for the future spread of urinary schistosomiasis in the SRB. Chemical and physical measurements from assorted habitats along the SRB, including pH, temperature, salinity, conductivity, and resistivity, are also reported.	Nat Hist Museum, Dept Zool, London SW7 5BD, England; Fac Vet Med, Dept Parasitol, B-9820 Merelbeke, Belgium; Reg Med St Louis, Programme Espoir, St Louis, Senegal; IRD Ex Orstom Bel Air, Lab Paludol, Dakar, Senegal	Southgate, VR (reprint author), Nat Hist Museum, Dept Zool, Cromwell Rd,S Kensington, London SW7 5BD, England.		Rollinson, David/C-7406-2009				CHAINE JP, 1983, TROP GEOGR MED, V35, P249; CHU KY, 1978, B WORLD HEALTH ORGAN, V56, P601; MALEK EA, 1981, NAUTILUS, V95, P193; Miller M.J., 1982, P279; Picquet M, 1996, T ROY SOC TROP MED H, V90, P340, DOI 10.1016/S0035-9203(96)90501-5; Rollinson D, 1997, ANN TROP MED PARASIT, V91, P371, DOI 10.1080/00034983.1997.11813152; Sene M., 1998, P231; SOUTHGATE VR, 1985, J NAT HIST, V19, P1249, DOI 10.1080/00222938500770801; Southgate VR, 1997, J HELMINTHOL, V71, P125, DOI 10.1017/S0022149X00015790; VERCRUYSSE J, 1994, TROP GEOGR MED, V46, P220; VERCRUYSSE J, 1985, ACTA TROP, V42, P249; VERLE P, 1994, T ROY SOC TROP MED H, V88, P401, DOI 10.1016/0035-9203(94)90400-6	12	9	9	0	4	CARFAX PUBLISHING	BASINGSTOKE	RANKINE RD, BASINGSTOKE RG24 8PR, HANTS, ENGLAND	0003-4983			ANN TROP MED PARASIT	Ann. Trop. Med. Parasitol.	MAR	2000	94	2					157	164		10.1080/00034983.2000.11813524				8	Public, Environmental & Occupational Health; Parasitology; Tropical Medicine	Public, Environmental & Occupational Health; Parasitology; Tropical Medicine	302TR	WOS:000086382200006	10827870				2019-03-26	
J	Pattyn, S; Grillone, S				Pattyn, S; Grillone, S			A 6 week quadruple drug regimen for the treatment of multibacillary leprosy	LEPROSY REVIEW			English	Article							MYCOBACTERIUM-LEPRAE; MINOCYCLINE; MICE; TUBERCULOSIS; DURATION; PIGMENTATION; OFLOXACIN; THERAPY		Inst Trop Med, Dept Microbiol, Mycobacteriol Unit, B-2000 Antwerp, Belgium; Serv Lepre TB, Anjouan, Comoros	Pattyn, S (reprint author), Inst Trop Med, Dept Microbiol, Mycobacteriol Unit, B-2000 Antwerp, Belgium.						Eisen D, 1998, DRUG SAFETY, V18, P431, DOI 10.2165/00002018-199818060-00004; Ganapati R, 1998, INT J LEPROSY, V66, P56; GELBER RH, 1987, J INFECT DIS, V156, P236, DOI 10.1093/infdis/156.1.236; GELBER RH, 1991, ANTIMICROB AGENTS CH, V35, P992, DOI 10.1128/AAC.35.5.992; JAMET P, 1995, INT J LEPROSY, V63, P195; Ji B, 1998, LEPROSY REV, V69, P106; JI B, 1993, J INFECT DIS, V169, P188; JI B, 1999, ANTIMICROB AGENTS CH, V41, P1953; Morrow GL, 1998, AM J OPHTHALMOL, V125, P396, DOI 10.1016/S0002-9394(99)80156-1; PATTYN SR, 1992, INT J LEPROSY, V60, P234; PATTYN SR, 1989, LEPROSY REV, V60, P109; PATTYN SR, 1992, LEPROSY REV, V63, P41; PATTYN SR, 1992, LEPROSY REV, V63, P36; PATTYN SR, 1991, INT J LEPROSY, V59, P613; PATTYN SR, 1987, ANTIMICROB AGENTS CH, V31, P671, DOI 10.1128/AAC.31.4.671; WAYNE LG, 1994, ANTIMICROB AGENTS CH, V38, P2054, DOI 10.1128/AAC.38.9.2054; Wayne LG, 1996, INFECT IMMUN, V64, P2062; WAYNE LG, 1994, EUR J CLIN MICROBIOL, V13, P908, DOI 10.1007/BF02111491; XIONG JH, 1994, INT J LEPROSY, V62, P37	19	3	3	0	0	LEPRA	COLCHESTER	FAIRFAX HOUSE, CAUSTON ROAD, COLCHESTER CO1 1PU, ENGLAND	0305-7518			LEPROSY REV	Lepr. Rev.	MAR	2000	71	1					43	46						4	Dermatology; Infectious Diseases; Pathology; Tropical Medicine	Dermatology; Infectious Diseases; Pathology; Tropical Medicine	313NM	WOS:000087005800005	10820986				2019-03-26	
J	De Clercq, D; Hanne, C; Vercruysse, J				De Clercq, D; Hanne, C; Vercruysse, J			Selected chemotherapy and seasonally transmitted Schistosoma haematobium infections in the middle valley of the Senegal River Basin	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						schistosomiasis; Schistosoma haematobium; school-age children; selected treatment; Senegal River Basin	4 VILLAGES; EPIDEMIOLOGY; MORBIDITY; MANSONI		Univ Ghent RUG, Dept Parasitol, Fac Med Vet, B-9820 Merelbeke, Belgium; Reg Med St Louis, St Louis, Senegal	De Clercq, D (reprint author), Univ Ghent RUG, Dept Parasitol, Fac Med Vet, Salisburylaan 133, B-9820 Merelbeke, Belgium.						ENGELS D, 1993, B WORLD HEALTH ORGAN, V71, P207; ETARD JF, 1990, PARASITOLOGY, V100, P399, DOI 10.1017/S0031182000078689; GRYSEELS B, 1991, PARASITOL TODAY, V7, P244, DOI 10.1016/0169-4758(91)90238-J; GRYSEELS B, 1990, THESIS U LEIDEN NETH; Jordan P, 1993, HUMAN SCHISTOSOMIASI; MOTT KE, 1985, B WORLD HEALTH ORGAN, V63, P125; SAVIOLI L, 1990, AM J TROP MED HYG, V43, P289, DOI 10.4269/ajtmh.1990.43.289; Shaw DJ, 1998, T ROY SOC TROP MED H, V92, P634, DOI 10.1016/S0035-9203(98)90791-X; Shaw DJ, 1999, T ROY SOC TROP MED H, V93, P142, DOI 10.1016/S0035-9203(99)90288-2; Southgate VR, 1997, J HELMINTHOL, V71, P125, DOI 10.1017/S0022149X00015790; VERCRUYSSE J, 1985, ACTA TROP, V42, P249; VERLE P, 1994, T ROY SOC TROP MED H, V88, P401, DOI 10.1016/0035-9203(94)90400-6; *WHO, 1985, WHOSCHISTO8371	13	6	6	0	0	ROYAL SOC TROPICAL MEDICINE	LONDON	MANSON HOUSE 26 PORTLAND PLACE, LONDON, ENGLAND W1N 4EY	0035-9203			T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	MAR-APR	2000	94	2					198	199		10.1016/S0035-9203(00)90276-1				2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	319LU	WOS:000087343600022	10897368				2019-03-26	
J	Verle, P; Nhan, DH; Tinh, TT; Uyen, TT; Thuong, ND; Kongs, A; Van der Stuyft, P; Coosemans, M				Verle, P; Nhan, DH; Tinh, TT; Uyen, TT; Thuong, ND; Kongs, A; Van der Stuyft, P; Coosemans, M			Glucose-6-phosphate dehydrogenase deficiency in northern Vietnam	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						G6PD deficiency; malaria transmission; selective advantage; Vietnam	G6PD DEFICIENCY	Glucose-6-phosphate dehydrogenase (G6PD) deficiency was evaluated in 1676 schoolboys in northern Vietnam. The trait was nearly absent in boys of the Kinh (0.5%) and the Mong (0.7%) ethnic groups that traditionally have lived outside malaria transmission areas. Prevalences among ethnic groups living in the foothills, the breeding area of the main malaria vector Anopheles minimus, ranged from 9.7% to 31%. These findings support the hypothesis of a selective advantage of the trait in Plasmodium falciparum-endemic areas.	Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium; Belgian Adm Dev Cooperat, Brussels, Belgium; Natl Inst Malariol Parasitol & Entomol, Hanoi, Vietnam	Coosemans, M (reprint author), Inst Trop Med Prince Leopold, Nationalestr 155, B-2000 Antwerp, Belgium.	marc.coosemans@itg.be					ALLISON AC, 1960, NATURE, V186, P531, DOI 10.1038/186531a0; Betke K., 1967, WHO TECHNICAL REPORT, V366; BEUTLER E, 1994, BLOOD, V84, P3613; BEUTLER E, 1980, BLOOD PURE ELOQUENT, P141; Chau TTH, 1996, CLIN INFECT DIS, V23, P1274, DOI 10.1093/clinids/23.6.1274; Du C S, 1988, Gene Geogr, V2, P71; Harrison B. A., 1980, Contributions of the American Entomological Institute, V17; Lewis N., 1951, DRAGON APPARENT TRAV; MEEK SR, 1995, ANN TROP MED PARASIT, V89, P135, DOI 10.1080/00034983.1995.11812944; OPPENHEIM A, 1993, HUM GENET, V91, P293; SON HV, 1978, GLUCOSE 6 PHOSPHATE; VAN DN, 1993, ETHNIES MINORITAIRES, P312; VERLE P, 1999, RES REV PARASITOLOGY, V58, P169; *WHO, 1992, CTD921 WHO EXP COMM	14	10	12	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	MAR	2000	5	3					203	206		10.1046/j.1365-3156.2000.00542.x				4	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	300WG	WOS:000086276300008	10747283	Bronze			2019-03-26	
J	Vlieghe, E				Vlieghe, E			Untitled	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Letter									Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium	Vlieghe, E (reprint author), Inst Trop Med, Dept Publ Hlth, Natl Str 155, B-2000 Antwerp, Belgium.						Sheik-Mohamed A, 1999, TROP MED INT HEALTH, V4, P695, DOI 10.1046/j.1365-3156.1999.00473.x; *ST KIZ HOSP, 1996, 1995 96 HOSP REP	2	0	0	0	0	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	FEB	2000	5	2					156	156		10.1046/j.1365-3156.2000.00526.x				1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	300UM	WOS:000086271300013	10766519				2019-03-26	
J	Osaer, S; Goossens, B; Eysker, M; Geerts, S				Osaer, S; Goossens, B; Eysker, M; Geerts, S			The effects of prophylactic anthelmintic treatment on the productivity of traditionally managed Djallonke sheep and West African Dwarf goats kept under high trypanosomosis risk	ACTA TROPICA			English	Article						sheep; goats; anthelmintic treatment; trypanotolerance; productivity; rural development	HAEMONCHUS-CONTORTUS; SMALL RUMINANTS; NDAMA CATTLE; TRICHOSTRONGYLUS-COLUBRIFORMIS; GASTROINTESTINAL NEMATODES; REPRODUCTIVE-PERFORMANCE; EXPERIMENTAL-INFECTION; SEASONAL EPIDEMIOLOGY; GAMBIA; CONGOLENSE	The effects of a prophylactic anthelmintic intervention on the productivity of village based sheep and goats was studied in an area of high trypanosomosis risk in The Gambia during 2 and 3 years, respectively. In total, 223 sheep and 385 goats from five villages were included. Allocation to treatment groups (treated-control) was randomised by village, based on age and sex. Three treatments per rainy season were applied with Fenbendazole (Panacur(R), Hoechst, 2.5%, 5 mg/kg). Mean nematode egg excretion per gram faeces (EPG) of the treated groups were significantly reduced by prophylactic anthelmintic treatment, indicating the efficiency of the treatment despite the risk of rapid reinfestation. Weight gain benefits of anthelmintic treatment were observed in all age categories ( > 6 month) of sheep but not in goats. Kidding rates were significantly increased whilst the same positive trends were observed for other reproductive parameters (litter size, parturition interval) in both goats and sheep without reaching statistical significance. Birth weights of offspring born out of treated does and ewes were higher (P < 0.05) than those from the controls. In contrast, growth rates until 3 months of age were not influenced by the treatment status of the dam. Mortality rates until the age of 3 months of kids from treated does were significantly lower than of those from control does. Mean Packed Red Cell Volume (PCV) levels during the rains were significantly higher in treated goats than in control goats. The same trend was observed in sheep. In general, there were no interactions between trypanosome infections and effect of anthelmintic treatment, thus both factors acted independently. Finally, the live weight productivity index (12 months old-offspring in kg/year per dam) for treated dams was 24% and 47% higher than in control ewes and does, respectively. It can be concluded that, despite the continuous risk of trypanosome infections which has a negative impact on their productivity, a beneficial effect of anthelmintic treatment was observed in both species but most obviously in goats, measured as an increased production and improved health status. A cost-benefit analysis should be carried out in order to confirm whether prophylactic anthelmintic treatment can be recommended to farmers to increase their income from small ruminant production. Nevertheless, anthelmintic treatment will certainly optimise the trypanotolerance in these breeds. (C) 2000 Elsevier Science B.V. All rights reserved.	Int Trypanotolerance Ctr, Banjul, Gambia; Univ Utrecht, Fac Vet Med, Inst Infect Dis & Immunol, Dept Parasitol & Trop Vet Med, NL-3508 TD Utrecht, Netherlands; Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium	Osaer, S (reprint author), Int Trypanotolerance Ctr, ITC PMB 14, Banjul, Gambia.			Geerts, Stanny/0000-0001-9885-8846			Albers G. A. A., 1984, Immunogenetic approaches to the control of endoparasites with particular reference to parasites of sheep. Proceedings of a workshop held at Sydney University, October 22-23 1983, on behalf of the Australian Wool Corporation., P41; Ankers P, 1998, PREV VET MED, V34, P215, DOI 10.1016/S0167-5877(97)00037-8; Ankers P, 1994, Rev Elev Med Vet Pays Trop, V47, P201; Barger I. A., 1982, Biology and control of endoparasites. McMaster Laboratory 50th Anniversary Symposium in Parasitology, University of Sydney, 5-6 November 1981., P133; BARGER IA, 1998, VET PARASITOL, V72, P493; BARGER IA, 1999, VET PARASITOL, V29, P41; BULLERDIECK P, 1996, THESIS; COBON DH, 1992, J AGR SCI, V118, P245, DOI 10.1017/S0021859600068854; *DLS ITC, 1993, LIV CENS; FRITSCHE T, 1993, VET PARASITOL, V49, P271, DOI 10.1016/0304-4017(93)90126-8; GOOSSEN B, 1998, VET PARASITOL, V85, P25; Goossens B, 1997, INT J PARASITOL, V27, P1579, DOI 10.1016/S0020-7519(97)00094-5; Goossens B, 1998, VET REC, V142, P277, DOI 10.1136/vr.142.11.277; Goossens B, 1997, RES VET SCI, V63, P169, DOI 10.1016/S0034-5288(97)90013-8; GREENWOOD AC, 1989, REPORT SMALL RUMINAN; HOSTE H, 1993, AM J VET RES, V54, P1886; Itty P., 1997, Quarterly Journal of International Agriculture, V36, P153; KAUFMANN J, 1990, VET PARASITOL, V37, P45, DOI 10.1016/0304-4017(90)90024-6; KAUFMANN J, 1993, TROP ANIM HLTH PROD, V27, P76; KIMAMBO AE, 1988, VET PARASITOL, V28, P191, DOI 10.1016/0304-4017(88)90107-0; KIMAMBO AE, 1988, VET PARASITOL, V28, P205, DOI 10.1016/0304-4017(88)90108-2; Mawuena K, 1987, Rev Elev Med Vet Pays Trop, V40, P55; MURRAY M, 1977, T ROY SOC TROP MED H, V71, P325, DOI 10.1016/0035-9203(77)90110-9; NDAO M, 1995, VET RES COMMUN, V19, P205, DOI 10.1007/BF01839299; Osaer S, 1999, VET PARASITOL, V82, P101, DOI 10.1016/S0304-4017(99)00011-4; Osaer S, 1997, SMALL RUMINANT RES, V24, P213, DOI 10.1016/S0921-4488(96)00944-3; OSAER S, 1994, VET PARASITOL, V51, P191, DOI 10.1016/0304-4017(94)90156-2; Panin A, 1997, SMALL RUMINANT RES, V25, P9, DOI 10.1016/S0921-4488(96)00967-4; PARIS J, 1982, ACTA TROP, V39, P307; Parkins J J, 1989, Nutr Res Rev, V2, P227, DOI 10.1079/NRR19890016; RAWLINGS P, 1993, B ENTOMOL RES, V83, P625, DOI 10.1017/S0007485300040050; RAWLINGS P, 1991, PARASITOLOGY, V102, P371, DOI 10.1017/S0031182000064325; *SAS, 1998, VERS 6 12; SHRAW KL, 1995, INT J PARASITOL, V25, P381; Snedecor G., 1980, STAT METHODS, P507; SUMBERG JE, 1985, TROP ANIM HEALTH PRO, V17, P135, DOI 10.1007/BF02355872; Tanner MA, 1993, TOOLS STAT INFERENCE; Thienpont D., 1979, DIAGNOSE VERMINOSE D; THOMAS RJ, 1983, INT J PARASITOL, V13, P393, DOI 10.1016/S0020-7519(83)80047-2; Tillard E, 1997, PROD ANIM, V10, P67; TILLARD E, 1992, 7 C INT I MED; UPTON M, 1985, AGR SYST, V17, P65, DOI 10.1016/0308-521X(85)90014-9; VASSILIADES G, 1984, REV ELEV MED VET PAY, V37, P293; Waller PJ, 1997, VET PARASITOL, V71, P195, DOI 10.1016/S0304-4017(97)00032-0; ZINSSTAG J, 1994, ACTA TROP, V58, P99, DOI 10.1016/0001-706X(94)90049-3	45	13	13	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0001-706X			ACTA TROP	Acta Trop.	JAN 5	2000	74	1					13	24		10.1016/S0001-706X(99)00042-X				12	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	267RJ	WOS:000084372900003	10643903				2019-03-26	
J	Boelaert, JR; Taramelli, D				Boelaert, JR; Taramelli, D			Untitled	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Letter									Algemeen Ziekenhuis St Jan, Infect Dis Unit, B-8000 Brugge, Belgium; Univ Milan, Inst Microbiol, I-20122 Milan, Italy; UNDP World Bank WHO Special Program Res & Trainin, Geneva, Switzerland	Boelaert, JR (reprint author), Algemeen Ziekenhuis St Jan, Infect Dis Unit, Ruddershovelaan 10, B-8000 Brugge, Belgium.			Taramelli, Donatella/0000-0001-5108-4492			BASILICO N, 1999, MOL PAR M WOODS HOL, P403; Boelaert JR, 1999, AIDS RES HUM RETROV, V15, P1241, DOI 10.1089/088922299310133; Seth P, 1999, AM J TROP MED HYG, V61, P180, DOI 10.4269/ajtmh.1999.61.180; Sperber K, 1997, CLIN THER, V19, P913, DOI 10.1016/S0149-2918(97)80045-8	4	0	0	0	0	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DRIVE SUITE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	JAN	2000	62	1					1	2						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	298NF	WOS:000086145500003	10761717				2019-03-26	
J	Yersin, C; Bovet, P; Merien, F; Clement, J; Laille, M; Van Ranst, M; Perolat, P				Yersin, C; Bovet, P; Merien, F; Clement, J; Laille, M; Van Ranst, M; Perolat, P			Pulmonary haemorrhage as a predominant cause of death in leptospirosis in Seychelles	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						leptospirosis; case fatality; pulmonary haemorrhage; Seychelles	POLYMERASE CHAIN-REACTION; HEMORRHAGIC-FEVER; WEILS DISEASE; THROMBOCYTOPENIA; DIAGNOSIS; MANIFESTATIONS; NICARAGUA; FEATURES	We examined the cause of death during a 12-month period (1995/96) in all consecutive patients admitted to hospital with leptospiral infection in Seychelles (Indian Ocean), Where the disease is endemic. Leptospirosis was diagnosed by use of he microscopic agglutination test acid a specific polymerase chain reaction assay on serum samples. Seventy-five cases were diagnosed and 6 patients died, a case fatality of 8%. All 6 patients died within 9 days of onset of symptoms and within 2 days of admission for 5 of them (5 days for the 6th). On autopsy, diffuse bilateral pulmonary haemorrhage (PH) was found in all fatalities. Renal, cardiac, digestive and cerebral haemorrhages were also found in 5, 3, 3 and 1 case(s), respectively. Incidentally, haemoptysis and lung infiltrate on chest radiographs, which suggest PH, were found in 8 of the 69 non-fatal cases. Dengue and hantavirus infections were ruled out. In conclusion, PH appeared to be a main cause of death in leptospirosis in this population, although haemorrhage in other organs may also have contributed to fatal outcomes. This cause of death contrasts with the findings generally reported in endemic settings.	Univ Lausanne, Inst Social & Prevent Med, Lausanne, Switzerland; Inst Pasteur, Leptospira Lab, Noumea, New Caledonia; Katholieke Univ Leuven Hosp, Dept Microbiol & Immunol, Virol Lab, Louvain, Belgium; Inst Pasteur, Arboviruses Lab, Noumea, New Caledonia	Yersin, C (reprint author), Victoria Hosp, Dept Internal Med, POB 52, Victoria, Seychelles.		Van Ranst, Marc/P-7522-2017; Bovet, Pascal/F-4477-2011	Van Ranst, Marc/0000-0002-1674-4157; Bovet, Pascal/0000-0002-0242-4259			ALLEN P, 1989, INTENS CARE MED, V15, P322; Bourdais A, 1988, Med Trop (Mars), V48, P149; Bovet P, 1999, INT J EPIDEMIOL, V28, P583, DOI 10.1093/ije/28.3.583; BROWN PD, 1995, J MED MICROBIOL, V43, P110, DOI 10.1099/00222615-43-2-110; BUNDO K, 1985, J VIROL METHODS, V11, P15, DOI 10.1016/0166-0934(85)90120-X; CLARKE DH, 1958, AM J TROP MED HYG, V7, P561, DOI 10.4269/ajtmh.1958.7.561; Courtin J.-P., 1998, Revue de Pneumologie Clinique, V54, P382; DAOUDAL P, 1978, NOUV PRESSE MED, V7, P3535; EDWARDS CN, 1986, AM J TROP MED HYG, V35, P352, DOI 10.4269/ajtmh.1986.35.352; EDWARDS CN, 1982, AM J TROP MED HYG, V31, P827, DOI 10.4269/ajtmh.1982.31.827; EVERARD COR, 1995, EUR J EPIDEMIOL, V11, P311, DOI 10.1007/BF01719436; Faine S., 1994, LEPTOSPIRA LEPTOSPIR; Gauthier R, 1969, Bull Soc Pathol Exot Filiales, V62, P493; HEATH CW, 1965, NEW ENGL J MED, V273, P915, DOI 10.1056/NEJM196510212731706; HEATH CW, 1965, NEW ENGL J MED, V273, P857, DOI 10.1056/NEJM196510142731606; IVANOV AP, 1988, ARCH VIROL, V100, P1, DOI 10.1007/BF01310902; KAHN JB, 1982, AM J TROP MED HYG, V31, P1213, DOI 10.4269/ajtmh.1982.31.1213; KIM JS, 1985, J KOREAN MED ASSOC, V28, P77; LANCIOTTI RS, 1992, J CLIN MICROBIOL, V30, P545; MERIEN F, 1995, J INFECT DIS, V172, P281, DOI 10.1093/infdis/172.1.281; Nicodemo AC, 1997, AM J TROP MED HYG, V56, P181, DOI 10.4269/ajtmh.1997.56.181; ONEIL KM, 1991, REV INFECT DIS, V13, P705; PARK SK, 1989, AM J TROP MED HYG, V41, P345, DOI 10.4269/ajtmh.1989.41.345; Perolat P, 1998, INT J SYST BACTERIOL, V48, P851, DOI 10.1099/00207713-48-3-851; PERTUISET E, 1988, REV MED INTERNE, V9, P487, DOI 10.1016/S0248-8663(88)80012-2; PINN TG, 1992, MED J AUSTRALIA, V156, P163; POH SC, 1970, THORAX, V25, P751, DOI 10.1136/thx.25.6.751; RAGNAUD JM, 1987, ANN MED INTERNE, V138, P282; RAMACHANDRAN S, 1977, T ROY SOC TROP MED H, V71, P56, DOI 10.1016/0035-9203(77)90209-7; RIOSGONCALVES AJ, 1990, ARQ BRAS MED, V64, P389; Shim YH, 1980, J KOREAN MED ASSOC, V23, P131; Trevejo RT, 1998, J INFECT DIS, V178, P1457, DOI 10.1086/314424; TURNER JS, 1989, Q J MED, V72, P841; WATT G, 1988, LANCET, V1, P433; Yersin C, 1998, AM J TROP MED HYG, V59, P933, DOI 10.4269/ajtmh.1998.59.933; YUKAWA M, 1994, J BASIC MICROB, V34, P49, DOI 10.1002/jobm.3620340110; Zaki SR, 1996, LANCET, V347, P535, DOI 10.1016/S0140-6736(96)91167-8; ZOLLER L, 1991, LANCET, V338, P183, DOI 10.1016/0140-6736(91)90169-P	38	59	63	0	3	ROYAL SOC TROPICAL MEDICINE	LONDON	MANSON HOUSE 26 PORTLAND PLACE, LONDON, ENGLAND W1N 4EY	0035-9203			T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	JAN-FEB	2000	94	1					71	76		10.1016/S0035-9203(00)90445-0				6	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	292ZH	WOS:000085825800025	10748905				2019-03-26	
J	De Clercq, D; Vercruysse, J; Verle, P; Niasse, F; Kongs, A; Diop, M				De Clercq, D; Vercruysse, J; Verle, P; Niasse, F; Kongs, A; Diop, M			Efficacy of artesunate against Schistosoma mansoni infections in Richard Toll, Senegal	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						chemotherapy; artesunate; schistosomiasis; Schistosoma mansoni; Senegal river basin			Univ Ghent, RUG, Fac Vet Med, Dept Parasitol, B-9820 Merelbeke, Belgium; Reg Med St Louis, Programme Espoir, St Louis, Senegal; Belgian Agcy Dev Cooperat, Hanoi, Vietnam	Vercruysse, J (reprint author), Univ Ghent, RUG, Fac Vet Med, Dept Parasitol, Salisburylaan 133, B-9820 Merelbeke, Belgium.						Picquet M, 1998, T ROY SOC TROP MED H, V92, P90, DOI 10.1016/S0035-9203(98)90971-3; SHUHUA X, 1989, ANTIMICROB AGENTS CH, V33, P1557, DOI 10.1128/AAC.33.9.1557; STELMA FF, 1997, THESIS U LEIDEN NETH; TALLA I, 1990, ANN SOC BELG MED TR, V70, P173; Wang JiaLong, 1997, Chinese Journal of Parasitology & Parasitic Diseases, V15, P138; WHITE NJ, 1994, T ROY SOC TROP MED H, V88, P3, DOI 10.1016/0035-9203(94)90459-6; Xiao SH, 1998, ACTA PHARMACOL SIN, V19, P63; Xu MingSheng, 1997, Chinese Journal of Schistosomiasis Control, V9, P268	8	31	32	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0035-9203	1878-3503		T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	JAN-FEB	2000	94	1					90	91		10.1016/S0035-9203(00)90453-X				2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	292ZH	WOS:000085825800030	10748910				2019-03-26	
J	Aventin, L; Matthys, F				Aventin, L; Matthys, F			Editorial: Do we negotiate human health ?	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Editorial Material						World Trade Organization (WTO); Millennium Rund; human health; drugs; developing countries			Med Sans Frontieres, B-1090 Brussels, Belgium	Aventin, L (reprint author), Med Sans Frontieres, 94 Rue Dupre, B-1090 Brussels, Belgium.						AVENTIN L, 1999, MILLENNIUM ROUND OMC; BENETT SD, 1997, EC SANTE MEDICAMENTS; MARITOUX J, 1999, REMED, V21, P7; *OMC, 1999, WTGCW302 OMC; UNDP, 1999, GLOB HUM FAC; *WHO, 1999, CONST WHO; *WTO, 1998, 983558 WTO COUNC TRA	7	2	2	0	0	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	JAN	2000	5	1					1	2		10.1046/j.1365-3156.2000.00519.x				2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	289QT	WOS:000085634000001	10672198				2019-03-26	
